FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Ma, KK Mele, L Landon, MB Spong, CY Ramin, SM Casey, B Wapner, RJ Varner, MW Rouse, DJ Thorp, JM Sciscione, A Catalano, P Harper, M Saade, G Caritis, SN Sorokin, Y Peaceman, AM AF Ma, Kimberly K. Mele, Lisa Landon, Mark B. Spong, Catherine Y. Ramin, Susan M. Casey, Brian Wapner, Ronald J. Varner, Michael W. Rouse, Dwight J. Thorp, John M., Jr. Sciscione, Anthony Catalano, Patrick Harper, Margaret Saade, George Caritis, Steve N. Sorokin, Yoram Peaceman, Alan M. CA Eunice Kennedy Shriver Natl Inst TI The Obstetric and Neonatal Implications of a Low Value on the 50-g Glucose Screening Test SO AMERICAN JOURNAL OF PERINATOLOGY LA English DT Article DE low glucose screening test; neonatal hypoglycemia ID INTRAUTERINE GROWTH-RETARDATION; TOLERANCE-TEST; ORAL GLUCOSE; HYPOGLYCEMIA; METABOLISM; PREGNANCY AB Objective To assess the relationship between a low 50-g 1-hour glucose loading test (GLT) and maternal and neonatal outcomes in women without diabetes. Study Design This was a secondary analysis of a multicenter observational cohort from a randomized trial of treatment for mild gestational diabetes. Maternal and neonatal outcomes were compared between women with GLT values < 90 mg/dL and those with results 90 to 119 mg/dL. Results Of 436 enrolled women, 297 (68.1%) had a GLT result of 90 to 119 mg/dL and 139 (31.9%) had a result of < 90 mg/dL. There was a lower incidence of neonatal hypoglycemia in those with a GLT < 90 mg/dL (5.7% versus 16.5%, p = 0.006). Other outcomes were not associated with test results. Conclusion A GLT result < 90 mg/dL compared with 90 to 119 mg/dL is associated with a lower risk of neonatal hypoglycemia, but no other significant findings. C1 [Ma, Kimberly K.] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA. [Mele, Lisa] George Washington Univ, Ctr Biostat, Rockville, MD USA. [Landon, Mark B.] Ohio State Univ, Columbus, OH 43210 USA. [Spong, Catherine Y.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA. [Ramin, Susan M.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Casey, Brian] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Wapner, Ronald J.] Columbia Univ, New York, NY USA. [Varner, Michael W.] Univ Utah, Salt Lake City, UT USA. [Rouse, Dwight J.] Univ Alabama Birmingham, Birmingham, AL USA. [Thorp, John M., Jr.] Univ N Carolina, Chapel Hill, NC USA. [Sciscione, Anthony] Drexel Univ, Philadelphia, PA 19104 USA. [Catalano, Patrick] Case Western Reserve Univ, MetroHlth Med Ctr, Cleveland, OH 44106 USA. [Harper, Margaret] Wake Forest Univ Hlth Sci, Winston Salem, NC USA. [Saade, George] Univ Texas Med Branch, Galveston, TX 77555 USA. [Caritis, Steve N.] Univ Pittsburgh, Pittsburgh, PA USA. [Sorokin, Yoram] Wayne State Univ, Detroit, MI USA. [Peaceman, Alan M.] Northwestern Univ, Chicago, IL 60611 USA. RP Ma, KK (reprint author), 1959 NE Pacific St,Box 356460, Seattle, WA 98195 USA. EM kkma@uw.edu RI Varner, Michael/K-9890-2013 OI caritis, steve/0000-0002-2169-0712; Peaceman, Alan/0000-0002-4515-4850; Varner, Michael/0000-0001-9455-3973 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development [HD27915, HD34116, HD40485, HD34208, HD27869, HD40500, HD40560, HD34136, HD40544, HD27860, HD40545, HD53097, HD21410, HD27917, HD40512, HD53118, HD36801]; General Clinical Research Centers Grant [M01-RR00034]; National Center for Research Resources [UL1-RR024989, M01-RR00080, UL1-RR025764, C06-RR11234] FX The project described was supported by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD27915, HD34116, HD40485, HD34208, HD27869, HD40500, HD40560, HD34136, HD40544, HD27860, HD40545, HD53097, HD21410, HD27917, HD40512, HD53118, HD36801), General Clinical Research Centers Grant (M01-RR00034), and the National Center for Research Resources (UL1-RR024989, M01-RR00080, UL1-RR025764, C06-RR11234) and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health and Human Development or the National Institutes of Health. NR 21 TC 2 Z9 2 U1 0 U2 0 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0735-1631 EI 1098-8785 J9 AM J PERINAT JI Am. J. Perinatol. PD OCT PY 2013 VL 30 IS 9 BP 714 EP 720 DI 10.1055/s-0032-1331027 PG 7 WC Obstetrics & Gynecology; Pediatrics SC Obstetrics & Gynecology; Pediatrics GA 217WI UT WOS:000324392900002 ER PT J AU Londhe, VA Nolen, TL Das, A Higgins, RD Tyson, JE Oh, W Devaskar, SU AF Londhe, Vedang A. Nolen, Tracy L. Das, Abhik Higgins, Rosemary D. Tyson, Jon E. Oh, William Devaskar, Sherin U. CA Eunice Kennedy Shriver Natl Inst TI Vitamin A Supplementation in Extremely Low-Birth-Weight Infants: Subgroup Analysis in Small-for-Gestational-Age Infants SO AMERICAN JOURNAL OF PERINATOLOGY LA English DT Article DE vitamin A; IUGRintrauterine growth restriction; BPDbronchopulmonary dysplasia; SGAsmall for gestational age; AGAappropriate for gestational age ID INTRAUTERINE GROWTH-RETARDATION; LUNG-FUNCTION; NEWBORN AB Objective Preterm infants with intrauterine growth restriction are at increased risk of respiratory distress syndrome and bronchopulmonary dysplasia (BPD). A randomized clinical trial by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network demonstrated that vitamin A supplementation in extremely low-birth-weight (ELBW) preterm infants requiring early respiratory support decreased the risk of developing BPD. Study Design A subgroup analysis of small-for-gestational-age (SGA) infants from the original NICHD trial was performed to test the hypothesis that in infants requiring early respiratory support, vitamin A supplementation decreases the relative risk of BPD or death in premature SGA infants to a greater extent than in gestational age-equivalent vitamin A-treated appropriate-for-gestational-age (AGA) infants. Results Although vitamin A supplementation significantly increased serum retinol concentrations in AGA ELBW infants (median [5th percentile, 95th percentile]: 16.3 [-7.0, 68.8] versus 2.4 [-13.9, 55.1]; p < 0.001), no increases were noted in SGA ELBW infants. Conclusions Given the limited power of this analysis due to a low number of SGA infants, these data did not provide evidence to support the hypothesis that vitamin A supplementation in preterm SGA infants requiring early respiratory support decreases the relative risk of BPD or death as compared with preterm AGA infants. C1 [Londhe, Vedang A.; Devaskar, Sherin U.] Univ Calif Los Angeles, David Geffen Sch Med, Div Neonatol & Dev Biol, Dept Pediat,Neonatal Res Ctr, Los Angeles, CA 90095 USA. [Nolen, Tracy L.; Das, Abhik] RTI Int, Stat & Epidemiol Unit, Res Triangle Pk, NC USA. [Higgins, Rosemary D.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA. [Tyson, Jon E.] Univ Texas Med Sch Houston, Dept Pediat, Houston, TX USA. [Oh, William] Brown Univ, Women & Infants Hosp, Dept Pediat, Providence, RI 02908 USA. RP Londhe, VA (reprint author), Dept Pediat, Div Neonatol & Dev Biol, 175217,B2-375 MDCC,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM vlondhe@mednet.ucla.edu FU National Institutes of Health; NICHD; National Center for Research Resources; National Center for Advancing Translational Sciences through UCLA CTSI [UL1TR000124] FX The National Institutes of Health, the NICHD, and the National Center for Research Resources provided grant support for the Neonatal Research Network's Vitamin A Trial.; Yale University and Yale-New Haven Children's Hospital (U10HD27871, M01 RR6022): Richard A. Ehrenkranz, MD; Patricia Gettner, RN; Monica Konstantino, RN, BSN; JoAnn Poulsen, RN; Sherin U. Devaskar was supported by the National Center for Advancing Translational Sciences through UCLA CTSI Grant UL1TR000124 NR 21 TC 4 Z9 4 U1 0 U2 3 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0735-1631 EI 1098-8785 J9 AM J PERINAT JI Am. J. Perinatol. PD OCT PY 2013 VL 30 IS 9 BP 770 EP 778 DI 10.1055/s-0032-1333410 PG 9 WC Obstetrics & Gynecology; Pediatrics SC Obstetrics & Gynecology; Pediatrics GA 217WI UT WOS:000324392900011 ER PT J AU Manasyan, A Saleem, S Koso-Thomas, M Althabe, F Pasha, O Chomba, E Goudar, SS Patel, A Esamai, F Garces, A Kodkany, B Belizan, J McClure, EM Derman, RJ Hibberd, P Liechty, EA Hambidge, KM Carlo, WA Buekens, P Moore, J Wright, LL Goldenberg, RL AF Manasyan, Albert Saleem, Sarah Koso-Thomas, Marion Althabe, Fernando Pasha, Omrana Chomba, Elwyn Goudar, Shivaprasad S. Patel, Archana Esamai, Fabian Garces, Ana Kodkany, Bhala Belizan, Jose McClure, Elizabeth M. Derman, Richard J. Hibberd, Patricia Liechty, Edward A. Hambidge, K. Michael Carlo, Waldemar A. Buekens, Pierre Moore, Janet Wright, Linda L. Goldenberg, Robert L. CA EmONC Trial Grp TI Assessment of Obstetric and Neonatal Health Services in Developing Country Health Facilities SO AMERICAN JOURNAL OF PERINATOLOGY LA English DT Article DE emergency obstetric and neonatal care; developing countries; perinatal mortality ID MATERNAL MORTALITY; CARE SERVICES; QUALITY AB Objective To describe the staffing and availability of medical equipment and medications and the performance of procedures at health facilities providing maternal and neonatal care at African, Asian, and Latin American sites participating in a multicenter trial to improve emergency obstetric/neonatal care in communities with high maternal and perinatal mortality. Study Design In 2009, prior to intervention, we surveyed 136 hospitals and 228 clinics in 7 sites in Africa, Asia, and Latin America regarding staffing, availability of equipment/medications, and procedures including cesarean section. Results The coverage of physicians and nurses/midwives was poor in Africa and Latin America. In Africa, only 20% of hospitals had full-time physicians. Only 70% of hospitals in Africa and Asia had performed cesarean sections in the last 6 months. Oxygen was unavailable in 40% of African hospitals and 17% of Asian hospitals. Blood was unavailable in 80% of African and Asian hospitals. Conclusions Assuming that adequate facility services are necessary to improve pregnancy outcomes, it is not surprising that maternal and perinatal mortality rates in the areas surveyed are high. The data presented emphasize that to reduce mortality in these areas, resources that result in improved staffing and sufficient equipment, supplies, and medication, along with training, are required. C1 [Manasyan, Albert; Chomba, Elwyn; Carlo, Waldemar A.] Ctr Infect Dis Zambia, Lusaka, Zambia. [Manasyan, Albert; Chomba, Elwyn] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA. [Saleem, Sarah; Pasha, Omrana] Aga Khan Univ, Dept Community Hlth Sci, Karachi, Pakistan. [Koso-Thomas, Marion] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Perinatol & Pregnancy Branch, Bethesda, MD USA. [Althabe, Fernando; Belizan, Jose] Inst Clin Effectiveness & Hlth Policy, Dept Mother & Child Hlth Res, Buenos Aires, DF, Argentina. [Chomba, Elwyn] Univ Zambia, Dept Pediat, Lusaka, Zambia. [Goudar, Shivaprasad S.] KLEs Jawaharlal Nehru Med Coll, Dept Physiol, Belgaum, India. [Patel, Archana] Indira Gandhi Govt Med Coll, Clin Epidemiol Unit, Nagpur, Maharashtra, India. [Esamai, Fabian] Moi Univ, Dept Pediat, Eldoret, Kenya. [Garces, Ana] Francisco Marroquin Univ, IMSALUD, Guatemala City, Guatemala. [Kodkany, Bhala] KLEs Jawaharlal Nehru Med Coll, Dept Obstet, Belgaum, India. [McClure, Elizabeth M.; Moore, Janet] Res Triangle Inst, Durham, NC 27709 USA. [Derman, Richard J.] Christiana Hlth Care, Dept Obstet, Newark, DE USA. [Hibberd, Patricia] Indiana Univ, Dept Pediat, Indianapolis, IN 46204 USA. [Liechty, Edward A.] Massachusetts Gen Hosp Children, Dept Pediat, Boston, MA USA. [Hambidge, K. Michael] Univ Colorado, Dept Pediat, Denver, CO 80202 USA. [Buekens, Pierre] Tulane Sch Publ Hlth & Trop Med, New Orleans, LA USA. [Wright, Linda L.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Ctr Res Mothers & Children, Bethesda, MD USA. [Goldenberg, Robert L.] Columbia Univ, Dept Obstet & Gynecol, New York, NY USA. RP McClure, EM (reprint author), Res Triangle Inst, Durham, NC 27709 USA. EM mcclure@rti.org OI GOUDAR, SHIVAPRASAD/0000-0002-8680-7053; Belizan, Jose/0000-0002-8412-3010 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development [U01 HD040477, U01 HD043464, U01 HD040657, U01 HD042372, U01 HD040607, U01 HD058322, U01 HD058326, U01 HD040636] FX This study was funded by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (U01 HD040477, U01 HD043464, U01 HD040657, U01 HD042372, U01 HD040607, U01 HD058322, U01 HD058326, and U01 HD040636). The authors declare that they have no conflicts of interest. NR 16 TC 13 Z9 13 U1 4 U2 7 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0735-1631 EI 1098-8785 J9 AM J PERINAT JI Am. J. Perinatol. PD OCT PY 2013 VL 30 IS 9 BP 787 EP 793 DI 10.1055/s-0032-1333409 PG 7 WC Obstetrics & Gynecology; Pediatrics SC Obstetrics & Gynecology; Pediatrics GA 217WI UT WOS:000324392900013 PM 23329566 ER PT J AU Abulaban, K Rovin, BH Nelson, S Song, HJ Kimmel, P Kusek, J Feldman, H Ramachandran, V Bennett, M Ying, J Brunner, H AF Abulaban, Khalid Rovin, Brad H. Nelson, Shannen Song, Huijuan Kimmel, Paul Kusek, John Feldman, Harold Ramachandran, Vasan Bennett, Michael Ying, Jun Brunner, Hermine TI Candidate Urinary Biomarkers May Predict The Future Development Of Renal Functional Loss With Lupus Nephritis In Children and Adults SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Abulaban, Khalid; Bennett, Michael; Brunner, Hermine] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Rovin, Brad H.; Song, Huijuan] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. [Nelson, Shannen] Cincinnati Childrens Hosp, Cincinnati, OH USA. [Kimmel, Paul; Kusek, John] NIDDK, NIH, Bethesda, MD USA. [Feldman, Harold] Univ Penn, Philadelphia, PA 19104 USA. [Ramachandran, Vasan] Boston Univ, Sch Med, Boston, MA 02118 USA. [Ying, Jun] Univ Cincinnati, Cincinnati, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 590 BP S254 EP S255 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359202102 ER PT J AU Aggarwal, R Ruperto, N Erman, B Feroz, S Vencovsky, J Huber, A Oliveira, SK Pistorio, A Pilkington, C Ravelli, A Feldman, BM Rockette, H Miller, FW Lachenbruch, PA Rider, LG AF Aggarwal, Rohit Ruperto, Nicolino Erman, Brian Feroz, Saad Vencovsky, Jiri Huber, Adam Oliveira, Sheila K. Pistorio, Angela Pilkington, Clarissa Ravelli, Angelo Feldman, Brian M. Rockette, Howard Miller, Frederick W. Lachenbruch, Peter A. Rider, Lisa G. TI Good Inter-Rater Reliability Of Myositis Experts In Assessing Clinical Improvement SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Aggarwal, Rohit; Rockette, Howard] Univ Pittsburgh, Pittsburgh, PA USA. [Ruperto, Nicolino] IRCCS G Gaslini, PRINTO, Genoa, Italy. [Erman, Brian] NIH, Bethesda, DC USA. [Feroz, Saad; Miller, Frederick W.; Lachenbruch, Peter A.; Rider, Lisa G.] NIEHS, NIH, Bethesda, MD USA. [Vencovsky, Jiri] Inst Rheumatol, Prague, Czech Republic. [Huber, Adam] IWK Hlth Ctr, Halifax, NS, Canada. [Oliveira, Sheila K.] Univ Fed Rio de Janeiro, IPPMG, Rio de Janeiro, Brazil. [Pistorio, Angela] PRINTO, Genoa, Italy. [Pilkington, Clarissa] Great Ormond St Hosp Sick Children, London, England. [Ravelli, Angelo] Ist Giannina Gaslini, I-16148 Genoa, Italy. [Feldman, Brian M.] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. RI Oliveira, Sheila/F-5213-2016 OI Oliveira, Sheila/0000-0002-2426-716X NR 0 TC 0 Z9 0 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2061 BP S879 EP S879 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359205009 ER PT J AU Aranow, C Cush, JJ Bolster, MB Striebich, CC Dall'Era, M Mackay, M Olech, E Frech, TM Box, J Keating, RM Wasko, MCM St Clair, EW Kivitz, A Diamond, B Davidson, A Spychala, M Goldmuntz, EA AF Aranow, Cynthia Cush, John J. Bolster, Marcy B. Striebich, Christopher C. Dall'Era, Maria Mackay, Meggan Olech, Ewa Frech, Tracy M. Box, J. Keating, Richard M. Wasko, Mary Chester M. St Clair, E. William Kivitz, Alan Diamond, Betty Davidson, Anne Spychala, Meagan Goldmuntz, Ellen A. CA Autoimmunity Ctr Excellence TI A Double-Blind Randomized Placebo-Controlled Trial Of Lovastatin in Patients with Rheumatoid Arthritis. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Aranow, Cynthia; Mackay, Meggan; Diamond, Betty; Davidson, Anne] Feinstein Inst Med Res, Manhasset, NY USA. [Cush, John J.] Baylor Res Inst, Dallas, TX USA. [Cush, John J.] Baylor Univ, Med Ctr, Dallas, TX USA. [Bolster, Marcy B.] Med Univ S Carolina, Charleston, SC 29425 USA. [Striebich, Christopher C.] Univ Colorado Denver, Aurora, CO USA. [Dall'Era, Maria] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Olech, Ewa] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. [Frech, Tracy M.] Univ Utah, Sch Med, Salt Lake City, UT USA. [Box, J.] Carolina Bone & Joint, Charlotte, NC USA. [Keating, Richard M.] Univ Chicago, Chicago, IL 60637 USA. [Wasko, Mary Chester M.] Temple Univ, Sch Med, Pittsburgh, PA USA. [St Clair, E. William] Duke Univ, Med Ctr, Durham, NC USA. [Kivitz, Alan] Altoona Ctr Clin Res, Duncansville, PA USA. [Spychala, Meagan] Rho Inc, Chapel Hill, NC USA. [Goldmuntz, Ellen A.] NIAID, NIH, Bethesda, MD 20892 USA. [Autoimmunity Ctr Excellence] NIH, Bethesda, MD 20892 USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2765 BP S1181 EP S1182 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359206194 ER PT J AU Barron, KS Ombrello, AK Goldsmith, DP Aksentijevich, I Jones, A Kastner, DL AF Barron, Karyl S. Ombrello, Amanda K. Goldsmith, Donald P. Aksentijevich, Ivona Jones, Anne Kastner, Daniel L. TI Single MVK Mutation and Recurrent Fevers SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Barron, Karyl S.] NIAID, NIH, Bethesda, MD 20892 USA. [Ombrello, Amanda K.; Aksentijevich, Ivona; Jones, Anne; Kastner, Daniel L.] NHGRI, NIH, Bethesda, MD 20892 USA. [Goldsmith, Donald P.] St Christophers Hosp Children, Drexel Coll Med, Philadelphia, PA 19133 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2172 BP S926 EP S926 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359205120 ER PT J AU Barron, KS Ombrello, AK Aksentijevich, I Jones, A Kastner, DL AF Barron, Karyl S. Ombrello, Amanda K. Aksentijevich, Ivona Jones, Anne Kastner, Daniel L. TI Clinical Variation In Children With Mutations In MEFV SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Barron, Karyl S.] NIAID, NIH, Bethesda, MD 20892 USA. [Ombrello, Amanda K.; Aksentijevich, Ivona; Jones, Anne; Kastner, Daniel L.] NHGRI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1781 BP S758 EP S758 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204240 ER PT J AU Cudrici, C Bourla, A Pelletier, M Billingham, L Ombrello, AK Murphy, M Kastner, DL Siegel, RM AF Cudrici, Cornelia Bourla, Ariel Pelletier, Martin Billingham, Leah Ombrello, Amanda K. Murphy, Michael Kastner, Daniel L. Siegel, Richard M. TI Oxidative Stress As a Disease Marker and Therapeutic Target In Patients With Tumor Necrosis Factor Receptor Associated Periodic Fever Syndrome SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Cudrici, Cornelia; Bourla, Ariel; Pelletier, Martin; Billingham, Leah] Autoimmun Branch, Immunoregulat Sect, Bethesda, MD USA. [Ombrello, Amanda K.; Kastner, Daniel L.] NHGRI, NIH, Bethesda, MD 20892 USA. [Murphy, Michael] Med Res Council Mitochondria Biol Unit Cambridge, Cambridge, England. [Siegel, Richard M.] NIAMSD, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1160 BP S491 EP S492 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359203144 ER PT J AU de Jesus, AA Niemela, J Liu, Y Boyden, S Aksentijevich, I Kastner, DL Fleisher, TA Goldbach-Mansky, R Deng, ZM AF de Jesus, Adriana Almeida Niemela, Julie Liu, Yin Boyden, Steven Aksentijevich, Ivona Kastner, Daniel L. Fleisher, Thomas A. Goldbach-Mansky, Raphaela Deng, Zuoming TI Whole Exome Sequencing In Pediatric Patients With Early Onset Rare Immunodysregulatory Diseases That Present With Fever and Systemic Inflammation SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [de Jesus, Adriana Almeida; Liu, Yin; Goldbach-Mansky, Raphaela; Deng, Zuoming] NIAMSD, NIH, Bethesda, MD 20892 USA. [Niemela, Julie; Fleisher, Thomas A.] NIH, Ctr Clin, Bethesda, MD 20892 USA. [Boyden, Steven; Aksentijevich, Ivona; Kastner, Daniel L.] NHGRI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2864 BP S1227 EP S1228 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359206291 ER PT J AU Edwan, JH Chae, JJ Goldbach-Mansky, RT Colbert, RA AF Edwan, Jehad H. Chae, Jae Jin Goldbach-Mansky, Raphaela T. Colbert, Robert A. TI Evidence That STAT3 controls NLRP3 inflammasome-dependent Release Of IL-1 beta and Pyronecrosis Through Regulation of mitochondrial activity SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Edwan, Jehad H.; Colbert, Robert A.] NIAMS, NIH, Bethesda, MD USA. [Chae, Jae Jin] NHGRI, NIH, Bethesda, MD 20892 USA. [Goldbach-Mansky, Raphaela T.] NIAMSD, NIH, Bethesda, MD 20892 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2741 BP S1170 EP S1170 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359206170 ER PT J AU Endres, T Hofer, F Goldbach-Mansky, RT Hoffman, HM Blank, N Krause, K Rietschel, C Horneff, G Lohse, P Kuemmerle-Deschner, JB AF Endres, Theresa Hofer, Ferdinand Goldbach-Mansky, Raphaela T. Hoffman, Hal M. Blank, Norbert Krause, Karoline Rietschel, Christoph Horneff, Gerd Lohse, Peter Kuemmerle-Deschner, Jasmin B. TI Low-Penetrance NLRP3-Variants SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Endres, Theresa; Hofer, Ferdinand; Kuemmerle-Deschner, Jasmin B.] Univ Tubingen Hosp, Tubingen, Germany. [Goldbach-Mansky, Raphaela T.] NIAMSD, NIH, Bethesda, MD 20892 USA. [Hoffman, Hal M.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Blank, Norbert] Heidelberg Univ, Heidelberg, Germany. [Krause, Karoline] Charite, Dept Dermatol & Allergy, Allergie Ctr Charite, D-13353 Berlin, Germany. [Rietschel, Christoph] Clementine Kinderhosp, Frankfurt, Germany. [Horneff, Gerd] Asklepios Klin St Augustin, St Augustin, Germany. [Lohse, Peter] Inst Lab Med & Humangenet, Singen, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1213 BP S513 EP S513 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359203197 ER PT J AU Fava, A Cimbro, R Rosen, A Liu, QR Wigley, FM Boin, F AF Fava, Andrea Cimbro, Raffaello Rosen, Antony Liu, Qing-Rong Wigley, Fredrick M. Boin, Francesco TI Topoisomerase-1 Specific T Cells Exhibit a Proinflammatory Th17 Phenotype and Are Associated With Interstitial Lung Disease In Scleroderma SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Fava, Andrea; Cimbro, Raffaello; Rosen, Antony] Johns Hopkins Univ, Baltimore, MD USA. [Liu, Qing-Rong] NIDA, NIH, Baltimore, MD USA. [Wigley, Fredrick M.; Boin, Francesco] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 661 BP S283 EP S284 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359202171 ER PT J AU Feroz, S Ruperto, N Vencovsky, J Lachenbruch, PA Erman, B Huber, A Feldman, BM Lundberg, IE Pistorio, A Rockette, H Miller, FW Aggarwal, R Rider, LG Ravelli, A Pilkington, C Oliveira, SK AF Feroz, Saad Ruperto, Nicolino Vencovsky, Jiri Lachenbruch, Peter A. Erman, Brian Huber, Adam Feldman, Brian M. Lundberg, Ingrid E. Pistorio, Angela Rockette, Howard Miller, Frederick W. Aggarwal, Rohit Rider, Lisa G. Ravelli, Angelo Pilkington, Clarissa Oliveira, Sheila K. CA ACR-EULAR Myositis Response TI Developing International Consensus Definitions Of Improvement For Adult and Juvenile Dermatomyositis and Polymyositis SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Feroz, Saad; Lachenbruch, Peter A.; Miller, Frederick W.; Rider, Lisa G.; ACR-EULAR Myositis Response] NIEHS, NIH, Bethesda, MD USA. [Ruperto, Nicolino] IRCCS G Gaslini, PRINTO, Genoa, Italy. [Vencovsky, Jiri] Charles Univ Prague, Fac Med 1, Dept Clin & Expt Rheumatol, Inst Rheumatol, Prague, Czech Republic. [Erman, Brian] SRA Int, Res Triangle Pk, NC USA. [Huber, Adam] IWK Hlth Ctr, Halifax, NS, Canada. [Feldman, Brian M.] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Lundberg, Ingrid E.] Karolinska Inst, Karolinska Univ Hosp Solna, Dept Med, Rheumatol Unit, Stockholm, Sweden. [Pistorio, Angela] PRINTO, Genoa, Italy. [Rockette, Howard; Aggarwal, Rohit] Univ Pittsburgh, Pittsburgh, PA USA. [Ravelli, Angelo] Ist Giannina Gaslini, Paediat Rheumatol Int Trials Org PRINTO, I-16148 Genoa, Italy. [Pilkington, Clarissa] Great Ormond St Hosp Sick Children, London WC1N 3JH, England. [Oliveira, Sheila K.] Univ Fed Rio de Janeiro, IPPMG, Rio De Janeiro, Brazil. RI Oliveira, Sheila/F-5213-2016 OI Oliveira, Sheila/0000-0002-2426-716X NR 0 TC 1 Z9 1 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1981 BP S844 EP S845 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204439 ER PT J AU Gallo, A Jang, SI Danielides, S Cotrim, AP Alevizos, I AF Gallo, Alessia Jang, Shih-Ing Danielides, Stamatina Cotrim, Ana Paola Alevizos, Ilias TI Comparative Study Of The Transcriptome Of Minor Salivary Gland Of Sjogren's Syndrome Patients Versus Healthy Controls Based On RNA-Seq SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Gallo, Alessia] NIDCR, Bethesda, MD USA. [Jang, Shih-Ing; Danielides, Stamatina; Cotrim, Ana Paola] NIH, Bethesda, MD 20892 USA. [Alevizos, Ilias] NIDCR NIH 10 1N110, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1490 BP S633 EP S633 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359203468 ER PT J AU Gallo, A Tandon, M Danielides, S Cotrim, AP Alevizos, I AF Gallo, Alessia Tandon, Mayank Danielides, Stamatina Cotrim, Ana Paola Alevizos, Ilias TI Discovery and Validation Of Novel Micrornas In Minor Salivary Glands Of Sjogren's Syndrome Patients SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Gallo, Alessia; Tandon, Mayank] NIDCR, Bethesda, MD USA. [Danielides, Stamatina; Cotrim, Ana Paola] NIH, Bethesda, MD 20892 USA. [Alevizos, Ilias] NIDCR NIH 10 1N110, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1491 BP S633 EP S633 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359203469 ER PT J AU Gensler, LS Ward, MM Lee, M Rahbar, M Brown, MA Reveille, JD Weisman, MH AF Gensler, Lianne S. Ward, Michael M. Lee, MinJae Rahbar, Mohammad Brown, Matthew A. Reveille, John D. Weisman, Michael H. TI Cardiovascular Disease Is Associated With Worse Functional Outcomes In Ankylosing Spondylitis SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Gensler, Lianne S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Ward, Michael M.] NIAMS, NIH, Bethesda, MD USA. [Lee, MinJae; Rahbar, Mohammad; Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Brown, Matthew A.] Univ Queensland, Diamantina Inst, Brisbane, Qld, Australia. [Weisman, Michael H.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2448 BP S1047 EP S1047 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359205394 ER PT J AU Gensler, LS Reveille, JD Lee, M Rahbar, M Ardjomand-Hessabi, M Brown, MA Weisman, MH Ward, MM AF Gensler, Lianne S. Reveille, John D. Lee, MinJae Rahbar, Mohammad Ardjomand-Hessabi, Manouchehr Brown, Matthew A. Weisman, Michael H. Ward, Michael M. TI Regular Exercise Is Associated With Better Functional Outcomes In Ankylosing Spondylitis SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Gensler, Lianne S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Reveille, John D.; Lee, MinJae; Rahbar, Mohammad; Ardjomand-Hessabi, Manouchehr] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Brown, Matthew A.] Univ Queensland, Diamantina Inst, Brisbane, Qld, Australia. [Weisman, Michael H.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Ward, Michael M.] NIAMS, NIH, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1542 BP S654 EP S655 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204007 ER PT J AU Grayson, PC Monach, PA Cuthbertson, D Carette, S Hoffman, GS Khalidi, NA Koening, CL Langford, CA Maksimowicz-McKinnon, K Pagnoux, C Seo, P Specks, U Ytterberg, SR Merkel, PA AF Grayson, Peter C. Monach, Paul A. Cuthbertson, David Carette, Simon Hoffman, Gary S. Khalidi, Nader A. Koening, C. L. Langford, Carol A. Maksimowicz-McKinnon, Kathleen Pagnoux, Christian Seo, Philip Specks, Ulrich Ytterberg, Steven R. Merkel, Peter A. TI Clinical Value Of Commonly-Measured Laboratory Tests In Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Grayson, Peter C.] NIH, Bethesda, MD 20892 USA. [Monach, Paul A.] Boston Univ, Boston, MA 02215 USA. [Cuthbertson, David] Univ S Florida, Tampa, FL USA. [Carette, Simon] UHN MSH, Toronto, ON, Canada. [Hoffman, Gary S.] Cleveland Clin Fdn, Cleveland, OH 44195 USA. [Khalidi, Nader A.] McMaster Univ, Hamilton, ON, Canada. [Koening, C. L.] Salt Lake City Vet Adm, Salt Lake City, UT USA. [Langford, Carol A.] Cleveland Clin, Cleveland, OH 44106 USA. [Maksimowicz-McKinnon, Kathleen] Henry Ford Hosp, Detroit, MI 48202 USA. [Pagnoux, Christian] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada. [Seo, Philip] Johns Hopkins Vasculitis Ctr, Baltimore, MD USA. [Specks, Ulrich; Ytterberg, Steven R.] Mayo Clin, Rochester, MN USA. [Merkel, Peter A.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 1 Z9 1 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 756 BP S319 EP S319 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359202261 ER PT J AU Gupta, S Tatouli, IP Rosen, LB Hasni, SA Siegel, RM Holland, SM Moutsopopoulos, HM Browne, SK AF Gupta, Sarthak Tatouli, Ioanna P. Rosen, Lindsey B. Hasni, Sarfaraz A. Siegel, Richard M. Holland, Steven M. Moutsopopoulos, Haralampos M. Browne, Sarah K. TI Rheumatoid Arthritis, Sjogren's Syndrome and Systemic Lupus Erythematosus Patients Have a Distinct Spectrum Of Serum Anticytokine Autoantibodies SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Gupta, Sarthak; Rosen, Lindsey B.; Holland, Steven M.; Browne, Sarah K.] NIAID, NIH, Bethesda, MD 20892 USA. [Tatouli, Ioanna P.; Moutsopopoulos, Haralampos M.] Natl Univ Athens, Sch Med, Athens, Greece. [Hasni, Sarfaraz A.; Siegel, Richard M.] NIAMSD, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1844 BP S787 EP S787 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204303 ER PT J AU Hasni, SA Illei, GG Nikolov, NP Hakim, F Leitman, S Balow, JE Austin, HA Gea-Banacloche, J Oh, U Muraro, P Sportes, C Lipsky, PE Gress, R Pavletic, S Grammer, A AF Hasni, Sarfaraz A. Illei, Gabor G. Nikolov, Nikolay P. Hakim, Francis Leitman, Susan Balow, James E. Austin, Howard A. Gea-Banacloche, Juan Oh, Unsong Muraro, Paulo Sportes, Claude Lipsky, Peter E. Gress, Ronald Pavletic, Steve Grammer, Amrie TI Lymphoablation Including B Cell Depletion and Autologous Hematopoietic Stem Cell Transplantation Leads To Long Remissions In Treatment-Resistant Systemic Lupus Erythematosus Patients SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Hasni, Sarfaraz A.] NIAMSD, NIH, Bethesda, MD 20892 USA. [Illei, Gabor G.; Nikolov, Nikolay P.] NIDCR, NIH, Bethesda, MD USA. [Hakim, Francis; Leitman, Susan; Gea-Banacloche, Juan; Sportes, Claude; Gress, Ronald; Pavletic, Steve] NCI, NIH, Bethesda, MD 20892 USA. [Balow, James E.] NIH, Bethesda, MD 20892 USA. [Austin, Howard A.] NIDDK, NIH, Bethesda, MD 20892 USA. [Oh, Unsong; Muraro, Paulo] NINDS, NIH, Bethesda, MD 20892 USA. [Lipsky, Peter E.; Grammer, Amrie] NIAMS, NIH, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1610 BP S683 EP S684 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204074 ER PT J AU Isenberg, DA Wofsy, D Li, Y Licu, D Wax, SD Gordon, C Rossi, CP AF Isenberg, David A. Wofsy, David Li, Yong Licu, Daiana Wax, Stephen D. Gordon, Caroline Rossi, Claudia Pena TI Pharmacodynamics and Predictive Biomarkers In Patients Treated With Atacicept: Data From The APRIL-SLE Trial SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Isenberg, David A.] UCL, London, England. [Wofsy, David] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Wofsy, David] NIAID Autoimmun Ctr Excellence, San Francisco, CA USA. [Li, Yong; Wax, Stephen D.] EMD Serono, Rockland, MA USA. [Licu, Daiana; Rossi, Claudia Pena] Merck Serono SA, Geneva, Switzerland. [Gordon, Caroline] Univ Birmingham, Birmingham, W Midlands, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2551 BP S1089 EP S1089 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359205496 ER PT J AU Kim, H de Jesus, AA Liu, Y Huang, Y Montealegre, G Chapelle, D Plass, N Tsai, WX Gadina, M Rider, LG Vanderver, A Goldbach-Mansky, R AF Kim, Hanna de Jesus, Adriana Almeida Liu, Yin Huang, Yan Montealegre, Gina Chapelle, Dawn Plass, Nicole Tsai, Wanxia Gadina, Massimo Rider, Lisa G. Vanderver, Adeline Goldbach-Mansky, Raphaela TI Clinical and Immunologic Description Of Pediatric Conditions With Interferon-Regulated Gene Signatures (Chronic Atypical Neutrophilic Dermatosis Lipodystrophy Elevated Tempature, Aicardi Goutieres Syndrome, Juvenile Dermatomyositis, Juvenile Systemic Lupus Erythematosus) SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Kim, Hanna; Huang, Yan; Plass, Nicole; Goldbach-Mansky, Raphaela] NIAMSD, NIH, Bethesda, MD 20892 USA. [de Jesus, Adriana Almeida; Liu, Yin; Montealegre, Gina; Chapelle, Dawn; Tsai, Wanxia] NIAMS, NIH, Bethesda, MD USA. [Gadina, Massimo] NIAMSD, Bethesda, MD 20892 USA. [Rider, Lisa G.] NIEHS, NIH, Bethesda, MD USA. [Vanderver, Adeline] Childrens Natl Med Ctr, Washington, DC 20010 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2190 BP S933 EP S934 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359205138 ER PT J AU Kwon, G Yang, E Sikora, KA Srinivasalu, H Layh-Schmitt, G Colbert, RA AF Kwon, Grace Yang, Eva Sikora, Keith A. Srinivasalu, Hemalatha Layh-Schmitt, Gerlinde Colbert, Robert A. TI Evidence For Enhanced Induction Of Unfolded Protein Response Target Genes In Peripheral Blood Mononuclear Cells From Spondyloarthritis Patients SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Kwon, Grace; Yang, Eva; Sikora, Keith A.; Srinivasalu, Hemalatha; Layh-Schmitt, Gerlinde; Colbert, Robert A.] NIAMS NIH, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 525 BP S230 EP S231 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359202038 ER PT J AU Mamyrova, G Rider, LG Jones, O Ehrlich, A Pachman, LM Nickeson, R Criscione-Schreiber, LG Miller, FW Jung, LK Katz, JD AF Mamyrova, Gulnara Rider, Lisa G. Jones, Olcay Ehrlich, Alison Pachman, Lauren M. Nickeson, Robert Criscione-Schreiber, Lisa G. Miller, Frederick W. Jung, Lawrence K. Katz, James D. TI Environmental Factors Associated With Disease Flare In Juvenile and Adult Dermatomyositis SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Mamyrova, Gulnara; Ehrlich, Alison; Katz, James D.] George Washington Univ, Washington, DC USA. [Rider, Lisa G.; Miller, Frederick W.] NIEHS, NIH, Bethesda, MD USA. [Jones, Olcay] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA. [Pachman, Lauren M.] Northwestern Univ, Feinberg Sch Med, Div Pediat Rheumatol, Chicago, IL 60611 USA. [Nickeson, Robert] Univ S Florida, All Childrens Hosp, St Petersburg, FL 33701 USA. [Criscione-Schreiber, Lisa G.] Duke Univ, Sch Med, Durham, NC USA. [Jung, Lawrence K.] Childrens Natl Med Ctr, Washington, DC 20010 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2083 BP S888 EP S888 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359205031 ER PT J AU Miloslavsky, E Specks, U Merkel, PA Seo, P Spiera, RF Langford, CA Hoffman, GS Kallenberg, CGM St Clair, EW Tchao, N Ding, L Ikle, D Jepson, B Brunetta, P Stone, JH AF Miloslavsky, Eli Specks, Ulrich Merkel, Peter A. Seo, Philip Spiera, Robert F. Langford, Carol A. Hoffman, Gary S. Kallenberg, Cees G. M. St Clair, E. William Tchao, Nadia Ding, Linna Ikle, David Jepson, Brett Brunetta, Paul Stone, John H. TI Retreatment With Rituximab In The Rituximab In ANCA-Associated Vasculitis (RAVE) Trial SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Miloslavsky, Eli] Massachusetts Gen Hopsital, Boston, MA USA. [Specks, Ulrich] Mayo Clin, Rochester, MN USA. [Merkel, Peter A.] Univ Penn, Philadelphia, PA 19104 USA. [Merkel, Peter A.] VA Med Ctr, Philadelphia, PA USA. [Seo, Philip] Johns Hopkins Vasculitis Ctr, Baltimore, MD USA. [Spiera, Robert F.] Hosp Special Surg, New York, NY 10021 USA. [Langford, Carol A.] Cleveland Clin, Cleveland, OH 44106 USA. [Hoffman, Gary S.] Cleveland Clin Fdn, Cleveland, OH 44195 USA. [Kallenberg, Cees G. M.] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands. [St Clair, E. William] Duke Unvers Med Ctr, Durham, NC USA. [Tchao, Nadia] Immune Tolerance Network, Bethesda, MD USA. [Ding, Linna] NIAID, Bethesda, MD 20892 USA. [Ikle, David; Jepson, Brett] Rho, Chapel Hill, NC USA. [Brunetta, Paul] Genentech Inc, So San Francisco, CA USA. [Stone, John H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2782 BP S1190 EP S1190 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359206211 ER PT J AU Miloslavsky, E Specks, U Merkel, PA Seo, P Spiera, RF Langford, CA Hoffman, GS Kallenberg, CGM St Clair, EW Tchao, N Ding, LN Ikle, D Jepson, B Brunetta, P Stone, JH AF Miloslavsky, Eli Specks, Ulrich Merkel, Peter A. Seo, Philip Spiera, Robert F. Langford, Carol A. Hoffman, Gary S. Kallenberg, Cees G. M. St Clair, E. William Tchao, Nadia Ding, Linna Ikle, David Jepson, Brett Brunetta, Paul Stone, John H. TI Efficacy Of Glucocorticoids To Treat Limited Flares In ANCA-Associated Vasculitis SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Miloslavsky, Eli] Massachusetts Gen Hopsital, Boston, MA USA. [Specks, Ulrich] Mayo Clin, Rochester, MN USA. [Merkel, Peter A.] Univ Penn, Philadelphia, PA 19104 USA. [Seo, Philip] Johns Hopkins Vasculitis Ctr, Baltimore, MD USA. [Spiera, Robert F.] Hosp Special Surg, New York, NY 10021 USA. [Langford, Carol A.] Cleveland Clin, Cleveland, OH 44106 USA. [Hoffman, Gary S.] Cleveland Clin Fdn, Cleveland, OH 44195 USA. [Kallenberg, Cees G. M.] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands. [St Clair, E. William] Duke Univ, Med Ctr, Durham, NC USA. [Tchao, Nadia] Immune Tolerance Network, Bethesda, MD USA. [Ding, Linna] NIAID, Bethesda, MD 20892 USA. [Ikle, David; Jepson, Brett] Rho, Chapel Hill, NC USA. [Brunetta, Paul] Genentech Inc, So San Francisco, CA USA. [Stone, John H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 3 Z9 3 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 747 BP S315 EP S316 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359202252 ER PT J AU Miloslavsky, E Specks, U Merkel, PA Seo, P Spiera, RF Langford, CA Hoffman, GS Kallenberg, CGM St Clair, EW Tchao, N Ding, LN Ikle, D Jepson, B Brunetta, P Stone, JH AF Miloslavsky, Eli Specks, Ulrich Merkel, Peter A. Seo, Philip Spiera, Robert F. Langford, Carol A. Hoffman, Gary S. Kallenberg, Cees G. M. St Clair, E. William Tchao, Nadia Ding, Linna Ikle, David Jepson, Brett Brunetta, Paul Stone, John H. TI Safety Of Remission Induction With Rituximab Versus Cyclosphosphamide In Patients 65 and Older With Severe ANCA-Associated Vasculitis SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Miloslavsky, Eli; Stone, John H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Specks, Ulrich] Mayo Clin, Rochester, MN USA. [Merkel, Peter A.] Univ Penn, Philadelphia, PA 19104 USA. [Merkel, Peter A.] VA Med Ctr, Philadelphia, PA USA. [Seo, Philip] Johns Hopkins Vasculitis Ctr, Baltimore, MD USA. [Spiera, Robert F.] Hosp Special Surg, New York, NY 10021 USA. [Langford, Carol A.] Cleveland Clin, Cleveland, OH 44106 USA. [Hoffman, Gary S.] Cleveland Clin Fdn, Cleveland, OH 44195 USA. [Kallenberg, Cees G. M.] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands. [St Clair, E. William] Duke Univ, Med Ctr, Durham, NC USA. [Tchao, Nadia] Immune Tolerance Network, Bethesda, MD USA. [Ding, Linna] NIAID, Bethesda, MD 20892 USA. [Ikle, David; Jepson, Brett] Rho, Chapel Hill, NC USA. [Brunetta, Paul] Genentech Inc, So San Francisco, CA USA. NR 0 TC 2 Z9 2 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 742 BP S313 EP S313 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359202247 ER PT J AU Ogdie, A Yu, YD Haynes, K Maliha, S Love, T Troxel, A Hennessy, S Margolis, D Kimmel, S Mehta, NN Choi, HK Gelfand, J AF Ogdie, Alexis Yu, Yiding Haynes, Kevin Maliha, Samantha Love, Thorvardur Troxel, Andrea Hennessy, Sean Margolis, David Kimmel, Stephen Mehta, Nehal N. Choi, Hyon K. Gelfand, Joel TI Risk Of Cardiovascular Events In Patients With Psoriatic Arthritis, Psoriasis, and Rheumatoid Arthritis: A General Population-Based Cohort Study SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Ogdie, Alexis; Haynes, Kevin; Maliha, Samantha; Troxel, Andrea; Hennessy, Sean; Margolis, David; Kimmel, Stephen; Gelfand, Joel] Univ Penn, Philadelphia, PA 19104 USA. [Yu, Yiding] Brigham & Womens Hosp, Boston, MA 02115 USA. [Love, Thorvardur] Univ Iceland, Fac Med, Reykjavik, Iceland. [Mehta, Nehal N.] NHLBI, NIH, Bethesda, MD 20892 USA. [Choi, Hyon K.] Boston Univ, Sch Med, Boston, MA 02118 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 303 BP S128 EP S128 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359201302 ER PT J AU Ombrello, AK Barron, KS Hoffmann, PM Jones, A Stone, D Kastner, DL AF Ombrello, Amanda K. Barron, Karyl S. Hoffmann, Patrycja M. Jones, Anne Stone, Deborah Kastner, Daniel L. TI An Escalating Dose Of Anakinra In Patients With Autoinflammatory Disease Is a Safe and Reasonable Therapeutic Option SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Ombrello, Amanda K.; Hoffmann, Patrycja M.; Jones, Anne; Stone, Deborah; Kastner, Daniel L.] NHGRI, NIH, Bethesda, MD 20892 USA. [Barron, Karyl S.] NIAID, NIH, Bethesda, MD 20892 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1203 BP S509 EP S509 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359203187 ER PT J AU Ombrello, MJ Remmers, EF Tachmazidou, I Grom, AA Foll, D Martini, A Gattorno, M Ozen, S Prahalad, S Bohnsack, JF Ilowite, NT Mellins, ED Russo, RAG Len, CA Oliveira, SK Yeung, RSM Wedderburn, LR Anton, J Langefeld, CD Thompson, SD Zeggini, E Thomson, W Kastner, DL Woo, P AF Ombrello, Michael J. Remmers, Elaine F. Tachmazidou, Ioanna Grom, Alexei A. Foell, Dirk Martini, Alberto Gattorno, Marco Ozen, Seza Prahalad, Sampath Bohnsack, John F. Ilowite, Norman T. Mellins, Elizabeth D. Russo, Ricardo A. G. Len, Claudio A. Oliveira, Sheila K. Yeung, Rae S. M. Wedderburn, Lucy R. Anton, Jordi Langefeld, Carl D. Thompson, Susan D. Zeggini, Eleftheria Thomson, Wendy Kastner, Daniel L. Woo, Patricia CA Int Childhood Arthrit Genetics TI Genome Wide Association Meta-Analysis Implicates HLA-DRB1, The BTNL2/HLA-DRA region, and a Novel Susceptibility Locus On Chromosome 1 In Systemic Juvenile Idiopathic Arthritis SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Ombrello, Michael J.] NIAMSD, NIH, Bethesda, MD 20892 USA. [Remmers, Elaine F.; Kastner, Daniel L.] NHGRI, NIH, Bethesda, MD 20892 USA. [Tachmazidou, Ioanna; Zeggini, Eleftheria] Wellcome Trust Sanger Inst, Cambridge, England. [Grom, Alexei A.; Thompson, Susan D.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Foell, Dirk] Univ Munster, D-48149 Munster, Germany. [Martini, Alberto] Ist Giannina Gaslini, I-16148 Genoa, Italy. [Gattorno, Marco] G Gaslini Inst Children, Genoa, Italy. [Ozen, Seza] Hacettepe Univ, Ankara, Turkey. [Prahalad, Sampath] Emory Childrens Ctr, Atlanta, GA USA. [Bohnsack, John F.] Univ Utah, Salt Lake City, UT USA. [Ilowite, Norman T.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Mellins, Elizabeth D.] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Russo, Ricardo A. G.] Hosp Pediat Garrahan, Buenos Aires, DF, Argentina. [Len, Claudio A.] Univ Fed Sao Paulo UNIFESP, Sao Paulo, Brazil. [Oliveira, Sheila K.] Univ Fed Rio de Janeiro, IPPMG, Rio De Janeiro, Brazil. [Yeung, Rae S. M.] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Yeung, Rae S. M.] Univ Toronto, Toronto, ON, Canada. [Wedderburn, Lucy R.] UCL, Great Ormond St Hosp Children, Arthrit Res UK Ctr Adolescent Rheumatol, London, England. [Wedderburn, Lucy R.] UCL, UCLH, London, England. [Anton, Jordi] Hosp St Joan de Deu, Barcelona, Spain. [Langefeld, Carl D.] Wake Forest Sch Med, Winston Salem, NC USA. [Thomson, Wendy] Univ Manchester, Manchester Acad Hlth Sci Ctr, Inst Inflammat & Repair, Arthrit Res UK Epidemiol Unit, Manchester, Lancs, England. [Woo, Patricia] UCL, London, England. [Int Childhood Arthrit Genetics] INCHARGE, London, England. RI Oliveira, Sheila/F-5213-2016 OI Oliveira, Sheila/0000-0002-2426-716X NR 0 TC 2 Z9 2 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2198 BP S937 EP S937 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359205146 ER PT J AU Ombrello, MJ Kirino, Y de Bakker, P Gul, A Remmers, EF Kastner, DL AF Ombrello, Michael J. Kirino, Yohei de Bakker, Paul Gul, Ahmet Remmers, Elaine F. Kastner, Daniel L. TI Major Histocompatibility Complex Class I Molecules Contribute To Behcet's Disease Risk Through Both Innate and Adaptive Immune Interactions SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Ombrello, Michael J.] NIAMSD, NIH, Bethesda, MD 20892 USA. [Kirino, Yohei; Remmers, Elaine F.; Kastner, Daniel L.] NHGRI, NIH, Bethesda, MD 20892 USA. [de Bakker, Paul] Univ Med Ctr Utrecht, Utrecht, Netherlands. [Gul, Ahmet] Istanbul Univ, Istanbul Fac Med, Istanbul, Turkey. RI de Bakker, Paul/B-8730-2009; zhang, jun/D-7782-2015 OI de Bakker, Paul/0000-0001-7735-7858; NR 0 TC 0 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1879 BP S800 EP S801 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204338 ER PT J AU Parks, CG D'Aloisio, A Sandler, D AF Parks, Christine G. D'Aloisio, Aimee Sandler, Dale TI Perinatal and Early Life Risk Factors For Systemic Lupus Erythematosus In a National Cohort Of Women SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Parks, Christine G.; D'Aloisio, Aimee; Sandler, Dale] NIEHS, NIH, Res Triangle Pk, NC 27709 USA. NR 0 TC 1 Z9 1 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1059 BP S452 EP S452 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359203045 ER PT J AU Patwardhan, A Lintner, K Rider, LG Miller, FW O'Hanlon, T Wu, YL Zhou, B Wang, HY Newsom, D White, P Spencer, CH Yu, CY AF Patwardhan, Anjali Lintner, Katherine Rider, Lisa G. Miller, Frederick W. O'Hanlon, Terrance Wu, Yee Ling Zhou, Bi Wang, Huanyu Newsom, David White, Peter Spencer, Charles H. Yu, C. Yung TI Copy Number Variations Of Complement C4A and C4B Genes Are Genetic Risk Factor and Disease Modification Factor, Respectively, For Juvenile Dermatomyositis SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Patwardhan, Anjali; Lintner, Katherine; Wu, Yee Ling; Zhou, Bi; Wang, Huanyu; Newsom, David; White, Peter; Yu, C. Yung] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA. [Patwardhan, Anjali; Lintner, Katherine; Wu, Yee Ling; Zhou, Bi; Wang, Huanyu; Newsom, David; White, Peter; Yu, C. Yung] Ohio State Univ, Columbus, OH 43210 USA. [Rider, Lisa G.; Miller, Frederick W.; O'Hanlon, Terrance] NIEHS, NIH, Bethesda, MD USA. [Spencer, Charles H.] Nationwide Childrens Hosp, Columbus, OH USA. RI Yu, Chack-Yung/E-4360-2011 NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2863 BP S1227 EP S1227 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359206290 ER PT J AU Perez-Aso, M Fernandez, P Mediero, A Chan, ESL Cronstein, BN AF Perez-Aso, Miguel Fernandez, Patricia Mediero, Aranzazu Chan, Edwin S. L. Cronstein, Bruce N. TI Adenosine 2A Receptor Promotes Collagen Production By Human Fibroblasts Via Smad2/3-Independent Pathways Involving Cyclic AMP and AKT SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Perez-Aso, Miguel; Mediero, Aranzazu; Chan, Edwin S. L.] NYU, Sch Med, New York, NY USA. [Fernandez, Patricia] NCI, NIH, Bethesda, MD 20892 USA. [Cronstein, Bruce N.] NYU, Sch Med, Div Rheumatol, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1851 BP S790 EP S790 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204310 ER PT J AU Reveille, JD Ward, MM Lee, M Rahbar, M Ardjomand-Hessabi, M Diekman, LA Brown, MA Gensler, LS Weisman, MH AF Reveille, John D. Ward, Michael M. Lee, MinJae Rahbar, Mohammad Ardjomand-Hessabi, Manouchehr Diekman, Laura A. Brown, Matthew A. Gensler, Lianne S. Weisman, Michael H. TI Opiate Use In Patients With Ankylosing Spondylitis SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Reveille, John D.; Lee, MinJae; Rahbar, Mohammad; Ardjomand-Hessabi, Manouchehr; Diekman, Laura A.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Ward, Michael M.] NIAMS, NIH, Bethesda, MD USA. [Brown, Matthew A.] Univ Queensland, Diamantina Inst, Brisbane, Qld, Australia. [Gensler, Lianne S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Weisman, Michael H.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2446 BP S1046 EP S1046 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359205392 ER PT J AU Ringold, S Weiss, PF Colbert, RA DeWitt, EM Lee, TC Onel, K Prahalad, S Schneider, R Shenoi, S Vehe, RK Kimura, Y AF Ringold, Sarah Weiss, Pamela F. Colbert, Robert A. DeWitt, Esi Morgan Lee, Tzielan C. Onel, Karen Prahalad, Sampath Schneider, Rayfel Shenoi, Susan Vehe, Richard K. Kimura, Yukiko TI Childhood Arthritis and Rheumatology Research Alliance (CARRA) Standardized Consensus Treatment Plans for New Onset Polyarticular Juvenile Idiopathic Arthritis SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Ringold, Sarah] Seattle Childrens Hosp, Seattle, WA USA. [Weiss, Pamela F.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Colbert, Robert A.] NIAMS, NIH, Bethesda, MD USA. [DeWitt, Esi Morgan] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Lee, Tzielan C.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Onel, Karen] PRCSG, Cincinnati, OH USA. [Prahalad, Sampath] Emory Childrens Ctr, Atlanta, GA USA. [Schneider, Rayfel] PRCSG, Cincinnati, OH USA. [Shenoi, Susan] Univ Washington, Seattle Childrens Hosp, Seattle, WA 98195 USA. [Vehe, Richard K.] Univ Minnesota, Minneapolis, MN USA. [Kimura, Yukiko] Hackensack Univ, Med Ctr, Joseph M Sanzari Childrens Hosp, Hackensack, NJ USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 277 BP S116 EP S116 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359201276 ER PT J AU Sanchez, GAM Reinhardt, AL Brogan, P Berkun, Y Brown, D Chira, P Gao, L Chapelle, DC Plass, N Kim, H Davis, M de Jesus, AA Liu, Y Huang, Y Hadigan, C Heller, T Zlotogorski, Z O'Shea, JJ Lee, CC Hill, SC Rother, K Gadina, M Goldbach-Mansky, RT AF Sanchez, Gina A. Montealegre Reinhardt, Adam L. Brogan, Paul Berkun, Yackov Brown, Diane Chira, Peter Gao, Ling Chapelle, Dawn C. Plass, Nicole Kim, Hanna Davis, Michael de Jesus, Adriana Almeida Liu, Yin Huang, Yan Hadigan, Colleen Heller, Theo Zlotogorski, Zlotogorski O'Shea, John J. Lee, Chyi-chia Hill, Suvimol C. Rother, Kristina Gadina, Massimo Goldbach-Mansky, Raphaela T. TI Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperatures (CANDLE): Clinical Characterization and Initial Response To Janus Kinase Inhibition With Baricitinib SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Sanchez, Gina A. Montealegre; Chapelle, Dawn C.; Plass, Nicole; Kim, Hanna; Davis, Michael; de Jesus, Adriana Almeida; Liu, Yin; Huang, Yan; O'Shea, John J.; Gadina, Massimo; Goldbach-Mansky, Raphaela T.] NIAMSD, NIH, Bethesda, MD 20892 USA. [Reinhardt, Adam L.] Childrens Hosp Omaha UNMC, Omaha, NE USA. [Brogan, Paul] Ist Giannina Gaslini, Paediat Rheumatol Int Trials Org PRINTO, I-16148 Genoa, Italy. [Berkun, Yackov] Hadassah Med Ctr, IL-91120 Jerusalem, Israel. [Brown, Diane] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Chira, Peter] Indiana Univ Sch Med, Riley Hosp Children, Indianapolis, IN 46202 USA. [Gao, Ling] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. [Hadigan, Colleen] NIAID, NIH, Bethesda, MD 20892 USA. [Heller, Theo; Rother, Kristina] NIDDK, NIH, Bethesda, MD USA. [Zlotogorski, Zlotogorski] Hadassah Hebrew Univ Med Ctr, Dept Dermatol, Jerusalem, Israel. [Lee, Chyi-chia] NCI, NIH, Bethesda, MD 20892 USA. [Hill, Suvimol C.] NIH, Ctr Clin, Bethesda, MD 20892 USA. NR 0 TC 1 Z9 1 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1782 BP S758 EP S759 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204241 ER PT J AU Saxena, P Loeser, RF Pathmasiri, W Sumner, S Beavers, D Hunter, DJ Messier, SP AF Saxena, Puja Loeser, Richard F. Pathmasiri, Wimal Sumner, Susan Beavers, Daniel Hunter, David J. Messier, Stephen P. TI Metabolomics For The Identification Of Urinary Biomarkers In Knee Osteoarthritis Progression. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Saxena, Puja; Beavers, Daniel] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA. [Loeser, Richard F.] Wake Forest Sch Med, Winston Salem, NC USA. [Pathmasiri, Wimal; Sumner, Susan] NIH Eastern Reg Comprehens Metabol Resource Core, Res Triangle Pk, NC USA. [Hunter, David J.] Univ Sydney, Sydney, NSW 2006, Australia. [Messier, Stephen P.] Wake Forest Univ, Winston Salem, NC 27109 USA. RI Beavers, Daniel/G-5338-2016 NR 0 TC 0 Z9 0 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2757 BP S1177 EP S1177 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359206186 ER PT J AU Schiffenbauer, A Turkbey, E Rider, LG Hill, S Whitt, IZ Liu, ST Bluemke, DA Miller, FW AF Schiffenbauer, Adam Turkbey, Evrim Rider, Lisa G. Hill, Suvimol Whitt, Irene Z. Liu, Songtao Bluemke, David A. Miller, Frederick W. TI Comparison Of Whole Body Versus Targeted Magnetic Resonance Imaging For Assessing Disease Activity and Damage In Idiopathic Inflammatory Myopathies. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Schiffenbauer, Adam; Rider, Lisa G.; Miller, Frederick W.] NIEHS, NIH, Bethesda, MD USA. [Turkbey, Evrim; Hill, Suvimol; Liu, Songtao; Bluemke, David A.] NIH, Bethesda, MD 20892 USA. [Whitt, Irene Z.] Duke, Durham, NC USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 222 BP S90 EP S91 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359201221 ER PT J AU Schwartz, DM Wang, RS Barron, KS Kastner, DL Ombrello, AK AF Schwartz, Daniella M. Wang, Runsheng Barron, Karyl S. Kastner, Daniel L. Ombrello, Amanda K. TI The Interleukin-1 Receptor Antagonist Anakinra Is Effective In The Treatment Of Undifferentiated Periodic Fever Syndromes SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Schwartz, Daniella M.] NIAMSD, NIH, Bethesda, MD 20892 USA. [Wang, Runsheng] NIAMS, NIH, Rheumatol Fellowship & Training Branch, Bethesda, MD USA. [Barron, Karyl S.] NIAID, NIH, Bethesda, MD 20892 USA. [Kastner, Daniel L.; Ombrello, Amanda K.] NHGRI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2173 BP S926 EP S927 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359205121 ER PT J AU Shahzad, A Jafri, F Rizvi, B Zhao, XC Waldman, M Hasni, SA AF Shahzad, Ali Jafri, Farheen Rizvi, Bisharah Zhao, Xiongce Waldman, Meryl Hasni, Sarfaraz A. TI Cyclophosphamide and Rituximab Combination Treatment For Severe Systemic Lupus erythematosus is Effective and Well Tolerated SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Shahzad, Ali] NIAMS, NIH, Bethesda, MD USA. [Jafri, Farheen; Rizvi, Bisharah] R Res, Hamilton, NJ USA. [Zhao, Xiongce; Waldman, Meryl] NIDDK, NIH, Bethesda, MD USA. [Hasni, Sarfaraz A.] NIAMSD, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1559 BP S662 EP S662 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204024 ER PT J AU Sharif, R Parekh, TM Gensler, LS Lee, M Rahbar, M Diekman, LA Weisman, MH Ward, MM Assassi, S Reveille, JD AF Sharif, Roozbeh Parekh, Trisha M. Gensler, Lianne S. Lee, MinJae Rahbar, Mohammad Diekman, Laura A. Weisman, Michael H. Ward, Michael M. Assassi, Shervin Reveille, John D. TI Predictors Of Spinal Mobility Progression In A Multi-ethnic Cohort Of Patients With Ankylosing Spondylitis. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Sharif, Roozbeh; Parekh, Trisha M.] Univ Texas Med Branch, Galveston, TX 77555 USA. [Gensler, Lianne S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Lee, MinJae; Rahbar, Mohammad; Diekman, Laura A.; Assassi, Shervin; Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Weisman, Michael H.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Ward, Michael M.] NIAMS, NIH, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2840 BP S1217 EP S1217 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359206268 ER PT J AU Sibley, C Hatemi, G Yazici, Y Liu, Y Brooks, S Yazici, H Goldbach-Mansky, R AF Sibley, Cailin Hatemi, Gulen Yazici, Yusuf Liu, Yin Brooks, Steve Yazici, Hasan Goldbach-Mansky, Raphaela TI Systems Approach To The Study Of the Microbiome and Inflammatory Pathways In Oral Ulcer Tissue From Patients With Active Behcet's Syndrome (BS) SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Sibley, Cailin; Liu, Yin; Brooks, Steve] NIAMS, NIH, Bethesda, MD USA. [Hatemi, Gulen] Istanbul Univ, Cerrahpasa Med Fac, Istanbul, Turkey. [Yazici, Yusuf] NYU, Hosp Joint Dis, New York, NY USA. [Yazici, Yusuf] NYU, Sch Med, New York, NY USA. [Yazici, Hasan] Istanbul Univ, Cerrahpasa Med Fac, Istanbul, Turkey. [Goldbach-Mansky, Raphaela] NIAMSD, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 1 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1165 BP S493 EP S493 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359203149 ER PT J AU Takeuchi, M Mizuki, N Meguro, A Ombrello, MJ Satorius, C Kirino, Y Kawagoe, T Ustek, D Tugal-tutkun, I Seyahi, E Ozyazgan, Y Ohno, S Ueda, A Ishigatsubo, Y Gul, A Kastner, DL Remmers, E AF Takeuchi, Masaki Mizuki, Nobuhisa Meguro, Akira Ombrello, Michael J. Satorius, Colleen Kirino, Yohei Kawagoe, Tatsukata Ustek, Duran Tugal-tutkun, Ilknur Seyahi, Emire Ozyazgan, Yilmaz Ohno, Shigeaki Ueda, Atsuhisa Ishigatsubo, Yoshiaki Gul, Ahmet Kastner, Daniel L. Remmers, Elaine TI High Density Genotyping Of Immune-Related Disease Genes Identifies 7 New Susceptibility Loci For Behcets Disease SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Takeuchi, Masaki; Satorius, Colleen; Kastner, Daniel L.; Remmers, Elaine] NHGRI, NIH, Bethesda, MD 20892 USA. [Mizuki, Nobuhisa; Meguro, Akira; Kirino, Yohei; Kawagoe, Tatsukata; Ueda, Atsuhisa; Ishigatsubo, Yoshiaki] Yokohama City Univ, Grad Sch Med, Yokohama, Kanagawa 232, Japan. [Ombrello, Michael J.] NIAMSD, NIH, Bethesda, MD 20892 USA. [Ustek, Duran] Istanbul Univ, Inst Expt Med, Istanbul, Turkey. [Tugal-tutkun, Ilknur; Gul, Ahmet] Istanbul Univ, Istanbul Fac Med, Istanbul, Turkey. [Seyahi, Emire; Ozyazgan, Yilmaz] Istanbul Univ, Cerrahpasa Fac Med, Istanbul, Turkey. [Ohno, Shigeaki] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido 060, Japan. RI Ustek, Duran/C-3484-2009 OI Ustek, Duran/0000-0002-0060-2859 NR 0 TC 0 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1703 BP S721 EP S722 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204164 ER PT J AU Tan, S Dasgupta, A Yao, JH Flynn, JA Yao, L Ward, MM AF Tan, Sovira Dasgupta, Abhijit Yao, Jianhua Flynn, John A. Yao, Lawrence Ward, Michael M. TI Syndesmophyte Distribution Along The Vertebral Rim In Ankylosing Spondylitis Is Non-Random SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Tan, Sovira; Dasgupta, Abhijit; Ward, Michael M.] NIAMS, NIH, Bethesda, MD USA. [Yao, Jianhua; Yao, Lawrence] NIH, Ctr Clin, Bethesda, MD 20892 USA. [Flynn, John A.] Johns Hopkins Univ, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2434 BP S1040 EP S1040 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359205380 ER PT J AU Teos, LY Swaim, B Cotrim, AP Grisius, M Bebris, L Ambudkar, I Illei, GG Alevizos, I AF Teos, Leyla Y. Swaim, Bill Cotrim, Ana Paola Grisius, Margaret Bebris, Lolita Ambudkar, Indu Illei, Gabor G. Alevizos, Ilias TI Hypofunction In Intact Cell Lobules Reflect Salivary Flow Rates In Sjogren's Patients SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Teos, Leyla Y.; Cotrim, Ana Paola; Grisius, Margaret] NIH, Bethesda, MD 20892 USA. [Swaim, Bill; Bebris, Lolita] NIDCR, NIH, Bethesda, MD USA. [Ambudkar, Indu] NIDCR, Bethesda, MD USA. [Illei, Gabor G.] MedImmune LLC, Gaithersburg, MD USA. [Alevizos, Ilias] NIDCR NIH 10 1N110, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1498 BP S635 EP S635 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359203475 ER PT J AU Tran, TM Hong, S Colbert, RA AF Tran, Tri M. Hong, Sohee Colbert, Robert A. TI Effects Of ERAP1 Knockdown On HLA Class I and HLA-B27 Expression In Human Monocytic U937 Cells SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Tran, Tri M.; Hong, Sohee; Colbert, Robert A.] NIAMS NIH, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 539 BP S235 EP S236 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359202051 ER PT J AU Wang, RS Meylan, F Zou, JZ Rao, M Siegel, RM AF Wang, Runsheng Meylan, Francoise Zou, Jizhong Rao, Mahendra Siegel, Richard M. TI Mesenchymal Stem Cells and Skin Fibroblasts Both Suppress Early Steps In T Cell Activation In a Nitric-Oxide Dependent Manner SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Wang, Runsheng] NIAMS, NIH, Rheumatol Fellowship & Training Branch, Bethesda, MD USA. [Meylan, Francoise] NIAMS, NIH, Autoimmun Branch, Bethesda, MD USA. [Zou, Jizhong; Rao, Mahendra] NIAMS, NIH, Ctr Regenerat Med, Bethesda, MD USA. [Siegel, Richard M.] NIAMSD, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 718 BP S304 EP S305 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359202224 ER PT J AU Weiss, PF Chauvin, N Klink, AJ Localio, RA Feudtner, C Jaramillo, D Colbert, RA Sherry, DD Keren, R AF Weiss, Pamela F. Chauvin, Nancy Klink, Andrew J. Localio, Russell A. Feudtner, Chris Jaramillo, Diego Colbert, Robert A. Sherry, David D. Keren, Ron TI Detection Of Enthesitis In Children With Enthesitis-Related Arthritis: Dolorimeter Examination Compared To Ultrasonography SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Weiss, Pamela F.; Chauvin, Nancy; Klink, Andrew J.; Jaramillo, Diego; Sherry, David D.; Keren, Ron] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Localio, Russell A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Feudtner, Chris] Childrens Hosp Philadelphia, Div Gen Pediat, Philadelphia, PA 19104 USA. [Feudtner, Chris] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Colbert, Robert A.] NIAMS, NIH, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1715 BP S726 EP S727 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204175 ER PT J AU Wessel, A Hsu, A Zilberman-Rudenko, J Goldbach-Mansky, R Siegel, RM Hanson, E AF Wessel, Alex Hsu, Amy Zilberman-Rudenko, Jevgenia Goldbach-Mansky, Raphaela Siegel, Richard M. Hanson, Eric TI Inflammatory Disease Due To Dysregulated Nuclear Factor-kappa B Activation and Impaired Type I Interferon Response Resulting From a De Novo Human NEMO Hypomorphic Mutation SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Wessel, Alex; Zilberman-Rudenko, Jevgenia; Goldbach-Mansky, Raphaela; Siegel, Richard M.; Hanson, Eric] NIAMSD, NIH, Bethesda, MD 20892 USA. [Hsu, Amy] NIAID, Lab Clin Infect Dis, Bethesda, MD 20892 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 764 BP S323 EP S323 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359202269 ER PT J AU Wofsy, D Isenberg, DA Licu, D Li, Y Rossi, CP Gordon, C AF Wofsy, David Isenberg, David A. Licu, Daiana Li, Yong Rossi, Claudia Pena Gordon, Caroline TI Efficacy and Safety Of Atacicept For Prevention Of Flares In Subjects With Moderate To Severe Systemic Lupus Erythematosus (SLE) SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Wofsy, David] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Wofsy, David] NIAID, Autoimmun Ctr Excellence, San Francisco, CA USA. [Isenberg, David A.] UCL, London, England. [Licu, Daiana; Rossi, Claudia Pena] Merck Serono SA, Geneva, Switzerland. [Li, Yong] EMD Serono, Rockland, MA USA. [Gordon, Caroline] Univ Birmingham, Birmingham, W Midlands, England. NR 0 TC 3 Z9 3 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1591 BP S675 EP S675 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204055 ER PT J AU Wofsy, D Askanase, A Cagnoli, PC Chatham, WW Contreras, G Dall'Era, M Dooley, MA Fragoso-Loyo, H Karp, DR Jolly, M Kalunian, K Kamen, DL Lee, I Levesque, MC Lim, SS Mackay, M Ramos-Remus, C Rovin, BH Utset, TO Venuturupalli, S Winchester, R Ding, LN Gao, WD Keyes-Elstein, L Tosta, P AF Wofsy, David Askanase, Anca Cagnoli, Patricia C. Chatham, W. Winn Contreras, Gabriel Dall'Era, Maria Dooley, Mary Anne Fragoso-Loyo, Hilda Karp, David R. Jolly, Meenakshi Kalunian, Kenneth Kamen, Diane L. Lee, Iris Levesque, Marc C. Lim, S. Sam Mackay, Meggan Ramos-Remus, Cesar Rovin, Brad H. Utset, Tammy O. Venuturupalli, Swamy Winchester, Robert Ding, Linna Gao, Wendy Keyes-Elstein, Lynette Tosta, Patti TI Treatment Of Lupus Nephritis With Abatacept Plus Low-Dose Pulse Cyclophosphamide Followed By Azathioprine (the Euro-Lupus Regimen): Twenty-Four Week Data From a Double-Blind Controlled Trial SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Wofsy, David] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Wofsy, David] NIAID Autoimmun Ctr Excellence, San Francisco, CA USA. [Askanase, Anca] NYU, Sch Med, New York, NY USA. [Cagnoli, Patricia C.] Univ Michigan Hlth, Ann Arbor, MI USA. [Chatham, W. Winn; Tosta, Patti] Univ Alabama Birmingham, Birmingham, AL USA. [Contreras, Gabriel] Univ Miami, Miami, FL USA. [Dall'Era, Maria] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Dooley, Mary Anne] Univ N Carolina, Chapel Hill, NC USA. [Fragoso-Loyo, Hilda] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico. [Karp, David R.] UT Southwestern Med Ctr, Dallas, TX USA. [Karp, David R.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Jolly, Meenakshi] UCSD Sch Med, La Jolla, CA USA. [Kalunian, Kenneth] Med Univ S Carolina, Charleston, SC 29425 USA. [Kamen, Diane L.] Temple Univ, Philadelphia, PA 19122 USA. [Lee, Iris] Univ Pittsburgh, Pittsburgh, PA USA. [Levesque, Marc C.] Emory Univ, Atlanta, GA 30322 USA. [Lim, S. Sam] Feinstein Inst Med Res, Manhasset, NY USA. [Mackay, Meggan] Unidad Invest Enfermedades Cronicodegenerat, Guadalajara, Mexico. [Ramos-Remus, Cesar] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. [Rovin, Brad H.] Univ Chicago, Dept Med, Chicago, IL 60637 USA. [Utset, Tammy O.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Venuturupalli, Swamy] Columbia Univ, New York, NY USA. [Winchester, Robert; Ding, Linna; Gao, Wendy] NIAID, Bethesda, MD 20892 USA. [Keyes-Elstein, Lynette] Rho Fed Syst Inc, Chapel Hill, NC USA. [Tosta, Patti] Immune Tolerance Network, San Francisco, CA USA. NR 0 TC 7 Z9 7 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 884 BP S379 EP S380 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359202389 ER PT J AU Yang, E Kwon, G Colbert, RA Layh-Schmitt, G AF Yang, Eva Kwon, Grace Colbert, Robert A. Layh-Schmitt, Gerlinde TI HLA-B27 Expression Prevents Tnf alpha-Induced Inhibition Of Bone Formation in Vitro In IFN gamma/Tnf alpha-Treated Osteoblasts. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Yang, Eva; Kwon, Grace; Colbert, Robert A.; Layh-Schmitt, Gerlinde] NIAMS, NIH, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2694 BP S1151 EP S1152 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359206124 ER PT J AU Zhou, Q Yang, D Zavialov, A Ombrello, A Kuehn, H Chae, JJ Zavialov, A Chin, D Stone, D Toro, C Milner, J Lee, CC Cowen, E Candotti, F Remmers, E Moir, S Sood, R Burgess, S Gadina, M Rosenzweig, S Hershfield, M Kastner, DL Boehm, M Aksentijevich, I AF Zhou, Qing Yang, Dan Zavialov, Andrey Ombrello, Amanda Kuehn, Hyesun Chae, Jae Jin Zavialov, Anton Chin, David Stone, Deborah Toro, Camilo Milner, Joshua Lee, Chyi-chia Cowen, Edward Candotti, Fabio Remmers, Elaine Moir, Susan Sood, Raman Burgess, Shawn Gadina, Massimo Rosenzweig, Sergio Hershfield, Michael Kastner, Daniel L. Boehm, Manfred Aksentijevich, Ivona TI Intermittent Fever, Immune Dysregulation, and Systemic Vasculopathy Due To Loss-Of-Function Mutations In Adenosine Deaminase2 SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Zhou, Qing; Ombrello, Amanda; Chae, Jae Jin; Chin, David; Stone, Deborah; Toro, Camilo; Candotti, Fabio; Remmers, Elaine; Sood, Raman; Burgess, Shawn; Kastner, Daniel L.; Aksentijevich, Ivona] NHGRI, NIH, Bethesda, MD 20892 USA. [Yang, Dan; Boehm, Manfred] NHLBI, NIH, Bethesda, MD 20892 USA. [Zavialov, Andrey; Zavialov, Anton] Univ Turku, Turku, Finland. [Kuehn, Hyesun] NIH, Ctr Clin, Bethesda, MD 20892 USA. [Milner, Joshua; Moir, Susan; Rosenzweig, Sergio] NIAID, NIH, Bethesda, MD 20892 USA. [Lee, Chyi-chia; Cowen, Edward] NCI, NIH, Bethesda, MD 20892 USA. [Gadina, Massimo] NIAMSD, Bethesda, MD 20892 USA. [Hershfield, Michael] Duke Univ, Med Ctr, Durham, NC USA. RI Zavialov, Anton/C-7664-2015 OI Zavialov, Anton/0000-0001-6191-5931 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 894 BP S383 EP S384 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359202399 ER PT J AU Schweitzer, CJ Liang, TJ AF Schweitzer, Cameron J. Liang, T. Jake TI Impact of host and virus genome variability on HCV replication and response to interferon SO CURRENT OPINION IN VIROLOGY LA English DT Article ID HEPATITIS-C-VIRUS; RIBAVIRIN COMBINATION THERAPY; AMINO-ACID SUBSTITUTIONS; NONSTRUCTURAL PROTEIN 5A; CORE PROTEIN; GENETIC-VARIATION; PEGYLATED-INTERFERON; INTERLEUKIN 28B; GENOTYPE 1B; IL28B GENOTYPE AB Since the discovery of hepatitis C virus (HCV), treatment has proven difficult and the regimen of pegylated interferon-alpha and ribavirin is only effective for half of patients. Evidence suggests that host and viral genome variations play a role in either viral clearance or persistence. Powerful genomic technologies have made it possible to study genome-wide associations with treatment response, which yielded critical genetic polymorphisms that predict treatment response. This has important implications for treatment of HCV infection and opened the door to the possibility of genetic marker-guided treatment (personalized medicine). This review will focus on the recent advances in understanding host and viral genetic variations with regards to treatment and the importance for future therapeutic intervention C1 [Schweitzer, Cameron J.; Liang, T. Jake] NIDDK, Liver Dis Branch, NIH, Bethesda, MD USA. RP Schweitzer, CJ (reprint author), NIDDK, Liver Dis Branch, NIH, Bethesda, MD USA. EM cameron.schweitzer@NIH.gov; jakel@bdg10.niddk.nih.gov FU Intramural NIH HHS [Z99 DK999999, ZIA DK054504-16, ZIA DK054511-05, ZIA DK054505-15, ZIA DK054504-15, ZIA DK054511-06, ZIA DK054505-16] NR 76 TC 4 Z9 4 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1879-6257 J9 CURR OPIN VIROL JI Curr. Opin. Virol. PD OCT PY 2013 VL 3 IS 5 BP 501 EP 507 DI 10.1016/j.coviro.2013.06.005 PG 7 WC Virology SC Virology GA 240ZN UT WOS:000326136300004 PM 23835049 ER PT J AU Koonin, EV Dolja, VV AF Koonin, Eugene V. Dolja, Valerian V. TI A virocentric perspective on the evolution of life SO CURRENT OPINION IN VIROLOGY LA English DT Article ID GENOME EVOLUTION; MOBILE ELEMENTS; REPLICATOR SYSTEMS; IMMUNE EVASION; CELLULAR GENES; VIRAL WORLD; DNA VIRUSES; ORIGIN; EUKARYOTES; DIVERSITY AB Viruses and/or virus-like selfish elements are associated with all cellular life forms and are the most abundant biological entities on Earth, with the number of virus particles in many environments exceeding the number of cells by one to two orders of magnitude. The genetic diversity of viruses is commensurately enormous and might substantially exceed the diversity of cellular organisms. Unlike cellular organisms with their uniform replication-expression scheme, viruses possess either RNA or DNA genomes and exploit all conceivable replication-expression strategies. Although viruses extensively exchange genes with their hosts, there exists a set of viral hallmark genes that are shared by extremely diverse groups of viruses to the exclusion of cellular life forms. Coevolution of viruses and host defense systems is a key aspect in the evolution of both viruses and cells, and viral genes are often recruited for cellular functions. Together with the fundamental inevitability of the emergence of genomic parasites in any evolving replicator system, these multiple lines of evidence reveal the central role of viruses in the entire evolution of life. C1 [Koonin, Eugene V.] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA. [Dolja, Valerian V.] Oregon State Univ, Dept Bot & Plant Pathol, Corvallis, OR 97331 USA. [Dolja, Valerian V.] Oregon State Univ, Ctr Genome Res & Biocomp, Corvallis, OR 97331 USA. RP Koonin, EV (reprint author), NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA. EM koonin@ncbi.nlm.nih.gov FU US Department of Health and Human Services FX EVK is supported by intramural funds of the US Department of Health and Human Services (to the National Library of Medicine, NIH). NR 88 TC 48 Z9 48 U1 4 U2 42 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1879-6257 J9 CURR OPIN VIROL JI Curr. Opin. Virol. PD OCT PY 2013 VL 3 IS 5 BP 546 EP 557 DI 10.1016/j.coviro.2013.06.008 PG 12 WC Virology SC Virology GA 240ZN UT WOS:000326136300011 PM 23850169 ER PT J AU Lado, WE Zhang, DP Mennigen, JA Zamora, JM Popesku, JT Trudeau, VL AF Lado, Wudu E. Zhang, Dapeng Mennigen, Jan A. Zamora, Jacob M. Popesku, Jason T. Trudeau, Vance L. TI Rapid modulation of gene expression profiles in the telencephalon of male goldfish following exposure to waterborne sex pheromones SO GENERAL AND COMPARATIVE ENDOCRINOLOGY LA English DT Article DE Microarray; Ependymin; Calmodulin; Aldolase C; GnRH; Pheromones; Sperm release ID GONADOTROPIN-RELEASING-HORMONE; NR2B-CONTAINING NMDA RECEPTORS; AMINO-ACID NEUROTRANSMITTERS; CARASSIUS-AURATUS; SPAWNING BEHAVIOR; FEMALE GOLDFISH; DIFFERENTIAL ROLES; KAINATE RECEPTORS; GABA(A) RECEPTORS; MICROARRAY DATA AB Sex pheromones rapidly affect endocrine physiology and behaviour, but little is known about their effects on gene expression in the neural tissues that mediate olfactory processing. In this study, we exposed male goldfish for 6 h to waterborne 17,20 beta P (4.3 nM) and PGF(2 alpha) (3 nM), the main pre-ovulatory and post-ovulatory pheromones, respectively. Both treatments elevated milt volume (P = 0.001). Microarray analysis of male telencephalon following PGF(2 alpha), treatment identified 71 unique transcripts that were differentially expressed (q < 5%; 67 up, 4 down). Functional annotation of these regulated genes indicates that PGF(2 alpha),1 pheromone exposure affects diverse biological processes including nervous system functions, energy metabolism, cholesterol/lipoprotein transport, translational regulation, transcription and chromatin remodelling, protein processing, cytoskeletal organization, and signalling. By using real-time RT-PCR, we further validated three candidate genes, ependymin-II, calmodulin-A and aldolase C, which exhibited 3-5-fold increase in expression following PGF(2 alpha), exposure. Expression levels of some other genes that are thought to be important for reproduction were also determined using real-time RT-PCR. Expression of sGnRH was increased by PGF(2 alpha), but not 17,20 beta P, whereas cGnRH expression was increased by 17,20 beta P but not PGF2a. In contrast, both pheromones increase the expression of glutamate (GluR2a, NR2A) and gamma-aminobutyric acid (GABA(A) gamma 2) receptor subunit mRNAs. Milt release and rapid modulation of neuronal transcription are part of the response of males to female sex pheromones. (C) 2013 Elsevier Inc. All rights reserved. C1 [Lado, Wudu E.; Zamora, Jacob M.; Trudeau, Vance L.] Univ Ottawa, Dept Biol, Ottawa, ON, Canada. [Zhang, Dapeng] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20892 USA. [Mennigen, Jan A.] UR Nutr Aquaculture & Genom Nutr Metab & Aquacult, Inst Natl Rech Agron, F-64310 Quartier Ibarron, St Pee Sur Nive, France. [Popesku, Jason T.] Univ British Columbia, Inst Life Sci, Dept Cellular & Physiol Sci, Vancouver, BC V6T 1Z3, Canada. RP Trudeau, VL (reprint author), Univ Ottawa, Dept Biol, Ottawa, ON, Canada. EM trudeauv@uottawa.ca OI Trudeau, Vance/0000-0002-0845-9444 FU University of Ottawa International scholarship; Ontario Graduate Scholarships; National Sciences and Engineering Research Council (NSERC) summer scholarship; Discovery programs FX This work was supported by a University of Ottawa International scholarship (DZ, JAM), Ontario Graduate Scholarships (WEL, JTP), National Sciences and Engineering Research Council (NSERC) summer scholarship (JMZ) and Discovery programs (VLT). NR 66 TC 4 Z9 4 U1 2 U2 16 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0016-6480 EI 1095-6840 J9 GEN COMP ENDOCR JI Gen. Comp. Endocrinol. PD OCT 1 PY 2013 VL 192 BP 204 EP 213 DI 10.1016/j.ygcen.2013.06.015 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 235QS UT WOS:000325736400023 PM 23800560 ER PT J AU Walker, L Curry, M Nayak, A Lange, N Pierpaoli, C AF Walker, Lindsay Curry, Michael Nayak, Amritha Lange, Nicholas Pierpaoli, Carlo CA Brain Dev Cooperative Grp TI A framework for the analysis of phantom data in multicenter diffusion tensor imaging studies SO HUMAN BRAIN MAPPING LA English DT Article DE diffusion tensor imaging; DTI; multicenter; reproducibility; accuracy; pediatric ID NORMAL BRAIN-DEVELOPMENT; FRACTIONAL ANISOTROPY; DISTORTION CORRECTION; WEIGHTED MRI; SPIN-ECHO; NIH MRI; NOISE; RELIABILITY; IMAGES; OPTIMIZATION AB Diffusion tensor imaging (DTI) is commonly used for studies of the human brain due to its inherent sensitivity to the microstructural architecture of white matter. To increase sampling diversity, it is often desirable to perform multicenter studies. However, it is likely that the variability of acquired data will be greater in multicenter studies than in single-center studies due to the added confound of differences between sites. Therefore, careful characterization of the contributions to variance in a multicenter study is extremely important for meaningful pooling of data from multiple sites. We propose a two-step analysis framework for first identifying outlier datasets, followed by a parametric variance analysis for identification of intersite and intrasite contributions to total variance. This framework is then applied to phantom data from the NIH MRI study of normal brain development (PedsMRI). Our results suggest that initial outlier identification is extremely important for accurate assessment of intersite and intrasite variability, as well as for early identification of problems with data acquisition. We recommend the use of the presented framework at frequent intervals during the data acquisition phase of multicenter DTI studies, which will allow investigators to identify and solve problems as they occur. Hum Brain Mapp 34:2439-2454, 2013. (c) 2012 Wiley Periodicals, Inc. C1 [Walker, Lindsay; Curry, Michael; Nayak, Amritha; Pierpaoli, Carlo] NICHD, Program Pediat Imaging & Tissue Sci, NIH, Bethesda, MD USA. [Walker, Lindsay; Nayak, Amritha] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA. [Lange, Nicholas] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Lange, Nicholas] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. RP Walker, L (reprint author), Bldg 13,Rm 3W16D,13 South Dr, Bethesda, MD 20892 USA. EM walkerlin@mail.nih.gov FU National Institute of Neurological Disorders and Stroke [N01-HD02-3343, N01-MH9-0002, N01-NS-9-2314, N01-NS-9-2315, N01-NS-9-2316, N01-NS-9-2317, N01-NS-9-2319, N01-NS-9-2320, NS34783]; National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute of Mental Health FX Contract grant sponsor: National Institute of Neurological Disorders and Stroke; Contract grant numbers: N01-HD02-3343, N01-MH9-0002, N01-NS-9-2314, N01-NS-9-2315, N01-NS-9-2316, N01-NS-9-2317, N01-NS-9-2319, N01-NS-9-2320, NS34783; Contract grant sponsors: National Institute of Child Health and Human Development; the National Institute on Drug Abuse; the National Institute of Mental Health. NR 39 TC 11 Z9 11 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1065-9471 EI 1097-0193 J9 HUM BRAIN MAPP JI Hum. Brain Mapp. PD OCT PY 2013 VL 34 IS 10 BP 2439 EP 2454 DI 10.1002/hbm.22081 PG 16 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 216TI UT WOS:000324306900007 PM 22461391 ER PT J AU Chakravarty, MM Steadman, P van Eede, MC Calcott, RD Gu, V Shaw, P Raznahan, A Collins, DL Lerch, JP AF Chakravarty, M. Mallar Steadman, Patrick van Eede, Matthijs C. Calcott, Rebecca D. Gu, Victoria Shaw, Philip Raznahan, Armin Collins, D. Louis Lerch, Jason P. TI Performing label-fusion-based segmentation using multiple automatically generated templates SO HUMAN BRAIN MAPPING LA English DT Article DE segmentation; label-fusion; multi-atlas; subcortical anatomy; striatum; globus pallidus; thalamus; small animal imaging; mouse imaging; atlases; nonlinear registration ID DEFORMATION-BASED MORPHOMETRY; MODEL-BASED SEGMENTATION; HUMAN BRAIN; PROBABILISTIC ATLAS; MOUSE-BRAIN; IMAGE SEGMENTATION; MR-IMAGES; NEUROANATOMICAL STRUCTURES; AUTOMATED SEGMENTATION; HIPPOCAMPAL SUBFIELDS AB Classically, model-based segmentation procedures match magnetic resonance imaging (MRI) volumes to an expertly labeled atlas using nonlinear registration. The accuracy of these techniques are limited due to atlas biases, misregistration, and resampling error. Multi-atlas-based approaches are used as a remedy and involve matching each subject to a number of manually labeled templates. This approach yields numerous independent segmentations that are fused using a voxel-by-voxel label-voting procedure. In this article, we demonstrate how the multi-atlas approach can be extended to work with input atlases that are unique and extremely time consuming to construct by generating a library of multiple automatically generated templates of different brains (MAGeT Brain). We demonstrate the efficacy of our method for the mouse and human using two different nonlinear registration algorithms (ANIMAL and ANTs). The input atlases consist a high-resolution mouse brain atlas and an atlas of the human basal ganglia and thalamus derived from serial histological data. MAGeT Brain segmentation improves the identification of the mouse anterior commissure (mean Dice Kappa values (kappa = 0.801), but may be encountering a ceiling effect for hippocampal segmentations. Applying MAGeT Brain to human subcortical structures improves segmentation accuracy for all structures compared to regular model-based techniques (kappa = 0.845, 0.752, and 0.861 for the striatum, globus pallidus, and thalamus, respectively). Experiments performed with three manually derived input templates suggest that MAGeT Brain can approach or exceed the accuracy of multi-atlas label-fusion segmentation (kappa = 0.894, 0.815, and 0.895 for the striatum, globus pallidus, and thalamus, respectively). Hum Brain Mapp 34:2635-2654, 2013. (c) 2012 Wiley Periodicals, Inc. C1 [Chakravarty, M. Mallar; Steadman, Patrick; van Eede, Matthijs C.; Calcott, Rebecca D.; Gu, Victoria; Lerch, Jason P.] Hosp Sick Children, Mouse Imaging Ctr, Toronto, ON M5G 1X8, Canada. [Chakravarty, M. Mallar] Ctr Addict & Mental Hlth, Kimel Family Translat Imaging Genet Res Lab, Toronto, ON, Canada. [Chakravarty, M. Mallar] Univ Toronto, Dept Psychiat, Toronto, ON M5S 1A1, Canada. [Steadman, Patrick; Lerch, Jason P.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada. [Shaw, Philip] NHGRI, Social & Behav Res Branch, Bethesda, MD 20892 USA. [Raznahan, Armin] NIMH, Child Psychiat Branch, Bethesda, MD 20892 USA. [Collins, D. Louis] McGill Univ, Montreal Neurol Inst, Brain Imaging Ctr, Montreal, PQ, Canada. RP Chakravarty, MM (reprint author), Hosp Sick Children, Mouse Imaging Ctr, 555 Univ Ave, Toronto, ON M5G 1X8, Canada. EM mallar_chakravarty@camh.net OI Steadman, Patrick/0000-0002-5814-4977 FU Canada Foundation for Innovation under the auspices of Compute Canada; Government of Ontario; Ontario Research Fund - Research Excellence; University of Toronto FX Computations were performed on the SciNet supercomputer at the SciNet HPC Consortium. SciNet is funded by the Canada Foundation for Innovation under the auspices of Compute Canada, the Government of Ontario, Ontario Research Fund - Research Excellence and the University of Toronto. MMC would also like to thank G. Clinton, E. Hazel, and B. Worrell for inspiring this work. NR 69 TC 54 Z9 54 U1 2 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1065-9471 EI 1097-0193 J9 HUM BRAIN MAPP JI Hum. Brain Mapp. PD OCT PY 2013 VL 34 IS 10 BP 2635 EP 2654 DI 10.1002/hbm.22092 PG 20 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 216TI UT WOS:000324306900021 PM 22611030 ER PT J AU Wei, HJ Viallon, M Delattre, BMA Wang, LH Pai, VM Wen, H Xue, H Guetter, C Croisille, P Zhu, YM AF Wei, Hongjiang Viallon, Magalie Delattre, Benedicte M. A. Wang, Lihui Pai, Vinay M. Wen, Han Xue, Hui Guetter, Christoph Croisille, Pierre Zhu, Yuemin TI Assessment of Cardiac Motion Effects on the Fiber Architecture of the Human Heart In Vivo SO IEEE TRANSACTIONS ON MEDICAL IMAGING LA English DT Article DE Diffusion tensor imaging (DTI); fiber architecture; in vivo heart; motion; polarized light imaging ID DIFFUSION-TENSOR MRI; IMAGING MATHEMATICS; ANISOTROPY; NOISE; LIMITATIONS; INFARCTION; STRAIN; ECHOES AB The use of diffusion tensor imaging (DTI) for studying the human heart in vivo is very challenging due to cardiac motion. This paper assesses the effects of cardiac motion on the human myocardial fiber architecture. To this end, a model for analyzing the effects of cardiac motion on signal intensity is presented. A Monte-Carlo simulation based on polarized light imaging data is then performed to calculate the diffusion signals obtained by the displacement of water molecules, which generate diffusion weighted (DW) images. Rician noise and in vivo motion data obtained from DENSE acquisition are added to the simulated cardiac DW images to produce motion-induced datasets. An algorithm based on principal components analysis filtering and temporal maximum intensity projection (PCATMIP) is used to compensate for motion-induced signal loss. Diffusion tensor parameters derived from motion-reduced DW images are compared to those derived from the original simulated DW images. Finally, to assess cardiac motion effects on in vivo fiber architecture, in vivo cardiac DTI data processed by PCATMIP are compared to those obtained from one trigger delay (TD) or one single phase acquisition. The results showed that cardiac motion produced overestimated fractional anisotropy and mean diffusivity as well as a narrower range of fiber angles. The combined use of shifted TD acquisitions and postprocessing based on image registration and PCATMIP effectively improved the quality of in vivo DW images and subsequently, the measurement accuracy of fiber architecture properties. This suggests new solutions to the problems associated with obtaining in vivo human myocardial fiber architecture properties in clinical conditions. C1 [Wei, Hongjiang; Viallon, Magalie; Delattre, Benedicte M. A.; Wang, Lihui; Croisille, Pierre; Zhu, Yuemin] CNRS, INSERM, CREATIS, UMR 5220,U1044, F-69100 Villeurbanne, France. [Wei, Hongjiang; Viallon, Magalie; Delattre, Benedicte M. A.; Wang, Lihui; Croisille, Pierre; Zhu, Yuemin] INSA Lyon, F-69100 Villeurbanne, France. [Wei, Hongjiang; Viallon, Magalie; Delattre, Benedicte M. A.; Wang, Lihui; Croisille, Pierre; Zhu, Yuemin] Univ Lyon, F-69100 Villeurbanne, France. [Pai, Vinay M.] NIBIB, Div Appl Sci & Technol, NIH, Bethesda, MD 20892 USA. [Wen, Han] NHLBI, Phys Lab, NIH, Bethesda, MD 20892 USA. [Xue, Hui; Guetter, Christoph] Siemens Corp, Corp Technol, Princeton, NJ 08540 USA. RP Wei, HJ (reprint author), CNRS, INSERM, CREATIS, UMR 5220,U1044, F-69100 Villeurbanne, France. RI Croisille, Pierre/H-4928-2014; Magalie, Viallon/H-4471-2014; Wen, Han/G-3081-2010 OI Croisille, Pierre/0000-0003-4019-3460; Magalie, Viallon/0000-0001-9118-0438; Wen, Han/0000-0001-6844-2997 FU French ANR [ANR-09-BLAN-0372-01] FX This work was supported by the French ANR 2009 (under ANR-09-BLAN-0372-01). NR 44 TC 12 Z9 12 U1 0 U2 16 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 0278-0062 EI 1558-254X J9 IEEE T MED IMAGING JI IEEE Trans. Med. Imaging PD OCT PY 2013 VL 32 IS 10 BP 1928 EP 1938 DI 10.1109/TMI.2013.2269195 PG 11 WC Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Engineering, Electrical & Electronic; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Engineering; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging GA 230YV UT WOS:000325380300015 PM 23797241 ER PT J AU Prescott, J Safronetz, D Haddock, E Robertson, S Scott, D Feldmann, H AF Prescott, Joseph Safronetz, David Haddock, Elaine Robertson, Shelly Scott, Dana Feldmann, Heinz TI The adaptive immune response does not influence hantavirus disease or persistence in the Syrian hamster SO IMMUNOLOGY LA English DT Article DE hantavirus; hantavirus cardiopulmonary syndrome; infectious disease; T cells; zoonosis ID SIN-NOMBRE-VIRUS; PEROMYSCUS-MANICULATUS MODEL; PULMONARY SYNDROME; T-CELLS; HEMORRHAGIC-FEVER; SEOUL-VIRUS; NONPATHOGENIC HANTAVIRUSES; CARDIOPULMONARY SYNDROME; ENDOTHELIAL-CELLS; RENAL SYNDROME AB Summary Pathogenic New World hantaviruses cause severe disease in humans characterized by a vascular leak syndrome, leading to pulmonary oedema and respiratory distress with case fatality rates approaching 40%. Hantaviruses infect microvascular endothelial cells without conspicuous cytopathic effects, indicating that destruction of the endothelium is not a mechanism of disease. In humans, high levels of inflammatory cytokines are present in the lungs of patients that succumb to infection. This, along with other observations, suggests that disease has an immunopathogenic component. Currently the only animal model available to study hantavirus disease is the Syrian hamster, where infection with Andes virus (ANDV), the primary agent of disease in South America, results in disease that closely mimics that seen in humans. Conversely, inoculation of hamsters with a passaged Sin Nombre virus (SNV), the virus responsible for most cases of disease in North America, results in persistent infection with high levels of viral replication. We found that ANDV elicited a stronger innate immune response, whereas SNV elicited a more robust adaptive response in the lung. Additionally, ANDV infection resulted in significant changes in the blood lymphocyte populations. To determine whether the adaptive immune response influences infection outcome, we depleted hamsters of CD4(+) and CD8(+) T cells before infection with hantaviruses. Depletion resulted in inhibition of virus-specific antibody responses, although the pathogenesis and replication of these viruses were unaltered. These data show that neither hantavirus replication, nor pathogenesis caused by these viruses, is influenced by the adaptive immune response in the Syrian hamster. C1 [Prescott, Joseph; Safronetz, David; Haddock, Elaine; Robertson, Shelly; Feldmann, Heinz] NIAID, Virol Lab, DIR, NIH,Rocky Mt Lab, Hamilton, MT 59840 USA. [Scott, Dana] NIAID, Rocky Mt Vet Branch, Div Intramural Res, NIH,Rocky Mt Labs, Hamilton, MT 59840 USA. RP Prescott, J (reprint author), NIAID, Virol Lab, DIR, NIH,Rocky Mt Lab, 903 South 4th St, Hamilton, MT 59840 USA. EM prescottjb@niaid.nih.gov; feldmannh@niaid.nih.gov FU Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health FX We would like to thank Dan Long, Tina Thomas and Rebecca Rosenke for histopathology work. We would also like to thank Anita Mora for the preparation of graphics. This work was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health. NR 42 TC 16 Z9 16 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0019-2805 EI 1365-2567 J9 IMMUNOLOGY JI Immunology PD OCT PY 2013 VL 140 IS 2 BP 168 EP 178 DI 10.1111/imm.12116 PG 11 WC Immunology SC Immunology GA 216SB UT WOS:000324303200003 PM 23600567 ER PT J AU Bernstein, M Garnett-Benson, C Zhang, H Hodge, JW Guha, C AF Bernstein, M. Garnett-Benson, C. Zhang, H. Hodge, J. W. Guha, C. TI Radiation Therapy Alters Tumor Cell Phenotypes and Enhances the Immune Response SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 55th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 22-25, 2013 CL Atlanta, GA SP Amer Soc Radiat Oncol C1 [Bernstein, M.; Zhang, H.; Guha, C.] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA. [Garnett-Benson, C.] Georgia State Univ, Atlanta, GA 30303 USA. [Hodge, J. W.] NCI, NIH, Bethesda, MD 20892 USA. RI Hodge, James/D-5518-2015 OI Hodge, James/0000-0001-5282-3154 NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2013 VL 87 IS 2 SU S BP S110 EP S110 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 219JY UT WOS:000324503600270 ER PT J AU Dan, T Simone, B Simone, C Scuito, L Smith, S Danforth, D Camphausen, K Simone, N AF Dan, T. Simone, B. Simone, C. Scuito, L. Smith, S. Danforth, D. Camphausen, K. Simone, N. TI Cosmetic Outcomes and Quality of Life are Similar in Patients Receiving Breast Conservation Versus Mastectomy: 25-Year Follow-up of the NCI Randomized Trial SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 55th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 22-25, 2013 CL Atlanta, GA SP Amer Soc Radiat Oncol C1 [Dan, T.; Simone, B.; Simone, N.] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA. [Simone, C.] Univ Penn, Philadelphia, PA 19104 USA. [Scuito, L.; Smith, S.; Danforth, D.; Camphausen, K.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2013 VL 87 IS 2 SU S BP S48 EP S48 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 219JY UT WOS:000324503600115 ER PT J AU Fasola, C Jones, JC Huang, D Le, Q Hoppe, RT AF Fasola, C. Jones, J. C. Huang, D. Le, Q. Hoppe, R. T. TI Low-Dose Radiation Therapy (2 Gy x 2) in the Treatment of Non-Hodgkin Lymphoma of the Ocular Adnexa SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 55th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 22-25, 2013 CL Atlanta, GA SP Amer Soc Radiat Oncol C1 [Fasola, C.; Le, Q.; Hoppe, R. T.] Stanford Canc Ctr, Stanford, CA USA. [Jones, J. C.] NCI, Bethesda, MD 20892 USA. [Huang, D.] Univ Calif Los Angeles Olive View, Sylmar, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2013 VL 87 IS 2 SU S BP S59 EP S60 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 219JY UT WOS:000324503600144 ER PT J AU Lautenschlaeger, T Perry, I Peereboom, D White, J Steeg, P Mehta, M Chakravarti, A AF Lautenschlaeger, T. Perry, I. Peereboom, D. White, J. Steeg, P. Mehta, M. Chakravarti, A. TI Cilengitide Inhibits Proliferation and Shows Combined Effects With Radiation in Breast Cancer Cell Lines SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 55th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 22-25, 2013 CL Atlanta, GA SP Amer Soc Radiat Oncol C1 [Lautenschlaeger, T.; Perry, I.; White, J.; Chakravarti, A.] Ohio State Univ, Columbus, OH 43210 USA. [Peereboom, D.] Cleveland Clin, Cleveland, OH 44106 USA. [Steeg, P.] NCI, Bethesda, MD 20892 USA. [Mehta, M.] Univ Maryland, Baltimore, MD 21201 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2013 VL 87 IS 2 SU S BP S658 EP S658 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 219JY UT WOS:000324503602391 ER PT J AU Lin, SH Zhang, J Giri, U Stephan, C Sobieski, MM Nguyen, N Davies, P Komaki, R Yoo, SS Heymach, JV AF Lin, S. H. Zhang, J. Giri, U. Stephan, C. Sobieski, M. M. Nguyen, N. Davies, P. Komaki, R. Yoo, S. S. Heymach, J. V. TI High Throughput Clonogenic Survival Screen Identifies Novel Radiation Sensitizers for K-ras Mutant Non-Small Cell Lung Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 55th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 22-25, 2013 CL Atlanta, GA SP Amer Soc Radiat Oncol C1 [Lin, S. H.; Zhang, J.; Giri, U.; Komaki, R.; Heymach, J. V.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Stephan, C.; Sobieski, M. M.; Nguyen, N.; Davies, P.] Texas A&M Hlth Sci Ctr, Houston, TX USA. [Yoo, S. S.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2013 VL 87 IS 2 SU S BP S651 EP S651 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 219JY UT WOS:000324503602370 ER PT J AU Logan, JK Hoang, AN Walton-Diaz, A Truong, H Citrin, DE Turkbey, B Choyke, PL Wood, BJ Pinto, PA AF Logan, J. K. Hoang, A. N. Walton-Diaz, A. Truong, H. Citrin, D. E. Turkbey, B. Choyke, P. L. Wood, B. J. Pinto, P. A. TI Salvage MR-Guided Focal Laser Ablation of Prostate Cancer After Brachytherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 55th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 22-25, 2013 CL Atlanta, GA SP Amer Soc Radiat Oncol C1 [Logan, J. K.; Hoang, A. N.; Walton-Diaz, A.; Truong, H.; Pinto, P. A.] NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA. [Citrin, D. E.] NCI, Radiat Oncol Branch, NIH, Bethesda, MD 20892 USA. [Turkbey, B.; Choyke, P. L.] NCI, Mol Imaging Program, NIH, Bethesda, MD 20892 USA. [Wood, B. J.; Pinto, P. A.] NCI, Ctr Intervent Oncol, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2013 VL 87 IS 2 SU S BP S349 EP S350 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 219JY UT WOS:000324503601298 ER PT J AU Matsuo, M Matsumoto, S Saito, K Takakusagi, Y Morris, D Munasinghe, J Devasahayam, N Subramanian, S Mitchell, J Krishna, M AF Matsuo, M. Matsumoto, S. Saito, K. Takakusagi, Y. Morris, D. Munasinghe, J. Devasahayam, N. Subramanian, S. Mitchell, J. Krishna, M. TI Hypoxic and Acute Hypoxic Intratumor Mapping by pO(2) Imaging SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 55th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 22-25, 2013 CL Atlanta, GA SP Amer Soc Radiat Oncol C1 [Matsuo, M.; Matsumoto, S.; Saito, K.; Takakusagi, Y.; Morris, D.; Munasinghe, J.; Devasahayam, N.; Subramanian, S.; Mitchell, J.; Krishna, M.] NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2013 VL 87 IS 2 SU S BP S644 EP S645 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 219JY UT WOS:000324503602354 ER PT J AU Schlaff, CD Arscott, WT Gordon, I Tandle, A Tofilon, P Camphausen, K AF Schlaff, C. D. Arscott, W. T. Gordon, I. Tandle, A. Tofilon, P. Camphausen, K. TI Radiosensitization Effects of Novel Triple-Inhibitor CUDC-101 in Glioblastoma Multiforme and Breast Cancer Cells In Vitro SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 55th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 22-25, 2013 CL Atlanta, GA SP Amer Soc Radiat Oncol C1 [Schlaff, C. D.; Arscott, W. T.; Gordon, I.; Tandle, A.; Tofilon, P.; Camphausen, K.] NCI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2013 VL 87 IS 2 SU S BP S650 EP S650 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 219JY UT WOS:000324503602369 ER PT J AU Simone, B Jin, L Dan, T Savage, J Minassian, H Lim, M Rosenberg, A Palazzo, J Simone, NL AF Simone, B. Jin, L. Dan, T. Savage, J. Minassian, H. Lim, M. Rosenberg, A. Palazzo, J. Simone, N. L. TI Caloric Restriction Coupled With Radiation Increases Overall Survival in a Metastatic Breast Cancer Model SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 55th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 22-25, 2013 CL Atlanta, GA SP Amer Soc Radiat Oncol C1 [Simone, B.; Jin, L.; Dan, T.; Minassian, H.; Lim, M.; Rosenberg, A.; Palazzo, J.; Simone, N. L.] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA. [Savage, J.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2013 VL 87 IS 2 SU S BP S649 EP S649 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 219JY UT WOS:000324503602365 ER PT J AU Tran, PT Bellovin, DI Adam, S Gentles, A Roessler, S Thiyagarajan, S Aziz, K Chettiar, S Luong, R Plevritis, S AF Tran, P. T. Bellovin, D. I. Adam, S. Gentles, A. Roessler, S. Thiyagarajan, S. Aziz, K. Chettiar, S. Luong, R. Plevritis, S. TI Twist1 Induces the Step-Wise Malignant Progression of Liver Cancer in Transgenic Mice Revealing a Prognostic 19-Gene Signature for Humans SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 55th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 22-25, 2013 CL Atlanta, GA SP Amer Soc Radiat Oncol C1 [Tran, P. T.; Thiyagarajan, S.; Aziz, K.; Chettiar, S.] Johns Hopkins Med, Baltimore, MD USA. [Bellovin, D. I.; Adam, S.; Gentles, A.; Luong, R.; Plevritis, S.] Stanford Univ, Stanford, CA 94305 USA. [Roessler, S.] NCI, Bethesda, MD 20892 USA. RI Chettiar, Sivarajan/K-2766-2014 OI Chettiar, Sivarajan/0000-0002-6864-7308 NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2013 VL 87 IS 2 SU S BP S169 EP S169 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 219JY UT WOS:000324503600419 ER PT J AU Wickerham, DL Julian, TB AF Wickerham, D. Lawrence Julian, Thomas B. TI Ductal Carcinoma In Situ: A Rose by Any Other Name SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Editorial Material ID BREAST-CANCER; PROGRESSION; TAMOXIFEN; MARKERS; TRIAL C1 [Wickerham, D. Lawrence; Julian, Thomas B.] Natl Surg Adjuvant Breast & Bowel Project, Pittsburgh, PA USA. [Wickerham, D. Lawrence; Julian, Thomas B.] Allegheny Gen Hosp, Allegheny Canc Ctr, Pittsburgh, PA 15212 USA. RP Wickerham, DL (reprint author), Four Allegheny Ctr, Natl Surg Adjuvant Breast & Bowel Project, 5th Fl, Pittsburgh, PA 15212 USA. EM larry.-wickerham@nsabp.org FU NCI NIH HHS [U10-CA-12027, U10-CA-37377, U10-CA-69651, U10-CA-69974] NR 18 TC 8 Z9 8 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-. Natl. Cancer Inst. PD OCT PY 2013 VL 105 IS 20 BP 1521 EP 1522 DI 10.1093/jnci/djt268 PG 2 WC Oncology SC Oncology GA 239RS UT WOS:000326043700003 PM 24068770 ER PT J AU Safaeian, M Sherman, ME AF Safaeian, Mahboobeh Sherman, Mark E. TI From Papanicolaou to Papillomaviruses: Evolving Challenges in Cervical Cancer Screening in the Era of Human Papillomavirus Vaccination SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Editorial Material ID UNITED-STATES; MORTALITY; TRENDS; WOMEN; RISK C1 [Safaeian, Mahboobeh] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Sherman, Mark E.] NCI, Canc Prevent Div, Bethesda, MD 20892 USA. RP Safaeian, M (reprint author), NCI, Div Canc Epidemiol & Genet, NIH, DHHS, 9609 Med Ctr Dr,6E224,MSC 9767, Bethesda, MD 20892 USA. EM safaeianm@mail.nih.gov FU Intramural NIH HHS NR 13 TC 4 Z9 4 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-. Natl. Cancer Inst. PD OCT PY 2013 VL 105 IS 20 BP 1524 EP 1526 DI 10.1093/jnci/djt267 PG 3 WC Oncology SC Oncology GA 239RS UT WOS:000326043700005 PM 24096622 ER PT J AU Forsythe, LP Parry, C Alfano, CM Kent, EE Leach, CR Haggstrom, DA Ganz, PA Aziz, N Rowland, JH AF Forsythe, Laura P. Parry, Carla Alfano, Catherine M. Kent, Erin E. Leach, Corinne R. Haggstrom, David A. Ganz, Patricia A. Aziz, Noreen Rowland, Julia H. TI Use of Survivorship Care Plans in the United States: Associations With Survivorship Care SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID FOLLOW-UP CARE; CANCER SURVIVORS; OUTCOMES RESEARCH; BREAST-CANCER; PHYSICIANS; HEALTH; VIEWS; RECOMMENDATIONS; ONCOLOGISTS; INFORMATION AB Survivorship care plans (SCPs), including a treatment summary and follow-up plan, intend to promote coordination of posttreatment cancer care; yet, little is known about the provision of these documents by oncologists to primary care physicians (PCPs). This study compared self-reported oncologist provision and PCP receipt of treatment summaries and follow-up plans, characterized oncologists who reported consistent provision of these documents to PCPs, and examined associations between PCP receipt of these documents and survivorship care. A nationally representative sample of medical oncologists (n 1130) and PCPs (n 1020) were surveyed regarding follow-up care for breast and colon cancer survivors. All statistical tests were two-sided. Multivariable regression models identified factors associated with oncologist provision of treatment summaries and SCPs to PCPs (always/almost always vs less frequent). Nearly half of oncologists reported always/almost always providing treatment summaries, whereas 20.2% reported always/almost always providing SCPs (treatment summary follow-up plan). Approximately one-third of PCPs indicated always/almost always receiving treatment summaries; 13.4% reported always/almost always receiving SCPs. Oncologists who reported training in late- and long-term effects of cancer and use of electronic medical records were more likely to report SCP provision (P < .05). PCP receipt of SCPs was associated with better PCP-reported care coordination, physicianphysician communication, and confidence in survivorship care knowledge compared to receipt of neither treatment summaries nor SCPs (P < .05). Providing SCPs to PCPs may enhance survivorship care coordination, physicianphysician communication, and PCP confidence. However, considerable progress will be necessary to achieve implementation of sharing SCPs among oncologists and PCPs. C1 [Forsythe, Laura P.; Parry, Carla; Alfano, Catherine M.; Kent, Erin E.; Rowland, Julia H.] NCI, Off Canc Survivorship, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA. [Forsythe, Laura P.; Kent, Erin E.] NCI, Canc Prevent Fellowship Program, Canc Prevent Div, NIH, Bethesda, MD 20892 USA. [Leach, Corinne R.] Amer Canc Soc, Behav Res Ctr, Atlanta, GA 30329 USA. [Haggstrom, David A.] Vet Affairs Hlth Serv Res & Dev Ctr Excellence Im, Indianapolis, IN USA. [Haggstrom, David A.] Indiana Univ Sch Med, Dept Med, Div Gen Internal Med & Geriatr, Indianapolis, IN 46202 USA. [Haggstrom, David A.] Indiana Univ, Ctr Hlth Serv & Outcomes Res, Regenstrief Inst Inc, Indianapolis, IN 46204 USA. [Ganz, Patricia A.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Ganz, Patricia A.] Jonsson Comprehens Canc Ctr, Sch Publ Hlth, Div Canc Prevent & Control Res, Los Angeles, CA 90034 USA. [Aziz, Noreen] NINR, Off Extramural Programs, NIH, Bethesda, MD 20892 USA. RP Forsythe, LP (reprint author), 1828 L St NW,Suite 900, Washington, DC 20036 USA. EM lforsythe@pcori.org FU National Cancer Institute [HHSN261200700068C]; American Cancer Society Behavioral Research Center Intramural Research funds FX This study was supported by the National Cancer Institute (contract number HHSN261200700068C) and the American Cancer Society Behavioral Research Center Intramural Research funds. NR 37 TC 36 Z9 36 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-. Natl. Cancer Inst. PD OCT PY 2013 VL 105 IS 20 BP 1579 EP 1587 DI 10.1093/jnci/djt258 PG 9 WC Oncology SC Oncology GA 239RS UT WOS:000326043700012 PM 24096621 ER PT J AU Wuthrich, M LeBert, V Galles, K Hu-Li, J Ben-Sasson, SZ Paul, WE Klein, BS AF Wuethrich, Marcel LeBert, Vanessa Galles, Kevin Hu-Li, Jane Ben-Sasson, Shlomo Z. Paul, William E. Klein, Bruce S. TI Interleukin 1 Enhances Vaccine-Induced Antifungal T-Helper 17 Cells and Resistance Against Blastomyces dermatitidis Infection SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE IL-1; adjuvant; T-cell priming; vaccine immunity; fungi ID IMMUNE-DEFICIENT HOSTS; ANTIGEN; FUNGI; TH17; INDUCTION; MICE; COCCIDIOIDOMYCOSIS; DIFFERENTIATION; REQUIREMENTS; EXPANSION AB Vaccine-induced T-helper 17 (Th17) cells are necessary and sufficient to protect against fungal infection. Although live fungal vaccines are efficient in driving protective Th17 responses and immunity, attenuated fungi may not be safe for human use. Heat-inactivated formulations and subunit vaccines are safer but less potent and require adjuvant to increase their efficacy. Here, we show that interleukin 1 (IL-1) enhances the capacity of weak vaccines to induce protection against lethal Blastomyces dermatitidis infection in mice and is far more effective than lipopolysaccharide. While IL-1 enhanced expansion and differentiation of fungus-specific T cells by direct action on those cells, cooperation with non-T cells expressing IL-1R1 was necessary to maximize protection. Mechanistically, IL-17 receptor signaling was required for the enhanced protection induced by IL-1. Thus, IL-1 enhances the efficacy of safe but inefficient vaccines against systemic fungal infection in part by increasing the expansion of CD4(+) T cells, allowing their entry into the lungs, and inducing their differentiation to protective Th17 cells. C1 [Wuethrich, Marcel; LeBert, Vanessa; Galles, Kevin; Klein, Bruce S.] Univ Wisconsin, Univ Wisconsin Hosp & Clin, Sch Med, Dept Pediat, Madison, WI 53706 USA. [Klein, Bruce S.] Univ Wisconsin, Univ Wisconsin Hosp & Clin, Sch Med, Dept Internal Med, Madison, WI 53706 USA. [Klein, Bruce S.] Univ Wisconsin, Univ Wisconsin Hosp & Clin, Sch Med, Dept Med Microbiol & Immunol, Madison, WI 53706 USA. [Hu-Li, Jane; Ben-Sasson, Shlomo Z.; Paul, William E.] NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA. [Ben-Sasson, Shlomo Z.] Hebrew Univ Jerusalem, Hadassah Med Ctr, Lautenberg Ctr Gen & Tumor Immunol, Jerusalem, Israel. RP Wuthrich, M (reprint author), Univ Wisconsin, Microbial Sci Bldg,1550 Linden Dr, Madison, WI 53706 USA. EM mwuethri@wisc.edu FU National Institutes of Health (NIH) [R01 AI093553, R01 AI40996]; Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH FX This work was supported by that National Institutes of Health (NIH; grants R01 AI093553 [to M. W.] and R01 AI40996 [to B. K.]) and the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH (to W. E. P.). NR 30 TC 9 Z9 9 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 1 PY 2013 VL 208 IS 7 BP 1175 EP 1182 DI 10.1093/infdis/jit283 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 239ST UT WOS:000326046400016 PM 23788728 ER PT J AU Durbin, AP Whitehead, SS AF Durbin, Anna P. Whitehead, Stephen S. TI Analyzing the Development of Vaccines for Flavivirus-Endemic Scenarios: The Case of Dengue and Dengue Vaccine in Peru Response SO JOURNAL OF INFECTIOUS DISEASES LA English DT Letter ID TRIAL C1 [Durbin, Anna P.; Whitehead, Stephen S.] Johns Hopking Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Whitehead, Stephen S.] NIAID, NIH, Bethesda, MD 20892 USA. RP Durbin, AP (reprint author), 624 N Broadway,Room 214, Baltimore, MD 21205 USA. EM adurbin@jhsph.edu NR 5 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 1 PY 2013 VL 208 IS 7 DI 10.1093/infdis/jit298 PG 1 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 239ST UT WOS:000326046400018 ER PT J AU Jones, KA Kim, PD Patel, BB Kelsen, SG Braverman, A Swinton, DJ Gafken, PR Jones, LA Lane, WS Neveu, JM Leung, HCE Shaffer, SA Leszyk, JD Stanley, BA Fox, TE Stanley, A Hall, MJ Hampel, H South, CD de la Chapelle, A Burt, RW Jones, DA Kopelovich, L Yeung, AT AF Jones, Kelly A. Kim, Phillip D. Patel, Bhavinkumar B. Kelsen, Steven G. Braverman, Alan Swinton, Derrick J. Gafken, Philip R. Jones, Lisa A. Lane, William S. Neveu, John M. Leung, Hon-Chiu E. Shaffer, Scott A. Leszyk, John D. Stanley, Bruce A. Fox, Todd E. Stanley, Anne Hall, Michael J. Hampel, Heather South, Christopher D. de la Chapelle, Albert Burt, Randall W. Jones, David A. Kopelovich, Levy Yeung, Anthony T. TI Immunodepletion Plasma Proteomics by TripleTOF 5600 and Orbitrap Elite/LTQ-Orbitrap Velos/Q Exactive Mass Spectrometers SO JOURNAL OF PROTEOME RESEARCH LA English DT Article DE immunodepletion; Seppro; IgY14; iTRAQ; EMMOL normalization; TripleTOF; Orbitrap; Q Exactive ID FINE-NEEDLE-ASPIRATION; FAMILIAL ADENOMATOUS POLYPOSIS; PANCREATIC CYSTIC NEOPLASMS; ISOBARIC TAGS; CANCER; ITRAQ; PROTEINS; CYTOLOGY; SEARCH; FLUID AB Plasma proteomic experiments performed rapidly and economically using several of the latest high-resolution mass spectrometers were compared. Four quantitative hyperfractionated plasma proteomics experiments were analyzed in replicates by two AB SCIEX TripleTOF 5600 and three Thermo Scientific Orbitrap (Elite/LTQ-Orbitrap Velos/Q Exactive) instruments. Each experiment compared two iTRAQ isobaric-labeled immunodepleted plasma proteomes, provided as 30 labeled peptide fractions, and 480 LC-MS/MS runs delivered >250 GB of data in 2 months. Several analysis algorithms were compared. At 1% false discovery rate, the relative comparative findings concluded that the Thermo Scientific Q Exactive Mass Spectrometer resulted in the highest number of identified proteins and unique sequences with iTRAQ quantitation. The confidence of iTRAQ fold-change for each protein is dependent on the overall ion statistics (Mascot Protein Score) attainable by each instrument. The benchmarking also suggested how to further improve the mass spectrometry parameters and HPLC conditions. Our findings highlight the special challenges presented by the low abundance peptide ions of iTRAQ plasma proteome because the dynamic range of plasma protein abundance is uniquely high compared with cell lysates, necessitating high instrument sensitivity. C1 [Jones, Kelly A.; Kim, Phillip D.; Patel, Bhavinkumar B.; Hall, Michael J.; Yeung, Anthony T.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Kelsen, Steven G.; Braverman, Alan] Temple Univ, Sch Med, Philadelphia, PA 19140 USA. [Swinton, Derrick J.] Lincoln Univ, Lincoln, PA 19352 USA. [Gafken, Philip R.; Jones, Lisa A.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. [Lane, William S.; Neveu, John M.] Harvard Univ, Mass Spectrometry & Prote Resource Lab, Cambridge, MA 02138 USA. [Leung, Hon-Chiu E.] Baylor Coll Med, Mass Spectrometry & Prote Core Facil, Houston, TX 77030 USA. [Shaffer, Scott A.; Leszyk, John D.] Univ Massachusetts, Sch Med, Prote & Mass Spectrometry Facil, Worcester, MA 01545 USA. [Stanley, Bruce A.; Fox, Todd E.; Stanley, Anne] Penn State Coll Med, Mass Spectrometry Core, Hershey, PA 17033 USA. [Hampel, Heather; South, Christopher D.; de la Chapelle, Albert] Ohio State Univ, Human Canc Genet Program, Columbus, OH 43210 USA. [Burt, Randall W.; Jones, David A.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA. [Kopelovich, Levy] NCI, Canc Prevent Div, Bethesda, MD 20892 USA. RP Yeung, AT (reprint author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA. EM anthony.yeung@fccc.edu OI Stanley, Bruce/0000-0003-1338-2928 FU NIH [RC2 HL101713, CA138017]; NCI [N01-CN-43309]; Driskill Foundation; Institutional Core Grants [P30 CA06927, P30 CA16058]; PA Dept. of Health FX We acknowledge John Cottrell for optimizing the peak-picking parameters for Mascot Distiller for this study. This work was partially supported by NIH grant RC2 HL101713, CA138017, the NCI Work Assignment 16 of N01-CN-43309, the Driskill Foundation, PA Dept. of Health, and Institutional Core Grants P30 CA06927 and P30 CA16058. We acknowledge the FCCC Biorepository, and Darshna Bhatt, Hopethe Hubbard, and Danielle J. Culbert of OSU, for assistance in the collection of some of the plasma samples. The authors received free demo licenses and advice from Thermo Scientific, AB SCIEX, and Matrix Science using their software. NR 36 TC 23 Z9 26 U1 5 U2 73 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1535-3893 EI 1535-3907 J9 J PROTEOME RES JI J. Proteome Res. PD OCT PY 2013 VL 12 IS 10 BP 4351 EP 4365 DI 10.1021/pr400307u PG 15 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 243MK UT WOS:000326320300008 PM 24004147 ER PT J AU Balsam, J Bruck, HA Rasooly, A AF Balsam, Joshua Bruck, Hugh Alan Rasooly, Avraham TI Orthographic projection capillary array fluorescent sensor for mHealth SO METHODS LA English DT Article DE mHealth; Capillary; Telecentric lens; Orthographic projection; Fluorescence; Mobile and smart phone; Camera ID CELL-PHONE; PLATFORM; HEALTH; POINT AB TO overcome the limited sensitivity of phone cameras for mobile health (mHealth) fluorescent detection, we have previously developed a capillary array which enables a similar to 100x increase in detection sensitivity. However, for an effective detection platform, the optical configuration must allow for uniform measurement sensitivity between channels when using such a capillary array sensor. This is a challenge due to the parallax inherent in imaging long parallel capillary tubes with typical lens configurations. To enable effective detection, we have developed an orthographic projection system in this work which forms parallel light projection images from the capillaries using an object-space telecentric lens configuration. This optical configuration results in a significantly higher degree of uniformity in measurement between channels, as well as a significantly reduced focal distance, which enables a more compact sensor. A plano-convex lens (f = 150 mm) was shown to produce a uniform orthographic projection when properly combined with the phone camera's built in lens (f = 4 mm), enabling measurements of long capillaries (125 mm) to be made from a distance of 160 mm. The number of parallel measurements which can be made is determined by the size of the secondary lens. Based on these results, a more compact configuration with shorter 32 mm capillaries and a plano-convex lens with a shorter focal length (f = 10 mm) was constructed. This optical system was used to measure serial dilutions of fluorescein with a limit of detection (LOD) of 10 nM, similar to the LOD of a commercial plate reader. However, many plate readers based on standard 96 well plate requires sample volumes of 100 Ill for measurement, while the capillary array requires a sample volume of less than 10 mu l. This optical configuration allows for a device to make use of the similar to 100x increase in fluorescent detection sensitivity produced by capillary amplification while maintaining a compact size and capability to analyze extremely small sample volumes. Such a device based on a phone or other optical mHealth technology will have the sensitivity of a conventional plate reader but have greater mHealth clinical utility, especially for telemedicine and for resource-poor settings and global health applications. Published by Elsevier Inc. C1 [Balsam, Joshua; Rasooly, Avraham] FDA, Div Biol, Off Sci & Engn, Silver Spring, MD 20993 USA. [Balsam, Joshua; Bruck, Hugh Alan] Univ Maryland, College Pk, MD 20742 USA. [Rasooly, Avraham] NCI, Div Canc Biol, Bethesda, MD 20892 USA. RP Balsam, J (reprint author), NCI, Div Canc Biol, Bethesda, MD 20892 USA. EM rasoolya@mail.nih.gov FU FDA's Center for Devices and Radiological Health, Division of Biology; National Cancer Institute FX This work was supported by the FDA's Center for Devices and Radiological Health, Division of Biology and the National Cancer Institute. The views expressed are those of the authors and do not represent those of the U.S. Government. NR 22 TC 2 Z9 2 U1 0 U2 14 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1046-2023 EI 1095-9130 J9 METHODS JI Methods PD OCT PY 2013 VL 63 IS 3 BP 276 EP 281 DI 10.1016/j.ymeth.2013.07.044 PG 6 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 240ZI UT WOS:000326135800010 PM 24018203 ER PT J AU Bruck, HA Yang, MH Kostov, Y Rasooly, A AF Bruck, Hugh Alan Yang, Minghui Kostov, Yordan Rasooly, Avraham TI Electrical percolation based biosensors SO METHODS LA English DT Article DE Biosensor; Semiconductor; Carbon nanotubes; Electrical percolation; Antibody ID STAPHYLOCOCCAL-ENTEROTOXIN-B; CARBON NANOTUBES; FOOD; FUNCTIONALIZATION; IMMUNODETECTION; IMMUNOASSAY; COMPOSITES; SENSORS; CONDUCTIVITY; WIRES AB A new approach to label free biosensing has been developed based on the principle of "electrical percolation". In electrical percolation, long-range electrical connectivity is formed in randomly oriented and distributed systems of discrete elements. By applying this principle to biological interactions, it is possible to measure biological components both directly and electronically. The main element for electrical percolation biosensor is the biological semiconductor (BSC) which is a multi-layer 3-D carbon nano-tube-antibody network. In the BSC, molecular interactions, such as binding of antigens to the antibodies, disrupt the network continuity causing increased resistance of the network. BSCs can be fabricated by immobilizing conducting elements, such as pre-functionalized single-walled carbon nanotubes (SWNTs)-antibody complex, directly onto a substrate, such as a Poly(methyl methacrylate) (PMMA) surface (also known as plexi-glass or Acrylic). BSCs have been demonstrated for direct (label-free) electronic measurements of antibody-antigen binding using SWNTs. If the concentration of the SWNT network is slightly above the electrical percolation threshold, then binding of a specific antigen to the pre-functionalized SWNT dramatically increases the electrical resistance due to changes in the tunneling between the SWNTs. Using anti-staphylococcal enterotoxin B (SEB) IgG as a "gate" and SEB as an "actuator", it was demonstrated that the BSC was able to detect SEB at concentrations of 1 ng/ml. Based on this concept, an automated configuration for BSCs is described here that enables real time continuous detection. The new BSC configuration may permit assembly of multiple sensors on the same chip to create "biological central processing units (CPUs)" with multiple biological elements, capable of processing and sorting out information on multiple analytes simultaneously. Published by Elsevier Inc. C1 [Bruck, Hugh Alan] Univ Maryland, College Pk, MD 20742 USA. [Yang, Minghui] Cent S Univ, Coll Chem & Chem Engn, Changsha 410083, Hunan, Peoples R China. [Kostov, Yordan] Univ Maryland Baltimore Cty, Baltimore, MD 21250 USA. [Rasooly, Avraham] US FDA, Div Biol, Off Sci & Engn, Silver Spring, MD 20993 USA. [Rasooly, Avraham] NCI, Rockville, MD 20850 USA. RP Rasooly, A (reprint author), NCI, NIH, 9609 Med Ctr Dr, Rockville, MD 20850 USA. EM rasoolya@mail.nih.gov FU Intramural NIH HHS [Z99 CA999999] NR 43 TC 2 Z9 2 U1 1 U2 20 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1046-2023 EI 1095-9130 J9 METHODS JI Methods PD OCT PY 2013 VL 63 IS 3 BP 282 EP 289 DI 10.1016/j.ymeth.2013.08.031 PG 8 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 240ZI UT WOS:000326135800011 PM 24041756 ER PT J AU Huang, JH Doria-Rose, NA Longo, NS Laub, L Lin, CL Turk, E Kang, BH Migueles, SA Bailer, RT Mascola, JR Connors, M AF Huang, Jinghe Doria-Rose, Nicole A. Longo, Nancy S. Laub, Leo Lin, Chien-Li Turk, Ellen Kang, Byong H. Migueles, Stephen A. Bailer, Robert T. Mascola, John R. Connors, Mark TI Isolation of human monoclonal antibodies from peripheral blood B cells SO NATURE PROTOCOLS LA English DT Article ID NEUTRALIZING ANTIBODIES; POTENT NEUTRALIZATION; PLASMA-CELLS; HIV-1; BROAD; GENERATION; ANTIGENS; CLONING AB Isolation of monoclonal antibodies is an important technique for understanding the specificities and characteristics of antibodies that underlie the humoral immune response to a given antigen. Here we describe a technique for isolating monoclonal antibodies from human peripheral blood mononuclear cells. The protocol includes strategies for the isolation of switch-memory B cells from peripheral blood, the culture of B cells, the removal of the supernatant for screening and the lysis of B cells in preparation for immunoglobulin heavy-chain and light-chain amplification and cloning. We have observed that the addition of cytokines IL-2, IL-21 and irradiated 3T3-msCD40L feeder cells can successfully stimulate switch-memory B cells to produce high concentrations of IgG in the supernatant. The supernatant may then be screened by appropriate assays for binding or for other functions. This protocol can be completed in 2 weeks. It is adaptable to use in other species and enables the efficient isolation of antibodies with a desired functional characteristic without prior knowledge of specificity. C1 [Huang, Jinghe; Laub, Leo; Kang, Byong H.; Migueles, Stephen A.; Connors, Mark] NIAID, HIV Specif Immun Sect, Immunoregulat Lab, US Natl Inst Hlth NIH, Bethesda, MD 20892 USA. [Doria-Rose, Nicole A.; Longo, Nancy S.; Lin, Chien-Li; Turk, Ellen; Bailer, Robert T.; Mascola, John R.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA. RP Connors, M (reprint author), NIAID, HIV Specif Immun Sect, Immunoregulat Lab, US Natl Inst Hlth NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. EM mconnors@nih.gov RI Huang, Jinghe/O-1986-2015 FU Intramural Research Programs of the NIAID FX This project has been funded in part with federal funds from the Intramural Research Programs of the NIAID. The content of this publication does not necessarily reflect the views or policies of the US Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government. NR 21 TC 25 Z9 25 U1 3 U2 23 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 EI 1750-2799 J9 NAT PROTOC JI Nat. Protoc. PD OCT PY 2013 VL 8 IS 10 BP 1907 EP 1915 DI 10.1038/nprot.2013.117 PG 9 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 241JQ UT WOS:000326163400006 PM 24030440 ER PT J AU Horner, AE Heath, CJ Hvoslef-Eide, M Kent, BA Kim, CH Nilsson, SRO Alsio, J Oomen, CA Holmes, A Saksida, LM Bussey, TJ AF Horner, Alexa E. Heath, Christopher J. Hvoslef-Eide, Martha Kent, Brianne A. Kim, Chi Hun Nilsson, Simon R. O. Alsioe, Johan Oomen, Charlotte A. Holmes, Andrew Saksida, Lisa M. Bussey, Timothy J. TI The touchscreen operant platform for testing learning and memory in rats and mice SO NATURE PROTOCOLS LA English DT Article ID CONDITIONAL VISUAL-DISCRIMINATION; PAVLOVIAN APPROACH BEHAVIOR; ANTERIOR CINGULATE CORTEX; NUCLEUS-ACCUMBENS CORE; SPATIAL-PATTERN SEPARATION; COMPUTER-GRAPHIC STIMULI; MEDIAL PREFRONTAL CORTEX; DORSAL STRIATAL SYSTEM; HIPPOCAMPAL-LESIONS; ALZHEIMERS-DISEASE AB An increasingly popular method of assessing cognitive functions in rodents is the automated touchscreen platform, on which a number of different cognitive tests can be run in a manner very similar to touchscreen methods currently used to test human subjects. This methodology is low stress (using appetitive rather than aversive reinforcement), has high translational potential and lends itself to a high degree of standardization and throughput. Applications include the study of cognition in rodent models of psychiatric and neurodegenerative diseases (e. g., Alzheimer's disease, schizophrenia, Huntington's disease, frontotemporal dementia), as well as the characterization of the role of select brain regions, neurotransmitter systems and genes in rodents. This protocol describes how to perform four touchscreen assays of learning and memory: visual discrimination, object-location paired-associates learning, visuomotor conditional learning and autoshaping. It is accompanied by two further protocols (also published in this issue) that use the touchscreen platform to assess executive function, working memory and pattern separation. C1 [Horner, Alexa E.] Synome Ltd, Cambridge, England. [Horner, Alexa E.; Heath, Christopher J.; Hvoslef-Eide, Martha; Kent, Brianne A.; Kim, Chi Hun; Nilsson, Simon R. O.; Alsioe, Johan; Oomen, Charlotte A.; Saksida, Lisa M.; Bussey, Timothy J.] Univ Cambridge, Dept Psychol, Cambridge, England. [Horner, Alexa E.; Heath, Christopher J.; Hvoslef-Eide, Martha; Kent, Brianne A.; Kim, Chi Hun; Nilsson, Simon R. O.; Alsioe, Johan; Oomen, Charlotte A.; Saksida, Lisa M.; Bussey, Timothy J.] Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge, England. [Holmes, Andrew] NIAAA, Lab Behav & Genom Neurosci, US Natl Inst Hlth, Bethesda, MD USA. RP Horner, AE (reprint author), Synome Ltd, Babraham Res Campus, Cambridge, England. EM alexa.horner@cantab.net RI Oomen, Charlotte/K-5259-2014; Bussey, Timothy/M-2758-2016; Saksida, Lisa/M-2753-2016; OI Bussey, Timothy/0000-0001-7518-4041; Saksida, Lisa/0000-0002-8416-8171; Kent, Brianne/0000-0003-0074-028X FU European Federation of Pharmaceutical Industries [115008]; European Union [241995, 242167]; Wellcome Trust/Medical Research Council [089703/Z/09/Z]; Alzheimer's Research UK [ART/PG2006/5]; Swedish Academy of Pharmaceutical Sciences; NIAAA Intramural Research Program FX The protocols described here are those that are currently used in our laboratory, and they were written by current members of the group. However, many researchers have contributed to the development of touchscreen tasks, and we gratefully acknowledge their contribution. They include S. Bartko, J. Brigman, S. Forwood, C. Graybeal, A. Izquierdo, L. Lyon, A. Marti, K. McAllister, S. McTighe, J. Nithianantharajah, C. Romberg, J. Talpos and B. Winters. The research leading to these results has received support from the Innovative Medicine Initiative Joint Undertaking under grant agreement no. 115008, of which resources are composed of a European Federation of Pharmaceutical Industries and Associations in-kind contribution and financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013); the Wellcome Trust/Medical Research Council (089703/Z/09/Z) and Alzheimer's Research UK (ART/PG2006/5). A.E.H. receives funding from the European Union Seventh Framework Programme under grant agreement nos. 241995 (Project 'GENCODYS') and 242167 (Project 'SYNSYS'). J.A. was supported by the Swedish Academy of Pharmaceutical Sciences. A.H. was supported by the NIAAA Intramural Research Program. NR 126 TC 54 Z9 54 U1 0 U2 42 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 EI 1750-2799 J9 NAT PROTOC JI Nat. Protoc. PD OCT PY 2013 VL 8 IS 10 BP 1961 EP 1984 DI 10.1038/nprot.2013.122 PG 24 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 241JQ UT WOS:000326163400010 PM 24051959 ER PT J AU Mar, AC Horner, AE Nilsson, SRO Alsio, J Kent, BA Kim, CH Holmes, A Saksida, LM Bussey, TJ AF Mar, Adam C. Horner, Alexa E. Nilsson, Simon R. O. Alsioe, Johan Kent, Brianne A. Kim, Chi Hun Holmes, Andrew Saksida, Lisa M. Bussey, Timothy J. TI The touchscreen operant platform for assessing executive function in rats and mice SO NATURE PROTOCOLS LA English DT Article ID REACTION-TIME-TASK; PREFRONTAL SEROTONIN DEPLETION; SPATIAL WORKING-MEMORY; REVERSAL-LEARNING TASK; FRONTAL-LOBE LESIONS; ORBITOFRONTAL CORTEX; VISUAL-DISCRIMINATION; FEAR EXTINCTION; COGNITIVE INFLEXIBILITY; SUSTAINED ATTENTION AB This protocol details a subset of assays developed within the touchscreen platform to measure various aspects of executive function in rodents. Three main procedures are included: extinction, measuring the rate and extent of curtailing a response that was previously, but is no longer, associated with reward; reversal learning, measuring the rate and extent of switching a response toward a visual stimulus that was previously not, but has become, associated with reward (and away from a visual stimulus that was previously, but is no longer, rewarded); and the 5-choice serial reaction time (5-CSRT) task, gauging the ability to selectively detect and appropriately respond to briefly presented, spatially unpredictable visual stimuli. These protocols were designed to assess both complementary and overlapping constructs including selective and divided visual attention, inhibitory control, flexibility, impulsivity and compulsivity. The procedures comprise part of a wider touchscreen test battery assessing cognition in rodents with high potential for translation to human studies. C1 [Mar, Adam C.; Horner, Alexa E.; Nilsson, Simon R. O.; Alsioe, Johan; Kent, Brianne A.; Kim, Chi Hun; Saksida, Lisa M.; Bussey, Timothy J.] Univ Cambridge, Dept Psychol, Cambridge, England. [Mar, Adam C.; Horner, Alexa E.; Nilsson, Simon R. O.; Alsioe, Johan; Kent, Brianne A.; Kim, Chi Hun; Saksida, Lisa M.; Bussey, Timothy J.] Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge, England. [Horner, Alexa E.] Synome Ltd, Cambridge, England. [Holmes, Andrew] NIAAA, Lab Behav & Genom Neurosci, NIH, Bethesda, MD 90034 USA. RP Mar, AC (reprint author), Univ Cambridge, Dept Psychol, Cambridge, England. EM am682@cam.ac.uk RI Bussey, Timothy/M-2758-2016; Saksida, Lisa/M-2753-2016; OI Bussey, Timothy/0000-0001-7518-4041; Saksida, Lisa/0000-0002-8416-8171; Kent, Brianne/0000-0003-0074-028X FU European Union [241995, 242167]; Wellcome Trust/Medical Research Council [089703/Z/09/Z]; Alzheimer's Research UK [ART/PG2006/5]; Swedish Academy of Pharmaceutical Sciences; NIAAA Intramural Research Program FX The protocols described here are those currently used in our laboratory and were written by current members of the group. However, many researchers have contributed to the development of touchscreen tasks and we would like to gratefully acknowledge their contribution. They include S. Bartko, J. Brigman, S. Forwood, C. Graybeal, A. Izquierdo, L. Lyon, A. Marti, K. McAllister, S. McTighe, J. Nithianantharajah, C. Romberg, J. Talpos and B. Winters. We also thank M. Hvoslef-Eide for her assistance in creating and modifying the mask schematics and flow charts. The research leading to these results has received support from the Innovative Medicine Initiative Joint Undertaking under grant agreement no. 115008, of which resources are composed of an European Federation of Pharmaceutical Industries and Associations in-kind contribution and financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013); from the Wellcome Trust/Medical Research Council (089703/Z/09/Z) and from Alzheimer's Research UK (ART/PG2006/5). A.E.H. receives funding from the European Union Seventh Framework Programme under grant agreement nos. 241995 (Project 'GENCODYS') and 242167 (Project 'SYNSYS'). J.A. was supported by the Swedish Academy of Pharmaceutical Sciences. A.E.H. was supported by the NIAAA Intramural Research Program. NR 102 TC 45 Z9 45 U1 2 U2 38 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 EI 1750-2799 J9 NAT PROTOC JI Nat. Protoc. PD OCT PY 2013 VL 8 IS 10 BP 1985 EP 2005 DI 10.1038/nprot.2013.123 PG 21 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 241JQ UT WOS:000326163400011 PM 24051960 ER PT J AU Wegienka, G Baird, D Cooper, T Woodcroft, K Havstad, S AF Wegienka, Ganesa Baird, Donna Cooper, Tracy Woodcroft, Kimberley Havstad, Suzanne TI Authors' Reply: Cytokines and Uterine Leiomyoma - A Novel Trustful Pathway? SO AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY LA English DT Letter C1 [Wegienka, Ganesa; Woodcroft, Kimberley; Havstad, Suzanne] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI 48202 USA. [Baird, Donna] Natl Inst Environm Hlth Sci, Epidemiol Branch, Dept Hlth & Human Serv, NIH, Res Triangle Pk, NC USA. [Cooper, Tracy] Henry Ford Hosp, Dept Diagnost Radiol, Div Ultrasound, Detroit, MI 48202 USA. RP Wegienka, G (reprint author), Henry Ford Hlth Syst, Dept Publ Hlth Sci, 1 Ford Pl,3E, Detroit, MI 48202 USA. EM gwegien1@hfhs.org RI Baird, Donna/D-5214-2017 OI Baird, Donna/0000-0002-5544-2653 NR 5 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1046-7408 EI 1600-0897 J9 AM J REPROD IMMUNOL JI Am. J. Reprod. Immunol. PD OCT PY 2013 VL 70 IS 4 BP 263 EP 263 DI 10.1111/aji.12147 PG 1 WC Immunology; Reproductive Biology SC Immunology; Reproductive Biology GA 217SD UT WOS:000324379800001 PM 23845097 ER PT J AU Lee, J Romero, R Chaiworapongsa, T Dong, Z Tarca, AL Xu, Y Chiang, PJ Kusanovic, JP Hassan, SS Yeo, L Yoon, BH Than, NG Kim, CJ AF Lee, JoonHo Romero, Roberto Chaiworapongsa, Tinnakorn Dong, Zhong Tarca, Adi L. Xu, Yi Chiang, Po Jen Pedro Kusanovic, Juan Hassan, Sonia S. Yeo, Lami Yoon, Bo Hyun Than, Nandor Gabor Kim, Chong Jai TI Characterization of the Fetal Blood Transcriptome and Proteome in Maternal Anti-Fetal Rejection: Evidence of a Distinct and Novel Type of Human Fetal Systemic Inflammatory Response SO AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY LA English DT Article DE Apolipoprotein C-III; CD 34; chronic placental inflammation; CXCL10; pregnancy ID PRETERM PREMATURE RUPTURE; AMNIOTIC-FLUID INTERLEUKIN-6; LEUKOCYTE ANTIGEN ANTIBODIES; PRETRANSPLANT SERUM CXCL10; NECROSIS-FACTOR-ALPHA; VERSUS-HOST-DISEASE; TOLL-LIKE RECEPTORS; REGULATORY T-CELLS; CHRONIC CHORIOAMNIONITIS; INTRAAMNIOTIC INFLAMMATION AB Background The human fetus is able to mount a systemic inflammatory response when exposed to microorganisms. This stereotypic response has been termed the 'fetal inflammatory response syndrome' (FIRS), defined as an elevation of fetal plasma interleukin-6 (IL-6). FIRS is frequently observed in patients whose preterm deliveries are associated with intra-amniotic infection, acute inflammatory lesions of the placenta, and a high rate of neonatal morbidity. Recently, a novel form of fetal systemic inflammation, characterized by an elevation of fetal plasma CXCL10, has been identified in patients with placental lesions consistent with 'maternal anti-fetal rejection'. These lesions include chronic chorioamnionitis, plasma cell deciduitis, and villitis of unknown etiology. In addition, positivity for human leukocyte antigen (HLA) panel-reactive antibodies (PRA) in maternal sera can also be used to increase the index of suspicion for maternal anti-fetal rejection. The purpose of this study was to determine (i) the frequency of pathologic lesions consistent with maternal anti-fetal rejection in term and spontaneous preterm births; (ii) the fetal serum concentration of CXCL10 in patients with and without evidence of maternal anti-fetal rejection; and (iii) the fetal blood transcriptome and proteome in cases with a fetal inflammatory response associated with maternal anti-fetal rejection. Method of study Maternal and fetal sera were obtained from normal term (n = 150) and spontaneous preterm births (n = 150). A fetal inflammatory response associated with maternal anti-fetal rejection was diagnosed when the patients met two or more of the following criteria: (i) presence of chronic placental inflammation; (ii) >= 80% of maternal HLA class I PRA positivity; and (iii) fetal serum CXCL10 concentration > 75th percentile. Maternal HLA PRA was analyzed by flow cytometry. The concentrations of fetal CXCL10 and IL-6 were determined by ELISA. Transcriptome analysis was undertaken after the extraction of total RNA from white blood cells with a whole-genome DASL assay. Proteomic analysis of fetal serum was conducted by two-dimensional difference gel electrophoresis. Differential gene expression was considered significant when there was a P < 0.01 and a fold-change > 1.5. Results (i) The frequency of placental lesions consistent with maternal anti-fetal rejection was higher in patients with preterm deliveries than in those with term deliveries (56% versus 32%; P < 0.001); (ii) patients with spontaneous preterm births had a higher rate of maternal HLA PRA class I positivity than those who delivered at term (50% versus 32%; P = 0.002); (iii) fetuses born to mothers with positive maternal HLA PRA results had a higher median serum CXCL10 concentration than those with negative HLA PRA results (P < 0.001); (iv) the median serum CXCL10 concentration (but not IL-6) was higher in fetuses with placental lesions associated with maternal anti-fetal rejection than those without such lesions (P < 0. 1); (v) a whole-genome DASL assay of fetal blood RNA demonstrated differential expression of 128 genes between fetuses with and without lesions associated with maternal anti-fetal rejection; and (vi) comparison of the fetal serum proteome demonstrated 20 proteins whose abundance differed between fetuses with and without lesions associated with maternal anti-fetal rejection. Conclusion We describe a systemic inflammatory response in human fetuses born to mothers with evidence of maternal anti-fetal rejection. The transcriptome and proteome of this novel type of fetal inflammatory response were different from that of FIRS type I (which is associated with acute infection/inflammation). C1 [Lee, JoonHo; Romero, Roberto; Chaiworapongsa, Tinnakorn; Dong, Zhong; Tarca, Adi L.; Xu, Yi; Chiang, Po Jen; Pedro Kusanovic, Juan; Hassan, Sonia S.; Yeo, Lami; Than, Nandor Gabor; Kim, Chong Jai] NICHD, Perinatol Res Branch, NIH, DHHS, Bethesda, MD USA. [Lee, JoonHo; Romero, Roberto; Chaiworapongsa, Tinnakorn; Dong, Zhong; Tarca, Adi L.; Xu, Yi; Chiang, Po Jen; Pedro Kusanovic, Juan; Hassan, Sonia S.; Yeo, Lami; Than, Nandor Gabor; Kim, Chong Jai] NICHD, Perinatol Res Branch, NIH, DHHS, Detroit, MI 48201 USA. [Chaiworapongsa, Tinnakorn; Hassan, Sonia S.; Yeo, Lami; Than, Nandor Gabor] Wayne State Univ, Sch Med, Dept Obstet & Gynecol, Detroit, MI 48201 USA. [Tarca, Adi L.] Wayne State Univ, Dept Comp Sci, Detroit, MI 48202 USA. [Pedro Kusanovic, Juan] Hosp Dr Sotero del Rio, Dept Obstet & Gynecol, Santiago, Chile. [Pedro Kusanovic, Juan] Pontificia Univ Catolica Chile, Sch Med, Dept Obstet & Gynecol, Santiago, Chile. [Yoon, Bo Hyun] Seoul Natl Univ, Coll Med, Dept Obstet & Gynecol, Seoul, South Korea. [Kim, Chong Jai] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul 138736, South Korea. RP Romero, R (reprint author), NICHD, Perinatol Res Branch, NIH, DHHS,Hutzel Womens Hosp, 3990 John R St, Detroit, MI 48201 USA. EM romeror@mail.nih.gov; ckim@amc.seoul.kr FU Perinatology Research Branch, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services (NICHD/NIH); NICHD, NIH [HHSN275201300006C] FX This research was supported, in part, by the Perinatology Research Branch, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services (NICHD/NIH); and, in part, with Federal funds from NICHD, NIH under Contract No. HHSN275201300006C. The authors are grateful to the patients who agreed to participate in our studies; to the nurses, laboratory staff, and clinicians who made this work possible; and to Maureen McGerty and Andrea Bernard (Wayne State University) for their critical readings of the manuscript. NR 171 TC 13 Z9 13 U1 0 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1046-7408 EI 1600-0897 J9 AM J REPROD IMMUNOL JI Am. J. Reprod. Immunol. PD OCT PY 2013 VL 70 IS 4 BP 265 EP 284 DI 10.1111/aji.12142 PG 20 WC Immunology; Reproductive Biology SC Immunology; Reproductive Biology GA 217SD UT WOS:000324379800003 PM 23905683 ER PT J AU Romero, R Whitten, A Korzeniewski, SJ Than, NG Chaemsaithong, P Miranda, J Dong, Z Hassan, SS Chaiworapongsa, T AF Romero, Roberto Whitten, Amy Korzeniewski, Steven J. Than, Nandor Gabor Chaemsaithong, Piya Miranda, Jezid Dong, Zhong Hassan, Sonia S. Chaiworapongsa, Tinnakorn TI Maternal Floor Infarction/Massive Perivillous Fibrin Deposition: A Manifestation of Maternal Antifetal Rejection? SO AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY LA English DT Article DE Fibrinoid deposition; HLA; plasma cell deciduitis; stillbirth; villitis; pregnancy; chorioamnionitis; VUE; PRA; CXCL; MPFD; MFI ID REGULATORY T-CELLS; RENAL-ALLOGRAFT REJECTION; VERSUS-HOST-DISEASE; LEUKOCYTE ANTIGEN ANTIBODIES; SOLID-ORGAN TRANSPLANTATION; CHEMOKINE RECEPTOR CXCR3; CHRONIC CHORIOAMNIONITIS; CLINICAL-SIGNIFICANCE; UNKNOWN ETIOLOGY; FETAL TOLERANCE AB Objective Massive perivillous fibrin deposition (MPFD) and maternal floor infarction (MFI) are related placental lesions often associated with fetal death and fetal growth restriction. A tendency to recur in subsequent pregnancies has been reported. This study was conducted to determine whether this complication of pregnancy could reflect maternal antifetal rejection. Methods Pregnancies with MPFD were identified (n=10). Controls consisted of women with uncomplicated pregnancies who delivered at term without MPFD (n=175). Second-trimester maternal plasma was analyzed for panel-reactive anti-HLA class I and class II antibodies. The prevalence of chronic chorioamnionitis, villitis of unknown etiology, and plasma cell deciduitis was compared between cases and controls. Immunohistochemistry was performed on available umbilical vein segments from cases with MPFD (n=4) to determine whether there was evidence of complement activation (C4d deposition). Specific maternal HLA-antibody and fetal HLA-antigen status were also determined in paired specimens (n=6). Plasma CXCL-10 concentrations were measured in longitudinal samples of cases (n=28 specimens) and controls (n=749 specimens) by ELISA. Linear mixed-effects models were used to test for differences in plasma CXCL-10 concentration. Results (i) The prevalence of plasma cell deciduitis in the placenta was significantly higher in cases with MPFD than in those with uncomplicated term deliveries (40% versus 8.6%, P=0.01), (ii) patients with MPFD had a significantly higher frequency of maternal anti-HLA class I positivity during the second trimester than those with uncomplicated term deliveries (80% versus 36%, P=0.01); (iii) strongly positive C4d deposition was observed on umbilical vein endothelium in cases of MPFD, (iv) a specific maternal antibody against fetal HLA antigen class I or II was identified in all cases of MPFD; and 5) the mean maternal plasma concentration of CXCL-10 was higher in patients with evidence of MPFD than in those without evidence of MFPD (P<0.001). Conclusion A subset of patients with MPFD has evidence of maternal antifetal rejection. C1 [Romero, Roberto; Whitten, Amy; Korzeniewski, Steven J.; Than, Nandor Gabor; Chaemsaithong, Piya; Miranda, Jezid; Dong, Zhong; Hassan, Sonia S.; Chaiworapongsa, Tinnakorn] NICHD, Perinatol Res Branch, NIH, DHHS, Detroit, MI USA. [Romero, Roberto; Whitten, Amy; Korzeniewski, Steven J.; Than, Nandor Gabor; Chaemsaithong, Piya; Miranda, Jezid; Dong, Zhong; Hassan, Sonia S.; Chaiworapongsa, Tinnakorn] NICHD, Perinatol Res Branch, NIH, DHHS, Bethesda, MD USA. [Whitten, Amy; Korzeniewski, Steven J.; Than, Nandor Gabor; Chaemsaithong, Piya; Miranda, Jezid; Hassan, Sonia S.; Chaiworapongsa, Tinnakorn] Wayne State Univ, Sch Med, Dept Obstet & Gynecol, Detroit, MI 48201 USA. RP Romero, R (reprint author), Wayne State Univ, Hutzel Womens Hosp, Perinatol Res Branch, NICHD,NIH,DHHS, 3990 John R,Box 4, Detroit, MI 48201 USA. EM romeror@mail.nih.gov FU Perinatology Research Branch, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services (NICHD/NIH); NICHD, NIH [HSN275201300006C] FX This research was supported, in part, by the Perinatology Research Branch, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services (NICHD/NIH); and, in part, with Federal funds from NICHD, NIH under Contract No. HSN275201300006C. NR 116 TC 12 Z9 12 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1046-7408 EI 1600-0897 J9 AM J REPROD IMMUNOL JI Am. J. Reprod. Immunol. PD OCT PY 2013 VL 70 IS 4 BP 285 EP 298 DI 10.1111/aji.12143 PG 14 WC Immunology; Reproductive Biology SC Immunology; Reproductive Biology GA 217SD UT WOS:000324379800004 PM 23905710 ER PT J AU Wegienka, G Baird, DD Cooper, T Woodcroft, KJ Havstad, S AF Wegienka, Ganesa Baird, Donna Day Cooper, Tracy Woodcroft, Kimberley J. Havstad, Suzanne TI Cytokine Patterns Differ Seasonally between Women with and without Uterine Leiomyomata SO AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY LA English DT Article DE chemokines; cytokines; growth factors; inflammation; leiomyoma ID REPRODUCTIVE FACTORS; MONONUCLEAR-CELLS; FIBROIDS; RISK; INFLAMMATION; HYPOTHESIS; CANCER; SUSCEPTIBILITY; ENDOMETRIOSIS; HYSTERECTOMY AB Problem Uterine leiomyomata are the most common reproductive tumor in women, and their cause is not known. Methods of Study Plasma samples from 155 women (74 with and 81 without ultrasound-confirmed leiomyoma) from a new study of leiomyoma risk factors in the Detroit, Michigan area, were examined for any cross-sectional associations between commonly examined cytokines and leiomyoma presence. Results Associations varied by season of sample collection defined a priori as winter (December-February) and non-winter seasons. In the winter months, interleukin (IL)13 and IL17 were positively and IP10 was inversely associated with having a leiomyoma. In the non-winter samples, VEGF, G-CSF, and IP10 were positively associated and Monocyte chemotactic protein-1, IL13, and IL17 were inversely associated with having a leiomyoma. Associations were not changed by adjustment for age or BMI. Conclusions These data suggest that new insight into leiomyoma formation may be acquired through investigation of the immune system. C1 [Wegienka, Ganesa; Woodcroft, Kimberley J.; Havstad, Suzanne] Henry Ford Hosp, Dept Publ Hlth Sci, Detroit, MI 48202 USA. [Baird, Donna Day] Natl Inst Environm Hlth Sci, Epidemiol Branch, Dept Hlth & Human Serv, NIH, Res Triangle Pk, NC USA. [Cooper, Tracy] Henry Ford Hosp, Dept Diagnost Radiol, Div Ultrasound, Detroit, MI 48202 USA. RP Wegienka, G (reprint author), 1 Ford Pl,3E, Detroit, MI 48202 USA. EM gwegien1@hfhs.org RI Baird, Donna/D-5214-2017 OI Baird, Donna/0000-0002-5544-2653 FU intramural program at the National Institute of Environmental Health Sciences, NIH FX Dr. Christie Barker-Cummings manages the Study of Environment Lifestyle and Fibroids. Project management at Henry Ford Health System was led by Karen Bourgeois, LPN, and Kyra Jones, MEd. Data collection was funded by the intramural program at the National Institute of Environmental Health Sciences, NIH. NR 41 TC 2 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1046-7408 EI 1600-0897 J9 AM J REPROD IMMUNOL JI Am. J. Reprod. Immunol. PD OCT PY 2013 VL 70 IS 4 BP 327 EP 335 DI 10.1111/aji.12127 PG 9 WC Immunology; Reproductive Biology SC Immunology; Reproductive Biology GA 217SD UT WOS:000324379800008 PM 23614810 ER PT J AU Andreopoulou, E Vigoda, IS Valero, V Hershman, DL Raptis, G Vahdat, LT Han, HS Wright, JJ Pellegrino, CM Cristofanilli, M Alvarez, RH Fehn, K Fineberg, S Sparano, JA AF Andreopoulou, Eleni Vigoda, Ivette S. Valero, Vicente Hershman, Dawn L. Raptis, George Vahdat, Linda T. Han, Hyo S. Wright, John J. Pellegrino, Christine M. Cristofanilli, Massimo Alvarez, Ricardo H. Fehn, Karen Fineberg, Susan Sparano, Joseph A. TI Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE Farnesyl transferase inhibitor; Tipifarnib; Ras; Breast cancer; Neoadjuvant chemotherapy; Inflammatory breast cancer ID PATHOLOGICAL COMPLETE RESPONSE; BIPOLAR SPINDLE FORMATION; RAS TRANSGENIC MICE; FARNESYLTRANSFERASE INHIBITOR; NEOADJUVANT CHEMOTHERAPY; CANCER CELLS; TUMOR-CELLS; EXPRESSION; R115777; KINASE AB Tipifarnib (T) is a farnesyl transferase inhibitor (FTI) that enhances the antineoplastic effects of cytotoxic therapy in vitro, has activity in metastatic breast cancer, and enhances the pathologic complete response (pCR) rate to neoadjuvant doxorubicin-cyclophosphamide (AC) chemotherapy. We, therefore, performed a phase I-II trial of T plus neoadjuvant sequential weekly paclitaxel and 2-week AC chemotherapy in locally advanced breast cancer. Eligible patients with HER2-negative clinical stage IIB-IIIC breast cancer received 12 weekly doses of paclitaxel (80 mg/m(2)) followed by AC (60/600 mg/m(2) every 2 weeks and filgrastim), plus T (100 or 200 mg PO on days 1-3 of each P dose, and 200 mg PO on days 2-7 of each AC cycle). The trial was powered to detect an improvement in breast pCR rate from 15 to 35 % (alpha = 0.10, beta = 0.10) in two strata, including ER and/or PR-positive, non-inflammatory (stratum A) and inflammatory carcinoma (stratum B). Of the 60 patients accrued, there were no dose-limiting toxicities among the first six patients treated at the first T dose level (100 mg BID; N = 3) or second T dose level (200 mg BID; N = 3) plus paclitaxel. Breast pCR occurred in 6/33 patients (18 %, 95 % confidence intervals (CI) 7-36 %) and 1/22 patients (4 %, 95 % CI 0-8 %) in stratum B. Combination of the FTI T with weekly paclitaxel-AC is unlikely to be associated with a breast pCR rate of 35 % or higher in patients with locally advanced HER2/neu-negative inflammatory or non-inflammatory ER- and/or PR-positive breast carcinoma. C1 [Andreopoulou, Eleni; Vigoda, Ivette S.; Pellegrino, Christine M.; Fehn, Karen; Fineberg, Susan; Sparano, Joseph A.] Albert Einstein Coll Med, Montefiore Med Ctr, Dept Oncol, Weiler Div, Bronx, NY 10461 USA. [Valero, Vicente; Alvarez, Ricardo H.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Hershman, Dawn L.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA. [Raptis, George] North Shore LIJ Canc Inst, Manhasset, NY USA. [Vahdat, Linda T.] Weill Cornell Med Coll, New York, NY USA. [Han, Hyo S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Wright, John J.] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA. [Cristofanilli, Massimo] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. RP Sparano, JA (reprint author), Albert Einstein Coll Med, Montefiore Med Ctr, Dept Oncol, Weiler Div, 2 South,1825 Eastchester Rd, Bronx, NY 10461 USA. EM jsparano@montefiore.org OI Vahdat, Linda/0000-0002-3522-7382 FU United States Department of Health and Human Service [N01-CM-62204]; [RO1CA98473] FX Supported by United States Department of Health and Human Service contract N01-CM-62204 (P. I. Joseph A. Sparano, MD) and Grant RO1CA98473 (P. I. Said Sebti, PhD, co-PI: Joseph A. Sparano, MD). NR 40 TC 4 Z9 5 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-6806 EI 1573-7217 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD OCT PY 2013 VL 141 IS 3 BP 429 EP 435 DI 10.1007/s10549-013-2704-x PG 7 WC Oncology SC Oncology GA 239QS UT WOS:000326041100011 PM 24068539 ER PT J AU Phan, GQ Rosenberg, SA AF Phan, Giao Q. Rosenberg, Steven A. TI Adoptive Cell Transfer for Patients With Metastatic Melanoma: The Potential and Promise of Cancer Immunotherapy SO CANCER CONTROL LA English DT Article ID TUMOR-INFILTRATING LYMPHOCYTES; CD8(+) T-CELLS; RECOMBINANT INTERLEUKIN-2 THERAPY; HIGH-DOSE INTERLEUKIN-2; ACTIVATED KILLER-CELLS; AUTOLOGOUS TUMOR; MALIGNANT-MELANOMA; CLINICAL-TRIAL; ADVERSE EVENT; REGRESSION AB Background: Current FDA-approved therapeutic options for patients with metastatic melanoma include dacarbazine, interleukin 2, ipilimumab, vemurafenib, dabrafenib, and trametinib, but long-term tumor regression using available agents remains out of reach for most patients. Adoptive cell transfer (ACT) with autologous tumor-infiltrating lymphocytes (TILs) has shown encouraging results in clinical trials, with evidence of durable ongoing complete responses in patients with advanced melanoma. Emerging techniques to engineer T-cell receptors (TCRs) or chimeric antigen receptors (CARs) using lymphocytes from peripheral blood may offer new tactics in ACT Methods: We reviewed the literature to provide a synopsis on the development and clinical trial results of ACT, as well as the future outlook for using ACT in patients with metastatic melanoma. Results: ACT with TILs as part of a lymphodepleting regimen has been shown in clinical trials to cause objective clinical responses in approximately 40% to 72% of patients with metastatic melanoma, with up to 40% of those patients experiencing complete responses lasting up to 7 years ongoing. Pilot trials using TCR-engineered cells against melanoma-associated antigens MART-1 and gp100 and the cancer-testis antigen NY-ESO-1 have shown clinical responses in patients with melanoma. CAR cells directed against melanoma have been tested only in preclinical models; however, CAR cells targeting other histologies such as lymphoma have elicited antitumor responses in patients. Conclusions: An example of state-of-the-art personalized medicine, ACT is a potentially curative therapy for patients with metastatic melanoma. Ongoing trials aiming to simplify the regimens may allow a broader range of patients to be treated and enable ACT to be offered by academic cancer centers. C1 [Phan, Giao Q.; Rosenberg, Steven A.] NCI, Surg Branch, NIH, Bethesda, MD 20892 USA. RP Phan, GQ (reprint author), NCI, Surg Branch, NIH, Bldg 10-CRC,Room 3-5760,10 Ctr Dr, Bethesda, MD 20892 USA. EM Giao.Phan@nih.gov NR 66 TC 37 Z9 40 U1 0 U2 14 PU H LEE MOFFITT CANCER CENTER & RESEARCH INST PI TAMPA PA 12902 MAGNOLIA DR, TAMPA, FL 33612 USA SN 1073-2748 J9 CANCER CONTROL JI Cancer Control PD OCT PY 2013 VL 20 IS 4 BP 289 EP 297 PG 9 WC Oncology SC Oncology GA 234RV UT WOS:000325662900006 PM 24077405 ER PT J AU Yutin, N Galperin, MY AF Yutin, Natalya Galperin, Michael Y. TI A genomic update on clostridial phylogeny: Gram-negative spore formers and other misplaced clostridia SO ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID RIBOSOMAL-RNA ANALYSIS; SP-NOV.; GEN. NOV.; HUMAN FECES; POSITIVE BACTERIA; OUTER-MEMBRANE; COMB. NOV; SEQUENCE; SPORULATION; DATABASE AB The class Clostridia in the phylum Firmicutes (formerly low-G+C Gram-positive bacteria) includes diverse bacteria of medical, environmental and biotechnological importance. The Selenomonas-Megasphaera-Sporomusa branch, which unifies members of the Firmicutes with Gram-negative-type cell envelopes, was recently moved from Clostridia to a separate class Negativicutes. However, draft genome sequences of the spore-forming members of the Negativicutes revealed typically clostridial sets of sporulation genes. To address this and other questions in clostridial phylogeny, we have compared a phylogenetic tree for a concatenated set of 50 widespread ribosomal proteins with the trees for beta subunits of the RNA polymerase (RpoB) and DNA gyrase (GyrB) and with the 16S rRNA-based phylogeny. The results obtained by these methods showed remarkable consistency, suggesting that they reflect the true evolutionary history of these bacteria. These data put the Selenomonas-Megasphaera-Sporomusa group back within the Clostridia. They also support placement of Clostridium difficile and its close relatives within the family Peptostreptococcaceae; we suggest resolving the long-standing naming conundrum by renaming it Peptoclostridium difficile. These data also indicate the existence of a group of cellulolytic clostridia that belong to the family Ruminococcaceae. As a tentative solution to resolve the current taxonomical problems, we propose assigning 78 validly described Clostridium species that clearly fall outside the family Clostridiaceae to six new genera: Peptoclostridium, Lachnoclostridium, Ruminiclostridium, Erysipelatoclostridium, Gottschalkia and Tyzzerella. This work reaffirms that 16S rRNA and ribosomal protein sequences are better indicators of evolutionary proximity than phenotypic traits, even such key ones as the structure of the cell envelope and Gram-staining pattern. C1 [Yutin, Natalya; Galperin, Michael Y.] Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA. RP Galperin, MY (reprint author), Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA. EM galperin@ncbi.nlm.nih.gov OI Galperin, Michael/0000-0002-2265-5572 FU NIH Intramural Research Program at the National Library of Medicine FX We thank Drs. Boris Belitsky, Elizaveta Bonch-Osmolovskaya, Ilya Borovok, Jean Paul Euzeby, William B. Whitman and Juergen Wiegel for critically reading the manuscript and many helpful comments and Drs. Yuri Wolf and Eugene Koonin for advice on the phylogenetic trees. This work was supported by the NIH Intramural Research Program at the National Library of Medicine. NR 59 TC 116 Z9 119 U1 8 U2 57 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1462-2912 EI 1462-2920 J9 ENVIRON MICROBIOL JI Environ. Microbiol. PD OCT PY 2013 VL 15 IS 10 BP 2631 EP 2641 DI 10.1111/1462-2920.12173 PG 11 WC Microbiology SC Microbiology GA 230TY UT WOS:000325367200001 PM 23834245 ER PT J AU Hankee, LD Preis, SR Beiser, AS Devine, SA Liu, YL Seshadri, S Wolf, PA Au, R AF Hankee, Lisa D. Preis, Sarah R. Beiser, Alexa S. Devine, Sherral A. Liu, Yulin Seshadri, Sudha Wolf, Philip A. Au, Rhoda TI QUALITATIVE NEUROPSYCHOLOGICAL MEASURES: NORMATIVE DATA ON EXECUTIVE FUNCTIONING TESTS FROM THE FRAMINGHAM OFFSPRING STUDY SO EXPERIMENTAL AGING RESEARCH LA English DT Article ID WHITE-MATTER HYPERINTENSITIES; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; OLDER-ADULTS; RISK PROFILE; BRAIN; AGE; ASSOCIATION; POPULATION; ATTENTION AB Background/Study Context: Studies have found that executive functioning is affected early in the pathophysiological processes associated with Alzheimer's disease and vascular dementia. There also exists a range of functioning on executive tasks during normal aging. Although qualitative data are commonly utilized in clinical practice for evaluating subtle changes in cognitive functioning and diagnostic discernment, it is not clear whether error responses used in clinical practice are also evident as normative behavior. Methods: As part of an extensive battery of neuropsychological tests, executive functioning measures (i.e., Trail Making Test Part B, Similarities and Verbal Fluency tests) were administered via standardized administration prescript. Regression analyses were used to determine associations between vascular aging indices and qualitative performance measures. Descriptive statistics are included for 1907 cognitively normal individuals. Results: Results suggest that although qualitative errors do occur, they are relatively infrequent within a presumably cognitively normal sample. Error commission rates on executive functioning tests are significantly associated with both age and education. Conclusion: Provided is a baseline profile of errors committed on tests of executive function across a range of age and educational levels. The normative data sets are included, stratified by age and educational achievement, for which to compare qualitative test performance of clinical and research populations. C1 [Hankee, Lisa D.; Beiser, Alexa S.; Devine, Sherral A.; Liu, Yulin; Seshadri, Sudha; Wolf, Philip A.; Au, Rhoda] Boston Univ, Sch Med, Boston, MA 02118 USA. [Hankee, Lisa D.; Preis, Sarah R.; Beiser, Alexa S.; Devine, Sherral A.; Liu, Yulin; Seshadri, Sudha; Wolf, Philip A.; Au, Rhoda] NHLBI, Framingham Heart Study, Framingham, MA USA. [Preis, Sarah R.; Beiser, Alexa S.] Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA. RP Au, R (reprint author), Boston Univ, Dept Neurol, Sch Med, 72 E Concord St,B-6, Boston, MA 02118 USA. EM rhodaau@bu.edu OI Beiser, Alexa/0000-0001-8551-7778 FU Framingham Heart Study's National Heart, Lung, and Blood Institute [N01-HC-25195]; National Institute on Aging [R01-AG16495, R01-AG08122, R01-AG033040]; National Institute of Neurological Disorders and Stroke [R01-NS17950] FX This work was supported by the Framingham Heart Study's National Heart, Lung, and Blood Institute contract (N01-HC-25195), by grants (R01-AG16495, R01-AG08122, R01-AG033040) from the National Institute on Aging, and by grant (R01-NS17950) from the National Institute of Neurological Disorders and Stroke. NR 44 TC 4 Z9 4 U1 0 U2 12 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0361-073X EI 1096-4657 J9 EXP AGING RES JI Exp. Aging Res. PD OCT 1 PY 2013 VL 39 IS 5 BP 515 EP 535 DI 10.1080/0361073X.2013.839029 PG 21 WC Geriatrics & Gerontology; Psychology SC Geriatrics & Gerontology; Psychology GA 239HH UT WOS:000326012700003 PM 24151914 ER PT J AU Wright, PW Huehn, A Cichocki, F Li, H Sharma, N Dang, H Lenvik, TR Woll, P Kaufman, D Miller, JS Anderson, SK AF Wright, P. W. Huehn, A. Cichocki, F. Li, H. Sharma, N. Dang, H. Lenvik, T. R. Woll, P. Kaufman, D. Miller, J. S. Anderson, S. K. TI Identification of a KIR antisense lncRNA expressed by progenitor cells SO GENES AND IMMUNITY LA English DT Article DE human NK cells; KIR; antisense; transcription; lncRNA ID ZINC-FINGER GENE; DNA METHYLATION; NK CELLS; TRANSCRIPTION; REPERTOIRE; PROMOTERS; PATTERNS; ELEMENT; BINDING; FAMILY AB Human NK cells express cell surface class I MHC receptors (killer cell immunoglobulin-like receptor, KIR) in a probabilistic manner. Previous studies have shown that a distal promoter acts in conjunction with a proximal bidirectional promoter to control the selective activation of KIR genes. We report here the presence of an intron 2 promoter in several KIR genes that produce a spliced antisense transcript. This long noncoding RNA (lncRNA) transcript contains antisense sequence complementary to KIR-coding exons 1 and 2 as well as the proximal promoter region of the KIR genes. The antisense promoter contains myeloid zinc finger 1 (MZF-1)-binding sites, a transcription factor found in hematopoietic progenitors and myeloid precursors. The KIR antisense lncRNA was detected only in progenitor cells or pluripotent cell lines, suggesting a function that is specific for stem cells. Overexpression of MZF-1 in developing NK cells led to decreased KIR expression, consistent with a role for the KIR antisense lncRNA in silencing KIR gene expression early in development. C1 [Wright, P. W.; Li, H.; Anderson, S. K.] SAIC Frederick Inc, Frederick Natl Lab, Expt Immunol Lab, Frederick, MD 21702 USA. [Huehn, A.; Sharma, N.; Dang, H.; Anderson, S. K.] NCI, Canc & Inflammat Program, CCR, Frederick, MD 21701 USA. [Cichocki, F.; Lenvik, T. R.; Miller, J. S.] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA. [Woll, P.; Kaufman, D.] Univ Minnesota, Stem Cell Inst, Minneapolis, MN USA. RP Anderson, SK (reprint author), SAIC Frederick Inc, Frederick Natl Lab, Expt Immunol Lab, Bldg 560,Room 31-93, Frederick, MD 21702 USA. EM andersonst@mail.nih.gov RI Anderson, Stephen/B-1727-2012; OI Anderson, Stephen/0000-0002-7856-4266; Miller, Jeffrey S/0000-0002-0339-4944; Woll, Petter S./0000-0002-2340-2526 FU National Cancer Institute (NCI), NIH [HHSN261200800001E]; NCI [P01 111412]; Intramural Research Program of the NIH, NCI, Center for Cancer Research FX This project has been funded in whole or in part with federal funds from the National Cancer Institute (NCI), NIH, under contract HHSN261200800001E and NCI grant P01 111412 (JSM, SKA). This research was supported in part by the Intramural Research Program of the NIH, NCI, Center for Cancer Research. NR 27 TC 9 Z9 9 U1 0 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1466-4879 EI 1476-5470 J9 GENES IMMUN JI Genes Immun. PD OCT PY 2013 VL 14 IS 7 BP 427 EP 433 DI 10.1038/gene.2013.36 PG 7 WC Genetics & Heredity; Immunology SC Genetics & Heredity; Immunology GA 240LR UT WOS:000326098300003 PM 23863987 ER PT J AU Gottesman, O Kuivaniemi, H Tromp, G Faucett, WA Li, RL Manolio, TA Sanderson, SC Kannry, J Zinberg, R Basford, MA Brilliant, M Carey, DJ Chisholm, RL Chute, CG Connolly, JJ Crosslin, D Denny, JC Gallego, CJ Haines, JL Hakonarson, H Harley, J Jarvik, GP Kohane, I Kullo, IJ Larson, EB McCarty, C Ritchie, MD Roden, DM Smith, ME Bottinger, EP Williams, MS AF Gottesman, Omri Kuivaniemi, Helena Tromp, Gerard Faucett, W. Andrew Li, Rongling Manolio, Teri A. Sanderson, Saskia C. Kannry, Joseph Zinberg, Randi Basford, Melissa A. Brilliant, Murray Carey, David J. Chisholm, Rex L. Chute, Christopher G. Connolly, John J. Crosslin, David Denny, Joshua C. Gallego, Carlos J. Haines, Jonathan L. Hakonarson, Hakon Harley, John Jarvik, Gail P. Kohane, Isaac Kullo, Iftikhar J. Larson, Eric B. McCarty, Catherine Ritchie, Marylyn D. Roden, Dan M. Smith, Maureen E. Bottinger, Erwin P. Williams, Marc S. CA eMerge Network TI The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future SO GENETICS IN MEDICINE LA English DT Review DE collaborative research; electronic medical records; genetics and genomics; genome-wide association studies; personalized medicine ID DECISION-SUPPORT-SYSTEMS; WIDE ASSOCIATION; PRACTITIONER PERFORMANCE; PATIENT OUTCOMES; CLINICAL IMPACT; PHENOME-WIDE; BASE-PAIRS; HEALTH; VARIANTS; DISCOVERIES AB The Electronic Medical Records and Genomics Network is a National Human Genome Research Institute-funded consortium engaged in the development of methods and best practices for using the electronic medical record as a tool for genomic research. Now in its sixth year and second funding cycle, and comprising nine research groups and a coordinating center, the network has played a major role in validating the concept that clinical data derived from electronic medical records can be used successfully for genomic research. Current work is advancing knowledge in multiple disciplines at the intersection of genomics and health. care informatics, particularly for electronic phenotyping, genome-wide association studies, genomic medicine implementation, and the ethical and regulatory issues associated with genomics research and returning results to study participants. Here, we describe the evolution, accomplishments, opportunities, and challenges of the network from its inception as a five-group consortium focused on genotype-phenotype associations for genomic discovery to its current form as a nine-group consortium pivoting toward the implementation of genomic medicine. C1 [Gottesman, Omri; Sanderson, Saskia C.; Kannry, Joseph; Zinberg, Randi; Bottinger, Erwin P.] Mt Sinai Sch Med, New York, NY 10029 USA. [Kuivaniemi, Helena; Tromp, Gerard; Faucett, W. Andrew; Carey, David J.; Williams, Marc S.] Weis Ctr Res, Geisinger Clin, Danville, PA 17822 USA. [Li, Rongling; Manolio, Teri A.] NHGRI, NIH, Bethesda, MD 20892 USA. [Basford, Melissa A.; Denny, Joshua C.; Haines, Jonathan L.; Roden, Dan M.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Brilliant, Murray] Marshfield Clin Res Fdn, Marshfield, WI USA. [Chisholm, Rex L.; Smith, Maureen E.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Chute, Christopher G.; Kullo, Iftikhar J.] Mayo Clin, Rochester, MN USA. [Connolly, John J.; Hakonarson, Hakon] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Crosslin, David; Gallego, Carlos J.; Jarvik, Gail P.] Univ Washington, Med Ctr, Seattle, WA 98195 USA. [Harley, John] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Kohane, Isaac] Boston Childrens Hosp, Boston, MA USA. [Larson, Eric B.] Grp Hlth Res Inst, Seattle, WA USA. [McCarty, Catherine] Essentia Inst Rural Hlth, Duluth, MN USA. [Ritchie, Marylyn D.] Penn State Univ, University Pk, PA 16802 USA. RP Gottesman, O (reprint author), Mt Sinai Sch Med, New York, NY 10029 USA. EM omri.gottesman@mssm.edu; shkuivaniemi@geisinger.edu RI Jarvik, Gail/N-6476-2014; Hulot, Jean-Sebastien/A-2278-2016; Wagner, Michael/E-6273-2016; Tromp, Gerard/B-2677-2017; OI Jarvik, Gail/0000-0002-6710-8708; Hulot, Jean-Sebastien/0000-0001-5463-6117; Overby, Casey/0000-0001-9302-5968; Wagner, Michael/0000-0003-3421-4763; Tromp, Gerard/0000-0002-7761-0806; Pan, Vivian/0000-0002-1666-9273; Williams, Marc/0000-0001-6165-8701; Kuivaniemi, Helena/0000-0001-5753-8766 FU NHGRI; National Institute of General Medical Sciences [U01HG004438, U01HG004424, U01HG004610, U01HG006375, U01HG004608, U01HG006389, U01HG04599, U01HG006379, U01HG004609, U01HG006388, U01HG04603, U01HG006378, U01HG006385, U01HG006382, U01HG006380, U01HG006830, U01HG006828]; Pennsylvania Commonwealth Universal Research Enhancement Program; Ben Franklin Technology Development Fund of PA; National Institutes of Health [P30DK072488, R01DK088231, R01DK091601]; Geisinger Clinical Research Fund; American Heart Association; Northwest Institute of Genetic Medicine; Washington State Life Sciences Discovery funds [265508] FX The eMERGE Network is funded by the NHGRI, with additional funding from the National Institute of General Medical Sciences through the following grants: U01HG004438 to Johns Hopkins University; U01HG004424 to the Broad Institute; U01HG004438 to Center for Inherited Disease Research; U01HG004610 and U01HG006375 to Group Health Cooperative; U01HG004608 to Marshfield Clinic; U01HG006389 to Essentia Institute of Rural Health; U01HG04599 and U01HG006379 to Mayo Clinic; U01HG004609 and U01HG006388 to Northwestern University; U01HG04603 and U01HG006378 to Vanderbilt University; U01HG006385 to the Coordinating Center; U01HG006382 to Geisinger Clinic; U01HG006380 to Mount Sinai School of Medicine; U01HG006830 to The Children's Hospital of Philadelphia; and U01HG006828 to Cincinnati Children's Hospital and Boston Children's Hospital.; The biobanking and genotyping at Geisinger Clinic was funded by the Pennsylvania Commonwealth Universal Research Enhancement Program, the Ben Franklin Technology Development Fund of PA, grants from the National Institutes of Health (P30DK072488, R01DK088231, and R01DK091601), the Geisinger Clinical Research Fund, and a grant-in-aid from the American Heart Association.; The Group Health subject collection was part of an ongoing National Institute on Aging project, Adult Changes in Thoughts (ACT) study (AG06781) and was also supported in part by the Northwest Institute of Genetic Medicine with funds from the Washington State Life Sciences Discovery funds (grant 265508). NR 52 TC 140 Z9 143 U1 2 U2 39 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 EI 1530-0366 J9 GENET MED JI Genet. Med. PD OCT PY 2013 VL 15 IS 10 BP 761 EP 771 DI 10.1038/gim.2013.72 PG 11 WC Genetics & Heredity SC Genetics & Heredity GA 234SQ UT WOS:000325665000002 PM 23743551 ER PT J AU Tarczy-Hornoch, P Amendola, L Aronson, SJ Garraway, L Gray, S Grundmeier, RW Hindorff, LA Jarvik, G Karavite, D Lebo, M Plon, SE Van Allen, E Weck, KE White, PS Yang, YP AF Tarczy-Hornoch, Peter Amendola, Laura Aronson, Samuel J. Garraway, Levi Gray, Stacy Grundmeier, Robert W. Hindorff, Lucia A. Jarvik, Gail Karavite, Dean Lebo, Matthew Plon, Sharon E. Van Allen, Eliezer Weck, Karen E. White, Peter S. Yang, Yaping TI A survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record SO GENETICS IN MEDICINE LA English DT Article DE clinical decision support; clinical sequencing; decision support rules; electronic health record; electronic medical record; next-generation sequencing ID MEDICAL-RECORDS; GENETIC-VARIANTS; DECISION-SUPPORT; KNOWLEDGE; INTEGRATION AB Purpose: Genome-scale clinical sequencing is being adopted more broadly in medical practice. The National Institutes of Health developed the Clinical Sequencing Exploratory Research (CSER) program to guide implementation and dissemination of best practices for the integration of sequencing into clinical care. This study describes and compares the state of the art of incorporating whole-exome and whole-genome sequencing results into the electronic health record, including approaches to decision support across the six current CSER sites. Methods: The CSER Medical Record Working Group collaboratively developed and completed an in-depth survey to assess the communication of genome-scale data into the electronic health record. We summarized commonalities and divergent approaches. Results: Despite common sequencing platform (Illumina) adoptions, there is a great diversity of approaches to annotation tools and workflow, as well as to report generation. At all sites, reports are human-readable structured documents available as passive decision support in the electronic health record. Active decision support is in early implementation at two sites. Conclusion: The parallel efforts across CSER sites in the creation of systems for report generation and integration of reports into the electronic health record, as well as the lack of standardized approaches to interfacing with variant databases to create active clinical decision support, create opportunities for cross-site and vendor collaborations. C1 [Tarczy-Hornoch, Peter; Amendola, Laura; Aronson, Samuel J.; Garraway, Levi; Grundmeier, Robert W.; Hindorff, Lucia A.; Karavite, Dean; Plon, Sharon E.; Van Allen, Eliezer; Weck, Karen E.; White, Peter S.] NHGRI, NIH, Clin Sequencing Exploratory Res Elect Med Records, Bethesda, MD 20892 USA. [Tarczy-Hornoch, Peter; Amendola, Laura; Jarvik, Gail] Univ Washington, Seattle, WA 98195 USA. [Aronson, Samuel J.; Lebo, Matthew] Partners HealthCare Ctr Personalized Genet Med, Boston, MA USA. [Garraway, Levi; Gray, Stacy; Van Allen, Eliezer] Dana Farber Canc Inst, Boston, MA 02115 USA. [Garraway, Levi; Gray, Stacy; Grundmeier, Robert W.; Lebo, Matthew; White, Peter S.] Harvard Univ, Sch Med, Boston, MA USA. [Gray, Stacy; Van Allen, Eliezer] Broad Inst MIT & Harvard, Cambridge, MA USA. [Grundmeier, Robert W.; Karavite, Dean; White, Peter S.] Childrens Hosp Philadelphia, Ctr Biomed Informat, Philadelphia, PA 19104 USA. [Hindorff, Lucia A.] NHGRI, NIH, Bethesda, MD 20892 USA. [Lebo, Matthew] Brigham & Womens Hosp, Boston, MA 02115 USA. [Plon, Sharon E.; Yang, Yaping] Baylor Coll Med, Houston, TX 77030 USA. [Weck, Karen E.] Univ N Carolina, Chapel Hill, NC USA. RP Tarczy-Hornoch, P (reprint author), NHGRI, NIH, Clin Sequencing Exploratory Res Elect Med Records, Bethesda, MD 20892 USA. EM pth@uw.edu RI Jarvik, Gail/N-6476-2014; OI Jarvik, Gail/0000-0002-6710-8708; Weck, Karen/0000-0002-8516-333X; Van Allen, Eliezer/0000-0002-0201-4444; Tarczy-Hornoch, Peter/0000-0003-1047-179X; Lebo, Matthew/0000-0002-9733-5207 FU National Institutes of Health [U01HG006507, U01HG00637, U01HG006500, U01HG606492, U01HG006487, U01HG006485, U01HG006546, KG100355, RC1LM010526, UL1RR02574, UL1TR000423, U01HL098188, 275200800001C-2-0-1]; Susan G. Komen foundation; Washington State Life Sciences Discovery Fund; Northwest Institute for Genetic Medicine; Dana-Farber Cancer Institute Leadership Council FX All the authors contributed equally to the writing of the this article. The authors thank the members of the Clinical Sequencing Exploratory Research (CSER) consortium, in particular all additional members of the informatics teams at each of the six current CSER sites. The following sources of funding supported parts of the work described in this article: National Institutes of Health extramural projects U01HG006507, U01HG00637, U01HG006500, U01HG606492, U01HG006487, U01HG006485, U01HG006546, KG100355, RC1LM010526, UL1RR02574, UL1TR000423, U01HL098188, and 275200800001C-2-0-1; the Susan G. Komen foundation; the Washington State Life Sciences Discovery Fund; the Northwest Institute for Genetic Medicine; and the Dana-Farber Cancer Institute Leadership Council. L.A.H. is a member of the National Human Genome Research Institute CSER staff team, responsible for scientific program management of the CSER program. NR 25 TC 22 Z9 22 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 EI 1530-0366 J9 GENET MED JI Genet. Med. PD OCT PY 2013 VL 15 IS 10 BP 824 EP 832 DI 10.1038/gim.2013.120 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA 234SQ UT WOS:000325665000010 PM 24071794 ER PT J AU Melnick, RL Ward, JM Huff, J AF Melnick, Ronald L. Ward, Jerrold M. Huff, James TI War on Carcinogens: Industry Disputes Human Relevance of Chemicals Causing Cancer in Laboratory Animals Based on Unproven Hypotheses, Using Kidney Tumors as an Example SO INTERNATIONAL JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH LA English DT Editorial Material DE carcinogenicity; chronic progressive nephropathy; human relevance; kidney; rats; renal tubule tumors; risk assessment ID CHRONIC PROGRESSIVE NEPHROPATHY; NATIONAL TOXICOLOGY PROGRAM; HUMAN RISK-ASSESSMENT; MALE F344 RATS; CHRONIC TOXICITY; IARC MONOGRAPHS; PUBLIC-HEALTH; ASSOCIATION; DISEASE; REEVALUATION AB Evidence from studies in animals is essential for identifying chemicals likely to cause or contribute to many diseases in humans, including cancers. Yet, to avoid or delay the implementation of protective public health standards, the chemical industry typically denies cancer causation by agents they produce. The spurious arguments put forward to discount human relevance are often based on inadequately tested hypotheses or modes of action that fail to meet Bradford Hill criteria for causation. We term the industry attacks on the relevance of animal cancer findings as the "War on Carcinogens.'' Unfortunately, this tactic has been effective in preventing timely and appropriate health protective actions on many economically important yet carcinogenic chemicals, including: arsenic, asbestos, benzene, 1,3-butadiene, formaldehyde, methylene chloride, phthalates, tobacco usage, trichloroethylene [TCE], and others. Recent examples of the "War on Carcinogens'' are chemicals causing kidney cancer in animals. Industry consultants argue that kidney tumor findings in rats with exacerbated chronic progressive nephropathy (CPN) are not relevant to humans exposed to these chemicals. We dispute and dismiss this unsubstantiated claim with data and facts, and divulge unprofessional actions from a leading toxicology journal. C1 [Melnick, Ronald L.] Ron Melnick Consulting LLC, North Logan, UT 84341 USA. [Ward, Jerrold M.] Global VetPathol, Montgomery Village, MD 20886 USA. [Huff, James] NIEHS, Res Triangle Pk, NC 27709 USA. RP Melnick, RL (reprint author), Ron Melnick Consulting LLC, 274 E 2280 N,B, North Logan, UT 84341 USA. NR 40 TC 2 Z9 2 U1 0 U2 10 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1077-3525 EI 2049-3967 J9 INT J OCCUP ENV HEAL JI Int. J. Occup. Environ. Health PD OCT PY 2013 VL 19 IS 4 BP 255 EP 260 DI 10.1179/1077352513Z.00000000090 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235XK UT WOS:000325755700001 PM 24588032 ER PT J AU An, CL Beard, WA Chen, DS Wilson, SH Makridakis, NM AF An, Changlong Beard, William A. Chen, Desheng Wilson, Samuel H. Makridakis, Nick M. TI Understanding the loss-of-function in a triple missense mutant of DNA polymerase beta found in prostate cancer SO INTERNATIONAL JOURNAL OF ONCOLOGY LA English DT Article DE DNA repair; polymerase; enzyme activity; expression analysis ID BASE EXCISION-REPAIR; CELLULAR-TRANSFORMATION; CRYSTAL-STRUCTURES; NUCLEAR EXTRACT; XENOPUS OOCYTES; ACTIVE-SITE; FIDELITY; MUTATIONS; MECHANISM; CELLS AB Human DNA polymerase (pol) beta is essential for base excision repair. We previously reported a triple somatic mutant of pol beta (p.P261L/T292A/I298T) found in an early onset prostate tumor. This mutation abolishes polymerase activity, and the wild-type allele was not present in the tumor, indicating a complete deficiency in pol beta function. The effect on polymerase activity is unexpected because the point mutations that comprise the triple mutant are not part of the active site. Herein, we demonstrate the mechanism of this loss-of-function. In order to understand the effect of the individual point mutations we biochemically analyzed all single and double mutants that comprise the triple mutant. We found that the p.I298T mutation is responsible for a marked instability of the triple mutant protein at 37 degrees C. At room temperature the triple mutant's low efficiency is also due to a decrease in the apparent binding affinity for the dNTP substrate, which is due to the p.T292A mutation. Furthermore, the triple mutant displays lower fidelity for transversions in vitro, due to the p.T292A mutation. We conclude that distinct mutations of the triple pol beta mutant are responsible for the loss of activity, lower fidelity, and instability observed in vitro. C1 [An, Changlong; Chen, Desheng; Makridakis, Nick M.] Tulane Univ, Dept Epidemiol, New Orleans, LA 70112 USA. [An, Changlong; Chen, Desheng; Makridakis, Nick M.] Tulane Univ, Tulane Canc Ctr, New Orleans, LA 70112 USA. [Beard, William A.; Wilson, Samuel H.] NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA. RP Makridakis, NM (reprint author), 1700 Tulane Ave,Rm 811, New Orleans, LA 70112 USA. EM nmakrida@tulane.edu FU National Institutes of Health, National Institute of Environmental Health Sciences [Z01-ES050158, Z01-ES050161]; National Institutes of Health [1U19CA105010, P20RR020152-06]; Department of Defense [PC094628]; NIH [P41 RR-01081] FX This research was supported by Research Project Numbers Z01-ES050158 and Z01-ES050161 in the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences and was in association with the National Institutes of Health Grant 1U19CA105010. NMM is supported by grant number P20RR020152-06 from the National Institutes of Health, and PC094628 from the Department of Defense. Molecular graphics images were produced using the Chimera package (35) from the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco (supported by NIH P41 RR-01081). NR 36 TC 1 Z9 1 U1 0 U2 5 PU SPANDIDOS PUBL LTD PI ATHENS PA POB 18179, ATHENS, 116 10, GREECE SN 1019-6439 EI 1791-2423 J9 INT J ONCOL JI Int. J. Oncol. PD OCT PY 2013 VL 43 IS 4 BP 1131 EP 1140 DI 10.3892/ijo.2013.2022 PG 10 WC Oncology SC Oncology GA 220RF UT WOS:000324603900021 PM 23877444 ER PT J AU Zhu, Y Wang, HS Sun, Y Yan, M Joo, J Sun, JF Chen, WP Qi, CF Lv, NH Morse, H AF Zhu, Yin Wang, Hongsheng Sun, Yan Yan, Ming Joo, Jungsoo Sun, Jiafang Chen, Weiping Qi, Chenfeng Lv, Nonghua Morse, Herbertcarpenter, III TI Identifying the role of interferon regulatory factor 8 in helicobacter pylori-induced inflammatory responses SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY LA English DT Meeting Abstract DE Helicobacter pylori; IRF8 C1 NIDDK, NIH, Bethesda, MD 20892 USA. NanChang Univ, Aiilated Hosp 1, Dept Gastroenterol, Nanchang, Peoples R China. NIAID, NIH, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0815-9319 EI 1440-1746 J9 J GASTROEN HEPATOL JI J. Gastroenterol. Hepatol. PD OCT PY 2013 VL 28 SU 3 BP 552 EP 552 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 226ER UT WOS:000325017803229 ER PT J AU Myers, M Parchen, D Geraci, M Brenholtz, R Knisely-Carrigan, D Hastings, C AF Myers, Mary Parchen, Debra Geraci, Marilla Brenholtz, Roger Knisely-Carrigan, Denise Hastings, Clare TI Using a Shared Governance Structure to Evaluate the Implementation of a New Model of Care SO JOURNAL OF NURSING ADMINISTRATION LA English DT Article ID PATIENT-SATISFACTION; OUTCOMES AB Sustaining change in the behaviors and habits of experienced practicing nurses can be frustrating and daunting, even when changes are based on evidence. Partnering with an active shared governance structure to communicate change and elicit feedback is an established method to foster partnership, equity, accountability, and ownership. Few recent exemplars in the literature link shared governance, change management, and evidence-based practice to transitions in care models. This article describes an innovative staff-driven approach used by nurses in a shared governance performance improvement committee to use evidence-based practice in determining the best methods to evaluate the implementation of a new model of care. C1 NIH, Ctr Clin, Nursing Serv, Bethesda, MD 20892 USA. NIH, Ctr Clin, Patient Care Serv, Bethesda, MD 20892 USA. RP Myers, M (reprint author), NIH, Ctr Clin, 9000 Rockville Pike,Bldg 10 Room 5-5441, Bethesda, MD 20892 USA. EM mmyers@cc.nih.gov FU Intramural NIH HHS [Z99 CL999999] NR 37 TC 3 Z9 3 U1 2 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-0443 EI 1539-0721 J9 J NURS ADMIN JI J. Nurs. Adm. PD OCT PY 2013 VL 43 IS 10 BP 509 EP 516 DI 10.1097/NNA.0b013e3182a3e7ff PG 8 WC Nursing SC Nursing GA 229NA UT WOS:000325271900006 PM 24061583 ER PT J AU Jeon, HS Choi, YY Fukuoka, J Fujii, M Lyakh, LA Song, SH Travis, WD Park, JY Jen, J AF Jeon, Hyo-Sung Choi, Yi Young Fukuoka, Junya Fujii, Makiko Lyakh, Lyudmila A. Song, Sang-Hyun Travis, William D. Park, Jae Yong Jen, Jin TI High expression of SNIP1 correlates with poor prognosis in Non-small cell lung cancer and SNIP1 interferes with the recruitment of HDAC1 to RB in vitro SO LUNG CANCER LA English DT Article DE SNIP1; RB; HDAC1; Prognosis; Lung cancer ID RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; REPRESS TRANSCRIPTION; DOMAIN; CYCLE AB The Rb tumor suppressor gene performs a critical role in controlling cell proliferation and tumorigenesis; it recruits HDAC1 protein into the E2F complexes to repress transcription. In this study, we demonstrate that SNIP1, RB and HDAC1 were significantly expressed in same lung cancer tissues in a tissue microarray (TMA) containing 300 non-small cell lung cancers (NSCLC). High expression level of SNIP) in tumor patients was significantly correlated with poor prognosis in NSCLC (log-rank P for OS = 0.01, log-rank P for DFS = 0.001). Functionally, SNIP1 competes with HDAC1 for binding to RB and reduces HDAC activity in vitro. Knockdown of SNIP1 reduced colony formation ability of lung cancer cells. These findings may indicate the involvement of SNIP1 in progression of lung cancer by regulating the RB/HDAC1 interaction. (C) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Jeon, Hyo-Sung; Choi, Yi Young; Park, Jae Yong] Kyungpook Natl Univ, Sch Med, Dept Biochem & Cell Biol, Taegu 700422, South Korea. [Fukuoka, Junya] Toyama Univ Hosp, Toyama Tissue Microarray Lab, Anat Pathol Lab, Toyama 9300194, Japan. [Fujii, Makiko] Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan. [Lyakh, Lyudmila A.] NCI, Canc & Inflammat Program, Ctr Canc Res, Frederick, MD 21702 USA. [Song, Sang-Hyun] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea. [Travis, William D.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA. [Jen, Jin] Mayo Clin, Dept Med, Div Pulm & Crit Care Med, Rochester, MN 55905 USA. RP Jeon, HS (reprint author), Kyungpook Natl Univ, Med Ctr, Lung Canc Ctr, 474 Hakjeongdong, Taegu 702210, South Korea. EM jeonh@knu.ac.kr; Jen.Jin@mayo.edu FU National Research Foundation of Korea (NRF); Ministry of Education, Science, and Technology [NRF2010-0004700] FX This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (NRF2010-0004700). NR 24 TC 2 Z9 2 U1 1 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0169-5002 EI 1872-8332 J9 LUNG CANCER JI Lung Cancer PD OCT PY 2013 VL 82 IS 1 BP 24 EP 30 DI 10.1016/j.lungcan.2013.07.015 PG 7 WC Oncology; Respiratory System SC Oncology; Respiratory System GA 236XU UT WOS:000325833600004 PM 23932364 ER PT J AU Ciribilli, Y Monti, P Bisio, A Nguyen, HT Ethayathulla, AS Ramos, A Foggetti, G Menichini, P Menendez, D Resnick, MA Viadiu, H Fronza, G Inga, A AF Ciribilli, Yari Monti, Paola Bisio, Alessandra Nguyen, H. Thien Ethayathulla, Abdul S. Ramos, Ana Foggetti, Giorgia Menichini, Paola Menendez, Daniel Resnick, Michael A. Viadiu, Hector Fronza, Gilberto Inga, Alberto TI Transactivation specificity is conserved among p53 family proteins and depends on a response element sequence code SO NUCLEIC ACIDS RESEARCH LA English DT Article ID DNA-BINDING DOMAIN; CRYSTAL-STRUCTURE; CORE DOMAIN; TRANSCRIPTION FACTOR; FUNCTIONAL ASSAY; APOPTOSIS INDUCTION; SPONTANEOUS TUMORS; GENE-EXPRESSION; TARGET GENES; MUTANT P53 AB Structural and biochemical studies have demonstrated that p73, p63 and p53 recognize DNA with identical amino acids and similar binding affinity. Here, measuring transactivation activity for a large number of response elements (REs) in yeast and human cell lines, we show that p53 family proteins also have overlapping transactivation profiles. We identified mutations at conserved amino acids of loops L1 and L3 in the DNA-binding domain that tune the transactivation potential nearly equally in p73, p63 and p53. For example, the mutant S139F in p73 has higher transactivation potential towards selected REs, enhanced DNA-binding cooperativity in vitro and a flexible loop L1 as seen in the crystal structure of the protein-DNA complex. By studying, how variations in the RE sequence affect transactivation specificity, we discovered a RE-transactivation code that predicts enhanced transactivation; this correlation is stronger for promoters of genes associated with apoptosis. C1 [Ciribilli, Yari; Bisio, Alessandra; Inga, Alberto] Univ Trento, Lab Transcript Networks, Ctr Integrat Biol CIBIO, I-38060 Trento, TN, Italy. [Monti, Paola; Foggetti, Giorgia; Menichini, Paola; Fronza, Gilberto] IRCSS Azienda Osped Univ San Martino IST, Ist Nazl Ric Canc, Mol Mutagenesis & DNA Repair Unit, I-16132 Genoa, Italy. [Nguyen, H. Thien; Ethayathulla, Abdul S.; Ramos, Ana; Viadiu, Hector] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA. [Menendez, Daniel; Resnick, Michael A.] NIEHS, Chromosome Stabil Grp, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA. RP Viadiu, H (reprint author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA. EM viadiu@ucsd.edu; gilberto.fronza@istge.it; inga@science.unitn.it FU Italian Association for Cancer Research (in part) (Associazione Italiana per la Ricerca sul Cancro), AIRC [IG9086, 5506]; CIBIO start-up funds; NIEHS intramural research funds [Z01-ES065079]; Marie-Curie/Autonomous-Province-of-Trento [40101712]; Department of Energy and National Institutes of Health [P41RR001209] FX Funding for open access charge: Italian Association for Cancer Research (in part) (Associazione Italiana per la Ricerca sul Cancro), AIRC [#IG9086 to AI and IG#5506 to G.F.] and CIBIO start-up funds; NIEHS intramural research funds (to M.A.R. and D.M.) project [Z01-ES065079 to M.A.R.]; Marie-Curie/Autonomous-Province-of-Trento (to Y.C.) (PAT) cofund grant [#40101712]; Diffraction data were collected at BL7-1 of the Stanford/Stanford Synchrotron Radiation Lightsource supported by the Department of Energy and National Institutes of Health [P41RR001209]. NR 85 TC 15 Z9 15 U1 0 U2 8 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-1048 EI 1362-4962 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PD OCT PY 2013 VL 41 IS 18 BP 8637 EP 8653 DI 10.1093/nar/gkt657 PG 17 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 236EG UT WOS:000325776600029 PM 23892287 ER PT J AU Kenyon, JC Prestwood, LJ Le Grice, SFJ Lever, AML AF Kenyon, Julia C. Prestwood, Liam J. Le Grice, Stuart F. J. Lever, Andrew M. L. TI In-gel probing of individual RNA conformers within a mixed population reveals a dimerization structural switch in the HIV-1 leader SO NUCLEIC ACIDS RESEARCH LA English DT Article ID PRIMER ACTIVATION SIGNAL; VIRUS TYPE-1 GENOME; PACKAGING SIGNAL; REVERSE TRANSCRIPTION; SHAPE CHEMISTRY; 5' REGION; INITIATION; PROTEIN; LOOP; GAG AB Definitive secondary structural mapping of RNAs in vitro can be complicated by the presence of more than one structural conformer or multimerization of some of the molecules. Until now, probing a single structure of conformationally flexible RNA molecules has typically relied on introducing stabilizing mutations or adjusting buffer conditions or RNA concentration. Here, we present an in-gel SHAPE (selective 2'OH acylation analysed by primer extension) approach, where a mixed structural population of RNA molecules is separated by non-denaturing gel electrophoresis and the conformers are individually probed within the gel matrix. Validation of the technique using a well-characterized RNA stem-loop structure, the HIV-1 trans-activation response element, showed that authentic structure was maintained and that the method was accurate and highly reproducible. To further demonstrate the utility of in-gel SHAPE, we separated and examined monomeric and dimeric species of the HIV-1 packaging signal RNA. Extensive differences in acylation sensitivity were seen between monomer and dimer. The results support a recently proposed structural switch model of RNA genomic dimerization and packaging, and demonstrate the discriminatory power of in-gel SHAPE. C1 [Kenyon, Julia C.; Prestwood, Liam J.; Lever, Andrew M. L.] Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 0QQ, England. [Le Grice, Stuart F. J.] NCI, HIV Drug Resistance Program, Ctr Canc Res, Frederick, MD 21702 USA. RP Lever, AML (reprint author), Univ Cambridge, Addenbrookes Hosp, Dept Med, Hills Rd, Cambridge CB2 0QQ, England. EM amll1@medschl.cam.ac.uk FU Biomedical Research Centre and the Medical Research Council [G0800142]; Intramural Research Program of the National Institutes of Health, National Cancer Institute; Medical Research Council [G0800142] FX Biomedical Research Centre and the Medical Research Council [G0800142 to A. L.] and the Intramural Research Program of the National Institutes of Health, National Cancer Institute [to S. Le G.]. Funding for open access charge: Medical Research Council [G0800142]. NR 47 TC 20 Z9 20 U1 1 U2 14 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-1048 EI 1362-4962 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PD OCT PY 2013 VL 41 IS 18 AR e174 DI 10.1093/nar/gkt690 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 236EG UT WOS:000325776600005 PM 23935074 ER PT J AU Rodgers, JE Sueta, CA Kucharska-Newton, A Stearns, S Chang, P Ni, HY Beyhaghi, H Zhou, L Blair, EA Federspiel, J AF Rodgers, Jo E. Sueta, Carla A. Kucharska-Newton, Anna Stearns, Sally Chang, Patricia Ni, Hanyu Beyhaghi, Hadi Zhou, Lei Blair, Elizabeth A. Federspiel, Jerome TI Predictors of medication adherence: results from the Atherosclerosis Risk in Communities Study SO PHARMACOTHERAPY LA English DT Meeting Abstract CT Annual Meeting of the American-College-of-Clinical-Pharmacy (ACCP) CY OCT 13-16, 2013 CL Albuquerque, NM SP Amer Coll Clin Pharm C1 [Rodgers, Jo E.; Blair, Elizabeth A.] Univ N Carolina, Div Pharmacotherapy & Expt Therapeut, Eshelman Scool Pharm, Chapel Hill, NC USA. [Sueta, Carla A.] Univ N Carolina, Div Cardiol, Sch Med, Chapel Hill, NC USA. [Kucharska-Newton, Anna] UNC Gillings Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA. [Stearns, Sally; Beyhaghi, Hadi; Zhou, Lei; Federspiel, Jerome] UNC Gillings Sch Publ Hlth, Chapel Hill, NC USA. [Chang, Patricia] Univ North Carolina Hlth Care, Div Cardiol, Dept Med, Chapel Hill, NC USA. [Ni, Hanyu] NHLBI, Dept Epidemiol, Chapel Hill, NC USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-0008 EI 1875-9114 J9 PHARMACOTHERAPY JI Pharmacotherapy PD OCT PY 2013 VL 33 IS 10 MA 32 BP E191 EP E192 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 230RM UT WOS:000325360100060 ER PT J AU Elman, I Borsook, D Volkow, ND AF Elman, Igor Borsook, David Volkow, Nora D. TI Pain and suicidality: Insights from reward and addiction neuroscience SO PROGRESS IN NEUROBIOLOGY LA English DT Review DE Anti-reward; Homeostasis; Allostasis; Habenula; Stress; Cross-sensitization; Aberrant learning ID POSTTRAUMATIC-STRESS-DISORDER; MAJOR DEPRESSIVE DISORDER; SELF-INJURIOUS-BEHAVIOR; INTERPERSONAL-PSYCHOLOGICAL THEORY; NATIONAL-COMORBIDITY-SURVEY; IRRITABLE-BOWEL-SYNDROME; DEFICIENCY SYNDROME RDS; OPPONENT-PROCESS THEORY; FREELY MOVING RATS; CHRONIC BACK-PAIN AB Suicidality is exceedingly prevalent in pain patients. Although the pathophysiology of this link remains unclear, it may be potentially related to the partial congruence of physical and emotional pain systems. The latter system's role in suicide is also conspicuous during setbacks and losses sustained in the context of social attachments. Here we propose a model based on the neural pathways mediating reward and anti-reward (i.e., allostatic adjustment to recurrent activation of the reward circuitry); both are relevant etiologic factors in pain, suicide and social attachments. A comprehensive literature search on neurobiology of pain and suicidality was performed. The collected articles were critically reviewed and relevant data were extracted and summarized within four key areas: (1) physical and emotional pain, (2) emotional pain and social attachments, (3) pain-and suicide-related alterations of the reward and anti-reward circuits as compared to addiction, which is the premier probe for dysfunction of these circuits and (4) mechanistically informed treatments of co-occurring pain and suicidality. Pain-, stress- and analgesic drugs-induced opponent and proponent states of the mesolimbic dopaminergic pathways may render reward and anti-reward systems vulnerable to sensitization, cross-sensitization and aberrant learning of contents and contexts associated with suicidal acts and behaviors. These findings suggest that pain patients exhibit alterations in the brain circuits mediating reward (depressed function) and anti-reward (sensitized function) that may affect their proclivity for suicide and support pain and suicidality classification among other "reward deficiency syndromes" and a new proposal for "enhanced anti-reward syndromes". We suggest that interventions aimed at restoring the balance between the reward and anti-reward networks in patients with chronic pain may help decreasing their suicide risk. Published by Elsevier Ltd. C1 [Elman, Igor] Harvard Univ, Sch Med, Providence VA Med Ctr, Somerville, MA 02143 USA. [Elman, Igor] Harvard Univ, Sch Med, Cambridge Hlth Alliance, Somerville, MA 02143 USA. [Borsook, David] Boston Childrens Hosp, PAIN Grp, Dept Anesthesiol, Boston, MA USA. [Borsook, David] Massachusetts Gen Hosp, Dept Radiol, Dept Psychiat & Radiol, Boston, MA 02114 USA. [Borsook, David] Harvard Univ, Sch Med, Dept Psychiat, McLean Hosp, Boston, MA 02115 USA. [Volkow, Nora D.] Natl Inst Drug Abuse, Bethesda, MD USA. RP Elman, I (reprint author), Harvard Univ, Sch Med, Providence VA Med Ctr, 26 Cent St, Somerville, MA 02143 USA. EM ielman@cha.harvard.edu FU Mayday Fund/Herlands Fund for Pain Systems Neuroscience Research; Providence VA Medical Center FX The authors gratefully acknowledge Ms. Adriana Johnson for her help with the preparation of the manuscript and support from the Mayday Fund/Herlands Fund for Pain Systems Neuroscience Research (DB).; This study was supported with resources and the use of facilities at the Providence VA Medical Center. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government. NR 467 TC 42 Z9 42 U1 7 U2 54 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0301-0082 J9 PROG NEUROBIOL JI Prog. Neurobiol. PD OCT PY 2013 VL 109 BP 1 EP 27 DI 10.1016/j.pneurobio.2013.06.003 PG 27 WC Neurosciences SC Neurosciences & Neurology GA 238AO UT WOS:000325913000001 PM 23827972 ER PT J AU Riedl, R Engels, EA Warren, JL Berghold, A Ricker, W Pfeiffer, RM AF Riedl, Regina Engels, Eric A. Warren, Joan L. Berghold, Andrea Ricker, Winnie Pfeiffer, Ruth M. TI Blood transfusions and the subsequent risk of cancers in the United States elderly SO TRANSFUSION LA English DT Article ID EPIDEMIOLOGY; METAANALYSIS; POPULATION; RECIPIENTS; ANEMIA; ADULTS AB BackgroundBlood transfusions are common in older adults and also may modulate the immune system. However, the impact of transfusion on cancer risk in the elderly has not been studied. Study Design and MethodsCancer risk after blood transfusion was evaluated in a US population-based case-control study using 552,951 elderly cases identified from cancer registries and 100,000 frequency-matched controls. Transfusions received 0 to 12, 13 to 30, and 31 to 48 months before cancer diagnosis or selection date were identified using Medicare claims. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using logistic regression models. A Bonferroni correction adjusted for multiple testing. ResultsTransfusions received 0 to 12 months before cancer diagnosis and/or selection were associated with significantly elevated risk of cancer overall (OR,2.05; 95% CI, 1.95-2.16) and cancer of the stomach; cancer of the colon; cancer of the liver, kidney, renal pelvis, and/or ureter; lymphoma; myeloma; and leukemia. No significant associations for cancer overall were observed for the two earlier intervals. No site was associated with transfusions received 13 to 30 or 31 to 48 months before diagnosis and/or selection. Nonetheless, overall cancer risk increased with the number of transfused periods (p-trend<0.0001). ConclusionRisk of overall cancer and specific sites was elevated 0 to 12 months after blood transfusion and associated with multiple transfusions, possibly due to reverse causation, that is, incipient cancers or cancer precursors causing anemia. C1 Med Univ Graz, Inst Med Informat Stat & Documentat, Graz, Austria. NCI, Div Canc Epidemiol & Genet, Rockville, MD USA. NCI, Div Canc Control & Populat Sci, Rockville, MD USA. Informat Management Serv Inc, Rockville, MD USA. RP Pfeiffer, RM (reprint author), NCI, Div Canc Epidemiol & Genet, NIH, HHS, 6120 Execut Blvd,EPS RM 8030, Bethesda, MD 20892 USA. EM pfeiffer@mail.nih.gov FU National Institute of Health, Division of Cancer Epidemiology and Genetics FX This research was supported by the Intramural Research Program of the National Institute of Health, Division of Cancer Epidemiology and Genetics. NR 23 TC 2 Z9 3 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD OCT PY 2013 VL 53 IS 10 BP 2198 EP 2206 DI 10.1111/trf.12071 PG 9 WC Hematology SC Hematology GA 230WP UT WOS:000325374300018 PM 23320915 ER PT J AU Cosson, P Perrin, J Bonifacino, JS AF Cosson, Pierre Perrin, Jackie Bonifacino, Juan S. TI Anchors aweigh: protein localization and transport mediated by transmembrane domains SO TRENDS IN CELL BIOLOGY LA English DT Review DE transmembrane domains; protein sorting; protein traffic; lipid domains; transmembrane receptors; endomembrane system ID GOLGI RETENTION SIGNAL; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEINS; UBIQUITIN LIGASE; RETRIEVAL RECEPTOR; PLASMA-MEMBRANE; DOWN-REGULATION; CELL-SURFACE; DEGRADATION; DETERMINANTS AB The transmembrane domains (TMDs) of integral membrane proteins have emerged as major determinants of intracellular localization and transport in the secretory and endocytic pathways. Unlike sorting signals in cytosolic domains, TMD sorting determinants are not conserved amino acid sequences but physical properties such as the length and hydrophilicity of the transmembrane span. The underlying sorting machinery is still poorly characterized, but several mechanisms have been proposed, including TMD recognition by transmembrane sorting receptors and partitioning into membrane lipid domains. Here we review the nature of TMD sorting determinants and how they may dictate transmembrane protein localization and transport. C1 [Cosson, Pierre; Perrin, Jackie] Ctr Med Univ Geneva, Dept Physiol Cellulaire & Metab, CH-1211 Geneva 4, Switzerland. [Bonifacino, Juan S.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Cell Biol & Metab Program, NIH, Bethesda, MD 20892 USA. RP Cosson, P (reprint author), Ctr Med Univ Geneva, Dept Physiol Cellulaire & Metab, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland. EM Pierre.Cosson@unige.ch; bonifacinoj@mail.nih.gov OI Bonifacino, Juan S./0000-0002-5673-6370 FU Intramural NIH HHS [ZIA HD001607-21] NR 63 TC 14 Z9 14 U1 4 U2 18 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0962-8924 J9 TRENDS CELL BIOL JI Trends Cell Biol. PD OCT PY 2013 VL 23 IS 10 BP 511 EP 517 DI 10.1016/j.tcb.2013.05.005 PG 7 WC Cell Biology SC Cell Biology GA 233SD UT WOS:000325588900006 PM 23806646 ER PT J AU Voss, MW Vivar, C Kramer, AF van Praag, H AF Voss, Michelle W. Vivar, Carmen Kramer, Arthur F. van Praag, Henriette TI Bridging animal and human models of exercise-induced brain plasticity SO TRENDS IN COGNITIVE SCIENCES LA English DT Review ID ADULT HIPPOCAMPAL NEUROGENESIS; TRANSGENIC MOUSE MODEL; GROWTH-FACTOR-I; ENHANCED SYNAPTIC PLASTICITY; ACTIVITY-DEPENDENT SECRETION; VOLUNTARY PHYSICAL-EXERCISE; NEUROTROPHIC FACTOR LEVELS; MILD COGNITIVE IMPAIRMENT; OBJECT RECOGNITION MEMORY; APOLIPOPROTEIN-E GENOTYPE AB Significant progress has been made in understanding the neurobiological mechanisms through which exercise protects and restores the brain. In this feature review, we integrate animal and human research, examining physical activity effects across multiple levels of description (neurons up to inter-regional pathways). We evaluate the influence of exercise on hippocampal structure and function, addressing common themes such as spatial memory and pattern separation, brain structure and plasticity, neurotrophic factors, and vasculature. Areas of research focused more within species, such as hippocampal neurogenesis in rodents, also provide crucial insight into the protective role of physical activity. Overall, converging evidence suggests exercise benefits brain function and cognition across the mammalian lifespan, which may translate into reduced risk for Alzheimer's disease (AD) in humans. C1 [Voss, Michelle W.] Univ Iowa, Dept Psychol, Iowa City, IA 52242 USA. [Vivar, Carmen; van Praag, Henriette] NIA, NIH, Neurosci Lab, Neuroplast & Behav Unit,Intramural Res Program, Baltimore, MD 21224 USA. [Kramer, Arthur F.] Univ Illinois, Dept Psychol, Urbana, IL 61801 USA. [Kramer, Arthur F.] Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA. [Voss, Michelle W.] Univ Iowa, AMBI, Iowa City, IA 52242 USA. RP Voss, MW (reprint author), Univ Iowa, Dept Psychol, Iowa City, IA 52242 USA. EM michelle-voss@uiowa.edu; vanpraagh@mail.nih.gov RI van Praag, Henriette/F-3939-2015 OI van Praag, Henriette/0000-0002-5727-434X FU Intramural Research Program of the National Institute on Aging; NIA [5R37AG025667]; University of Iowa FX This work was supported in part by the Intramural Research Program of the National Institute on Aging. A.F.K. was supported by 5R37AG025667 from the NIA. M.W.V. was supported by start-up funds from the University of Iowa. We thank Linda Kitabayashi for preparation of the photomicrograph and Dr Justin Rhodes and Martina Mustroph for sharing images. NR 298 TC 155 Z9 157 U1 14 U2 88 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1364-6613 J9 TRENDS COGN SCI JI TRENDS COGN. SCI. PD OCT PY 2013 VL 17 IS 10 BP 525 EP 544 DI 10.1016/j.tics.2013.08.001 PG 20 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 233SE UT WOS:000325589000010 PM 24029446 ER PT J AU Gasser, DL Winkler, CA Peng, M An, P McKenzie, LM Kirk, GD Shi, YC Xie, LTX Marbois, BN Clarke, CF Kopp, JB AF Gasser, David L. Winkler, Cheryl A. Peng, Min An, Ping McKenzie, Louise M. Kirk, Gregory D. Shi, Yuchen Xie, Letian X. Marbois, Beth N. Clarke, Catherine F. Kopp, Jeffrey B. TI Focal segmental glomerulosclerosis is associated with a PDSS2 haplotype and, independently, with a decreased content of coenzyme Q(10) SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE nephrotic syndrome; collapsing glomerulopathy; focal segmental glomerulosclerosis; mitochondria; ubiquinone ID DIPHOSPHATE SYNTHASE SUBUNIT-2; INDUCED MITOCHONDRIAL INJURY; HIV-ASSOCIATED NEPHROPATHY; KIDNEY-DISEASE; KD/KD MICE; NEPHROTIC SYNDROME; PROXIMAL TUBULES; TUBULOINTERSTITIAL NEPHRITIS; SACCHAROMYCES-CEREVISIAE; HYPOXIA-REOXYGENATION AB Gasser DL, Winkler CA, Peng M, An P, McKenzie LM, Kirk GD, Shi Y, Xie LX, Marbois BN, Clarke CF, Kopp JB. Focal segmental glomerulosclerosis is associated with a PDSS2 haplotype and, independently, with a decreased content of coenzyme Q(10). Am J Physiol Renal Physiol 305: F1228-F1238, 2013. First published August 7, 2013; doi:10.1152/ajprenal.00143.2013.-Focal segmental glomerulosclerosis (FSGS) and collapsing glomerulopathy are common causes of nephrotic syndrome. Variants in >20 genes, including genes critical for mitochondrial function, have been associated with these podocyte diseases. One such gene, PDSS2, is required for synthesis of the decaprenyl tail of coenzyme Q(10) (Q(10)) in humans. The mouse gene Pdss2 is mutated in the kd/kd mouse model of collapsing glomerulopathy. We examined the hypothesis that human PDSS2 polymorphisms are associated with podocyte diseases. We genotyped 377 patients with primary FSGS or collapsing glomerulopathy, together with 900 controls, for 9 single-nucleotide polymorphisms in the PDSS2 gene in a case-control study. Subjects included 247 African American (AA) and 130 European American (EA) patients and 641 AA and 259 EA controls. Among EAs, a pair of proxy SNPs was significantly associated with podocyte disease, and patients homozygous for one PDSS2 haplotype had a strongly increased risk for podocyte disease. By contrast, the distribution of PDSS2 genotypes and haplotypes was similar in AA patients and controls. Thus a PDSS2 haplotype, which has a frequency of 13% in the EA control population and a homozygote frequency of 1.2%, is associated with a significantly increased risk for FSGS and collapsing glomerulopathy in EAs. Lymphoblastoid cell lines from FSGS patients had significantly less Q(10) than cell lines from controls; contrary to expectation, this finding was independent of PDSS2 haplotype. These results suggest that FSGS patients have Q(10) deficiency and that this deficiency is manifested in patient-derived lymphoblastoid cell lines. C1 [Gasser, David L.; Peng, Min] Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA. [Winkler, Cheryl A.; An, Ping; McKenzie, Louise M.] SAIC Frederick, Frederick Natl Lab Canc Res, Basic Res Lab, Ctr Canc Res, Frederick, MD USA. [Kirk, Gregory D.] Johns Hopkins Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Shi, Yuchen; Xie, Letian X.; Marbois, Beth N.; Clarke, Catherine F.] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90024 USA. [Shi, Yuchen; Xie, Letian X.; Marbois, Beth N.; Clarke, Catherine F.] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA. [Kopp, Jeffrey B.] NIDDK, Kidney Dis Sect, NIH, Bethesda, MD USA. RP Gasser, DL (reprint author), Univ Penn, Sch Med, Dept Genet, 415 Curie Blvd, Philadelphia, PA 19104 USA. EM gasserd@mail.med.upenn.edu OI Kopp, Jeffrey/0000-0001-9052-186X FU National Cancer Institute [HHSN26120080001E]; Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research; National Institute of Diabetes and Digestive and Kidney Diseases; NIH [R01 DK-55852, R01 GM-45952]; National Cancer Institute Division of Cancer Treatment and Diagnosis [N01 CO-12400]; Ruth L. Kirschstein National Service Award [GM-007185]; National Center for Research Resources Grant [S10 RR-024605]; National Institute on Drug Abuse [R01-DA-04334] FX This project has been funded in whole or in part with federal funds from the National Cancer Institute under Contract HHSN26120080001E. Research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, and National Institute of Diabetes and Digestive and Kidney Diseases Intramural Research Programs and was supported by NIH Grants R01 DK-55852 (D. L. Gasser), R01 GM-45952 (C. F. Clarke), and National Cancer Institute Division of Cancer Treatment and Diagnosis under contract N01 CO-12400. L. X. Xie was supported by the Ruth L. Kirschstein National Service Award GM-007185. The HPLC-MS/MS determination of quinones was supported in part by National Center for Research Resources Grant S10 RR-024605. Recruitment of controls through the ALIVE study was supported by National Institute on Drug Abuse Grant R01-DA-04334. NR 67 TC 13 Z9 15 U1 0 U2 6 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X EI 1522-1466 J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD OCT PY 2013 VL 305 IS 8 BP F1228 EP F1238 DI 10.1152/ajprenal.00143.2013 PG 11 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 236RF UT WOS:000325816200017 PM 23926186 ER PT J AU Miller, PE McKinnon, RA Krebs-Smith, SM Subar, AF Chriqui, J Kahle, L Reedy, J AF Miller, Paige E. McKinnon, Robin A. Krebs-Smith, Susan M. Subar, Amy F. Chriqui, Jamie Kahle, Lisa Reedy, Jill TI Sugar-Sweetened Beverage Consumption in the US Novel Assessment Methodology SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID SOFT DRINK CONSUMPTION; METABOLIC SYNDROME; DIET QUALITY; RISK-FACTORS; WEIGHT-GAIN; BODY-WEIGHT; CHILDREN; ADOLESCENTS; ADULTS; YOUNG AB Background: Sugar-sweetened beverage (SSB) consumption has been linked with poor diet quality, weight gain, and increased risk for obesity, diabetes, and cardiovascular disease. Previous studies have been hampered by inconsistent definitions and a failure to capture all types of SSBs. Purpose: To comprehensively examine total SSB consumption in the U.S. using an all-encompassing definition that includes beverages calorically sweetened after purchase in addition to presweetened beverages. Methods: Data from the 2005-2008 National Health and Nutrition Examination Survey (N=17,078) were analyzed in September 2012 and used to estimate calories (kilocalories) of added sugars from SSBs and to identify top sources of SSBs. Results: On average, Americans aged >= 2 years consumed 171 kcal (8% of total kcal) per day from added sugars in SSBs; the top sources were soda, fruit drinks, tea, coffee, energy/sports drinks, and flavored milks. Male adolescents (aged 12-19 years) had the highest mean intakes (293 kcal/day; 12% of total kcal). Conclusions: Americans consume more calories from added sugars in beverages than previously reported. The methodology presented in this paper allows for more-comprehensive estimates than those previously used regarding the extent to which SSBs provide calories from added sugars. (C) 2013 American Journal of Preventive Medicine. All rights reserved. C1 [Miller, Paige E.] NCI, Canc Prevent Fellowship Program, Rockville, MD USA. [McKinnon, Robin A.; Krebs-Smith, Susan M.; Subar, Amy F.; Reedy, Jill] NCI, Div Canc Control & Populat Sci, Rockville, MD USA. [Kahle, Lisa] Informat Management Serv Inc, Calverton, MD USA. [Miller, Paige E.] Exponent Inc, Ctr Epidemiol Biostat & Computat Biol, Chicago, IL 60661 USA. [Chriqui, Jamie] Univ Illinois, Inst Hlth Res & Policy, Chicago, IL USA. RP Miller, PE (reprint author), Exponent Inc, 525 West Monroe St,Suite 1050, Chicago, IL 60661 USA. EM pmiller@exponent.com FU Cancer Prevention Fellowship Program of the National Cancer Institute FX This research was supported by the Cancer Prevention Fellowship Program of the National Cancer Institute. NR 36 TC 21 Z9 21 U1 1 U2 31 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2013 VL 45 IS 4 BP 416 EP 421 DI 10.1016/j.amepre.2013.05.014 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 228NQ UT WOS:000325193900006 PM 24050417 ER PT J AU Fleischhacker, SE Evenson, KR Sharkey, J Pitts, SBJ Rodriguez, DA AF Fleischhacker, Sheila E. Evenson, Kelly R. Sharkey, Joseph Pitts, Stephanie B. Jilcott Rodriguez, Daniel A. TI Validity of Secondary Retail Food Outlet Data A Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID COMMERCIAL DATA SOURCES; PHYSICAL-ACTIVITY; FIELD VALIDATION; NEIGHBORHOOD ENVIRONMENTS; NORTH-CAROLINA; HEALTHY FOODS; GOOGLE EARTH; ACCESS; STORES; URBAN AB Context: Improving access to healthy foods is a promising strategy to prevent nutrition-related chronic diseases. To characterize retail food environments and identify areas with limited retail access, researchers, government programs, and community advocates have primarily used secondary retail food outlet data sources (e.g., InfoUSA or government food registries). To advance the state of the science on measuring retail food environments, this systematic review examined the evidence for validity reported for secondary retail food outlet data sources for characterizing retail food environments. Evidence acquisition: A literature search was conducted through December 31, 2012, to identify peer-reviewed published literature that compared secondary retail food outlet data sources to primary data sources (i.e., field observations) for accuracy of identifying the type and location of retail food outlets. Data were analyzed in 2013. Evidence synthesis: Nineteen studies met the inclusion criteria. The evidence for validity reported varied by secondary data sources examined, primary data-gathering approaches, retail food outlets examined, and geographic and sociodemographic characteristics. More than half of the studies (53%) did not report evidence for validity by type of food outlet examined and by a particular secondary data source. Conclusions: Researchers should strive to gather primary data but if relying on secondary data sources, InfoUSA and government food registries had higher levels of agreement than reported by other secondary data sources and may provide sufficient accuracy for exploring these associations in large study areas. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Fleischhacker, Sheila E.] NIDDK, Div Nutr Res Coordinat, NIH, Bethesda, MD 20892 USA. [Evenson, Kelly R.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Rodriguez, Daniel A.] Univ N Carolina, Dept City & Reg Planning, Chapel Hill, NC USA. [Pitts, Stephanie B. Jilcott] E Carolina Univ, Dept Publ Hlth, Greenville, NC USA. [Sharkey, Joseph] Texas A&M Hlth Sci Ctr, Sch Rural Publ Hlth, College Stn, TX USA. RP Fleischhacker, SE (reprint author), NIDDK, Div Nutr Res Coordinat, NIH, DHHS, 2 Democracy Plaza,Room 635,6707 Democracy Blvd,MS, Bethesda, MD 20892 USA. EM sheila.fleisch-hacker@nih.gov FU Health-e NC, an initiative of the University Cancer Research Fund at the University of North Carolina-Chapel Hill; Healthy Eating Research, a national program of the Robert Wood Johnson Foundation (RWJF) [66958] FX Support for preliminary work on this project was provided by the Health-e NC, an initiative of the University Cancer Research Fund at the University of North Carolina-Chapel Hill and by Healthy Eating Research, a national program of the Robert Wood Johnson Foundation (RWJF), ID #66958. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, Health-e NC, or RWJF. Heather D'Angelo, MHS, Robin McKinnon, PhD, MPA, Margaret McDowell, PhD, MPH, RD, and Van Hubbard, MD, PhD, as well as members of the CDC's Nutrition and Obesity Policy Research and Evaluation Network Rural Food Access Working Group provided feedback on the paper. NR 51 TC 17 Z9 17 U1 0 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2013 VL 45 IS 4 BP 462 EP 473 DI 10.1016/j.amepre.2013.06.009 PG 12 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 228NQ UT WOS:000325193900012 PM 24050423 ER PT J AU Gronley, J Gerber, L Rasch, EK AF Gronley, JoAnne Gerber, Lynn Rasch, Elizabeth K. TI In Memoriam: A Tribute to Jacqueline Perry SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Biographical-Item C1 [Gronley, JoAnne] Rancho Los Amigos Natl Rehabil Ctr, Pathokinesiol Lab, Downey, CA 90242 USA. [Gerber, Lynn] George Mason Univ, Ctr Study Chron Illness & Disabil, Fairfax, VA 22030 USA. [Rasch, Elizabeth K.] NIH, Dept Rehabil Med, Clin Res Ctr, Bethesda, MD 20892 USA. RP Gronley, J (reprint author), Rancho Los Amigos Natl Rehabil Ctr, Pathokinesiol Lab, Downey, CA 90242 USA. NR 1 TC 0 Z9 0 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD OCT PY 2013 VL 94 IS 10 BP 2036 EP 2037 DI 10.1016/j.apmr.2013.07.001 PG 2 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 231TU UT WOS:000325442100027 ER PT J AU Terracciano, A Chan, W AF Terracciano, Antonio Chan, Wayne TI Personality traits, national character stereotypes, and climate-economic conditions SO BEHAVIORAL AND BRAIN SCIENCES LA English DT Editorial Material ID UNITED-STATES; CULTURES AB Cross-cultural personality research suggests that individuals from wealthier countries tend to be more open-minded. This openness to values may support more democratic governments and the expansion of fundamental freedoms. The link between wealth and freedom is evident in cold-to-temperate climates, but not across wealthy nations in hot climates. Furthermore, temperature and economic conditions shape perceptions of national character stereotypes. C1 [Terracciano, Antonio] Florida State Univ, Coll Med, Dept Geriatr, Tallahassee, FL 32306 USA. [Terracciano, Antonio; Chan, Wayne] NIA, NIH, Baltimore, MD 21224 USA. RP Terracciano, A (reprint author), Florida State Univ, Coll Med, Dept Geriatr, Tallahassee, FL 32306 USA. EM antonio.terracciano@med.fsu.edu; wayne.chan@rutgers.edu OI Chan, Wayne/0000-0001-5061-1713 FU Intramural NIH HHS NR 12 TC 2 Z9 2 U1 1 U2 7 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0140-525X EI 1469-1825 J9 BEHAV BRAIN SCI JI Behav. Brain Sci. PD OCT PY 2013 VL 36 IS 5 BP 501 EP 502 DI 10.1017/S0140525X1300023X PG 2 WC Psychology, Biological; Behavioral Sciences; Neurosciences SC Psychology; Behavioral Sciences; Neurosciences & Neurology GA 234YR UT WOS:000325681000024 PM 23985221 ER PT J AU Ito, S Pophali, P Wu, CO Koklanaris, EK Superata, J Fahle, GA Childs, R Battiwalla, M Barrett, AJ AF Ito, S. Pophali, P. Wu, C. O. Koklanaris, E. K. Superata, J. Fahle, G. A. Childs, R. Battiwalla, M. Barrett, A. J. TI CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML SO BONE MARROW TRANSPLANTATION LA English DT Article DE HSCT; relapse; CMV reactivation; CML ID STEM-CELL TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; CORD BLOOD TRANSPLANTATION; POLYMERASE-CHAIN-REACTION; CYTOMEGALOVIRUS-INFECTION; LYMPHOCYTE-PROLIFERATION; MOLECULAR REMISSION; PREEMPTIVE THERAPY; PERIPHERAL-BLOOD AB Preemptive therapy at CMV reactivation has diminished post-transplant CMV mortality. Furthermore, recent studies suggest a favorable 'virus-versus-leukemia' effect from reactivating CMV, reducing relapse of AML after SCT. We studied the relationship of CMV reactivation with leukemic relapse in 110 patients with CML receiving HLA-identical sibling SCT between 1993 and 2008. Of these, 79 (72%) were in chronic phase, 5 in second chronic phase, 17 in accelerated phase and 9 in blast phase. A total of 97 patients (88%) received a myeloablative conditioning regimen, 97 received 4-log ex vivo T cell-depleted grafts and 13 received T-replete grafts. CMV reactivation before day 100 was observed in 72 patients (65.5%). At a median follow-up of 6.2 years, CMV reactivation < day 100 as a time-dependent covariate was an independent factor associated with decreased relapse. We conclude that CMV reactivation may contribute to a beneficial GVL effect in CML transplant recipients. C1 [Ito, S.; Pophali, P.; Koklanaris, E. K.; Superata, J.; Childs, R.; Battiwalla, M.; Barrett, A. J.] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA. [Wu, C. O.] NHLBI, Off Biostat Res, NIH, Bethesda, MD 20892 USA. [Fahle, G. A.] NIH, Dept Lab Med, Ctr Clin, Bethesda, MD 20892 USA. RP Ito, S (reprint author), NHLBI, Hematol Branch, NIH, 10 CRC Room 3E-5288,10 Ctr Dr, Bethesda, MD 20892 USA. EM itos2@mail.nih.gov RI Pophali, Priyanka/P-8646-2016 FU National institutes of Health, at the National Heart, Lung, and Blood Institute FX This research was supported by the Intramural Research Program of the National institutes of Health, at the National Heart, Lung, and Blood Institute. NR 26 TC 37 Z9 39 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 EI 1476-5365 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD OCT PY 2013 VL 48 IS 10 BP 1313 EP 1316 DI 10.1038/bmt.2013.49 PG 4 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA 234KW UT WOS:000325643700009 PM 23562969 ER PT J AU Fitzhugh, CD Weitzel, RP Hsieh, MM Phang, OA Madison, C Luznik, L Powell, JD Tisdale, JF AF Fitzhugh, C. D. Weitzel, R. P. Hsieh, M. M. Phang, O. A. Madison, C. Luznik, L. Powell, J. D. Tisdale, J. F. TI Sirolimus and post transplant Cy synergistically maintain mixed chimerism in a mismatched murine model SO BONE MARROW TRANSPLANTATION LA English DT Article DE sirolimus; Cy; CSA; mixed chimerism; murine ID BONE-MARROW-TRANSPLANTATION; VERSUS-HOST-DISEASE; STEM-CELL TRANSPLANTATION; TOTAL-BODY IRRADIATION; REGULATORY T-CELLS; POSTTRANSPLANTATION CYCLOPHOSPHAMIDE; HEMATOLOGIC MALIGNANCIES; HEMATOPOIETIC CHIMERISM; DOSE CYCLOPHOSPHAMIDE; ANTILYMPHOCYTE-SERUM AB Because of the toxicity associated with myeloablative conditioning, nonmyeloablative regimens are increasingly being used in vulnerable patient populations. For patients with sickle cell disease, stable mixed chimerism has proven sufficient to reverse the phenotype. Because the vast majority of patients do not have an HLA-matched sibling, a safe nonmyeloablative regimen that could be applied to the haploidentical setting would be ideal. We employed a mismatched mouse model using BALB/c donors and C57BL/6 recipients. Recipient mice were conditioned with 200 cGy TBI and sirolimus or CSA with or without post transplant Cy (PT-Cy). Our data show that when sirolimus or PT-Cy alone is given to C57BL/6 recipients, donor cells are not detected. However, when sirolimus is administered for 15 or 31 days starting 1 day before or up to 6 days after transplant with PT-Cy, all mice maintain stable mixed chimerism. In contrast, conventional therapy employing CSA with or without PT-Cy does not result in stable mixed chimerism. Lastly, mice with stable mixed chimerism after sirolimus display decreased reactivity to donor Ag both in vitro and in vivo. These data identify a novel strategy for inducing mixed chimerism for the treatment of nonmalignant hematologic diseases. C1 [Fitzhugh, C. D.; Weitzel, R. P.; Hsieh, M. M.; Phang, O. A.; Madison, C.; Tisdale, J. F.] Natl Inst Diabet & Digest & Kidney Dis, NIH, NHLBI, Mol & Cellular Hematol Branch, Bethesda, MD 20892 USA. [Luznik, L.; Powell, J. D.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. RP Tisdale, JF (reprint author), Natl Inst Diabet & Digest & Kidney Dis, NIH, NHLBI, Mol & Cellular Hematol Branch, 9000 Rockville Pike,Bldg 10,Room 9N-112, Bethesda, MD 20892 USA. EM johntis@nhlbi.nih.gov FU Intramural NIH HHS [Z99 HL999999, ZIA HL006007-06] NR 42 TC 9 Z9 9 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 EI 1476-5365 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD OCT PY 2013 VL 48 IS 10 BP 1335 EP 1341 DI 10.1038/bmt.2013.60 PG 7 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA 234KW UT WOS:000325643700013 PM 23604009 ER PT J AU Wood, WA Deal, AM Reeve, BB Abernethy, AP Basch, E Mitchell, SA Shatten, C Kim, YH Whitley, J Serody, JS Shea, T Battaglini, C AF Wood, W. A. Deal, A. M. Reeve, B. B. Abernethy, A. P. Basch, E. Mitchell, S. A. Shatten, C. Kim, Y. Hie Whitley, J. Serody, J. S. Shea, T. Battaglini, C. TI Cardiopulmonary fitness in patients undergoing hematopoietic SCT: a pilot study SO BONE MARROW TRANSPLANTATION LA English DT Article DE cardiopulmonary fitness; symptoms; health-related quality of life; hematopoietic SCT ID QUALITY-OF-LIFE; STEM-CELL TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; COMORBIDITY INDEX; AEROBIC EXERCISE; RANDOMIZED-TRIAL; OLDER PATIENTS; LUNG-CANCER; PERFORMANCE; MORTALITY AB Hematopoietic cell transplantation (HCT) is a life-saving treatment for patients with high-risk hematological malignancies. Prognostic measures to determine fitness for HCT are needed to inform decision-making and interventions. VO2peak is obtained by measuring gas exchange during cycle ergometry and has not been studied as a prognostic factor in HCT. Thirty-two autologous and allogeneic HCT patients underwent VO2peak and 6 Minute Walk (6MW) testing before HCT, and provided weekly symptom and health-related quality of life (HRQOL) assessments before HCT and concluding at Day 100. Twenty-nine patients completed pre-HCT testing. Pre-HCT VO2peak was positively correlated with pre-HCT 6MW (r=0.65, P<0.001) and negatively correlated with number of chemotherapy regimens and months of chemotherapy. Patients with lower VO2peak reported higher symptom burden and inferior HRQOL at baseline and during early post-HCT period. Patients with pre-HCT VO2peak <16 mL/kg/min had higher risk of mortality post HCT (entire cohort: hazard ratio (HR) 9.1 (1.75-47.0), P=0.01; allogeneic HCT patients only: HR 6.70 (1.29-34.75), P=0.02) and more hospitalized days before Day 100 (entire cohort: median 33 vs 19, P=0.003; allogeneic HCT patients only: median 33 vs 21, P=0.004). VO2peak pre-HCT is feasible and might predict symptom severity, HRQOL and mortality. Additional studies are warranted. C1 [Wood, W. A.; Basch, E.; Shatten, C.; Whitley, J.; Serody, J. S.; Shea, T.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Deal, A. M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Biostat Core Facil, Chapel Hill, NC 27599 USA. [Reeve, B. B.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, Chapel Hill, NC 27599 USA. [Abernethy, A. P.] Duke Univ, Med Ctr, Duke Canc Inst, Div Med Oncol, Durham, NC USA. [Mitchell, S. A.] Natl Canc Inst, Div Canc Control & Populat Sci, Outcomes Res Branch, Bethesda, MD USA. [Kim, Y. Hie] E Carolina Univ, Brody Sch Med, Greenville, NC USA. [Battaglini, C.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA. RP Wood, WA (reprint author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Hematol & Oncol, Campus Box 7305,3rd Floor,Physicians Off Bldg,170, Chapel Hill, NC 27599 USA. EM wwood@unch.unc.edu OI Wood, William/0000-0001-7439-2543; Serody, Jonathan/0000-0003-4568-1092 FU National Institutes of Health [KL2TR000084] FX This work was supported by the National Institutes of Health Grant KL2TR000084. NR 35 TC 18 Z9 18 U1 3 U2 7 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 EI 1476-5365 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD OCT PY 2013 VL 48 IS 10 BP 1342 EP 1349 DI 10.1038/bmt.2013.58 PG 8 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA 234KW UT WOS:000325643700014 PM 23584437 ER PT J AU Ellis, MJ Gillette, M Carr, SA Paulovich, AG Smith, RD Rodland, KK Townsend, RR Kinsinger, C Mesri, M Rodriguez, H Liebler, DC AF Ellis, Matthew J. Gillette, Michael Carr, Steven A. Paulovich, Amanda G. Smith, Richard D. Rodland, Karin K. Townsend, R. Reid Kinsinger, Christopher Mesri, Mehdi Rodriguez, Henry Liebler, Daniel C. CA CPTAC TI Connecting Genomic Alterations to Cancer Biology with Proteomics: The NCI Clinical Proteomic Tumor Analysis Consortium SO CANCER DISCOVERY LA English DT Editorial Material ID MASS-SPECTROMETRY; CELL-LINES; QUANTIFICATION; PROTEINS AB The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium is applying the latest generation of proteomic technologies to genomically annotated tumors from The Cancer Genome Atlas (TCGA) program, a joint initiative of the NCI and the National Human Genome Research Institute. By providing a fully integrated accounting of DNA, RNA, and protein abnormalities in individual tumors, these datasets will illuminate the complex relationship between genomic abnormalities and cancer phenotypes, thus producing biologic insights as well as a wave of novel candidate biomarkers and therapeutic targets amenable to verifi cation using targeted mass spectrometry methods. (C) 2013 AACR. C1 [Ellis, Matthew J.] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA. [Townsend, R. Reid] Washington Univ, Sch Med, Dept Med, Div Endocrinol & Metab, St Louis, MO 63110 USA. [Gillette, Michael; Carr, Steven A.] Broad Inst MIT & Harvard, Cambridge, MA USA. [Paulovich, Amanda G.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Smith, Richard D.; Rodland, Karin K.] Pacific NW Natl Lab, Div Biol Sci, Richland, WA 99352 USA. [Kinsinger, Christopher; Mesri, Mehdi; Rodriguez, Henry] NCI, Off Canc Clin Prote Res, NIH, Bethesda, MD 20892 USA. [Liebler, Daniel C.] Vanderbilt Ingram Canc Ctr, Jim Ayers Inst Canc Detect & Diag, Nashville, TN USA. RP Liebler, DC (reprint author), Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Jim Ayers Inst Canc Detect & Diag, U1213 MRBIII,465 21st Ave South, Nashville, TN 37232 USA. EM mellis@dom.wustl.edu; daniel.liebler@vanderbilt.edu RI Smith, Richard/J-3664-2012; OI Smith, Richard/0000-0002-2381-2349; Liebler, Daniel/0000-0002-7873-3031 FU NCI NIH HHS [U24 CA159988, U24 CA160019, U24 CA160034, U24 CA160035, U24 CA160036, U24CA159988, U24CA160019, U24CA160034, U24CA160035, U24CA160036] NR 20 TC 48 Z9 49 U1 2 U2 13 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 2159-8274 EI 2159-8290 J9 CANCER DISCOV JI Cancer Discov. PD OCT PY 2013 VL 3 IS 10 BP 1108 EP 1112 DI 10.1158/2159-8290.CD-13-0219 PG 5 WC Oncology SC Oncology GA 235WH UT WOS:000325751600021 PM 24124232 ER PT J AU Rabin, BA Gaglio, B Sanders, T Nekhlyudov, L Dearing, JW Bull, S Glasgow, RE Marcus, A AF Rabin, Borsika A. Gaglio, Bridget Sanders, Tristan Nekhlyudov, Larissa Dearing, James W. Bull, Sheana Glasgow, Russell E. Marcus, Alfred TI Predicting Cancer Prognosis Using Interactive Online Tools: A Systematic Review and Implications for Cancer Care Providers SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Review ID OF-THE-LITERATURE; DECISION AIDS; HEALTH INFORMATION; PROSTATE-CANCER; BREAST-CANCER; COMMUNICATION; RISK; PREFERENCES; THERAPY; MODEL AB Cancer prognosis is of keen interest for patients with cancer, their caregivers, and providers. Prognostic tools have been developed to guide patient-physician communication and decision-making. Given the proliferation of prognostic tools, it is timely to review existing online cancer prognostic tools and discuss implications for their use in clinical settings. Using a systematic approach, we searched the Internet, Medline, and consulted with experts to identify existing online prognostic tools. Each was reviewed for content and format. Twenty-two prognostic tools addressing 89 different cancers were identified. Tools primarily focused on prostate (n = 11), colorectal (n = 10), breast (n = 8), and melanoma (n = 6), although at least one tool was identified for most malignancies. The input variables for the tools included cancer characteristics (n = 22), patient characteristics (n = 18), and comorbidities (n = 9). Effect of therapy on prognosis was included in 15 tools. The most common predicted outcome was cancer-specific survival/mortality (n = 17). Only a few tools (n = 4) suggested patients as potential target users. A comprehensive repository of online prognostic tools was created to understand the state-of-the-art in prognostic tool availability and characteristics. Use of these tools may support communication and understanding about cancer prognosis. Dissemination, testing, refinement of existing, and development of new tools under different conditions are needed. (C) 2013 AACR. C1 [Rabin, Borsika A.; Dearing, James W.] Inst Hlth Res, Canc Res Network, Canc Commun Res Ctr, Denver, CO USA. [Sanders, Tristan] Kaiser Permanente Colorado, Denver, CO 80231 USA. [Bull, Sheana; Marcus, Alfred] Univ Colorado, Denver, CO 80202 USA. [Gaglio, Bridget] Kaiser Permanente, Mid Atlantic Permanente Res Inst, Rockville, MD USA. [Glasgow, Russell E.] NCI, Rockville, MD USA. [Nekhlyudov, Larissa] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Nekhlyudov, Larissa] Harvard Vanguard Med Associates, Dept Med, Boston, MA USA. RP Rabin, BA (reprint author), Kaiser Permanente Colorado, Legacy Highlands Bldg,10065 E Harvard Ave,Suite 3, Denver, CO 80231 USA. EM borsika.a.rabin@gmail.com FU National Cancer Institute [P20 CA137219] FX This work was supported by the National Cancer Institute (P20 CA137219). The authors of this manuscript (all except R.E. Glasgow) have received financial support from the National Cancer Institute to evaluate the feasibility and small-scale implementation of one of the cancer prognostic tools (Cancer Survival Query System) included in this review. NR 35 TC 9 Z9 11 U1 3 U2 8 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD OCT PY 2013 VL 22 IS 10 BP 1645 EP 1656 DI 10.1158/1055-9965.EPI-13-0513 PG 12 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 234GT UT WOS:000325631200001 PM 23956026 ER PT J AU Palmer, NRA Geiger, AM Lu, LY Case, LD Weaver, KE AF Palmer, Nynikka R. A. Geiger, Ann M. Lu, Lingyi Case, L. Douglas Weaver, Kathryn E. TI Impact of Rural Residence on Forgoing Healthcare after Cancer Because of Cost SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID MEDICARE BENEFICIARIES; AMERICAN SOCIETY; UNITED-STATES; ACCESS; DISPARITIES; URBAN; POPULATION; SURVIVORS; ADULTS; BARRIERS AB Background: Routine follow-up care is recommended to promote the well-being of cancer survivors, but financial difficulties may interfere. Rural-urban disparities in forgoing healthcare due to cost have been observed in the general population; however, it is unknown whether this disparity persists among survivors. The purpose of this study was to examine rural-urban disparities in forgoing healthcare after cancer due to cost. Methods: We analyzed data from 7,804 cancer survivors in the 2006 to 2010 National Health Interview Survey. Logistic regression models, adjusting for sociodemographic and clinical characteristics, were used to assess rural-urban disparities in forgoing medical care, prescription medications, and dental care due to cost, stratified by age (younger: 18-64, older: 65+). Results: Compared with urban survivors, younger rural survivors were more likely to forgo medical care (P < 0.001) and prescription medications (P < 0.001) due to cost; older rural survivors were more likely to forgo medical (P < 0.001) and dental care (P = 0.05). Rural-urban disparities did not persist among younger survivors in adjusted analyses; however, older rural survivors remained more likely to forgo medical [OR = 1.66, 95% confidence interval (CI) = 1.11-2.48] and dental care (OR = 1.54, 95%CI = 1.08-2.20). Conclusions: Adjustment for health insurance and other sociodemographic characteristics attenuates rural-urban disparities in forgoing healthcare among younger survivors, but not older survivors. Financial factors relating to healthcare use among rural survivors should be a topic of continued investigation. Impact: Addressing out-of-pocket costs may be an important step in reducing rural-urban disparities in healthcare, especially for older survivors. It will be important to monitor how healthcare reform efforts impact disparities observed in this vulnerable population. (C) 2013 AACR. C1 [Palmer, Nynikka R. A.; Geiger, Ann M.; Weaver, Kathryn E.] Wake Forest Sch Med, Winston Salem, NC 27157 USA. [Lu, Lingyi; Case, L. Douglas] Wake Forest Sch Med, Div Publ Hlth Sci, Winston Salem, NC 27157 USA. [Geiger, Ann M.] NCI, Hlth Serv & Econ Branch, Appl Res Program, Div Canc Control & Populat Sci, Rockville, MD USA. RP Weaver, KE (reprint author), Wake Forest Sch Med, Dept Social Sci & Hlth Policy, Med Ctr Blvd, Winston Salem, NC 27157 USA. EM keweaver@wakehealth.edu OI Palmer, Nynikka/0000-0002-5311-447X FU National Cancer Institute at the National Institutes of Health [R03 CA156641-01]; Wake Forest School of Medicine Cancer Prevention and Control Training Program [5R25CA122061] FX This work was financially supported by the National Cancer Institute at the National Institutes of Health (grant no. R03 CA156641-01). N.R.A. Palmer is supported by the Wake Forest School of Medicine Cancer Prevention and Control Training Program-5R25CA122061. NR 42 TC 7 Z9 7 U1 4 U2 9 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD OCT PY 2013 VL 22 IS 10 BP 1668 EP 1676 DI 10.1158/1055-9965.EPI-13-0421 PG 9 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 234GT UT WOS:000325631200003 PM 24097196 ER PT J AU Zhang, W Xiang, YB Li, HL Yang, G Cai, H Ji, BT Gao, YT Zheng, W Shu, XO AF Zhang, Wei Xiang, Yong-Bing Li, Hong-Lan Yang, Gong Cai, Hui Ji, Bu-Tian Gao, Yu-Tang Zheng, Wei Shu, Xiao-Ou TI Vegetable-based dietary pattern and liver cancer risk: Results from the Shanghai Women's and Men's Health Studies SO CANCER SCIENCE LA English DT Article ID HEPATOCELLULAR-CARCINOMA; HEPATITIS-B; COLORECTAL-CANCER; STOMACH CANCERS; CONSUMPTION; CHINA; METAANALYSIS; COHORT; FRUIT; REPRODUCIBILITY AB Although dietary patterns, specific foods, and their constituents have been linked to cancer risk, the role of dietary patterns and specific food groups in liver cancer risk has not been investigated. In the Shanghai Women's Health Study (SWHS) and Shanghai Men's Health Study (SMHS), two cohort studies of 132837 Chinese women and men, we evaluated the relationship between dietary patterns, food groups, and liver cancer risk. Through in-person interviews, dietary information intake over the preceding year was collected by using a validated food-frequency questionnaire. Cox regression model was used to estimate hazard ratios and 95% confidence intervals with adjustment for potential confounders. During an average follow-up of 10.9 (SWHS) or 5.5 (SMHS) years, 267 incident liver cancer cases were identified after the first 2years of study enrolment. Three dietary patterns were derived by factor analysis. A vegetable-based dietary pattern was inversely associated with liver cancer; hazard ratios (95% confidence intervals) for the lowest to highest quartiles were: 1.00; 0.98 (0.71-1.35); 0.93 (0.67-1.29); and 0.58 (0.40-0.84); P-trend=0.01. The association was stronger among participants with a history of chronic liver disease. Further analyses showed high intakes of celery, mushrooms, allium vegetables, composite vegetables (including asparagus lettuce and garland chrysanthemum), legumes and legume products were associated with reduced liver cancer risk (all P-trend<0.05). Fruit- and meat-based dietary patterns were not associated with liver cancer risk. Our study suggests that a vegetable-based dietary pattern is associated with reduced liver cancer risk. C1 [Zhang, Wei; Xiang, Yong-Bing; Li, Hong-Lan] Shanghai Jiao Tong Univ, Sch Med, Shanghai Canc Inst, State Key Lab Oncogene & Related Genes,Renji Hosp, Shanghai 200030, Peoples R China. [Zhang, Wei; Xiang, Yong-Bing; Li, Hong-Lan; Gao, Yu-Tang] Shanghai Jiao Tong Univ, Sch Med, Shanghai Canc Inst, Dept Epidemiol,Renji Hosp, Shanghai 200030, Peoples R China. [Yang, Gong; Cai, Hui; Zheng, Wei; Shu, Xiao-Ou] Vanderbilt Univ, Sch Med, Div Epidemiol, Dept Med,Vanderbilt Epidemiol Ctr,Vanderbilt Ingr, Nashville, TN 37212 USA. [Ji, Bu-Tian] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA. RP Xiang, YB (reprint author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Canc Inst, State Key Lab Oncogene & Related Genes,Renji Hosp, Shanghai 200030, Peoples R China. EM ybxiang@shsci.org FU State Key Project Specialized for Infectious Diseases of China [2008ZX10002-015, 2012ZX10002008-002]; Shanghai Municipal Bureau of Public Health [2008144]; US National Institutes of Health [R37 CA070867, R01 CA82729]; Fogarty International Center [D43 TW008313] FX The authors thank the participants and research staff of the SWHS and SMHS for their contributions to this article. We also thank Dr. Shenghui Wu for verifying the statistical analysis and Ms. Bethanie Rammer and Mrs. Jacqueline Stern for their technical assistance in editing and preparing the manuscript. This study was supported by the funds of the State Key Project Specialized for Infectious Diseases of China (No. 2008ZX10002-015 and No. 2012ZX10002008-002 to Y-B Xiang), the research fund of the Shanghai Municipal Bureau of Public Health (No. 2008144 to W. Zhang), as well as grants (R37 CA070867 to W. Zheng) and R01 CA82729 to X-O Shu) from the US National Institutes of Health for the parent studies. Wei Zhang was supported by a training grant from the Fogarty International Center (D43 TW008313 to X-O Shu). The funding organization played no role in the design or conduct of the study, collection, management, analysis, or interpretation of the data, or the preparation, review, or approval of the manuscript. Drs. Xiang and Shu had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. NR 42 TC 10 Z9 10 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1349-7006 J9 CANCER SCI JI Cancer Sci. PD OCT PY 2013 VL 104 IS 10 BP 1353 EP 1361 DI 10.1111/cas.12231 PG 9 WC Oncology SC Oncology GA 234ZK UT WOS:000325683200012 PM 23841909 ER PT J AU Ramamoorthy, M May, A Tadokoro, T Popuri, V Seidman, MM Croteau, DL Bohr, VA AF Ramamoorthy, Mahesh May, Alfred Tadokoro, Takashi Popuri, Venkateswarlu Seidman, Michael M. Croteau, Deborah L. Bohr, Vilhelm A. TI The RecQ helicase RECQL5 participates in psoralen-induced interstrand cross-link repair SO CARCINOGENESIS LA English DT Article ID NUCLEOTIDE EXCISION-REPAIR; RNA-POLYMERASE-II; WERNER-SYNDROME PROTEIN; INDUCED DNA-DAMAGE; BLOOM-SYNDROME; CELLULAR-RESPONSES; COCKAYNE-SYNDROME; REPLICATION FORK; HUMAN RECQ5-BETA; FANCONI-ANEMIA AB Interstrand cross-links (ICLs) are very severe lesions as they are absolute blocks of replication and transcription. This property of interstrand cross-linking agents has been exploited clinically for the treatment of cancers and other diseases. ICLs are repaired in human cells by specialized DNA repair pathways including components of the nucleotide excision repair pathway, double-strand break repair pathway and the Fanconi anemia pathway. In this report, we identify the role of RECQL5, a member of the RecQ family of helicases, in the repair of ICLs. Using laser-directed confocal microscopy, we demonstrate that RECQL5 is recruited to ICLs formed by trioxalen (a psoralen-derived compound) and ultraviolet irradiation A. Using single-cell gel electrophoresis and proliferation assays, we identify the role of RECQL5 in the repair of ICL lesions. The domain of RECQL5 that recruits to the site of ICL was mapped to the KIX region between amino acids 500 and 650. Inhibition of transcription and of topoisomerases did not affect recruitment, which was inhibited by DNA-intercalating agents, suggesting that the DNA structure itself may be responsible for the recruitment of RECQL5 to the sites of ICLs. C1 [Ramamoorthy, Mahesh; May, Alfred; Tadokoro, Takashi; Popuri, Venkateswarlu; Seidman, Michael M.; Croteau, Deborah L.; Bohr, Vilhelm A.] NIA, Biomed Res Ctr, Lab Mol Gerontol, Baltimore, MD 21224 USA. RP Bohr, VA (reprint author), NIA, Biomed Res Ctr, Lab Mol Gerontol, 251 Bayview Blvd,Suite 100, Baltimore, MD 21224 USA. EM vbohr@nih.gov OI Ramamoorthy, Mahesh/0000-0002-2359-5647 FU National Institutes of Health Intramural Program of the National Institute on Aging [Z01-AG000726-17] FX National Institutes of Health Intramural Program of the National Institute on Aging (Z01-AG000726-17). NR 61 TC 7 Z9 8 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 EI 1460-2180 J9 CARCINOGENESIS JI Carcinogenesis PD OCT PY 2013 VL 34 IS 10 BP 2218 EP 2230 DI 10.1093/carcin/bgt183 PG 13 WC Oncology SC Oncology GA 232IH UT WOS:000325486200004 PM 23715498 ER PT J AU Koutros, S Meyer, TE Fox, SD Issaq, HJ Veenstra, TD Huang, WY Yu, K Albanes, D Chu, LW Andriole, G Hoover, RN Hsing, AW Berndt, SI AF Koutros, Stella Meyer, Tamra E. Fox, Stephen D. Issaq, Haleem J. Veenstra, Timothy D. Huang, Wen-Yi Yu, Kai Albanes, Demetrius Chu, Lisa W. Andriole, Gerald Hoover, Robert N. Hsing, Ann W. Berndt, Sonja I. TI Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial SO CARCINOGENESIS LA English DT Article ID RECTAL EXAMINATION FAILS; DIABETES-MELLITUS; SMOKING; URINE; MARKER; IDENTIFICATION; METAANALYSIS; BIOMARKER; PROFILES; COHORT AB Metabolomic profiling has identified, sarcosine, a derivative of the amino acid glycine, as an important metabolite involved in the etiology or natural history of prostate cancer. We examined the association between serum sarcosine levels and risk of prostate cancer in 1122 cases (813 non-aggressive and 309 aggressive) and 1112 controls in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Sarcosine was quantified using high-throughput liquid chromatographymass spectrometry. A significantly increased risk of prostate cancer was observed with increasing levels of sarcosine (odds ratio [OR] for the highest quartile of exposure [Q4] versus the lowest quartile [Q1] 1.30, 95% confidence interval [CI]: 1.02, 1.65; P-trend 0.03). When stratified by disease aggressiveness, we observed a stronger association for non-aggressive cases (OR for Q4 versus Q1 1.44, 95% CI: 1.11, 1.88; P-trend 0.006) but no association for aggressive prostate cancer (OR for Q4 versus Q1 1.03, 95% CI: 0.73, 1.47; P-trend 0.89). Although not statistically significant, temporal analyses showed a stronger association between sarcosine and prostate cancer for serum collected closer to diagnosis, suggesting that sarcosine may be an early biomarker of disease. Interestingly, the association between sarcosine and prostate cancer risk was stronger among men with diabetes (OR 2.66, 95% CI: 1.04, 6.84) compared with those without reported diabetes (OR 1.23, 95% CI: 0.951.59, P-interaction 0.01). This study found that elevated levels of serum sarcosine are associated with an increased prostate cancer risk and evidence to suggest that sarcosine may be an early biomarker for this disease. C1 [Koutros, Stella; Huang, Wen-Yi; Yu, Kai; Albanes, Demetrius; Hoover, Robert N.; Berndt, Sonja I.] NCI, Div Canc Epidemiol & Genet, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Meyer, Tamra E.] Off Surg Gen, Dept Army, Silver Spring, MD 20910 USA. [Fox, Stephen D.; Issaq, Haleem J.; Veenstra, Timothy D.] Frederick Natl Lab Canc Res, SAIC Frederick, Adv Technol Program, Lab Prote & Analyt Technol, Frederick, MD 21701 USA. [Chu, Lisa W.; Hsing, Ann W.] Stanford Canc Inst, Canc Prevent Inst Calif, Fremont, CA 94538 USA. [Andriole, Gerald] Washington Univ, Sch Med, Div Urol Surg, St Louis, MO 63110 USA. RP Koutros, S (reprint author), NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, 6120 Execut Blvd,EPS 8112,MSC 7240, Rockville, MD 20852 USA. EM KoutrosS@mail.nih.gov RI Albanes, Demetrius/B-9749-2015 FU Intramural Research Program of the National Institutes of Health; National Cancer Institute; Division of Cancer Epidemiology and Genetics [Z01 CP010152] FX Intramural Research Program of the National Institutes of Health, National Cancer Institute and Division of Cancer Epidemiology and Genetics (Z01 CP010152). NR 35 TC 14 Z9 14 U1 1 U2 14 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 EI 1460-2180 J9 CARCINOGENESIS JI Carcinogenesis PD OCT PY 2013 VL 34 IS 10 BP 2281 EP 2285 DI 10.1093/carcin/bgt176 PG 5 WC Oncology SC Oncology GA 232IH UT WOS:000325486200011 PM 23698636 ER PT J AU Izzotti, A Balansky, R D'Agostini, F Longobardi, M Cartiglia, C La Maestra, S Micale, RT Camoirano, A Ganchev, G Iltcheva, M Steele, VE De Flora, S AF Izzotti, Alberto Balansky, Roumen D'Agostini, Francesco Longobardi, Mariagrazia Cartiglia, Cristina La Maestra, Sebastiano Micale, Rosanna T. Camoirano, Anna Ganchev, Gancho Iltcheva, Marietta Steele, Vernon E. De Flora, Silvio TI Relationships between pulmonary micro-RNA and proteome profiles, systemic cytogenetic damage and lung tumors in cigarette smoke-exposed mice treated with chemopreventive agents SO CARCINOGENESIS LA English DT Article ID MOUSE LUNG; PHENETHYL ISOTHIOCYANATE; N-ACETYLCYSTEINE; TOBACCO-SMOKE; EXPRESSION; CARCINOGENESIS; PREVENTION; TUMORIGENESIS; PIOGLITAZONE; COMBINATION AB Assessing the correlation between molecular endpoints and cancer induction or prevention aims at validating the use of intermediate biomarkers. We previously developed murine models that are suitable to detect both the carcinogenicity of mainstream cigarette smoke (MCS) and the induction of molecular alterations. In this study, we used 931 Swiss mice in two parallel experiments and in a preliminary toxicity study. The chemopreventive agents included vorinostat, myo-inositol, bexarotene, pioglitazone and a combination of bexarotene and pioglitazone. Pulmonary micro-RNAs and proteins were evaluated by microarray analyses at 10 weeks of age in male and female mice, either unexposed or exposed to MCS since birth, and either untreated or receiving each one of the five chemopreventive regimens with the diet after weaning. At 4 months of age, the frequency of micronucleated normochromatic erythrocytes was evaluated. At 7 months, the lungs were subjected to standard histopathological analysis. The results showed that exposure to MCS significantly downregulated the expression of 79 of 694 lung micro-RNAs (11.4%) and upregulated 66 of 1164 proteins (5.7%). Administration of chemopreventive agents modulated the baseline micro-RNA and proteome profiles and reversed several MCS-induced alterations, with some intergender differences. The stronger protective effects were produced by the combination of bexarotene and pioglitazone, which also inhibited the MCS-induced clastogenic damage and the yield of malignant tumors. Pioglitazone alone increased the yield of lung adenomas. Thus, micro-RNAs, proteins, cytogenetic damage and lung tumors were closely related. The molecular biomarkers contributed to evaluate both protective and adverse effects of chemopreventive agents and highlighted the mechanisms involved. C1 [Izzotti, Alberto; Balansky, Roumen; D'Agostini, Francesco; Longobardi, Mariagrazia; Cartiglia, Cristina; La Maestra, Sebastiano; Micale, Rosanna T.; Camoirano, Anna; De Flora, Silvio] Univ Genoa, Dept Hlth Sci, I-16132 Genoa, Italy. [Balansky, Roumen; Ganchev, Gancho; Iltcheva, Marietta] Natl Oncol Ctr, Lab Chem Mutagenesis & Carcinogenesis, Sofia 1756, Bulgaria. [Steele, Vernon E.] NCI, Chemoprevent Agent Dev Res Program, Canc Prevent Div, Bethesda, MD 20892 USA. RP De Flora, S (reprint author), Univ Genoa, Dept Hlth Sci, Via A Pastore 1, I-16132 Genoa, Italy. EM sdf@unige.it OI izzotti, alberto/0000-0002-8588-0347 FU United States National Cancer Institute [N01-CN 53301]; Bulgarian Ministry of Education, Youth and Science (National Science Foundation); Hasumi International Research Foundation (Bulgaria) FX United States National Cancer Institute (Contract N01-CN 53301); Bulgarian Ministry of Education, Youth and Science (National Science Foundation); Hasumi International Research Foundation (Bulgaria). NR 40 TC 18 Z9 18 U1 0 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 EI 1460-2180 J9 CARCINOGENESIS JI Carcinogenesis PD OCT PY 2013 VL 34 IS 10 BP 2322 EP 2329 DI 10.1093/carcin/bgt178 PG 8 WC Oncology SC Oncology GA 232IH UT WOS:000325486200017 PM 23708261 ER PT J AU Kim, DW Walker, RL Meltzer, PS Cheng, SY AF Kim, Dong Wook Walker, Robert L. Meltzer, Paul S. Cheng, Sheue-yann TI Complex temporal changes in TGF oncogenic signaling drive thyroid carcinogenesis in a mouse model SO CARCINOGENESIS LA English DT Article ID GROWTH-FACTOR-BETA; EPITHELIAL-MESENCHYMAL TRANSITION; HORMONE RECEPTOR-BETA; BREAST-CANCER CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; GENE-EXPRESSION; E-CADHERIN; TRANSCRIPTIONAL REGULATION; MESANGIAL CELLS; COLLAGEN-III AB Despite recent advances, understanding of molecular genetic alterations underlying thyroid carcinogenesis remains unclear. One key question is how dynamic temporal changes in global genomic expression affect carcinogenesis as the disease progresses. To address this question, we used a mouse model that spontaneously develops follicular thyroid cancer similar to human cancer (Thrb(PV/PV) mice). Using complementary DNA microarrays, we compared global gene expression profiles of thyroid tumors of Thrb(PV/PV) mice with the age- and gender-matched thyroids of wild-type mice at 3 weeks and at 2, 4, 6 and 14 months. These time points covered the pathological progression from early hyperplasia to capsular invasion, vascular invasion and eventual metastasis. Microarray data indicated that 462 genes were upregulated (Up-cluster genes) and 110 genes were downregulated (Down-cluster genes). Three major expression patterns (trending up, cyclical and spiking up and then down) and two (trending down and cyclical) were apparent in the Up-cluster and Down-cluster genes, respectively. Functional clustering of tumor-related genes followed by Ingenuity Pathways Analysis identified the transforming growth factor (TGF )-mediated network as key signaling pathways. Further functional analyses showed sustained activation of TGF receptorpSMAD2/3 signaling, leading to decreased expression of E-cadherin and increased expression of fibronectin, vimentin, collagens and laminins. These TGF-induced changes facilitated epithelial-to-mesenchymal transition, which promotes cancer invasion and migration. Thus, complex temporal changes in gene expression patterns drive thyroid cancer progression, and persistent activation of TGFTGFRIIpSMAD2/3 signaling leads to EMT, thus promoting metastasis. This study provides new understanding of progression and metastatic spread of human thyroid cancer. C1 [Kim, Dong Wook; Cheng, Sheue-yann] NCI, Gene Regulat Sect, Mol Biol Lab, NIH, Bethesda, MD 20892 USA. [Walker, Robert L.; Meltzer, Paul S.] NCI, Mol Genet Sect, Genet Branch, NIH, Bethesda, MD 20892 USA. RP Cheng, SY (reprint author), NCI, Gene Regulat Sect, Mol Biol Lab, NIH, Room 5128,37 Convent Dr MSC 4264, Bethesda, MD 20892 USA. EM chengs@mail.nih.gov FU Intramural Research Program at the Center for Cancer Research, National Cancer Institute, National Institutes of Health FX Intramural Research Program at the Center for Cancer Research, National Cancer Institute, National Institutes of Health. NR 74 TC 5 Z9 6 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 EI 1460-2180 J9 CARCINOGENESIS JI Carcinogenesis PD OCT PY 2013 VL 34 IS 10 BP 2389 EP 2400 DI 10.1093/carcin/bgt175 PG 12 WC Oncology SC Oncology GA 232IH UT WOS:000325486200024 PM 23698635 ER PT J AU Liu, Y Wan, B Yin, J Horvath, K Sarkar, J Lu, J Lei, M AF Liu, Y. Wan, B. Yin, J. Horvath, K. Sarkar, J. Lu, J. Lei, M. TI SLX4 AND TRF2 INTERACTION IS REQUIRED FOR TELOMERE STRUCTURE AND LENGTH REGULATION SO CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY LA English DT Meeting Abstract CT 4th Meeting of the Australia-Chinese-Association-for-Biomedical-Sciences-Inc (ACABS) CY OCT 10-13, 2013 CL Hangzhou, PEOPLES R CHINA SP Australia Chinese Assoc Biomed Sci Inc C1 [Liu, Y.; Yin, J.; Horvath, K.; Sarkar, J.; Lu, J.] NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA. [Wan, B.; Lei, M.] Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, Shanghai, Peoples R China. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1440-1681 J9 CLIN EXP PHARMACOL P JI Clin. Exp. Pharmacol. Physiol. PD OCT PY 2013 VL 40 SU 1 SI SI BP 30 EP 30 PG 1 WC Pharmacology & Pharmacy; Physiology SC Pharmacology & Pharmacy; Physiology GA 234MA UT WOS:000325647200078 ER PT J AU McCullough, PA Barnard, D Clare, R Ellis, SJ Fleg, JL Fonarow, GC Franklin, BA Kilpatrick, RD Kitzman, DW O'Connor, CM Pina, IL Thadani, U Thohan, V Whellan, DJ AF McCullough, Peter A. Barnard, Denise Clare, Robert Ellis, Stephen J. Fleg, Jerome L. Fonarow, Gregg C. Franklin, Barry A. Kilpatrick, Ryan D. Kitzman, Dalane W. O'Connor, Christopher M. Pina, Ileana L. Thadani, Udho Thohan, Vinay Whellan, David J. CA HF-ACTION Investigators TI Anemia and Associated Clinical Outcomes in Patients With Heart Failure Due to Reduced Left Ventricular Systolic Function SO CLINICAL CARDIOLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; SURVEY NHANES 1999-2004; EVALUATION PROGRAM KEEP; NATIONAL-HEALTH; HF-ACTION; CARDIOVASCULAR RISK; CONTROLLED-TRIAL; NUTRITION; CKD; DYSFUNCTION AB Background: Anemia is associated with decreased functional capacity, reduced quality of life, and worsened outcomes among patients with heart failure (HF) due to reduced left ventricular ejection fraction (HFREF). We sought to evaluate the independent effect of anemia on clinical outcomes among those with HFREF. HypothesisAnemia is associated with cardiovascular events in patients with heart failure. MethodsThe HF-ACTION trial was a prospective, randomized trial of exercise therapy vs usual care in 2331 patients with HFREF. Patients with New York Heart Association class II to IV HF and left ventricular ejection fractions of 35% were recruited. Hemoglobin (Hb) was measured up to 1 year prior to entry and was stratified by quintile. Anemia was defined as baseline Hb <13 g/dL and <12 g/dL in men and women, respectively. Hemoglobin was assessed in 2 models: a global prediction model that had been previously developed, and a modified model including variables associated with anemia and the studied outcomes. ResultsHemoglobin was available at baseline in 1763 subjects (76% of total study population); their median age was 59.0 years, 73% were male, and 62% were Caucasian. The prevalence of anemia was 515/1763 (29%). Older age, female sex, African American race, diabetes, hypertension, and lower estimated glomerular filtration rates were all more frequent in lower Hb quintiles. Over a median follow-up of 30 months, the primary outcome of all-cause mortality or all-cause hospitalization occurred in 78% of those with anemia and 64% in those without (P < 0.001). The secondary outcomes of all-cause mortality alone,cardiovascular (CV) mortality or CV hospitalization, and CV mortality or HF hospitalization occurred in 23% vs 15%, 67% vs 54%, and 44 vs 29%, respectively (P < 0.001). Heart failure hospitalizations occurred in 36% vs 22%, and urgent outpatient visits for HF exacerbations occurred in 67% and 55%, respectively (P < 0.001). For the global model, there was an association observed for anemia and all-cause mortality or hospitalization (adjusted hazard ratio [HR]: 1.15, 95% confidence interval [CI]: 1.01-1.32, P = 0.04), but other outcomes were not significant at P < 0.05. In the modified model, the adjusted HR for anemia and the primary outcome of all-cause mortality or all-cause hospitalization was 1.25 (95% CI: 1.10-1.42, P < 0.001). There were independent associations between anemia and all-cause death (HR: 1.11, 95% CI: 0.87-1.42, P = 0.38), CV death or CV hospitalization (HR: 1.16, 95% CI: 1.01-1.33, P = 0.035), and CV death and HF hospitalization (HR: 1.27, 95% CI: 1.06-1.51, P = 0.008). ConclusionsAnemia modestly is associated with increased rates of death, hospitalization, and HF exacerbation in patients with chronic HFREF. After adjusting for other important covariates, anemia is independently associated with an excess hazard for all-cause mortality and all-cause hospitalization. Anemia is also associated with combinations of CV death and CV/HF hospitalizations as composite endpoints. C1 [McCullough, Peter A.] St John Providence Hlth Syst, Dept Cardiovasc Med, Warren, MI USA. [McCullough, Peter A.] St John Hosp & Med Ctr, Detroit, MI USA. [McCullough, Peter A.] St John Hosp Macomb Oakland Ctr, Madison Hts, MI USA. [McCullough, Peter A.] Providence Hosp & Med Ctr, Southfield, MI USA. [McCullough, Peter A.] Providence Hosp & Med Ctr, Novi, MI USA. [McCullough, Peter A.] Providence Pk Heart Inst, Novi, MI USA. [Barnard, Denise] Univ Calif San Diego, Sch Med, Dept Cardiol, UCSD Hlth Syst, San Diego, CA 92103 USA. [Clare, Robert; Ellis, Stephen J.; O'Connor, Christopher M.] Duke Univ, Duke Clin Res Inst, Durham, NC USA. [Fleg, Jerome L.] NHLBI, Bethesda, MD 20892 USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Sch Med, Dept Cardiol, Los Angeles, CA USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Sch Med, Ahmanson UCLA Cardiomyopathy Ctr, Los Angeles, CA USA. [Franklin, Barry A.] Oakland Univ, William Beaumont Hosp, William Beaumont Sch Med, Dept Cardiac Rehabil, Royal Oak, MI USA. [Kilpatrick, Ryan D.] Amgen Inc, Thousand Oaks, CA 91320 USA. [Kitzman, Dalane W.; Thohan, Vinay] Wake Forest Baptist Hlth, Adv Cardiac Care & Heart Transplant Program, Winston Salem, NC USA. [Pina, Ileana L.] Albert Einstein Coll Med, Montefiore Med Ctr, Div Cardiol, Heart Failure Transplant Program, New York, NY USA. [Thadani, Udho] Univ Oklahoma, Hlth Sci Ctr, Dept Cardiol, Oklahoma City, OK USA. [Thadani, Udho] Vet Adm Med Ctr, Oklahoma City, OK 73104 USA. [Whellan, David J.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Philadelphia, PA 19107 USA. RP McCullough, PA (reprint author), Providence Pk Heart Inst, 47601 Grand River Ave,Suite B-125, Novi, MI 48374 USA. EM peteramccullough@gmail.com FU National Heart, Lung, and Blood Institute of the National Institutes of Health; Amgen, Inc. FX This work was funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health. The authors acknowledge the HF-ACTION Trial and Amgen, Inc., for partial support of statistical analyses and manuscript preparation and finalization. Dr. Kilpatrick is an employee and stockholder of Amgen, Inc., which provided funding for this analysis. ClinicalTrials.gov identifier: NCT00047437. NR 36 TC 7 Z9 7 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0160-9289 EI 1932-8737 J9 CLIN CARDIOL JI Clin. Cardiol. PD OCT PY 2013 VL 36 IS 10 BP 611 EP 620 DI 10.1002/clc.22181 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 232KZ UT WOS:000325493900014 PM 23929781 ER PT J AU Sacks, DB AF Sacks, David B. TI Reporting Hemoglobin A(1c): Do the Units Matter? SO CLINICAL CHEMISTRY LA English DT Editorial Material ID DIABETES-MELLITUS; STANDARDIZATION; CARE; COMPLICATIONS; BLOOD; A1C C1 [Sacks, David B.] NIH, Dept Lab Med, Bethesda, MD 20892 USA. RP Sacks, DB (reprint author), Dept Lab Med, Bldg 10,Rm 2C306,10 Ctr Dr, Bethesda, MD 20892 USA. EM sacksdb@mail.nih.gov OI Sacks, David/0000-0003-3100-0735 FU Intramural NIH HHS NR 15 TC 0 Z9 1 U1 0 U2 3 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 EI 1530-8561 J9 CLIN CHEM JI Clin. Chem. PD OCT PY 2013 VL 59 IS 10 BP 1427 EP 1429 DI 10.1373/clinchem.2013.211227 PG 3 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 231FG UT WOS:000325399800001 PM 23877379 ER PT J AU Berg, RA Sutton, RM Holubkov, R Nicholson, CE Dean, JM Harrison, R Heidemann, S Meert, K Newth, C Moler, F Pollack, M Dalton, H Doctor, A Wessel, D Berger, J Shanley, T Carcillo, J Nadkarni, VM AF Berg, Robert A. Sutton, Robert M. Holubkov, Richard Nicholson, Carol E. Dean, J. Michael Harrison, Rick Heidemann, Sabrina Meert, Kathleen Newth, Christopher Moler, Frank Pollack, Murray Dalton, Heidi Doctor, Allan Wessel, David Berger, John Shanley, Thomas Carcillo, Joseph Nadkarni, Vinay M. CA Eunice Kennedy Shriver Natl Inst C Amer Heart Assoc TI Ratio of PICU Versus Ward Cardiopulmonary Resuscitation Events Is Increasing SO CRITICAL CARE MEDICINE LA English DT Article DE cardiac arrest; cardiopulmonary resuscitation; children; intensive care; pediatrics ID AMERICAN-HEART-ASSOCIATION; HOSPITAL CARDIAC-ARREST; MEDICAL EMERGENCY TEAM; INTENSIVE-CARE UNITS; CHILDREN; OUTCOMES; MORTALITY; DISCHARGE; ICU AB Objectives: The aim of this study was to evaluate the relative frequency of pediatric in-hospital cardiopulmonary resuscitation events occurring in ICUs compared to general wards. We hypothesized that the proportion of pediatric cardiopulmonary resuscitation provided in ICUs versus general wards has increased over the past decade, and this shift is associated with improved resuscitation outcomes. Design: Prospective and observational study. Setting: Total of 315 hospitals in the American Heart Association's Get With The Guidelines-Resuscitation database. Patients: Total of 5,870 pediatric cardiopulmonary resuscitation events between January 1, 2000 and September 14, 2010. Cardiopulmonary resuscitation events were defined as external chest compressions longer than 1 minute. Interventions: None. Measurements and Main Results: The primary outcome was proportion of total ICU versus general ward cardiopulmonary resuscitation events over time evaluated by chi-square test for trend. Secondary outcome included return of spontaneous circulation following the cardiopulmonary resuscitation event. Among 5,870 pediatric cardiopulmonary resuscitation events, 5,477 (93.3%) occurred in ICUs compared to 393 (6.7%) in inpatient wards. Over time, significantly more of these cardiopulmonary resuscitation events occurred in the ICU compared to the wards (test for trend: p < 0.01), with a prominent shift noted between 2003 and 2004 (2000-2003: 87-91% vs 2004-2010: 94-96%). In a multivariable model controlling for within center variability and other potential confounders, return of spontaneous circulation increased in 2004-2010 compared with 2000-2003 (relative risk, 1.08; 95% CI, 1.03-1.13). Conclusions: In-hospital pediatric cardiopulmonary resuscitation is much more commonly provided in ICUs than in wards, and the proportion has increased significantly over the past decade, with concomitant increases in return of spontaneous circulation. C1 [Berg, Robert A.; Sutton, Robert M.; Nadkarni, Vinay M.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care, Div Crit Care Med, Philadelphia, PA 19104 USA. [Berg, Robert A.; Sutton, Robert M.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Holubkov, Richard; Dean, J. Michael] Univ Utah, Dept Pediat, Salt Lake City, UT USA. [Nicholson, Carol E.] NICHHD, Div Crit Care Med, Dept Pediat, Bethesda, MD 20892 USA. [Harrison, Rick] Univ Calif Los Angeles, Dept Pediat, Div Crit Care Med, Los Angeles, CA 90024 USA. [Heidemann, Sabrina; Meert, Kathleen] Childrens Hosp Michigan, Dept Pediat, Div Crit Care Med, Detroit, MI 48201 USA. [Newth, Christopher] Childrens Hosp Los Angeles, Dept Anesthesiol & Crit Care, Div Crit Care Med, Los Angeles, CA 90027 USA. [Moler, Frank; Shanley, Thomas] Univ Michigan, Dept Pediat, Div Crit Care Med, Ann Arbor, MI 48109 USA. [Moler, Frank; Shanley, Thomas] Mott Childrens Hosp, Ann Arbor, MI USA. [Pollack, Murray; Dalton, Heidi] Phoenix Childrens Hosp, Div Crit Care Med, Dept Pediat, Phoenix, AZ USA. [Doctor, Allan] Washington Univ, Sch Med, Dept Pediat, Div Crit Care Med, St Louis, MO 63110 USA. [Wessel, David; Berger, John] Childrens Natl Med Ctr, Dept Pediat, Div Crit Care Med, Washington, DC 20010 USA. [Carcillo, Joseph] UPMC, Childrens Hosp Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA. RP Berg, RA (reprint author), Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care, Div Crit Care Med, Philadelphia, PA 19104 USA. EM bergra@email.chop.edu OI Doctor, Allan/0000-0002-6096-6400 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Department of Health and Human Services (DHHS) [U10-HD050012, U10-HD050096, U10-HD063108, U10-HD049983, U10-HD049981, U10-HD063114, U10-HD063106]; National Institutes of Health (NIH); NIH NICHD; Collaborative Pediatric Critical Care Research Network; NIH FX Supported, in part, by the following cooperative agreements from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Department of Health and Human Services (DHHS): U10-HD050012, U10-HD050096, U10-HD063108, U10-HD049983, U10-HD049981, U10-HD063114, and U10-HD063106.; Drs. Berg, Holubkov, Nicholson, Dean, Harrison, Meert, Newth, Moler, Pollack, Dalton, Doctor, Wessel, Berger, and Carcillo received funding from the National Institutes of Health (NIH). Dr. Sutton received grant support from NIH NICHD (K3 Career Development Award). Dr. Sabrina Heidemann received grant support from the Collaborative Pediatric Critical Care Research Network and funding from NIH. Dr. Shanley received grant support from NIH, served as a board member for the Society of Pediatric Research (Secretary/Treasurer), received textbook royalties from Springer, and received support for travel from the University of Cincinnati and Case Western Reserve (external advisory boards). Dr. Nadkarni disclosed that he does not have any potential conflicts of interest. NR 18 TC 21 Z9 22 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 EI 1530-0293 J9 CRIT CARE MED JI Crit. Care Med. PD OCT PY 2013 VL 41 IS 10 BP 2292 EP 2297 DI 10.1097/CCM.0b013e31828cf0c0 PG 6 WC Critical Care Medicine SC General & Internal Medicine GA 225AP UT WOS:000324935000024 PM 23921270 ER PT J AU Qiu, P Cui, XZ Sun, JF Welsh, J Natanson, C Eichacker, PQ AF Qiu, Ping Cui, Xizhong Sun, Junfeng Welsh, Judith Natanson, Charles Eichacker, Peter Q. TI Antitumor Necrosis Factor Therapy Is Associated With Improved Survival in Clinical Sepsis Trials: A Meta-Analysis SO CRITICAL CARE MEDICINE LA English DT Article DE sepsis; septic shock; treatment; tumor necrosis factor ID FACTOR ANTIBODY-FRAGMENT; PLACEBO-CONTROLLED TRIAL; RECEPTOR FUSION PROTEIN; SEPTIC SHOCK; FACTOR-ALPHA; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; MULTICENTER; EFFICACY; SAFETY AB Objectives: Sepsis is a lethal syndrome annually affecting approximately 900,000 patients in the United States alone. Despite their benefit in rheumatoid disease, selective antitumor necrosis factor agents failed to improve outcome in early sepsis trials in the 1990s. However, data from additional sepsis trials testing these agents are now available. We therefore sought to determine the effect on survival of selective antitumor necrosis factor agents in randomized clinical sepsis trials.. Data Sources: PubMed, Scopus, Embase, and Web of Science. Study Selection: Randomized human sepsis trials of selective antitumor necrosis factor agents reporting survival rates. Data Extraction: Two investigators independently collected relevant data on study characteristics, treatment interventions, and patients from each study. Data Synthesis: Antitumor necrosis factor agents in 15 sepsis trials (n = 8,896 patients) meeting inclusion criteria had similar effects (I-2 = 0, p = 0.84) and compared with controls (placebo in 14 trials or a lower dose in one trial) overall decreased the relative risk of death (95% CI) (0.93 [0.88-0.98], p = 0.01). In subgroup analysis, tumor necrosis factor monoclonal antibodies (10 trials, n = 6,818) alone produced a significant survival benefit (0.93 [0.87, 0.99], p = 0.02) (I-2 = 0, p = 0.83). Tumor necrosis factor polyclonal antibodies (two trials, n = 151) and low-molecular-weight soluble receptor (two trials, n = 1,786) had similar beneficial effects to antitumor necrosis factor agents overall (0.82 [0.49-1.37], p = 0.45; 0.93 [0.81-1.08], p = 0.33, respectively). The effect of tumor necrosis factor high-molecular-weight soluble receptor (one trial, n = 141) was not significantly different from other agents but was on the side of harm (1.50 [0.86-2.61], p = 0.16). Conclusion: Antitumor necrosis factor agents produced a modest but significant decrease in the risk of dying with sepsis. Prior individual trials failed to demonstrate benefit, likely because they were underpowered. A definitive trial demonstrating the potential benefit of such agents might require 10,000 or more patients with sepsis. C1 [Qiu, Ping; Cui, Xizhong; Sun, Junfeng; Natanson, Charles; Eichacker, Peter Q.] NIH, Crit Care Med Dept, Ctr Clin, Bethesda, MD 20892 USA. [Welsh, Judith] NIH, Natl Inst Hlth Lib, Ctr Clin, Bethesda, MD 20892 USA. RP Eichacker, PQ (reprint author), NIH, Crit Care Med Dept, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA. EM peichacker@mail.nih.gov FU Intramural Research Program of the National Institutes of Health (NIH); NIH Clinical Center, Bethesda, MD; National Institutes of Health FX Supported, in part, by the Intramural Research Program of the National Institutes of Health (NIH) and the NIH Clinical Center, Bethesda, MD.; Drs. Eichacker, Qiu, Cui, Sun, and Natanson received funding from the National Institutes of Health. Dr. Welsh disclosed that she does not have any potential conflicts of interest. NR 32 TC 9 Z9 9 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 EI 1530-0293 J9 CRIT CARE MED JI Crit. Care Med. PD OCT PY 2013 VL 41 IS 10 BP 2419 EP 2429 DI 10.1097/CCM.0b013e3182982add PG 11 WC Critical Care Medicine SC General & Internal Medicine GA 225AP UT WOS:000324935000038 PM 23887234 ER PT J AU Mbulaiteye, SM Kemp, T Gage, JC Ajenifuja, KO Kiruthu, C Wentzensen, NA Adepiti, C Wacholder, S Burk, RD Schiffman, M Pinto, L AF Mbulaiteye, S. M. Kemp, T. Gage, J. C. Ajenifuja, K. O. Kiruthu, C. Wentzensen, N. A. Adepiti, C. Wacholder, S. Burk, R. D. Schiffman, M. Pinto, L. TI Plasma cytokine levels and human papillomavirus infection at the cervix in rural Nigerian women SO CYTOKINE LA English DT Article DE Cytokines; Cervical cancer; Inflammation; Plasmodium falciparum malaria ID CANCER; INFLAMMATION; PREVALENCE; AFRICANS; LESIONS; GUINEA; GRADE; RISK AB Introduction: We conducted a study to test the hypothesis that systemic dysregulation of Th1/Th2 cytokine levels was associated with detection of carcinogenic or overall human papillomavirus (HPV) at the cervix among 964 women residing in a rural village in Nigeria. Methods: Levels in plasma were measured for 19 cytokines, including Th1-like cytokines IL-2, IL-12 (p40), TNF-a, IFN-g; Th2-like cytokines IL-4, IL-5, IL-6, IL-10, IL-13; innate/inflammation cytokines IL-1a, IL-1b, IL-8, eotaxin, MCP-1, MIP-1a, and IL-7; and cell development cytokines G-CSF, VEGF, and IL-17. Analysis was restricted to 5 cytokines, TNF-alpha, (Th1), IL-8 (Th2), eotaxin and MCP-1 (innate/inflammation), and G-CSF (cell development), whose levels were detected in 80% or more of the samples measured as well as had a coefficient of variation of <30%. Results: Strong correlations were noted between levels of eotaxin and TNF-alpha (r = 0.75), IL-8 and MCP-1 (r = 0.60), eotaxin and G-CSF (r = 0.44), and G-CSF and IFN-gamma (r = 0.43). Detection of carcinogenic or non-carcinogenic HPV DNA was unrelated to cytokine levels, except for levels of eotaxin and TNF-alpha, which were inversely correlated, albeit weakly, with detection of any carcinogenic HPV (P = 0.048 and P = 0.067, respectively). In analyses stratified by age group, levels of eotaxin were inversely correlated with detection of any HPV DNA (P = 0.026) and carcinogenic HPV (P = 0.042) in older, but not younger, women. Conclusions: Our results do not support the hypothesis of association between systemic cytokine dysregulation and detection of HPV at the cervix in Nigerian women, but subgroup analyses raise questions about inverse associations between eotaxin and TNF-alpha in older women. Published by Elsevier Ltd. C1 [Mbulaiteye, S. M.; Gage, J. C.; Kiruthu, C.; Wentzensen, N. A.; Wacholder, S.; Schiffman, M.] NCI, NIH, Div Canc Epidemiol & Genet, DHHS, Bethesda, MD 20892 USA. [Kemp, T.; Pinto, L.] Sci Applicat Int Corp, Frederick, MD USA. [Ajenifuja, K. O.; Adepiti, C.] Obafemi Awolowo Univ, Dept Obstet Gynaecol & Perinatol, Ife, Nigeria. [Burk, R. D.] Yeshiva Univ, Albert Einstein Coll Med, The Bronx, NY USA. RP Mbulaiteye, SM (reprint author), NCI, NIH, DCEG, Infect & Immunoepidemiol Branch, 9609 Med Ctr Dr Rm 6E118 MSC 9704, Bethesda, MD 20892 USA. EM mbulaits@mail.nih.gov FU Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services NIH [5U01CA078527-13, HHSN261200900303P] FX We would like to thank Mr. David Check at the Biostatistics Branch at the National Cancer Institute (Rockville, Maryland) for help drawing the graphs. The study was supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services NIH Grant # 5U01CA078527-13 & NIH contract HHSN261200900303P. The CareHPV equipment and supplies used in this study were donated by Qiagen Corporation (Gaithersburg, MD); CareHPV is not the subject of this report. The authors report no conflicts of interest. NR 21 TC 6 Z9 8 U1 0 U2 4 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1043-4666 EI 1096-0023 J9 CYTOKINE JI Cytokine PD OCT PY 2013 VL 64 IS 1 BP 146 EP 151 DI 10.1016/j.cyto.2013.07.028 PG 6 WC Biochemistry & Molecular Biology; Cell Biology; Immunology SC Biochemistry & Molecular Biology; Cell Biology; Immunology GA 231UA UT WOS:000325442700025 PM 23972725 ER PT J AU Berlin, I Singleton, EG Heishman, SJ AF Berlin, Ivan Singleton, Edward G. Heishman, Stephen J. TI Predicting smoking relapse with a multidimensional versus a single-item tobacco craving measure SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Tobacco craving; Smoking relapse; Prognostic markers; Screening ID MAXIMUM-LIKELIHOOD-ESTIMATION; TRANSCRANIAL MAGNETIC STIMULATION; NICOTINE WITHDRAWAL SYMPTOMS; BINORMAL ROC CURVES; CIGARETTE WITHDRAWAL; MYOCARDIAL-INFARCTION; OUTCOME EXPECTANCIES; PROGNOSTIC MODELS; FRENCH VERSION; QUIT SMOKING AB Background: Research suggests that craving is a predictor of smoking relapse. Craving can be assessed by multiple item or multifactorial scales or by single items. However, no systematic comparisons of their prognostic validity or accuracy have been published. Methods: The French versions of the 12-item Tobacco Craving Questionnaire (FTCQ-12) and the single craving item on the Minnesota Nicotine Withdrawal Scale (MNWS) are brief, valid, and reliable self-report measures of tobacco craving. In this secondary study, we analyzed data from French smokers with health-related problems enrolled in the Adjustment of DOses of Nicotine in Smoking (ADONIS) cessation trial. We estimated prediction models for each measure and compared their ability to distinguish correctly participants who relapsed from those who did not at 1-8 weeks after their quit date. Results: Adjusted for all potential confounders FTCQ-12 risk score (RS; Factor 2, Expectancy plus Factor 4, Purposefulness) and MNWS craving were valid predictors of smoking relapse at endpoints measured 1-7 weeks apart. Prognostic accuracy of FTCQ-12 RS was greatest at 1-2 weeks follow-up compared to only 1 week for MNWS craving. Sensitivity for FTCQ-12 RS and MNWS craving was 85% and 53%, respectively. Conclusions: FTCQ-12 RS suggests a relapse process involving urges and desires in anticipation of the positive benefits of smoking linked with intent and planning to smoke. Findings also suggest that FTCQ-12 RS may be a better predictor instrument for smoking relapse than MNWS craving. (C) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Berlin, Ivan] Univ Paris 06, INSERM, Hop La Pitie Salpetriere, Dept Pharmacol,Fac Med,U669, Paris, France. [Singleton, Edward G.] MayaTech Corp, Silver Spring, MD USA. [Heishman, Stephen J.] NIDA, Nicotine Psychopharmacol Sect, Intramural Res Program, NIH, Baltimore, MD USA. RP Berlin, I (reprint author), Hop La Pitie Salpetriere, Dept Pharmacol, 47 Bd Hop, F-75013 Paris, France. EM ivan.berlin@psl.aphp.fr OI Singleton, Edward G./0000-0003-3442-877X FU French Ministry of Health Programme Hospitalier de Recherche Clinique Loco-regional [AOR04001//P040406, 050558]; Agence francaise de securite sanitaire des produits de sante, Convention Pharmacologie Clinique et Therapeutique [RAF02020]; Intramural Research Program (IRP) of the National Institutes of Health, National Institute on Drug Abuse; Assistance publique-Hopitaux de Paris, France [AOR04001-FAP11014, P040406] FX This study was supported by the French Ministry of Health Programme Hospitalier de Recherche Clinique Loco-regional 2004 (AOR04001//P040406, registration number: 050558); by the Agence francaise de securite sanitaire des produits de sante, Convention Pharmacologie Clinique et Therapeutique 2003, RAF02020 and the Intramural Research Program (IRP) of the National Institutes of Health, National Institute on Drug Abuse. Contribution of E.G. Singleton was partly funded by the research grant AOR04001-FAP11014, P040406 of Assistance publique-Hopitaux de Paris, France. The authors thank Mrs. Shoreh Azimi, research coordinator, for her assistance with the study. NR 84 TC 16 Z9 18 U1 3 U2 21 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD OCT 1 PY 2013 VL 132 IS 3 BP 513 EP 520 DI 10.1016/j.drugalcdep.2013.03.017 PG 8 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 232RC UT WOS:000325510700017 PM 23623506 ER PT J AU Eckelman, WC Jones, AG Duatti, A Reba, RC AF Eckelman, William C. Jones, Alun G. Duatti, Adriano Reba, Richard C. TI Progress using Tc-99m radiopharmaceuticals for measuring high capacity sites and low density sites SO DRUG DISCOVERY TODAY LA English DT Review ID MEMBRANE ANTIGEN; IMAGING AGENT; TECHNETIUM-99M; PERFUSION; INHIBITORS; SPECT; COMPLEXES; ACID; TRACERS; NUCLEAR AB Technetium-99m (Tc-99m) has long been a mainstay in clinical nuclear medicine, primarily monitoring biological processes in the heart, kidney, liver, and brain. More recently, Tc-99m chelates have been used as the reporter in targeted nuclear medicine probes that monitor changes in specific protein expression products. The strengths remain the inexpensive source of Tc-99m from the Mo-99/Tc-99m generator, its rich chemistry, high-yield kit formulation, and its widespread availability. Hardware and software advances, such as OSEM reconstructions with scatter and attenuation corrections, have led to quantitation of the injected radioactivity in terms of kBq/cm. C1 [Eckelman, William C.] Mol Tracer LLC, Bethesda, MD 20814 USA. [Jones, Alun G.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Duatti, Adriano] Univ Ferrara, I-44121 Ferrara, Italy. [Reba, Richard C.] NIAID Integrated Res Facil, Frederick, MD 21702 USA. RP Eckelman, WC (reprint author), Mol Tracer LLC, Bethesda, MD 20814 USA. EM wceckelman@verizon.net OI Duatti, Adriano/0000-0001-6567-6245 NR 58 TC 8 Z9 8 U1 0 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1359-6446 EI 1878-5832 J9 DRUG DISCOV TODAY JI Drug Discov. Today PD OCT PY 2013 VL 18 IS 19-20 BP 984 EP 991 DI 10.1016/j.drudis.2013.06.008 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 232QX UT WOS:000325510200009 PM 23806975 ER PT J AU Williams, RV Margossian, R Lu, MM Atz, AM Bradley, TJ Campbell, MJ Colan, SD Gallagher, D Lai, WW Pearson, GD Prakash, A Shirali, G Cohen, MS AF Williams, Richard V. Margossian, Renee Lu, Minmin Atz, Andrew M. Bradley, Timothy J. Campbell, Michael Jay Colan, Steven D. Gallagher, Dianne Lai, Wyman W. Pearson, Gail D. Prakash, Ashwin Shirali, Girish Cohen, Meryl S. CA Pediat Heart Network Investigators TI Factors Impacting Echocardiographic Imaging after the Fontan Procedure: A Report from the Pediatric Heart Network Fontan Cross-Sectional Study SO ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES LA English DT Article DE Fontan procedure; echocardiographic quality ID MAGNETIC-RESONANCE; MULTICENTER; DISEASE AB Echocardiographic image quality in Fontan survivors may be limited by a variety of factors. We sought to describe echocardiographic quality and factors associated with study quality in subjects participating in the Pediatric Heart Network Fontan Cross-Sectional Study. Echocardiograms were obtained at 7 clinical sites using a standard protocol. Quality grading and analysis were performed by a core laboratory. Univariate and multivariable modeling were performed to assess factors associated with quality and ability to obtain images sufficient for prespecified quantitative analysis. A total of 543 echocardiograms were obtained. The quality of echocardiograms improved over the duration of the study. The great arteries, systemic veins, and pulmonary veins were less likely to be adequately imaged than other cardiac structures. Quantitative analysis of ventricular volume was possible in 76% overall, but only 41% of those with mixed ventricular morphology. Factors independently associated with better quality included younger age, levocardia, acquisition of the echocardiogram at a longer time since the beginning of enrollment, absence of a pulmonary artery stent, and clinical site. Patient and center-specific factors are associated with echocardiographic quality after the Fontan procedure. Increased familiarity and experience with a standard imaging protocol is likely to result in improved quality. C1 [Williams, Richard V.] Univ Utah, Salt Lake City, UT 84113 USA. [Margossian, Renee; Colan, Steven D.; Prakash, Ashwin] Childrens Hosp Boston, Boston, MA USA. [Lu, Minmin; Gallagher, Dianne] New England Res Inst, Watertown, MA 02172 USA. [Atz, Andrew M.; Shirali, Girish] Med Univ S Carolina, Charleston, SC 29425 USA. [Bradley, Timothy J.] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Campbell, Michael Jay] Duke Univ, Durham, NC USA. [Lai, Wyman W.] Columbia Univ, New York, NY USA. [Pearson, Gail D.] NHLBI, NIH, Bethesda, MD 20892 USA. [Cohen, Meryl S.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. RP Williams, RV (reprint author), Univ Utah, 100 North Mario Capecchi Dr, Salt Lake City, UT 84113 USA. EM richard.williams@imail.org RI Hurwitz Koweek, lynne/N-1351-2015 OI Hurwitz Koweek, lynne/0000-0001-9990-3397 FU National Heart, Lung, and Blood Institute [HL068269, HL068270, HL068279, HL068281, HL068285, HL068292, HL068290, HL068288] FX Supported by U01 grants from the National Heart, Lung, and Blood Institute (HL068269, HL068270, HL068279, HL068281, HL068285, HL068292, HL068290, HL068288). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the NHLBI. NR 16 TC 2 Z9 2 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0742-2822 EI 1540-8175 J9 ECHOCARDIOGR-J CARD JI Echocardiography-J. Cardiovasc. Ultrasound Allied Tech. PD OCT PY 2013 VL 30 IS 9 BP 1098 EP 1106 DI 10.1111/echo.12219 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 232IC UT WOS:000325485700028 PM 23614708 ER PT J AU Xekouki, P Mastroyiannis, SA Avgeropoulos, D Sierra, MDL Trivellin, G Gourgari, EA Lyssikatos, C Quezado, M Patronas, N Kanaka-Gantenbein, C Chrousos, GP Stratakis, CA AF Xekouki, Paraskevi Mastroyiannis, Spyridon A. Avgeropoulos, Dimitrios Sierra, Maria de la Luz Trivellin, Giampaolo Gourgari, Evgenia A. Lyssikatos, Charalampos Quezado, Martha Patronas, Nicholas Kanaka-Gantenbein, Christina Chrousos, George P. Stratakis, Constantine A. TI Familial pituitary apoplexy as the only presentation of a novel AIP mutation SO ENDOCRINE-RELATED CANCER LA English DT Letter ID ADENOMAS; HEMORRHAGE; GENE C1 [Xekouki, Paraskevi; Mastroyiannis, Spyridon A.; Avgeropoulos, Dimitrios; Sierra, Maria de la Luz; Trivellin, Giampaolo; Gourgari, Evgenia A.; Lyssikatos, Charalampos; Stratakis, Constantine A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Endocrinol & Genet, Program Dev Endocrinol & Genet PDEGEN, NIH,NIH Clin Res Ctr, Bethesda, MD 20892 USA. [Xekouki, Paraskevi; Mastroyiannis, Spyridon A.; Avgeropoulos, Dimitrios; Sierra, Maria de la Luz; Trivellin, Giampaolo; Gourgari, Evgenia A.; Lyssikatos, Charalampos; Stratakis, Constantine A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Endocrinol Inter Inst Training Program, NIH, NIH Clin Res Ctr, Bethesda, MD 20892 USA. [Quezado, Martha] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA. [Patronas, Nicholas] NIH, Dept Diagnost Radiol, Clin Res Ctr, Bethesda, MD 20892 USA. [Kanaka-Gantenbein, Christina; Chrousos, George P.] Univ Athens, Aghia Sophia Childrens Hosp, Dept Pediat 1, Endocrine Unit, Athens, Greece. RP Stratakis, CA (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Endocrinol & Genet, Program Dev Endocrinol & Genet PDEGEN, NIH,NIH Clin Res Ctr, 10 Ctr Dr,Bldg 10,Room 1-3330,MSC1103, Bethesda, MD 20892 USA. EM stratakc@mail.nih.gov RI Trivellin, Giampaolo/J-6583-2016 OI Trivellin, Giampaolo/0000-0003-2384-4153 FU Intramural NIH HHS [ZIA HD008920-01] NR 10 TC 6 Z9 6 U1 0 U2 1 PU BIOSCIENTIFICA LTD PI BRISTOL PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND SN 1351-0088 EI 1479-6821 J9 ENDOCR-RELAT CANCER JI Endocr.-Relat. Cancer PD OCT PY 2013 VL 20 IS 5 BP L11 EP L14 DI 10.1530/ERC-13-0218 PG 4 WC Oncology; Endocrinology & Metabolism SC Oncology; Endocrinology & Metabolism GA 234HP UT WOS:000325633800002 PM 24025584 ER PT J AU Major, EO Douek, DC Frohman, EM Walsh, DR AF Major, Eugene O. Douek, Daniel C. Frohman, Elliot M. Walsh, Declan R. TI Two demyelinating diseases in the brain of a single patient, PML and MS: how to minimize 'one' while treating the 'other' SO EXPERT REVIEW OF CLINICAL IMMUNOLOGY LA English DT Editorial Material DE demyelinating diseases; JCV; natalizumab; patients ID JC VIRUS; PATHOGENESIS C1 [Major, Eugene O.] NINDS, Lab Mol Med & Neurosci, NIH, Bethesda, MD 20892 USA. [Douek, Daniel C.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA. [Frohman, Elliot M.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA. [Frohman, Elliot M.] Univ Texas SW Med Ctr Dallas, Dept Ophthalmol, Dallas, TX 75390 USA. [Walsh, Declan R.] DeFerno Trust, Sligo, Ireland. RP Major, EO (reprint author), NINDS, Lab Mol Med & Neurosci, NIH, Bethesda, MD 20892 USA. EM majorg@ninds.nih.gov NR 11 TC 0 Z9 0 U1 0 U2 0 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1744-666X EI 1744-8409 J9 EXPERT REV CLIN IMMU JI Expert Rev. Clin. Immunol. PD OCT PY 2013 VL 9 IS 10 BP 887 EP 890 DI 10.1586/1744666X.2013.841559 PG 4 WC Immunology SC Immunology GA 234IV UT WOS:000325637500002 PM 24128152 ER PT J AU Berzofsky, JA Wood, LV Terabe, M AF Berzofsky, Jay A. Wood, Lauren V. Terabe, Masaki TI Cancer vaccines: 21st century approaches to harnessing an ancient modality to fight cancer SO EXPERT REVIEW OF VACCINES LA English DT Editorial Material DE beta-mannosylceramide; cancer immunotherapy; cancer vaccines; epitope enhancement; NK T cells; prostate cancer; TARP antigen; transforming growth factor-beta ID CD8(+) T-CELLS; TUMOR IMMUNOSURVEILLANCE; SUPPRESSOR-CELLS; NKT CELL; IMMUNITY; EFFICACY; IMMUNOTHERAPY; PROSTATE; IL-13; HELP C1 [Berzofsky, Jay A.; Wood, Lauren V.; Terabe, Masaki] NCI, Vaccine Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. RP Berzofsky, JA (reprint author), NCI, Vaccine Branch, Ctr Canc Res, NIH, Bldg 41 Room D702D,41 Medlars Dr, Bethesda, MD 20892 USA. EM berzofsj@mail.nih.gov NR 34 TC 3 Z9 3 U1 0 U2 3 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1476-0584 EI 1744-8395 J9 EXPERT REV VACCINES JI Expert Rev. Vaccines PD OCT PY 2013 VL 12 IS 10 BP 1115 EP 1118 DI 10.1586/14760584.2013.836906 PG 4 WC Immunology SC Immunology GA 234GM UT WOS:000325630400003 PM 24124874 ER PT J AU Rees, J Schlom, J AF Rees, Jenaid Schlom, Jeffrey TI Recombinant cancer vaccines and new vaccine targets SO EXPERT REVIEW OF VACCINES LA English DT Editorial Material AB Interview by Jenaid Rees, Commissioning Editor Jeffrey Schlom obtained his PhD from Rutgers University (NJ, USA). After obtaining his PhD, he worked at Columbia University (NY, USA) before moving in 1973 to the National Cancer Institute, National Institutes of Health (MD, USA). Since then he has served as the Chief of several sections, including his present position as the Chief of the Laboratory of Tumor Immunology and Biology in the Center for Cancer Research which he has held for the past 30 years. During this period, he has worked as an Adjunct Professor at George Washington University (Washington, DC, USA), served on the Editorial Board of several journals and holds membership in a number of committees. He holds over 30 patents and patent applications in the areas of vaccines, tumor antigens and monoclonal antibodies and has received honors and awards throughout his career. Jeffrey Schlom has been involved in translational research involving the immunotherapy of a range of carcinomas and predominantly works in the areas of tumor immunology, mechanisms of tumor cell-immune cell interactions and immune mechanisms. He has recently been working on the design and characterization of recombinant vaccines for cancer therapy. C1 [Schlom, Jeffrey] NCI, Tumor Immunol & Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. EM js141c@nih.gov NR 0 TC 1 Z9 1 U1 0 U2 3 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1476-0584 EI 1744-8395 J9 EXPERT REV VACCINES JI Expert Rev. Vaccines PD OCT PY 2013 VL 12 IS 10 BP 1121 EP 1124 DI 10.1586/14760584.2013.836913 PG 4 WC Immunology SC Immunology GA 234GM UT WOS:000325630400007 ER PT J AU Ali, T Choyke, PL Kobayashi, H AF Ali, Towhid Choyke, Peter L. Kobayashi, Hisataka TI Endoscopic molecular imaging of cancer SO FUTURE ONCOLOGY LA English DT Article DE cancer; fluorescence endoscopy; imaging probe; molecular imaging ID CONFOCAL LASER ENDOMICROSCOPY; GROWTH-FACTOR RECEPTOR; CERVICAL INTRAEPITHELIAL NEOPLASIA; HIGH-GRADE DYSPLASIA; LOWER-GI TRACT; IN-VIVO; COLORECTAL-CANCER; INDOCYANINE GREEN; BARRETTS-ESOPHAGUS; OVARIAN-CANCER AB White light endoscopy has proven to be a very powerful tool in oncology. There is still, however, a need for better endoscopic techniques to overcome the current limitations of white light optics. New technologies that allow higher sensitivity, improved microanatomy and molecular characterization have been available for in vitro microscopy and are now being translated into in vivo endoscopy. Endoscopic molecular imaging is still in its infancy but holds the promise for enhancing sensitivity for early lesions, thus allowing earlier diagnosis and enabling early image-guided endoscopic intervention. A key feature of endoscopic molecular imaging is its increased sensitivity and specificity, which will be illustrated in this article, as well as describing perspectives on its future use in oncologic surgery. C1 [Ali, Towhid; Choyke, Peter L.; Kobayashi, Hisataka] NCI, Mol Imaging Program, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. RP Kobayashi, H (reprint author), NCI, Mol Imaging Program, Ctr Canc Res, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA. EM kobayash@mail.nih.gov FU Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research; NIH FX The authors are employees of the NIH. This work was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. This work was made possible through the NIH Medical Research Scholars Program, a public-private partnership supported jointly by the NIH and generous contributions to the Foundation for the NIH from Pfizer Inc., The Leona M and Harry B Helmsley Charitable Trust, and the Howard Hughes Medical Institute, as well as other private donors. For a complete list, please visit the Foundation website at www.fnih.org/work/programs-development/medical-research-scholars-program . The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 80 TC 1 Z9 1 U1 4 U2 9 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1479-6694 EI 1744-8301 J9 FUTURE ONCOL JI Future Oncol. PD OCT PY 2013 VL 9 IS 10 BP 1501 EP 1513 DI 10.2217/fon.13.123 PG 13 WC Oncology SC Oncology GA 231IT UT WOS:000325410600017 PM 24106901 ER PT J AU Koonin, EV AF Koonin, Eugene V. TI A flea has smaller fleas that on him prey: giant viruses, their parasites and evolutionary networks SO FUTURE VIROLOGY LA English DT Article DE giant viruses; transposable elements; transpovirons; virophages; virus evolution ID ORTHOLOGOUS GENES; DNA TRANSPOSONS; VIROPHAGE; MIMIVIRUS; RECONSTRUCTION; TRANSPOVIRONS; CLUSTERS; GENOMES; ORIGIN C1 NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA. RP Koonin, EV (reprint author), NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA. EM koonin@ncbi.nlm.nih.gov NR 20 TC 0 Z9 0 U1 1 U2 16 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1746-0794 EI 1746-0808 J9 FUTURE VIROL JI Future Virol. PD OCT PY 2013 VL 8 IS 10 BP 937 EP 940 DI 10.2217/fvl.13.79 PG 4 WC Virology SC Virology GA 218IL UT WOS:000324425900002 ER PT J AU Flood, TF Gorczyca, M White, BH Ito, K Yoshihara, M AF Flood, Thomas F. Gorczyca, Michael White, Benjamin H. Ito, Kei Yoshihara, Motojiro TI A Large-Scale Behavioral Screen to Identify Neurons Controlling Motor Programs in the Drosophila Brain SO G3-GENES GENOMES GENETICS LA English DT Article DE command neurons; Drosophila; Gal4; TRPM8; TrpA1 ID SWIMMERET MOVEMENTS; DECISION NETWORK; COURTSHIP SONG; MELANOGASTER; SYSTEMS; INTERNEURONS; NEUROBIOLOGY; CRAYFISH; EXPRESSION; PROTEIN AB Drosophila is increasingly used for understanding the neural basis of behavior through genetically targeted manipulation of specific neurons. The primary approach in this regard has relied on the suppression of neuronal activity. Here, we report the results of a novel approach to find and characterize neural circuits by expressing neuronal activators to stimulate subsets of neurons to induce behavior. Classical electrophysiological studies demonstrated that stimulation of command neurons could activate neural circuits to trigger fixed action patterns. Our method was designed to find such command neurons for diverse behaviors by screening flies in which random subsets of brain cells were activated. We took advantage of the large collection of Gal4 lines from the NP project and crossed 835 Gal4 strains with relatively limited Gal4 expression in the brain to flies carrying a UAS transgene encoding TRPM8, a cold-sensitive ion channel. Low temperatures opened the TRPM8 channel in Gal4- expressing cells, leading to their excitation, and in many cases induced overt behavioral changes in adult flies. Paralysis was reproducibly observed in the progeny of crosses with 84 lines, whereas more specific behaviors were induced with 24 other lines. Stimulation performed using the heat-activated channel, TrpA1, resulted in clearer and more robust behaviors, including flight, feeding, and egg-laying. Through follow-up studies starting from this screen, we expect to find key components of the neural circuits underlying specific behaviors, thus providing a new avenue for their functional analysis. C1 [Flood, Thomas F.; Gorczyca, Michael; Yoshihara, Motojiro] Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA USA. [White, Benjamin H.] NIMH, Mol Biol Lab, Bethesda, MD 20892 USA. [Ito, Kei] Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo, Japan. RP Yoshihara, M (reprint author), MIT, Picower Inst Learning & Memory, 77 Massachusetts Ave, Cambridge, MA 02139 USA. EM motojiro@mit.edu FU National Institute of Mental Health [MH85958]; Worcester Foundation; Japan Society for the Promotion of Science/National Science Foundation; National Institute of Mental Health Intramural Research Program FX We thank S. Waddell for critical discussion, S. Waddell, T. Lee, M. Alkema, and T. Ip for discussions, members of the NP consortium for NP lines, S. Waddell, T. Lee, and P. Garrity for fly stocks, and K. Ikeda for technical advice. This work was supported by National Institute of Mental Health Grant MH85958, the Worcester Foundation (to M.Y.), fellowship of the Japan Society for the Promotion of Science/National Science Foundation (to T.F.F.), grant-in-aid for the Promotion of Science (to K.I.), and the National Institute of Mental Health Intramural Research Program (to B.H.W.) NR 44 TC 5 Z9 5 U1 0 U2 18 PU GENETICS SOC AM PI BETHESDA PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA SN 2160-1836 J9 G3-GENES GENOM GENET JI G3-Genes Genomes Genet. PD OCT 1 PY 2013 VL 3 IS 10 BP 1629 EP 1637 DI 10.1534/g3.113.006205 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA 232IJ UT WOS:000325486500002 PM 23934998 ER PT J AU Lai, XN Beilharz, T Au, WC Hammet, A Preiss, T Basrai, MA Heierhorst, J AF Lai, Xianning Beilharz, Traude Au, Wei-Chun Hammet, Andrew Preiss, Thomas Basrai, Munira A. Heierhorst, Joerg TI Yeast hEST1A/B (SMG5/6)-Like Proteins Contribute to Environment-Sensing Adaptive Gene Expression Responses SO G3-GENES GENOMES GENETICS LA English DT Article DE hEST1; SMG5; SMG6; gene expression; genetic interactions ID MESSENGER-RNA DECAY; CARBON METABOLISM REGULON; 18S RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; QUALITY-CONTROL; TELOMERE MAINTENANCE; MAMMALIAN TELOMERES; INTERACTING PROTEIN; POLY(A) POLYMERASE; CELL-SURFACE AB During its natural life cycle, budding yeast (Saccharomyces cerevisiae) has to adapt to drastically changing environments, but how environmental-sensing pathways are linked to adaptive gene expression changes remains incompletely understood. Here, we describe two closely related yeast hEST1A-B (SMG5-6)-like proteins termed Esl1 and Esl2 that contain a 14-3-3-like domain and a putative PilT N-terminus ribonuclease domain. We found that, unlike their metazoan orthologs, Esl1 and Esl2 were not involved in nonsense-mediated mRNA decay or telomere maintenance pathways. However, in genomewide expression array analyses, absence of Esl1 and Esl2 led to more than two-fold deregulation of similar to 50 transcripts, most of which were expressed inversely to the appropriate metabolic response to environmental nutrient supply; for instance, normally glucose-repressed genes were derepressed in esl1 Delta esl2 Delta double mutants during growth in a high-glucose environment. Likewise, in a genome-wide synthetic gene array screen, esl1 Delta esl2 Delta double mutants were synthetic sick with null mutations for Rim8 and Dfg16, which form the environmental-sensing complex of the Rim101 pH response gene expression pathway. Overall, these results suggest that Esl1 and Esl2 contribute to the regulation of adaptive gene expression responses of environmental sensing pathways. C1 [Lai, Xianning; Hammet, Andrew; Heierhorst, Joerg] St Vincents Inst Med Res, Melbourne, Vic 3065, Australia. [Lai, Xianning; Heierhorst, Joerg] Univ Melbourne, St Vincents Hosp, Dept Med, Melbourne, Vic 3065, Australia. [Beilharz, Traude; Preiss, Thomas] Victor Chang Cardiac Res Inst, Sydney, NSW 2010, Australia. [Au, Wei-Chun; Basrai, Munira A.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20889 USA. RP Heierhorst, J (reprint author), St Vincents Inst Med Res, 9 Princes St, Melbourne, Vic 3065, Australia. EM jheierhorst@svi.edu.au OI Beilharz, Traude/0000-0002-8942-9502; Preiss, Thomas/0000-0001-6273-784X FU NHMRC; Victorian Government's Operational Infrastructure Support Program; Melbourne International Research Scholarship; Melbourne International Fee Remission Scholarship; ARC discovery project; Australian Research Fellowship [DP0878224] FX Supported by NHMRC project grants and NHMRC Senior Research Fellowships (J.H. and T.P.), the Victorian Government's Operational Infrastructure Support Program (J.H.), a Melbourne International Research Scholarship and Melbourne International Fee Remission Scholarship (X.L.), an ARC discovery project (T.P.), and Australian Research Fellowship (DP0878224) (T.H.B.). NR 54 TC 2 Z9 4 U1 2 U2 6 PU GENETICS SOC AM PI BETHESDA PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA SN 2160-1836 J9 G3-GENES GENOM GENET JI G3-Genes Genomes Genet. PD OCT 1 PY 2013 VL 3 IS 10 BP 1649 EP 1659 DI 10.1534/g3.113.006924 PG 11 WC Genetics & Heredity SC Genetics & Heredity GA 232IJ UT WOS:000325486500004 PM 23893744 ER PT J AU Klar, AJS AF Klar, Amar J. S. TI Schizosaccharomyces japonicus Yeast Poised to Become a Favorite Experimental Organism for Eukaryotic Research SO G3-GENES GENOMES GENETICS LA English DT Article DE Schizosaccharomyces japonicus; fission yeast; fast growing; rapid meiotic analysis; organism conducive for research ID TRANSFORMATION; MECHANISM AB Both budding yeast Saccharomyces cerevisiae and fission yeast Schizosaccahromyces pombe have been very popular organisms used for biological research with eukaryotes for many decades. Judging from the fission yeast Schizosaccharomyces japonicus DNA sequence determined 2 years ago, this species is evolutionarily very much unrelated to the commonly used yeasts for research. Indicating evolutionary divergence, the S. japonicus makes 8-spored asci and mitosis occurs with a partial breakdown of nuclear membrane whereas the other yeasts make 4-spored asci and cells divide without nuclear breakdown. The commonly used yeast species exhibit a generation time between 1.5 and 2.0 hr, and their genetic cross takes a period of more than 7 working d. As described here, a generation time of only 63 min and meiotic analysis completed in just 2.5 d, the S. japonicus fission yeast is predicted to become a choice organism for future research on the biology of eukaryotes. C1 NCI, Gene Regulat & Chromosome Biol Lab, Ctr Canc Res, NIH, Frederick, MD 21702 USA. RP Klar, AJS (reprint author), NCI, Gene Regulat & Chromosome Biol Lab, Ctr Canc Res, NIH, Bldg 539,Room 154, Frederick, MD 21702 USA. EM klara@mail.nih.gov FU National Cancer Institute, National Institutes of Health FX I thank Michael Bonaduce for providing technical support and Dr. C. Cagliero for helping to take photographs of yeast cells. Dr. H. Niki (National Institute of Genetics, Japan) is thanked for providing strains of japonicus variety. The Intramural Research Program of the National Cancer Institute, National Institutes of Health, supports this research. NR 21 TC 3 Z9 3 U1 0 U2 9 PU GENETICS SOCIETY AMERICA PI BETHESDA PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA SN 2160-1836 J9 G3-GENES GENOM GENET JI G3-Genes Genomes Genet. PD OCT 1 PY 2013 VL 3 IS 10 BP 1869 EP 1873 DI 10.1534/g3.113.007187 PG 5 WC Genetics & Heredity SC Genetics & Heredity GA 232IJ UT WOS:000325486500026 PM 23934997 ER PT J AU Song, PH Reiter, KL Weiner, BJ Minasian, L McAlearney, AS AF Song, Paula H. Reiter, Kristin L. Weiner, Bryan J. Minasian, Lori McAlearney, Ann Scheck TI The business case for provider participation in clinical trials research: An application to the National Cancer Institute's community clinical oncology program SO HEALTH CARE MANAGEMENT REVIEW LA English DT Article DE business case; clinical trials; oncology; provider-based research network; return on investment ID TRANSLATING RESEARCH; RESEARCH-NETWORKS; DIFFUSION; QUALITY; SYSTEM AB Background: Provider-based research networks (PBRNs) make clinical trials available in community-based practice settings, where most people receive their care, but provider participation requires both financial and in-kind contributions. Purpose: The aim of this study was to explore whether providers believe there is a business case for participating in PBRNs and what factors contribute to the business case. Methodology/Approach: We use a multiple case study methodology approach to examine the National Cancer Institute's community clinical oncology program, a long-standing federally funded PBRN. Interviews with 41 key informants across five sites, selected on the basis of organizational maturity, were conducted using a semistructured interview guide. We analyzed interview transcripts using an iterative, deductive process to identify themes and subthemes in the data. Findings: We found that a business case for provider participation in PBRNs may exist if both direct and indirect financial benefits are identified and included in the analysis and if the time horizon is long enough to allow those benefits to be realized. We identified specific direct and indirect financial benefits that were perceived as important contributors to the business case and the perceived length of time required for a positive return to accrue. Practice Implications: As the lack of a business case may result in provider reluctance to participate in PBRNs, knowledge of the benefits we identified may be crucial to encouraging and sustaining participation, thereby preserving patient access to innovative community-based treatments. The results are also relevant to federally funded PBRNs outside of oncology or to providers considering participation in any clinical trials research. C1 [Song, Paula H.; McAlearney, Ann Scheck] Ohio State Univ, Coll Publ Hlth, Div Hlth Serv Management & Policy, Columbus, OH 43210 USA. [Reiter, Kristin L.; Weiner, Bryan J.] Univ N Carolina, Dept Hlth Policy & Management, Chapel Hill, NC USA. [Minasian, Lori] NCI, Community Oncol & Prevent Trials Res Grp, Canc Prevent Div, Bethesda, MD 20892 USA. [McAlearney, Ann Scheck] Ohio State Univ, Coll Med, Dept Family Med, Columbus, OH 43210 USA. RP Song, PH (reprint author), Ohio State Univ, Coll Publ Hlth, Div Hlth Serv Management & Policy, Columbus, OH 43210 USA. EM psong@cph.osu.edu; reiter@email.unc.edu; weiner@email.unc.edu; minasilo@mail.nih.gov; Ann.McAlearney@osumc.edu FU NCI NIH HHS [R01CA124402, R01 CA124402] NR 27 TC 4 Z9 4 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0361-6274 EI 1550-5030 J9 HEALTH CARE MANAGE R JI Health Care Manage. Rev. PD OCT-DEC PY 2013 VL 38 IS 4 BP 284 EP 294 DI 10.1097/HMR.0b013e31827292fc PG 11 WC Health Policy & Services SC Health Care Sciences & Services GA 222TO UT WOS:000324754700003 PM 23044836 ER PT J AU Daniels, MLA Leigh, MW Davis, SD Armstrong, MC Carson, JL Hazucha, M Dell, SD Eriksson, M Collins, FS Knowles, MR Zariwala, MA AF Daniels, M. Leigh Anne Leigh, Margaret W. Davis, Stephanie D. Armstrong, Michael C. Carson, Johnny L. Hazucha, Milan Dell, Sharon D. Eriksson, Maria Collins, Francis S. Knowles, Michael R. Zariwala, Maimoona A. TI Founder Mutation in RSPH4A Identified in Patients of Hispanic Descent with Primary Ciliary Dyskinesia SO HUMAN MUTATION LA English DT Article DE cilia; Kartagener syndrome; sequencing; RSPH4A ID MTDNA AB Primary ciliary dyskinesia (PCD) is a rare, autosomal recessive, genetically heterogeneous disorder characterized by ciliary dysfunction resulting in chronic oto-sino-pulmonary disease, respiratory distress in term neonates, laterality (situs) defects, and bronchiectasis. Diagnosis has traditionally relied on ciliary ultrastructural abnormalities seen by electron microscopy. Mutations in radial spoke head proteins occur in PCD patients with central apparatus defects. Advances in genetic testing have been crucial in addressing the diagnostic challenge. Here, we describe a novel splice-site mutation (c.921+3_6delAAGT) in RSPH4A, which leads to a premature translation termination signal in nine subjects with PCD (seven families). Loss-of-function was confirmed with quantitative ciliary ultrastructural analysis, measurement of ciliary beat frequency and waveform, and transcript analysis. All nine individuals carrying c.921+3_6delAAGT splice-site mutation in RSPH4A were Hispanic with ancestry tracing to Puerto Rico. This mutation is a founder mutation and a common cause of PCD without situs abnormalities in patients of Puerto Rican descent. Published 2013 Wiley Periodicals, Inc. C1 [Daniels, M. Leigh Anne; Armstrong, Michael C.; Hazucha, Milan; Knowles, Michael R.] UNC Sch Med, Dept Med, Chapel Hill, NC 27599 USA. [Leigh, Margaret W.; Davis, Stephanie D.; Carson, Johnny L.] UNC Sch Med, Dept Pediat, Chapel Hill, NC 27599 USA. [Dell, Sharon D.] Univ Toronto, Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada. [Eriksson, Maria] Karolinska Inst, Ctr Biosci, Dept Biosci & Nutr, Huddinge, Sweden. [Collins, Francis S.] NHGRI, NIH, Bethesda, MD 20892 USA. [Zariwala, Maimoona A.] UNC Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA. RP Zariwala, MA (reprint author), UNC Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA. EM Knowles@med.unc.edu; zariwala@med.unc.edu FU US National Institute of Health (NIH) Office of the Director; Office of Rare Diseases Research (ORDR); National Heart, Lung, and Blood Institute (NHLBI); US National Institutes of Health (NIH)-National Heart, Lung, and Blood Institute (NHLBI) [5R01HL071798]; T32 Research Training Program "Multidisciplinary Research Training in Pulmonary Diseases" [T32 HL007106]; National Human Genome Research Institute (NHGRI); National Center for Advancing Translational Sciences (NCATS) [UL1 TR000083, CFF R026-CR07]; ORDR; NHLBI; NHGRI; NCATS; NIH Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS); National Heart Lung and Blood Institute; [5 U54 HL096458-06] FX Contract grant sponsors: US National Institute of Health (NIH) Office of the Director; Office of Rare Diseases Research (ORDR); National Heart, Lung, and Blood Institute (NHLBI); (5 U54 HL096458-06); US National Institutes of Health (NIH)-National Heart, Lung, and Blood Institute (NHLBI) (5R01HL071798); T32 Research Training Program "Multidisciplinary Research Training in Pulmonary Diseases" (T32 HL007106); National Human Genome Research Institute (NHGRI); National Center for Advancing Translational Sciences (NCATS) (UL1 TR000083, CFF R026-CR07); ORDR; NHLBI; NHGRI; NCATS. The Genetic Disorders of Mucociliary Clearance (U54HL096458) is a part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), supported through collaboration between the NIH Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS), and the National Heart Lung and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 20 TC 7 Z9 8 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1059-7794 EI 1098-1004 J9 HUM MUTAT JI Hum. Mutat. PD OCT PY 2013 VL 34 IS 10 BP 1352 EP 1356 DI 10.1002/humu.22371 PG 5 WC Genetics & Heredity SC Genetics & Heredity GA 222SW UT WOS:000324752700006 PM 23798057 ER PT J AU Landoure, G Zhu, PP Lourenco, CM Johnson, JO Toro, C Bricceno, KV Rinaldi, C Meilleur, KG Sangare, M Diallo, O Pierson, TM Ishiura, H Tsuji, S Hein, N Fink, JK Stoll, M Nicholson, G Gonzalez, MA Speziani, F Durr, A Stevanin, G Biesecker, LG Accardi, J Landis, DMD Gahl, WA Traynor, BJ Marques, W Zuchner, S Blackstone, C Fischbeck, KH Burnett, BG AF Landoure, Guida Zhu, Peng-Peng Lourenco, Charles M. Johnson, Janel O. Toro, Camilo Bricceno, Katherine V. Rinaldi, Carlo Meilleur, Katherine G. Sangare, Modibo Diallo, Oumarou Pierson, Tyler M. Ishiura, Hiroyuki Tsuji, Shoji Hein, Nichole Fink, John K. Stoll, Marion Nicholson, Garth Gonzalez, Michael A. Speziani, Fiorella Duerr, Alexandra Stevanin, Giovanni Biesecker, Leslie G. Accardi, John Landis, Dennis M. D. Gahl, William A. Traynor, Bryan J. Marques, Wilson, Jr. Zuechner, Stephan Blackstone, Craig Fischbeck, Kenneth H. Burnett, Barrington G. CA NIH Intramural Sequencing Ctr TI Hereditary Spastic Paraplegia Type 43 (SPG43) is Caused by Mutation in C19orf12 SO HUMAN MUTATION LA English DT Article DE SPG43; NBIA; C19orf12; hereditary spastic paraplegia ID BRAIN IRON ACCUMULATION; NEURODEGENERATION; PREVALENCE; SUBTYPE; PROTEIN; LOCUS; NBIA; FORM AB We report here the genetic basis for a form of progressive hereditary spastic paraplegia (SPG43) previously described in two Malian sisters. Exome sequencing revealed a homozygous missense variant (c.187G>C; p.Ala63Pro) in C19orf12, a gene recently implicated in neurodegeneration with brain iron accumulation (NBIA). The same mutation was subsequently also found in a Brazilian family with features of NBIA, and we identified another NBIA patient with a three-nucleotide deletion (c.197_199del; p.Gly66del). Haplotype analysis revealed that the p.Ala63Pro mutations have a common origin, but MRI scans showed no brain iron deposition in the Malian SPG43 subjects. Heterologous expression of these SPG43 and NBIA variants resulted in similar alterations in the subcellular distribution of C19orf12. The SPG43 and NBIA variants reported here as well as the most common C19orf12 missense mutation reported in NBIA patients are found within a highly conserved, extended hydrophobic domain in C19orf12, underscoring the functional importance of this domain. Published 2013 Wiley Periodicals, Inc. C1 [Landoure, Guida] Ctr Hosp Univ Point G, Serv Neurol, Bamako, Mali. [Landoure, Guida; Zhu, Peng-Peng; Bricceno, Katherine V.; Rinaldi, Carlo; Sangare, Modibo; Diallo, Oumarou; Pierson, Tyler M.; Blackstone, Craig; Fischbeck, Kenneth H.; Burnett, Barrington G.] NINDS, Neurogenet Branch, NIH, Bethesda, MD 20892 USA. [Lourenco, Charles M.; Marques, Wilson, Jr.] Univ Sao Polo, Sch Med Ribeirao Preto, Dept Neurosci & Behav Sci, Sao Polo, Brazil. [Johnson, Janel O.; Traynor, Bryan J.] NIA, Lab Neurogenet, NIH, Bethesda, MD 20892 USA. [Toro, Camilo; Pierson, Tyler M.; Accardi, John; Landis, Dennis M. D.; Gahl, William A.] NIH, NIH Undiagnosed Dis Program, NIH Common Fund, Off Director, Bethesda, MD 20892 USA. [Meilleur, Katherine G.] NINR, Tissue Injury Branch, NIH, Bethesda, MD 20892 USA. [Ishiura, Hiroyuki; Tsuji, Shoji] Univ Tokyo, Dept Neurol, Grad Sch Med, Tokyo, Japan. [Hein, Nichole; Fink, John K.] Univ Michigan, Sch Med, Dept Neurol, Ann Arbor, MI USA. [Fink, John K.] Univ Michigan, Ann Arbor Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Ann Arbor, MI 48109 USA. [Stoll, Marion; Nicholson, Garth] Univ Sydney, ANZAC Res Inst, Northcott Neurosci Lab, Sydney, NSW 2006, Australia. [Gonzalez, Michael A.; Speziani, Fiorella; Zuechner, Stephan] Univ Miami, Miller Sch Med, Dept Human Genet, Miami, FL 33136 USA. [Gonzalez, Michael A.; Speziani, Fiorella; Zuechner, Stephan] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA. [Duerr, Alexandra; Stevanin, Giovanni] Hop La Pitie Salpetriere, Dept Genet & Cytogenet, AP HP, Paris, France. [Duerr, Alexandra; Stevanin, Giovanni] Hop La Pitie Salpetriere, CNRS UMR7225, INSERM UPMC UMRS975, Ctr Rech Inst Cerveau & Moelle Epiniere, Paris, France. [Stevanin, Giovanni] EPHE, F-75006 Paris, France. [Biesecker, Leslie G.] NIH, Genet Dis Res Branch, Bethesda, MD 20892 USA. [Biesecker, Leslie G.] NIH, NIH Intramural Sequencing Ctr, Bethesda, MD 20892 USA. RP Landoure, G (reprint author), Ctr Hosp Univ Point G, Serv Neurol, POB 333, Bamako, Mali. EM landoureg@ninds.nih.gov RI Traynor, Bryan/G-5690-2010; Lourenco, Charles/O-2731-2013; Marques, Wilson/G-4240-2012; Stevanin, Giovanni/E-5038-2016; OI Marques, Wilson/0000-0002-4589-2749; Stevanin, Giovanni/0000-0001-9368-8657 FU NIH/NINDS Intramural Research Funds [1ZIA NS002974-13]; NHGRI; NIH [R01NS072248, R01NS054132]; l'Agence Nationale pour la Recherche (SPAX); VERUM Foundation; Association Strumpell-Lorrain FX Contract grant sponsors: NIH/NINDS Intramural Research Funds (1ZIA NS002974-13); NHGRI; NIH (R01NS072248, R01NS054132); l'Agence Nationale pour la Recherche (SPAX); VERUM Foundation and Association Strumpell-Lorrain. NR 17 TC 23 Z9 24 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1059-7794 EI 1098-1004 J9 HUM MUTAT JI Hum. Mutat. PD OCT PY 2013 VL 34 IS 10 BP 1357 EP 1360 DI 10.1002/humu.22378 PG 4 WC Genetics & Heredity SC Genetics & Heredity GA 222SW UT WOS:000324752700007 PM 23857908 ER PT J AU Brinton, LA Westhoff, CL Scoccia, B Lamb, EJ Trabert, B Niwa, S Moghissi, KS AF Brinton, Louise A. Westhoff, Carolyn L. Scoccia, Bert Lamb, Emmet J. Trabert, Britton Niwa, Shelley Moghissi, Kamran S. TI Fertility drugs and endometrial cancer risk: results from an extended follow-up of a large infertility cohort SO HUMAN REPRODUCTION LA English DT Article DE endometrial cancer; risk; infertility; clomiphene citrate; gonadotrophins ID IN-VITRO FERTILIZATION; GYNECOLOGIC CANCERS; OVULATION INDUCTION; UTERINE-CANCER; BREAST; THERAPY; WOMEN AB Do fertility drugs influence the subsequent risk of endometrial cancer in a manner that is independent of other risk predictors, such as parity? In this follow-up of a large cohort of women evaluated for infertility and for whom information was captured on fertility drugs, indications for usage and other risk factors that might influence cancer risk, we found no evidence for a substantial relationship between fertility drug use and endometrial cancer risk. Although the hormonal etiology of endometrial cancer has been well established, it remains unclear whether the use of fertility drugs has an influence on risk. Results regarding the effects of fertility drugs on endometrial cancer risk have been inconsistent, although several studies have shown some evidence for possible increases in risk. The relationship is of particular interest given that clomiphene, a commonly prescribed drug, is a selective estrogen receptor modulator, with chemical properties similar to tamoxifen, another drug linked to an increase in endometrial cancer risk. In a retrospective cohort of 12 193 women evaluated for infertility between 1965 and 1988 at five US sites, follow-up was pursued through 2010 via both passive as well as active (questionnaire) means. Among the 9832 subjects for whom follow-up was allowed and achieved, 259 346 at-risk person-years (i.e. prior to hysterectomy) were accrued, and 118 invasive endometrial cancers identified. Cox regression determined hazard ratios (HRs) and 95 confidence intervals (CIs) for fertility treatments adjusted for endometrial cancer risk factors and causes of infertility. Although we observed slight increases in endometrial cancer risk associated with clomiphene (HR 1.39, 95 CI: 0.962.01) and the less commonly prescribed gonadotrophins (1.34, 0.762.37), there were no convincing relationships of risk with either cycles of use or cumulative exposures for either drug. A statistically significant risk associated with the use of clomiphene among women who began use at younger ages (30) (1.93, 1.243.00) may have reflected indications for drug usage rather than the effect of the drug itself. Women who received clomiphene followed by gonadotrophins were at a non-significantly elevated risk (1.77, 0.983.19). Like most studies of endometrial cancer, we were limited by sample sizes, particularly for evaluating subgroup associations. We were also unable to follow all women and were not able to obtain complete risk factor information (including hysterectomy status) for the entire cohort. Although we found no support for a relationship between fertility drugs and endometrial cancer risk, the association should continue to be monitored given that our study population was still young and had not yet reached the age of peak endometrial cancer incidence. This project was supported in part by funds from the intramural research program of the National Cancer Institute, National Institutes of Health. None of the authors has any conflicting interests to declare. C1 [Brinton, Louise A.; Trabert, Britton] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA. [Westhoff, Carolyn L.] Columbia Univ, Dept Obstet & Gynecol, New York, NY USA. [Scoccia, Bert] Univ Illinois, Dept Obstet & Gynecol, Chicago, IL 60612 USA. [Lamb, Emmet J.] Stanford Univ, Stanford, CA 94305 USA. [Niwa, Shelley] Westat Corp, Rockville, MD USA. [Moghissi, Kamran S.] Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI USA. RP Brinton, LA (reprint author), NCI, Div Canc Epidemiol & Genet, Rockville, MD USA. EM brinton@nih.gov RI Brinton, Louise/G-7486-2015; Trabert, Britton/F-8051-2015 OI Brinton, Louise/0000-0003-3853-8562; FU National Cancer Institute, National Institutes of Health FX This project was supported in part by funds from the intramural research program of the National Cancer Institute, National Institutes of Health. NR 22 TC 9 Z9 10 U1 0 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1161 EI 1460-2350 J9 HUM REPROD JI Hum. Reprod. PD OCT PY 2013 VL 28 IS 10 BP 2813 EP 2821 DI 10.1093/humrep/det323 PG 9 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 223UI UT WOS:000324836300024 PM 23943795 ER PT J AU Jukic, AM Baird, DD Weinberg, CR McConnaughey, DR Wilcox, AJ AF Jukic, A. M. Baird, D. D. Weinberg, C. R. McConnaughey, D. R. Wilcox, A. J. TI Length of human pregnancy and contributors to its natural variation SO HUMAN REPRODUCTION LA English DT Article DE gestational length; pregnancy; variability; implantation; corpus luteum ID BASAL BODY-TEMPERATURE; CHORIONIC-GONADOTROPIN; OVULATION DETECTION; CORPUS-LUTEUM; RHESUS-MONKEY; RISK-FACTORS; WOMANS LIFE; BIRTH; IMPLANTATION; PROBABILITY AB How variable is the length of human pregnancy, and are early hormonal events related to gestational length? Among natural conceptions where the date of conception (ovulation) is known, the variation in pregnancy length spanned 37 days, even after excluding women with complications or preterm births. Previous studies of length of gestation have either estimated gestational age by last menstrual period (LMP) or ultrasound (both imperfect measures) or included pregnancies conceived through assisted reproductive technology. The Early Pregnancy Study was a prospective cohort study (198285) that followed 130 singleton pregnancies from unassisted conception to birth, with detailed hormonal measurements through the conception cycle; 125 of these pregnancies were included in this analysis. We calculated the length of gestation beginning at conception (ovulation) in 125 naturally conceived, singleton live births. Ovulation, implantation and corpus luteum (CL) rescue pattern were identified with urinary hormone measurements. We accounted for events that artificially shorten the natural length of gestation (Cesarean delivery or labor induction, i.e. censoring) using KaplanMeier curves and proportional hazards models. We examined hormonal and other factors in relation to length of gestation. We did not have ultrasound information to compare with our gold standard measure. The median time from ovulation to birth was 268 days (38 weeks, 2 days). Even after excluding six preterm births, the gestational length range was 37 days. The coefficient of variation was higher when measured by LMP (4.9) than by ovulation (3.7), reflecting the variability of time of ovulation. Conceptions that took longer to implant also took longer from implantation to delivery (P 0.02). CL rescue pattern (reflecting ovarian response to implantation) was predictive (P 0.006): pregnancies with a rapid progesterone rise were longer than those with delayed rise (a 12-day difference in the median gestational length). Mothers with longer gestations were older (P 0.02), had longer pregnancies in other births (P 0.0001) and were heavier at birth (P 0.01). We did not see an association between the length of gestation and several factors that have been associated with gestational length in previous studies: body mass index, alcohol intake, parity or offspring sex. The sample size was small and some exposures were rare, reducing power to detect weak associations. Human gestational length varies considerably even when measured exactly (from ovulation). An individual womans deliveries tend to occur at similar gestational ages. Events in the first 2 weeks after conception are predictive of subsequent pregnancy length, and may suggest pathways underlying the timing of delivery. This research was supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences. None of the authors has any conflict of interest to declare. C1 [Jukic, A. M.; Baird, D. D.; Wilcox, A. J.] NIEHS, Epidemiol Branch, Durham, NC 27709 USA. [Weinberg, C. R.] NIEHS, Biostat Branch, Durham, NC 27709 USA. [McConnaughey, D. R.] Westat Corp, Durham, NC 27709 USA. RP Jukic, AM (reprint author), NIEHS, Epidemiol Branch, POB 12233, Durham, NC 27709 USA. EM jukica@niehs.nih.gov RI Baird, Donna/D-5214-2017; OI Baird, Donna/0000-0002-5544-2653; Wilcox, Allen/0000-0002-3376-1311 FU Intramural Research Program of the NIH, National Institute of Environmental Health Sciences FX This research was supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences. NR 36 TC 26 Z9 26 U1 2 U2 31 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1161 EI 1460-2350 J9 HUM REPROD JI Hum. Reprod. PD OCT PY 2013 VL 28 IS 10 BP 2848 EP 2855 DI 10.1093/humrep/det297 PG 8 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 223UI UT WOS:000324836300028 PM 23922246 ER PT J AU McBride, CM Persky, S Wagner, LK Faith, MS Ward, DS AF McBride, C. M. Persky, S. Wagner, L. K. Faith, M. S. Ward, D. S. TI Effects of providing personalized feedback of child's obesity risk on mothers' food choices using a virtual reality buffet SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Article DE genomic risk; parents; communication; family health history ID INFORMATION-SEEKING; PREDICTING OBESITY; PARENTAL OBESITY; FAMILY-HISTORY; PUBLIC-HEALTH; BEHAVIORS; PERSPECTIVE; DISEASE; COMMUNICATION; ADOLESCENTS AB BACKGROUND: Providing personalized genetic-risk feedback of a child's susceptibility to adult-onset health conditions is a topic of considerable debate. Family health history (FHH), specifically parental overweight/obesity status, is a useful assessment for evaluating a child's genetic and environmental risk of becoming obese. It is unclear whether such risk information may influence parents' efforts to reduce their child's risk of obesity. PURPOSE: To evaluate whether telling mothers the magnitude of their child's risk of becoming obese based on personal FHH influenced food choices for their young child from a virtual reality-based buffet restaurant. METHODS: Overweight/obese mothers of a child aged 4-5 years who met eligibility criteria (N=221) were randomly assigned to one of three experimental arms, which emphasized different health information: arm 1, food safety control (Control); arm 2, behavioral-risk information (BRI) alone or arm 3, behavioral-risk information plus personal FHH-based risk assessment (BRI + FHH). Mothers donned a head-mounted display to be immersed in a virtual restaurant buffet, where they selected virtual food and beverages as a lunch for their child. RESULTS: Mothers who were randomized to BRI + FHH filled the index child's plate with an average of 45 fewer calories than those in the Control arm (P<0.05); those in the BRI arm filled the plate with 35 fewer calories than the Control arm, a non-significant difference. Calorie restriction was greatest among mothers in the BRI + FHH arm who received the weaker-risk message (that is, only one overweight parent). CONCLUSIONS: The influence of communicating a child's inherited risk of obesity on mothers' feeding practices may vary by the risk level conveyed. High-risk messages may best be coupled with strategies to increase mother's perceptions that efforts can be undertaken to reduce risk and build requisite behavioral skills to reduce risk. C1 [McBride, C. M.; Persky, S.; Wagner, L. K.] NHGRI, Social & Behav Res Branch, Bethesda, MD 20892 USA. [Faith, M. S.; Ward, D. S.] Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC USA. RP McBride, CM (reprint author), NHGRI, Social & Behav Res Branch, Bldg 31,MSC 2073,31 Ctr Dr,Room B1B54, Bethesda, MD 20892 USA. EM cmcbride@mail.nih.gov NR 35 TC 6 Z9 6 U1 1 U2 9 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 EI 1476-5497 J9 INT J OBESITY JI Int. J. Obes. PD OCT PY 2013 VL 37 IS 10 BP 1322 EP 1327 DI 10.1038/ijo.2013.87 PG 6 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 233CG UT WOS:000325542200005 PM 23736369 ER PT J AU Jones, RE Zheng, W McKew, JC Chen, CZ AF Jones, Raisa E. Zheng, Wei McKew, John C. Chen, Catherine Z. TI An Alternative Direct Compound Dispensing Method Using the HP D300 Digital Dispenser SO JALA LA English DT Article DE compound dispenser; liquid handler; compound screen; serial dilution; direct dilution AB Evaluation of compound activity in vitro is crucial to drug discovery efforts and require that the compounds be accurately and reliably titrated and dispensed to the assay wells. The HP D300 dispenser uses inkjet technology to achieve small-volume dispensing that allows concentration-response testing using the direct dilution paradigm. Although inkjet technology has been long in existence, it is new to the field of screening and drug development. We have evaluated the D300 dispenser in a biochemical assay, a cell-based reporter gene assay, and a cytotoxicity assay. The software for this instrument is user friendly, and the compound-dispensing process is streamlined. However, a limitation is that this dispenser is currently applicable to only 96-well and 384-well plate formats and not to 1536-well high-density plates. Our results indicate that the D300 generates clean and reproducible results that correlate with those produced with more commonly used instruments such as the pin tool. We found that the instrument is useful and can improve the throughput of compound dispensing in 96-well and 384-well plates. C1 [Jones, Raisa E.; Zheng, Wei; McKew, John C.; Chen, Catherine Z.] NIH, Natl Ctr Adv Translat Sci, Bethesda, MD 20892 USA. RP Chen, CZ (reprint author), NIH, Natl Ctr Adv Translat Sci, 9800 Med Ctr Dr,MSC 3370, Bethesda, MD 20892 USA. EM chenc4@mail.nih.gov OI Zheng, Wei/0000-0003-1034-0757 FU Intramural Research Program of the Therapeutics for Rare and Neglected Diseases, National Center for Advancing Translational Sciences, NIH FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Intramural Research Program of the Therapeutics for Rare and Neglected Diseases, National Center for Advancing Translational Sciences, NIH. NR 9 TC 6 Z9 6 U1 2 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 2211-0682 EI 1540-2452 J9 JALA-J LAB AUTOM JI JALA PD OCT PY 2013 VL 18 IS 5 BP 367 EP 374 DI 10.1177/2211068213491094 PG 8 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA 220YM UT WOS:000324623400003 PM 23708834 ER PT J AU Annunziata, CM Kohn, EC AF Annunziata, Christina M. Kohn, Elise C. TI Novel Facts About FAK: New Connections to Drug Resistance? SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Editorial Material ID FOCAL ADHESION KINASE; MARKER NANOG; CANCER-CELLS; EXPRESSION; PACLITAXEL; INHIBITOR; CD44; GENE; MDR1 C1 [Annunziata, Christina M.] NCI, Ctr Canc Res, Bethesda, MD 20892 USA. [Kohn, Elise C.] NCI, Clin Invest Branch, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA. RP Kohn, EC (reprint author), NCI, Canc Therapy Evaluat Program, NIH, 9609 Med Ctr Dr MSC 5W426 MSC9737, Rockville, MD 20850 USA. EM kohne@mail.nih.gov RI Annunziata, Christina/L-3219-2016 OI Annunziata, Christina/0000-0003-2033-6532 NR 21 TC 3 Z9 3 U1 0 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-. Natl. Cancer Inst. PD OCT PY 2013 VL 105 IS 19 BP 1430 EP 1431 DI 10.1093/jnci/djt255 PG 3 WC Oncology SC Oncology GA 232GZ UT WOS:000325482100006 PM 24062526 ER PT J AU Barsevick, AM Irwin, MR Hinds, P Miller, A Berger, A Jacobsen, P Ancoli-Israel, S Reeve, BB Mustian, K O'Mara, A Lai, JS Fisch, M Cella, D AF Barsevick, Andrea M. Irwin, Michael R. Hinds, Pamela Miller, Andrew Berger, Ann Jacobsen, Paul Ancoli-Israel, Sonia Reeve, Bryce B. Mustian, Karen O'Mara, Ann Lai, Jin-Shei Fisch, Michael Cella, David TI Recommendations for High-Priority Research on Cancer-Related Fatigue in Children and Adults SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Editorial Material ID PATIENT-REPORTED OUTCOMES; QUALITY-OF-LIFE; SIGNIFICANTLY IMPROVES FATIGUE; PROPOSED DIAGNOSTIC-CRITERIA; COGNITIVE-BEHAVIORAL THERAPY; METASTATIC COLORECTAL-CANCER; RANDOMIZED CLINICAL-TRIAL; PRIMARY BREAST-CANCER; PHYSICAL-ACTIVITY; FUNCTIONAL ASSESSMENT AB Over the past decades, some scientific progress has been made in understanding and treating cancer-related fatigue (CRF). However, three major problems have limited further progress: lack of agreement about measurement, inadequate understanding of the underlying biology, and problems in the conduct of clinical trials for CRF. This commentary reports the recommendations of a National Cancer Institute Clinical Trials Planning Meeting and an ongoing National Cancer Institute working group to address these problems so that high-priority research and clinical trials can be conducted to advance the science of CRF and its treatment. Recommendations to address measurement issues included revising the current case definition to reflect more rigorous criteria, adopting the Patient Reported Outcomes Measurement Information System fatigue scales as standard measures of CRF, and linking legacy measures to the scales. With regard to the biology of CRF, the group identified the need for longitudinal research to examine biobehavioral mechanisms underlying CRF and testing mechanistic hypotheses within the context of intervention research. To address clinical trial issues, recommendations included using only placebo-controlled trial designs. setting eligibility to minimize sample heterogeneity or enable subgroup analysis, establishing a CRF severity threshold for participation in clinical trials, conducting dissemination trials of efficacious interventions (such as exercise), and combining nonpharmacologic and pharmacologic interventions to exploit the potential synergy between these approaches. Accomplishing these goals has the potential to advance the science of CRF and improve the clinical management of this troubling symptom. C1 [Barsevick, Andrea M.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Irwin, Michael R.] Univ Calif Los Angeles, Los Angeles, CA USA. [Hinds, Pamela] Childrens Natl Med Ctr, Washington, DC 20010 USA. [Miller, Andrew] Emory Univ, Atlanta, GA 30322 USA. [Berger, Ann] Univ Nebraska Med Ctr, Omaha, NE USA. [Jacobsen, Paul] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Ancoli-Israel, Sonia] Univ Calif San Diego, San Diego, CA 92103 USA. Univ N Carolina, Chapel Hill, NC USA. [Mustian, Karen] Univ Rochester, Rochester, NY USA. [O'Mara, Ann] NCI, Bethesda, MD 20892 USA. [Lai, Jin-Shei; Cella, David] Northwestern Univ, Chicago, IL 60611 USA. [Fisch, Michael] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. RP Barsevick, AM (reprint author), Thomas Jefferson Univ, 834 Chestnut St,Suite 314, Philadelphia, PA 19107 USA. EM Andrea.barsevick@jefferson.edu RI Irwin, Michael/H-4870-2013; OI Irwin, Michael/0000-0002-1502-8431; Barsevick, Andrea/0000-0003-1829-6826 FU NCI NIH HHS [P30 CA016086, R25 CA102618, U10 CA037420] NR 138 TC 35 Z9 36 U1 6 U2 22 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-. Natl. Cancer Inst. PD OCT PY 2013 VL 105 IS 19 BP 1432 EP 1440 DI 10.1093/jnci/djt242 PG 9 WC Oncology SC Oncology GA 232GZ UT WOS:000325482100007 PM 24047960 ER PT J AU Citrin, DE Shankavaram, U Horton, JA Shield, W Zhao, SP Asano, H White, A Sowers, A Thetford, A Chung, EJ AF Citrin, Deborah E. Shankavaram, Uma Horton, Jason A. Shield, William, III Zhao, Shuping Asano, Hiroaki White, Ayla Sowers, Anastasia Thetford, Angela Chung, Eun Joo TI Role of Type II Pneumocyte Senescence in Radiation-Induced Lung Fibrosis SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID IDIOPATHIC PULMONARY-FIBROSIS; EPITHELIAL-CELL SENESCENCE; NORMAL HUMAN FIBROBLASTS; GROWTH ARREST; OXIDATIVE STRESS; GENE-EXPRESSION; TGF-BETA; INJURY; TOXICITY; MUTATIONS AB Background Radiation is a commonly delivered therapeutic modality for cancer. The causes underlying the chronic, progressive nature of radiation injury in the lung are poorly understood. Methods C57Bl/6NCr mice were exposed to thoracic irradiation (n = 3 per dose and time point for tissue collection). Microarray analysis of gene expression from irradiated murine lung was performed using one-way analysis of variance with post hoc Scheffe analysis. Senescence and type II airway epithelial cell (AECII) count were assayed in irradiated murine lung tissue (n = 3 per condition). Irradiated mice were treated with diphenyleneiodonium (DPI), an inhibitor of NADPH oxidase (NOX), and fibrosis was assessed by collagen assays. All statistical tests were two-tailed. Results Gene expression in lung tissue from mice irradiated to 17.5 Gy clustered with that of aged unirradiated mice. Only fibrogenic exposures led to AECII senescence (0 Gy: 0.66% +/- 0.67%; 5 Gy: 4.5% +/- 1.19%; 17.5 Gy: 18.7% +/- 3.05; P = .007) and depletion (0 Gy: 2.89 per alveolus +/- 0.26; 5 Gy: 2.41 +/- 0.19; 17.5 Gy: 1.6 +/- 0.14; P < .001) at 30 weeks. Treatment of irradiated mice with DPI for 16 weeks markedly reduced collagen accumulation (5 x 6 Gy: 57.26 mu g/lung +/- 9.91; 5 x 6 Gy +/- DPI: 36.54 mu g/lung +/- 4.39; P = .03) and AECII senescence (5 x 6 Gy: 37.61% +/- 4.82%; 5 x 6 Gy +/- DPI: 12.38% +/- 2.78; P < .001). Conclusions These studies identify senescence as an important process in AECII in vivo and indicate that NOX is a critical mediator of radiation-induced AECII senescence and pulmonary fibrosis. C1 [Citrin, Deborah E.; Shankavaram, Uma; Horton, Jason A.; Shield, William, III; Zhao, Shuping; Asano, Hiroaki; Chung, Eun Joo] NIH, Radiat Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA. [Sowers, Anastasia; Thetford, Angela] NIH, Radiat Biol Branch, Ctr Canc Res, Bethesda, MD 20892 USA. RP Citrin, DE (reprint author), NCI, Radiat Oncol Branch, Bldg 10 CRC,B2-3500, Bethesda, MD USA. EM citrind@mail.nih.gov FU National Institutes of Health, National Cancer Institute FX All authors were supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute. NR 41 TC 18 Z9 18 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-. Natl. Cancer Inst. PD OCT PY 2013 VL 105 IS 19 BP 1474 EP 1484 DI 10.1093/jnci/djt212 PG 11 WC Oncology SC Oncology GA 232GZ UT WOS:000325482100011 PM 24052614 ER PT J AU Ho, JE Chen, WY Chen, MH Larson, MG McCabe, EL Cheng, SS Ghorbani, A Coglianese, E Emilsson, V Johnson, AD Walter, S Franceschini, N O'Donnell, CJ Dehghan, A Lu, C Levy, D Newton-Cheh, C Lin, HH Felix, JF Schreiter, ER Vasan, RS Januzzi, JL Lee, RT Wang, TJ AF Ho, Jennifer E. Chen, Wei-Yu Chen, Ming-Huei Larson, Martin G. McCabe, Elizabeth L. Cheng, Susan Ghorbani, Anahita Coglianese, Erin Emilsson, Valur Johnson, Andrew D. Walter, Stefan Franceschini, Nora O'Donnell, Christopher J. Dehghan, Abbas Lu, Chen Levy, Daniel Newton-Cheh, Christopher Lin, Honghuang Felix, Janine F. Schreiter, Eric R. Vasan, Ramachandran S. Januzzi, James L. Lee, Richard T. Wang, Thomas J. CA CARDIoGRAM Consortium CHARGE Inflammation Working Grp CHARGE Heart Failure Working Grp TI Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID RECEPTOR FAMILY-MEMBER; DECOMPENSATED HEART-FAILURE; SOLUBLE ST2; MYOCARDIAL-INFARCTION; NATRIURETIC PEPTIDE; CELIAC-DISEASE; ACUTE DYSPNEA; SERUM-LEVELS; LARGE-SCALE; MAST-CELLS AB The suppression of turnorigenicity 2/IL-33 (ST2/IL-33) pathway has been implicated in several immune and inflammatory diseases. ST2 is produced as 2 isoforms. The membrane-bound isoform (ST2L) induces an immune response when bound to its ligand, IL-33. The other isoform is a soluble protein (sST2) that is thought to be a decoy receptor for IL-33 signaling. Elevated sST2 levels in serum are associated with an increased risk for cardiovascular disease. We investigated the determinants of sST2 plasma concentrations in 2,991 Framingham Offspring Cohort participants. While clinical and environmental factors explained some variation in sST2 levels, much of the variation in sST2 production was driven by genetic factors. In a genome-wide association study (GWAS), multiple SNPs within IL1RL1 (the gene encoding ST2) demonstrated associations with sST2 concentrations. Five missense variants of IL1RL1 correlated with higher sST2 levels in the GWAS and mapped to the intracellular domain of ST2, which is absent in sST2. In a cell culture model, IL1RL1 missense variants increased sST2 expression by inducing IL-33 expression and enhancing IL-33 responsiveness (via ST2L). Our data suggest that genetic variation in IL1RL1 can result in increased levels of sST2 and alter immune and inflammatory signaling through the ST2/IL-33 pathway. C1 [Ho, Jennifer E.; Chen, Ming-Huei; Larson, Martin G.; Cheng, Susan; Johnson, Andrew D.; O'Donnell, Christopher J.; Levy, Daniel; Newton-Cheh, Christopher; Lin, Honghuang; Vasan, Ramachandran S.; Wang, Thomas J.] NHLBI, Framingham Heart Study, Framingham, MA USA. [Ho, Jennifer E.; Chen, Ming-Huei; Larson, Martin G.; Cheng, Susan; Johnson, Andrew D.; O'Donnell, Christopher J.; Levy, Daniel; Newton-Cheh, Christopher; Lin, Honghuang; Vasan, Ramachandran S.; Wang, Thomas J.] Boston Univ, Sch Med, Framingham, MA USA. [Ho, Jennifer E.] Boston Univ, Sch Med, Dept Med, Cardiovasc Med Sect, Boston, MA 02118 USA. [Chen, Wei-Yu; Cheng, Susan; Lee, Richard T.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiol, Boston, MA USA. [Chen, Ming-Huei] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Larson, Martin G.; Lu, Chen] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA. [McCabe, Elizabeth L.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Ghorbani, Anahita; O'Donnell, Christopher J.; Newton-Cheh, Christopher; Januzzi, James L.; Wang, Thomas J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA. [Coglianese, Erin] Loyola Univ Hlth Syst, Chicago, IL USA. [Emilsson, Valur] Iceland Heart Assoc, Kopavogur, Iceland. [Walter, Stefan] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. [Walter, Stefan] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands. [Walter, Stefan; Dehghan, Abbas; Felix, Janine F.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands. [Franceschini, Nora] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Newton-Cheh, Christopher] Broad Inst Harvard & MIT, Cambridge, MA USA. [Newton-Cheh, Christopher] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Lin, Honghuang; Vasan, Ramachandran S.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Schreiter, Eric R.] Univ Puerto Rico, Dept Chem, San Juan, PR 00936 USA. [Schreiter, Eric R.] Howard Hughes Med Inst, Ashburn, VA USA. [Wang, Thomas J.] Vanderbilt Univ, Dept Med, Div Cardiovasc Med, Nashville, TN 37232 USA. RP Wang, TJ (reprint author), Vanderbilt Univ, Med Ctr, Div Cardiovasc Med, 2220 Pierce Ave,383 Preston Res Bldg, Nashville, TN 37232 USA. EM rlee@partners.org; thomas.j.wang@vanderbilt.edu RI Altshuler, David/A-4476-2009; Schreiber, Stefan/B-6748-2008; Willenborg, Christina/D-2668-2012; Lu, Chen/D-8514-2015; Boehm, Bernhard/F-8750-2015; Gudnason, Vilmundur/K-6885-2015; Meitinger, Thomas/O-1318-2015; Johnson, Andrew/G-6520-2013; OI Kleber, Marcus/0000-0003-0663-7275; Dehghan, Abbas/0000-0001-6403-016X; Lin, Honghuang/0000-0003-3043-3942; Ramachandran, Vasan/0000-0001-7357-5970; Altshuler, David/0000-0002-7250-4107; Schreiber, Stefan/0000-0003-2254-7771; Willenborg, Christina/0000-0001-5217-6882; Gudnason, Vilmundur/0000-0001-5696-0084; Felix, Janine/0000-0002-9801-5774 FU National Heart, Lung and Blood Institute's Framingham Heart Study [N01-HC-25195]; Affymetrix Inc. for genotyping services [N02-HL-6-4278]; NIH [R01-NS017950-28, R01-HL093328-01, R01 HL092930, R01-HL086875, 1K23-HL116780]; Boston University School of Medicine Department of Medicine Career Investment Award; Ellison Foundation; Taiwan National Science Council [101-2917-I-564-057]; AHA postdoctoral fellowship [13POST16940030]; NWO grant (veni) [916.12.154]; EUR fellowship; Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine; Boston Medical Center FX This work was partially supported by the National Heart, Lung and Blood Institute's Framingham Heart Study (N01-HC-25195), its contract with Affymetrix Inc. for genotyping services (N02-HL-6-4278), and NIH grants R01-NS017950-28 and R01-HL093328-01 (to R.S. Vasan), R01 HL092930 (to R.T. Lee), R01-HL086875 (to T.J. Wang), and 1K23-HL116780 (to J.E. Ho). J.E. Ho is supported by a Boston University School of Medicine Department of Medicine Career Investment Award. Measurement of sST2 was performed by Critical Diagnostics Inc. S. Cheng is supported by an award from the Ellison Foundation. W.-Y. Chen is supported by awards from the Taiwan National Science Council (101-2917-I-564-057) and an AHA postdoctoral fellowship (13POST16940030). A. Dehghan is supported by a NWO grant (veni, 916.12.154) and the EUR fellowship. The analyses reflect intellectual input and resource development from the Framingham Heart Study investigators participating in the SNP Health Association Resource (SHARe) project. A portion of this research used the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center. Please see Supplemental Acknowledgments for CHARGE and CARDIoGRAM consortium details. NR 50 TC 35 Z9 35 U1 1 U2 11 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD OCT PY 2013 VL 123 IS 10 BP 4208 EP 4218 DI 10.1172/JCI67119 PG 11 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 231UE UT WOS:000325443100017 PM 23999434 ER PT J AU Wang, TJ Ngo, D Psychogios, N Dejam, A Larson, MG Vasan, RS Ghorbani, A O'Sullivan, J Cheng, S Rhee, EP Sinha, S McCabe, E Fox, CS O'Donnell, CJ Ho, JE Florez, JC Magnusson, M Pierce, KA Souza, AL Yu, Y Carter, C Light, PE Melander, O Clish, CB Gerszten, RE AF Wang, Thomas J. Ngo, Debby Psychogios, Nikolaos Dejam, Andre Larson, Martin G. Vasan, Ramachandran S. Ghorbani, Anahita O'Sullivan, John Cheng, Susan Rhee, Eugene P. Sinha, Sumita McCabe, Elizabeth Fox, Caroline S. O'Donnell, Christopher J. Ho, Jennifer E. Florez, Jose C. Magnusson, Martin Pierce, Kerry A. Souza, Amanda L. Yu, Yi Carter, Christian Light, Peter E. Melander, Olle Clish, Clary B. Gerszten, Robert E. TI 2-Aminoadipic acid is a biomarker for diabetes risk SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; INSULIN-RESISTANCE; LIFE-STYLE; MELLITUS; METABOLISM; SECRETION; FREQUENCY; OXIDATION; MARKER AB Improvements in metabolite-profiling techniques are providing increased breadth of coverage of the human metabolome and may highlight biomarkers and pathways in common diseases such as diabetes. Using a metabolomics platform that analyzes intermediary organic acids, purines, pyrimidines, and other compounds, we performed a nested case-control study of 188 individuals who developed diabetes and 188 propensity-matched controls from 2,422 normoglycemic participants followed for 12 years in the Framingham Heart Study. The metabolite 2-aminoadipic acid (2-AAA) was most strongly associated with the risk of developing diabetes. Individuals with 2-AAA concentrations in the top quartile had greater than a 4-fold risk of developing diabetes. Levels of 2-AAA were not well correlated with other metabolite biomarkers of diabetes, such as branched chain amino acids and aromatic amino acids, suggesting they report on a distinct pathophysiological pathway. In experimental studies, administration of 2-AAA lowered fasting plasma glucose levels in mice fed both standard chow and high-fat diets. Further, 2-AAA treatment enhanced insulin secretion from a pancreatic beta cell line as well as murine and human islets. These data highlight a metabolite not previously associated with diabetes risk that is increased up to 12 years before the onset of overt disease. Our findings suggest that 2-AAA is a marker of diabetes risk and a potential modulator of glucose homeostasis in humans. C1 [Wang, Thomas J.; Ngo, Debby; Psychogios, Nikolaos; Dejam, Andre; O'Sullivan, John; Rhee, Eugene P.; Sinha, Sumita; Gerszten, Robert E.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02115 USA. [Wang, Thomas J.; Ghorbani, Anahita; O'Donnell, Christopher J.; Gerszten, Robert E.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02115 USA. [Wang, Thomas J.; Larson, Martin G.; Vasan, Ramachandran S.; Ghorbani, Anahita; Cheng, Susan; Fox, Caroline S.; O'Donnell, Christopher J.; Ho, Jennifer E.] NHLBI, Framingham Heart Study, Framingham, MA USA. [Wang, Thomas J.; Larson, Martin G.; Vasan, Ramachandran S.; Ghorbani, Anahita; Cheng, Susan; Fox, Caroline S.; O'Donnell, Christopher J.; Ho, Jennifer E.] Boston Univ, Sch Med, Framingham, MA USA. [Wang, Thomas J.] Vanderbilt Univ, Div Cardiovasc Med, Nashville, TN 37235 USA. [Ngo, Debby] Harvard Univ, Sch Med, Div Pulm, Boston, MA USA. [Larson, Martin G.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA. [Vasan, Ramachandran S.; Ho, Jennifer E.] Boston Univ, Dept Med, Prevent Med Sect, Boston, MA 02215 USA. [Cheng, Susan] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA. [Rhee, Eugene P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Renal, Boston, MA USA. [Rhee, Eugene P.; Florez, Jose C.; Pierce, Kerry A.; Souza, Amanda L.; Clish, Clary B.; Gerszten, Robert E.] MIT, Broad Inst, Cambridge, MA 02139 USA. [Rhee, Eugene P.; Florez, Jose C.; Pierce, Kerry A.; Souza, Amanda L.; Clish, Clary B.; Gerszten, Robert E.] Harvard, Cambridge, MA USA. [McCabe, Elizabeth] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA. [Fox, Caroline S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Endocrinol, Boston, MA 02115 USA. [Fox, Caroline S.; O'Donnell, Christopher J.] NHLBI, Div Intramural Res, Bethesda, MD 20892 USA. [Florez, Jose C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Diabets Unit, Boston, MA USA. [Florez, Jose C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res, Boston, MA USA. [Magnusson, Martin] Skane Univ Hosp, Dept Cardiol, Malmo, Sweden. [Magnusson, Martin; Melander, Olle] Lund Univ, Dept Clin Sci, Malmo, Sweden. [Yu, Yi; Carter, Christian; Light, Peter E.] Univ Alberta, Dept Pharmacol, Alberta Diabet Inst, Edmonton, AB, Canada. [Melander, Olle] Skane Univ Hosp, Ctr Emergency Med, Malmo, Sweden. RP Gerszten, RE (reprint author), Massachusetts Gen Hosp, Div Cardiol, 185 Cambridge St, Boston, MA 02114 USA. EM thomas.j.wang@vanderbilt.edu; rgerszten@partners.org OI Ho, Jennifer/0000-0002-7987-4768; Psychogios, Nikolaos/0000-0002-2747-6012; Magnusson, Martin/0000-0003-1710-5936; Ramachandran, Vasan/0000-0001-7357-5970 FU NIH [NO1-HC-25195, R01-DK-HL081572]; Leducq Foundation; Canadian Institutes of Health Research; American Heart Association FX This work was supported by NIH contract NO1-HC-25195, R01-DK-HL081572, the Leducq Foundation, the Canadian Institutes of Health Research, and the American Heart Association. NR 28 TC 77 Z9 77 U1 6 U2 36 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD OCT PY 2013 VL 123 IS 10 BP 4309 EP 4317 DI 10.1172/JCI64801 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 231UE UT WOS:000325443100026 PM 24091325 ER PT J AU Sukumar, M Liu, J Ji, Y Subramanian, M Crompton, JG Yu, ZY Roychoudhuri, R Palmer, DC Muranski, P Karoly, ED Mohney, RP Klebanoff, CA Lal, A Finkel, T Restifo, NP Gattinoni, L AF Sukumar, Madhusudhanan Liu, Jie Ji, Yun Subramanian, Murugan Crompton, Joseph G. Yu, Zhiya Roychoudhuri, Rahul Palmer, Douglas C. Muranski, Pawel Karoly, Edward D. Mohney, Robert P. Klebanoff, Christopher A. Lal, Ashish Finkel, Toren Restifo, Nicholas P. Gattinoni, Luca TI Inhibiting glycolytic metabolism enhances CD8(+) T cell memory and antitumor function SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID EFFECTOR FUNCTIONS; DIFFERENTIATION; IMMUNOTHERAPY; IMMUNITY; MAINTENANCE; LYMPHOCYTES; ACTIVATION; MIGRATION; BINDING; LIFE AB Naive CD8(+) T cells rely upon oxidation of fatty acids as a primary source of energy. After antigen encounter, T cells shift to a glycolytic metabolism to sustain effector function. It is unclear, however, whether changes in glucose metabolism ultimately influence the ability of activated. T cells to become long-lived memory cells. We used a fluorescent glucose analog, 2-NBDG, to quantify glucose uptake in activated CD8(+) T cells. We found that cells exhibiting limited glucose incorporation had a molecular profile characteristic of memory precursor cells and an increased capacity to enter the memory pool compared with cells taking up high amounts of glucose. Accordingly, enforcing glycolytic metabolism by overexpressing the glycolytic enzyme phosphoglycerate mutase-1 severely impaired the ability of CD8(+) T cells to form long-term memory. Conversely, activation of CD8(+) T cells in the presence of an inhibitor of glycolysis, 2-deoxyglucose, enhanced the generation of memory cells and antitumor functionality. Our data indicate that augmenting glycolytic flux drives CD8(+) T cells toward a terminally differentiated state, while its inhibition preserves the formation of long-lived memory CD8(+) T cells. These results have important implications for improving the efficacy of T cell-based therapies against chronic infectious diseases and cancer. C1 [Sukumar, Madhusudhanan; Crompton, Joseph G.; Yu, Zhiya; Roychoudhuri, Rahul; Palmer, Douglas C.; Muranski, Pawel; Klebanoff, Christopher A.; Restifo, Nicholas P.] NCI, Ctr Canc Res, Surg Branch, Bethesda, MD 20892 USA. [Liu, Jie; Finkel, Toren] NHLBI, Ctr Mol Med, Bethesda, MD 20892 USA. [Ji, Yun; Gattinoni, Luca] NCI, Ctr Canc Res, Expt Transplantat & Immunol Branch, Bethesda, MD 20892 USA. [Subramanian, Murugan; Lal, Ashish] NIH, Ctr Mol Genet, Bethesda, MD 20892 USA. [Karoly, Edward D.; Mohney, Robert P.] Metabolon Inc, Durham, NC USA. [Klebanoff, Christopher A.] NCI, Clin Investigator Dev Program, NIH, Bethesda, MD 20892 USA. RP Sukumar, M (reprint author), NCI, Ctr Canc Res, Surg Branch, NIH,Clin Res Ctr, Room 3W-5816, Bethesda, MD 20892 USA. EM sukumarm2@mail.nih.gov; gattinol@mail.nih.gov RI Gattinoni, Luca/A-2281-2008; Ji, Yun/B-7245-2009; Palmer, Douglas/B-9454-2008; Roychoudhuri, Rahul/A-7442-2010; OI Gattinoni, Luca/0000-0003-2239-3282; Ji, Yun/0000-0001-6340-7009; Palmer, Douglas/0000-0001-5018-5734; Roychoudhuri, Rahul/0000-0002-5392-1853; Restifo, Nicholas P./0000-0003-4229-4580 FU Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research FX This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The authors thank N. Acquavella, D. Clever, E. Tran, and M. Rao for critical review of the manuscript; A. Mixon, S. Farid, and G. Wiegand of the Flow Cytometry Unit for help with cell sorting; and D. Goldstein and M. Malik for catalyzing interactions with Metabolon. We sincerely thank Steven A. Rosenberg for his continuous support. NR 55 TC 128 Z9 129 U1 2 U2 27 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD OCT PY 2013 VL 123 IS 10 BP 4479 EP 4488 DI 10.1172/JCI69389 PG 10 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 231UE UT WOS:000325443100040 PM 24091329 ER PT J AU Duncan, BB Highfill, SL Qin, HY Bouchkouj, N Larabee, S Zhao, P Woznica, I Liu, YX Li, YH Wu, WG Lai, JH Jones, B Mackall, CL Bachovchin, WW Fry, TJ AF Duncan, Brynn B. Highfill, Steven L. Qin, Haiying Bouchkouj, Najat Larabee, Shannon Zhao, Peng Woznica, Iwona Liu, Yuxin Li, Youhua Wu, Wengen Lai, Jack H. Jones, Barry Mackall, Crystal L. Bachovchin, William W. Fry, Terry J. TI A Pan-Inhibitor of DASH Family Enzymes Induces Immune-mediated Regression of Murine Sarcoma and Is a Potent Adjuvant to Dendritic Cell Vaccination and Adoptive T-cell Therapy SO JOURNAL OF IMMUNOTHERAPY LA English DT Article DE adjuvant; postproline cleaving enzymes; dipeptidyl peptidases; rhabdomyosarcoma; immunotherapy ID TUMOR-ASSOCIATED ANTIGENS; ACTIVATION PROTEIN-ALPHA; DIPEPTIDYL PEPTIDASE IV; SUPPRESSOR-CELLS; CANCER-IMMUNOTHERAPY; CHILDHOOD-CANCER; BEARING MICE; IN-VIVO; RHABDOMYOSARCOMA; RESPONSES AB Multimodality therapy consisting of surgery, chemotherapy, and radiation will fail in approximately 40% of patients with pediatric sarcomas and result in substantial long-term morbidity in those who are cured. Immunotherapeutic regimens for the treatment of solid tumors typically generate antigen-specific responses too weak to overcome considerable tumor burden and tumor suppressive mechanisms and are in need of adjuvant assistance. Previous work suggests that inhibitors of DASH (dipeptidyl peptidase IV activity and/or structural homologs) enzymes can mediate tumor regression by immune-mediated mechanisms. Herein, we demonstrate that the DASH inhibitor, ARI-4175, can induce regression and eradication of well-established solid tumors, both as a single agent and as an adjuvant to a dendritic cell (DC) vaccine and adoptive cell therapy (ACT) in mice implanted with the M3-9-M rhabdomyosarcoma cell line. Treatment with effective doses of ARI-4175 correlated with recruitment of myeloid (CD11b(+)) cells, particularly myeloid DCs, to secondary lymphoid tissues and with reduced frequency of intratumoral monocytic (CD11b(+)Ly6-C(hi)Ly6-G(lo)) myeloid-derived suppressor cells. In immunocompetent mice, combining ARI-4175 with a DC vaccine or ACT with tumor-primed T cells produced significant improvements in tumor responses against well-established M3-9-M tumors. In M3-9-M-bearing immunodeficient (Rag1(-/-)) mice, ACT combined with ARI-4175 produced greater tumor responses and significantly improved survival compared with either treatment alone. These studies warrant the clinical investigation of ARI-4175 for treatment of sarcomas and other malignancies, particularly as an adjuvant to tumor vaccines and ACT. C1 [Duncan, Brynn B.; Highfill, Steven L.; Qin, Haiying; Bouchkouj, Najat; Larabee, Shannon; Mackall, Crystal L.; Fry, Terry J.] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA. [Bouchkouj, Najat] MedStar Georgetown Univ Hosp, Div Pediat Hematol Oncol, Dept Pediat, Washington, DC USA. [Zhao, Peng; Woznica, Iwona; Liu, Yuxin; Li, Youhua; Wu, Wengen; Lai, Jack H.; Jones, Barry; Bachovchin, William W.] Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA. RP Fry, TJ (reprint author), NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bldg 10,Room 1-3940,10 Ctr Dr, Bethesda, MD 20892 USA. EM fryt@mail.nih.gov FU Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research; Arasaph Pharmaceuticals FX This study was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.; B.J. and W.W.B. receive consulting fees and grant support from Arasaph Pharmaceuticals. All the remaining authors have declared there are no financial conflicts of interest in regard to this work. NR 53 TC 2 Z9 3 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1524-9557 EI 1537-4513 J9 J IMMUNOTHER JI J. Immunother. PD OCT PY 2013 VL 36 IS 8 BP 400 EP 411 DI 10.1097/CJI.0b013e3182a80213 PG 12 WC Oncology; Immunology; Medicine, Research & Experimental SC Oncology; Immunology; Research & Experimental Medicine GA 220YJ UT WOS:000324623100002 PM 23994886 ER PT J AU Schaffer, AA AF Schaeffer, Alejandro A. TI Digenic inheritance in medical genetics SO JOURNAL OF MEDICAL GENETICS LA English DT Review DE Digenic inheritance; protein-protein interactions; high-throughput sequencing; epistatis; facioscapulohumeral muscular dystrophy ID BARDET-BIEDL-SYNDROME; LONG-QT SYNDROME; FAMILIAL EXUDATIVE VITREORETINOPATHY; GENOTYPE-PHENOTYPE CORRELATION; 2-TRAIT-LOCUS LINKAGE ANALYSIS; RECESSIVE OCULAR ALBINISM; MARIE-TOOTH-DISEASE; HEARING IMPAIRMENT; 2-LOCUS MODELS; HYPOGONADOTROPIC HYPOGONADISM AB Digenic inheritance (DI) is the simplest form of inheritance for genetically complex diseases. By contrast with the thousands of reports that mutations in single genes cause human diseases, there are only dozens of human disease phenotypes with evidence for DI in some pedigrees. The advent of high-throughput sequencing (HTS) has made it simpler to identify monogenic disease causes and could similarly simplify proving DI because one can simultaneously find mutations in two genes in the same sample. However, through 2012, I could find only one example of human DI in which HTS was used; in that example, HTS found only the second of the two genes. To explore the gap between expectation and reality, I tried to collect all examples of human DI with a narrow definition and characterise them according to the types of evidence collected, and whether there has been replication. Two strong trends are that knowledge of candidate genes and knowledge of protein-protein interactions (PPIs) have been helpful in most published examples of human DI. By contrast, the positional method of genetic linkage analysis, has been mostly unsuccessful in identifying genes underlying human DI. Based on the empirical data, I suggest that combining HTS with growing networks of established PPIs may expedite future discoveries of human DI and strengthen the evidence for them. C1 NIH, Computat Biol Branch, Natl Ctr Biotechnol Informat, US Dept HHS, Bethesda, MD 20894 USA. RP Schaffer, AA (reprint author), NIH, Computat Biol Branch, Natl Ctr Biotechnol Informat, US Dept HHS, 8600 Rockville Pike, Bethesda, MD 20894 USA. EM schaffer@helix.nih.gov FU National Institutes of Health FX National Institutes of Health, Intramural Research Program. NR 125 TC 33 Z9 33 U1 3 U2 11 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0022-2593 EI 1468-6244 J9 J MED GENET JI J. Med. Genet. PD OCT PY 2013 VL 50 IS 10 BP 641 EP 652 DI 10.1136/jmedgenet-2013-101713 PG 12 WC Genetics & Heredity SC Genetics & Heredity GA 221FO UT WOS:000324643400001 PM 23785127 ER PT J AU Bondy, C Bakalov, VK Cheng, C Olivieri, L Rosing, DR Arai, AE AF Bondy, Carolyn Bakalov, Vladimir K. Cheng, Clara Olivieri, Laura Rosing, Douglas R. Arai, Andrew E. TI Bicuspid aortic valve and aortic coarctation are linked to deletion of the X chromosome short arm in Turner syndrome SO JOURNAL OF MEDICAL GENETICS LA English DT Article DE Aneuploidy; Congenital heart disease; Chromosomal; Developmental ID PULMONARY VENOUS DRAINAGE; HYPOPLASTIC LEFT-HEART; CARDIOVASCULAR MALFORMATIONS; Y-CHROMOSOME; DISEASE; PREVALENCE; ASSOCIATION; LYMPHEDEMA; ANOMALIES; MONOSOMY AB Background Congenital heart disease (CHD) is a cardinal feature of X chromosome monosomy, or Turner syndrome (TS). Haploinsufficiency for gene(s) located on Xp have been implicated in the short stature characteristic of the syndrome, but the chromosomal region related to the CHD phenotype has not been established. Design We used cardiac MRI to diagnose cardiovascular abnormalities in four non-mosaic karyotype groups based on 50-metaphase analyses: 45,X (n=152); 46,X,del(Xp) (n=15); 46,X,del(Xq) (n=4); and 46,X,i(Xq) (n=14) from peripheral blood cells. Results Bicuspid aortic valves (BAV) were found in 52/152 (34%) 45,X study subjects and aortic coarctation (COA) in 19/152 (12.5%). Isolated anomalous pulmonary veins (APV) were detected in 15/152 (10%) for the 45,X study group, and this defect was not correlated with the presence of BAV or COA. BAVs were present in 28.6% of subjects with Xp deletions and COA in 6.7%. APV were not found in subjects with Xp deletions. The most distal break associated with the BAV/COA trait was at cytologic band Xp11.4 and ChrX:41,500000. One of 14 subjects (7%) with the 46,X,i(Xq) karyotype had a BAV and no cases of COA or APV were found in this group. No cardiovascular defects were found among four patients with Xq deletions. Conclusions The high prevalence of BAV and COA in subjects missing only the X chromosome short arm indicates that haploinsufficiency for Xp genes contributes to abnormal aortic valve and aortic arch development in TS. C1 [Bondy, Carolyn; Bakalov, Vladimir K.; Cheng, Clara] NICHHD, Sect Epigenet & Dev, Bethesda, MD 20892 USA. [Olivieri, Laura; Rosing, Douglas R.; Arai, Andrew E.] NHLBI, Cardiovasc & Pulm Branch, NIH, Bethesda, MD 20892 USA. RP Bondy, C (reprint author), NICHHD, Sect Epigenet & Dev, NIH, CRC 1-3330,10 Ctr Dr, Bethesda, MD 20892 USA. EM bondyc@mail.nih.gov FU Nationals Institutes of Health Division of Intramural Research FX This work was supported the Nationals Institutes of Health Division of Intramural Research. NR 38 TC 17 Z9 19 U1 0 U2 6 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0022-2593 EI 1468-6244 J9 J MED GENET JI J. Med. Genet. PD OCT PY 2013 VL 50 IS 10 BP 662 EP 665 DI 10.1136/jmedgenet-2013-101720 PG 4 WC Genetics & Heredity SC Genetics & Heredity GA 221FO UT WOS:000324643400003 PM 23825392 ER PT J AU Li, JM Foo, JN Schoof, N Varghese, JS Fernandez-Navarro, P Gierach, GL Quek, ST Hartman, M Nord, S Kristensen, VN Pollan, M Figueroa, JD Thompson, DJ Li, Y Khor, CC Humphreys, K Liu, JJ Czene, K Hall, P AF Li, Jingmei Foo, Jia Nee Schoof, Nils Varghese, Jajini S. Fernandez-Navarro, Pablo Gierach, Gretchen L. Quek, Swee Tian Hartman, Mikael Nord, Silje Kristensen, Vessela N. Pollan, Marina Figueroa, Jonine D. Thompson, Deborah J. Li, Yi Khor, Chiea Chuen Humphreys, Keith Liu, Jianjun Czene, Kamila Hall, Per TI Large-scale genotyping identifies a new locus at 22q13.2 associated with female breast size SO JOURNAL OF MEDICAL GENETICS LA English DT Article DE Cancer: breast; Epidemiology; Genetic epidemiology; Genome-wide; Complex traits ID GENOME-WIDE ASSOCIATION; CANCER RISK; MEGAKARYOBLASTIC LEUKEMIA; PRINCIPAL-COMPONENTS; VARIANTS; WOMEN; ADJUSTMENT; PROJECT; IMPACT; STATES AB Background Individual differences in breast size are a conspicuous feature of variation in human females and have been associated with fecundity and advantage in selection of mates. To identify common variants that are associated with breast size, we conducted a large-scale genotyping association meta-analysis in 7169 women of European descent across three independent sample collections with digital or screen film mammograms. Methods The samples consisted of the Swedish KARMA, LIBRO-1 and SASBAC studies genotyped on iCOGS, a custom illumina iSelect genotyping array comprising of 211155 single nucleotide polymorphisms (SNPs) designed for replication and fine mapping of common and rare variants with relevance to breast, ovary and prostate cancer. Breast size of each subject was ascertained by measuring total breast area (mm(2)) on a mammogram. Results We confirm genome-wide significant associations at 8p11.23 (rs10086016, p=1.3x10(-14)) and report a new locus at 22q13 (rs5995871, p=3.2x10(-8)). The latter region contains the MKL1 gene, which has been shown to impact endogenous oestrogen receptor transcriptional activity and is recruited on oestradiol sensitive genes. We also replicated previous genome-wide association study findings for breast size at four other loci. Conclusions A new locus at 22q13 may be associated with female breast size. C1 [Li, Jingmei; Foo, Jia Nee; Li, Yi; Khor, Chiea Chuen; Liu, Jianjun] Genome Inst Singapore, Singapore, Singapore. [Schoof, Nils; Humphreys, Keith; Czene, Kamila; Hall, Per] Karolinska Inst, Dept Med Epidemiol & Biostat, S-17177 Stockholm, Sweden. [Varghese, Jajini S.; Thompson, Deborah J.] Univ Cambridge, Ctr Genet Epidemiol, Dept Publ Hlth & Primary Care, Cambridge, England. [Varghese, Jajini S.] Royal Free Hosp, Plast Surg Unit, London NW3 2QG, England. [Fernandez-Navarro, Pablo; Pollan, Marina] Carlos III Inst Hlth, Canc & Environm Epidemiol Unit, Natl Ctr Epidemiol, Madrid, Spain. [Fernandez-Navarro, Pablo; Pollan, Marina] CIBERESP, Consortium Biomed Res Epidemiol & Publ Hlth, Madrid, Spain. [Gierach, Gretchen L.; Figueroa, Jonine D.] NCI, Hormonal & Reprod Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Quek, Swee Tian] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Diagnost Radiol, Singapore 117595, Singapore. [Hartman, Mikael; Liu, Jianjun] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore. [Hartman, Mikael; Liu, Jianjun] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Surg, Singapore 117595, Singapore. [Nord, Silje; Kristensen, Vessela N.] Radiumhospitalet, Inst Canc Res, Dept Genet, Oslo Univ Hosp, Oslo, Norway. [Kristensen, Vessela N.] Akershus Univ Hosp, Div Med, Dept Clin Mol Biol, Ahus, Norway. RP Hall, P (reprint author), Karolinska Inst, Dept Med Epidemiol & Biostat, Box 281, S-17177 Stockholm, Sweden. EM Per.Hall@ki.se RI Li, Jingmei/I-2904-2012; Hartman, Mikael/B-4324-2011; Pollan, Marina/M-3259-2014; Foo, Jia Nee/D-6069-2014; Gierach, Gretchen/E-1817-2016; Nord, Silje/R-5212-2016; OI Pollan, Marina/0000-0002-4328-1565; Li, Jingmei/0000-0001-8587-7511; Foo, Jia Nee/0000-0001-9899-2308; Gierach, Gretchen/0000-0002-0165-5522; Nord, Silje/0000-0002-3271-5356; Czene, Kamila/0000-0002-3233-5695; Khor, Chiea Chuen/0000-0002-1128-4729 FU Marit and Hans Rausings Initiative Against Breast Cancer; Cancer Risk Prediction Center (CRisP); Linneus Centre [70867902]; Swedish Research Council; Agency for Science, Technology and Research of Singapore (A*STAR); US National Institute of Health (NIH); Susan G Komen Breast Cancer Foundation; European Community [223175 (HEALTH-F2-2009-223175)]; European Union [HEALTH-F2-2009-223175]; Cancer Research UK [C1287/A10710, C1287/A10118, C1287/A12014]; Canadian Institutes of Health Research (CIHR); Ministry of Economic Development, Innovation and Export Trade of Quebec [PSR-SIIRI-701]; US National Institutes of Health (NIH) Cancer Post-Cancer GWAS initiative [1 U19 CA 148065-01]; US National Cancer Institute, Department of Health and Human Services, USA FX KARMA was supported by Marit and Hans Rausings Initiative Against Breast Cancer. KARMA and LIBRO-1 were supported the Cancer Risk Prediction Center (CRisP; www.crispcenter.org), a Linneus Centre (Contract ID 70867902) financed by the Swedish Research Council. SASBAC was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the US National Institute of Health (NIH) and the Susan G Komen Breast Cancer Foundation. All three studies are genotyped as part of the Collaborative Oncological Gene-environment Study (COGS), which is supported by the European Community's Seventh Framework Programme under grant agreement 223175 (HEALTH-F2-2009-223175) (COGS). Genotyping of the iCOGS array was funded by the European Union (HEALTH-F2-2009-223175), Cancer Research UK (C1287/A10710), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer program and the Ministry of Economic Development, Innovation and Export Trade of Quebec (grant PSR-SIIRI-701). BCAC is funded by Cancer Research UK (C1287/A10118 and C1287/A12014). Combining the GWAS data was supported in part by the US National Institutes of Health (NIH) Cancer Post-Cancer GWAS initiative grant 1 U19 CA 148065-01 (DRIVE, part of the GAME-ON initiative). This work was also supported, in part, by the Intramural Research Program of the US National Cancer Institute, Department of Health and Human Services, USA. NR 36 TC 6 Z9 6 U1 0 U2 18 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0022-2593 EI 1468-6244 J9 J MED GENET JI J. Med. Genet. PD OCT PY 2013 VL 50 IS 10 BP 666 EP 673 DI 10.1136/jmedgenet-2013-101708 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA 221FO UT WOS:000324643400004 PM 23825393 ER PT J AU Wu, F Kirmaier, A Ourmanov, I Goeken, R Matsuda, K Whitted, S Buckler-White, A Tomioka, K Plishka, R Johnson, WE Hirsch, VM AF Wu, Fan Kirmaier, Andrea Ourmanov, Ilnour Goeken, Robert Matsuda, Kenta Whitted, Sonya Buckler-White, Alicia Tomioka, Keiko Plishka, Ronald Johnson, Welkin E. Hirsch, Vanessa M. TI ESCAPE OF SIVSME543 FROM TRIM5 ALPHA RESTRICTION IN RHESUS MACAQUES SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Wu, Fan; Ourmanov, Ilnour; Goeken, Robert; Matsuda, Kenta; Whitted, Sonya; Buckler-White, Alicia; Tomioka, Keiko; Plishka, Ronald; Hirsch, Vanessa M.] NIAID, Mol Microbiol Lab, NIH, Bethesda, MD USA. [Kirmaier, Andrea; Johnson, Welkin E.] Harvard Univ, Sch Med, New England Primate Res Ctr, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 1 BP 254 EP 254 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000007 ER PT J AU Del Prete, GQ Scarlotta, M Kreis, L Parodi, LM Roser, JD Oswald, K Miller, CJ Desrosiers, RC Barouch, DH Pal, R Piatak, M Chertova, E O'Connor, DH Giavedoni, LD Lifson, JD Keele, BF AF Del Prete, Gregory Q. Scarlotta, Matthew Kreis, Laura Parodi, Laura M. Roser, James D. Oswald, Kelli Miller, Christopher J. Desrosiers, Ronald C. Barouch, Dan H. Pal, Ranajit Piatak, Michael, Jr. Chertova, Elena O'Connor, David H. Giavedoni, Luis D. Lifson, Jeffrey D. Keele, Brandon F. TI COMPARATIVE CHARACTERIZATION OF TRANSFECTION-AND INFECTION-DERIVED SIV CHALLENGE STOCKS FOR IN VIVO NONHUMAN PRIMATE STUDIES SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Del Prete, Gregory Q.; Kreis, Laura; Roser, James D.; Oswald, Kelli; Piatak, Michael, Jr.; Chertova, Elena; Lifson, Jeffrey D.; Keele, Brandon F.] SAIC Frederick Inc, AIDS & Canc Virus Program, Frederick Natl Lab Canc Res, Frederick, MD USA. [Scarlotta, Matthew; O'Connor, David H.] Univ Wisconsin Madison, Dept Pathol & Lab Med, Wisconsin Natl Primate Res Ctr, Madison, WI USA. [Miller, Christopher J.] Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA. [Miller, Christopher J.] Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA. [Desrosiers, Ronald C.] Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, New England Primate Res Ctr, Cambridge, MA 02138 USA. [O'Connor, David H.] Univ Wisconsin Madison, Wisconsin Natl Primate Res Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 3 BP 255 EP 255 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000009 ER PT J AU Keele, BF DelPrete, GQ Park, H Reid, C Oswald, K Estes, JD Kahl, C Macallister, R Smedley, J Piatak, M Lifson, JD Picker, LJ AF Keele, Brandon F. DelPrete, Gregory Q. Park, Haesun Reid, Carolyn Oswald, Kelli Estes, Jacob D. Kahl, Christoph Macallister, Rhonda Smedley, Jeremy Piatak, Michael, Jr. Lifson, Jeffrey D. Picker, Louis J. TI SUCCESSFUL IN VIVO TITRATION FOLLOWING INTRARECTAL AND INTRAVENOUS CHALLENGE WITH MOLECULARLY-TAGGED SIVMAC239 USING 293T TRANSFECTION PRODUCED VIRUS AND RHPBMC EXPANDED VIRUS SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Keele, Brandon F.; DelPrete, Gregory Q.; Reid, Carolyn; Oswald, Kelli; Estes, Jacob D.; Piatak, Michael, Jr.; Lifson, Jeffrey D.] SAIC Frederick Inc, Frederick Natl Lab Canc Res, AIDS & Canc Virus Program, Frederick, MD USA. [Park, Haesun; Kahl, Christoph; Picker, Louis J.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Oregon Natl Primate Res Ctr, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 10 BP 257 EP 257 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000016 ER PT J AU Estes, JD Brenchley, JM Vinton, C Tabb, B Hao, XP Connick, E Pairidini, M Lifson, JD Silvestri, G AF Estes, Jacob D. Brenchley, Jason M. Vinton, Carol Tabb, Brian Hao, Xing Pei Connick, Elizabeth Pairidini, Mirko Lifson, Jeffrey D. Silvestri, Guido TI DIFFERENTIAL INFECTION PATTERNS OF CD4+T CELLS AND LYMPHOID TISSUE VIRAL BURDEN DISTINGUISH PROGRESSIVE AND NONPROGRESSIVE LENTIVIRAL INFECTIONS SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Estes, Jacob D.; Tabb, Brian; Lifson, Jeffrey D.] SAIC Frederick Inc, AIDS & Canc Virus Program, Frederick Natl Lab Canc Res, Frederick, MD USA. [Brenchley, Jason M.; Vinton, Carol] NIAID, Program Barrier Immun & Repair, NIH, Bethesda, MD 20892 USA. [Brenchley, Jason M.; Vinton, Carol] NIAID, Immunopathogenesis Unit, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA. [Brenchley, Jason M.; Vinton, Carol] NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA. [Hao, Xing Pei] SAIC Frederick Inc, Pathol & Histotechnol Lab, Frederick Natl Lab Canc Res, Frederick, MD USA. [Connick, Elizabeth] Univ Colorado Denver, Div Infect Dis, Aurora, CO USA. [Pairidini, Mirko; Silvestri, Guido] Emory Univ, Div Microbiol & Immunol, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 11 BP 258 EP 258 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000017 ER PT J AU Henning, TC Butler, K Mitchell, J Bachman, S Deyounks, F Farshy, C Phillips, C Papp, J Caldwell, H Sturdevant, G McNicholl, J Kersh, E AF Henning, Tara C. Butler, Katherine Mitchell, James Bachman, Shanon Deyounks, Frank Farshy, Carol Phillips, Christi Papp, John Caldwell, Harlan Sturdevant, Gail McNicholl, Janet Kersh, Ellen TI DEVELOPMENT OF A RECTAL SEXUALLY TRANSMITTED INFECTION (STI) - HIV COINFECTION MACAQUE MODEL UTILIZING CHLAMYDIA TRACHOMATIS AND SHIVSF162P3 SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Henning, Tara C.; Butler, Katherine; Mitchell, James; Bachman, Shanon; Deyounks, Frank; Farshy, Carol; Phillips, Christi; McNicholl, Janet; Kersh, Ellen] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Papp, John] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Atlanta, GA USA. [Caldwell, Harlan; Sturdevant, Gail] NIAID, NIH, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 14 BP 259 EP 259 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000020 ER PT J AU Okoye, AA Rohankhedkar, M Konfe, A Fukazawa, Y Lum, R Park, H Axthelm, IB Legasse, A Axthelm, MK Oswald, K Estes, J Wai, J Piatak, M Lifson, JD Chomont, N Hazuda, D Sekaly, RP Picker, LJ AF Okoye, Afam A. Rohankhedkar, Mukta Konfe, Audrie Fukazawa, Yoshinori Lum, Richard Park, Haesun Axthelm, Isaac B. Legasse, Alfred Axthelm, Michael K. Oswald, Kelli Estes, Jacob Wai, John Piatak, Michael, Jr. Lifson, Jeffrey D. Chomont, Nicolas Hazuda, Daria Sekaly, Rafick P. Picker, Louis J. TI MODULATION OF THE PD-1 PATHWAY TO ENHANCE VIRUS PRODUCTION AND ELIMINATION OF LATENTLY INFECTED T CELLS IN SIV-INFECTED RHESUS MACAQUES ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Okoye, Afam A.; Rohankhedkar, Mukta; Konfe, Audrie; Fukazawa, Yoshinori; Lum, Richard; Park, Haesun; Axthelm, Isaac B.; Legasse, Alfred; Axthelm, Michael K.; Picker, Louis J.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA. [Okoye, Afam A.; Rohankhedkar, Mukta; Konfe, Audrie; Fukazawa, Yoshinori; Lum, Richard; Park, Haesun; Axthelm, Isaac B.; Legasse, Alfred; Axthelm, Michael K.; Picker, Louis J.] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Beaverton, OR 97006 USA. [Oswald, Kelli; Estes, Jacob; Piatak, Michael, Jr.; Lifson, Jeffrey D.] Frederick Natl Lab Canc Res, SAIC Frederick, AIDS & Canc Virus Program, Frederick, MD USA. [Chomont, Nicolas; Sekaly, Rafick P.] Vaccine & Gene Therapy Inst Florida, Port St Lucie, FL 34987 USA. [Wai, John; Hazuda, Daria] Merck Res Labs, White Horse Junction, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 17 BP 260 EP 260 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000023 ER PT J AU DeGottardi, MQ Okoye, AA Rohankhedkar, M Konfe, A Turner, J Legasse, A Estes, J Piatak, M Lifson, JD Axthelm, MK Picker, LJ AF DeGottardi, M. Quinn Okoye, Afam A. Rohankhedkar, Mukta Konfe, Audrie Turner, John Legasse, Alfred Estes, Jake Piatak, Michael, Jr. Lifson, Jeffrey D. Axthelm, Michael K. Picker, Louis J. TI UNDERSTANDING THE ROLE OF IL-15 IN SIV PATHOGENESIS SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [DeGottardi, M. Quinn; Okoye, Afam A.; Rohankhedkar, Mukta; Konfe, Audrie; Turner, John; Legasse, Alfred; Axthelm, Michael K.; Picker, Louis J.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA. [DeGottardi, M. Quinn; Okoye, Afam A.; Rohankhedkar, Mukta; Konfe, Audrie; Turner, John; Legasse, Alfred; Axthelm, Michael K.; Picker, Louis J.] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Beaverton, OR 97006 USA. [Estes, Jake; Piatak, Michael, Jr.; Lifson, Jeffrey D.] Frederick Natl Lab Canc Res, SAIC Frederick, AIDS & Canc Virus Program, Frederick, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 19 BP 261 EP 261 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000025 ER PT J AU Klatt, NR Canary, LA Vinton, CL Morcock, D Pierce, J Estes, JD Brenchley, JM AF Klatt, Nichole R. Canary, Lauren A. Vinton, Carol L. Morcock, David Pierce, Jordan Estes, Jacob D. Brenchley, Jason M. TI RATE OF AIDS PROGRESSION IS ASSOCIATED WITH PRE-EXISTING MICROBIAL TRANSLOCATION IN PIGTAIL MACAQUES SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Klatt, Nichole R.; Canary, Lauren A.; Vinton, Carol L.; Pierce, Jordan; Brenchley, Jason M.] NIAID, Mol Microbiol Lab, Program Barrier Immun & Repair, NIH, Bethesda, MD 20892 USA. [Morcock, David; Estes, Jacob D.] SAIC Frederick Inc, AIDS Canc & Virus Program, Frederick Natl Lab Canc Res, Frederick, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 20 BP 261 EP 261 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000026 ER PT J AU Breed, MW Aye, PP Lichtveld, CF Midkiff, C Schiro, F Zelman, S Jordan, APO Sugimoto, C Alvarez, X Sandler, NG Douek, DC Kuroda, MJ Pahar, B Piatak, M Lifson, JD Keele, BF Lackner, AA Hoxie, JA AF Breed, Matthew W. Aye, Pyone P. Lichtveld, Cornelis F. Midkiff, Cecily Schiro, Faith Zelman, Samra Jordan, Andrea P. O. Sugimoto, Chie Alvarez, Xavier Sandler, Netanya G. Douek, Daniel C. Kuroda, Marcelo J. Pahar, Bapi Piatak, Michael, Jr. Lifson, Jeffrey D. Keele, Brandon F. Lackner, Andrew A. Hoxie, James A. TI ELITE CONTROL AND PROTECTION FROM A PATHOGENIC HETEROLOGOUS SIV CHALLENGE IN PIGTAIL MACAQUES INFECTED WITH A CYTOPLASMIC TAIL MUTANT OF SIVMAC239 SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Breed, Matthew W.; Aye, Pyone P.; Lichtveld, Cornelis F.; Midkiff, Cecily; Schiro, Faith; Sugimoto, Chie; Alvarez, Xavier; Kuroda, Marcelo J.; Pahar, Bapi; Lackner, Andrew A.] Tulane Natl Primate Res Ctr, Covington, LA USA. [Zelman, Samra; Jordan, Andrea P. O.; Hoxie, James A.] Univ Penn, Philadelphia, PA 19104 USA. [Sandler, Netanya G.; Douek, Daniel C.] NIAID, Human Immunol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA. [Piatak, Michael, Jr.; Lifson, Jeffrey D.; Keele, Brandon F.] SAIC Frederick Inc, Frederick Natl Lab Canc Res, Frederick, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 25 BP 263 EP 263 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000031 ER PT J AU Demberg, T Brocca-Cofano, E Xiao, P Venzon, D Vargas-Inchaustegui, D Lee, EM Kalisz, I Kalyanaraman, VS DiPasquale, J McKinnon, K Robert-Guroff, M AF Demberg, Thorsten Brocca-Cofano, Egidio Xiao, Peng Venzon, David Vargas-Inchaustegui, Diego Lee, Eun Mi Kalisz, Irene Kalyanaraman, V. S. DiPasquale, Janet McKinnon, Katherine Robert-Guroff, Marjorie TI MEMORY B-CELL POPULATIONS DURING ANTIRETROVIRAL THERAPY AND THERAPEUTIC ENVELOPE BOOSTING IN SIVMAC251-INFECTED RHESUS MACAQUES SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Demberg, Thorsten; Brocca-Cofano, Egidio; Xiao, Peng; Vargas-Inchaustegui, Diego; DiPasquale, Janet; McKinnon, Katherine; Robert-Guroff, Marjorie] NCI, Vaccine Branch, Bethesda, MD 20892 USA. [Venzon, David] NCI, Biostat & Data Management Sect, Bethesda, MD 20892 USA. [Lee, Eun Mi; Kalisz, Irene; Kalyanaraman, V. S.] Adv BioSci Labs Inc, Rockville, MD 20850 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 32 BP 265 EP 265 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000038 ER PT J AU Shingai, M Donau, OK Schmidt, SD Gautam, R Plishka, RJ Buckler-White, A Sadjadpour, R Lee, W LaBranche, CC Montefiori, D Mascola, JR Nishimura, Y Martin, MA AF Shingai, Masashi Donau, Olivia K. Schmidt, Stephen D. Gautam, Rajeev Plishka, Ronald J. Buckler-White, Alicia Sadjadpour, Reza Lee, Wendy LaBranche, Celia C. Montefiori, David Mascola, John R. Nishimura, Yoshiaki Martin, Malcolm A. TI THE VAST MAJORITY OF RHESUS MACAQUES INFECTED WITH THE R5-TROPIC SHIVAD8 GENERATE CROSS-REACTIVE ANTIBODIES THAT NEUTRALIZE MULTIPLE HIV-1 STRAINS SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Shingai, Masashi; Donau, Olivia K.; Gautam, Rajeev; Plishka, Ronald J.; Buckler-White, Alicia; Sadjadpour, Reza; Lee, Wendy; Nishimura, Yoshiaki; Martin, Malcolm A.] NIAID, Mol Microbiol Lab, NIH, Bethesda, MD USA. [Schmidt, Stephen D.; Mascola, John R.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD USA. [LaBranche, Celia C.; Montefiori, David] Duke Univ, Dept Surg, Med Ctr, Durham, NC 27706 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 43 BP 269 EP 269 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000049 ER PT J AU Ayala, VI Barsov, EV Trivett, MT Jain, S Ott, DE Ohlen, C AF Ayala, Victor I. Barsov, Eugene V. Trivett, Matthew T. Jain, Sumiti Ott, David E. Ohlen, Claes TI TRANSDUCTION OF AN SIV SPECIFIC TCR INTO DIFFERENT RHESUS CD3+T CELL POPULATIONS AND COMPARISON OF THEIR ABILITY TO SUPPRESS SIV INFECTION SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Ayala, Victor I.; Barsov, Eugene V.; Trivett, Matthew T.; Jain, Sumiti; Ott, David E.; Ohlen, Claes] SAIC Frederick Inc, AIDS & Canc Virus Program, Frederick Natl Lab Canc Res, Frederick, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 50 BP 271 EP 272 PG 2 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000056 ER PT J AU Foulds, KE Donaldson, MM Kao, SF Quinn, DS Fischer, W Korber, BT Letvin, NL Koup, RA Rao, SS Mascola, JR Nabel, GJ Roederer, M AF Foulds, Kathryn E. Donaldson, Mitzi M. Kao, Shing-Fen Quinn, David S. Fischer, Will Korber, Bette T. Letvin, Norman L. Koup, Richard A. Rao, Srinivas S. Mascola, John R. Nabel, Gary J. Roederer, Mario TI IMMUNOGENICITY OF SIV ENV AND GAG MOSAIC CONSTRUCTS IN RHESUS MACAQUES SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Foulds, Kathryn E.; Donaldson, Mitzi M.; Kao, Shing-Fen; Quinn, David S.; Koup, Richard A.; Rao, Srinivas S.; Mascola, John R.; Nabel, Gary J.; Roederer, Mario] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA. [Fischer, Will; Korber, Bette T.] Los Alamos Natl Lab, Los Alamos, NM USA. [Letvin, Norman L.] Harvard Univ, Beth Israel Deaconess Med Ctr, Med School, Div Viral Pathogenesis,Dept Med, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 48 BP 271 EP 271 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000054 ER PT J AU Gautam, R Nishimura, Y Lee, WR Donau, O Buckler-White, A Shingai, M Sadjadpour, R Schmidt, SD LaBranche, CC Keele, BF Montefiori, D Mascola, JR Martin, MA AF Gautam, Rajeev Nishimura, Yoshiaki Lee, Wendy R. Donau, Olivia Buckler-White, Alicia Shingai, Masashi Sadjadpour, Reza Schmidt, Stephen D. LaBranche, Celia C. Keele, Brandon F. Montefiori, David Mascola, John R. Martin, Malcolm A. TI PATHOGENICITY AND MUCOSAL TRANSMISSIBILITY OF R5-TROPIC SIMIAN/HUMAN IMMUNODEFICIENCY VIRUSES SHIVAD8 IN RHESUS MACAQUES: IMPLICATIONS FOR THEIR USE IN VACCINE STUDIES SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Gautam, Rajeev; Nishimura, Yoshiaki; Lee, Wendy R.; Donau, Olivia; Buckler-White, Alicia; Shingai, Masashi; Sadjadpour, Reza; Martin, Malcolm A.] NIAID, Mol Microbiol Lab, NIH, Bethesda, MD USA. [Schmidt, Stephen D.; Mascola, John R.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD USA. [Keele, Brandon F.] SAIC Frederick Inc, Frederick Natl Lab Canc Res, AIDS & Canc Virus Program, Frederick, MD USA. [LaBranche, Celia C.; Montefiori, David] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27706 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 59 BP 274 EP 274 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000065 ER PT J AU Jain, S Ayala, VI Trivett, MT Barsov, EV Ohlen, C Ott, DE AF Jain, Sumiti Ayala, Victor I. Trivett, Matthew T. Barsov, Eugene V. Ohlen, Claes Ott, David E. TI USING TRIM5 alpha TO PRODUCE DURABLE ANTI-VIRAL CD4+EFFECTOR T CELLS FOR BOTH IN VITRO AND IN VIVO SIV SUPPRESSION STUDIES SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Jain, Sumiti; Ayala, Victor I.; Trivett, Matthew T.; Barsov, Eugene V.; Ohlen, Claes; Ott, David E.] SAIC Frederick Inc, AIDS & Canc Vaccine Program, Frederick Natl Lab Canc Res, Frederick, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 68 BP 277 EP 277 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000074 ER PT J AU Matsuda, K Brown, CR Foley, B Goeken, R Whitted, S Dang, Q Wu, F Plishka, R White, AB Hirsch, VM AF Matsuda, Kenta Brown, Charles R. Foley, Brian Goeken, Robert Whitted, Sonya Dang, Que Wu, Fan Plishka, Ronald White, Alicia-Buckler Hirsch, Vanessa M. TI LASER CAPTURE MICRODISSECTION STUDY OF VIRAL POPULATIONS IN THE CENTRAL NERVOUS SYSTEM OF MACAQUES WITH SIV ENCEPHALITIS SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Matsuda, Kenta; Brown, Charles R.; Goeken, Robert; Whitted, Sonya; Dang, Que; Wu, Fan; Plishka, Ronald; White, Alicia-Buckler; Hirsch, Vanessa M.] NIH, Bethesda, MD USA. [Foley, Brian] Los Alamos Natl Lab, Los Alamos, NM 87545 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 73 BP 278 EP 279 PG 2 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000079 ER PT J AU Patterson, J McKinnon, K Parish, S Berzofsky, J Robert-Guroff, M Terabe, M AF Patterson, Jean McKinnon, Kathy Parish, Stan Berzofsky, Jay Robert-Guroff, Marjorie Terabe, Masaki TI FUNCTIONAL NKT AND B CELLS IN THE BONE MARROW ARE ASSOCIATED WITH CONTROL OF SIV INFECTION IN THE RHESUS MACAQUE MODEL OF AIDS SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Patterson, Jean; McKinnon, Kathy; Robert-Guroff, Marjorie] NCI, Sect Immune Biol Retroviral Infect, Vaccine Branch, NIH, Bethesda, MD 20892 USA. [Parish, Stan; Berzofsky, Jay; Terabe, Masaki] NCI, Mol Genet & Vaccine Res Sect, Vaccine Branch, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 75 BP 279 EP 279 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000081 ER PT J AU Warrier, R Barouch, DH Miller, CJ Hahn, BH Shaw, GM Keele, BF AF Warrier, Ranjit Barouch, Dan H. Miller, Christopher J. Hahn, Beatrice H. Shaw, George M. Keele, Brandon F. TI NO EVIDENCE OF UNIDENTIFIED TRANSMITTED/FOUNDER VARIANTS IN RHESUS MACAQUES UP TO SIX MONTHS POST-INFECTION SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Warrier, Ranjit; Hahn, Beatrice H.; Shaw, George M.] Univ Penn, Philadelphia, PA 19104 USA. [Barouch, Dan H.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Miller, Christopher J.] Univ Calif Davis, Davis, CA 95616 USA. [Keele, Brandon F.] SAIC Frederick Inc, Frederick Natl Lab Canc Res, Frederick, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 91 BP 284 EP 284 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000097 ER PT J AU Anderson, C von Geldern, G Johnson, T Sacktor, N McArthur, J Nath, A AF Anderson, Caroline von Geldern, Gloria Johnson, Tory Sacktor, Ned McArthur, Justin Nath, Avindra TI Accumulation of neurofilament heavy chain in neurons and CSF of HIV patients on antiretroviral drugs with normal neurocognitive function SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Anderson, Caroline; von Geldern, Gloria; Johnson, Tory; Nath, Avindra] NINDS, Sect Infect Nervous Syst, NIH, Bethesda, MD 20892 USA. [Sacktor, Ned; McArthur, Justin] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA. EM caroline.anderson2@nih.gov NR 0 TC 0 Z9 0 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P9 BP S4 EP S5 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200010 ER PT J AU Anderson, M Enose-Akahata, Y Massoud, R Ngouth, N Tanaka, Y Oh, U Jacobson, S AF Anderson, Monique Enose-Akahata, Yoshimi Massoud, Raya Ngouth, Nyater Tanaka, Yuetsu Oh, Unsong Jacobson, Steven TI HTLV-1 epigenetic modification of the FoxP3 TSDR in HAM/TSP decreases the functional proliferative suppression of Tregs SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Anderson, Monique] NINDS, Neuroimmunol Branch, NIH, UVA, Bethesda, MD 20892 USA. [Enose-Akahata, Yoshimi; Massoud, Raya; Ngouth, Nyater; Jacobson, Steven] NINDS, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA. [Oh, Unsong] Virginia Commonwealth Univ, Dept Neurol, Richmond, VA 23284 USA. EM andersonmr2@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P10 BP S5 EP S5 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200011 ER PT J AU Bae, M Bandaru, VVR Lee, M Nath, A Chen, XS Geiger, JD Gorospe, MM Mattson, MP Haughey, N AF Bae, Mihyun Bandaru, Veera Venkata Ratnam Lee, Myounghwa Nath, Avindra Chen, Xuesong Geiger, Jonathan D. Gorospe, Myriam M. Mattson, Mark P. Haughey, Norman TI Activation of TRPML1 clears intraneuronal Abeta in pre-clinical models of HIV infection SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Bae, Mihyun; Bandaru, Veera Venkata Ratnam; Haughey, Norman] Johns Hopkins Univ, Sch Med, Dept Neurol, Div Neuroimmunol & Neurol Infect, Baltimore, MD 21205 USA. [Lee, Myounghwa; Nath, Avindra] NINDS, Sect Infect Nervous Syst, NIH, Bethesda, MD 20892 USA. [Chen, Xuesong; Geiger, Jonathan D.] Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, Grand Forks, ND 58201 USA. [Gorospe, Myriam M.] NIA, Genet Lab, NIH, Baltimore, MD 21224 USA. [Mattson, Mark P.] NIA, Lab Neurosci, NIH, Baltimore, MD 21224 USA. EM mbae002@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P15 BP S7 EP S7 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200016 ER PT J AU Billioux, BJ Leibovitch, E Brunetto, G Dustin, IM Inati, S Schreiber, J Eze, C Zaghloul, K Jacobson, S Theodore, WH AF Billioux, Bridgette Jeanne Leibovitch, Emily Brunetto, Giovanna Dustin, Irene M. Inati, Sarah Schreiber, John Eze, Chigo Zaghloul, Kareem Jacobson, Steve Theodore, William H. TI Human Herpes Virus 6 in Human Epilepsy: Data from Surgical Resections SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Billioux, Bridgette Jeanne; Leibovitch, Emily; Brunetto, Giovanna; Jacobson, Steve] NINDS, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA. [Dustin, Irene M.; Schreiber, John; Eze, Chigo; Theodore, William H.] NINDS, Clin Epilepsy Sect, NIH, Bethesda, MD 20892 USA. [Inati, Sarah] NINDS, EEG Lab, NIH, Bethesda, MD 20892 USA. [Zaghloul, Kareem] NINDS, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA. EM bridgette.billioux@nih.gov NR 0 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P28 BP S14 EP S14 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200029 ER PT J AU Bora, A Mohien, CU Chaerkady, R Chang, LD Moxley, R Sacktor, N McArthur, JC Haughey, N Nath, A Graham, DR AF Bora, Adriana Mohien, Ceereena Ubaida Chaerkady, Raghothama Chang, Linda Moxley, Richard Sacktor, Ned McArthur, Justin C. Haughey, Norm Nath, Avindra Graham, David R. TI Proteomics evaluation of CSF patients with HIV-associated neurocognitive impairment using iTRAQ labeling SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Bora, Adriana; Moxley, Richard; Sacktor, Ned; McArthur, Justin C.; Haughey, Norm] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD USA. [Mohien, Ceereena Ubaida; Graham, David R.] Johns Hopkins Sch Med, Dept Mol & Comparat Pathobiol, Baltimore, MD USA. [Chaerkady, Raghothama] Johns Hopkins Sch Med, Prote Core Facil, Baltimore, MD USA. [Chang, Linda] Univ Hawaii, John A Burns Sch Med, Dept Med, Honolulu, HI 96822 USA. [Nath, Avindra] NINDS, NIH, Bethesda, MD 20892 USA. EM abora1@jhmi.edu NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P31 BP S15 EP S16 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200032 ER PT J AU Byrareddy, S Thorat, S Sharma, P Hemashettar, GH Matsuda, K Hirsch, V Girolami, U Novembre, F Villinger, F Ruprecht, R AF Byrareddy, Siddappa Thorat, Swati Sharma, Prachi Hemashettar, Girish Hemashettar Matsuda, Kenta Hirsch, Vanessa Girolami, Umberto Novembre, Francis Villinger, Francois Ruprecht, Ruth TI Macrophage/microglia lineage-related R5-tropic simian-human immunodeficiency viruses as tools to induce and study HAND SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Byrareddy, Siddappa; Villinger, Francois] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. [Byrareddy, Siddappa; Thorat, Swati; Hemashettar, Girish Hemashettar; Ruprecht, Ruth] Dana Farber Canc Inst, Boston, MA 02115 USA. [Byrareddy, Siddappa; Thorat, Swati; Hemashettar, Girish Hemashettar; Ruprecht, Ruth] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Sharma, Prachi; Novembre, Francis; Villinger, Francois] Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA. [Matsuda, Kenta; Hirsch, Vanessa] NIAID, Mol Microbiol Lab, NIH, Bethesda, MD USA. [Girolami, Umberto] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. EM siddappa.n.byrareddy@emory.edu NR 0 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P34 BP S17 EP S17 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200035 ER PT J AU Caruso, B Brunetto, G Massoud, R Switzer, B Jacobson, S AF Caruso, Breanna Brunetto, Giovanna Massoud, Raya Switzer, Bill Jacobson, Steven TI Digital Droplet PCR for Precise Quantification of Human T-Lymphotropic Virus 1 SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Caruso, Breanna; Brunetto, Giovanna; Massoud, Raya; Jacobson, Steven] NINDS, NIB, NIH, Bethesda, MD 20892 USA. [Switzer, Bill] CDC, NCHHSTP, OID, Atlanta, GA 30333 USA. EM breanna.caruso@nih.gov NR 0 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P38 BP S19 EP S19 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200039 ER PT J AU Enose-Akahata, Y Massoud, R Virtanen, J Jacobson, S AF Enose-Akahata, Yoshimi Massoud, Raya Virtanen, Jussi Jacobson, Steven TI Correlation of increased CXCL13/IL-21 with intrathecal humoral immune responses to HTLV-1 in CSF of patients with HAM/TSP SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Enose-Akahata, Yoshimi; Massoud, Raya; Virtanen, Jussi; Jacobson, Steven] NINDS, Viral Immunol Sect, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA. EM akahatay@ninds.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P54 BP S26 EP S26 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200055 ER PT J AU Ferenczy, M Johnson, K Major, E AF Ferenczy, Michael Johnson, Kory Major, Eugene TI Cell culture and bioinformatic identification of putative progressive multifocal leukoencephalopathy risk factors SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Ferenczy, Michael; Major, Eugene] NINDS, Lab Mol Med & Neurosci, NIH, Bethesda, MD 20892 USA. [Johnson, Kory] NINDS, Bioinformat Sect, NIH, Bethesda, MD 20892 USA. EM michael.ferenczy@nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P59 BP S28 EP S29 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200060 ER PT J AU Gerena, Y Menendez-Delmestre, R Skolasky, R Hechavarria, R Perez, S Hilera, C Gonzalez, C Nath, A Wojna, V AF Gerena, Yamil Menendez-Delmestre, Raissa Skolasky, Richard Hechavarria, Rosa Perez, Sebastian Hilera, Claudia Gonzalez, Claribel Nath, Avindra Wojna, Valerie TI Higher Levels of Plasma Soluble Insulin-Like Growth Factor-1 Receptor are Associated with Severity of HAND in HIV-seropositive Women SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Gerena, Yamil] Univ Puerto Rico Med Sci Campus, NeuroAIDS Res Program, Dept Pharmaceut Sci, San Juan, PR USA. [Gerena, Yamil] Univ Puerto Rico Med Sci Campus, NeuroAIDS Res Program, Dept Pharmacol, San Juan, PR USA. [Menendez-Delmestre, Raissa; Gonzalez, Claribel] Univ Puerto Rico Med Sci Campus, NeuroAIDS Res Program, San Juan, PR USA. [Skolasky, Richard] Johns Hopkins Univ, Dept Orthopaed Surg, Baltimore, MD USA. [Hechavarria, Rosa] Univ Puerto Rico Med Sci Campus, NeuroAIDS Res Program, Dept Phys Med & Rehabil, San Juan, PR USA. [Perez, Sebastian] Univ Puerto Rico Med Sci Campus, Sch Med, San Juan, PR USA. [Hilera, Claudia] Univ Puerto Rico Rio Piedras Campus, Dept Biol, San Juan, PR USA. [Nath, Avindra] NINDS, NIH, Bethesda, MD 20892 USA. [Wojna, Valerie] Univ Puerto Rico Med Sci Campus, NeuroAIDS Res Program, Div Neurol, Dept Internal Med, San Juan, PR USA. EM yamil.gerena@upr.edu NR 0 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P67 BP S32 EP S32 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200068 ER PT J AU Hategan, AP Steiner, J Dimitriadis, E Nath, A AF Hategan, Alina Popescu Steiner, Joseph Dimitriadis, Emilios Nath, Avindra TI HIV-Tat protein enhances amyloid beta aggregation SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Hategan, Alina Popescu; Steiner, Joseph; Nath, Avindra] NINDS, NIH, Sect Infect Nervous Syst, Bethesda, MD 20892 USA. NIBIB, NIH, Scanning Probe Microscopy Unit, Bethesda, MD USA. EM alina.popescu@nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P140 BP S66 EP S66 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200141 ER PT J AU Herz, J McGavern, D AF Herz, Jasmin McGavern, Dorian TI Therapeutic Clearance of the Virally Infected Nervous System is Mediated by Noncytopathic T cell interactions with Resident Microglia SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Herz, Jasmin; McGavern, Dorian] NINDS, NIH, Bethesda, MD 20892 USA. EM herzjn@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P78 BP S37 EP S38 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200079 ER PT J AU Iordanskiy, S Van Duyne, R Sampey, G Fry, K Romerio, F Kashanchi, F AF Iordanskiy, Sergey Van Duyne, Rachel Sampey, Gavin Fry, Kelsi Romerio, Fabio Kashanchi, Fatah TI Irradiation-induced cellular stress activates virus replication and apoptosis in HIV-1 infected macrophage model cells and in the brain of infected humanized mice SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Iordanskiy, Sergey; Van Duyne, Rachel; Sampey, Gavin; Fry, Kelsi; Kashanchi, Fatah] George Mason Univ, Natl Ctr Biodef & Infect Dis, Dept Mol & Microbiol, Fairfax, VA 22030 USA. [Van Duyne, Rachel] NCI, Virus Cell Interact Sect, HIV Drug Resistance Program, NIH, Bethesda, MD 20892 USA. [Romerio, Fabio] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA. EM siord6@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P81 BP S39 EP S39 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200082 ER PT J AU Johnson, T von Geldern, G Tyagi, R Sacktor, N McArthur, J Letendre, S Hasbun, R Petito, C Roh, D Verma, A Nath, A AF Johnson, Tory von Geldern, Gloria Tyagi, Richa Sacktor, Ned McArthur, Justin Letendre, Scott Hasbun, Rodrigo Petito, Carol Roh, David Verma, Ashok Nath, Avindra TI Detection of HIV-Tat protein in brain and CSF of patients on antiretroviral therapy SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Johnson, Tory; von Geldern, Gloria; Tyagi, Richa; Nath, Avindra] NINDS, NIH, Bethesda, MD 20892 USA. [Sacktor, Ned; McArthur, Justin] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD USA. [Letendre, Scott] Univ Calif San Diego, San Diego, CA 92103 USA. [Hasbun, Rodrigo] Univ Texas Houston, Houston, TX USA. [Petito, Carol; Roh, David; Verma, Ashok] Univ Miami, Jackson Mem Hosp, Coral Gables, FL 33124 USA. EM tory.johnson@nih.gov NR 0 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P84 BP S40 EP S41 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200085 ER PT J AU Leibovitch, E Brunetto, G Caruso, B Fenton, K Ohayon, J Reich, D Jacobson, S AF Leibovitch, Emily Brunetto, Giovanna Caruso, Breanna Fenton, Kaylan Ohayon, Joan Reich, Daniel Jacobson, Steven TI Coinfection of human herpesviruses 6A (HHV-6A) and HHV-6B demonstrated by digital droplet PCR SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Leibovitch, Emily; Brunetto, Giovanna; Caruso, Breanna; Fenton, Kaylan; Ohayon, Joan; Reich, Daniel; Jacobson, Steven] NINDS, NIH, Bethesda, MD 20892 USA. EM emily.leibovitch@nih.gov RI Reich, Daniel/E-5701-2010 OI Reich, Daniel/0000-0002-2628-4334 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P101 BP S48 EP S49 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200102 ER PT J AU Li, WX Tyagi, R Henderson, L Nath, A AF Li, Wenxue Tyagi, Richa Henderson, Lisa Nath, Avindra TI Activation of HERV-K expression in the brain of ALS patients SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Li, Wenxue; Tyagi, Richa; Henderson, Lisa; Nath, Avindra] NINDS, Sect Infect Nervous Syst, NIH, Bethesda, MD 20892 USA. EM liw8@mail.nih.gov NR 0 TC 0 Z9 0 U1 3 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P103 BP S49 EP S50 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200104 ER PT J AU Liu, W Massoud, R Reich, D Nair, G Jacobson, S AF Liu, Winston Massoud, Raya Reich, Daniel Nair, Govind Jacobson, Steve TI Quantifying Spinal Cord Cross-sectional Area in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis and Multiple Sclerosis SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Liu, Winston; Massoud, Raya; Reich, Daniel; Nair, Govind; Jacobson, Steve] NINDS, Bethesda, MD 20892 USA. EM winston.w.liu@gmail.com RI Reich, Daniel/E-5701-2010 OI Reich, Daniel/0000-0002-2628-4334 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P104 BP S50 EP S50 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200105 ER PT J AU Massoud, R Enose-Akahata, Y Ohayon, J Fenton, K Cortese, I Jacobson, S Waldmann, T AF Massoud, Raya Enose-Akahata, Yoshimi Ohayon, Joan Fenton, Kaylan Cortese, Irene Jacobson, Steven Waldmann, Thomas TI Clinical trial of a humanized monoclonal anti-IL15Rbeta (CD122) antibody, in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Massoud, Raya; Enose-Akahata, Yoshimi; Ohayon, Joan; Fenton, Kaylan; Cortese, Irene; Jacobson, Steven] NINDS, NIH, Bethesda, MD 20892 USA. [Waldmann, Thomas] NCI, NIH, Bethesda, MD 20892 USA. EM raya.massoud@nih.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P113 BP S54 EP S54 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200114 ER PT J AU Nayak, D McGavern, D AF Nayak, Debasis McGavern, Dorian TI Tetherin is critical for the resolution of a persistent viral infection SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Nayak, Debasis; McGavern, Dorian] NINDS, NIH, Bethesda, MD 20892 USA. EM nayakdn@ninds.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P131 BP S62 EP S63 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200132 ER PT J AU Park, M Tran, T El Baz, R Cuconati, A Arthos, J Duffy, C Chaiken, I Schnur, D Song, FB Lam, P Reynolds, C Reitz, A Khan, Z Jain, P AF Park, Michael Thuong Tran El Baz, Rasha Cuconati, Andrea Arthos, James Duffy, Caitlin Chaiken, Irwin Schnur, Dora Song, Fengbin Lam, Patrick Reynolds, Charles Reitz, Allen Khan, Zafar Jain, Pooja TI DC-SIGN as potential target for early intervention and transmission of HIV-1 SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Park, Michael; Thuong Tran; El Baz, Rasha; Khan, Zafar; Jain, Pooja] Drexel Univ, Coll Med, Drexel Inst Biotechnol & Virol Res, Philadelphia, PA USA. [Park, Michael; Thuong Tran; El Baz, Rasha; Khan, Zafar; Jain, Pooja] Drexel Univ, Coll Med, Dept Microbiol & Immunol, Philadelphia, PA USA. [Cuconati, Andrea; Song, Fengbin; Reynolds, Charles] Hepatitis B Fdn, Inst Hepatitis & Virus Res, Philadelphia, PA USA. [Arthos, James] NIAID, Lab Immunoregulat, Boston, MA USA. [Duffy, Caitlin; Chaiken, Irwin] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA USA. EM zafar.khan@drexelmed.edu NR 0 TC 0 Z9 0 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P135 BP S64 EP S64 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200136 ER PT J AU Sagar, D Masih, S Schell, T Jacobson, S Wigdahl, B Jain, P Khan, Z AF Sagar, Divya Masih, Shet Schell, Todd Jacobson, Steven Wigdahl, Brian Jain, Pooja Khan, Zafar TI In vivo immunogenicity of Tax 11-19 epitope in HLA-A2/DTR transgenic mice: implication for dendritic cell-based anti-HTLV-1 vaccine SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Sagar, Divya; Masih, Shet; Jain, Pooja; Khan, Zafar] Drexel Univ, Coll Med, Dept Microbiol & Immunol, Philadelphia, PA USA. [Schell, Todd] Penn State Univ, Coll Med, Dept Microbiol & Immunol, University Pk, PA 16802 USA. [Jacobson, Steven] NIH, Viral Immunol Sect, Neuroimmunol Branch, Bethesda, MD USA. [Wigdahl, Brian] Drexel Univ, Inst Mol Med & Infect Dis, Dept Microbiol & Immunol, Ctr Mol Virol & Translat Neurosci,Coll Med, Philadelphia, PA USA. EM pooja.jain@drexelmed.edu NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P149 BP S70 EP S70 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200150 ER PT J AU Taylor, K Woods, T Peterson, K AF Taylor, Katherine Woods, Tyson Peterson, Karin TI Innate immune induced neuronal death during bunyavirus infection is mediated by SARM SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Taylor, Katherine; Woods, Tyson; Peterson, Karin] NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, NIH, Bethesda, MD 20892 USA. EM petersonka@niaid.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P173 BP S81 EP S81 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200174 ER PT J AU Taylor, K Woods, T Winkler, C Peterson, K AF Taylor, Katherine Woods, Tyson Winkler, Clayton Peterson, Karin TI Age-dependent susceptibility to La Crosse Virus-induced neurological disease mediated by TLR3/RLR signaling pathways SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Taylor, Katherine; Woods, Tyson; Winkler, Clayton; Peterson, Karin] NIH, Rocky Mt Lab, LPVD, Neuroimmunol Unity, Bethesda, MD 20892 USA. EM katherine.taylor@nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P172 BP S81 EP S81 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200173 ER PT J AU Tyagi, R Li, WX Parades, D Nath, A AF Tyagi, Richa Li, Wenxue Parades, Danelvis Nath, Avindra TI Recycling HIVAntiretrovirals for inhibition of Human Endogenous Retrovirus-K SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Tyagi, Richa; Li, Wenxue; Parades, Danelvis; Nath, Avindra] NINDS, Sect Infect Nervous Syst, NIH, Bethesda, MD 20892 USA. EM tyagi.richa@nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P179 BP S84 EP S84 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200180 ER PT J AU Virtanen, JO Enose-Akahata, Y Massoud, R Jacobson, S AF Virtanen, Jussi Oskari Enose-Akahata, Yoshimi Massoud, Raya Jacobson, Steven TI Intrathecal immune response to HTLV-1 antigens in HAM/TSP SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Virtanen, Jussi Oskari; Enose-Akahata, Yoshimi; Massoud, Raya; Jacobson, Steven] NINDS, NIH, Bethesda, MD 20892 USA. EM virtanenjo@ninds.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P185 BP S87 EP S87 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200186 ER PT J AU Virtanen, JO Kowalak, J Leibovitch, E Lee, N Enose-Akahata, Y Jacobson, S AF Virtanen, Jussi Oskari Kowalak, Jeffrey Leibovitch, Emily Lee, Naomi Enose-Akahata, Yoshimi Jacobson, Steve TI Virus-induced cellular targets for intrathecal autoimmunity in multiple sclerosis SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Virtanen, Jussi Oskari; Kowalak, Jeffrey; Leibovitch, Emily; Lee, Naomi; Enose-Akahata, Yoshimi; Jacobson, Steve] NINDS, NIH, Bethesda, MD 20892 USA. [Kowalak, Jeffrey] NIMH, Bethesda, MD USA. EM virtanenjo@ninds.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P184 BP S86 EP S86 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200185 ER PT J AU Winkler, C Woods, T Peterson, KE AF Winkler, Clayton Woods, Tyson Peterson, Karin E. TI Leukocyte CNS infiltration precedes neurological disease following La Crosse virus infection SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Winkler, Clayton; Woods, Tyson; Peterson, Karin E.] NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, Bethesda, MD USA. EM clayton.winkler@nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P192 BP S90 EP S90 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200193 ER PT J AU Benzo, R Siemion, W Novotny, P Sternberg, A Kaplan, RM Ries, A Wise, R Martinez, F Utz, J Sciurba, F AF Benzo, Roberto Siemion, Wendy Novotny, Paul Sternberg, Alice Kaplan, Robert M. Ries, Andrew Wise, Robert Martinez, Fernando Utz, James Sciurba, Frank CA Natl Emphysema Treatment Trial NET TI Factors to Inform Clinicians About the End of Life in Severe Chronic Obstructive Pulmonary Disease SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Chronic obstructive pulmonary disease; severe COPD; end-stage COPD; palliative care; end-of-life care; gait speed; mortality; prediction tools ID AIR-FLOW OBSTRUCTION; OF-LIFE; PALLIATIVE CARE; SEVERE COPD; PHYSICAL-ACTIVITY; SEVERE EMPHYSEMA; HEALTH-STATUS; GAIT SPEED; MORTALITY; HOSPITALIZATION AB Context. Palliative services have historically been offered to terminal patients with cancer, but much less so in other chronic illnesses such as chronic obstructive pulmonary disease (COPD) because of difficulties in predicting the trajectory to death. Objectives. The goal of this study was to determine if the change over time of the key parameters (trajectory) in patients with severe COPD can independently predict short-term mortality. Methods. We analyzed data from 1218 patients with severe COPD. Multivariate models for trajectory change were used to forecast mortality at 12 months. Results. Changes in several variables by defined cutpoints increase significantly and independently the odds of dying in 12 months. The earliest and strongest predictors were the decrease in gait speed by 0.14 m/s or six-minute walk by 50 m (odds ratio [OR] 4.40, P < 0.0001). Alternatively, if six-minute walk or gait speed were not used, change toward perceiving a very sedentary state using a single question (OR 3.56, P=0.0007) and decrease in maximal inspiratory pressure greater than 11 cmH(2)O (OR 2.19, P=0.0217) were predictive, followed by change toward feeling upset or downhearted (OR 2.44, P=0.0250), decrease in room air resting partial pressure of oxygen greater than 5 mmHg (OR 2.46, P=0.0156), and increase in room air resting partial pressure of carbon dioxide greater than 3 mmHg (OR 2.8, P=0.0039). Change over time models were more discriminative (higher c-statistics) than change from baseline models. Conclusion. The changes in defined variables and patient-reported outcomes by defined cutpoints were independently associated with increased 12-month mortality in patients with severe COPD. These results may inform clinicians when to initiate end-of-life communications and palliative care. (C) 2013 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. C1 [Benzo, Roberto; Siemion, Wendy; Utz, James] Mayo Clin, Dept Med, Rochester, MN 55902 USA. [Novotny, Paul] Mayo Clin, Ctr Canc, Rochester, MN 55902 USA. [Sternberg, Alice] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA. [Wise, Robert] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. [Kaplan, Robert M.] NIH, Off Behav & Social Sci Res, Bethesda, MD 20892 USA. [Ries, Andrew] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA. [Martinez, Fernando] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. [Sciurba, Frank] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. RP Benzo, R (reprint author), Mayo Clin, Dept Med, Div Pulm & Crit Care, Mindful Breathing Lab, 200 1st St SW, Rochester, MN 55902 USA. EM benzo.roberto@mayo.edu OI Wise, Robert/0000-0002-8353-2349 FU National Heart Lung and Blood Institute, National Institutes of Health [1R01CA163293-01]; National Heart, Lung, and Blood Institute [N01HR76101, N01HR76102, N01HR76103, N01HR76104, N01HR76105, N01HR76106, N01HR76107, N01HR76108, N01HR76109, N01HR76110,, N01HR76111, N01HR76112, N01HR76113, N01HR76114, N01HR76115, N01HR76116, N01HR76118, N01HR76119]; Centers for Medicare and Medicaid Services (formerly the Health Care Financing Administration); Agency for Healthcare Research and Quality FX Dr. Benzo is supportedby grant 1R01CA163293-01 from the National Heart Lung and Blood Institute, National Institutes of Health. The National Emphysema Treatment Trial (NETT) is supported by contracts with the National Heart, Lung, and Blood Institute (N01HR76101, N01HR76102, N01HR76103, N01HR76104, N01HR76105, N01HR76106, N01HR76107, N01HR76108, N01HR76109, N01HR76110, N01HR76111, N01HR76112, N01HR76113, N01HR76114, N01HR76115, N01HR76116, N01HR76118, and N01HR76119), the Centers for Medicare and Medicaid Services (formerly the Health Care Financing Administration), and the Agency for Healthcare Research and Quality. The authors declare no conflicts of interest. NR 30 TC 13 Z9 13 U1 2 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD OCT PY 2013 VL 46 IS 4 BP 491 EP + DI 10.1016/j.jpainsymman.2012.10.283 PG 13 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 232BL UT WOS:000325463300008 PM 23522520 ER PT J AU Murnane, KS Andersen, ML Rice, KC Howell, LL AF Murnane, Kevin S. Andersen, Monica L. Rice, Kenner C. Howell, Leonard L. TI Selective serotonin 2A receptor antagonism attenuates the effects of amphetamine on arousal and dopamine overflow in non-human primates SO JOURNAL OF SLEEP RESEARCH LA English DT Article DE 5-HT2A; amphetamine; arousal; M100907; microdialysis; rhesus monkeys ID RHESUS-MONKEYS; 3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; PARKINSONS-DISEASE; MONOAMINE CONTENT; SLEEP; WAKEFULNESS; NEURONS; COCAINE; STEREOISOMERS; LESIONS AB The objective of the present study was to further elucidate the mechanisms involved in the wake-promoting effects of psychomotor-stimulants. Many previous studies have tightly linked the effects of stimulants to dopamine neurotransmission, and some studies indicate that serotonin 2A receptors modulate these effects. However, the role of dopamine in arousal is controversial, most notably because dopamine neurons do not change firing rates across arousal states. In the present study, we examined the wake-promoting effects of the dopamine-releaser amphetamine using non-invasive telemetric monitoring. These effects were evaluated in rhesus monkeys as a laboratory animal model with high translational relevance for human disorders of sleep and arousal. To evaluate the role of dopamine in the wake-promoting effects of amphetamine, we used in vivo microdialysis targeting the caudate nucleus, as this approach provides clearly interpretable measures of presynaptic dopamine release. This is beneficial in the present context because some of the inconsistencies between previous studies examining the role of dopamine in arousal may be related to differences between postsynaptic dopamine receptors. We found that amphetamine significantly and dose-dependently increased arousal at doses that engendered higher extracellular dopamine levels. Moreover, antagonism of serotonin 2A receptors attenuated the effects of amphetamine on both wakefulness and dopamine overflow. These findings further elucidate the role of dopamine and serotonin 2A receptors in arousal, and they suggest that increased dopamine neurotransmission may be necessary for the wake-promoting effects of amphetamine, and possibly other stimulants. C1 [Murnane, Kevin S.; Andersen, Monica L.; Howell, Leonard L.] Yerkes Natl Primate Res Ctr, Div Neuropharmacol & Neurol Dis, Atlanta, GA USA. [Andersen, Monica L.] Univ Fed Sao Paulo UNIFESP, Dept Psicobiol, Sao Paulo, Brazil. [Rice, Kenner C.] NIDA, Chem Biol Res Branch, NIH, Bethesda, MD 20892 USA. [Rice, Kenner C.] NIAAA, NIH, Bethesda, MD USA. [Howell, Leonard L.] Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA. RP Howell, LL (reprint author), Emory Univ, Yerkes Natl Primate Res Ctr, 954 Gatewood Rd, Atlanta, GA 30322 USA. EM lhowell@emory.edu RI Andersen, Monica/C-7616-2012 OI Andersen, Monica/0000-0002-1894-6748 FU USPHS [DA010344, DA012514, RR000165]; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism FX The authors would like to thank both Juliet Brown and Lisa Neidert for their expert technical assistance. These studies were supported by USPHS grants (DA010344, DA012514 and RR000165). A portion of this work was supported by the Intramural Research Programs of National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism. NR 28 TC 5 Z9 5 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0962-1105 EI 1365-2869 J9 J SLEEP RES JI J. Sleep Res. PD OCT PY 2013 VL 22 IS 5 BP 581 EP 588 DI 10.1111/jsr.12045 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 217CW UT WOS:000324335300013 PM 23879373 ER PT J AU Heymann, JB Winkler, DC Yim, YI Eisenberg, E Greene, LE Steven, AC AF Heymann, J. Bernard Winkler, Dennis C. Yim, Yang-In Eisenberg, Evan Greene, Lois E. Steven, Alasdair C. TI Clathrin-coated vesicles from brain have small payloads: A cryo-electron tomographic study SO JOURNAL OF STRUCTURAL BIOLOGY LA English DT Article DE Clathrin-mediated endocytosis; Cryo-electron microscopy; Three-dimensional image reconstruction; Adaptor proteins; Fullerenes ID TRANSMISSION ELECTRON-MICROSCOPY; MEDIATED ENDOCYTOSIS; BINDING SUBUNIT; PROTEIN COMPLEX; KIDNEY-CELL; MEMBRANE; AP-2; AUXILIN; VISUALIZATION; RESOLUTION AB Clathrin coats, which stabilize membrane curvature during endocytosis and vesicular trafficking, form highly polymorphic fullerene lattices. We used cryo-electron tomography to visualize coated particles in isolates from bovine brain. The particles range from similar to 66 to similar to 134 nm in diameter, and only 20% of them (all >= 80 nm) contain vesicles. The remaining 80% are clathrin "baskets", presumably artifactual assembly products. Polyhedral models were built for 54 distinct coat geometries. In true coated vesicles (CVs), most vesicles are offset to one side, leaving a crescent of interstitial space between the coat and the membrane for adaptor proteins and other components. The latter densities are fewer on the membrane-proximal side, which may represent the last part of the vesicle to bud off. A small number of densities - presumably cargo proteins - are associated with the interior surface of the vesicles. The clathrin coat, adaptor proteins, and vesicle membrane contribute almost all of the mass of a CV, with most cargoes accounting for only a few percent. The assembly of a CV therefore represents a massive biosynthetic effort to internalize a relatively diminutive payload. Such a high investment may be needed to overcome the resistance of membranes to high curvature. Published by Elsevier Inc. C1 [Heymann, J. Bernard; Winkler, Dennis C.; Steven, Alasdair C.] NIAMSD, Struct Biol Res Lab, Bethesda, MD 20892 USA. [Yim, Yang-In; Eisenberg, Evan; Greene, Lois E.] NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA. RP Heymann, JB (reprint author), NIH, Bldg 50,Room 1515,50 South Dr MSC 8025, Bethesda, MD 20892 USA. EM Bernard_Heymann@nih.gov OI Heymann, Bernard/0000-0002-8872-5326 FU Intramural Research Program of NIAMS, NIH; Intramural Research Program of NHLBI, NIH; [NIHP41RR-01081] FX Molecular graphics images were produced using the UCSF Chimera package from the Resource for Biocomputing, Visualization and Informatics at the University of California, San Francisco (supported by NIHP41RR-01081). This work was supported by the Intramural Research Programs of NIAMS and NHLBI, NIH. NR 73 TC 3 Z9 4 U1 0 U2 15 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1047-8477 EI 1095-8657 J9 J STRUCT BIOL JI J. Struct. Biol. PD OCT PY 2013 VL 184 IS 1 BP 43 EP 51 DI 10.1016/j.jsb.2013.05.006 PG 9 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 234WM UT WOS:000325675000006 PM 23688956 ER PT J AU Noinaj, N Cornelissen, CN Buchanan, SK AF Noinaj, Nicholas Cornelissen, Cynthia Nau Buchanan, Susan K. TI Structural insight into the lactoferrin receptors from pathogenic Neisseria SO JOURNAL OF STRUCTURAL BIOLOGY LA English DT Article DE Neisseria meningitidis; Gonorrhoeae; Lactoferrin; Transferrin; Iron acquisition; TonB ID HUMAN SERUM TRANSFERRIN; BINDING-PROTEIN B; N-LOBE; SWISS-MODEL; CRYSTAL-STRUCTURE; PROVIDES INSIGHT; IRON; MENINGITIDIS; GONORRHOEAE; IDENTIFICATION AB Neisseria are pathogenic bacteria that cause gonorrhea, septicemia, and meningitis. Like other pathogenic bacteria, Neisseria must acquire iron for survival from their local environment within the human host. Instead of secreting siderophores to scavenge iron, Neisseria steal iron from human iron binding proteins such as hemoglobin, transferrin and lactoferrin for survival. Recently we reported the crystal structures of the Neisseria meningitidis transferrin receptors TbpA and TbpB, as well as the structures of apo and holo human transferrin. We also analyzed these proteins using small angle X-ray scattering and electron microscopy to provide the molecular details explaining how Neisseria are able to interact with and extract iron from transferrin. Here, we utilize the structural reports, as well as the recently reported structure of the N-lobe of LbpB from Moraxella bovis, to assemble improved 3D homology models for the neisserial lactoferrin import receptors LbpA and LbpB, both of which are important vaccine targets against N. meningitidis. We then analyzed these models to gain structural insights into the lactoferrin-iron import system and form a mechanistic model fashioned in parallel to the homologous transferrin-iron import system. Published by Elsevier Inc. C1 [Noinaj, Nicholas; Buchanan, Susan K.] NIDDK, NIH, Bethesda, MD 20892 USA. [Cornelissen, Cynthia Nau] Virginia Commonwealth Univ, Med Ctr, Dept Microbiol & Immunol, Richmond, VA 23298 USA. RP Buchanan, SK (reprint author), NIDDK, NIH, Bethesda, MD 20892 USA. EM skbuchan@helix.nih.gov FU Intramural Program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; U.S. Public Health Service from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health [AI065555, AI084400]; SE STI Center from the National Institute of Allergy and Infectious Diseases [U19 AI31496] FX N.N. and S.K.B. are supported by the Intramural Program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. Funding was provided to C.N.C. by U.S. Public Health Service grant numbers AI065555 and AI084400 from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. C.N.C. is also supported by the SE STI Center grant (U19 AI31496) from the National Institute of Allergy and Infectious Diseases. NR 43 TC 12 Z9 12 U1 3 U2 15 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1047-8477 EI 1095-8657 J9 J STRUCT BIOL JI J. Struct. Biol. PD OCT PY 2013 VL 184 IS 1 BP 83 EP 92 DI 10.1016/j.jsb.2013.02.009 PG 10 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 234WM UT WOS:000325675000010 PM 23462098 ER PT J AU Vasunilashorn, S Ferrucci, L Crimmins, EM Bandinelli, S Guralnik, JM Patel, KV AF Vasunilashorn, Sarinnapha Ferrucci, Luigi Crimmins, Eileen M. Bandinelli, Stefania Guralnik, Jack M. Patel, Kushang V. TI Association of Inflammation with Loss of Ability to Walk 400 Meters: Longitudinal Findings from the Invecchiare in Chianti Study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE inflammation; mobility; 400-m walk; functional limitation; aging ID C-REACTIVE PROTEIN; OLDER PERSONS; PHYSICAL FUNCTION; CARDIOVASCULAR-DISEASE; MOBILITY LIMITATION; PERFORMANCE; MORTALITY; INCHIANTI; MARKERS; DISABILITY AB ObjectivesTo examine relationships between eight markers of inflammation (interleukin (IL)-6, IL-6 receptor (R), C-reactive protein (CRP), tumor necrosis factor (TNF)-alpha, TNF receptor 1 (R1), TNFR2, IL-1 receptor antagonist, IL-18) and incident loss of ability to walk 400m. DesignProspective cohort study. SettingOlder adults enrolled in the Invecchiare in Chianti Study. ParticipantsCommunity-dwelling participants aged 65 and older (N=1,006). MeasurementsThe eight inflammatory markers were measured at baseline, and an inflammation score was calculated based on the number of inflammatory markers for which the participant was in the highest quartile. Incidence of mobility disability was determined in participants able to walk 400m at baseline. Logistic regression models were used to determine whether each of the inflammatory markers and the inflammation score predicted loss of the ability to walk 400m at 6-year follow-up. ResultsAfter adjusting for covariates, individuals with a TNFR1 level in each of the highest three quartiles (Q2, 3, 4) were more likely to be unable to walk 400m at follow-up than those with TNFR1 levels in Q1. When adjusting for the same covariates, participants with an inflammation score of 3 or 4 were more likely to become unable to walk 400m at follow-up than participants with a score of 0. ConclusionThese results provide additional evidence that inflammation is a factor in the mechanisms that cause incident mobility disability and suggest that a combined measure of inflammatory markers may improve prediction of functional prognosis. C1 [Vasunilashorn, Sarinnapha] Princeton Univ, Off Populat Res, Princeton, NJ 08544 USA. [Ferrucci, Luigi] NIA, Longitudinal Studies Sect, Clin Res Branch, Baltimore, MD 21224 USA. [Crimmins, Eileen M.] Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA. [Bandinelli, Stefania] Azienda Sanit Firenze, Geriatr Unit, Florence, Italy. [Guralnik, Jack M.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA. [Patel, Kushang V.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA. RP Vasunilashorn, S (reprint author), Princeton Univ, Off Populat Res, 263 Wallace Hall, Princeton, NJ 08544 USA. EM svasunil@princeton.edu FU Italian Ministry of Health [ICS 110.1/RS97.71]; National Institutes of Health (NIH), National Institute on Aging [N01-AG-1-2111]; NIH from the Eunice Kennedy Shriver National Institute of Child Health and Human Development [R24HD047879] FX The InCHIANTI Study was supported as a targeted project (ICS 110.1/RS97.71) by the Italian Ministry of Health and in part by the Intramural Research Program of the National Institutes of Health (NIH), National Institute on Aging (Contract N01-AG-1-2111). This research was supported in part by NIH Grant R24HD047879 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. NR 25 TC 3 Z9 3 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD OCT PY 2013 VL 61 IS 10 BP 1743 EP 1749 DI 10.1111/jgs.12446 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 233FG UT WOS:000325551500014 PM 24083386 ER PT J AU Murphy, TP Reynolds, MR Cohen, DJ Regensteiner, JG Massaro, JM Cutlip, DE Mohler, ER Cerezo, J Oldenburg, NC Thum, CC Goldberg, S Hirsch, AT AF Murphy, Timothy P. Reynolds, Matthew R. Cohen, David J. Regensteiner, Judith G. Massaro, Joseph M. Cutlip, Donald E. Mohler, Emile R. Cerezo, Joselyn Oldenburg, Niki C. Thum, Claudia C. Goldberg, Suzanne Hirsch, Alan T. TI Correlation of Patient-reported Symptom Outcomes and Treadmill Test Outcomes after Treatment for Aortoiliac Claudication SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article ID QUALITY-OF-LIFE; ENDOLUMINAL REVASCULARIZATION CLEVER; PERIPHERAL ARTERIAL-DISEASE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; SUPERVISED EXERCISE PROGRAM; RANDOMIZED CONTROLLED-TRIAL; INTERMITTENT CLAUDICATION; ENDOVASCULAR REVASCULARIZATION; FUNCTIONAL STATUS; PERFORMANCE AB Purpose: To examine the relationship between objective treadmill test outcomes and subjective symptom outcomes among patients. with claudication treated with stent revascularization (ST) compared with supervised exercise (SE). Materials and Methods: Five scales of the Peripheral Artery Questionnaire and Walking Impairment Questionnaire were correlated with peak walking time and treadmill claudication onset time. Results: The correlation between change in disease-specific quality of life (QOL) and change in peak walking time differed according to treatment group, With statistically significant correlations for all five scales for the ST group and weaker trends for the SE group, only one of which was statistically significant. In contrast, improvements in disease-specific QOL correlated well with increases in claudication onset time, with no significant interaction with treatment group for any of the five scales. Conclusions: Disease-specific QOL results at 6 months in the Claudication: Exercise Vs. Endoluminal Revascularization (CLEVER) study show that improved maximal treadmill walking in patients with claudication treated with SE correlated poorly with self-reported symptom relief. Conversely, patients treated with ST showed good correlation between improved maximal treadmill walking and self-reported symptom improvement. The correlation between claudication onset time and self-reported symptom relief was good across treatment groups. This finding indicates that traditional objective treadmill test outcomes may not correlate well with symptom relief in patients with claudication. Future studies should investigate these data and improve understanding of patient relevance of traditional Objective treadmill-based treatment outcomes. C1 [Murphy, Timothy P.; Cerezo, Joselyn] Rhode Isl Hosp, Vasc Dis Res Ctr, Dept Diagnost Imaging, Providence, RI 02903 USA. [Reynolds, Matthew R.; Cutlip, Donald E.] Boston Univ, Dept Internal Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Thum, Claudia C.] Boston Univ, Harvard Clin Res Inst, Boston, MA 02215 USA. [Massaro, Joseph M.] Boston Univ, Dept Biostat, Boston, MA 02215 USA. [Cohen, David J.] Univ Missouri, Dept Internal Med, Kansas City, MO 64110 USA. [Regensteiner, Judith G.] Univ Colorado, Sch Med, Dept Exercise Physiol, Aurora, CO USA. [Mohler, Emile R.] Univ Penn, Dept Internal Med, Philadelphia, PA 19104 USA. [Oldenburg, Niki C.] Univ Minnesota, Sch Med, Dept Epidemiol, Minneapolis, MN 55455 USA. [Hirsch, Alan T.] Univ Minnesota, Sch Med, Dept Internal Med, Minneapolis, MN 55455 USA. [Goldberg, Suzanne] NHLBI, Bethesda, MD 20892 USA. RP Murphy, TP (reprint author), Rhode Isl Hosp, Vasc Dis Res Ctr, Dept Diagnost Imaging, Gerry 337,593 Eddy St, Providence, RI 02903 USA. EM tmurphy@lifespan.org FU Medtronic; Boston Scientific; Abbott Vascular; Medrad; Medtronic, Inc.; Amylin; American Diabetes Association; National Institutes of Health; Aastrom Biosciences; Cytokinetics; VM Biopharma; Cordis/Johnson Johnson; Otsuka Pharmaceuticals; National Heart, Lung and Blood Institute [HL77221, HL081656]; Cordis/Johnson & Johnson (Warren, New Jersey); eV3 (Plymouth, Minnesota); Boston Scientific (Natick, Massachusetts) FX T.P.M. received grant support from Abbott Vascular, Cordis/Johnson & Johnson, and Otsuka Pharmaceuticals and is a consultant for Microvention/Terumo, Inc. D.J.C. received research grant support from Medtronic, Boston Scientific, Abbott Vascular, and Medrad and is a consultant for Medtronic, Inc. M.R.R. is a paid consultant for Medtronic, Inc. J.G.R. received research grant support from Amylin, the American Diabetes Association, and the National Institutes of Health. E.R.M. is a Data Safety Monitoring Board member for Viromed BioPharma/Synteract. A.T.H. received research grants from Abbott Vascular, Aastrom Biosciences, Cytokinetics, and VM Biopharma and is a consultant for AstraZeneca, Merck, Novartis, Pozen, and Shire HGT. None of the other authors have identified a conflict of interest.; The CLEVER (Claudication: Exercise Vs. Endoluminal Revascularization) study was sponsored mostly by the National Heart, Lung and Blood Institute (grants HL77221 and HL081656) and also received financial support from Cordis/Johnson & Johnson (Warren, New Jersey), eV3 (Plymouth, Minnesota), and Boston Scientific (Natick, Massachusetts). Otsuka America Inc (San Francisco, California) donated cilostazol for all study participants throughout the study. Omron Healthcare Inc (Lake Forest Illinois) donated pedometers. Krames Staywell (San Bruno, California) donated pnnt materials for study participants on exercise and diet. NR 26 TC 7 Z9 7 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 EI 1535-7732 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD OCT PY 2013 VL 24 IS 10 BP 1427 EP 1435 DI 10.1016/j.jvir.2013.05.057 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA 231TW UT WOS:000325442300001 PM 23906799 ER PT J AU Clark, C AF Clark, Cindy TI Copyright Questions and Answers for Information Professionals: From the Columns of Against the Grain SO LEARNED PUBLISHING LA English DT Book Review C1 [Clark, Cindy] NIH, Natl Inst Hlth NIH Lib, Off Res Serv, Bethesda, MD 20892 USA. RP Clark, C (reprint author), NIH, Natl Inst Hlth NIH Lib, Off Res Serv, Bethesda, MD 20892 USA. EM clarkc@ors.od.nih.gov NR 1 TC 0 Z9 0 U1 1 U2 5 PU ASSOC LEARNED PROFESSIONAL SOC PUBL PI W SUSSEX PA SOUTH HOUSE, THE STREET WORTHING, W SUSSEX BN13 3UU, ENGLAND SN 0953-1513 EI 1741-4857 J9 LEARN PUBL JI Learn. Publ. PD OCT PY 2013 VL 26 IS 4 BP 310 EP 310 DI 10.1087/201304011 PG 1 WC Information Science & Library Science SC Information Science & Library Science GA 231VA UT WOS:000325445300011 ER PT J AU Bergsagel, PL Kuehl, WM AF Bergsagel, P. L. Kuehl, W. M. TI Degree of focal immunoglobulin heavy chain locus deletion as a measure of B-cell tumor purity SO LEUKEMIA LA English DT Letter ID MYELOMA C1 [Bergsagel, P. L.] Mayo Clin, Ctr Comprehens Canc, Scottsdale, AZ 85259 USA. [Kuehl, W. M.] Natl Canc Inst, Ctr Canc Res, Genet Branch, Bethesda, MD USA. RP Bergsagel, PL (reprint author), Mayo Clin, Ctr Comprehens Canc, Scottsdale, AZ 85259 USA. EM Bergsagel.Leif@mayo.edu FU NIA NIH HHS [R01 AG020686] NR 4 TC 2 Z9 2 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 EI 1476-5551 J9 LEUKEMIA JI Leukemia PD OCT PY 2013 VL 27 IS 10 BP 2067 EP 2068 DI 10.1038/leu.2013.139 PG 2 WC Oncology; Hematology SC Oncology; Hematology GA 234KN UT WOS:000325642600015 PM 23644420 ER PT J AU Prasad, V AF Prasad, Vinay TI Why Randomized Controlled Trials Are Needed to Accept New Practices: 2 Medical Worldviews SO MAYO CLINIC PROCEEDINGS LA English DT Editorial Material ID CLINICAL-PRACTICE GUIDELINES; CONFLICTS-OF-INTEREST; CYP2C19 GENOTYPE; CARDIOVASCULAR EVENTS; METAANALYSIS; REVERSAL; BENEFITS; EFFICACY; APPENDECTOMY; TECHNOLOGIES C1 NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA. RP Prasad, V (reprint author), NCI, Med Oncol Branch, NIH, 10 Ctr Dr,10-12N226, Bethesda, MD 20892 USA. EM vinayak.prasad@nih.gov NR 39 TC 5 Z9 5 U1 2 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 EI 1942-5546 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD OCT PY 2013 VL 88 IS 10 BP 1046 EP 1050 DI 10.1016/j.mayocp.2013.04.026 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 232DR UT WOS:000325470800008 PM 24079676 ER PT J AU Prasad, V Cifu, A AF Prasad, Vinay Cifu, Adam TI In reply I-Reversal of Medical Practices SO MAYO CLINIC PROCEEDINGS LA English DT Letter C1 [Prasad, Vinay] NCI, Bethesda, MD 20892 USA. [Cifu, Adam] Univ Chicago, Chicago, IL 60637 USA. RP Prasad, V (reprint author), NCI, Bethesda, MD 20892 USA. NR 6 TC 2 Z9 2 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 EI 1942-5546 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD OCT PY 2013 VL 88 IS 10 BP 1183 EP 1184 DI 10.1016/j.mayocp.2013.08.011 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 232DR UT WOS:000325470800028 PM 24079692 ER PT J AU Willis, GB Smith, T Lee, HJ AF Willis, Gordon B. Smith, Tenbroeck Lee, Hyunshik J. TI Do Additional Recontacts to Increase Response Rate Improve Physician Survey Data Quality? SO MEDICAL CARE LA English DT Article DE survey research; physician survey; response rate; data quality; recontact ID NONRESPONSE; ATTITUDES AB Background:Although response rates for physician surveys have been decreasing, it is not clear whether this trend is associated with an increase in survey nonresponse bias. One means for assessing potential bias is to conduct a level-of-effort analysis that compares data estimates for respondents interviewed during the first recruitment contact to respondents interviewed at later recontact cycles.Methods:We compared early and later responders within the Survey of Physician Attitudes Regarding the Care of Cancer Survivors with respect to both demographic characteristics and aggregate survey responses to items on survivor care knowledge, attitudes, and practices.Results:Accumulating additional completions across each of 4 respondent contact attempts improved weighted response rates (35.0%, 46.9%, 52.3%, and 57.6%, respectively). However, the majority of estimates for analyzed variables remained relatively unchanged over additional cycles of recontact.Conclusions:We conclude that additional respondent recontact attempts, especially beyond a single recontact, had little influence on key data distributions, suggesting that these were ineffective in reducing nonresponse bias. Further, the conduct of additional recruitment recontacts was an inefficient means for increasing statistical power. For the conduct of physician surveys, a practice that may in some cases be cost-effective, while also controlling total survey error, is to establish a larger initial sample; to either eliminate nonresponse follow-up or to limit this to one recontact; and to accept a somewhat lower final overall survey response rate. C1 [Willis, Gordon B.] NCI, Bethesda, MD 20892 USA. [Smith, Tenbroeck] Amer Canc Soc Inc, Atlanta, GA USA. [Lee, Hyunshik J.] WESTAT Corp, Rockville, MD 20850 USA. RP Willis, GB (reprint author), NCI, 9609 Med Ctr Dr,Rm 3E358,MSC 9762, Bethesda, MD 20892 USA. EM willisg@mail.nih.gov FU Intramural NIH HHS [Z99 CA999999] NR 15 TC 16 Z9 16 U1 2 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD OCT PY 2013 VL 51 IS 10 BP 945 EP 948 PG 4 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 222SI UT WOS:000324751000014 PM 23969583 ER PT J AU Liu, YX Liu, ST Nacif, MS Sibley, CT Bluemke, DA Summers, RM Yao, JH AF Liu, Yixun Liu, Songtao Nacif, Marcelo S. Sibley, Christopher T. Bluemke, David A. Summers, Ronald M. Yao, Jianhua TI A framework to measure myocardial extracellular volume fraction using dual-phase low dose CT images SO MEDICAL PHYSICS LA English DT Article DE extracellular volume fraction; low dose; cardiac CT; deformable model; modeling ID SEGMENTATION; HEART; FIBROSIS; T1; MR; ENHANCEMENT; RESOLUTION; MODEL AB Purpose: Myocardial extracellular volume fraction (ECVF) is a surrogate imaging biomarker of diffuse myocardial fibrosis, a hallmark of pathologic ventricular remodeling. Low dose cardiac CT is emerging as a promising modality to detect diffuse interstitial myocardial fibrosis due to its fast acquisition and low radiation; however, the insufficient contrast in the low dose CT images poses great challenge to measure ECVF from the image. Methods: To deal with this difficulty, the authors present a complete ECVF measurement framework including a point-guided myocardial modeling, a deformable model-based myocardium segmentation, nonrigid registration of pre- and post-CT, and ECVF calculation. Results: The proposed method was evaluated on 20 patients by two observers. Compared to the manually delineated reference segmentations, the accuracy of our segmentation in terms of true positive volume fraction (TPVF), false positive volume fraction (FPVF), and average surface distance (ASD), were 92.18% +/- 3.52%, 0.31% +/- 0.10%, 0.69 +/- 0.14 mm, respectively. The interobserver variability measured by concordance correlation coefficient regarding TPVF, FPVF, and ASD were 0.95, 0.90, 0.94, respectively, demonstrating excellent agreement. Bland-Altman method showed 95% limits of agreement between ECVF at CT and ECVF at MR. Conclusions: The proposed framework demonstrates its efficiency, accuracy, and noninvasiveness in ECVF measurement and dramatically advances the ECVF at cardiac CT toward its clinical use. (C) 2013 American Association of Physicists in Medicine. C1 [Liu, Yixun; Summers, Ronald M.; Yao, Jianhua] NIH, Clin Image Proc Serv, Ctr Clin, Bethesda, MD 20892 USA. [Liu, Songtao; Nacif, Marcelo S.; Sibley, Christopher T.; Bluemke, David A.] NIH, Ctr Clin, Bethesda, MD 20892 USA. [Liu, Songtao; Sibley, Christopher T.; Bluemke, David A.] Natl Inst Biomed Imaging & Bioengn, Mol Biomed Imaging Lab, NIH, Ctr Clin, Bethesda, MD 20892 USA. RP Yao, JH (reprint author), NIH, Clin Image Proc Serv, Ctr Clin, Bethesda, MD 20892 USA. EM JYao@cc.nih.gov OI Bluemke, David/0000-0002-8323-8086 FU Intramural Research Program of the Clinical Center, National Institutes of Health (NIH); NIH Intramural program FX This research was supported in part by the Intramural Research Program of the Clinical Center, National Institutes of Health (NIH). Funded by the NIH Intramural program. The segmentation method of the proposed framework was accepted at RSNA2012. The software system of the proposed framework was accepted for demonstration in Quantitative Imaging Reading Room (QIRR) at RSNA2012. The authors declare that they have no competing interests. NR 24 TC 0 Z9 0 U1 0 U2 3 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD OCT PY 2013 VL 40 IS 10 AR 103501 DI 10.1118/1.4819936 PG 12 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 231DT UT WOS:000325394400048 PM 24089934 ER PT J AU Xie, TW Bolch, WE Lee, C Zaidi, H AF Xie, Tianwu Bolch, Wesley E. Lee, Choonsik Zaidi, Habib TI Pediatric radiation dosimetry for positron-emitting radionuclides using anthropomorphic phantoms SO MEDICAL PHYSICS LA English DT Article DE radiation dosimetry; PET; Monte Carlo; computational models; pediatrics ID INTERNAL DOSE ASSESSMENT; PERSONAL-COMPUTER SOFTWARE; NUCLEAR-MEDICINE; COMPUTATIONAL PHANTOMS; S-VALUES; NEWBORN PATIENT; VOXEL PHANTOMS; CAMERA IMAGES; HUMAN ANATOMY; UF SERIES AB Purpose: Positron emission tomography (PET) plays an important role in the diagnosis, staging, treatment, and surveillance of clinically localized diseases. Combined PET/CT imaging exhibits significantly higher sensitivity, specificity, and accuracy than conventional imaging when it comes to detecting malignant tumors in children. However, the radiation dose from positron-emitting radionuclide to the pediatric population is a matter of concern since children are at a particularly high risk when exposed to ionizing radiation. Methods: The authors evaluate the absorbed fractions and specific absorbed fractions (SAFs) of monoenergy photons/electrons as well as S-values of 9 positron-emitting radionuclides (C-11, N-13, O-15, F-18, Cu-64, Ga-68, Rb-82, Y-86, and I-124) in 48 source regions for 10 anthropomorphic pediatric hybrid models, including the reference newborn, 1-, 5-, 10-, and 15-yr-old male and female models, using the Monte Carlo N-Particle eXtended general purpose Monte Carlo transport code. Results: The self-absorbed SAFs and S-values for most organs were inversely related to the age and body weight, whereas the cross-dose terms presented less correlation with body weight. For most source/target organ pairs, Rb-82 and Y-86 produce the highest self-absorbed and cross-absorbed S-values, respectively, while Cu-64 produces the lowest S-values because of the low-energy and high-frequency of electron emissions. Most of the total self-absorbed S-values are contributed from non-penetrating particles (electrons and positrons), which have a linear relationship with body weight. The dependence of self-absorbed S-values of the two annihilation photons varies to the reciprocal of 0.76 power of the mass, whereas the self-absorbed S-values of positrons vary according to the reciprocal mass. Conclusions: The produced S-values for common positron-emitting radionuclides can be exploited for the assessment of radiation dose delivered to the pediatric population from various PET radiotracers used in clinical and research settings. The mass scaling method for positron-emitters can be used to derive patient-specific S-values from data of reference phantoms. (C) 2013 American Association of Physicists in Medicine. C1 [Xie, Tianwu; Zaidi, Habib] Univ Hosp Geneva, Div Nucl Med & Mol Imaging, CH-1211 Geneva 4, Switzerland. [Bolch, Wesley E.] Univ Florida, Dept Biomed Engn, Gainesville, FL 32611 USA. [Lee, Choonsik] NCI, Div Canc Epidemiol & Genet, NIH, Rockville, MD 20850 USA. [Zaidi, Habib] Univ Geneva, Geneva Neurosci Ctr, CH-1205 Geneva, Switzerland. [Zaidi, Habib] Univ Groningen, Univ Med Ctr Groningen, Dept Nucl Med & Mol Imaging, NL-9700 RB Groningen, Netherlands. RP Zaidi, H (reprint author), Univ Hosp Geneva, Div Nucl Med & Mol Imaging, CH-1211 Geneva 4, Switzerland. EM habib.zaidi@hcuge.ch FU Swiss National Science Foundation [SNSF 31003A-135576]; Geneva Cancer League FX This work was supported by the Swiss National Science Foundation under Grant No. SNSF 31003A-135576 and the Geneva Cancer League. NR 62 TC 3 Z9 3 U1 0 U2 9 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD OCT PY 2013 VL 40 IS 10 AR 102502 DI 10.1118/1.4819939 PG 14 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 231DT UT WOS:000325394400037 PM 24089923 ER PT J AU Gherardini, FC AF Gherardini, Frank C. TI Borrelia burgdorferi HtrA may promote dissemination and irritation SO MOLECULAR MICROBIOLOGY LA English DT Editorial Material ID HIGH-TEMPERATURE REQUIREMENT; HUMAN ARTICULAR CHONDROCYTES; LYME-DISEASE SPIROCHETE; MYCOBACTERIUM-TUBERCULOSIS; FIBRONECTIN FRAGMENTS; STRESS-RESPONSE; E-CADHERIN; PROTEASE; BINDING; GLYCOSAMINOGLYCAN C1 [Gherardini, Frank C.] NIAID, Lab Zoonot Pathogens, Div Intramural Res, Hamilton, MT 59840 USA. [Gherardini, Frank C.] NIAID, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA. RP Gherardini, FC (reprint author), NIAID, Lab Zoonot Pathogens, Div Intramural Res, Hamilton, MT 59840 USA. EM fgherardini@niaid.nih.gov NR 32 TC 7 Z9 7 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0950-382X EI 1365-2958 J9 MOL MICROBIOL JI Mol. Microbiol. PD OCT PY 2013 VL 90 IS 2 BP 209 EP 213 DI 10.1111/mmi.12390 PG 5 WC Biochemistry & Molecular Biology; Microbiology SC Biochemistry & Molecular Biology; Microbiology GA 232IG UT WOS:000325486100001 PM 23998919 ER PT J AU Altschul, S Demchak, B Durbin, R Gentleman, R Krzywinski, M Li, H Nekrutenko, A Robinson, J Rasband, W Taylor, J Trapnell, C AF Altschul, Stephen Demchak, Barry Durbin, Richard Gentleman, Robert Krzywinski, Martin Li, Heng Nekrutenko, Anton Robinson, James Rasband, Wayne Taylor, James Trapnell, Cole TI The anatomy of successful computational biology software SO NATURE BIOTECHNOLOGY LA English DT Editorial Material AB Creators of software widely used in computational biology discuss the factors that contributed to their success C1 [Altschul, Stephen] Natl Lib Med, Natl Ctr Biotechnol Informat, Bethesda, MD 20894 USA. [Demchak, Barry] Univ Calif San Diego, La Jolla, CA 92093 USA. [Durbin, Richard] Wellcome Trust Sanger Inst, Hinxton, England. [Gentleman, Robert] Genentech Inc, San Francisco, CA USA. [Krzywinski, Martin] British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada. [Li, Heng; Robinson, James] Broad Inst, Cambridge, MA USA. [Nekrutenko, Anton] Penn State Univ, University Pk, PA 16802 USA. [Rasband, Wayne] NIMH, Bethesda, MD 20892 USA. [Taylor, James] Emory Univ, Atlanta, GA 30322 USA. [Trapnell, Cole] Harvard Univ, Cambridge, MA 02138 USA. RP Altschul, S (reprint author), Natl Lib Med, Natl Ctr Biotechnol Informat, Bethesda, MD 20894 USA. RI Tang, Macy/B-9798-2014; Li, Heng/D-9344-2011; Taylor, James/F-1026-2011; OI Li, Heng/0000-0003-4874-2874; Taylor, James/0000-0001-5079-840X; Durbin, Richard/0000-0002-9130-1006; Demchak, Barry/0000-0001-7065-7786; Nekrutenko, Anton/0000-0002-5987-8032 FU Intramural NIH HHS [ZIA LM000072-18]; NIGMS NIH HHS [R01 GM070743] NR 0 TC 8 Z9 8 U1 0 U2 15 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1087-0156 EI 1546-1696 J9 NAT BIOTECHNOL JI Nat. Biotechnol. PD OCT PY 2013 VL 31 IS 10 BP 894 EP 897 DI 10.1038/nbt.2721 PG 4 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA 233CA UT WOS:000325541300017 PM 24104757 ER PT J AU Aguilar-Arnal, L Hakim, O Patel, VR Baldi, P Hager, GL Sassone-Corsi, P AF Aguilar-Arnal, Lorena Hakim, Ofir Patel, Vishal R. Baldi, Pierre Hager, Gordon L. Sassone-Corsi, Paolo TI Cycles in spatial and temporal chromosomal organization driven by the circadian clock SO NATURE STRUCTURAL & MOLECULAR BIOLOGY LA English DT Article ID REGULATORY MOTIF SITES; GENE-EXPRESSION; HUMAN GENOME; DBP TRANSCRIPTION; 3 DIMENSIONS; E-BOX; CHROMATIN; METABOLISM; ARCHITECTURE; MAMMALS AB Dynamic transitions in the epigenome have been associated with regulated patterns of nuclear organization. The accumulating evidence that chromatin remodeling is implicated in circadian function prompted us to explore whether the clock may control nuclear architecture. We applied the chromosome conformation capture on chip technology in mouse embryonic fibroblasts (MEFs) to demonstrate the presence of circadian long-range interactions using the clock-controlled Dbp gene as bait. The circadian genomic interactions with Dbp were highly specific and were absent in MEFs whose clock was disrupted by ablation of the Bmal1 gene (also called Arntl). We establish that the Dbp circadian interactome contains a wide variety of genes and clock-related DNA elements. These findings reveal a previously unappreciated circadian and clock-dependent shaping of the nuclear landscape. C1 [Aguilar-Arnal, Lorena; Sassone-Corsi, Paolo] Univ Calif Irvine, Dept Biol Chem, Ctr Epigenet & Metab, Irvine, CA 92717 USA. [Hakim, Ofir; Hager, Gordon L.] NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA. [Patel, Vishal R.; Baldi, Pierre] Univ Calif Irvine, Dept Comp Sci, Inst Genom & Bioinformat, Irvine, CA USA. RP Sassone-Corsi, P (reprint author), Univ Calif Irvine, Dept Biol Chem, Ctr Epigenet & Metab, Irvine, CA 92717 USA. EM pfbaldi@ics.uci.edu; psc@uci.edu FU European Molecular Biology Organization (EMBO) [ALTF 411-2009]; NIH [R01-GM081634, AG041504, AG033888, LM010235-01A1, 5T15LM007743]; Sirtris Pharmaceuticals [SP-48984]; National Science Foundation [IIS-0513376] FX We thank R. L. Schiltz and T. A. Johnson (NCI, NIH) for assisting with cell culture; R. Orozco-Solis, K. Eckel-Mahan, S. Sahar (Center for Epigenetics and Metabolism, University of California Irvine) and M. Groudine (Fred Hutchinson Cancer Research Center) for critical reading of the manuscript; S. Dilag (Center for Epigenetics and Metabolism, University of California Irvine) for technical support; X. Kong (Department of Biological Chemistry, University of California Irvine) for sharing FISH expertise and reagents; and all the members of the P. S.-C., G. L. H. and P. B. laboratories for discussions. This work was supported in part by the following grants: European Molecular Biology Organization (EMBO) long-term fellowship ALTF 411-2009 (to L. A.-A.), NIH grants R01-GM081634, AG041504 and AG033888 (to P. S.-C.) and Sirtris Pharmaceuticals grant SP-48984 (to P. S.-C.). The work of V. R. P. and P. B. is supported by the following grants: National Science Foundation grant IIS-0513376 and NIH grants LM010235-01A1 and 5T15LM007743 (to P.B.). NR 77 TC 31 Z9 31 U1 1 U2 11 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1545-9993 EI 1545-9985 J9 NAT STRUCT MOL BIOL JI Nat. Struct. Mol. Biol. PD OCT PY 2013 VL 20 IS 10 BP 1206 EP + DI 10.1038/nsmb.2667 PG 10 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 230UV UT WOS:000325369500012 PM 24056944 ER PT J AU Vandevijvere, S Monteiro, C Krebs-Smith, SM Lee, A Swinburn, B Kelly, B Neal, B Snowdon, W Sacks, G AF Vandevijvere, S. Monteiro, C. Krebs-Smith, S. M. Lee, A. Swinburn, B. Kelly, B. Neal, B. Snowdon, W. Sacks, G. CA INFORMAS TI Monitoring and benchmarking population diet quality globally: a step-wise approach SO OBESITY REVIEWS LA English DT Review DE Diet quality; INFORMAS; monitoring; ultra-processed foods ID HEALTHY EATING INDEX; EXPENDITURES SURVEYS HCES; CORONARY-HEART-DISEASE; CARDIOVASCULAR RISK-FACTORS; FOOD BALANCE SHEETS; OUT-OF-HOME; GESTATIONAL DIABETES-MELLITUS; N-3 FATTY-ACIDS; MEDITERRANEAN DIET; NUTRITION TRANSITION AB INFORMAS (International Network for Food and Obesity/non-communicable diseases Research, Monitoring and Action Support) aims to monitor and benchmark the healthiness of food environments globally. In order to assess the impact of food environments on population diets, it is necessary to monitor population diet quality between countries and over time. This paper reviews existing data sources suitable for monitoring population diet quality, and assesses their strengths and limitations. A step-wise framework is then proposed for monitoring population diet quality. Food balance sheets (FBaS), household budget and expenditure surveys (HBES) and food intake surveys are all suitable methods for assessing population diet quality. In the proposed minimal' approach, national trends of food and energy availability can be explored using FBaS. In the expanded' and optimal' approaches, the dietary share of ultra-processed products is measured as an indicator of energy-dense, nutrient-poor diets using HBES and food intake surveys, respectively. In addition, it is proposed that pre-defined diet quality indices are used to score diets, and some of those have been designed for application within all three monitoring approaches. However, in order to enhance the value of global efforts to monitor diet quality, data collection methods and diet quality indicators need further development work. C1 [Vandevijvere, S.; Swinburn, B.] Univ Auckland, Sch Populat Hlth, Auckland 1142, New Zealand. [Monteiro, C.] Univ Sao Paulo, Ctr Epidemiol Studies Hlth & Nutr, BR-05508 Sao Paulo, Brazil. [Krebs-Smith, S. M.] NCI, Bethesda, MD 20892 USA. [Lee, A.] Queensland Univ Technol, Sch Publ Hlth & Social Work, Brisbane, Qld 4001, Australia. [Lee, A.] Queensland Univ Technol, Sch Exercise & Nutr Sci, Brisbane, Qld 4001, Australia. [Swinburn, B.; Snowdon, W.; Sacks, G.] Deakin Univ, WHO Collaborating Ctr Obes Prevent, Burwood, Vic, Australia. [Kelly, B.] Univ Wollongong, Sch Hlth & Soc, Wollongong, NSW, Australia. [Neal, B.] Univ Sydney, George Inst Global Hlth, Sydney, NSW 2006, Australia. [Snowdon, W.] Pacific Res Ctr Prevent Obes & Noncommunicable Di, Suva, Fiji. RP Vandevijvere, S (reprint author), Univ Auckland, Sch Populat Hlth, Private Bag 92019, Auckland 1142, New Zealand. EM s.vandevijvere@auckland.ac.nz RI Monteiro, Carlos/F-9892-2012; OI Lee, Amanda/0000-0001-6887-5426; Sacks, Gary/0000-0001-9736-1539 FU Rockefeller Foundation; International Obesity Taskforce (IOTF); University of Auckland; Deakin University; George Institute, University of Sydney; Queensland University of Technology; University of Oxford; University of Pennsylvania Perelman School of Medicine; World Cancer Research Fund International; University of Toronto; Australian National University; Faculty of Health at Deakin University FX The authors wish to thank Janice Albert and Piero Conforti from the Food and Agricultural Organisation (FAO) for their helpful comments on this paper. The Rockefeller Foundation kindly supported the work of INFORMAS by hosting the first formal meeting of INFORMAS at the Rockefeller Foundation Bellagio Centre, Italy, from 19 to 23 November 2012. The following organizations provided funding support for the travel of participants to Italy for this meeting and the preparation of background research papers: The Rockefeller Foundation, International Obesity Taskforce (IOTF), University of Auckland, Deakin University, The George Institute, University of Sydney, Queensland University of Technology, University of Oxford, University of Pennsylvania Perelman School of Medicine, World Cancer Research Fund International, University of Toronto, The Australian National University. The Faculty of Health at Deakin University kindly supported the costs for open access availability of this paper, and the Australian National Health and Medical Research Council Centre for Research Excellence in Obesity Policy and Food Systems (APP1041020) supported the coordination and finalizing of INFORMAS manuscripts. NR 203 TC 17 Z9 17 U1 0 U2 20 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1467-7881 EI 1467-789X J9 OBES REV JI Obes. Rev. PD OCT PY 2013 VL 14 SU 1 SI SI BP 135 EP 149 DI 10.1111/obr.12082 PG 15 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 226ZJ UT WOS:000325076200012 PM 24074217 ER PT J AU Zinkel, SRJ Moe, M Stern, EA Hubbard, VS Yanovski, SZ Yanovski, JA Schoeller, DA AF Zinkel, S. R. J. Moe, M., III Stern, E. A. Hubbard, V. S. Yanovski, S. Z. Yanovski, J. A. Schoeller, D. A. TI Comparison of total energy expenditure between school and summer months SO PEDIATRIC OBESITY LA English DT Article DE Adolescents; obesity; overweight; seasonal variation; doubly labeled water ID BODY-MASS INDEX; PHYSICAL-ACTIVITY; SEASONAL-VARIATION; YOUNG-CHILDREN; RISK-FACTORS; US CHILDREN; OBESITY; OVERWEIGHT; PREVALENCE; CHILDHOOD AB ObjectiveRecent data report that the youth experience greater weight gain during summer than during school months. We tested the hypothesis that a difference in total energy expenditure (TEE) between school and summer months exists and may contribute to summer weight gain. Subjects and methodsA secondary analysis was performed on cross-sectional TEE data from school-age, sedentary African-American and Caucasian youth based in or near the District of Columbia who were at-risk for adult obesity because they had body mass index (BMI)85th percentile or had overweight parents. TEE was estimated from 18-O and deuterium measurements during 1-week intervals using urine samples collected after ingestion of doubly labelled water. Differences in summer- and school-time TEE were assessed using analysis of covariance. The data were adjusted for fat-free mass (FFM) as determined by deuterium dilution to adjust for the effect of body size on TEE. ResultsData were collected from 162 youth (average age 102 years, BMI 28 +/- 8kgm(-2) and BMIz-score 1.96+0.96). Of these, 96 youth had TEE measured during the school year (September-June); 66 different youths had TEE measured during summer months (June-August). After adjustment for FFM, average summertime TEE was 2450 +/- 270 kcald(-1) and average school-time TEE was 2510 +/- 350 kcald(-1) (P=0.26). ConclusionNo difference in TEE was detected between the school year and the summer months. These data suggest that seasonal differences in youth weight gain are not necessarily due to differences in energy expenditures. C1 [Zinkel, S. R. J.; Moe, M., III; Schoeller, D. A.] Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA. [Stern, E. A.; Yanovski, S. Z.; Yanovski, J. A.] NICHD, Sect Growth & Obes, PREGEN, Hatfield Clin Res Ctr,NIH, Bethesda, MD USA. [Hubbard, V. S.] NIDDK, Div Nutr Res Coordinat, NIH, Bethesda, MD USA. [Yanovski, J. A.] NIDDK, Div Digest Dis & Nutr, NIH, Bethesda, MD USA. RP Schoeller, DA (reprint author), 1415 Linden Dr, Madison, WI 53706 USA. EM dschoell@nutrisci.wisc.edu OI Yanovski, Jack/0000-0001-8542-1637 FU NIH: NICHD; NIH: NIDDK; NIH: NIMHD; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Center on Minority Health and Health Disparities of the National Institutes of Health; National Institutes of Diabetes and Digestive and Kidney Diseases [T32DK007665] FX This research was supported in part by the Intramural and Extramural Research Programs of the NIH: NICHD, NIDDK, and NIMHD. Dr. J. Yanovski is a Commissioned Officer in the United States Public Health Service and is supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Center on Minority Health and Health Disparities of the National Institutes of Health. S. Zinkel was supported by training grant T32DK007665 from the National Institutes of Diabetes and Digestive and Kidney Diseases. The National Institute of Diabetes and Digestive and Kidney Diseases had no role in the preparation, review or approval of the manuscript. NR 31 TC 7 Z9 7 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-6310 EI 2047-6302 J9 PEDIATR OBES JI Pediatr. Obes. PD OCT PY 2013 VL 8 IS 5 BP 404 EP 410 DI 10.1111/j.2047-6310.2012.00120.x PG 7 WC Pediatrics SC Pediatrics GA 218VY UT WOS:000324461800012 PM 23637099 ER PT J AU Sherafat-Kazemzadeh, R Ivey, L Kahn, SR Sapp, JC Hicks, MD Kim, RC Krause, AJ Shomaker, LB Biesecker, LG Han, JC Yanovski, JA AF Sherafat-Kazemzadeh, R. Ivey, L. Kahn, S. R. Sapp, J. C. Hicks, M. D. Kim, R. C. Krause, A. J. Shomaker, L. B. Biesecker, L. G. Han, J. C. Yanovski, J. A. TI Hyperphagia among patients with Bardet-Biedl syndrome SO PEDIATRIC OBESITY LA English DT Article DE Bardet-Biedl syndrome; hyperphagia; obesity syndromes; polyphagia ID PRADER-WILLI-SYNDROME; OBESITY; MUTATION AB BackgroundThe importance of hyperphagia as a cause for energy imbalance in humans with Bardet-Biedl syndrome (BBS) has not been established. We therefore compared hyperphagic symptoms in patients with BBS vs. controls. Methods:We studied 13 patients with BBS and 23 non-syndromic controls with similar age, sex and body mass index (BMI) z-score. A 13-item hyperphagia questionnaire was completed by patients' parents/guardians. ResultsTotal hyperphagia questionnaire score was higher in BBS than controls (27.69.0 vs. 19.1 +/- 7.9, P=0.005). Behaviour and drive subscales were higher for BBS than controls (12.5 +/- 4.1 vs. 7.8 +/- 3.2, P=0.001, and 11.2 +/- 4.1 vs. 8.3 +/- 3.8, P=0.04, respectively); severity was not significantly different between groups (3.8 +/- 1.5 vs. 3.0 +/- 1.3, P=0.072). After adjustment for demographic variables and BMI z-score, total and behaviour subscale scores remained significantly different between groups, suggesting food-seeking activity, rather than preoccupation with food may be the main hyperphagic feature among patients with BBS. ConclusionAppetite dysregulation may contribute to obesity in BBS. C1 [Sherafat-Kazemzadeh, R.; Kahn, S. R.; Hicks, M. D.; Kim, R. C.; Krause, A. J.; Shomaker, L. B.; Han, J. C.; Yanovski, J. A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, SGO, Program Dev Endocrinol & Genet PDEGEN, NIH,DHHS, Bethesda, MD USA. [Ivey, L.; Sapp, J. C.; Biesecker, L. G.] NHGRI, Human Dev Sect, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA. [Hicks, M. D.; Kim, R. C.; Han, J. C.] NICHD, Unit Metab & Neuroendocrinol, SGO, PDEGEN,NIH,DHHS, Bethesda, MD 20892 USA. RP Yanovski, JA (reprint author), NICHD, Sect Growth & Obes, Program Dev Endocrinol & Genet, NIH,Hatfield Clin Res Ctr, 10 Ctr Dr,Room 1E 3330,MSC 1103, Bethesda, MD 20892 USA. EM jy15i@nih.gov OI Yanovski, Jack/0000-0001-8542-1637 FU NICHD; NHGRI, NIH FX This research was supported by the Intramural Research Programs of the NICHD, and NHGRI, NIH. J.A.Y. is a Commissioned Officer in the U. S. Public Health Service, Department of Health and Human Services. The funding organizations played no role in the design and conduct of the study; the collection, management, analysis, and interpretation of data; or the preparation or review of the manuscript. NR 20 TC 3 Z9 3 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-6310 EI 2047-6302 J9 PEDIATR OBES JI Pediatr. Obes. PD OCT PY 2013 VL 8 IS 5 BP E64 EP E67 DI 10.1111/j.2047-6310.2013.00182.x PG 4 WC Pediatrics SC Pediatrics GA 218VY UT WOS:000324461800004 PM 23776152 ER PT J AU Bornstein, MH Hahn, CS Suwalsky, JTD AF Bornstein, Marc H. Hahn, Chun-Shin Suwalsky, Joan T. D. TI Physically Developed and Exploratory Young Infants Contribute to Their Own Long-Term Academic Achievement SO PSYCHOLOGICAL SCIENCE LA English DT Article DE academic achievement; adolescent development; cognitive development; infant development ID FIT INDEXES; 3-MONTH-OLD INFANTS; PERCEPTION; MOTOR; CHILDHOOD; ATTENTION; CASCADES; BEHAVIOR; SYSTEMS; SKILLS AB A developmental cascade defines a longitudinal relation in which one psychological characteristic uniquely affects another psychological characteristic later in time, separately from other intrapersonal and extrapersonal factors. Here, we report results of a large-scale (N = 374), normative, prospective, 14-year longitudinal, multivariate, multisource, controlled study of a developmental cascade from infant motor-exploratory competence at 5 months to adolescent academic achievement at 14 years, through conceptually related and age-appropriate measures of psychometric intelligence at 4 and 10 years and academic achievement at 10 years. This developmental cascade applied equally to girls and boys and was independent of children's behavioral adjustment and social competence; mothers' supportive caregiving, verbal intelligence, education, and parenting knowledge; and the material home environment. Infants who were more motorically mature and who explored more actively at 5 months of age achieved higher academic levels as 14-year-olds. RP Bornstein, MH (reprint author), NICHHD, 6705 Rockledge Dr,Suite 8030, Bethesda, MD 20892 USA. EM Marc_H_Bornstein@nih.gov FU Intramural NIH HHS [ZIA HD001119-26] NR 47 TC 24 Z9 24 U1 1 U2 27 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0956-7976 EI 1467-9280 J9 PSYCHOL SCI JI Psychol. Sci. PD OCT PY 2013 VL 24 IS 10 BP 1906 EP 1917 DI 10.1177/0956797613479974 PG 12 WC Psychology, Multidisciplinary SC Psychology GA 233GC UT WOS:000325554800004 PM 23964000 ER PT J AU Lomax, GP Hull, SC Lowenthal, J Rao, M Isasi, R AF Lomax, Geoffrey P. Hull, Sara Chandros Lowenthal, Justin Rao, Mahendra Isasi, Rosario TI The DISCUSS Project: Induced Pluripotent Stem Cell Lines From Previously Collected Research Biospecimens and Informed Consent: Points to Consider SO STEM CELLS TRANSLATIONAL MEDICINE LA English DT Article AB Human somatic cell reprogramming is a leading technology for accelerating disease modeling and drug discovery. Research organizations are sponsoring initiatives to create libraries of induced pluripotent stem cell (iPSC) lines for broad distribution and application. Donor informed consent plays a critical role in supporting the ethical conduct of iPSC research. To date, our organizations have focused on informed consent considerations for somatic cell collection intended specifically for iPSC derivation and distribution. This article considers how somatic cells obtained under general (biomedical) research protocols can be used for iPSC derivation. We present draft Points to Consider regarding the use of human somatic cells for iPSC research. Our goal is to initiate a process designed to develop consensus for the use of previously collected specimens for iPSC research. We anticipate publishing final considerations in early 2014. C1 [Lomax, Geoffrey P.] Calif Inst Regenerat Med, San Francisco, CA USA. [Hull, Sara Chandros] NHGRI, NIH, Off Clin Director, Bethesda, MD 20892 USA. [Hull, Sara Chandros; Lowenthal, Justin] NIH, Ctr Clin, Dept Bioeth, Bethesda, MD 20892 USA. [Rao, Mahendra] NIH, Ctr Regenerat Med, Bethesda, MD 20892 USA. [Rao, Mahendra] NIAMSD, NIH, Lab Stem Cell Biol, Bethesda, MD 20892 USA. [Isasi, Rosario] McGill Univ, Fac Med, Ctr Genom & Policy, Dept Human Genet, Montreal, PQ, Canada. RP Lomax, GP (reprint author), 210 King St, San Francisco, CA 94107 USA. EM glomax@cirm.ca.gov OI Lowenthal, Justin/0000-0001-5909-0520 NR 11 TC 8 Z9 8 U1 0 U2 7 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 2157-6564 EI 2157-6580 J9 STEM CELL TRANSL MED JI Stem Cells Transl. Med. PD OCT PY 2013 VL 2 IS 10 BP 727 EP 730 DI 10.5966/sctm.2013-0099 PG 4 WC Cell & Tissue Engineering SC Cell Biology GA 231AE UT WOS:000325384600007 PM 23990574 ER PT J AU Gutova, M Frank, JA D'Apuzzo, M Khankaldyyan, V Gilchrist, MM Annala, AJ Metz, MZ Abramyants, Y Herrmann, KA Ghoda, LY Najbauer, J Brown, CE Blanchard, MS Lesniak, MS Kim, SU Barish, ME Aboody, KS Moats, RA AF Gutova, Margarita Frank, Joseph A. D'Apuzzo, Massimo Khankaldyyan, Vazgen Gilchrist, Megan M. Annala, Alexander J. Metz, Marianne Z. Abramyants, Yelena Herrmann, Kelsey A. Ghoda, Lucy Y. Najbauer, Joseph Brown, Christine E. Blanchard, M. Suzette Lesniak, Maciej S. Kim, Seung U. Barish, Michael E. Aboody, Karen S. Moats, Rex A. TI Magnetic Resonance Imaging Tracking of Ferumoxytol-Labeled Human Neural Stem Cells: Studies Leading to Clinical Use SO STEM CELLS TRANSLATIONAL MEDICINE LA English DT Article DE Cell transplantation; Cellular therapy; Clinical trials; In vivo tracking; Neural stem cell; Stem cell; Stem cell transplantation ID SUPERPARAMAGNETIC IRON-OXIDE; SOLID TUMORS; NANOPARTICLES; RECEPTOR; BRAIN; MRI; PROTAMINE; TOXICITY; DELIVERY; THERAPY AB Numerous stem cell-based therapies are currently under clinical investigation, including the use of neural stem cells (NSCs) as delivery vehicles to target therapeutic agents to invasive brain tumors. The ability to monitor the time course, migration, and distribution of stem cells following transplantation into patients would provide critical information for optimizing treatment regimens. No effective cell-tracking methodology has yet garnered clinical acceptance. A highly promising noninvasive method for monitoring NSCs and potentially other cell types in vivo involves preloading them with ultrasmall superparamagnetic iron oxide nanoparticles (USPIOs) to enable cell tracking using magnetic resonance imaging (MRI). We report here the preclinical studies that led to U.S. Food and Drug Administration approval for first-in-human investigational use of ferumoxytol to label NSCs prior to transplantation into brain tumor patients, followed by surveillance serial MRI. A combination of heparin, protamine sulfate, and ferumoxytol (HPF) was used to label the NSCs. HPF labeling did not affect cell viability, growth kinetics, or tumor tropism in vitro, and it enabled MRI visualization of NSC distribution within orthotopic glioma xenografts. MRI revealed dynamic in vivo NSC distribution at multiple time points following intracerebral or intravenous injection into glioma-bearing mice that correlated with histological analysis. Preclinical safety/toxicity studies of intracerebrally administered HPF-labeled NSCs in mice were also performed, and they showed no significant clinical or behavioral changes, no neuronal or systemic toxicities, and no abnormal accumulation of iron in the liver or spleen. These studies support the clinical use of ferumoxytol labeling of cells for post-transplant MRI visualization and tracking. C1 [Gutova, Margarita; Gilchrist, Megan M.; Annala, Alexander J.; Metz, Marianne Z.; Abramyants, Yelena; Herrmann, Kelsey A.; Ghoda, Lucy Y.; Najbauer, Joseph; Barish, Michael E.; Aboody, Karen S.] City Hope Natl Med Ctr, Dept Neurosci, Duarte, CA 91010 USA. [D'Apuzzo, Massimo] City Hope Natl Med Ctr, Dept Pathol, Duarte, CA 91010 USA. [Brown, Christine E.] City Hope Natl Med Ctr, Dept Canc Immunotherapy & Tumor Immunol, Duarte, CA 91010 USA. [Blanchard, M. Suzette] City Hope Natl Med Ctr, Dept Informat Sci, Duarte, CA 91010 USA. [Aboody, Karen S.] City Hope Natl Med Ctr, Div Neurosurg, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA. [Frank, Joseph A.] Ctr Clin, Frank Lab Radiol & Imaging Sci, Bethesda, MD USA. [Frank, Joseph A.] Natl Inst Biomed Imaging & Bioengn, NIH, Bethesda, MD USA. [Khankaldyyan, Vazgen; Moats, Rex A.] Univ So Calif, Keck Sch Med, CHLA, Dept Radiol, Los Angeles, CA 90033 USA. [Khankaldyyan, Vazgen; Moats, Rex A.] Univ So Calif, Keck Sch Med, CHLA, Dept Pathol, Los Angeles, CA 90033 USA. [Khankaldyyan, Vazgen; Moats, Rex A.] Univ So Calif, Keck Sch Med, CHLA, Dept Biomed Engn, Los Angeles, CA 90033 USA. [Lesniak, Maciej S.] Univ Chicago, Pritzker Sch Med, Brain Tumor Ctr, Chicago, IL 60637 USA. [Kim, Seung U.] Univ British Columbia, Dept Med, Div Neurol, UBC Hosp, Vancouver, BC, Canada. RP Moats, RA (reprint author), Dept Radiol, 4650 Sunset Blvd, Los Angeles, CA 90027 USA. EM kaboody@coh.org; RMoats@chla.usc.edu RI Moats, Rex/F-5995-2015 FU Naval Research Grant [N00014-02-1 0958]; California Institute for Regenerative Medicine [DR1-01421]; NIH/National Institute of Neurological Disorders and Stroke [U01 NS069997]; NIH/National Cancer Institute [P30-CA033572]; Rosalinde and Arthur Gilbert Foundation; STOP Cancer FX We acknowledge the technical support of Elizabeth Garcia, Soraya Aramburo, and Valerie V. Valenzuela; the technical expertise and advice of Sofia Loera of the Pathology Core and Drs. Marcia Miller and Zhuo Li in the Electron Microscopy Core (supported by funding from Naval Research Grant N00014-02-1 0958); and the editorial assistance of Dr. Keely L. Walker (City of Hope). We thank Catherine Matsumoto and Katherine Furness of the Office of IND Development and Research Affairs (City of Hope) for their assistance with preparation of the IND amendment to the FDA. We also thank the Imaging Group at CHLA especially Gevorg Karapetyan, Ira Harutyunyan, Anahit Hovsepyan, and Seda Mkhitaryan. This work was supported by funding from the California Institute for Regenerative Medicine (DR1-01421), NIH/National Institute of Neurological Disorders and Stroke (U01 NS069997), NIH/National Cancer Institute (P30-CA033572), the Rosalinde and Arthur Gilbert Foundation, and STOP Cancer. NR 42 TC 34 Z9 37 U1 2 U2 36 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 2157-6564 EI 2157-6580 J9 STEM CELL TRANSL MED JI Stem Cells Transl. Med. PD OCT PY 2013 VL 2 IS 10 BP 766 EP 775 DI 10.5966/sctm.2013-0049 PG 10 WC Cell & Tissue Engineering SC Cell Biology GA 231AE UT WOS:000325384600011 PM 24014682 ER PT J AU Clore, GM Venditti, V AF Clore, G. Marius Venditti, Vincenzo TI Structure, dynamics and biophysics of the cytoplasmic protein-protein complexes of the bacterial phosphoenolpyruvate: sugar phosphotransferase system SO TRENDS IN BIOCHEMICAL SCIENCES LA English DT Review DE signal transduction; protein-protein recognition; bacterial phosphotransferase system; NMR spectroscopy; hybrid methods in structure determination; residual dipolar couplings; solution X-ray scattering; sparsely populated states; encounter complexes ID PHOSPHORYL TRANSFER COMPLEX; RESIDUAL DIPOLAR COUPLINGS; PARAMAGNETIC RELAXATION ENHANCEMENT; MANNITOL TRANSPORTER IIMANNITOL; N-TERMINAL DOMAIN; X-RAY-SCATTERING; TRANSIENT ENCOUNTER COMPLEXES; RESTRAINED MOLECULAR-DYNAMICS; HIGH-RESOLUTION STRUCTURE; COLI GLUCOSE-TRANSPORTER AB The bacterial phosphotransferase system (PTS) couples phosphoryl transfer, via a series of bimolecular protein-protein interactions, to sugar transport across the membrane. The multitude of complexes in the PTS provides a paradigm for studying protein interactions, and for understanding how the same binding surface can specifically recognize a diverse array of targets. Fifteen years of work aimed at solving the solution structures of all soluble protein-protein complexes of the PTS has served as a test bed for developing NMR and integrated hybrid approaches to study larger complexes in solution and to probe transient, spectroscopically invisible states, including encounter complexes. We review these approaches, highlighting the problems that can be tackled with these methods, and summarize the current findings on protein interactions. C1 [Clore, G. Marius; Venditti, Vincenzo] NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA. RP Clore, GM (reprint author), NIDDK, Chem Phys Lab, NIH, Bldg 2, Bethesda, MD 20892 USA. EM mariusc@mail.nih.gov RI Clore, G. Marius/A-3511-2008 OI Clore, G. Marius/0000-0003-3809-1027 FU Intramural Program of the NIH, NIDDK; Intramural AIDS Targeted Antiviral Program of the Office of the Director of the NIH FX G.M.C. thanks members of his laboratory, past and present, and colleagues who have made major contributions to the work on complexes of the PTS, in particular, D. Garrett, M. Cai, G. Wang, G. Cornilescu, D. Williams, J. Hu, K Hu, J-Y. Suh, Y-S. Jung, C. Tang, J. Iwahara, Y. Takayama, A. Grishaev, and C. Schwieters. This work was supported by funds from the Intramural Program of the NIH, NIDDK, and the Intramural AIDS Targeted Antiviral Program of the Office of the Director of the NIH (to G.M.C.). NR 100 TC 13 Z9 13 U1 0 U2 27 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0968-0004 J9 TRENDS BIOCHEM SCI JI Trends Biochem.Sci. PD OCT PY 2013 VL 38 IS 10 BP 515 EP 530 DI 10.1016/j.tibs.2013.08.003 PG 16 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 233VG UT WOS:000325597000006 PM 24055245 ER PT J AU Yaniv, Y Juhaszova, M Sollott, SJ AF Yaniv, Yael Juhaszova, Magdalena Sollott, Steven J. TI Age-related changes of myocardial ATP supply and demand mechanisms SO TRENDS IN ENDOCRINOLOGY AND METABOLISM LA English DT Review DE aging; cardiac work; bioenergetics; mitochondria; respiration ID RAT-HEART MITOCHONDRIA; OXIDATIVE-PHOSPHORYLATION; SUBSTRATE METABOLISM; CARDIAC MITOCHONDRIA; ESSENTIAL COMPONENT; DIASTOLIC FUNCTION; RESPIRATORY-CHAIN; LIPID-COMPOSITION; SKELETAL-MUSCLE; LEFT-VENTRICLE AB In advanced age, the resting myocardial oxygen consumption rate (MVO2) and cardiac work (CW) in the rat remain intact. However, MVO2, CW and cardiac efficiency achieved at high demand are decreased with age, compared to maximal values in the young. Whether this deterioration is due to decrease in myocardial ATP demand, ATP supply, or the control mechanisms that match them remains controversial Here we discuss evolving perspectives of age-related changes of myocardial ATP supply and demand mechanisms, and critique experimental models used to investigate aging. Specifically, we evaluate experimental data collected at the level of isolated mitochondria, tissue, or organism, and discuss how mitochondrial energetic mechanisms change in advanced age, both at basal and high energy-demand levels. C1 [Yaniv, Yael; Juhaszova, Magdalena; Sollott, Steven J.] NIA, Cardiovasc Sci Lab, Biomed Res Ctr, Intramural Res Program,NIH, Baltimore, MD 21224 USA. RP Sollott, SJ (reprint author), NIA, Cardiovasc Sci Lab, Biomed Res Ctr, Intramural Res Program,NIH, Baltimore, MD 21224 USA. EM sollotts@mail.nih.gov RI Yaniv, Yael/B-3311-2015 OI Yaniv, Yael/0000-0002-5183-6284 FU Intramural Research Program of the National Institute on Aging, National Institutes of Health FX We thank Dr Edward G. Lakatta for useful discussions. This work was supported entirely by the Intramural Research Program of the National Institute on Aging, National Institutes of Health. NR 93 TC 9 Z9 9 U1 1 U2 7 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1043-2760 J9 TRENDS ENDOCRIN MET JI Trends Endocrinol. Metab. PD OCT PY 2013 VL 24 IS 10 BP 495 EP 505 DI 10.1016/j.tem.2013.06.001 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 233RY UT WOS:000325588400003 PM 23845538 ER PT J AU Svatek, RS Rosenberg, JE Galsky, MD Lee, CT Latini, DM Bochner, BH Weizer, AZ Apolo, AB Sridhar, SS Kamat, AM Hansel, D Flaig, TW Smith, ND Lotan, Y AF Svatek, Robert S. Rosenberg, Jonathan E. Galsky, Matthew D. Lee, Cheryl T. Latini, David M. Bochner, Bernard H. Weizer, Alon Z. Apolo, Andrea B. Sridhar, Srikala S. Kamat, Ashish M. Hansel, Donna Flaig, Thomas W. Smith, Norm D. Lotan, Yair TI Summary of the 6th annual bladder cancer think tank: New directions in urologic research SO UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS LA English DT Review AB The 6th Annual Bladder Cancer Think Tank brought together a multidisciplinary group of clinicians, researchers, and representatives from the National Cancer Institute and Industry in an effort to advance bladder cancer research efforts. This year's meeting comprised panel discussions and research involving 5 separate working groups, including the Survivorship, Clinical Trials, Standardization of Care, Data Mining, and Translational Science working groups. In this manuscript, the accomplishments and objectives of the working groups are summarized. Notable efforts include: (1) the development of a survivorship care plan for early and late-stage bladder cancer; (2) the development of consensus criteria for eligibility and endpoints for bladder cancer clinical trials; (3) an improved understanding of current practice patterns regarding the use of perioperative chemotherapy in an effort to standardize care; (4) creation of a comprehensive handbook to assist researchers with developing bladder cancer databases; and (5) identification of response to therapy of high-grade non muscle invasive disease through a collaborative exchange of expertise and resources. (C) 2013 Elsevier Inc. All rights reserved. C1 [Svatek, Robert S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA. [Rosenberg, Jonathan E.] Harvard Univ, Sch Med, Lank Ctr Genitourinary Oncol, Boston, MA 02215 USA. [Galsky, Matthew D.] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY 10029 USA. [Lee, Cheryl T.; Weizer, Alon Z.] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA. [Latini, David M.] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA. [Bochner, Bernard H.] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10065 USA. [Apolo, Andrea B.] NCI, Med Oncol Branch & Affiliates, Bethesda, MD 20892 USA. [Sridhar, Srikala S.] Univ Toronto, Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada. [Kamat, Ashish M.] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA. [Hansel, Donna] Cleveland Clin, Dept Pathol, Cleveland, OH 44195 USA. [Flaig, Thomas W.] Univ Colorado, Sch Med, Div Med Oncol, Aurora, CO 80045 USA. [Smith, Norm D.] Univ Chicago, Dept Urol, Chicago, IL 60637 USA. [Lotan, Yair] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA. RP Lotan, Y (reprint author), Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA. EM yair.lotan@utsouthwestern.edu OI Latini, David/0000-0002-6161-4861 NR 3 TC 3 Z9 3 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1078-1439 EI 1873-2496 J9 UROL ONCOL-SEMIN ORI JI Urol. Oncol.-Semin. Orig. Investig. PD OCT PY 2013 VL 31 IS 7 BP 968 EP 973 DI 10.1016/j.urolonc.2011.12.017 PG 6 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA 234SJ UT WOS:000325664300003 PM 22300756 ER PT J AU Lambert, PF McBride, A Bernard, HU AF Lambert, Paul F. McBride, Alison Bernard, Hans Ulrich TI Special issue: The Papillomavirus Episteme SO VIROLOGY LA English DT Editorial Material C1 [Lambert, Paul F.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA. [McBride, Alison] NIH, Bethesda, MD USA. [Bernard, Hans Ulrich] Univ Calif Irvine, Irvine, CA USA. RP Lambert, PF (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, 1400 Univ Ave, Madison, WI 53706 USA. EM plambert@wisc.edu OI McBride, Alison/0000-0001-5607-5157 NR 0 TC 1 Z9 1 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD OCT PY 2013 VL 445 IS 1-2 BP 1 EP 1 DI 10.1016/j.virol.2013.07.017 PG 1 WC Virology SC Virology GA 229YY UT WOS:000325305000001 ER PT J AU Van Doorslaer, K AF Van Doorslaer, Koenraad TI Evolution of the Papillomaviridae SO VIROLOGY LA English DT Article DE Papillomayiridae; Co-evolution; Evolution; Niche adaptation; Recombination; Codon usage; Mutation rate ID HUMAN ALPHA-PAPILLOMAVIRUS; CODON USAGE BIAS; HPV E6 PROTEINS; PHYLOGENETIC ANALYSIS; DIVERSIFYING SELECTION; MOLECULAR EVOLUTION; DNA VIRUSES; RISK CLASSIFICATION; TUMOR-SUPPRESSOR; P53 DEGRADATION AB Viruses belonging to the Papillomaviridae family have been isolated from a variety of mammals, birds and non-avian reptiles. It is likely that most, if not all, amniotes carry a broad array of viral types. To date, the complete genomic sequence of more than 240 distinct viral types has been characterized at the nucleotide level. The analysis of this sequence information has begun to shed light on the evolutionary history of this important virus family. The available data suggests that many different evolutionary mechanisms have influenced the papillomavirus phylogenetic tree. Increasing evidence supports that the ancestral papillomavirus initially specialized to infect different ecological niches on the host. This episode of niche sorting was followed by extensive episodes of co-speciation with the host. This review attempts to summarize our current understanding of the papillomavirus evolution. Published by Elsevier Inc. C1 NIAID, DNA Tumor Virus Sect, Viral Dis Lab, NIH, Bethesda, MD USA. RP Van Doorslaer, K (reprint author), NIAID, DNA Tumor Virus Sect, Viral Dis Lab, NIH, Bethesda, MD USA. EM Koenraad.vandoorslaer@nih.gov OI Van Doorslaer, Koenraad/0000-0002-2985-0733 FU Intramural Research Program of the NIH, NIAID FX I am grateful to Drs. McBride, Khan and Heslin for critical reading of the manuscript. The author's research is supported by the Intramural Research Program of the NIH, NIAID. NR 100 TC 26 Z9 26 U1 3 U2 30 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD OCT PY 2013 VL 445 IS 1-2 BP 11 EP 20 DI 10.1016/j.viro1.2013.05.012 PG 10 WC Virology SC Virology GA 229YY UT WOS:000325305000003 PM 23769415 ER PT J AU McBride, AA AF McBride, Alison A. TI The Papillomavirus E2 proteins SO VIROLOGY LA English DT Article DE HPV; Papillomavirus; E2; Replication; Transcription; Tethering; Genomics; Structure; Mutation ID DNA-BINDING DOMAIN; CERVICAL-CARCINOMA CELLS; COTTONTAIL RABBIT PAPILLOMAVIRUS; TRANSCRIPTIONAL ACTIVATION FUNCTION; HPV18 REGULATORY REGION; CARBOXY-TERMINAL DOMAIN; E1 REPLICATION PROTEIN; TYPE-8 LATE PROMOTER; HIGH-COPY-NUMBER; BOVINE PAPILLOMAVIRUS AB The papillomavirus E2 proteins are pivotal to the viral life cycle and have well characterized functions in transcriptional regulation, initiation of DNA replication and partitioning the viral genome. The E2 proteins also function in vegetative DNA replication, post-transcriptional processes and possibly packaging. This review describes structural and functional aspects of the E2 proteins and their binding sites on the viral genome. It is intended to be a reference guide to this viral protein. Published by Elsevier Inc. C1 [McBride, Alison A.] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA. RP McBride, AA (reprint author), Room 3W20B4,Bldg 33,33 North Dr, Bethesda, MD 20892 USA. EM amcbride@nih.gov OI McBride, Alison/0000-0001-5607-5157 FU Intramural Research Program of the NIAID, NIH. FX I am grateful to Koenraad van Doorslaer for critical reading of the manuscript. I apologize to authors whose work I have omitted because of space constraints. This work was funded by the Intramural Research Program of the NIAID, NIH. NR 291 TC 63 Z9 64 U1 1 U2 27 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD OCT PY 2013 VL 445 IS 1-2 BP 57 EP 79 DI 10.1016/j.viro1.2013.06.006 PG 23 WC Virology SC Virology GA 229YY UT WOS:000325305000006 PM 23849793 ER PT J AU Buck, CB Day, PM Trus, BL AF Buck, Christopher B. Day, Patricia M. Trus, Benes L. TI The papillomavirus major capsid protein L1 SO VIROLOGY LA English DT Article DE HPV; HPV16; Virion; Papillomaviridae; L2; Maturation ID VIRUS-LIKE PARTICLES; SURFACE HEPARAN-SULFATE; NUCLEAR IMPORT; HPV16 L1; MONOCLONAL-ANTIBODIES; HUMAN KERATINOCYTES; DNA-BINDING; IN-VIVO; INFECTION; TYPE-16 AB The elegant icosahedral surface of the papillomavirus virion is formed by a single protein called Ll. Recombinant Ll proteins can spontaneously self-assemble into a highly immunogenic structure that closely mimics the natural surface of native papillomavirus virions. This has served as the basis for two highly successful vaccines against cancer-causing human papillomaviruses (HPVs). During the viral life cycle, the capsid must undergo a variety of conformational changes, allowing key functions including the encapsidation of the similar to 8 kb viral genomic DNA, maturation into a more stable state to survive transit between hosts, mediating attachment to new host cells, and finally releasing the viral DNA into the newly infected host cell. This brief review focuses on conserved sequence and structural features that underlie the functions of this remarkable protein. (C) 2013 Elsevier Inc. All rights reserved. C1 [Buck, Christopher B.; Day, Patricia M.] NCI, Cellular Oncol Lab, Ctr Canc Res, Bethesda, MD 20892 USA. [Trus, Benes L.] NIH, Imaging Sci Lab, Ctr Informat Technol, Bethesda, MD 20892 USA. RP Buck, CB (reprint author), NCI, Cellular Oncol Lab, Ctr Canc Res, Bldg 37,Room 4118,9000 Rockville Pike, Bethesda, MD 20892 USA. EM buckc@mail.nih.gov RI Kim, Seongman/N-6910-2014; OI Buck, Christopher/0000-0003-3165-8094 FU Intramural Research Program of the NIH; Center for Information Technology (CIT); National Cancer Institute's Center for Cancer Research; National Institute of Arthritis, Musculoskeletal and Skin Diseases FX This research was supported in part by the Intramural Research Program of the NIH, the Center for Information Technology (CIT), the National Cancer Institute's Center for Cancer Research, and the National Institute of Arthritis, Musculoskeletal and Skin Diseases. The authors are grateful to Alasdair Steven and Naiqian Cheng for their work on the HPV16 capsid structure shown in Fig. 1 and to Tom Magaldi for assistance in rendering the structures shown in Fig. 2. NR 69 TC 30 Z9 30 U1 3 U2 19 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD OCT PY 2013 VL 445 IS 1-2 BP 169 EP 174 DI 10.1016/j.virol.2013.05.038 PG 6 WC Virology SC Virology GA 229YY UT WOS:000325305000011 PM 23800545 ER PT J AU Zajicek, A Fossler, MJ Barrett, JS Worthington, JH Ternik, R Charkoftaki, G Lum, S Breitkreutz, J Baltezor, M Macheras, P Khan, M Agharkar, S MacLaren, DD AF Zajicek, Anne Fossler, Michael J. Barrett, Jeffrey S. Worthington, Jeffrey H. Ternik, Robert Charkoftaki, Georgia Lum, Susan Breitkreutz, Joerg Baltezor, Mike Macheras, Panos Khan, Mansoor Agharkar, Shreeram MacLaren, David Douglas TI A Report from the Pediatric Formulations Task Force: Perspectives on the State of Child-Friendly Oral Dosage Forms SO AAPS JOURNAL LA English DT Editorial Material DE children; drugs; formulations; manufacturing; palatability; pediatrics; regulatory ID BIOPHARMACEUTICS CLASSIFICATION-SYSTEM; ELECTRONIC TONGUE; DOSING ACCURACY; YOUNG-CHILDREN; DRUGS; SUSPENSIONS; ADHERENCE; SELECTION; DELIVERY; DEVICES AB Despite the fact that a significant percentage of the population is unable to swallow tablets and capsules, these dosage forms continue to be the default standard. These oral formulations fail many patients, especially children, because of large tablet or capsule size, poor palatability, and lack of correct dosage strength. The clinical result is often lack of adherence and therapeutic failure. The American Association of Pharmaceutical Scientists formed a Pediatric Formulations Task Force, consisting of members with various areas of expertise including pediatrics, formulation development, clinical pharmacology, and regulatory science, in order to identify pediatric, manufacturing, and regulatory issues and areas of needed research and regulatory guidance. Dosage form and palatability standards for all pediatric ages, relative bioavailability requirements, and small batch manufacturing capabilities and creation of a viable economic model were identified as particular needs. This assessment is considered an important first step for a task force seeking creative approaches to providing more appropriate oral formulations for children. C1 [Zajicek, Anne] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA. [Fossler, Michael J.] GlaxoSmithKline, Clin Pharmacol Modeling & Simulat, King Of Prussia, PA USA. [Barrett, Jeffrey S.] Childrens Hosp Philadelphia, Clin Pharmacol & Therapeut Div, Philadelphia, PA 19104 USA. [Worthington, Jeffrey H.] Senopsys LLC, Woburn, MA USA. [Ternik, Robert] Eli Lilly & Co, Small Mol Design & Dev, Indianapolis, IN 46285 USA. [Charkoftaki, Georgia; Macheras, Panos] Univ Athens, Fac Pharm, Lab Biopharmaceut & Pharmacokinet, Athens 11528, Greece. [Lum, Susan] Hlth Canada, Bur Pharmaceut Sci, Therapeut Prod Directorate, Ottawa, ON K1A 0L2, Canada. [Breitkreutz, Joerg] Univ Dusseldorf, Inst Pharmaceut & Biopharmaceut, D-40225 Dusseldorf, Germany. [Baltezor, Mike] Univ Kansas, Inst Adv Med Innovat, Biotechnol Innovat & Optimizat Ctr, Lawrence, KS 66045 USA. [Khan, Mansoor] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA. [Agharkar, Shreeram] Sanofi R&D, Global CMC Strategy & Sci Affairs, Lead Generat & Candidate Realizat, Bridgewater, NJ USA. [MacLaren, David Douglas] Eli Lilly & Co, Drug Product Dev & CT Mfg, Indianapolis, IN 46285 USA. RP Zajicek, A (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA. EM zajiceka@mail.nih.gov RI Breitkreutz, Joerg/B-9581-2017 OI Breitkreutz, Joerg/0000-0002-3982-9823 NR 49 TC 17 Z9 17 U1 1 U2 27 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1550-7416 J9 AAPS J JI AAPS J. PD OCT PY 2013 VL 15 IS 4 BP 1072 EP 1081 DI 10.1208/s12248-013-9511-5 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 227PR UT WOS:000325126300018 PM 23907486 ER PT J AU Gandhi, AS Zhu, MS Pang, SK Wohlfarth, A Scheidweiler, KB Liu, HF Huestis, MA AF Gandhi, Adarsh S. Zhu, Mingshe Pang, Shaokun Wohlfarth, Ariane Scheidweiler, Karl B. Liu, Hua-fen Huestis, Marilyn A. TI First Characterization of AKB-48 Metabolism, a Novel Synthetic Cannabinoid, Using Human Hepatocytes and High-Resolution Mass Spectrometry SO AAPS JOURNAL LA English DT Article DE AKB-48; cannabinoids; human hepatocytes; metabolism; time-of-flight mass spectrometry ID LC-MS/MS; HUMAN URINE; JWH-018 AB Since the federal authorities scheduled the first synthetic cannabinoids, JWH-018 and JWH-073, new synthetic cannabinoids were robustly marketed. N-(1-Adamantyl)-1-pentylindazole-3-carboxamide (AKB-48), also known as APINACA, was recently observed in Japanese herbal smoking blends. The National Forensic Laboratory Information System registered 443 reports of AKB-48 cases in the USA from March 2010 to January 2013. In May 2013, the Drug Enforcement Administration listed AKB-48 as a Schedule I drug. Recently, AKB-48 was shown to have twice the CB1 receptor binding affinity than CB2. These pharmacological effects and the difficulty in detecting the parent compound in urine highlight the importance of metabolite identification for developing analytical methods for clinical and forensic investigations. Using human hepatocytes and TripleTOF mass spectrometry, we identified 17 novel phase I and II AKB-48 metabolites, products of monohydroxylation, dihydroxylation, or trihydroxylation on the aliphatic adamantane ring or N-pentyl side chain. Glucuronide conjugation of some mono- and dihydroxylated metabolites also occurred. Oxidation and dihydroxylation on the adamantane ring and N-pentyl side chain formed a ketone. More metabolites were identified after 3 h of incubation than at 1 h. For the first time, we present a AKB-48 metabolic scheme obtained from human hepatocytes and high-resolution mass spectrometry. These data are needed to develop analytical methods to identify AKB-48 consumption in clinical and forensic testing. C1 [Gandhi, Adarsh S.; Wohlfarth, Ariane; Scheidweiler, Karl B.; Huestis, Marilyn A.] NIDA, Intramural Res Program, NIH, Baltimore, MD 21224 USA. [Zhu, Mingshe] Bristol Myers Squibb Res & Dev, Dept Biotransformat, Princeton, NJ 08543 USA. [Pang, Shaokun; Liu, Hua-fen] AB SCIEX, Foster City, CA 94404 USA. RP Huestis, MA (reprint author), NIDA, Intramural Res Program, NIH, 251 Bayview Blvd,Suite 200,Room 05A-721, Baltimore, MD 21224 USA. EM mhuestis@intra.nida.nih.gov FU National Institute on Drug Abuse, National Institutes of Health FX This research was supported by the Intramural Research Program of the National Institute on Drug Abuse, National Institutes of Health. NR 23 TC 37 Z9 37 U1 3 U2 22 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1550-7416 J9 AAPS J JI AAPS J. PD OCT PY 2013 VL 15 IS 4 BP 1091 EP 1098 DI 10.1208/s12248-013-9516-0 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 227PR UT WOS:000325126300020 PM 23913126 ER PT J AU Glaus, J Vandeleur, C Gholam-Rezaee, M Castelao, E Perrin, M Rothen, S Bovet, P Marques-Vidal, P von Kanel, R Merikangas, K Mooser, V Waterworth, DM Waeber, G Vollenweider, P Preisig, M AF Glaus, J. Vandeleur, C. Gholam-Rezaee, M. Castelao, E. Perrin, M. Rothen, S. Bovet, P. Marques-Vidal, P. von Kaenel, R. Merikangas, K. Mooser, V. Waterworth, D. M. Waeber, G. Vollenweider, P. Preisig, M. TI Atypical depression and alcohol misuse are related to the cardiovascular risk in the general population SO ACTA PSYCHIATRICA SCANDINAVICA LA English DT Article DE depression; substance use disorders; weight gain; risk factors; cardio-vascular diseases ID CORONARY-HEART-DISEASE; TEST-RETEST RELIABILITY; GENETIC-STUDIES DIGS; PSYCHIATRIC-DISORDERS; DIAGNOSTIC INTERVIEW; METABOLIC SYNDROME; ANXIETY DISORDERS; MENTAL-HEALTH; UNITED-STATES; META-ANALYSIS AB ObjectiveThe aims of the present study were to assess the associations between mood, anxiety and substance use disorders, including their subtypes, and the prevalence of cardiovascular risk factors (CVRFs). MethodThorough physical investigations, biological measures and standardized interview techniques were used to assess 3716 subjects of an urban area, aged 35-66 years. ResultsAtypical depression was associated with increased prevalence of overweight, diabetes and the metabolic syndrome (OR=1.5, 95% C.I. 1.1-2.0; OR=2.0, 95% C.I. 1.1-3.5, OR=1.6, 95% C.I. 1.0-2.4 respectively), whereas decreased prevalence of overweight was found in melancholic (OR=0.7, 95% C.I. 0.6-0.9) and unspecified depression (OR=0.8, 95% C.I. 0.7-1.0). Alcohol abuse was associated with diabetes (OR=1.8, 95% C.I. 1.1-2.9) and dyslipidemia (OR=1.3, 95% C.I. 1.0-1.8), alcohol dependence with dyslipidemia only (OR=1.4, 95% C.I. 1.0-2.0). Almost all mental disorders were associated with a lifetime history of regular cigarette smoking, and atypical depression, alcohol misuse and drug dependence were associated with inactivity. ConclusionTo conclude results emphasize the need to subtype depression and to pay particular attention to the atypical subtype. Comorbid alcohol misuse may further increase the cardiovascular risk. Efforts to diminish smoking in subjects with mental disorders could be crucial measures to reduce their high incidence of cardiovascular disease. C1 [Glaus, J.; Vandeleur, C.; Gholam-Rezaee, M.; Castelao, E.; Perrin, M.; Rothen, S.; Preisig, M.] Univ Lausanne Hosp, Dept Psychiat, Lausanne, Switzerland. [Bovet, P.; Marques-Vidal, P.] Univ Lausanne Hosp, Inst Social & Prevent, Lausanne, Switzerland. [von Kaenel, R.] Univ Hosp Bern, Dept Gen Internal Med, CH-3010 Bern, Switzerland. [Merikangas, K.] NIMH, Genet Epidemiol Res Branch, Intramural Res Program, Bethesda, MD 20892 USA. [Mooser, V.; Waterworth, D. M.] GlaxoSmithKline, Med Genet, Philadelphia, PA USA. [Waeber, G.; Vollenweider, P.] Univ Lausanne Hosp, Dept Internal Med, Lausanne, Switzerland. RP Glaus, J (reprint author), Univ Lausanne Hosp, Dept Psychiat, Ctr Res Psychiat Epidemiol & Psychopathol CEPP, Site Cery, CH-1008 Prilly, Switzerland. EM jennifer.glaus@chuv.ch RI Colaus, PsyColaus/K-6607-2013; Rothen, Stephane/E-8325-2014; Bovet, Pascal/F-4477-2011; Glaus, Jennifer/C-7887-2017; Marques-Vidal, Pedro/C-9449-2009 OI Rothen, Stephane/0000-0003-3891-277X; Bovet, Pascal/0000-0002-0242-4259; Glaus, Jennifer/0000-0001-8883-9473; Marques-Vidal, Pedro/0000-0002-4548-8500 FU Swiss National Science Foundation [32003B-105993, 32003B-118308, 33CSC0-122661]; GlaxoSmithKline Clinical Genetics FX The authors express their gratitude to the Lausanne inhabitants who volunteered to participate in the PsyCoLaus study and to the collaborators who contributed to the coordination of the study and the collection of data. They also thank all the investigators of the CoLaus study, who made the psychiatric study possible, as well as many GSK employees who contributed to the execution of this study. This research was supported by three grants from the Swiss National Science Foundation (#32003B-105993, #32003B-118308 and #33CSC0-122661 to M. Preisig) and two grants from GlaxoSmithKline Clinical Genetics to G. Waeber, P. Vollenweider and M. Preisig. The funding organization played no role in the design or conduct of the study, the collection, management, analysis, or interpretation of the data; or the preparation, review, or approval of the manuscript. NR 62 TC 13 Z9 13 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0001-690X J9 ACTA PSYCHIAT SCAND JI Acta Psychiatr. Scand. PD OCT PY 2013 VL 128 IS 4 BP 282 EP 293 DI 10.1111/acps.12057 PG 12 WC Psychiatry SC Psychiatry GA 224WQ UT WOS:000324922700006 PM 23216242 ER PT J AU Sparta, DR Hopf, FW Gibb, SL Cho, SL Stuber, GD Messing, RO Ron, D Bonci, A AF Sparta, Dennis R. Hopf, Frederic Woodward Gibb, Stuart L. Cho, Saemi L. Stuber, Garret D. Messing, Robert O. Ron, Dorit Bonci, Antonello TI Binge Ethanol-Drinking Potentiates Corticotropin Releasing Factor R1 Receptor Activity in the Ventral Tegmental Area SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Corticotropin Releasing Factor; Ethanol; Binge Drinking; Ventral Tegmental Area; NMDA ID STRESS-INDUCED RELAPSE; CRF-BINDING-PROTEIN; ADULT MALE RATS; C57BL/6J MICE; ALCOHOL-DRINKING; EXCITATORY TRANSMISSION; POSTNATAL-DEVELOPMENT; DOPAMINE NEURONS; SEEKING BEHAVIOR; DARK PROCEDURES AB BackgroundCorticotropin releasing factor (CRF) and urocortin play an important role in many stress responses and also can regulate ethanol (EtOH) intake. Adaptations in CRF signaling in the central amygdala promote EtOH consumption after long-term EtOH intake in dependent animals and also after brief periods of binge EtOH intake. Thus, even brief episodes of EtOH consumption can alter the function of the CRF system, allowing CRF to regulate EtOH intake. Here, we examined whether brief binge EtOH consumption leads to CRF receptor adaptations within the ventral tegmental area (VTA), a structure involved in signaling rewarding and aversive events and important in the development and expression of drug and alcohol addiction. MethodsWe utilized a mouse model of binge drinking known as drinking in the dark (DID), where C57BL/6J mice drink approximately 6g/kg in 4 hours and achieve blood EtOH concentrations of approximately 100mg/dl, which is equivalent to binge drinking in humans. We used ex vivo whole-cell recordings from putative VTA dopamine (DA) neurons to examine CRF regulation of NMDA receptor (NMDAR) currents. We also examined the impact of CRF receptor antagonist injection in the VTA on binge EtOH intake. ResultsEx vivo whole-cell recordings from putative VTA DA neurons showed enhanced CRF-mediated potentiation of NMDAR currents in juvenile mice that consumed EtOH in the DID procedure. CRF-induced potentiation of NMDAR currents in EtOH-drinking mice was blocked by administration of CP-154,526 (3M), a selective CRF1 receptor antagonist. Furthermore, intra-VTA infusion of CP-154,526 (1g) significantly reduced binge EtOH consumption in adult mice. These results were not due to alterations of VTA NMDAR number or function, suggesting that binge drinking may enhance signaling through VTA CRF1 receptors onto NMDARs. ConclusionsAltered CRF1 receptor-mediated signaling in the VTA promotes binge-like EtOH consumption in mice, which supports the idea that CRF1 receptors may therefore be a promising pharmacological target for reducing binge drinking in humans. C1 [Sparta, Dennis R.; Hopf, Frederic Woodward; Gibb, Stuart L.; Cho, Saemi L.; Stuber, Garret D.; Messing, Robert O.; Ron, Dorit] Univ Calif San Francisco, Dept Neurol, Ernest Gallo Clin & Res Ctr, San Francisco, CA USA. [Bonci, Antonello] NIDA, Intramural Res Program, Baltimore, MD 21224 USA. [Bonci, Antonello] Johns Hopkins Sch Med, Solomon H Snyder Neurosci Inst, Baltimore, MD USA. RP Hopf, FW (reprint author), Gallo Res Ctr, 5858 Horton St,Suite 200, Emeryville, CA 94608 USA. EM woody@gallo.ucsf.edu; antonello.bonci@nih.gov RI Messing, Robert/D-3642-2015; Stuber, Garret/E-1160-2011 OI Messing, Robert/0000-0002-5345-4431; FU NIH [7F32AA0 18610]; NIH/NIAAA [R01A/MH13438, DA016782-06]; State of California for medical research on alcohol and substance abuse through the University of California, San Francisco FX We thank A. Koopmans, L. Wang, R. Kermarrec, and A. Kisch-Hancock for assistance with behavioral experiments. This study was supported by NIH through 7F32AA0 18610 (DRS), NIH/NIAAA R01A/MH13438 (DR), and DA016782-06 (AB), and funds provided by the State of California for medical research on alcohol and substance abuse through the University of California, San Francisco (ROM, DR, AB). NR 59 TC 18 Z9 18 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD OCT PY 2013 VL 37 IS 10 BP 1680 EP 1687 DI 10.1111/acer.12153 PG 8 WC Substance Abuse SC Substance Abuse GA 229KR UT WOS:000325263500007 PM 23763790 ER PT J AU Khan, S Okuda, M Hasin, DS Secades-Villa, R Keyes, K Lin, KH Grant, B Blanco, C AF Khan, Sharaf Okuda, Mayumi Hasin, Deborah S. Secades-Villa, Roberto Keyes, Katherine Lin, Keng-Han Grant, Bridget Blanco, Carlos TI Gender Differences in Lifetime Alcohol Dependence: Results from the National Epidemiologic Survey on Alcohol and Related Conditions SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE NESARC; Alcohol Dependence; Gender Differences; Epidemiology ID GENERAL-POPULATION SAMPLE; PSYCHIATRIC DIAGNOSTIC MODULES; SUBSTANCE-ABUSE TREATMENT; IV AUDADIS-IV; UNITED-STATES; FAMILY-HISTORY; RISK-FACTORS; USE-DISORDER; ENVIRONMENTAL CONTRIBUTIONS; 12-MONTH PREVALENCE AB BackgroundAn extensive clinical literature has noted gender differences in the etiology and clinical characteristics of individuals with alcohol dependence (AD). Despite this knowledge, many important questions remain. MethodsUsing the 2001 to 2002 National Epidemiologic Survey on Alcohol and Related Conditions (n=43,093), we examined differences in sociodemographic characteristics, psychiatric and medical comorbidities, clinical correlates, risk factors, and treatment-utilization patterns of men (N=2,974) and women (N=1,807) with lifetime AD. ResultsMen with lifetime AD were more likely than women to be diagnosed with any substance use disorder and antisocial personality disorder, whereas women were more likely to have mood and anxiety disorders. After adjusting for sociodemographic characteristics and gender differences in psychiatric comorbidity in the general population, AD was associated with externalizing disorders and any mood disorder among women only. Men with AD met more criteria, had longer episodes, and were younger at the age of first drink. There were no gender differences in remission rates. Women with AD were more likely to have a family and a spouse with history of alcohol use disorders. Treatment rates were low for both genders, and women were more likely to report social stigmatization as a treatment barrier. ConclusionsThere are important gender differences in the psychiatric comorbidities, risk factors, clinical characteristics, and treatment-utilization patterns among individuals with lifetime AD. C1 [Khan, Sharaf; Okuda, Mayumi; Hasin, Deborah S.; Secades-Villa, Roberto; Keyes, Katherine; Lin, Keng-Han; Blanco, Carlos] Columbia Univ, New York State Psychiat Inst, Dept Psychiat, New York, NY USA. [Secades-Villa, Roberto] Univ Oviedo, Dept Psychol, Oviedo 33003, Spain. [Grant, Bridget] NIAAA, Lab Epidemiol & Biometry, Div Intramural Clin & Biol Res, Dept Hlth & Human Serv,NIH, Bethesda, MD 90034 USA. RP Secades-Villa, R (reprint author), Univ Oviedo, Fac Psicol, Plaza Feijoo S-N, Oviedo 33003, Spain. EM secades@uniovi.es RI Okuda, Mayumi/L-6210-2013; OI Okuda, Mayumi/0000-0002-3479-5599; Secades-Villa, Roberto/0000-0001-8106-6594 FU NIH [DA019606-S3, DA020783-S4, DA019606, DA020783, DA023200, DA023973, MH076051, MH082773, CA133050, AA014223, AA018111]; American Foundation for Suicide Prevention; New York State Psychiatric Institute; Spanish Ministry of Education [PR2010-0501] FX Work on this manuscript was supported by NIH grants DA019606-S3 and DA020783-S4 (SK), DA019606, DA020783, DA023200, DA023973, MH076051, MH082773, and CA133050 (CB) and AA014223 and AA018111 (DSH), a grant from the American Foundation for Suicide Prevention (CB), the New York State Psychiatric Institute (CB, DSH), and by Spanish Ministry of Education grant PR2010-0501 (RS-V). NR 50 TC 20 Z9 21 U1 4 U2 24 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD OCT PY 2013 VL 37 IS 10 BP 1696 EP 1705 DI 10.1111/acer.12158 PG 10 WC Substance Abuse SC Substance Abuse GA 229KR UT WOS:000325263500009 PM 23763329 ER PT J AU Xuan, ZM Nelson, TF Heeren, T Blanchette, J Nelson, DE Gruenewald, P Naimi, TS AF Xuan, Ziming Nelson, Toben F. Heeren, Timothy Blanchette, Jason Nelson, David E. Gruenewald, Paul Naimi, Timothy S. TI Tax Policy, Adult Binge Drinking, and Youth Alcohol Consumption in the United States SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Youth Drinking; Adult Drinking; Binge Drinking; Tax; Alcohol Policy ID RISK BEHAVIORS; HIGH-SCHOOL; DRUG-USE; STUDENTS; SMOKING; AGE; US AB BackgroundPrior research attributed youth alcohol consumption to the attitudes and drinking patterns among adults. Yet at a population level, few have examined the relationship between state-level adult binge drinking prevalence and youth drinking behaviors, or whether tax policy plays a role in this relationship. MethodsWe analyzed 6 biennial surveys (1999 to 2009) of individual-level youth alcohol use and related behaviors from state-based Youth Risk Behavior Surveys and corresponding years of state-level adult binge drinking prevalence from the Behavioral Risk Factor Surveillance System. We employed logistic regression with generalized estimating equations method to assess the extent to which state adult binge drinking predicted individual-level youth drinking outcomes and examined the role of alcohol taxes in that relationship. ResultsPopulation-aggregate analyses based on 194 state-year strata showed a positive correlation between state adult binge drinking and youth binge drinking (Pearson r=0.40, p<0.01). For individual-level youth drinking outcomes, a 5 percentage point increase in binge drinking prevalence among adults was associated with a 12% relative increase in the odds of alcohol use (adjusted OR=1.12, 95% CI: 1.08, 1.16). Taxes were strongly inversely related with adult and youth drinking measures, and the effect of tax on youth drinking was attenuated after controlling for adult binge drinking. ConclusionsBoth tax and adult binge drinking are strong predictors of youth drinking. Tax may affect youth drinking through its effect on adult alcohol consumption. Implementing effective alcohol policies to reduce excessive drinking in the general population is an important strategy to reduce youth drinking. C1 [Xuan, Ziming] Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, Boston, MA 02118 USA. [Nelson, Toben F.] Univ Minnesota Epidemiol & Community Hlth, Minneapolis, MN USA. [Heeren, Timothy] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA. [Blanchette, Jason; Naimi, Timothy S.] Boston Med Ctr, Boston, MA USA. [Nelson, David E.] NCI, NIH, Bethesda, MD 20892 USA. [Gruenewald, Paul] Pacific Inst Res & Evaluat, Prevent Res Ctr, Berkeley, CA USA. RP Xuan, ZM (reprint author), Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, 801 Massachusetts Ave, Boston, MA 02118 USA. EM zxuan@bu.edu OI Nelson, Toben/0000-0001-9934-7546 FU U.S. National Institutes of Health [1R01AA018377-01A1] FX This research was supported by a grant from the U.S. National Institutes of Health grant no. 1R01AA018377-01A1 (PI: Timothy S. Naimi). The authors would like to thank Ms. Lisa Whittle from the CDC for her support in providing state-based YRBS data sets and related documents, and Dr. Dafna Kanny from the CDC for her review and comments on this manuscript. NR 24 TC 14 Z9 14 U1 0 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD OCT PY 2013 VL 37 IS 10 BP 1713 EP 1719 DI 10.1111/acer.12152 PG 7 WC Substance Abuse SC Substance Abuse GA 229KR UT WOS:000325263500011 PM 23711219 ER PT J AU Hanlon, JT Boudreau, RM Perera, S Strotmeyer, ES Newman, AB Simonsick, EM Shorr, RI Bauer, DC Donohue, JM AF Hanlon, Joseph T. Boudreau, Robert M. Perera, Subashan Strotmeyer, Elsa S. Newman, Anne B. Simonsick, Eleanor M. Shorr, Ronald I. Bauer, Douglas C. Donohue, Julie M. TI Racial differences in antilipemic use and lipid control in high-risk older adults: Post-Medicare Part D SO AMERICAN HEART JOURNAL LA English DT Article ID HEALTH-CARE ACCESS; BODY-COMPOSITION; CARDIOVASCULAR-DISEASE; ELDERLY-PATIENTS; HEART-DISEASE; CHOLESTEROL; DISPARITIES; SENIORS; ASSOCIATION; QUALITY AB Background Older blacks are less likely to receive guideline-recommended antilipemic therapy and achieve lipid control than older whites because, in part, of out-of-pocket costs. We sought to determine whether racial differences in antilipemic use and lipid control narrowed after Medicare Part D's implementation. Methods This before-after study included 1,091 black and white adults 70 years or older with coronary heart disease and/or diabetes mellitus from the Health Aging and Body Composition Study. Primary outcomes were antilipemic use and low-density lipoprotein cholesterol control. Key independent variables were race, time (pre-Part D vs post-Part D), and their interaction. Results Before Part D, fewer blacks than whites reported taking an antilipemic (32.70% vs 49.35%), and this difference was sustained after Part D (blacks 48.30% vs whites 64.57%). Multivariable generalized estimating equations confirmed no post-Part D change in racial differences in antilipemic use (adjusted ratio of the odds ratio 1.07, 95% CI 0.79-1.45). Compared with whites, more blacks had poor lipid control both before Part D (24.30% vs 12.36%, respectively) and after Part D (24.46% vs 13.72%, respectively), with no post-Part D change in racial differences in lipid control (adjusted ratio of the odds ratio 0.82, 95% CI 0.51-1.33). Conclusion Although antilipemic use increased after Medicare Part D for both races, this policy change was associated with a change neither in lipid control for either racial group nor in the racial differences in antilipemic use or lipid control. C1 [Hanlon, Joseph T.; Perera, Subashan] Univ Pittsburgh, Dept Med Geriatr, Pittsburgh, PA USA. [Boudreau, Robert M.; Strotmeyer, Elsa S.; Newman, Anne B.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Simonsick, Eleanor M.] NIA, Intramural Res Program, Baltimore, MD 21224 USA. [Shorr, Ronald I.] North Florida South Georgia Vet Hlth Syst GRECC, Gainesville, FL USA. [Bauer, Douglas C.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. [Donohue, Julie M.] Univ Pittsburgh, Dept Hlth Policy & Management, Pittsburgh, PA USA. RP Hanlon, JT (reprint author), Kaufman Med Bldg,Suite 514,3471 5th Ave, Pittsburgh, PA 15213 USA. EM jth14@pitt.edu RI Perera, Subashan/D-7603-2014; Strotmeyer, Elsa/F-3015-2014; Newman, Anne/C-6408-2013; OI Newman, Anne/0000-0002-0106-1150; Strotmeyer, Elsa/0000-0002-4093-6036; Boudreau, Robert/0000-0003-0162-5187; Donohue, Julie/0000-0003-2418-6017 FU AHRQ HHS [K12 HS019461, R01 HS017695, R01 HS018721]; NCATS NIH HHS [KL2 TR000146, UL1 TR000005]; NIA NIH HHS [K07 AG033174, P30 AG024827, R01 AG027017, R01 AG028050, R01 AG034056, T32 AG021885]; NINR NIH HHS [R01 NR010135, R01 NR012459] NR 43 TC 3 Z9 3 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD OCT PY 2013 VL 166 IS 4 BP 792 EP 797 DI 10.1016/j.ahj.2013.07.001 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 227EL UT WOS:000325092300036 PM 24093862 ER PT J AU Chuang, SC Rota, M Gunter, MJ Zeleniuch-Jacquotte, A Eussen, SJPM Vollset, SE Ueland, PM Norat, T Ziegler, RG Vineis, P AF Chuang, Shu-Chun Rota, Matteo Gunter, Marc J. Zeleniuch-Jacquotte, Anne Eussen, Simone J. P. M. Vollset, Stein Emil Ueland, Per Magne Norat, Teresa Ziegler, Regina G. Vineis, Paolo TI Quantifying the Dose-Response Relationship Between Circulating Folate Concentrations and Colorectal Cancer in Cohort Studies: A Meta-Analysis Based on a Flexible Meta-Regression Model SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Review DE circulating folate; colorectal cancer; dose-response relationship ID NESTED CASE-CONTROL; METHYLENETETRAHYDROFOLATE REDUCTASE POLYMORPHISM; FOLIC-ACID FORTIFICATION; PLASMA FOLATE; SERUM FOLATE; DEGRADATION-PRODUCTS; ANALYTICAL RECOVERY; US POPULATION; RISK; DIETARY AB Most epidemiologic studies on folate intake suggest that folate may be protective against colorectal cancer, but the results on circulating (plasma or serum) folate are mostly inconclusive. We conducted a meta-analysis of case-control studies nested within prospective studies on circulating folate and colorectal cancer risk by using flexible meta-regression models to test the linear and nonlinear dose-response relationships. A total of 8 publications (10 cohorts, representing 3,477 cases and 7,039 controls) were included in the meta-analysis. The linear and nonlinear models corresponded to relative risks of 0.96 (95 confidence interval (CI): 0.91, 1.02) and 0.99 (95 CI: 0.96, 1.02), respectively, per 10 nmol/L of circulating folate in contrast to the reference value. The pooled relative risks when comparing the highest with the lowest category were 0.80 (95 CI: 0.61, 0.99) for radioimmunoassay and 1.03 (95 CI: 0.83, 1.22) for microbiological assay. Overall, our analyses suggest a null association between circulating folate and colorectal cancer risk. The stronger association for the radioimmunoassay-based studies could reflect differences in cohorts and study designs rather than assay performance. Further investigations need to integrate more accurate measurements and flexible modeling to explore the effects of folate in the presence of genetic, lifestyle, dietary, and hormone-related factors. C1 [Chuang, Shu-Chun] Natl Hlth Res Inst, Inst Populat Hlth Sci, Div Hlth Policy Translat, Miaoli, Taiwan. [Chuang, Shu-Chun; Gunter, Marc J.; Norat, Teresa; Vineis, Paolo] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, London, England. [Rota, Matteo] Univ Milano Bicocca, Dept Hlth Sci, Ctr Biostat Clin Epidemiol, Monza, Italy. [Zeleniuch-Jacquotte, Anne] NYU, Sch Med, Dept Populat Hlth, New York, NY USA. [Eussen, Simone J. P. M.; Ueland, Per Magne] Univ Bergen, Inst Med, Pharmacol Sect, Bergen, Norway. [Eussen, Simone J. P. M.; Vollset, Stein Emil] Univ Bergen, Dept Publ Hlth & Primary Hlth Care, Bergen, Norway. [Eussen, Simone J. P. M.] Maastricht Univ, Med Ctr, Dept Epidemiol, Sch Publ Hlth & Primary Care, Maastricht, Netherlands. [Vollset, Stein Emil] Norwegian Inst Publ Hlth, Div Epidemiol, Bergen, Norway. [Ueland, Per Magne] Haukeland Hosp, Lab Clin Biochem, N-5021 Bergen, Norway. [Ziegler, Regina G.] NCI, Epidemiol & Biostat Program, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. RP Chuang, SC (reprint author), Natl Hlth Res Inst, Inst Populat Hlth Sci, Div Hlth Policy Translat, 35 Keyan Rd, Zhunan 35053, Miaoli County, Taiwan. EM scchuang@nhri.org.tw RI Chuang, Shu-Chun/N-3358-2013; Rota, Matteo/B-7488-2013; Ueland, Per/C-7340-2013; eussen, simone/C-7851-2017; OI Zeleniuch-Jacquotte, Anne/0000-0001-9350-1303 FU World Cancer Research Fund [2008/51]; European Commission [ECNIS2-266198]; National Health Research Institutes, Taiwan [PH-102-PP-29] FX This paper was made possible by grant 2008/51 from the World Cancer Research Fund, grant ECNIS2-266198 to P.V. from the European Commission, and grant PH-102-PP-29 to S-C.C. from the National Health Research Institutes, Taiwan. NR 49 TC 4 Z9 4 U1 0 U2 12 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD OCT 1 PY 2013 VL 178 IS 7 BP 1028 EP 1037 DI 10.1093/aje/kwt083 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 227YN UT WOS:000325151700005 PM 23863758 ER PT J AU Richard, SA Black, RE Gilman, RH Guerrant, RL Kang, G Lanata, CF Molbak, K Rasmussen, ZA Sack, RB Valentiner-Branth, P Checkley, W AF Richard, Stephanie A. Black, Robert E. Gilman, Robert H. Guerrant, Richard L. Kang, Gagandeep Lanata, Claudio F. Molbak, Kare Rasmussen, Zeba A. Sack, R. Bradley Valentiner-Branth, Palle Checkley, William CA Childhood Malnutrition Infection N TI Diarrhea in Early Childhood: Short-term Association With Weight and Long-term Association With Length SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE child health; diarrhea; malnutrition; stunting; wasting ID RURAL BANGLADESH; PERUVIAN CHILDREN; LINEAR GROWTH; RISK-FACTORS; YOUNG-CHILDREN; MALNUTRITION; INFECTION; COMMUNITY; HEALTH; MORBIDITY AB The short-term association between diarrhea and weight is well-accepted, but the long-term association between diarrhea and growth is less clear. Using data from 7 cohort studies (Peru, 19851987; Peru, 19891991; Peru, 19951998; Brazil, 19891998; Guinea-Bissau, 19871990; Guinea-Bissau, 19961997; and Bangladesh, 19931996), we evaluated the lagged relationship between diarrhea and growth in the first 2 years of life. Our analysis included 1,007 children with 597,638 child-days of diarrhea surveillance and 15,629 anthropometric measurements. We calculated the associations between varying diarrhea burdens during lagged 30-day periods and length at 24 months of age. The cumulative association between the average diarrhea burden and length at age 24 months was 0.38 cm (95 confidence interval: 0.59, 0.17). Diarrhea during the 30 days prior to anthropometric measurement was consistently associated with lower weight at most ages, but there was little indication of a short-term association with length. Diarrhea was associated with a small but measurable decrease in linear growth over the long term. These findings support a focus on prevention of diarrhea as part of an overall public health strategy for improving child health and nutrition; however, more research is needed to explore catch-up growth and potential confounders. C1 [Richard, Stephanie A.; Black, Robert E.; Gilman, Robert H.; Sack, R. Bradley; Checkley, William] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA. [Guerrant, Richard L.] Univ Virginia, Sch Med, Ctr Global Hlth, Charlottesville, VA 22908 USA. [Kang, Gagandeep] Christian Med Coll & Hosp, Dept Gastrointestinal Sci, Vellore, Tamil Nadu, India. [Lanata, Claudio F.] Inst Invest Nutr, Lima, Peru. [Molbak, Kare; Valentiner-Branth, Palle] Statens Serum Inst, Dept Epidemiol,Statens, DK-2300 Copenhagen, Denmark. [Richard, Stephanie A.; Rasmussen, Zeba A.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. RP Checkley, W (reprint author), Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, 1800 Orleans Ave,Suite 9121, Baltimore, MD 21205 USA. EM wcheckle@jhsph.edu OI Kang, Gagandeep/0000-0002-3656-564X FU Bill and Melinda Gates Foundation of the Etiology, Risk Factors and Interactions of Enteric Infections and Malnutrition; Consequences for Child Health and Development (MAL-ED) Project; National Heart, Lung, and Blood Institute, National Institutes of Health [R00HL096955] FX Drs. Stephanie A. Richard and William Checkley were supported in part by a Bill and Melinda Gates Foundation Award as part of the Etiology, Risk Factors and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development (MAL-ED) Project. Dr. Stephanie A. Richard was a Sommer Scholar in the Department of International Health, Johns Hopkins Bloomberg School of Public Health, during the conduct of this work. Dr. William Checkley was supported by a Pathway to Independence Award (R00HL096955) from the National Heart, Lung, and Blood Institute, National Institutes of Health. NR 45 TC 30 Z9 31 U1 2 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD OCT 1 PY 2013 VL 178 IS 7 BP 1129 EP 1138 DI 10.1093/aje/kwt094 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 227YN UT WOS:000325151700017 PM 23966558 ER PT J AU Gail, MH Sheehy, T Cosentino, M Pee, D Diaz-Mayoral, NA Garcia-Closas, M Caporaso, NE Pitt, K Ziegler, RG AF Gail, Mitchell H. Sheehy, Tim Cosentino, Mark Pee, David Diaz-Mayoral, Norma A. Garcia-Closas, Montserrat Caporaso, Neil E. Pitt, Karen Ziegler, Regina G. TI Maximizing DNA Yield for Epidemiologic Studies: No More Buffy Coats? SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE all-cell-pellet fraction; buffy coat; DNA extraction yield; residual blood cells; whole blood ID BLOOD; STORAGE AB Some molecular analyses require microgram quantities of DNA, yet many epidemiologic studies preserve only the buffy coat. In Frederick, Maryland, in 2010, we estimated DNA yields from 5 mL of whole blood and from equivalent amounts of all-cell-pellet (ACP) fraction, buffy coat, and residual blood cells from fresh blood (n 10 volunteers) and from both fresh and frozen blood (n 10). We extracted DNA with the QIAamp DNA Blood Midi Kit (Qiagen Sciences, Germantown, Maryland) for silica spin column capture and measured double-stranded DNA. Yields from frozen blood fractions were not statistically significantly different from those obtained from fresh fractions. ACP fractions yielded 80.6 (95 confidence interval: 66, 97) of the yield of frozen whole blood and 99.3 (95 confidence interval: 86, 100) of the yield of fresh blood. Frozen buffy coat and residual blood cells each yielded only half as much DNA as frozen ACP, and the yields were more variable. Assuming that DNA yield and quality from frozen ACP are stable, we recommend freezing plasma and ACP. Not only does ACP yield twice as much DNA as buffy coat but it is easier to process, and its yield is less variable from person to person. Long-term stability studies are needed. If one wishes to separate buffy coat before freezing, one should also save the residual blood cell fraction, which contains just as much DNA. C1 [Gail, Mitchell H.; Caporaso, Neil E.; Pitt, Karen; Ziegler, Regina G.] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA. [Cosentino, Mark; Diaz-Mayoral, Norma A.] SAIC Frederick Inc, Lab Biospecimen & Biorepository Res, Frederick Natl Lab Canc Res, Frederick, MD USA. [Pee, David] Informat Management Serv Inc, Rockville, MD USA. [Sheehy, Tim] Promega, Global Genom, Madison, WI USA. [Garcia-Closas, Montserrat] Inst Canc Res, Div Genet & Epidemiol, Sutton, Surrey, England. RP Gail, MH (reprint author), NCI, Div Canc Epidemiol & Genet, 9609 Med Ctr Dr,Room 7-E138, Bethesda, MD 20892 USA. EM gailm@mail.nih.gov RI Diaz-Mayoral, Norma/B-8416-2012; Garcia-Closas, Montserrat /F-3871-2015 OI Garcia-Closas, Montserrat /0000-0003-1033-2650 FU National Cancer Institute, National Institutes of Health [HHSN261200800001E]; Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health FX This project was funded in whole or in part by the National Cancer Institute, National Institutes of Health, under contract HHSN261200800001E and by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health. NR 7 TC 3 Z9 3 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD OCT 1 PY 2013 VL 178 IS 7 BP 1170 EP 1176 DI 10.1093/aje/kwt079 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 227YN UT WOS:000325151700022 PM 23857774 ER PT J AU Pantin, J Tian, X Shah, AA Kurlander, R Ramos, C Cook, L Khuu, H Stroncek, D Leitman, S Barrett, J Donohue, T Young, NS Geller, N Childs, RW AF Pantin, Jeremy Tian, Xin Shah, Avni A. Kurlander, Roger Ramos, Catalina Cook, Lisa Khuu, Hahn Stroncek, David Leitman, Susan Barrett, John Donohue, Theresa Young, Neal S. Geller, Nancy Childs, Richard W. TI Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Article ID SEVERE APLASTIC-ANEMIA; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; COLONY-STIMULATING FACTOR; IDENTICAL SIBLING TRANSPLANTATION; ANTITHYMOCYTE GLOBULIN; IRON OVERLOAD; STEM-CELLS; IMMUNOSUPPRESSIVE THERAPY; MYELODYSPLASTIC SYNDROME; UNRELATED DONORS AB The risk of graft-rejection after allogeneic hematopoietic cell transplantation using conventional cyclophosphamide-based conditioning is increased in patients with bone marrow failure syndromes (BMFS) who are heavily transfused and often HLA-alloimmunized. Fifty-six patients with BMFS underwent fludarabine-based reduced-intensity conditioning and allogeneic peripheral blood progenitor cell (PBPC) transplantation at a single institution. The conditioning regimen consisted of intravenous cyclophosphamide, fludarabine, and equine antithymocyte globulin. Graft-versus-host disease (GVHD) prophylaxis included cyclosporine A alone or in combination with either mycophenolate mofetil or methotrexate. To reduce the risk of graft-rejection/failure, unmanipulated G-CSF mobilized PBPCs obtained from an HLA-identical or single HLA-antigen mismatched relative were transplanted rather than donor bone marrow. Despite a high prevalence of pretransplant HLA-alloimmunization (41%) and a heavy prior transfusion burden, graft-failure did not occur with all patients having sustained donor lympho-hematopoietic engraftment. The cumulative incidence of grade II-IV acute-GVHD and chronic-GVHD was 51.8% and 72%, respectively; with 87.1% surviving at a median follow-up of 4.5 years. A multivariate analysis showed pretransplant alloimmunization and rapid donor T-cell engraftment (95% donor by day 30) were both significantly (P < 0.05) associated with the development of chronic-GVHD (adjusted HR 2.13 and 2.99, respectively). These data show fludarabine-based PBPC transplantation overcomes the risk of graft-failure in patients with BMFS, although rapid donor T-cell engraftment associated with this approach appears to increase the risk of chronic-GVHD. (Clinicaltrials.gov identifier: NCT00003838). Am. J. Hematol. 88:874-882, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Pantin, Jeremy; Ramos, Catalina; Cook, Lisa; Barrett, John; Donohue, Theresa; Young, Neal S.; Childs, Richard W.] NHLBI, Hematol Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Pantin, Jeremy] Georgia Regents Univ, Div Hematol Med Oncol & BMT, Dept Med, Augusta, GA USA. [Tian, Xin; Geller, Nancy] NHLBI, Off Biostat Res, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Shah, Avni A.] NCI, Med Oncol Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Kurlander, Roger] NIH, Dept Lab Med, Clin Res Ctr, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Khuu, Hahn; Stroncek, David; Leitman, Susan] NIH, Dept Transfus Med, Clin Res Ctr, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. RP Childs, RW (reprint author), NHLBI, Hematol Branch, NIH, 10 Ctr Dr,Bldg 10 CRC Rm 3E-5330, Bethesda, MD 20892 USA. EM childsr@nih.gov OI Pantin, Jeremy/0000-0001-7536-0623 FU NIH, NHLBI FX Contract grant sponsor: Intramural Research Program of the NIH, NHLBI. NR 60 TC 3 Z9 3 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0361-8609 J9 AM J HEMATOL JI Am. J. Hematol. PD OCT PY 2013 VL 88 IS 10 BP 874 EP 882 DI 10.1002/ajh.23526 PG 9 WC Hematology SC Hematology GA 224UP UT WOS:000324915600009 PM 23813900 ER PT J AU Lai, WS Stumpo, DJ Kennington, EA Burkholder, AB Ward, JM Fargo, DL Blackshear, PJ AF Lai, Wi S. Stumpo, Deborah J. Kennington, Elizabeth A. Burkholder, Adam B. Ward, James M. Fargo, David L. Blackshear, Perry J. TI Life without TTP: apparent absence of an important anti-inflammatory protein in birds SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE tristetraprolin; zinc finger proteins; innate immunity; AU-rich elements; mRNA turnover ID TRISTETRAPROLIN-DEFICIENCY SYNDROME; MESSENGER-RNA DECAY; TNF-ALPHA; CHICKEN; CELLS; SENSITIVITY; ZFP36L3; GENOME; FAMILY; MEMBER AB Both innate and adaptive immunity in birds are different from their mammalian counterparts. Understanding bird immunity is important because of the enormous potential impact of avian infectious diseases, both in their role as food animals and as potential carriers of zoonotic diseases in man. The anti-inflammatory protein tristetraprolin (TTP) is an important component of the mammalian innate immune response, in that it binds to and destabilizes key cytokine mRNAs. TTP knockout mice exhibit a severe systemic inflammatory syndrome, and they are abnormally sensitive to innate immune stimuli such as LPS. TTP orthologs have been found in most vertebrates studied, including frogs. Here, we attempted to identify TTP orthologs in chicken and other birds, using database searches and deep mRNA sequencing. Although sequences encoding the two other widely expressed TTP family members, ZFP36L1 and ZFP36L2, were identified, we did not find sequences corresponding to TTP in any bird species. Sequences corresponding to TTP were identified in both lizards and alligators, close evolutionary relatives of birds. The induction kinetics of Zfp36l1 and Zfp36l2 mRNAs in LPS-stimulated chicken macrophages or serum-stimulated chick embryo fibroblasts did not resemble the normal mammalian TTP response to these stimuli, suggesting that the other two family members might not compensate for the TTP deficiency in regulating rapidly induced mRNA targets. Several mammalian TTP target transcripts have chicken counterparts that contain one or more potential TTP binding sites, raising the possibility that birds express other proteins that subsume TTP's function as a rapidly inducible regulator of AU-rich element (ARE)-dependent mRNA turnover. C1 [Lai, Wi S.; Stumpo, Deborah J.; Kennington, Elizabeth A.; Blackshear, Perry J.] NIEHS, Lab Signal Transduct, Res Triangle Pk, NC 27709 USA. [Burkholder, Adam B.; Ward, James M.; Fargo, David L.] NIEHS, Integrat Bioinformat Grp, Res Triangle Pk, NC 27709 USA. [Blackshear, Perry J.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Blackshear, Perry J.] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA. RP Blackshear, PJ (reprint author), NIEHS, Box F1-13,Bldg 101,111 Alexander Dr, Res Triangle Pk, NC 27709 USA. EM black009@niehs.nih.gov FU NIH, National Institute of Environmental Health Sciences FX We are grateful to the members of the National Institutes of Health (NIH) Intramural Sequencing Center for their help with mRNASeq. We thank Drs. Jacqueline Smith and David Burt for helpful discussions, Dr. Uma Babu of the FDA for the HD11 cells, and Dr. Tom Randall for help with the phylogenetic analysis. We thank Drs. Dori Germolec and Bill Schrader for critical review of the manuscript. This study was supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences. NR 32 TC 8 Z9 8 U1 0 U2 7 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD OCT PY 2013 VL 305 IS 7 BP R689 EP R700 DI 10.1152/ajpregu.00310.2013 PG 12 WC Physiology SC Physiology GA 230PB UT WOS:000325353000004 PM 23904106 ER PT J AU Deveney, CM Connolly, ME Haring, CT Bones, BL Reynolds, RC Kim, P Pine, DS Leibenluft, E AF Deveney, Christen M. Connolly, Megan E. Haring, Catherine T. Bones, Brian L. Reynolds, Richard C. Kim, Pilyoung Pine, Daniel S. Leibenluft, Ellen TI Neural Mechanisms of Frustration in Chronically Irritable Children SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID PEDIATRIC BIPOLAR DISORDER; SEVERE MOOD DYSREGULATION; EMOTION REGULATION; BEHAVIORAL-RESPONSES; NEGATIVE AFFECT; REWARD; CORTEX; ANGER; RISK AB Objective: Irritability is common in children and adolescents and is the cardinal symptom of disruptive mood dysregulation disorder, a new DSM-5 disorder, yet its neural correlates remain largely unexplored. The authors conducted a functional MRI study to examine neural responses to frustration in children with severe mood dysregulation. Method: The authors compared emotional responses, behavior, and neural activity between 19 severely irritable children (operationalized using criteria for severe mood dysregulation) and 23 healthy comparison children during a cued-attention task completed under nonfrustrating and frustrating conditions. Results: Children in both the severe mood dysregulation and the healthy comparison groups reported increased frustration and exhibited decreased ability to shift spatial attention during the frustration condition relative to the nonfrustration condition. However, these effects of frustration were more marked in the severe. mood dysregulation group than in the comparison group.. During the frustration condition, participants in the severe mood dysregulation group exhibited deactivation of the left amygdala, the left and right striatum, the parietal cortex, and the posterior cingulate on negative feedback trials, relative to the comparison group (i.e., between-group effect) and to the severe mood dysregulation group's responses on positive feedback trials (i.e., within-group effect). In contrast, neural response to positive feedback during the frustration condition did not differ between groups. Conclusions: In response to negative feedback received in the context of frustration, children with severe, chronic irritability showed abnormally reduced activation in regions implicated in emotion, attention, and reward processing. Frustration appears to reduce attention flexibility, particularly in severely irritable children, which may contribute to emotion regulation deficits in this population. Further research is needed to relate these findings to irritability specifically, rather than to other clinical features of severe mood dysregulation. C1 [Deveney, Christen M.] NIMH, Emot & Dev Branch, Bethesda, MD 20892 USA. NIMH, Sci & Stat Comp Core, Bethesda, MD 20892 USA. RP Deveney, CM (reprint author), NIMH, Emot & Dev Branch, Bethesda, MD 20892 USA. EM deveneycm@mail.nih.gov FU NIMH Intramural Research Program FX Supported by the NIMH Intramural Research Program. NR 26 TC 26 Z9 26 U1 1 U2 21 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD OCT PY 2013 VL 170 IS 10 BP 1186 EP 1194 DI 10.1176/appi.ajp.2013.12070917 PG 9 WC Psychiatry SC Psychiatry GA 230ZV UT WOS:000325383700020 PM 23732841 ER PT J AU Britton, JC Grillon, C Lissek, S Norcross, MA Szuhany, KL Chen, G Ernst, M Nelson, EE Leibenluft, E Shechner, T Pine, DS AF Britton, Jennifer C. Grillon, Christian Lissek, Shmuel Norcross, Maxine A. Szuhany, Kristin L. Chen, Gang Ernst, Monique Nelson, Eric E. Leibenluft, Ellen Shechner, Tomer Pine, Daniel S. TI Response to Learned Threat: An fMRI Study in Adolescent and Adult Anxiety SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID CONDITIONED FEAR; CHILDHOOD ANXIETY; PREFRONTAL CORTEX; PANIC DISORDER; EXTINCTION; HUMANS; MECHANISMS; CHILDREN; RISK; AMYGDALA AB Objective: Poor threat-safety discrimination reflects prefrontal cortex dysfunction in adult anxiety disorder's. While adolescent anxiety disorders are impairing and predict high risk for adult anxiety disorders, the neural correlates of threat-safety discrimination have not been investigated in this population. The authors compared prefrontal cortex function in anxious and healthy adolescents and adults following conditioning and extinction, processes requiring threat-safety learning. Method: Anxious and healthy adolescents and adults (N=114) completed fear conditioning and extinction in the clinic. The conditioned stimuli (CS+) were neutral faces, paired with an aversive scream. Physiological and subjective data were acquired. Three weeks later, 82 participants viewed the CS+ and morphed images resembling the CS+ in an MRI scanner. During scanning, participants made difficult threat-safety discriminations while appraising threat and explicit memory of the CS+. Results: During conditioning and extinction, the anxious groups reported more fear than the healthy groups, but the anxious adolescent and adult groups did not differ on physiological measures. During imaging, both anxious adolescents and adults exhibited lower activation in the subgenual anterior cingulate cortex than their healthy counterparts, specifically when appraising threat. Compared with their age-matched counterpart groups, anxious adults exhibited reduced activation in the ventromedial prefrontal cortex when appraising threat, whereas anxious adolescents exhibited a U-shaped pattern of activation, with greater activation in response to the most extreme CS+ and CS-. Conclusions: Two regions of the prefrontal cortex are involved in anxiety disorders. Reduced subgenual anterior cingulate cortex engagement is a shared feature in adult and adolescent anxiety disorders, but ventromedial prefrontal cortex dysfunction is age-specific. The unique U-shaped pattern of activation in the ventromedial prefrontal cortex in many anxious adolescents may reflect heightened sensitivity to threat and safety conditions. How variations in the pattern relate to later risk for adult illness remains to be determined. C1 [Britton, Jennifer C.] Univ Miami, Dept Psychol, Coral Gables, FL 33124 USA. NIMH, Bethesda, MD 20892 USA. Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA. Johns Hopkins Univ, Sch Med, Baltimore, MD USA. Boston Univ, Dept Psychol, Boston, MA 02215 USA. RP Britton, JC (reprint author), Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA. EM j.britton@miami.edu OI Nelson, Eric/0000-0002-3376-2453 FU Intramural Research Program of NIMH/NIH [K99-MH-091183] FX Supported in part by grant K99-MH-091183 from the Intramural Research Program of NIMH/NIH (to Dr. Britton). NR 35 TC 28 Z9 28 U1 3 U2 20 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD OCT PY 2013 VL 170 IS 10 BP 1195 EP 1204 DI 10.1176/appi.ajp.2013.12050651 PG 10 WC Psychiatry SC Psychiatry GA 230ZV UT WOS:000325383700021 PM 23929092 ER PT J AU Rajendran, K Trampush, JW Rindskopf, D Marks, DJ O'Neill, S Halperin, JM AF Rajendran, Khushmand Trampush, Joey W. Rindskopf, David Marks, David J. O'Neill, Sarah Halperin, Jeffrey M. TI Association Between Variation in Neuropsychological Development and Trajectory of ADHD Severity in Early Childhood SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; ADOLESCENTS/YOUNG ADULTS; PREFRONTAL CORTEX; BRAIN-DEVELOPMENT; TEACHER RATINGS; DIAGNOSED ADHD; CHILDREN; PRESCHOOL; SYMPTOMS; IMPACT AB Objective: This longitudinal study examined if changes in neuropsychological functioning were associated with the trajectory of symptoms related to attention deficit hyperactivity disorder (ADHD) and impairment between preschool and school age. Method: The sample consisted of 3- and 4-year-old children (N=138) who were identified as being at risk for ADHD based on parent and teacher reports. Neuropsychological functioning was measured annually using the NEPSY at four time points (mean ages, 4.19, 5.36, 6.35, and 7.35 years). ADHD symptoms and impairment were assessed with semiannual parent and teacher reports using the ADHD Rating Scale-IV and the Children's Problems Checklist at 10 time points (mean ages at baseline and final assessment, 4.19 and 8.81 years, respectively). Hierarchical linear modeling was used to assess the trajectories of change in neuropsychological functioning and ADHD severity as well as the association of change in neuropsychological functioning with change in ADHD severity over time. Results: Baseline neuropsychological functioning was not significantly associated with the slope of change in ADHD severity. However, the magnitude of change in neuropsychological functioning was linearly associated with the trajectory of ADHD symptom severity and impairment, such that individuals with greater neuropsychological growth over time had a greater diminution of ADHD severity and impairment. Family socioeconomic status at baseline was significantly associated with initial ADHD severity and impairment, but not with change over time. Conclusions: Interventions that enhance neuropsychological functioning at an early age may be beneficial in attenuating long-term ADHD severity and impairment. C1 [Halperin, Jeffrey M.] CUNY Queens Coll, Dept Psychol, Flushing, NY 11367 USA. Zucker Hillside Hosp, Div Psychiat Res, Glen Oaks, NY USA. Feinstein Inst Med Res, Ctr Psychiat Neurosci, Glen Oaks, NY USA. NIMH, Clin Brain Disorders Branch, Genes Cognit & Psychosis Program, Bethesda, MD 20892 USA. CUNY, Grad Ctr, New York, NY USA. NYU, Langone Med Ctr, Ctr Child Study, New York, NY 10003 USA. RP Halperin, JM (reprint author), CUNY Queens Coll, Dept Psychol, Flushing, NY 11367 USA. EM jeffrey.halperin@qc.cuny.edu OI Marks, David/0000-0002-8133-2730 FU NIMH [R01MH068286] FX Supported by NIMH grant R01MH068286 (principal investigator, J.M.H.). NR 39 TC 17 Z9 17 U1 1 U2 20 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD OCT PY 2013 VL 170 IS 10 BP 1205 EP 1211 DI 10.1176/appi.ajp.2012.12101360 PG 7 WC Psychiatry SC Psychiatry GA 230ZV UT WOS:000325383700022 PM 23897408 ER PT J AU Sayers, BC Taylor, AJ Glista-Baker, EE Shipley-Phillips, JK Dackor, RT Edin, ML Lih, FB Tomer, KB Zeldin, DC Langenbach, R Bonner, JC AF Sayers, Brian C. Taylor, Alexia J. Glista-Baker, Ellen E. Shipley-Phillips, Jeanette K. Dackor, Ryan T. Edin, Matthew L. Lih, Fred B. Tomer, Kenneth B. Zeldin, Darryl C. Langenbach, Robert Bonner, James C. TI Role of Cyclooxygenase-2 in Exacerbation of Allergen-Induced Airway Remodeling by Multiwalled Carbon Nanotubes SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY LA English DT Article DE carbon nanotubes; nanoparticles; asthma; inflammation; COX-2 ID ULTRAFINE PARTICLES; PROSTAGLANDIN D-2; EPITHELIAL-CELLS; LUNG-DISEASES; ASTHMA; MICE; INFLAMMATION; INTERLEUKIN-13; IL-13; HYPERRESPONSIVENESS AB The emergence of nanotechnology has produced a multitude of engineered nanomaterials such as carbon nanotubes (CNTs), and concerns have been raised about their effects on human health, especially for susceptible populations such as individuals with asthma. Multiwalled CNTs (MWCNTs) have been shown to exacerbate ovalbumin (OVA)-induced airway remodeling in mice. Moreover, cyclooxygenase-2 (COX-2) has been described as a protective factor in asthma. We postulated that COX-2-deficient (COX-2(-/-)) mice would be susceptible to MWCNT-induced exacerbations of allergen-induced airway remodeling, including airway inflammation, fibrosis, and mucus-cell metaplasia (i.e., the formation of goblet cells). Wild-type (WT) or COX-2(-/-) mice were sensitized to OVA to induce allergic airway inflammation before a single dose of MWCNTs (4 mg/kg) delivered to the lungs by oropharyngeal aspiration. MWCNTs significantly increased OVA-induced lung inflammation and mucus-cell metaplasia in COX-2(-/-) mice compared with WT mice. However, airway fibrosis after exposure to allergen and MWCNTs was no different between WT and COX-2(-/-) mice. Concentrations of certain prostanoids (prostaglandinD2 and thromboxane B-2) were enhanced by OVA or MWCNTs in COX-2(-/-) mice. No differences in COX-1 mRNA concentrations were evident between WT and COX-2(-/-) mice treated with OVA and MWCNTs. Interestingly, MWCNTs significantly enhanced allergen-induced cytokines involved in Th2 (IL-13 and IL-5), Th1 (CXCL10), and Th17 (IL-17A) inflammatory responses in COX-2(-/-) mice, but not in WT mice. We conclude that exacerbations of allergen-induced airway inflammation and mucus-cell metaplasia by MWCNTs are enhanced by deficiencies in COX-2, and are associated with the activation of a mixed Th1/Th2/Th17 immune response. C1 [Sayers, Brian C.; Taylor, Alexia J.; Glista-Baker, Ellen E.; Bonner, James C.] N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA. [Shipley-Phillips, Jeanette K.] N Carolina State Univ, Coll Vet Med, Dept Populat Hlth & Pathobiol, Lab Adv Elect & Light Opt Methods, Raleigh, NC USA. [Dackor, Ryan T.; Edin, Matthew L.; Zeldin, Darryl C.] NIEHS, Lab Resp Biol, Res Triangle Pk, NC 27709 USA. [Lih, Fred B.; Tomer, Kenneth B.] NIEHS, Struct Biol Lab, Res Triangle Pk, NC 27709 USA. [Langenbach, Robert] NIEHS, Lab Toxicol & Pharmacol, Res Triangle Pk, NC 27709 USA. RP Bonner, JC (reprint author), N Carolina State Univ, Dept Environm & Mol Toxicol, Campus Box 7633, Raleigh, NC 27695 USA. EM james_bonner@ncsu.edu OI Edin, Matthew/0000-0002-7042-500X FU National Institute of Environmental Health Sciences [RC2-ES018772, R01-ES020897]; Intramural Research Program of the National Institutes of Health; National Institutes of Environmental Health Sciences [T32-ES007046-31] FX This work was funded by National Institute of Environmental Health Sciences grants RC2-ES018772 (J.C.B.) and R01-ES020897 (J.C.B.), and the Intramural Research Program of the National Institutes of Health and the National Institutes of Environmental Health Sciences (D. C. Z., R. L., R. T. D., M. L. E., F. B. L., and K. B. T.). E.E.G.-B. and B. C. S. are supported by National Institute of Environmental Health Sciences training grant T32-ES007046-31. NR 51 TC 11 Z9 12 U1 0 U2 7 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1044-1549 J9 AM J RESP CELL MOL JI Am. J. Respir. Cell Mol. Biol. PD OCT PY 2013 VL 49 IS 4 BP 525 EP 535 DI 10.1165/rcmb.2013-0019OC PG 11 WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System GA 230OQ UT WOS:000325351700004 PM 23642096 ER PT J AU Hricik, DE Nickerson, P Formica, RN Poggio, ED Rush, D Newell, KA Goebel, J Gibson, IW Fairchild, RL Riggs, M Spain, K Ikle, D Bridges, ND Heeger, PS AF Hricik, D. E. Nickerson, P. Formica, R. N. Poggio, E. D. Rush, D. Newell, K. A. Goebel, J. Gibson, I. W. Fairchild, R. L. Riggs, M. Spain, K. Ikle, D. Bridges, N. D. Heeger, P. S. CA CTOT-01 Consortium TI Multicenter Validation of Urinary CXCL9 as a Risk-Stratifying Biomarker for Kidney Transplant Injury SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE Acute rejection; biomarker; chemokines; kidney allograft; kidney graft function ID RENAL-ALLOGRAFT REJECTION; MESSENGER-RNA; T-CELLS; MODELS; CXCR3; CLASSIFICATION; INFLAMMATION; EXPRESSION; PREDICTION; CHEMOKINES AB Noninvasive biomarkers are needed to assess immune risk and ultimately guide therapeutic decision-making following kidney transplantation. A requisite step toward these goals is validation of markers that diagnose and/or predict relevant transplant endpoints. The Clinical Trials in Organ Transplantation-01 protocol is a multicenter observational study of biomarkers in 280 adult and pediatric first kidney transplant recipients. We compared and validated urinary mRNAs and proteins as biomarkers to diagnose biopsy-proven acute rejection (AR) and stratify patients into groups based on risk for developing AR or progressive renal dysfunction. Among markers tested for diagnosing AR, urinary CXCL9 mRNA (odds ratio [OR] 2.77, positive predictive value [PPV] 61.5%, negative predictive value [NPV] 83%) and CXCL9 protein (OR 3.40, PPV 67.6%, NPV 92%) were the most robust. Low urinary CXCL9 protein in 6-month posttransplant urines obtained from stable allograft recipients classified individuals least likely to develop future AR or a decrement in estimated glomerular filtration rate between 6 and 24 months (92.5-99.3% NPV). Our results support using urinary CXCL9 for clinical decision-making following kidney transplantation. In the context of acute dysfunction, low values can rule out infectious/immunological causes of injury. Absent urinary CXCL9 at 6 months posttransplant defines a subgroup at low risk for incipient immune injury. C1 [Hricik, D. E.] Univ Hosp Case Med Ctr, Cleveland, OH USA. [Nickerson, P.; Rush, D.; Gibson, I. W.] Univ Manitoba, Winnipeg, MB, Canada. [Formica, R. N.] Yale Univ, Sch Med, New Haven, CT USA. [Poggio, E. D.; Fairchild, R. L.] Cleveland Clin, Cleveland, OH 44106 USA. [Newell, K. A.] Emory Univ, Med Ctr, Atlanta, GA 30322 USA. [Goebel, J.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Riggs, M.; Spain, K.; Ikle, D.] Rho, Chapel Hill, NC USA. [Bridges, N. D.] NIAID, Transplantat Branch, NIH, Bethesda, MD 20892 USA. [Heeger, P. S.] Mt Sinai, Icahn Sch Med, New York, NY 10029 USA. RP Heeger, PS (reprint author), Mt Sinai, Icahn Sch Med, New York, NY 10029 USA. EM peter.heeger@mssm.edu OI Rush, David/0000-0002-3451-9447; Nickerson, Peter/0000-0002-7393-7799 FU National Institutes of Health [AI63594-06] FX The study was supported by National Institutes of Health U01 grant AI63594-06 awarded to P. Heeger. The CTOT-01 consortium members thank the following personnel for the support of the work: Cincinnati Children's Hospital, Cincinnati, OH: Barbara Logan; Cleveland Clinic, Cleveland, OH: Jennifer Czerr and Leslie Iosue; Emory University Medical Center, Atlanta, GA: Brandi Johnson, Margret Kamel and Amy S. Newell; Icahn School of Medicine at Mount Sinai, New York, NY: Dean Firkus, Brandy Haydel, Neha Karajgikhar, Sherif Mikhail, Katya Ostrow, Yasir Qureshi, Jason Rothfeld, Jennifer Smar, Paulina Trzcinka, Rosie Wickham, Tina Yao and Praeophayom Wauhop; University Hospitals Case Medical Center, Cleveland, OH: Victoria Rodriguez, Maureen Tessman and Tracey Lee; University of Manitoba, Winnipeg Manitoba, Canada: Jennifer Bestland, Iga Dembinski, Shirley Frederickson, Susan McMurrich and Myrna Ross. NR 30 TC 52 Z9 53 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD OCT PY 2013 VL 13 IS 10 BP 2634 EP 2644 DI 10.1111/ajt.12426 PG 11 WC Surgery; Transplantation SC Surgery; Transplantation GA 224ZN UT WOS:000324932200018 PM 23968332 ER PT J AU Kelly, RJ Thomas, A Rajan, A Chun, G Lopez-Chavez, A Szabo, E Spencer, S Carter, CA Guha, U Khozin, S Poondru, S Van Sant, C Keating, A Steinberg, SM Figg, W Giaccone, G AF Kelly, R. J. Thomas, A. Rajan, A. Chun, G. Lopez-Chavez, A. Szabo, E. Spencer, S. Carter, C. A. Guha, U. Khozin, S. Poondru, S. Van Sant, C. Keating, A. Steinberg, S. M. Figg, W. Giaccone, G. TI A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer SO ANNALS OF ONCOLOGY LA English DT Article DE survivin; non-small-cell lung cancer; apoptosis; sepantronium bromide ID SOLID TUMORS; APOPTOSIS; PATHWAY AB This phase I/II study examined the safety and efficacy of Sepantronium Bromide (S), a small-molecule selective survivin suppressant, administered in combination with carboplatin (C) and paclitaxel (P). Forty-one patients were treated on study. Twenty-two patients received escalating doses of S (3.6-12 mg/m(2)) and 19 with untreated stage IV non-small-cell lung cancer (NSCLC) were treated with the maximum tolerated dose of 10 mg/m(2) in combination with standard doses of C (AUC6) and P (200 mg/m(2)) for six cycles. S was administered as a continuous intravenous infusion (CIVI) over 72 h in 21-day treatment cycles. Study end points included safety and toxic effect, response rate, progression-free and overall survival (PFS and OS), as well as exploratory pharmacodynamic correlates. Treatment with S was well tolerated, and toxic effects were mostly hematological in the phase II study. Two (11%) partial responses were observed with a median PFS of 5.7 months and median OS 16.1 months. Pharmacodynamic analysis did not demonstrate an association with response. The combination of S (10 mg/m(2)/day 72-h CIVI) administered with C and P every 3 weeks exhibited a favorable safety profile but failed to demonstrate an improvement in response rate in advanced NSCLC. NCT01100931. C1 [Kelly, R. J.] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Thomas, A.; Rajan, A.; Chun, G.; Lopez-Chavez, A.; Spencer, S.; Guha, U.; Khozin, S.; Figg, W.; Giaccone, G.] NCI, Med Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA. [Szabo, E.] NCI, Lung & Upper Aerodigest Canc Res Grp, Canc Prevent Div, Bethesda, MD 20892 USA. [Carter, C. A.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA. [Poondru, S.; Van Sant, C.; Keating, A.] Astellas Pharma Global Dev, Northbrook, IL USA. [Steinberg, S. M.] NCI, Biostat & Data Management Sect, Off Clin Director, Ctr Canc Res, Bethesda, MD 20892 USA. RP Giaccone, G (reprint author), NCI, Ctr Canc Res, 10 Ctr Dr,Room 12N226, Bethesda, MD 20892 USA. EM giacconeg@mail.nih.gov RI Figg Sr, William/M-2411-2016; Giaccone, Giuseppe/E-8297-2017; OI Giaccone, Giuseppe/0000-0002-5023-7562; Thomas, Anish/0000-0003-3293-3115 FU National Cancer Institute, National Institutes of Health; NIH, National Cancer Institute, Center for Cancer Research FX This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health. This work was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. NR 22 TC 38 Z9 41 U1 1 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 J9 ANN ONCOL JI Ann. Oncol. PD OCT PY 2013 VL 24 IS 10 BP 2601 EP 2606 DI 10.1093/annonc/mdt249 PG 6 WC Oncology SC Oncology GA 227ZI UT WOS:000325153800023 PM 23857959 ER PT J AU Kroneman, A Vega, E Vennema, H Vinje, J White, PA Hansman, G Green, K Martella, V Katayama, K Koopmans, M AF Kroneman, Annelies Vega, Everardo Vennema, Harry Vinje, Jan White, Peter A. Hansman, Grant Green, Kim Martella, Vito Katayama, Kazuhiko Koopmans, Marion TI Proposal for a unified norovirus nomenclature and genotyping SO ARCHIVES OF VIROLOGY LA English DT Article ID NORWALK-LIKE VIRUSES; INFECTIOUS INTESTINAL DISEASE; UNITED-STATES; ACUTE GASTROENTERITIS; MOLECULAR EPIDEMIOLOGY; ENTERIC CALICIVIRUSES; MAXIMUM-LIKELIHOOD; OUTBREAKS; CLASSIFICATION; TAXONOMY AB Noroviruses belong to a genus of genetically diverse viruses within the family Caliciviridae and cause acute gastroenteritis in humans and animals. They are subdivided into genogroups, each of which further segregates into genotypes. Until recently, a new genotype was based on a defined pairwise distance cutoff of complete VP1 sequences, but with the increasing number of available norovirus sequences, this cutoff is no longer accurate, and sequences in the public database have been misclassified. In this paper, we demonstrate that the pairwise distance cutoff method can no longer be used and outline a phylogenetic approach to classify noroviruses. Furthermore, we propose a dual nomenclature using both ORF1 and VP1 sequences, as recombination is common and recognizing recombinant viruses may be relevant. With the continuing emergence of new norovirus lineages, we propose to coordinate nomenclature of new norovirus genotypes through an international norovirus working group. C1 [Kroneman, Annelies; Vennema, Harry; Koopmans, Marion] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands. [Vega, Everardo; Vinje, Jan] Ctr Dis Control & Prevent, Atlanta, GA USA. [White, Peter A.] Univ New S Wales, Sch Biotechnol & Biomol Sci, Fac Sci, Sydney, NSW, Australia. [Hansman, Grant] Heidelberg Univ, CHS Fdn, Heidelberg, Germany. [Green, Kim] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA. [Green, Kim] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA. [Martella, Vito] Univ Bari Aldo Moro, Dept Vet Publ Hlth, Valenzano, Italy. [Katayama, Kazuhiko] Natl Inst Infect Dis, Dept Virol 2, Tokyo, Japan. [Koopmans, Marion] Erasmus MC, Dept Virol, Rotterdam, Netherlands. RP Kroneman, A (reprint author), Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands. EM annelies.kroneman@rivm.nl RI White, Peter/C-6573-2012; Martella, Vito/K-3146-2016; OI White, Peter/0000-0002-6046-9631; Martella, Vito/0000-0002-5740-6947; Hansman, Grant/0000-0001-8735-4618; Vinje, Jan/0000-0002-1530-3675 NR 49 TC 173 Z9 183 U1 5 U2 61 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 0304-8608 EI 1432-8798 J9 ARCH VIROL JI Arch. Virol. PD OCT PY 2013 VL 158 IS 10 BP 2059 EP 2068 DI 10.1007/s00705-013-1708-5 PG 10 WC Virology SC Virology GA 226BA UT WOS:000325008000004 PM 23615870 ER PT J AU Kuhn, JH Bekal, S Cai, YY Clawson, AN Domier, LL Herrel, M Jahrling, PB Kondo, H Lambert, KN Mihindukulasuriya, KA Nowotny, N Radoshitzky, SR Schneider, U Staeheli, P Suzuki, N Tesh, RB Wang, D Wang, LF Dietzgen, RG AF Kuhn, Jens H. Bekal, Sadia Cai, Yingyun Clawson, Anna N. Domier, Leslie L. Herrel, Marieke Jahrling, Peter B. Kondo, Hideki Lambert, Kris N. Mihindukulasuriya, Kathie A. Nowotny, Norbert Radoshitzky, Sheli R. Schneider, Urs Staeheli, Peter Suzuki, Nobuhiro Tesh, Robert B. Wang, David Wang, Lin-Fa Dietzgen, Ralf G. TI Nyamiviridae: Proposal for a new family in the order Mononegavirales SO ARCHIVES OF VIROLOGY LA English DT Article ID ARGAS-PERSICARGAS-ARBOREUS; METAGENOMIC ANALYSIS; QUARANFIL CHENUDA; NYAMANINI VIRUSES; MATRIX PROTEIN; VIRAL WORLD; RNA VIRUSES; ARBOVIRUSES; TICKS; EGYPT AB Nyamanini virus (NYMV) and Midway virus (MIDWV) are unclassified tick-borne agents that infect land birds and seabirds, respectively. The recent molecular characterization of both viruses confirmed their already known close serological relationship and revealed them to be nonsegmented, single- and negative-stranded RNA viruses that are clearly related to, but quite distinct from, members of the order Mononegavirales (bornaviruses, filoviruses, paramyxoviruses, and rhabdoviruses). A third agent, soybean cyst nematode virus 1 (SbCNV-1, previously named soybean cyst nematode nyavirus), was recently found to be an additional member of this new virus group. Here, we review the current knowledge about all three viruses and propose classifying them as members of a new mononegaviral family, Nyamiviridae. C1 [Kuhn, Jens H.; Cai, Yingyun; Clawson, Anna N.; Jahrling, Peter B.] NIAID, Integrated Res Facil Ft Detrick IRF Frederick, Div Clin Res DCR, NIH, Frederick, MD 21702 USA. [Bekal, Sadia] Univ Illinois, Dept Agr & Biol Engn, Chicago, IL 60680 USA. [Domier, Leslie L.; Lambert, Kris N.] Univ Illinois, Dept Crop Sci, Chicago, IL 60680 USA. [Herrel, Marieke; Schneider, Urs; Staeheli, Peter] Univ Freiburg, Dept Virol, D-79106 Freiburg, Germany. [Kondo, Hideki; Suzuki, Nobuhiro] Okayama Univ, Inst Plant Sci & Resources, Kurashiki, Okayama, Japan. [Mihindukulasuriya, Kathie A.] Washington Univ, Sch Med, Genome Inst, St Louis, MO USA. [Nowotny, Norbert] Univ Vet Med, Vienna, Austria. [Nowotny, Norbert] Sultan Qaboos Univ, Coll Med & Hlth Sci, Muscat, Oman. [Radoshitzky, Sheli R.] US Army Med Res Inst Infect Dis, Frederick, MD USA. [Tesh, Robert B.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA. [Tesh, Robert B.] Univ Texas Med Branch, Ctr Biodef & Emerging Infect Dis, Galveston, TX 77555 USA. [Wang, David] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA. [Wang, David] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA. [Wang, Lin-Fa] CSIRO, Australian Anim Hlth Lab, Geelong, Vic, Australia. [Wang, Lin-Fa] Duke Natl Univ Singapore NUS, Grad Sch Med, Program Emerging Infect Dis, Singapore, Singapore. [Dietzgen, Ralf G.] Univ Queensland, Queensland Alliance Agr & Food Innovat, St Lucia, Qld, Australia. RP Kuhn, JH (reprint author), NIAID, Integrated Res Facil Ft Detrick IRF Frederick, Div Clin Res DCR, NIH, B-8200 Res Plaza, Frederick, MD 21702 USA. EM kuhnjens@mail.nih.gov RI Suzuki, Nobuhiro/B-2517-2011; Kuhn, Jens H./B-7615-2011; OI Kuhn, Jens H./0000-0002-7800-6045; Mihindukulasuriya, Kathie/0000-0001-9372-3758 FU Intramural NIH HHS [Z99 AI999999] NR 69 TC 8 Z9 9 U1 1 U2 16 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 0304-8608 EI 1432-8798 J9 ARCH VIROL JI Arch. Virol. PD OCT PY 2013 VL 158 IS 10 BP 2209 EP 2226 DI 10.1007/s00705-013-1674-y PG 18 WC Virology SC Virology GA 226BA UT WOS:000325008000028 PM 23636404 ER PT J AU Haroon, N Inman, RD Learch, TJ Weisman, MH Lee, M Rahbar, MH Ward, MM Reveille, JD Gensler, LS AF Haroon, Nigil Inman, Robert D. Learch, Thomas J. Weisman, Michael H. Lee, MinJae Rahbar, Mohammad H. Ward, Michael M. Reveille, John D. Gensler, Lianne S. TI The Impact of Tumor Necrosis Factor alpha Inhibitors on Radiographic Progression in Ankylosing Spondylitis SO ARTHRITIS AND RHEUMATISM LA English DT Article ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; AXIAL SPONDYLOARTHRITIS; SPINAL MOBILITY; DOUBLE-BLIND; TRIAL; EFFICACY; SAFETY; COHORT; DAMAGE; SEVERITY AB ObjectiveTo study the effect of tumor necrosis factor (TNF) inhibitors on progressive spinal damage in patients with ankylosing spondylitis (AS). MethodsAll AS patients meeting the modified New York criteria who had been monitored prospectively and had at least 2 sets of spinal radiographs a minimum of 1.5 years apart were included in the study (n = 334). The patients received standard therapy, which included nonsteroidal antiinflammatory drugs and TNF inhibitors. Radiographic severity was assessed by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). Patients with a rate of AS progression that was 1 mSASSS unit/year were considered progressors. Univariable and multivariable regression analyses were done. Propensity score matching and sensitivity analysis were performed. A zero-inflated negative binomial (ZINB) model was used to analyze the effect of TNF inhibitors on the change in the mSASSS with varying followup periods. Potential confounders, such as disease activity (as assessed by the Bath Ankylosing Spondylitis Disease Activity Index), the erythrocyte sedimentation rate, C-reactive protein level, HLA-B27 positivity, sex, age at onset, smoking burden (number of pack-years), and baseline damage, were included in the model. ResultsTNF inhibitor treatment was associated with a 50% reduction in the odds of progression, with an odds ratio (OR) of 0.52 (95% confidence interval [95% CI] 0.30-0.88, P = 0.02). Patients with a delay of >10 years in starting therapy were more likely to experience progression as compared to those who started earlier (OR 2.4 [95% CI 1.09-5.3], P = 0.03). In the ZINB model, the use of TNF inhibitors significantly reduced disease progression when the gap between radiographs was >3.9 years. The protective effect of TNF inhibitors was stronger after propensity score matching. ConclusionTreatment with TNF inhibitors appears to reduce radiographic progression in AS patients, especially with early initiation and with longer duration of followup. C1 [Haroon, Nigil; Inman, Robert D.] Univ Hlth Network, Toronto, ON, Canada. [Haroon, Nigil; Inman, Robert D.] Univ Toronto, Toronto, ON M5T 2S8, Canada. [Learch, Thomas J.; Weisman, Michael H.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Lee, MinJae; Rahbar, Mohammad H.; Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Ward, Michael M.] NIAMSD, NIH, Bethesda, MD 20892 USA. [Gensler, Lianne S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Haroon, N (reprint author), Univ Toronto, Div Rheumatol, 1E-425,399 Bathurst St, Toronto, ON M5T 2S8, Canada. EM Nigil.Haroon@uhn.ca; Lianne.Gensler@ucsf.edu FU NIH [UL1-TR-000124]; Arthritis Society, Canada; Arthritis Research Foundation, Toronto (CIBC); Rosalind Russell Medical Research Center for Arthritis; Spondylitis Association of America; NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases) [P01-AR-052915-06A1]; Janssen; AbbVie; Amgen; Pfizer; Amgen Canada; Pfizer Canada; Janssen Canada; Abbott Canada; UCB; Abbott; AbbVie for Advisory Board service FX Supported by the NIH (initially by National Center for Research Resources grant UL1-RR-033176 and currently by National Center for Advancing Translational Sciences grant UL1-TR-000124). Dr. Haroon's work was supported by The Arthritis Society, Canada and by the Arthritis Research Foundation, Toronto (CIBC Young Investigator award). Dr. Gensler's work was supported by the Rosalind Russell Medical Research Center for Arthritis, the Spondylitis Association of America (Young Investigator award), and the NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases grant P01-AR-052915-06A1). Administrative costs for the Spondyloarthritis Research Consortium of Canada database, which includes the patients from Toronto, are supported in part by The Arthritis Society, Canada and by unrestricted educational grants from Janssen, AbbVie, Amgen, and Pfizer.; Dr. Haroon has received consulting fees, speaking fees, and/or honoraria from Amgen Canada, Pfizer Canada, AbbVie, and Janssen Canada (less than $10,000 each). Dr. Inman has received consulting fees, speaking fees, and/or honoraria from Pfizer Canada, Abbott Canada, Janssen Canada, and UCB (less than $10,000 each). Dr. Reveille has received consulting fees, speaking fees, and/or honoraria from Abbott and UCB (less than $10,000 each). Dr. Gensler has received consulting fees and/or honoraria from UCB and AbbVie for Advisory Board service (less than $10,000 each). NR 32 TC 115 Z9 125 U1 1 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 IS 10 BP 2645 EP 2654 DI 10.1002/art.38070 PG 10 WC Rheumatology SC Rheumatology GA 227TE UT WOS:000325136600019 ER PT J AU Wang, JH New, JS Xie, ST Yang, PA Wu, Q Li, J Luo, B Ding, YN Druey, KM Hsu, HC Mountz, JD AF Wang, John H. New, James S. Xie, Shutao Yang, PingAr Wu, Qi Li, Jun Luo, Bao Ding, Yanna Druey, Kirk M. Hsu, Hui-Chen Mountz, John D. TI Extension of the Germinal Center Stage of B Cell Development Promotes Autoantibodies in BXD2 Mice SO ARTHRITIS AND RHEUMATISM LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; CYCLIC CITRULLINATED PEPTIDE; INDUCED CYTIDINE DEAMINASE; FOLLICULAR DENDRITIC CELLS; ANTIBODY CLASS SWITCH; RHEUMATOID-ARTHRITIS; PATHOGENIC AUTOANTIBODIES; PLASMA-CELLS; HAPTEN NP; T-CELLS AB ObjectiveRegulator of G protein signaling (RGS) proteins inhibit chemokine signaling by desensitizing G protein-coupled receptor signals. This study was undertaken to determine the mechanisms by which RGS13 promotes the generation of pathogenic autoantibodies in germinal centers (GCs), using BXD2-Rgs13(-/-) mice. MethodsConfocal and light microscopy imaging techniques were used to determine the location of cells that express RGS13 and activation-induced cytidine deaminase (AID) in the mouse spleen, and the number of plasmablasts. The levels of GC and plasma cell program transcripts in GC B cells were determined by real-time quantitative polymerase chain reaction (qPCR). Differential interleukin-17 (IL-17)-mediated expression of RGS13 in GC versus non-GC B cells was analyzed using A20 and 70Z/3 B cells. ResultsIn the spleens of BXD2 mice, RGS13 was mainly expressed by GC B cells and was stimulated by IL-17 but not IL-21. IL-17 up-regulated RGS13 in A20 GC cells but not 70Z/3 non-GC B cells. BXD2- Rgs13(-/-) mice exhibited smaller GCs and lower AID levels, suggesting lower somatic hypermutation and affinity maturation. However, GC B cells from BXD2- Rgs13(-/-) mice showed increased levels of IgM(bright) plasmablasts, up-regulation of the genes encoding plasma program, including interferon regulatory factor 4, B lymphocyte-induced maturation protein 1, and X-box binding protein 1 and the p-CREB target genes Fosb and Obf1, and down-regulation of the GC program genes Aid, Pax5, and Bach2 compared to BXD2 mice. BXD2-Rgs13(-/-) mice had lower titers of IgG autoantibodies and IgG deposits in the glomeruli, suggesting reduced autoantibody pathogenicity. ConclusionRGS13 deficiency is associated with a reduction in GC program genes and the exit of fewer pathogenic IgM plasmablasts in BXD2 mice. Our findings indicate that prolonged GC program, mediated by up-regulation of RGS13, enhances AID expression and enables the generation of pathogenic autoantibodies in autoreactive GCs. C1 [Wang, John H.; New, James S.; Xie, Shutao; Yang, PingAr; Wu, Qi; Li, Jun; Luo, Bao; Ding, Yanna; Hsu, Hui-Chen; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [Druey, Kirk M.] NIAID, NIH, Bethesda, MD 20892 USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Mountz, JD (reprint author), Univ Alabama Birmingham, SHEL 307,1825 Univ Blvd, Birmingham, AL 35294 USA. EM jdmountz@uab.edu FU NIH (National Institute of Allergy and Infectious Diseases) [1-AI-071110, ARRA 3R01-AI-71110-02S1, 1R01-AI-083705]; NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases) [P30-AR-048311, P30-AI-027767]; NIH (National Institute of Allergy and Infectious Diseases Intramural Research Program); Department of Veterans Affairs [1I01BX000600-01]; Rheumatology Research Foundation; Alliance for Lupus Research; Arthritis Foundation; Lupus Research Institute; NIH [P30-AR-048311, P30-A-I027767] FX Supported by the NIH (National Institute of Allergy and Infectious Diseases grants 1-AI-071110, ARRA 3R01-AI-71110-02S1, and 1R01-AI-083705, National Institute of Arthritis and Musculoskeletal and Skin Diseases grants P30-AR-048311 and P30-AI-027767, and the National Institute of Allergy and Infectious Diseases Intramural Research Program), the Department of Veterans Affairs (Merit Review grant 1I01BX000600-01), the Rheumatology Research Foundation (Within Our Reach grant), the Alliance for Lupus Research, the Arthritis Foundation, and the Lupus Research Institute. Flow cytometry and confocal imaging data acquisition were performed at the University of Alabama at Birmingham Comprehensive Flow Cytometry Core (supported by NIH grants P30-AR-048311 and P30-A-I027767) and Analytic Imaging and Immunoreagents Core (supported by NIH grant P30-AR-048311). NR 48 TC 9 Z9 9 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 IS 10 BP 2703 EP 2712 DI 10.1002/art.38059 PG 10 WC Rheumatology SC Rheumatology GA 227TE UT WOS:000325136600026 PM 23818250 ER PT J AU Lunenfeld, B Stratton, P AF Lunenfeld, Bruno Stratton, Pamela TI The clinical consequences of an ageing world and preventive strategies SO BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY LA English DT Article DE ageing; life expectancy; health expectancy; preventive strategies; fertility rate ID HORMONE REPLACEMENT THERAPY; CORONARY-HEART-DISEASE; QUALITY-OF-LIFE; CANCER-RISK; ORAL-CONTRACEPTIVES; OVARIAN-CANCER; POSTMENOPAUSAL WOMEN; CARDIOVASCULAR RISK; HEALTH EXPECTANCY; COLORECTAL-CANCER AB Over the past century, the world has seen unprecedented declines in mortality rates, leading to an accelerated increase in the world population. This century will realise falling fertility rates alongside ageing populations. The 20th century was the century of population growth; the 21st century will be remembered as the century of ageing. Increase in life expectancy is one of the highest achievements of humankind; however, ageing and age-related disease is a mounting challenge for individuals, families, and for social, economic, and healthcare systems. Since healthy life expectancy has lagged behind the increase in life expectancy, the rise in morbidity will increase the burden on healthcare systems. Implementation of preventive health strategies to decrease, delay or prevent frailty, lung, breast and colon cancer, cardiovascular disease, metabolic syndrome, osteoporosis and osteopaenia, may increase health expectancy, and permit women to age gracefully and maintain independent living, without disability, for as long as possible. Published by Elsevier Ltd. C1 [Lunenfeld, Bruno] Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel. [Stratton, Pamela] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, NIH, Bethesda, MD USA. RP Lunenfeld, B (reprint author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel. EM blunenfeld@gmail.com FU Intramural Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development; NIH Clinical Center FX This work was supported in part by the Intramural Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the NIH Clinical Center. We thank Nancy Terry, MLS, informationist at the NIH Clinical Center for her assistance in formatting the references for publication. NR 84 TC 10 Z9 10 U1 1 U2 13 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1521-6934 J9 BEST PRACT RES CL OB JI Best Pract. Res. Clin. Obstet. Gynaecol. PD OCT PY 2013 VL 27 IS 5 BP 643 EP 659 DI 10.1016/j.bpobgyn.2013.02.005 PG 17 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 227ML UT WOS:000325117900002 PM 23541823 ER PT J AU Barao, I Wright, PW Sungur, CM Anderson, SK Redelman, D Murphy, WJ AF Barao, Isabel Wright, Paul W. Sungur, Can M. Anderson, Stephen K. Redelman, Doug Murphy, William J. TI Differential Expression of the Ly49G(B6), but Not the Ly49G(BALB), Receptor Isoform during Natural Killer Cell Reconstitution after Hematopoietic Stem Cell Transplantation SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Ly49G; Natural killer cell; Hematopoietic stem cell transplantation ID CLASS-I MOLECULES; MHC CLASS-I; INHIBITORY RECEPTORS; NK CELLS; SELF-TOLERANCE; MISSING SELF; REPERTOIRE; EDUCATION; RECOGNITION; ACTIVATION AB Inhibitory natural killer (NK) cell receptors specific for major histocompatibility complex class I (MHC-I) molecules include Ly49 receptors in mice and killer immunoglobulin-like receptors (KIR) in humans. The "licensing" or "arming" models imply that engagement of these receptors to self MHC-I molecules during NK cell development educates NK cells to be more responsive to cancer and viral infection. We recently reported that hematopoietic stem cell transplantation (HSCT) induced rapid and preferential expansion of functionally competent Ly49G(+), but not other Ly49 family, NK cells independent of NK cell licensing via Ly49 MHC-I interactions. We now extend these studies to evaluate expression of the two Ly49G receptor isoforms Ly49G(B6) and Ly49G(BALB), using mice with different MHC-I haplotypes that express one or both of the isoforms. NK cells from CB6F(1) (H-2(bxd)). j hybrid mice express two different alleles for Ly49G receptor, Ly49G(B6) and Ly49G(BALB). We found that CB6F(1) mice had more Ly49G(B6+) NK cells than Ly49(BALB+) NK cells, and that only Ly49G(B6+) NK cells increased in relative numbers and in Ly49G mean fluorescence intensity values after HSCT similar to the B6 parental strain. We further observed that Ly49G(+) NK cells in BALB/c (H-2(d)) and BALB.B (H-2(b)) mice, which have the same background genes, recover slowly after HSCT, in contrast to Ly49G(+) NK cells in B6 (H-2(b)) recipients. The difference in expression of Ly49G(B6) relative to Ly49G(BALB) was linked to differences in the activity of the Prol promoter between the two alleles. Thus, we conclude that the Ly49G(B6) receptor dominates Ly49G expression on NK cells after HSCT in strains in which that allele is expressed. The data suggest that Ly49 allelic polymorphism within a particular Ly49 family member can differentially affect NK cell recovery after HSCT depending on the background genes of the recipient, not on the MHC-I haplotype. (C) 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved. C1 [Barao, Isabel] Univ Nevada, Dept Microbiol & Immunol, Reno, NV 89557 USA. [Wright, Paul W.; Anderson, Stephen K.] SAIC Frederick, Canc & Inflammat Program, Lab Expt Immunol, Frederick, MD USA. [Wright, Paul W.; Anderson, Stephen K.] NCI, Frederick, MD 21701 USA. [Redelman, Doug] Univ Nevada, Dept Physiol, Reno, NV 89557 USA. [Sungur, Can M.; Murphy, William J.] Univ Calif Davis, Dept Dermatol, Sacramento, CA 95817 USA. RP Murphy, WJ (reprint author), Univ Calif Davis, Sch Med, CTSC IRC, Dept Dermatol, Suite 1630,2921 Stockton Blvd, Sacramento, CA 95817 USA. EM wmjmurphy@ucdavis.edu RI Anderson, Stephen/B-1727-2012 OI Anderson, Stephen/0000-0002-7856-4266 FU National Cancer Institute, National Institutes of Health [HHSN261200800001 E]; NIH, National Cancer Institute, Center for Cancer Research FX This project was funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN261200800001 E. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. NR 29 TC 1 Z9 1 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD OCT PY 2013 VL 19 IS 10 BP 1446 EP 1452 DI 10.1016/j.bbmt.2013.07.021 PG 7 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 225PO UT WOS:000324975000007 PM 23911940 ER PT J AU Salit, RB Fowler, DH Dean, RM Pavletic, SZ Hakim, FT Steinberg, SM Hardy, NT Sportes, C Gress, RE Bishop, MR AF Salit, Rachel B. Fowler, Daniel H. Dean, Robert M. Pavletic, Steven Z. Hakim, Frances T. Steinberg, Seth M. Hardy, Nancy T. Sportes, Claude Gress, Ronald E. Bishop, Michael R. TI Host Lymphocyte Depletion as a Strategy to Facilitate Early Full Donor Chimerism after Reduced-Intensity Allogeneic Stem Cell Transplantation SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Reduced-intensity transplantation; Engraftment; Lymphocyte depletion ID BONE-MARROW-TRANSPLANTATION; MINIMAL RESIDUAL DISEASE; HEMATOLOGIC MALIGNANCIES; CONDITIONING REGIMEN; MYELOGENOUS LEUKEMIA; MULTIPLE-MYELOMA; T-CELLS; ENGRAFTMENT; IMPACT; CHEMOTHERAPY AB Reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (RIC-alloHSCT) is associated with lower toxicity but higher rates of prolonged mixed chimerism than myeloablative conditioning. Decreased pretransplantation host T cell numbers are associated with less graft rejection and early full donor chimerism. To compensate for variability in pretransplantation host lymphocyte numbers and facilitate the achievement of rapid full donor chimerism, we tested a strategy of targeted lymphocyte depletion (TLD) using chemotherapy at conventional doses to provide cytoreduction and lymphocyte depletion before RIC-alloHSCT. In our study, 111 patients with advanced hematologic malignancies received 1 to 3 cycles of conventional-dose chemotherapy to reduce circulating lymphocytes to a predetermined level. Patients then underwent RIC-alloHSCT from HLA-matched siblings. Patients received a median of 2 cycles of TLD chemotherapy, resulting in a median 71% decline in CD4(+) count. All patients engrafted; there were no late graft failures. By day +14, median CD3(+) chimerism was 99% donor and was significantly associated with lower post-TLD CD4(+) counts (P = .012). One- and 5-year treatment-related mortality were 15% and 21%, respectively. At 1-year follow-up, 66% of patients had achieved complete remission (CR) of which 92% were not in CR at the time of transplantation. Overall survival at 1 and 5 years post transplantation were 66% and 47%, respectively. (C) 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved. C1 [Salit, Rachel B.; Fowler, Daniel H.; Pavletic, Steven Z.; Hakim, Frances T.; Hardy, Nancy T.; Sportes, Claude; Gress, Ronald E.; Bishop, Michael R.] NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, Bethesda, MD 20892 USA. [Salit, Rachel B.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. [Dean, Robert M.] Cleveland Clin Fdn, Taussig Canc Ctr, Cleveland, OH 44195 USA. [Steinberg, Seth M.] NCI, Biostat & Data Management Sect, Ctr Canc Res, Bethesda, MD 20892 USA. [Bishop, Michael R.] Univ Chicago, Chicago, IL 60637 USA. RP Salit, RB (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,D2-100,POB 19024, Seattle, WA 98109 USA. EM rsalit@fhcrc.org NR 39 TC 2 Z9 2 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD OCT PY 2013 VL 19 IS 10 BP 1509 EP 1513 DI 10.1016/j.bbmt.2013.08.001 PG 5 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 225PO UT WOS:000324975000016 PM 23948062 ER PT J AU Rezvani, K Brody, JD Kohrt, HE Logan, AC Advani, R Czerwinski, DK Weng, WK Negrin, RS Carlton, V Faham, M Levy, R Barrett, J AF Rezvani, Katayoun Brody, Joshua D. Kohrt, Holbrook E. Logan, Aaron C. Advani, Ranjana Czerwinski, Debra Katherine Weng, Wen-Kai Negrin, Robert S. Carlton, Victoria Faham, Malek Levy, Ronald Barrett, John TI Cancer Vaccines and T Cell Therapy (vol 19, pg S97, 2013) SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Correction C1 [Rezvani, Katayoun] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA. [Brody, Joshua D.] Mt Sinai Sch Med, Lymphoma Immunotherapy Program, New York, NY USA. [Kohrt, Holbrook E.; Logan, Aaron C.; Advani, Ranjana; Czerwinski, Debra Katherine; Weng, Wen-Kai; Negrin, Robert S.; Levy, Ronald] Stanford Univ, Med Ctr, Dept Med, Stanford, CA 94305 USA. [Carlton, Victoria; Faham, Malek] Sequenta Inc, San Francisco, CA USA. [Barrett, John] NHLBI, Stem Cell Transplantat Sect, Hematol Branch, NIH, Bethesda, MD 20892 USA. RP Rezvani, K (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA. NR 1 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD OCT PY 2013 VL 19 IS 10 BP 1530 EP 1530 DI 10.1016/j.bbmt.2013.03.005 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 225PO UT WOS:000324975000023 ER PT J AU Yaniv, Y Stern, MD Lakatta, EG Maltsev, VA AF Yaniv, Yael Stern, Michael D. Lakatta, Edward G. Maltsev, Victor A. TI Mechanisms of Beat-to-Beat Regulation of Cardiac Pacemaker Cell Function by Ca2+ Cycling Dynamics SO BIOPHYSICAL JOURNAL LA English DT Article ID SINOATRIAL NODE CELLS; RYANODINE RECEPTOR; K+ CURRENT; CAFFEINE; PHOSPHODIESTERASE; AUTOMATICITY; RELEASE; CALCIUM; RHYTHM; MODELS AB Whether intracellular Ca2+ cycling dynamics regulate cardiac pacemaker cell function on a beat-to-beat basis remains unknown. Here we show that under physiological conditions, application of low concentrations of caffeine (2-4 mM) to isolated single rabbit sinoatrial node cells acutely reduces their spontaneous action potential cycle length (CL) and increases Ca2+ transient amplitude for several cycles. Numerical simulations, using a modified Maltsev-Lakatta coupled-clock model, faithfully reproduced these effects, and also the effects of CL prolongation and dysrhythmic spontaneous beating (produced by cytosolic Ca2+ buffering) and an acute CL reduction (produced by flash-induced Ca2+ release from a caged Ca2+ buffer), which we had reported previously. Three contemporary numerical Models (including the original Maltsev-Lakatta model) failed to reproduce the experimental results. In our proposed new model, Ca2+ releases acutely change the CL via activation of the Na+/Ca2+ exchanger current. Time-dependent CL reductions after flash-induced Ca2+ releases (the memory effect) are linked to changes in Ca2+ available for pumping into sarcoplasmic reticulum which, in turn, changes the sarcoplasmic reticulum Ca2+ load, diastolic Ca2+ releases, and Na+/Ca2+ exchanger current. These results support the idea that Ca2+ regulates CL in cardiac pacemaker cells on a beat-to-beat basis, and suggest a more realistic numerical mechanism of this regulation. C1 [Yaniv, Yael; Stern, Michael D.; Lakatta, Edward G.; Maltsev, Victor A.] NIA, Cardiovasc Sci Lab, Intramural Res Program, NIH, Baltimore, MD 21224 USA. RP Maltsev, VA (reprint author), NIA, Cardiovasc Sci Lab, Intramural Res Program, NIH, Baltimore, MD 21224 USA. EM maltsevvi@grc.nia.nih.gov RI Yaniv, Yael/B-3311-2015 OI Yaniv, Yael/0000-0002-5183-6284 FU Intramural Research Program of the National Institute on Aging, National Institutes of Health FX The work was supported by the Intramural Research Program of the National Institute on Aging, National Institutes of Health. NR 38 TC 15 Z9 15 U1 0 U2 11 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0006-3495 J9 BIOPHYS J JI Biophys. J. PD OCT 1 PY 2013 VL 105 IS 7 BP 1551 EP 1561 DI 10.1016/j.bpj.2013.08.024 PG 11 WC Biophysics SC Biophysics GA 230ZO UT WOS:000325383000004 PM 24094396 ER PT J AU Cope, SM Shinde, S Best, RB Ghirlanda, G Vaiana, SM AF Cope, Stephanie M. Shinde, Sandip Best, Robert B. Ghirlanda, Giovanna Vaiana, Sara M. TI Cyclic N-Terminal Loop of Amylin Forms Non Amyloid Fibers SO BIOPHYSICAL JOURNAL LA English DT Article ID GENE-RELATED PEPTIDE; CIRCULAR-DICHROISM; DIABETES-MELLITUS; FIBRIL FORMATION; ALPHA-HELICES; BETA-SHEETS; HUMAN IAPP; POLYPEPTIDE; PROTEINS; CALCITONIN AB We report for the first time, to our knowledge, that the N-terminal loop (N_loop) of amylin (islet amyloid polypeptide (IAPP) residues 1-8) forms extremely long and stable non-beta-sheet fibers in solution under the same conditions in which human amylin (hIAPP) forms amyloid fibers. This observation applies to the cyclic, oxidized form of the N_loop but not to the linear, reduced form, which does not form fibers. Our findings indicate a potential role of direct N_loop-N_loop interactions in hIAPP aggregation, which has not been previously explored, with important implications for the mechanism of hIAPP amyloid fiber formation, the inhibitory action of IAPP variants, and the competition between ordered and disordered aggregation in peptides of the calcitonin peptide family. C1 [Cope, Stephanie M.; Vaiana, Sara M.] Arizona State Univ, Ctr Biol Phys, Tempe, AZ 85287 USA. [Cope, Stephanie M.; Vaiana, Sara M.] Arizona State Univ, Dept Phys, Tempe, AZ 85287 USA. [Shinde, Sandip; Ghirlanda, Giovanna] Arizona State Univ, Dept Chem & Biochem, Tempe, AZ USA. [Best, Robert B.] Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England. [Best, Robert B.] NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA. RP Vaiana, SM (reprint author), Arizona State Univ, Ctr Biol Phys, Tempe, AZ 85287 USA. EM sara.vaiana@asu.edu RI Best, Robert/H-7588-2016 OI Best, Robert/0000-0002-7893-3543 FU ASU; National Science Foundation [0449842]; Royal Society University Research Fellowship; Intramural research program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH) FX This work was supported by ASU start-up funds to S.M.V. G.G. and S.S. were supported in part by National Science Foundation CAREER award 0449842. R.B.B. was supported by a Royal Society University Research Fellowship and by the Intramural research program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH). NR 62 TC 4 Z9 4 U1 1 U2 32 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0006-3495 J9 BIOPHYS J JI Biophys. J. PD OCT 1 PY 2013 VL 105 IS 7 BP 1661 EP 1669 DI 10.1016/j.bpj.2013.08.026 PG 9 WC Biophysics SC Biophysics GA 230ZO UT WOS:000325383000015 PM 24094407 ER PT J AU Shi, ZM Zhang, CL Zhou, MH Zhen, SQ Taylor, AW AF Shi, Zumin Zhang, Cuilin Zhou, Minghao Zhen, Shiqi Taylor, Anne W. TI Exposure to the Chinese famine in early life and the risk of anaemia in adulthood SO BMC PUBLIC HEALTH LA English DT Article DE Chinese famine; Anemia; Adults; Fetal exposure ID LONG-TERM HEALTH; IRON-DEFICIENCY; METABOLIC SYNDROME; MATERNAL STRESS; DUTCH FAMINE; GREAT LEAP; CONSEQUENCES; ASSOCIATION; OVERWEIGHT; CHILDREN AB Background: Famine exposure during the early stage of life is related to a number of adulthood diseases. The objective of this study was to examine the association of early life exposure to the famine in China (1959-1961) with the risk of anaemia in adulthood. Methods: We used the data of 2007 adults born between 1954 and 1964 in Jiangsu province from the 2002 Chinese National Nutrition and Health Survey. Anaemia was defined as haemoglobin concentration <12 g/dl in women and <13 g/dl in men. Results: Prevalence of anaemia in adulthood in nonexposed, fetal-exposed, early-childhood, mid-childhood, and late-childhood exposed to famine groups were 26.0%, 33.8%, 28.1%, 28.2% and 29.7%, respectively. Overall, fetal-exposed to famine was associated with 37% increased risk of anaemia as compared with those non-exposed after adjusting for income, education, place of residence, smoking, alcohol drinking, job, hypertension and BMI; relative risk (95% confidence interval) (RR (95% CI)) was 1.37 (1.09, 1.71). In general, this association appeared to be stronger among men, those who were currently overweight or obese, or those of lower educational levels. Corresponding RR (95% CI) was 1.87 (1.21-2.87), 1.75 (1.20-2.56), and 2.07 (1.37-3.12), respectively. Conclusions: Fetal exposure to the Chinese famine was associated with an increased risk of anaemia in adulthood. C1 [Shi, Zumin; Zhen, Shiqi] Jiangsu Prov Ctr Dis Control & Prevent, Dept Nutr & Foodborne Dis Prevent, Nanjing, Jiangsu, Peoples R China. [Shi, Zumin; Taylor, Anne W.] Univ Adelaide, Discipline Med, Adelaide, SA 5000, Australia. [Zhang, Cuilin] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Epidemiol Branch, Div Epidemiol Stat & Prevent Res, Bethesda, MD 20852 USA. [Zhou, Minghao] Jiangsu Prov Ctr Dis Control & Prevent, Nanjing 210009, Jiangsu, Peoples R China. RP Shi, ZM (reprint author), Jiangsu Prov Ctr Dis Control & Prevent, Dept Nutr & Foodborne Dis Prevent, Nanjing, Jiangsu, Peoples R China. EM zumin.shi@adelaide.edu.au RI Shi, Zumin/A-1093-2009; Taylor, Anne/F-5708-2010 OI Shi, Zumin/0000-0002-3099-3299; Taylor, Anne/0000-0002-4422-7974 FU Jiangsu Provincial Natural Science Foundation [BK2008464]; Jiangsu Provincial Health Bureau, China; Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Institutes of Health FX The study is supported by Jiangsu Provincial Natural Science Foundation (BK2008464) and the Jiangsu Provincial Health Bureau, China.; Dr. Cuilin Zhang were supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Institutes of Health. NR 33 TC 2 Z9 3 U1 2 U2 10 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD OCT 1 PY 2013 VL 13 AR 904 DI 10.1186/1471-2458-13-904 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 227RJ UT WOS:000325131100001 PM 24079608 ER PT J AU Chen, Y Copeland, WK Vedanthan, R Grant, E Lee, JE Gu, DF Gupta, PC Ramadas, K Inoue, M Tsugane, S Tamakoshi, A Gao, YT Yuan, JM Shu, XO Ozasa, K Tsuji, I Kakizaki, M Tanaka, H Nishino, Y Chen, CJ Wang, RW Yoo, KY Ahn, YO Ahsan, H Pan, WH Chen, CS Pednekar, MS Sauvaget, C Sasazuki, S Yang, G Koh, WP Xiang, YB Ohishi, W Watanabe, T Sugawara, Y Matsuo, K You, SL Park, SK Kim, DH Parvez, F Chuang, SY Ge, WZ Rolland, B McLerran, D Sinha, R Thornquist, M Kang, D Feng, Z Boffetta, P Zheng, W He, J Potter, JD AF Chen, Yu Copeland, Wade K. Vedanthan, Rajesh Grant, Eric Lee, Jung Eun Gu, Dongfeng Gupta, Prakash C. Ramadas, Kunnambath Inoue, Manami Tsugane, Shoichiro Tamakoshi, Akiko Gao, Yu-Tang Yuan, Jian-Min Shu, Xiao-Ou Ozasa, Kotaro Tsuji, Ichiro Kakizaki, Masako Tanaka, Hideo Nishino, Yoshikazu Chen, Chien-Jen Wang, Renwei Yoo, Keun-Young Ahn, Yoon-Ok Ahsan, Habibul Pan, Wen-Harn Chen, Chung-Shiuan Pednekar, Mangesh S. Sauvaget, Catherine Sasazuki, Shizuka Yang, Gong Koh, Woon-Puay Xiang, Yong-Bing Ohishi, Waka Watanabe, Takashi Sugawara, Yumi Matsuo, Keitaro You, San-Lin Park, Sue K. Kim, Dong-Hyun Parvez, Faruque Chuang, Shao-Yuan Ge, Wenzhen Rolland, Betsy McLerran, Dale Sinha, Rashmi Thornquist, Mark Kang, Daehee Feng, Ziding Boffetta, Paolo Zheng, Wei He, Jiang Potter, John D. TI Association between body mass index and cardiovascular disease mortality in east Asians and south Asians: pooled analysis of prospective data from the Asia Cohort Consortium SO BMJ-BRITISH MEDICAL JOURNAL LA English DT Article ID CORONARY-HEART-DISEASE; INDIVIDUAL PATIENT DATA; ALL-CAUSE MORTALITY; MIDDLE-AGED MEN; FAT-FREE MASS; RISK-FACTORS; FOLLOW-UP; WEIGHT CHANGE; HEMORRHAGIC STROKE; ISCHEMIC-STROKE AB Objective To evaluate the association between body mass index and mortality from overall cardiovascular disease and specific subtypes of cardiovascular disease in east and south Asians. Design Pooled analyses of 20 prospective cohorts in Asia, including data from 835 082 east Asians and 289 815 south Asians. Cohorts were identified through a systematic search of the literature in early 2008, followed by a survey that was sent to each cohort to assess data availability. Setting General populations in east Asia (China, Taiwan, Singapore, Japan, and Korea) and south Asia (India and Bangladesh). Participants 1 124 897 men and women (mean age 53.4 years at baseline). Main outcome measures Risk of death from overall cardiovascular disease, coronary heart disease, stroke, and (in east Asians only) stroke subtypes. Results 49 184 cardiovascular deaths (40 791 in east Asians and 8393 in south Asians) were identified during a mean follow-up of 9.7 years. East Asians with a body mass index of 25 or above had a raised risk of death from overall cardiovascular disease, compared with the reference range of body mass index (values 22.5-24.9; hazard ratio 1.09 (95% confidence interval 1.03 to 1.15), 1.27 (1.20 to 1.35), 1.59 (1.43 to 1.76), 1.74 (1.47 to 2.06), and 1.97 (1.44 to 2.71) for body mass index ranges 25.0-27.4, 27.5-29.9, 30.0-32.4, 32.5-34.9, and 35.0-50.0, respectively). This association was similar for risk of death from coronary heart disease and ischaemic stroke; for haemorrhagic stroke, the risk of death was higher at body mass index values of 27.5 and above. Elevated risk of death from cardiovascular disease was also observed at lower categories of body mass index (hazard ratio 1.19 (95% confidence interval 1.02 to 1.39) and 2.16 (1.37 to 3.40) for body mass index ranges 15.0-17.4 and <15.0, respectively), compared with the reference range. In south Asians, the association between body mass index and mortality from cardiovascular disease was less pronounced than that in east Asians. South Asians had an increased risk of death observed for coronary heart disease only in individuals with a body mass index greater than 35 (hazard ratio 1.90, 95% confidence interval 1.15 to 3.12). Conclusions Body mass index shows a U shaped association with death from overall cardiovascular disease among east Asians: increased risk of death from cardiovascular disease is observed at lower and higher ranges of body mass index. A high body mass index is a risk factor for mortality from overall cardiovascular disease and for specific diseases, including coronary heart disease, ischaemic stroke, and haemorrhagic stroke in east Asians. Higher body mass index is a weak risk factor for mortality from cardiovascular disease in south Asians. C1 [Chen, Yu; Ge, Wenzhen] NYU, Sch Med, Dept Populat Hlth, New York, NY USA. [Copeland, Wade K.; Rolland, Betsy; McLerran, Dale; Thornquist, Mark; Potter, John D.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA. [Vedanthan, Rajesh] Icahn Sch Med Mt Sinai, Zena & Michael Wiener Cardiovasc Inst, New York, NY USA. [Grant, Eric; Ozasa, Kotaro] Radiat Effects Res Fdn, Dept Epidemiol, Hiroshima, Japan. [Lee, Jung Eun] Sookmyung Womens Univ, Dept Food & Nutr, Seoul, South Korea. [Gu, Dongfeng] Chinese Acad Med Sci, Dept Evidence Based Med, Beijing 100730, Peoples R China. [Gu, Dongfeng] Chinese Acad Med Sci, Dept Populat Genet & Prevent, Fu Wai Hosp, Beijing 100730, Peoples R China. [Gu, Dongfeng] Chinese Acad Med Sci, Cardiovasc Inst, Beijing 100730, Peoples R China. [Gu, Dongfeng] Peking Union Med Coll, Beijing 100021, Peoples R China. [Gupta, Prakash C.; Pednekar, Mangesh S.] Healis Sekhsaria Inst Publ Hlth, Navi Mumbai, India. [Ramadas, Kunnambath] Reg Canc Ctr, Div Radiat Oncol, Trivandrum 695011, Kerala, India. [Inoue, Manami; Tsugane, Shoichiro; Sasazuki, Shizuka] Natl Canc Ctr, Res Ctr Canc Prevent & Screening, Epidemiol & Prevent Div, Tokyo 104, Japan. [Tamakoshi, Akiko] Hokkaido Univ, Grad Sch Med, Dept Publ Hlth, Sapporo, Hokkaido, Japan. [Inoue, Manami] Univ Tokyo, Grad Sch Med, AXA Dept Hlth & Human Secur, Tokyo, Japan. [Gao, Yu-Tang; Xiang, Yong-Bing] Shanghai Canc Inst, Dept Epidemiol, Shanghai, Peoples R China. [Yuan, Jian-Min; Wang, Renwei] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. [Yuan, Jian-Min] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Shu, Xiao-Ou; Yang, Gong; Zheng, Wei] Vanderbilt Univ, Sch Med, Dept Med,Div Epidemiol, Vanderbilt Epidemiol Ctr,Vanderbilt Ingram Canc C, Nashville, TN 37212 USA. [Tsuji, Ichiro; Kakizaki, Masako] Tohoku Univ, Grad Sch Med, Dept Publ Hlth & Forens Med, Div Epidemiol, Sendai, Miyagi 980, Japan. [Tanaka, Hideo; Matsuo, Keitaro] Aichi Canc Ctr Res Inst, Div Epidemiol & Prevent, Nagoya, Aichi, Japan. [Nishino, Yoshikazu] Miyagi Canc Ctr Res Inst, Div Canc Epidemiol & Prevent, Sendai, Miyagi, Japan. [Chen, Chien-Jen; You, San-Lin] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan. [Chen, Chien-Jen; Pan, Wen-Harn] Natl Taiwan Univ, Coll Publ Hlth, Grad Inst Epidemiol & Prevent Med, Taipei 10764, Taiwan. [Yoo, Keun-Young; Ahn, Yoon-Ok; Park, Sue K.; Kang, Daehee] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea. [Ahsan, Habibul] Univ Chicago, Ctr Comprehens Canc, Dept Hlth Studies, Chicago, IL 60637 USA. [Ahsan, Habibul] Univ Chicago, Ctr Comprehens Canc, Dept Med, Chicago, IL 60637 USA. [Ahsan, Habibul] Univ Chicago, Ctr Comprehens Canc, Dept Human Genet, Chicago, IL 60637 USA. [Pan, Wen-Harn; Chuang, Shao-Yuan] Natl Hlth Res Inst, Inst Populat Hlth Sci, Div Prevent Med & Hlth Serv Res, Miaoli, Taiwan. [Pan, Wen-Harn] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan. [Chen, Chung-Shiuan; He, Jiang] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA USA. [Sauvaget, Catherine] Int Agcy Res Canc, Screening Grp, F-69372 Lyon, France. [Koh, Woon-Puay] Natl Univ Singapore, Duke NUS Grad Med Sch Singapore, Singapore 117548, Singapore. [Koh, Woon-Puay] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore. [Ohishi, Waka] Radiat Effects Res Fdn, Dept Clin Studies, Hiroshima, Japan. [Watanabe, Takashi; Sugawara, Yumi] Tohoku Univ, Grad Sch Med, Dept Publ Hlth & Forens Med, Div Epidemiol, Sendai, Miyagi 980, Japan. [You, San-Lin] Fu Jen Catholic Univ, Dept Publ Hlth, Taipei, Taiwan. [Park, Sue K.; Kang, Daehee] Seoul Natl Univ, Grad Sch, Dept Biomed Sci, Canc Res Inst, Seoul, South Korea. [Kim, Dong-Hyun] Hallym Univ, Coll Med, Dept Social & Prevent Med, Seoul, South Korea. [Parvez, Faruque] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA. [Sinha, Rashmi] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Boffetta, Paolo] Icahn Sch Med Mt Sinai, Tisch Canc Inst & Inst Translat Epidemiol, New York, NY USA. [Boffetta, Paolo] Int Prevent Res Inst, Lyon, France. [Potter, John D.] Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand. [Feng, Ziding] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA. [Matsuo, Keitaro] Kyushu Univ, Fac Med Sci, Dept Prevent Med, Fukuoka 812, Japan. [Potter, John D.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Potter, JD (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA. EM yu.chen@nyumc.org RI Chen, Chien-Jen/C-6976-2008; Chuang, Shao-Yuan/B-3478-2011; Tsugane, Shocichiro/A-2424-2015; Sinha, Rashmi/G-7446-2015; Tanaka, Hideo/A-8145-2016; OI Sinha, Rashmi/0000-0002-2466-7462; Potter, John/0000-0001-5439-1500; Kakizaki, Masako/0000-0001-6030-8953; Yuan, Jian-Min/0000-0002-4620-3108; Sauvaget, Catherine/0000-0002-8053-4963; Matsuo, Keitaro/0000-0003-1761-6314 FU US National Cancer Institute at the National Institutes of Health [R03CA150038]; Fred Hutchinson Cancer Research Center; Ministry of Health, Labour and Welfare, Japan; Radiation Effects Research Foundation (RERF); Ministry of Education, Culture, Sports, Science and Technology, Japan; China National Hypertension Survey Epidemiology Follow-up Study (CHEFS); American Heart Association [9750612N]; National Heart, Lung, and Blood Institute [U01 HL072507]; Chinese Academy of Medical Sciences Shanghai Cohort Study (SCS); National Institutes for Health [R01CA0403092, R01CA144034, R37CA70867, R01CA55069, R35CA53890, R01CA80205, P42ES010349, R01CA102484, R01CA107431]; Shanghai Men's Health Study (SMHS; National Institutes for Health [RO1 CA 82729]; Shanghai Women's Health Study (SWHS); Community-Based Cancer Screening Project (CBCSP); National Science Council and Department of Health, Taiwan; Disease risk FACtor Two-township Study (CVDFACTS); Department of Health, Taiwan [DOH80-27, DOH81-021, DOH8202-1027, DOH83-TD-015, DOH84-TD-006]; Korea Multi-center Cancer Cohort (KMCC); Ministry of Education, Science and Technology, Korea [2009-0087452]; National Research Foundation of Korea [2009-0087452]; Singapore Chinese Health Study (SCHS); Health Effects of Arsenic Longitudinal Study (HEALS); Trivandrum Oral Cancer Screening (TOCS) trial (Association for International Cancer Research, Scotland, UK; and Cancer Research UK); Mumbai Cohort Study (MCS); International Agency for Research on Cancer, Lyon, France; Clinical Trials Service Unit, Oxford, UK; World Health Organisation, Geneva, Switzerland FX This work was supported by the US National Cancer Institute at the National Institutes of Health (R03CA150038) and by the Fred Hutchinson Cancer Research Center. The cohorts participating in the pooled analysis were supported by the following grants: 3-Prefecture Aichi, Ibaraki, Japan Collaborative Cohort Study (JACC), Japan Public Health Center-Based Study 1 (JPHC1), Japan Public Health Center-Based Study 2 (JPHC2), and 3-Prefecture Miyagi, Miyagi, Ohsaki (National Cancer Center Research and Development Fund, A Grant-in-Aid for Cancer Research; Grant for Health Services and Grant for Comprehensive Research on Cardiovascular and Life-Style Related Diseases from the Ministry of Health, Labour and Welfare, Japan; Grant for the Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan); Radiation Effects Research Foundation (RERF; Hiroshima and Nagasaki, Japan is a private, non-profit foundation funded by the Japanese Ministry of Health, Labour, and Welfare and the US Department of Energy; grant for scientific research from the Ministry of Education, Culture, Sports, Science and Technology, Japan); China National Hypertension Survey Epidemiology Follow-up Study (CHEFS; American Heart Association (9750612N); National Heart, Lung, and Blood Institute (U01 HL072507)); Chinese Academy of Medical Sciences Shanghai Cohort Study (SCS; National Institutes for Health (R01CA0403092, R01CA144034)); Shanghai Men's Health Study (SMHS; National Institutes for Health (RO1 CA 82729)); Shanghai Women's Health Study (SWHS; National Institutes for Health (R37CA70867)); Community-Based Cancer Screening Project (CBCSP; National Science Council and Department of Health, Taiwan); Disease risk FACtor Two-township Study (CVDFACTS; Department of Health, Taiwan (DOH80-27, DOH81-021, DOH8202-1027, DOH83-TD-015, and DOH84-TD-006)); Korea Multi-center Cancer Cohort (KMCC; Ministry of Education, Science and Technology, Korea (2009-0087452), National Research Foundation of Korea (2009-0087452)); Singapore Chinese Health Study (SCHS; National Institutes for Health (R01CA55069, R35CA53890, R01CA80205, R01CA144034)); Health Effects of Arsenic Longitudinal Study (HEALS; National Institutes for Health (P42ES010349, R01CA102484, R01CA107431)); Trivandrum Oral Cancer Screening (TOCS) trial (Association for International Cancer Research, Scotland, UK; and Cancer Research UK); Mumbai Cohort Study (MCS; International Agency for Research on Cancer, Lyon, France; Clinical Trials Service Unit, Oxford, UK; World Health Organisation, Geneva, Switzerland). NR 91 TC 15 Z9 16 U1 5 U2 24 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1756-1833 J9 BMJ-BRIT MED J JI BMJ-British Medical Journal PD OCT 1 PY 2013 VL 347 AR f5446 DI 10.1136/bmj.f5446 PG 19 WC Medicine, General & Internal SC General & Internal Medicine GA 231OK UT WOS:000325426300001 PM 24473060 ER PT J AU Irani, SR Stagg, CJ Schott, JM Rosenthal, CR Schneider, SA Pettingill, P Pettingill, R Waters, P Thomas, A Voets, NL Cardoso, MJ Cash, DM Manning, EN Lang, B Smith, SJM Vincent, A Johnson, MR AF Irani, Sarosh R. Stagg, Charlotte J. Schott, Jonathan M. Rosenthal, Clive R. Schneider, Susanne A. Pettingill, Philippa Pettingill, Rosemary Waters, Patrick Thomas, Adam Voets, Natalie L. Cardoso, Manuel J. Cash, David M. Manning, Emily N. Lang, Bethan Smith, Shelagh J. M. Vincent, Angela Johnson, Michael R. TI Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype SO BRAIN LA English DT Article DE faciobrachial dystonic seizures; LGI1; limbic encephalitis; autoimmune; epilepsy ID POTASSIUM-CHANNEL ANTIBODY; CONTACTIN-ASSOCIATED PROTEIN-2; CENTRAL-NERVOUS-SYSTEM; LIMBIC ENCEPHALITIS; MOVEMENT-DISORDER; MORVANS-SYNDROME; LEUCINE-RICH; EPILEPSY; AUTOIMMUNITY; NEUROMYOTONIA AB Voltage-gated potassium channel complex antibodies, particularly those directed against leucine-rich glioma inactivated 1, are associated with a common form of limbic encephalitis that presents with cognitive impairment and seizures. Faciobrachial dystonic seizures have recently been reported as immunotherapy-responsive, brief, frequent events that often predate the cognitive impairment associated with this limbic encephalitis. However, these observations were made from a retrospective study without serial cognitive assessments. Here, we undertook the first prospective study of faciobrachial dystonic seizures with serial assessments of seizure frequencies, cognition and antibodies in 10 cases identified over 20 months. We hypothesized that (i) faciobrachial dystonic seizures would show a differential response to anti-epileptic drugs and immunotherapy; and that (ii) effective treatment of faciobrachial dystonic seizures would accelerate recovery and prevent the development of cognitive impairment. The 10 cases expand both the known age at onset (28 to 92 years, median 68) and clinical features, with events of longer duration, simultaneously bilateral events, prominent automatisms, sensory aura, and post-ictal fear and speech arrest. Ictal epileptiform electroencephalographic changes were present in three cases. All 10 cases were positive for voltage-gated potassium channel-complex antibodies (346-4515 pM): nine showed specificity for leucine-rich glioma inactivated 1. Seven cases had normal clinical magnetic resonance imaging, and the cerebrospinal fluid examination was unremarkable in all seven tested. Faciobrachial dystonic seizures were controlled more effectively with immunotherapy than anti-epileptic drugs (P = 0.006). Strikingly, in the nine cases who remained anti-epileptic drug refractory for a median of 30 days (range 11-200), the addition of corticosteroids was associated with cessation of faciobrachial dystonic seizures within 1 week in three and within 2 months in six cases. Voltage-gated potassium channel-complex antibodies persisted in the four cases with relapses of faciobrachial dystonic seizures during corticosteroid withdrawal. Time to recovery of baseline function was positively correlated with time to immunotherapy (r = 0.74; P = 0.03) but not time to anti-epileptic drug administration (r = 0.55; P = 0.10). Of 10 cases, the eight cases who received anti-epileptic drugs (n = 3) or no treatment (n = 5) all developed cognitive impairment. By contrast, the two who did not develop cognitive impairment received immunotherapy to treat their faciobrachial dystonic seizures (P = 0.02). In eight cases without clinical magnetic resonance imaging evidence of hippocampal signal change, cross-sectional volumetric magnetic resonance imaging post-recovery, after accounting for age and head size, revealed cases (n = 8) had smaller brain volumes than healthy controls (n = 13) (P < 0.001). In conclusion, faciobrachial dystonic seizures can be prospectively identified as a form of epilepsy with an expanding phenotype. Immunotherapy is associated with excellent control of the frequently anti-epileptic drug refractory seizures, hastens time to recovery, and may prevent the subsequent development of cognitive impairment observed in this study. C1 [Irani, Sarosh R.; Rosenthal, Clive R.; Pettingill, Philippa; Pettingill, Rosemary; Waters, Patrick; Lang, Bethan; Vincent, Angela] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford OX3 9DS, England. [Stagg, Charlotte J.; Thomas, Adam; Voets, Natalie L.] John Radcliffe Hosp, Oxford Ctr Funct MRI Brain, Nuffield Dept Clin Neurosci, Oxford OX3 9DU, England. [Schott, Jonathan M.; Cardoso, Manuel J.; Cash, David M.; Manning, Emily N.] UCL, Inst Neurol, Dementia Res Ctr, London, England. [Schneider, Susanne A.] Univ Kiel, Dept Neurol, D-24105 Kiel, Germany. [Thomas, Adam] NIMH, Funct MRI Facil, NIH, Bethesda, MD 20892 USA. [Cardoso, Manuel J.; Cash, David M.] UCL, Ctr Med Image Comp, London WC1E 6BT, England. [Smith, Shelagh J. M.] Natl Hosp Neurol & Neurosurg, Dept Clin Neurophysiol, London WC1N 3BG, England. [Johnson, Michael R.] Univ London Imperial Coll Sci Technol & Med, Div Brain Sci, London, England. RP Irani, SR (reprint author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Oxford OX3 9DS, England. EM saroshirani@doctors.net.uk RI Schott, Jonathan/A-9065-2011; OI Schott, Jonathan/0000-0003-2059-024X; Stagg, Charlotte/0000-0002-5542-5036; Thomas, Adam/0000-0002-2850-1419; Irani, Sarosh/0000-0002-7667-9748 FU National Institute for Health Research, Department of Health, UK [RDA/07/03/036]; US-UK Fulbright Commission; MS Society; Oxford NIHR Biomedical Research Centre; Medical Research Council; Imperial College Healthcare Trust Biomedical Research Centre; Epilepsy Research UK FX This work was supported by the National Institute for Health Research, Department of Health, UK (RDA/07/03/036 S.R.I.), 'US-UK Fulbright Commission and the MS Society' (S.R.I.), the Oxford NIHR Biomedical Research Centre (P.W., A.V.), Medical Research Council (P.P.), Imperial College Healthcare Trust Biomedical Research Centre (M.R.J.), and Epilepsy Research UK (S.R.I., B.L.). NR 41 TC 87 Z9 91 U1 0 U2 14 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 J9 BRAIN JI Brain PD OCT PY 2013 VL 136 BP 3151 EP 3162 DI 10.1093/brain/awt212 PN 10 PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 228DU UT WOS:000325166500029 PM 24014519 ER PT J AU Pesatori, AC Carugno, M Consonni, D Hung, RJ Papadoupolos, A Landi, MT Brenner, H Muller, H Harris, CC Duell, EJ Andrew, AS McLaughlin, JR Schwartz, AG Wenzlaff, AS Stucker, I AF Pesatori, A. C. Carugno, M. Consonni, D. Hung, R. J. Papadoupolos, A. Landi, M. T. Brenner, H. Mueller, H. Harris, C. C. Duell, E. J. Andrew, A. S. McLaughlin, J. R. Schwartz, A. G. Wenzlaff, A. S. Stucker, I. TI Hormone use and risk for lung cancer: a pooled analysis from the International Lung Cancer Consortium (ILCCO) SO BRITISH JOURNAL OF CANCER LA English DT Article DE lung cancer; exogenous hormones; oral contraceptives; hormone replacement therapy; pooled analysis ID PRACTITIONERS ORAL-CONTRACEPTION; REPLACEMENT THERAPY; REPRODUCTIVE FACTORS; POSTMENOPAUSAL WOMEN; ESTROGEN-RECEPTOR; RANDOMIZED-TRIAL; ROYAL-COLLEGE; COHORT; EXPRESSION; HEALTH AB Background: The association between oral contraceptive (OC) use, hormone replacement therapy (HRT) and lung cancer risk in women is still debated. Methods: We performed a pooled analysis of six case-control studies (1961 cases and 2609 controls) contributing to the International Lung Cancer Consortium. Potential associations were investigated with multivariable unconditional logistic regression and meta-analytic models. Multinomial logistic regressions were performed to investigate lung cancer risk across histologic types. Results: A reduced lung cancer risk was found for OC (odds ratio (OR) = 0.81; 95% confidence interval (CI): 0.68-0.97) and HRT ever users (OR = 0.77; 95% CI: 0.66-0.90). Both oestrogen only and oestrogen vertical bar progestin HRT were associated with decreased risk (OR = 0.76; 95% CI: 0.61-0.94, and OR = 0.66; 95% CI: 0.49-0.88, respectively). No dose-response relationship was observed with years of OC/HRT use. The greatest risk reduction was seen for squamous cell carcinoma (OR = 0.53; 95% CI: 0.37-0.76) in OC users and in both adenocarcinoma (OR = 0.79; 95% CI: 0.66-0.95) and small cell carcinoma (OR = 0.37; 95% CI: 0.19-0.71) in HRT users. No interaction with smoking status or BMI was observed. Conclusion: Our findings suggest that exogenous hormones can play a protective role in lung cancer aetiology. However, given inconsistencies with epidemiological evidence from cohort studies, further and larger investigations are needed for a more comprehensive view of lung cancer development in women. C1 [Pesatori, A. C.; Carugno, M.] Univ Milan, Epidemiol Res Ctr, Dept Clin Sci & Community Hlth, EPOCA, I-20122 Milan, Italy. [Pesatori, A. C.; Carugno, M.; Consonni, D.] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Epidemiol Unit, I-20122 Milan, Italy. [Hung, R. J.; McLaughlin, J. R.] Univ Toronto, Div Epidemiol, Canc Care Ontario Res Chair Populat Studies, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada. [Papadoupolos, A.; Stucker, I.] INSERM, Environm Epidemiol Canc Team, Ctr Res Epidemiol & Populat Hlth CESP, U108, F-94807 Villejuif, France. [Papadoupolos, A.; Stucker, I.] Univ Paris Sud, UMRS 1018, F-94807 Villejuif, France. [Landi, M. T.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Brenner, H.; Mueller, H.] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, D-69120 Heidelberg, Germany. [Harris, C. C.] NCI, Lab Human Carcinogenesis, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Duell, E. J.] Hosp Llobregat, Catalan Inst Oncol ICO IDIBELL, Canc Epidemiol Res Program, Unit Nutr Environm & Canc, Barcelona 08908, Spain. [Andrew, A. S.] Geisel Sch Med Dartmouth, Dept Community & Family Med, Sect Biostat & Epidemiol, Lebanon, NH 03756 USA. [McLaughlin, J. R.] Publ Hlth Ontario, Toronto, ON M5G 1V2, Canada. [Schwartz, A. G.; Wenzlaff, A. S.] Wayne State Univ, Karmanos Canc Inst, Sch Med, Detroit, MI 48201 USA. RP Pesatori, AC (reprint author), Univ Milan, Epidemiol Res Ctr, Dept Clin Sci & Community Hlth, EPOCA, Via San Barnaba 8, I-20122 Milan, Italy. EM angela.pesatori@unimi.it RI Hung, Rayjean/A-7439-2013; Consonni, Dario/K-7943-2016; Brenner, Hermann/B-4627-2017; OI Consonni, Dario/0000-0002-8935-3843; Brenner, Hermann/0000-0002-6129-1572; Duell, Eric J/0000-0001-5256-0163; pesatori, angela/0000-0002-0261-3252 FU Intramural Research Program of the National Institutes of Health (National Cancer Institute, Division of Cancer Epidemiology and Genetics); Lombardy Region (Environmental Epidemiology Program); CARIPLO Foundation (Milan, Italy); National Cancer Institute Grant [R01CA87895] FX This work was supported by Intramural Research Program of the National Institutes of Health (National Cancer Institute, Division of Cancer Epidemiology and Genetics), Lombardy Region (Environmental Epidemiology Program), CARIPLO Foundation (Milan, Italy) and National Cancer Institute Grant R01CA87895. We express our gratitude to all the study participants and collaborators whose commitment made this pooled analysis possible. NR 50 TC 10 Z9 11 U1 1 U2 13 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0007-0920 EI 1532-1827 J9 BRIT J CANCER JI Br. J. Cancer PD OCT 1 PY 2013 VL 109 IS 7 BP 1954 EP 1964 DI 10.1038/bjc.2013.506 PG 11 WC Oncology SC Oncology GA 228UM UT WOS:000325216700032 PM 24002594 ER PT J AU Wang, JB Abnet, CC Chen, W Dawsey, SM Fan, JH Yin, LY Yin, J Major, JM Taylor, PR Qiao, YL Freedman, ND AF Wang, J-B Abnet, C. C. Chen, W. Dawsey, S. M. Fan, J-H Yin, L-Y Yin, J. Major, J. M. Taylor, P. R. Qiao, Y-L Freedman, N. D. TI Association between serum 25(OH) vitamin D, incident liver cancer and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: a nested case-control study SO BRITISH JOURNAL OF CANCER LA English DT Article DE serum vitamin D; chronic liver disease; liver cancer; a nested case-control study ID CIRCULATING 25-HYDROXYVITAMIN D; METABOLIC BONE-DISEASE; 1,25-DIHYDROXYVITAMIN D-3; PARATHYROID-HORMONE; IN-VITRO; RISK; ESOPHAGEAL; HEPATITIS; CIRRHOSIS; CHINA AB Background: Although vitamin D deficiency has been noted in cross-sectional studies of chronic liver disease and laboratory studies suggest possible benefits of vitamin D in preventing liver cancer, little epidemiologic data are available. Methods: We performed a nested case-control study in the Linxian Nutrition Intervention Trials on participants developing incident liver cancer or dying from chronic liver disease over 22 years of follow-up. Baseline serum 25(OH) vitamin D was measured for 226 incident liver cancer cases, 282 chronic liver disease deaths and 1063 age-, sex- and trial-matched controls. Unconditional logistical regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). Results: The median serum vitamin D level in controls was low (20 nmol l(-1)). Compared with the lowest quartile, subjects in the fourth quartile had lower risk of chronic liver disease death (OR = 0.34, 95% CI = 0.21-0.55). For liver cancer incidence, risk estimates were below one, but were not statistically significant. Associations, however, were significant among participants with higher serum calcium levels (Q4 vs Q1, OR = 0.43, 95% CI = 0.21-0.89). Results for chronic liver disease did not vary by serum calcium level. Conclusion: In a low vitamin D population, higher serum 25(OH) vitamin D concentrations were associated with significantly lower risk of chronic liver disease deaths, and among those with higher serum calcium, incident liver cancer. Our results suggest a possible protective role for vitamin D in these diseases. C1 [Wang, J-B; Chen, W.; Fan, J-H; Yin, J.; Qiao, Y-L] Chinese Acad Med Sci, Dept Canc Epidemiol, Canc Inst Hosp, Beijing 100021, Peoples R China. [Wang, J-B; Chen, W.; Fan, J-H; Yin, J.; Qiao, Y-L] Peking Union Med Coll, Beijing 100021, Peoples R China. [Wang, J-B; Abnet, C. C.; Dawsey, S. M.; Major, J. M.; Freedman, N. D.] NCI, Nutr Epidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD 20850 USA. [Yin, L-Y] Chongqing Med Univ, Dept Occupat & Environm Hlth, Sch Publ Hlth, Chongqing 400016, Peoples R China. [Taylor, P. R.] NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD 20850 USA. RP Qiao, YL (reprint author), Chinese Acad Med Sci, Dept Canc Epidemiol, Canc Inst Hosp, Beijing 100021, Peoples R China. EM qiaoy@cicams.ac.cn; freedmanne@mail.nih.gov RI Qiao, You-Lin/B-4139-2012; Abnet, Christian/C-4111-2015; Freedman, Neal/B-9741-2015 OI Qiao, You-Lin/0000-0001-6380-0871; Abnet, Christian/0000-0002-3008-7843; Freedman, Neal/0000-0003-0074-1098 FU National Cancer Institute [N01-SC-91030, N01-RC-47701]; Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health; Cancer Institute, Chinese Academy of Medical Sciences FX This work was supported in part by National Cancer Institute contracts (N01-SC-91030 and N01-RC-47701 to the Cancer Institute, Chinese Academy of Medical Sciences); in part by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health; and in part by Cancer Institute, Chinese Academy of Medical Sciences. This study was approved by the Institutional Review Boards of US National Institutes of Health and the Chinese Academy of Medical Science, and all NIT participants gave informed consent for the use of their blood samples and all data. NR 39 TC 10 Z9 10 U1 1 U2 13 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0007-0920 J9 BRIT J CANCER JI Br. J. Cancer PD OCT 1 PY 2013 VL 109 IS 7 BP 1997 EP 2004 DI 10.1038/bjc.2013.546 PG 8 WC Oncology SC Oncology GA 228UM UT WOS:000325216700037 PM 24008664 ER PT J AU Enewold, L McGlynn, KA Zahm, SH Jatoi, I Anderson, WF Gill, AA Shriver, CD Zhu, KM AF Enewold, Lindsey McGlynn, Katherine A. Zahm, Shelia H. Jatoi, Ismail Anderson, William F. Gill, Abegail A. Shriver, Craig D. Zhu, Kangmin TI Surveillance Mammography Among Female Department of Defense Beneficiaries A Study by Race and Ethnicity SO CANCER LA English DT Article DE breast cancer; mammography; surveillance; survivor; epidemiology; health care access ID BREAST-CANCER SURVIVORS; AMERICAN-SOCIETY; PATTERNS; WOMEN AB BACKGROUNDAnnual surveillance mammography is recommended after a diagnosis of breast cancer. Previous studies have suggested that surveillance mammography varies by demographics and initial tumor characteristics, which are related to an individual's access to health care. The Military Health System of the Department of Defense provides beneficiaries with equal access health care and thus offers an excellent opportunity to assess whether racial differences in surveillance mammography persist when access to care is equal. METHODSAmong female beneficiaries with a history of breast cancer, logistic regression was used to assess racial/ethnic variations in the use of surveillance mammography during 3 periods of 12 months each, beginning 1 year after diagnosis adjusting for demographic, tumor, and health characteristics. RESULTSThe rate of overall surveillance mammography decreased from 70% during the first year to 59% during the third year (P<.01). Although there was an overall tendency for surveillance mammography to be higher among minority women compared with non-Hispanic white women, after adjusting for covariates, the difference was found to be significant only during the first year among black women (odds ratio [OR], 1.46; 95% confidence interval [95% CI], 1.10-1.95) and the second year among Asian/Pacific Islander (OR, 2.29; 95%CI, 1.52-3.44) and Hispanic (OR, 1.92; 95%CI, 1.17-3.18) women. When stratified by age at diagnosis and type of breast cancer surgery performed, significant racial differences tended to be observed among younger women (aged <50 years) and only among women who had undergone mastectomies. CONCLUSIONSMinority women were equally or more likely than non-Hispanic white women to receive surveillance mammography within the Military Health System. The racial disparities in surveillance mammography reported in other studies were not observed in a system with equal access to health care. Cancer 2013;119:3531-3538.. (c) 2013 American Cancer Society. Although minority women are often less likely than non-Hispanic white women to receive surveillance mammography, this finding was not observed within an equal access health care system. The racial disparities in surveillance mammography reported in other studies may be due to racial/ethnic variations in health care access. C1 [Enewold, Lindsey; Gill, Abegail A.; Zhu, Kangmin] Walter Reed Natl Mil Med Ctr, John P Murtha Canc Ctr, Div Mil Epidemiol & Populat Sci, Rockville, MD USA. [Enewold, Lindsey; McGlynn, Katherine A.; Zahm, Shelia H.; Anderson, William F.] NCI, NIH, Bethesda, MD 20892 USA. [Jatoi, Ismail] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA. [Shriver, Craig D.] Walter Reed Natl Mil Med Ctr, John P Murtha Canc Ctr, Bethesda, MD USA. [Shriver, Craig D.] Walter Reed Natl Mil Med Ctr, Breast Ctr, Bethesda, MD USA. [Shriver, Craig D.] Walter Reed Natl Mil Med Ctr, Gen Surg Serv, Bethesda, MD USA. [Shriver, Craig D.; Zhu, Kangmin] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA. RP Enewold, L (reprint author), NCI Shady Grove, DCCPS, ARP, Hlth Serv Econ Branch, 9609 Med Ctr Dr,Room 3E506, Bethesda, MD 20892 USA. EM enewoldlr@mail.nih.gov RI Zahm, Shelia/B-5025-2015 FU John P. Murtha Cancer Center; Walter Reed National Military Cancer Center via the Uniformed Services University of the Health Sciences under the Henry M. Jackson Foundation for the Advancement of Military Medicine. FX Supported by the John P. Murtha Cancer Center, Walter Reed National Military Cancer Center via the Uniformed Services University of the Health Sciences under the auspices of the Henry M. Jackson Foundation for the Advancement of Military Medicine. NR 26 TC 4 Z9 4 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD OCT 1 PY 2013 VL 119 IS 19 BP 3531 EP 3538 DI 10.1002/cncr.28242 PG 8 WC Oncology SC Oncology GA 224XK UT WOS:000324925500017 PM 23913448 ER PT J AU Driver, DI Gogtay, N Rapoport, JL AF Driver, David I. Gogtay, Nitin Rapoport, Judith L. TI Childhood Onset Schizophrenia and Early Onset Schizophrenia Spectrum Disorders SO CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article DE Schizophrenia; Childhood onset schizophrenia; Childhood psychosis ID COMPLEX DEVELOPMENTAL DISORDER; CORTICAL BRAIN-DEVELOPMENT; TREATMENT DELAY; 1ST-EPISODE PSYCHOSIS; UNTREATED PSYCHOSIS; GRAY-MATTER; NONPSYCHOTIC CHILDREN; PSYCHIATRIC-DISORDERS; PREMORBID ADJUSTMENT; EMOTIONAL DISORDERS AB The clinical severity, impact on development, and poor prognosis of childhood onset schizophrenia may represent a more homogeneous group. Positive symptoms in children are necessary for the diagnosis and hallucinations are more often multimodal. In healthy children and children with a variety of other psychiatric illnesses, hallucinations are not uncommon and diagnosis should not be based on these alone. Childhood onset schizophrenia is an extraordinarily rare illness that is poorly understood but seems continuous with the adult onset disorder. Once a diagnosis is affirmed, aggressive medication treatment combined with family education and individual counseling may defer further deterioration. C1 [Driver, David I.; Gogtay, Nitin; Rapoport, Judith L.] NIMH, Child Psychiat Branch, NIH, Bethesda, MD 20892 USA. RP Rapoport, JL (reprint author), NIMH, Child Psychiat Branch, NIH, Bldg 10,Room 3N202,10 Ctr Dr,MSC 1600, Bethesda, MD 20892 USA. EM rapoporj@mail.nih.gov RI Gogtay, Nitin/A-3035-2008 FU Intramural NIH HHS [Z01 MH002581-17] NR 102 TC 13 Z9 14 U1 1 U2 32 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1056-4993 J9 CHILD ADOL PSYCH CL JI Child Adolesc. Psychiatr. N. Am. PD OCT PY 2013 VL 22 IS 4 BP 539 EP + DI 10.1016/j.chc.2013.04.001 PG 18 WC Psychiatry SC Psychiatry GA 228MP UT WOS:000325191200002 PM 24012072 ER PT J AU Kwong, MLM Neyns, B Yang, JC AF Kwong, Mei Li M. Neyns, Bart Yang, James C. TI Adoptive T-cell Transfer Therapy and Oncogene-Targeted Therapy for Melanoma: The Search for Synergy SO CLINICAL CANCER RESEARCH LA English DT Article ID METASTATIC MELANOMA; BRAF INHIBITION; TUMOR INFILTRATION; ANTIGEN-EXPRESSION; ANTITUMOR-ACTIVITY; PHASE-II; VEMURAFENIB; IMMUNOTHERAPY; SURVIVAL; MEK AB The clinical strengths of immunotherapy and small-molecule inhibitors targeting the mitogen-activated protein kinase (MAPK) pathway appear to be largely complementary for the treatment of advanced melanoma. In current practice, most patients with BRAF V600 mutant melanomas will see both modalities. Several in vitro and in vivo studies suggest that combining immunotherapy with MAPK inhibition may have synergistic effects. First, mouse models show that adoptive cell therapy (ACT) can be enhanced by vaccination. Rapid tumor destruction by vemurafenib could provide a vaccine-like stimulus to adoptively transferred T cells. Second, both in mice and in early clinical trials, melanoma metastases treated with MAPK inhibitors seem to display increased T-cell infiltrates. Third, MAPK inhibition upregulates the expression of some melanoma antigens and, therefore, may enhance T-cell recognition of vemurafenib-treated melanomas. Fourth, vemurafenib may sensitize tumor cells to immune destruction. Finally, some investigators have found that an optimal antitumor effect from MAPK inhibition is dependent on an intact host immune response. Currently, the Surgery Branch of the National Cancer Institute has initiated a phase II trial combining the BRAF inhibitor vemurafenib with ACT using tumor-infiltrating lymphocytes in patients with BRAF-mutant tumors to investigate the safety and efficacy of this combination. The proposed mechanisms for synergy between these two modalities can be complex, and their optimal combination may require testing a variety of sequences and schedules. (C) 2013 AACR. C1 [Kwong, Mei Li M.; Yang, James C.] NCI, Surg Branch, NIH, Bethesda, MD 20892 USA. [Neyns, Bart] Univ Ziekenhuis Brussel, Dept Med Oncol, Brussels, Belgium. RP Yang, JC (reprint author), NCI, 10 Ctr Dr,Rm 3-5952, Bethesda, MD 20892 USA. EM JamesYang@mail.nih.gov OI Yang, James Chih-Hsin/0000-0002-5586-5138 FU Intramural NIH HHS [Z99 CA999999] NR 30 TC 9 Z9 9 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD OCT 1 PY 2013 VL 19 IS 19 BP 5292 EP 5299 DI 10.1158/1078-0432.CCR-13-0261 PG 8 WC Oncology SC Oncology GA 228RA UT WOS:000325203700006 PM 24089442 ER PT J AU Harford, TC Yi, HY Grant, BF AF Harford, Thomas C. Yi, Hsiao-ye Grant, Bridget F. TI Other- and self-directed forms of violence and their relationships to DSM-IV substance use and other psychiatric disorders in a national survey of adults SO COMPREHENSIVE PSYCHIATRY LA English DT Article ID ENVIRONMENTAL RISK-FACTORS; COMMON MENTAL-DISORDERS; EPIDEMIOLOGIC SURVEY; UNITED-STATES; SUICIDE ATTEMPTS; EXTERNALIZING PSYCHOPATHOLOGY; PERSONALITY-DISORDERS; ALCOHOL; BEHAVIOR; POPULATION AB Objective: To examine associations between DSM-IV psychiatric disorders and other- and self-directed violence in the general population. Methods: Data were obtained from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) Waves 1 & 2 (n = 34,653). Four violence categories were derived from a latent class analysis (LCA) of 5 other-directed and 4 self-directed violent behavior indicators. Multinomial logistic regression examined class associations for gender, race ethnicity, age and DSM-IV substance use, mood, anxiety, and personality disorders. Results: Approximately 16% of adults reported some form of violent behavior distributed as follows: other-directed only, 4.6%; self-directed only, 9.3%; combined self- and other-directed, 2.0%; and no violence, 84.1%. The majority of the DSM-IV disorders included in this study were significantly and independently related to each form of violence. Generally, other-directed violence was more strongly associated with any substance use disorders (81%) and any personality disorders (42%), while self-directed violence was more strongly associated with mood (41%) and anxiety disorders (57%). Compared with these two forms of violence, the smaller group with combined self- and other-directed violence was more strongly associated with any substance use disorders (88%), mood disorders (63%), and personality disorders (76%). Conclusion: Findings from this study are consistent with recent conceptualizations of disorders as reflecting externalizing disorders and internalizing disorders. The identification of the small category with combined forms of violence further extends numerous clinical studies which established associations between self- and other-directed violent behaviors. The extent to which the combined violence category represents a meaningful and reliable category of violence requires further detailed studies. (C) 2013 Elsevier Inc. All rights reserved. C1 [Harford, Thomas C.; Yi, Hsiao-ye] CSR Inc, Alcohol Epidemiol Data Syst, Arlington, VA 22201 USA. [Grant, Bridget F.] NIAAA, NIH, Bethesda, MD USA. RP Yi, HY (reprint author), NIAAA, Alcohol Epidemiol Data Syst, NIH, CSR Inc, Arlington, VA 22201 USA. EM hyi@csrincorporated.com FU Intramural Research Program of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH); Alcohol Epidemiologic Data System; NIAAA [HHSN267200800023C] FX This research was supported in part by the Intramural Research Program of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH), and by the Alcohol Epidemiologic Data System funded by NIAAA Contract No. HHSN267200800023C to CSR, Incorporated. The views and opinions expressed in this report are those of the authors and should not be construed to represent the views of the sponsoring agency or the Federal Government. NR 44 TC 10 Z9 10 U1 3 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0010-440X EI 1532-8384 J9 COMPR PSYCHIAT JI Compr. Psychiat. PD OCT PY 2013 VL 54 IS 7 BP 731 EP 739 DI 10.1016/j.comppsych.2013.02.003 PG 9 WC Psychiatry SC Psychiatry GA 226ME UT WOS:000325039600001 PM 23587529 ER PT J AU Okano, T Kelley, MW AF Okano, Takayuki Kelley, Matthew W. TI Expression of Insulin-Like Growth Factor Binding Proteins During Mouse Cochlear Development SO DEVELOPMENTAL DYNAMICS LA English DT Article DE differentiation; cellular patterning; gradient ID MAMMALIAN INNER-EAR; GENE-EXPRESSION; CELL-PROLIFERATION; MESSENGER-RNA; FACTOR SYSTEM; FACTOR IGF; DIFFERENTIATION; ORGAN; CORTI; MICE AB Background: Insulin-like growth factor (IGF) signaling plays important roles in growth and cellular differentiation in the cochlear sensory epithelium. However, the roles of IGF binding proteins (IGFBPs), a family of IGF modulators, remain to be elucidated in this system. To begin to examine the role of IGFBPs, we used reverse transcription polymerase chain reaction (RT-PCR) and in situ hybridization to determine the temporal and spatial patterns of expression for Igfbps within the developing mouse cochlea. Results: RT-PCR analysis indicates that Igfpb2-5 are expressed in the cochlea between embryonic day (E) 13.5 and postnatal day (P) 0. In addition, the expression of each Igfbp significantly increased between E13.5 and P0. In situ hybridization indicates that Igfbp2, 3, 4, and 5 have distinct and complementary expression patterns in the developing cochlea. Moreover, expression patterns of Igfbp3 and 5 demonstrate contrasting gradients along the basal-to-apical axis of the cochlea. Conclusions:Igfbp2-5 are expressed in distinct and complementary patterns during cochlear development. These data suggest that IGFBPs may act to precisely regulate activation of IGF signaling in the developing cochlea in a cell type-specific manner, contributing to cellular patterning and differentiation in the cochlea. Developmental Dynamics 242:1210-1221, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Okano, Takayuki; Kelley, Matthew W.] Natl Inst Deafness & Other Commun Disorders, Lab Cochlear Dev, NIH, Bethesda, MD USA. RP Kelley, MW (reprint author), Porter Neurosci Res Ctr, 35 Convent Dr,Bldg 35,2A-100, Bethesda, MD USA. EM kelleymt@nidcd.nih.gov FU NIH; Intramural Program FX Grant sponsors: NIH; Intramural Program. NR 43 TC 3 Z9 3 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1058-8388 J9 DEV DYNAM JI Dev. Dyn. PD OCT PY 2013 VL 242 IS 10 BP 1210 EP 1221 DI 10.1002/dvdy.24005 PG 12 WC Anatomy & Morphology; Developmental Biology SC Anatomy & Morphology; Developmental Biology GA 227IV UT WOS:000325107000009 PM 23813480 ER PT J AU Fiori, JL Shin, YK Kim, W Krzysik-Walker, SM Gonzalez-Mariscal, I Carlson, OD Sanghvi, M Moaddel, R Farhang, K Gadkaree, SK Doyle, ME Pearson, KJ Mattison, JA de Cabo, R Egan, JM AF Fiori, Jennifer L. Shin, Yu-Kyong Kim, Wook Krzysik-Walker, Susan M. Gonzalez-Mariscal, Isabel Carlson, Olga D. Sanghvi, Mitesh Moaddel, Ruin Farhang, Kathleen Gadkaree, Shekhar K. Doyle, Maire E. Pearson, Kevin J. Mattison, Julie A. de Cabo, Rafael Egan, Josephine M. TI Resveratrol Prevents beta-Cell Dedifferentiation in Nonhuman Primates Given a High-Fat/High-Sugar Diet SO DIABETES LA English DT Article ID GLUCAGON-LIKE PEPTIDE-1; PROTEIN-KINASE-C; INSULIN SENSITIVITY; GLUCOSE-TOLERANCE; SUPPLEMENTATION; ACTIVATION; APOPTOSIS; RECEPTOR; PROLIFERATION; DETERMINANTS AB Eating a Westernized diet high in fat and sugar leads to weight gain and numerous health problems, including the development of type 2 diabetes mellitus (T2DM). Rodent studies have shown that resveratrol supplementation reduces blood glucose levels, preserves -cells in islets of Langerhans, and improves insulin action. Although rodent models are helpful for understanding -cell biology and certain aspects of T2DM pathology, they fail to reproduce the complexity of the human disease as well as that of nonhuman primates. Rhesus monkeys were fed a standard diet (SD), or a high-fat/high-sugar diet in combination with either placebo (HFS) or resveratrol (HFS+Resv) for 24 months, and pancreata were examined before overt dysglycemia occurred. Increased glucose-stimulated insulin secretion and insulin resistance occurred in both HFS and HFS+Resv diets compared with SD. Although islet size was unaffected, there was a significant decrease in -cells and an increase in -cells containing glucagon and glucagon-like peptide 1 with HFS diets. Islets from HFS+Resv monkeys were morphologically similar to SD. HFS diets also resulted in decreased expression of essential -cell transcription factors forkhead box O1 (FOXO1), NKX6-1, NKX2-2, and PDX1, which did not occur with resveratrol supplementation. Similar changes were observed in human islets where the effects of resveratrol were mediated through Sirtuin 1. These findings have implications for the management of humans with insulin resistance, prediabetes, and diabetes. C1 [Fiori, Jennifer L.; Shin, Yu-Kyong; Kim, Wook; Krzysik-Walker, Susan M.; Gonzalez-Mariscal, Isabel; Carlson, Olga D.; Sanghvi, Mitesh; Moaddel, Ruin; Farhang, Kathleen; Gadkaree, Shekhar K.; Egan, Josephine M.] NIA, Clin Invest Lab, NIH, Baltimore, MD 21224 USA. [Shin, Yu-Kyong] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA. [Kim, Wook] Ajou Univ, Dept Mol Sci & Technol, Suwon 441749, South Korea. [Doyle, Maire E.] Johns Hopkins Bayview Med Ctr, Div Endocrinol, Baltimore, MD USA. [Pearson, Kevin J.; Mattison, Julie A.; de Cabo, Rafael] NIA, Translat Gerontol Branch, NIH, Baltimore, MD 21224 USA. [Pearson, Kevin J.] Univ Kentucky, Coll Med, Grad Ctr Nutr Sci, Lexington, KY USA. RP Egan, JM (reprint author), NIA, Clin Invest Lab, NIH, Baltimore, MD 21224 USA. EM eganj@grc.nia.nih.gov RI de Cabo, Rafael/J-5230-2016; OI de Cabo, Rafael/0000-0002-3354-2442; Gonzalez Mariscal, Isabel/0000-0003-1186-1212 FU Intramural Research Program of the National Institute on Aging; Office of Dietary Supplements; Basic Science Research Program through the National Research Foundation of Korea (NRF); Ministry of Science, ICT, and Future Planning [2012R1A1A1041352]; JDRF; Sanford Project, Sioux Falls, SD FX This work was supported by the Intramural Research Program of the National Institute on Aging and by a grant from the Office of Dietary Supplements awarded to K.J.P. W. K. was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) and funded by the Ministry of Science, ICT, and Future Planning (2012R1A1A1041352). M. E. D. was supported by the JDRF and The Sanford Project, Sioux Falls, SD. NR 54 TC 48 Z9 48 U1 3 U2 15 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD OCT PY 2013 VL 62 IS 10 BP 3500 EP 3513 DI 10.2337/db13-0266 PG 14 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 222RG UT WOS:000324748200033 PM 23884882 ER PT J AU Genuth, SM Backlund, JYC Bayless, M Bluemke, DA Cleary, PA Crandall, J Lachin, JM Lima, JAC Miao, CL Turkbey, EB AF Genuth, Saul M. Backlund, Jye-Yu C. Bayless, Margaret Bluemke, David A. Cleary, Patricia A. Crandall, Jill Lachin, John M. Lima, Joao A. C. Miao, Culian Turkbey, Evrim B. CA DCCT EDIC Res Grp TI Effects of Prior Intensive Versus Conventional Therapy and History of Glycemia on Cardiac Function in Type 1 Diabetes in the DCCT/EDIC SO DIABETES LA English DT Article ID CORONARY-HEART-DISEASE; COMPLICATIONS TRIAL COHORT; INTIMA-MEDIA THICKNESS; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; RISK-FACTORS; PULSE PRESSURE; MAGNETIC-RESONANCE; FOLLOW-UP; MELLITUS AB Intensive diabetes therapy reduces the prevalence of coronary calcification and progression of atherosclerosis and the risk of cardiovascular disease (CVD) events in the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) study. The effects of intensive therapy on measures of cardiac function and structure and their association with glycemia have not been explored in type 1 diabetes (T1DM). We assess whether intensive treatment compared with conventional treatment during the DCCT led to differences in these parameters during EDIC. After 6.5 years of intensive versus conventional therapy in the DCCT, and 15 years of additional follow-up in EDIC, left ventricular (LV) indices were measured by cardiac magnetic resonance (CMR) imaging in 1,017 of the 1,371 members of the DCCT cohort. There were no differences between the DCCT intensive versus conventional treatment in end diastolic volume (EDV), end systolic volume, stroke volume (SV), cardiac output (CO), LV mass, ejection fraction, LV mass/EDV, or aortic distensibility (AD). Mean DCCT/EDIC HbA(1c) over time was associated with EDV, SV, CO, LV mass, LV mass/EDV, and AD. These associations persisted after adjustment for CVD risk factors. Cardiac function and remodeling in T1DM assessed by CMR in the EDIC cohort was associated with prior glycemic exposure, but there was no effect of intensive versus conventional treatment during the DCCT on cardiac parameters. C1 [Genuth, Saul M.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Backlund, Jye-Yu C.; Cleary, Patricia A.; Lachin, John M.] George Washington Univ, Ctr Biostat, Rockville, MD USA. [Bayless, Margaret] Univ Iowa, Iowa City, IA USA. [Bluemke, David A.; Turkbey, Evrim B.] NIH, Bethesda, MD 20892 USA. [Crandall, Jill] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Lima, Joao A. C.; Miao, Culian] Johns Hopkins Univ, Baltimore, MD USA. RP Genuth, SM (reprint author), Case Western Reserve Univ, Cleveland, OH 44106 USA. EM smg15@case.edu OI Lachin, John/0000-0001-9838-2841; Bluemke, David/0000-0002-8323-8086 FU Division of Diabetes, Endocrinology, and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Eye Institute; National Institute of Neurological Disorders and Stroke; General Clinical Research Centers Program, National Center for Research Resources; Clinical and Translation Science Centers Program, National Center for Research Resources; Genentech; NIDDK FX The DCCT/EDIC project is supported by contracts with the Division of Diabetes, Endocrinology, and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Eye Institute, the National Institute of Neurological Disorders and Stroke, the General Clinical Research Centers Program and the Clinical and Translation Science Centers Program, the National Center for Research Resources, and Genentech through a Cooperative Research and Development Agreement with the NIDDK. NR 56 TC 12 Z9 12 U1 0 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD OCT PY 2013 VL 62 IS 10 BP 3561 EP 3569 DI 10.2337/db12-0546 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 222RG UT WOS:000324748200040 PM 23520132 ER PT J AU Yaghootkar, H Lamina, C Scott, RA Dastani, Z Hivert, MF Warren, LL Stancakova, A Buxbaum, SG Lyytikaeinen, LP Henneman, P Wu, Y Cheung, CYY Pankow, JS Jackson, AU Gustafsson, S Zhao, JH Ballantyne, CM Xie, WJ Bergman, RN Boehnke, M el Bouazzaoui, F Collins, FS Dunn, SH Dupuis, J Forouhi, NG Gillson, C Hattersley, AT Hong, JY Kaehoenen, M Kuusisto, J Kedenko, L Kronenberg, F Doria, A Assimes, TL Ferrannini, E Hansen, T Hao, K Haering, H Knowles, JW Lindgren, CM Nolan, JJ Paananen, J Pedersen, O Quertermous, T Smith, U Lehtimaeki, T Liu, CT Loos, RJF McCarthy, MI Morris, AD Vasan, RS Spector, TD Teslovich, TM Tuomilehto, J van Dijk, KW Viikari, JS Zhu, N Langenberg, C Ingelsson, E Semple, RK Sinaiko, AR Palmer, CNA Walker, M Lam, KSL Paulweber, B Mohlke, KL van Duijn, C Raitakari, OT Bidulescu, A Wareham, NJ Laakso, M Waterworth, DM Lawlor, DA Meigs, JB Richards, JB Frayling, TM AF Yaghootkar, Hanieh Lamina, Claudia Scott, Robert A. Dastani, Zari Hivert, Marie-France Warren, Liling L. Stancakova, Alena Buxbaum, Sarah G. Lyytikaeinen, Leo-Pekka Henneman, Peter Wu, Ying Cheung, Chloe Y. Y. Pankow, James S. Jackson, Anne U. Gustafsson, Stefan Zhao, Jing Hua Ballantyne, Christie M. Xie, Weijia Bergman, Richard N. Boehnke, Michael el Bouazzaoui, Fatiha Collins, Francis S. Dunn, Sandra H. Dupuis, Josee Forouhi, Nita G. Gillson, Christopher Hattersley, Andrew T. Hong, Jaeyoung Kaehoenen, Mika Kuusisto, Johanna Kedenko, Lyudmyla Kronenberg, Florian Doria, Alessandro Assimes, Themistocles L. Ferrannini, Ele Hansen, Torben Hao, Ke Haering, Hans Knowles, Joshua W. Lindgren, Cecilia M. Nolan, John J. Paananen, Jussi Pedersen, Oluf Quertermous, Thomas Smith, Ulf Lehtimaeki, Terho Liu, Ching-Ti Loos, Ruth J. F. McCarthy, Mark I. Morris, Andrew D. Vasan, Ramachandran S. Spector, Tim D. Teslovich, Tanya M. Tuomilehto, Jaakko van Dijk, Ko Willems Viikari, Jorma S. Zhu, Na Langenberg, Claudia Ingelsson, Erik Semple, Robert K. Sinaiko, Alan R. Palmer, Colin N. A. Walker, Mark Lam, Karen S. L. Paulweber, Bernhard Mohlke, Karen L. van Duijn, Cornelia Raitakari, Olli T. Bidulescu, Aurelian Wareham, Nick J. Laakso, Markku Waterworth, Dawn M. Lawlor, Debbie A. Meigs, James B. Richards, J. Brent Frayling, Timothy M. CA GENESIS Consortium RISC Consortium TI Mendelian Randomization Studies Do Not Support a Causal Role for Reduced Circulating Adiponectin Levels in Insulin Resistance and Type 2 Diabetes SO DIABETES LA English DT Article ID MOLECULAR-WEIGHT ADIPONECTIN; GREATER-THAN-G; PLASMA ADIPONECTIN; ADIPOSE-TISSUE; ASSOCIATION ANALYSES; METABOLIC PROFILE; GENETIC-VARIANTS; SUPPRESSION TEST; GLYCEMIC TRAITS; OBESE WOMEN AB Adiponectin is strongly inversely associated with insulin resistance and type 2 diabetes, but its causal role remains controversial. We used a Mendelian randomization approach to test the hypothesis that adiponectin causally influences insulin resistance and type 2 diabetes. We used genetic variants at the ADIPOQ gene as instruments to calculate a regression slope between adiponectin levels and metabolic traits (up to 31,000 individuals) and a combination of instrumental variables and summary statistics-based genetic risk scores to test the associations with gold-standard measures of insulin sensitivity (2,969 individuals) and type 2 diabetes (15,960 case subjects and 64,731 control subjects). In conventional regression analyses, a 1-SD decrease in adiponectin levels was correlated with a 0.31-SD (95% CI 0.26-0.35) increase in fasting insulin, a 0.34-SD (0.30-0.38) decrease in insulin sensitivity, and a type 2 diabetes odds ratio (OR) of 1.75 (1.47-2.13). The instrumental variable analysis revealed no evidence of a causal association between genetically lower circulating adiponectin and higher fasting insulin (0.02 SD; 95% CI -0.07 to 0.11; N = 29,771), nominal evidence of a causal relationship with lower insulin sensitivity (-0.20 SD; 95% CI -0.38 to -0.02; N = 1,860), and no evidence of a relationship with type 2 diabetes (OR 0.94; 95% CI 0.75-1.19; N = 2,777 case subjects and 13,011 control subjects). Using the ADIPOQ summary statistics genetic risk scores, we found no evidence of an association between adiponectin-lowering alleles and insulin sensitivity (effect per weighted adiponectin-lowering allele: -0.03 SD; 95% CI -0.07 to 0.01; N = 2,969) or type 2 diabetes (OR per weighted adiponectin-lowering allele: 0.99; 95% CI 0.95-1.04; 15,960 case subjects vs. 64,731 control subjects). These results do not provide any consistent evidence that interventions aimed at increasing adiponectin levels will improve insulin sensitivity or risk of type 2 diabetes. C1 [Yaghootkar, Hanieh; Xie, Weijia; Hattersley, Andrew T.; Frayling, Timothy M.] Univ Exeter, Sch Med, Exeter, Devon, England. [Lamina, Claudia; Kronenberg, Florian] Med Univ Innsbruck, Dept Med Genet Mol & Clin Pharmacol, Div Genet Epidemiol, A-6020 Innsbruck, Austria. [Scott, Robert A.; Zhao, Jing Hua; Forouhi, Nita G.; Gillson, Christopher; Loos, Ruth J. F.; Langenberg, Claudia; Wareham, Nick J.] Inst Met Sci, MRC Epidemiol Unit, Cambridge, England. [Dastani, Zari] McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ H3T 1E2, Canada. [Hivert, Marie-France] Univ Sherbrooke, Dept Med, Sherbrooke, PQ J1K 2R1, Canada. [Hivert, Marie-France; Meigs, James B.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. [Warren, Liling L.] GlaxoSmithKline, Res Triangle Pk, NC USA. [Stancakova, Alena; Kuusisto, Johanna; Hao, Ke; Paananen, Jussi; Laakso, Markku] Univ Eastern Finland, Kuopio, Finland. [Buxbaum, Sarah G.] Jackson State Univ, Sch Hlth Sci, Jackson, MS USA. [Lyytikaeinen, Leo-Pekka; Lehtimaeki, Terho] Fimlab Labs, Dept Clin Chem, Tampere, Finland. [Lyytikaeinen, Leo-Pekka; Lehtimaeki, Terho] Univ Tampere, Sch Med, Dept Clin Chem, FIN-33101 Tampere, Finland. [Henneman, Peter; el Bouazzaoui, Fatiha; van Dijk, Ko Willems] Leiden Univ, Dept Human Genet, Med Ctr, NL-2300 RA Leiden, Netherlands. [Wu, Ying; Mohlke, Karen L.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA. [Cheung, Chloe Y. Y.; Lam, Karen S. L.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Med, Hong Kong, Hong Kong, Peoples R China. [Pankow, James S.; Zhu, Na] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Jackson, Anne U.; Boehnke, Michael; Teslovich, Tanya M.] Univ Michigan, Dept Biostat & Ctr Stat Genet, Ann Arbor, MI 48109 USA. [Gustafsson, Stefan; Ingelsson, Erik] Uppsala Univ, Mol Epidemiol & Sci Life Lab, Dept Med Sci, Uppsala, Sweden. [Ballantyne, Christie M.] Baylor Coll Med, Houston, TX USA. [Ballantyne, Christie M.] Methodist DeBakey Heart & Vasc Ctr, Houston, TX USA. [Bergman, Richard N.] Cedars Sinai Med Ctr, Diabetes & Obes Res Inst, Los Angeles, CA 90048 USA. [Collins, Francis S.] Natl Inst Hlth, Natl Human Genome Res Inst, Genome Technol Branch, Bethesda, MD USA. [Dunn, Sandra H.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA. [Dupuis, Josee; Hong, Jaeyoung; Liu, Ching-Ti] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Kaehoenen, Mika] Tampere Univ Hosp, Dept Clin Psychol, Tampere, Finland. [Kaehoenen, Mika] Univ Tampere, Sch Med, FIN-33101 Tampere, Finland. [Kedenko, Lyudmyla; Paulweber, Bernhard] Paracelsus Private Med Univ Salzburg, St Johann Spital, Dept Internal Med 1, Salzburg, Austria. [Doria, Alessandro] Joslin Diabet Ctr, Sect Genet & Epidemiol, Boston, MA 02215 USA. [Assimes, Themistocles L.; Knowles, Joshua W.; Quertermous, Thomas] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA. [Assimes, Themistocles L.; Knowles, Joshua W.; Quertermous, Thomas] Stanford Univ, Sch Med, Cardiovasc Inst, Stanford, CA 94305 USA. Univ Pisa, Dept Internal Med, Pisa, Italy. [Haering, Hans; Pedersen, Oluf] Univ Copenhagen, Fac Hlth Sci, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark. Univ Southern Denmark, Fac Hlth Sci, Odense, Denmark. Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA. Univ Tubingen, Dept Internal Med, Div Endocrinol Diabetol Nephrol Vasc Med & Clin C, Tubingen, Germany. [Ferrannini, Ele; Lindgren, Cecilia M.; McCarthy, Mark I.; Ingelsson, Erik] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England. [Hansen, Torben; Nolan, John J.] Steno Diabet Ctr, DK-2820 Gentofte, Denmark. [Haering, Hans] Hagedorn Res Inst, Copenhagen, Denmark. [Haering, Hans] Univ Copenhagen, Fac Hlth Sci, Inst Biomed Sci, Copenhagen, Denmark. [Haering, Hans] Univ Aarhus, Fac Hlth Sci, Aarhus, Denmark. [Smith, Ulf] Sahlgrens Acad, Lundberg Lab Diabet Res, Dept Mol & Clin Med, Gothenburg, Sweden. [Loos, Ruth J. F.] Inst Child Hlth & Dev, Charles Bronfman Inst Personalized Med, Mt Sinai Sch Med, Dept Prevent Med, New York, NY USA. [McCarthy, Mark I.] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England. [McCarthy, Mark I.] Churchill Hosp, Oxford Natl Inst Hlth Res Biomed Res Ctr, Oxford OX3 7LJ, England. [Morris, Andrew D.; Palmer, Colin N. A.] Univ Dundee, Ninewells Hosp & Med Sch, Med Res Inst, Dundee DD1 9SY, Scotland. [Vasan, Ramachandran S.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Vasan, Ramachandran S.] Framingham Heart Dis Epidemiol Study, Framingham, MA USA. [Spector, Tim D.; Richards, J. Brent] Kings Coll London, Twin Res & Genet Epidemiol, London WC2R 2LS, England. [Tuomilehto, Jaakko] Natl Inst Hlth & Welf, Diabetes Prevent Unit, Helsinki, Finland. [Tuomilehto, Jaakko] King Abdulaziz Univ, Jeddah 21413, Saudi Arabia. [Tuomilehto, Jaakko] Hosp Univ La Paz, Red RECAVA Grp RD06 0014 0015, Madrid, Spain. [Tuomilehto, Jaakko] Danube Univ Krems, Ctr Vasc Prevent, Krems, Austria. [Viikari, Jorma S.] Turku Univ Hosp, Dept Med, FIN-20520 Turku, Finland. [Viikari, Jorma S.] Univ Turku, Dept Med, Turku, Finland. [Semple, Robert K.] Natl Inst Hlth Res Cambridge Biomed Res Ctr, Cambridge, England. [Semple, Robert K.] Univ Cambridge, Metab Res Labs, Inst Metab Sci, Cambridge, England. [Sinaiko, Alan R.] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA. [Walker, Mark] Newcastle Univ, Sch Med, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Lam, Karen S. L.] Univ Hong Kong, Li Ka Shing Fac Med, Res Ctr Heart Brain Hormone & Hlth Aging, Hong Kong, Hong Kong, Peoples R China. [van Duijn, Cornelia] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands. [Raitakari, Olli T.] Turku Univ Hosp, Dept Clin Physiol & Nucl Med, FIN-20520 Turku, Finland. [Raitakari, Olli T.] Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, Turku, Finland. [Bidulescu, Aurelian] Inst Cardiovasc Res, Morehouse Sch Med, Atlanta, GA USA. [Bidulescu, Aurelian] Morehouse Sch Med, Dept Community Hlth & Prevent Med, Atlanta, GA 30310 USA. [Waterworth, Dawn M.] GlaxoSmithKline, Upper Merion, PA USA. [Lawlor, Debbie A.] Univ Bristol, Dept Social Med, Bristol, Avon, England. [Richards, J. Brent] McGill Univ, Dept Med Human Genet Epidemiol & Biostat, Montreal, PQ, Canada. RP Frayling, TM (reprint author), Univ Exeter, Sch Med, Exeter, Devon, England. EM tim.frayling@pms.ac.uk RI Colaus, PsyColaus/K-6607-2013; Palmer, Colin/C-7053-2008; Willems van Dijk, Ko/A-1798-2008; Bidulescu, Aurelian/N-2617-2014; Kronenberg, Florian/B-1736-2008; Lyytikainen, Leo-Pekka/C-8544-2016; Study, GoDARTS/K-9448-2016; Buxbaum, Sarah/E-1970-2013; OI Palmer, Colin/0000-0002-6415-6560; Willems van Dijk, Ko/0000-0002-2172-7394; Ramachandran, Vasan/0000-0001-7357-5970; Semple, Robert/0000-0001-6539-3069; Bidulescu, Aurelian/0000-0001-8211-8309; Kronenberg, Florian/0000-0003-2229-1120; Lyytikainen, Leo-Pekka/0000-0002-7200-5455; Paananen, Jussi/0000-0001-5100-4907; Buxbaum, Sarah/0000-0002-4886-3564; Forouhi, Nita/0000-0002-5041-248X; Lawlor, Debbie A/0000-0002-6793-2262; Pankow, James/0000-0001-7076-483X; Hattersley, Andrew/0000-0001-5620-473X FU Biotechnology and Biological Sciences Research Council [G20234]; Canadian Institutes of Health Research; Diabetes UK [12/0004470]; FIC NIH HHS [TW05596]; Intramural NIH HHS; Medical Research Council [G0500070, G0600705, MC_U106179471, MC_U106188470, MC_UP_A100_1003, MC_UU_12013/5]; NCATS NIH HHS [UL1 TR000454]; NCRR NIH HHS [MO1-RR-00400, RR20649, UL1 RR025008, UL1RR025005]; NHGRI NIH HHS [1Z01 HG000024, N01-HG-65403, U01HG004402]; NHLBI NIH HHS [HL52851, HL085144, N01-HC-25195, N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022, N01-HC-95170, N01-HC-95171, N01-HC-95172, R01 HL105756, R01HL086694, R01HL087641, R01HL59367, RC2 HL102419, UH1 HL073461]; NIDDK NIH HHS [DK062370, DK072193, DK078150, DK36836-25, DK56350, K24 DK080140, P30 DK020572, R01 DK072193, R01 DK078616, R01 DK093757, R01DK056918]; NIEHS NIH HHS [ES10126]; NIMHD NIH HHS [P20 MD006899]; NINR NIH HHS [T32 NR009759]; Wellcome Trust [, 090532, 098498, 100574] NR 58 TC 42 Z9 42 U1 0 U2 26 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD OCT PY 2013 VL 62 IS 10 BP 3589 EP 3598 DI 10.2337/db13-0128 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 222RG UT WOS:000324748200043 PM 23835345 ER PT J AU Mahendran, Y Vangipurapu, J Cederberg, H Stancakova, A Pihlajamaki, J Soininen, P Kangas, AJ Paananen, J Civelek, M Saleem, NK Pajukanta, P Lusis, AJ Bonnycastle, LL Morken, MA Collins, FS Mohlke, KL Boehnke, M Ala-Korpela, M Kuusisto, J Laakso, M AF Mahendran, Yuvaraj Vangipurapu, Jagadish Cederberg, Henna Stancakova, Alena Pihlajamaki, Jussi Soininen, Pasi Kangas, Antti J. Paananen, Jussi Civelek, Mete Saleem, Niyas K. Pajukanta, Paeivi Lusis, Aldons J. Bonnycastle, Lori L. Morken, Mario A. Collins, Francis S. Mohlke, Karen L. Boehnke, Michael Ala-Korpela, Mika Kuusisto, Johanna Laakso, Markku TI Association of Ketone Body Levels With Hyperglycemia and Type 2 Diabetes in 9,398 Finnish Men SO DIABETES LA English DT Article ID GENOME-WIDE ASSOCIATION; PANCREATIC BETA-CELLS; FREE-FATTY-ACID; GLUCOSE-TOLERANCE; INSULIN SENSITIVITY; CHRONIC EXPOSURE; BLOOD KETONE; LOCI; HYDROXYBUTYRATE; BODIES AB We investigated the association of the levels of ketone bodies (KBs) with hyperglycemia and with 62 genetic risk variants regulating glucose levels or type 2 diabetes in the population-based Metabolic Syndrome in Men (METSIM) study, including 9,398 Finnish men without diabetes or newly diagnosed type 2 diabetes. Increasing fasting and 2-h plasma glucose levels were associated with elevated levels of acetoacetate (AcAc) and -hydroxybutyrate (BHB). AcAc and BHB predicted an increase in the glucose area under the curve in an oral glucose tolerance test, and AcAc predicted the conversion to type 2 diabetes in a 5-year follow-up of the METSIM cohort. Impaired insulin secretion, but not insulin resistance, explained these findings. Of the 62 single nucleotide polymorphisms associated with the risk of type 2 diabetes or hyperglycemia, the glucose-increasing C allele of GCKR significantly associated with elevated levels of fasting BHB levels. Adipose tissue mRNA expression levels of genes involved in ketolysis were significantly associated with insulin sensitivity (Matsuda index). In conclusion, high levels of KBs predicted subsequent worsening of hyperglycemia, and a common variant of GCKR was significantly associated with BHB levels. C1 [Mahendran, Yuvaraj; Vangipurapu, Jagadish; Cederberg, Henna; Stancakova, Alena; Pihlajamaki, Jussi; Paananen, Jussi; Saleem, Niyas K.; Kuusisto, Johanna; Laakso, Markku] Univ Eastern Finland, Dept Med, Kuopio, Finland. [Cederberg, Henna; Pihlajamaki, Jussi; Kuusisto, Johanna; Laakso, Markku] Kuopio Univ Hosp, SF-70210 Kuopio, Finland. [Pihlajamaki, Jussi] Univ Eastern Finland, Dept Clin Nutr, Kuopio, Finland. [Soininen, Pasi; Kangas, Antti J.; Ala-Korpela, Mika] Univ Oulu, Inst Hlth Sci, Oulu, Finland. [Soininen, Pasi; Ala-Korpela, Mika] Univ Eastern Finland, Sch Pharm, Nucl Magnet Resonance Metabol Lab, Kuopio, Finland. [Civelek, Mete; Lusis, Aldons J.] Univ Calif Los Angeles, Dept Human Genet, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA USA. [Civelek, Mete; Lusis, Aldons J.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Pajukanta, Paeivi] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Bonnycastle, Lori L.; Morken, Mario A.; Collins, Francis S.] NHGRI, NIH, Bethesda, MD 20892 USA. [Mohlke, Karen L.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA. [Boehnke, Michael] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA. [Boehnke, Michael] Univ Michigan, Sch Publ Hlth, Ctr Stat Genet, Ann Arbor, MI 48109 USA. [Ala-Korpela, Mika] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England. [Ala-Korpela, Mika] Oulu Univ Hosp, Unit Gen Practice, Oulu, Finland. RP Laakso, M (reprint author), Univ Eastern Finland, Dept Med, Kuopio, Finland. EM markku.laakso@kuh.fi OI Paananen, Jussi/0000-0001-5100-4907; Civelek, Mete/0000-0002-8141-0284 FU Academy of Finland; Finnish Diabetes Research Foundation; Finnish Cardiovascular Research Foundation; Jenny and Antti Wihuri Foundation; University of Oulu; University of Eastern Finland; EVO from the Kuopio University Hospital [5263]; National Institutes of Health (NIH) [HL-095056, HL-28481, DK-093757, DK-072193]; [DK-062370]; [1Z01-HG-000024] FX This work was supported by the Academy of Finland (A. S. and M. L.; Responding to Public Health Challenges Research Programme to M.A.-K.), the Finnish Diabetes Research Foundation (M. L.), the Finnish Cardiovascular Research Foundation (M.A.-K. and M. L.), the Jenny and Antti Wihuri Foundation (A.J.K.), Strategic Research Funding from the University of Oulu (M.A.-K.), Strategic Research Funding from the University of Eastern Finland (M. L.), EVO Grant 5263 from the Kuopio University Hospital (M. L.), DK-062370 (M. B.), 1Z01-HG-000024 (F. S. C.), National Institutes of Health (NIH) Grant HL-095056 (P. P.), NIH Grant HL-28481 (P. P. and A.J.L.), and NIH grants DK-093757 and DK-072193 (K.L.M.). NR 40 TC 26 Z9 27 U1 2 U2 12 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD OCT PY 2013 VL 62 IS 10 BP 3618 EP 3626 DI 10.2337/db12-1363 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 222RG UT WOS:000324748200046 PM 23557707 ER PT J AU Chakkera, HA Chang, YH Ayub, A Gonwa, TA Weil, EJ Knowler, WC AF Chakkera, Harini A. Chang, Yu-Hui Ayub, Asad Gonwa, Thomas A. Weil, E. Jennifer Knowler, William C. TI Validation of a Pretransplant Risk Score for New-Onset Diabetes After Kidney Transplantation SO DIABETES CARE LA English DT Article ID INTERNAL VALIDATION; PREDICTION MODELS; MELLITUS; RECIPIENTS; HYPERGLYCEMIA; IMPACT AB OBJECTIVEIdentification of patients at high risk for new-onset diabetes after kidney transplantation (NODAT) will facilitate clinical trials for its prevention.RESEARCH DESIGN AND METHODSWe previously described a pretransplant predictive risk model for NODAT using seven pretransplant variables (age, planned use of maintenance corticosteroids, prescription for gout medicine, BMI, fasting glucose, fasting triglycerides, and family history of diabetes). We have now applied the initial model to a cohort of 474 transplant recipients from another center for validation. We performed two analyses in the validation cohort. The first was a standard model with variables derived from the original study. The second was a summary score model, in which the sum of dichotomized variables (all the variables dichotomized at clinically relevant cut points) was used to categorize, individuals into low (0-1), intermediate (2, 3), or high (4-7) risk groups. We also conducted a combined database analyses, merging the initial and validation cohorts (n = 792) to obtain better estimates for a prediction equation.RESULTSAlthough the frequency of several risk factors differed significantly between the two cohorts, the models performed similarly in each cohort. Using the summary score model, incidences of NODAT in low-risk, medium-risk, and high-risk groups in the initial cohort were 12, 29, and 56%, and in the validation cohort incidences were 11, 29, and 51%.CONCLUSIONSA pretransplant model for NODAT, including many type 2 diabetes risk factors, predicted NODAT in the validation cohort. C1 [Chakkera, Harini A.] Mayo Clin, Div Nephrol, Scottsdale, AZ USA. [Chakkera, Harini A.] Mayo Clin, Div Transplantat, Scottsdale, AZ USA. [Chang, Yu-Hui] Mayo Clin, Div Hlth Sci Res, Scottsdale, AZ USA. [Ayub, Asad; Gonwa, Thomas A.] Mayo Clin, Div Nephrol, Jacksonville, FL 32224 USA. [Ayub, Asad; Gonwa, Thomas A.] Mayo Clin, Div Transplantat, Jacksonville, FL 32224 USA. [Weil, E. Jennifer; Knowler, William C.] Natl Inst Diabet & Digest & Kidney Dis, NIH, Phoenix, AZ USA. RP Chakkera, HA (reprint author), Mayo Clin, Div Nephrol, Scottsdale, AZ USA. EM chakkera.harini@mayo.edu FU Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases; Mayo Clinic Foundation FX This research was supported in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases and a Mayo Clinic Foundation Career Development Grant. NR 25 TC 5 Z9 5 U1 0 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD OCT PY 2013 VL 36 IS 10 BP 2881 EP 2886 DI 10.2337/dc13-0428 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 222RT UT WOS:000324749500017 PM 24009296 ER PT J AU Jensen, MK Bartz, TM Djousse, L Kizer, JR Zieman, SJ Rimm, EB Siscovick, DS Psaty, BM Ix, JH Mukamal, KJ AF Jensen, Majken K. Bartz, Traci M. Djousse, Luc Kizer, Jorge R. Zieman, Susan J. Rimm, Eric B. Siscovick, David S. Psaty, Bruce M. Ix, Joachim H. Mukamal, Kenneth J. TI Genetically Elevated Fetuin-A Levels, Fasting Glucose Levels, and Risk of Type 2 Diabetes The Cardiovascular Health Study SO DIABETES CARE LA English DT Article ID RECEPTOR TYROSINE KINASE; INSULIN-RECEPTOR; FATTY LIVER; GLYCOPROTEIN GENE; ASSOCIATION; POLYMORPHISM; INHIBITOR; AHSG; MELLITUS; DESIGN AB OBJECTIVEFetuin-A levels are associated with higher risk of type 2 diabetes, but it is unknown if the association is causal. We investigated common (>5%) genetic variants in the fetuin-A gene (AHSG) fetuin-A levels, fasting glucose, and risk of type 2 diabetes.RESEARCH DESIGN AND METHODSGenetic variation, fetuin-A levels, and fasting glucose were assessed in 2,893 Caucasian and 542 African American community-living individuals 65 years of age or older in 1992-1993.RESULTSCommon AHSG variants (rs4917 and rs2248690) were strongly associated with fetuin-A concentrations (P < 0.0001). In analyses of 259 incident cases of type 2 diabetes, the single nucleotide polymorphisms (SNPs) were not associated with diabetes risk during follow-up and similar null associations were observed when 579 prevalent cases were included. As expected, higher fetuin-A levels were associated with higher fasting glucose concentrations (1.9 mg/dL [95% CI, 1.2-2.7] higher per SD in Caucasians), but Mendelian randomization analyses using both SNPs as unbiased proxies for measured fetuin-A did not support an association between genetically predicted fetuin-A levels and fasting glucose (-0.3 mg/dL [95% CI, -1.9 to 1.3] lower per SD in Caucasians). The difference between the associations of fasting glucose with actual and genetically predicted fetuin-A level was statistically significant (P = 0.001). Results among the smaller sample of African Americans trended in similar directions but were statistically insignificant.CONCLUSIONSCommon variants in the AHSG gene are strongly associated with plasma fetuin-A concentrations, but not with risk of type 2 diabetes or glucose concentrations, raising the possibility that the association between fetuin-A and type 2 diabetes may not be causal. C1 [Jensen, Majken K.; Rimm, Eric B.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Bartz, Traci M.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Djousse, Luc] Brigham & Womens Hosp, Div Aging, Boston, MA 02115 USA. [Djousse, Luc] Boston Vet Affairs Healthcare Syst, Boston, MA USA. [Kizer, Jorge R.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Kizer, Jorge R.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA. [Zieman, Susan J.] NIA, NIH, Bethesda, MD 20892 USA. [Rimm, Eric B.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med,Dept Med, Boston, MA 02115 USA. [Siscovick, David S.; Psaty, Bruce M.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Siscovick, David S.; Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Siscovick, David S.; Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Siscovick, David S.; Psaty, Bruce M.] Grp Hlth Res Inst, Grp Hlth Cooperat, Seattle, WA USA. [Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA USA. [Ix, Joachim H.] Univ Calif San Diego, Div Nephrol, San Diego, CA 92103 USA. [Ix, Joachim H.] Univ Calif San Diego, Div Prevent Med, San Diego, CA 92103 USA. [Mukamal, Kenneth J.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA. RP Jensen, MK (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. EM mkjensen@hsph.harvard.edu RI Djousse, Luc/F-5033-2017 OI Djousse, Luc/0000-0002-9902-3047 FU National Heart, Lung, and Blood Institute (NHLBI) [R01 HL094555]; NHLBI CARe project (Broad Institute of Massachusetts Institute of Technology and Harvard) [N01HC65226]; NHLBI [HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, HL080295]; National Institute on Aging [AG023629] FX This study was supported by a grant from the National Heart, Lung, and Blood Institute (NHLBI) (R01 HL094555 to L.D., J.R.K., S.J.Z., J.H.I., and K.J.M.), and genotyping was funded by the NHLBI CARe project (Broad Institute of Massachusetts Institute of Technology and Harvard, N01HC65226). The CHS was supported by contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, and N01HC85086 and by grant HL080295 from the NHLBI, with additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support was provided by AG023629 from the National Institute on Aging. NR 26 TC 14 Z9 14 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD OCT PY 2013 VL 36 IS 10 BP 3121 EP 3127 DI 10.2337/dc12-2323 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 222RT UT WOS:000324749500051 PM 23801724 ER PT J AU Orchard, TJ Lyons, TJ Cleary, PA Braffett, BH Maynard, J Cowie, C Gubitosi-Klug, RA Way, J Anderson, K Barnie, A Villavicencio, S AF Orchard, Trevor J. Lyons, Timothy J. Cleary, Patricia A. Braffett, Barbara H. Maynard, John Cowie, Catherine Gubitosi-Klug, Rose A. Way, Jeff Anderson, Karen Barnie, Annette Villavicencio, Stephan CA DCCT EDIC Res Grp TI The Association of Skin Intrinsic Fluorescence With Type 1 Diabetes Complications in the DCCT/EDIC Study SO DIABETES CARE LA English DT Article ID ADVANCED GLYCATION ENDPRODUCTS; CORONARY-ARTERY CALCIFICATION; GLOMERULAR-FILTRATION-RATE; END-PRODUCTS; COLLAGEN GLYCATION; TRIAL COHORT; INTERVENTIONS; MELLITUS; TRIAL/EPIDEMIOLOGY; EPIDEMIOLOGY AB OBJECTIVETo determine whether skin intrinsic fluorescence (SIF) is associated with long-term complications of type 1 diabetes (T1D) and, if so, whether it is independent of chronic glycemic exposure and previous intensive therapy.RESEARCH DESIGN AND METHODSWe studied 1,185 (92%) of 1,289 active Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) participants from 2010 to 2011. SIF was determined using a fluorescence spectrometer and related cross-sectionally to recently determined measures of retinopathy (stereo fundus photography), cardiac autonomic neuropathy (CAN; R-R interval), confirmed clinical neuropathy, nephropathy (albumin excretion rate [AER]), and coronary artery calcification (CAC).RESULTSOverall, moderately strong associations were seen with all complications, before adjustment for mean HbA(1c) over time, which rendered these associations nonsignificant with the exception of sustained AER >30 mg/24 h and CAC, which were largely unaffected by adjustment. However, when examined within the former DCCT treatment group, associations were generally weaker in the intensive group and nonsignificant after adjustment, while in the conventional group, associations remained significant for CAN, sustained AER >30 mg/24 h, and CAC even after mean HbA(1c) adjustment.CONCLUSIONSSIF is associated with T1D complications in DCCT\EDIC. Much of this association appears to be related to historical glycemic exposure, particularly in the previously intensively treated participants, in whom adjustment for HbA(1c) eliminates statistical significance. C1 [Orchard, Trevor J.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Lyons, Timothy J.] Univ Oklahoma, Oklahoma City, OK USA. [Cleary, Patricia A.; Braffett, Barbara H.; Anderson, Karen; Villavicencio, Stephan] George Washington Univ, Rockville, MD USA. [Maynard, John; Way, Jeff] VeraLight Inc, Albuquerque, NM USA. [Cowie, Catherine] NIDDK, Bethesda, MD USA. [Gubitosi-Klug, Rose A.] Univ Hosp Case Med Ctr, Cleveland, OH USA. [Barnie, Annette] Univ Toronto, Toronto, ON, Canada. RP Orchard, TJ (reprint author), Univ Pittsburgh, Pittsburgh, PA 15260 USA. EM tjo@pitt.edu OI orchard, trevor/0000-0001-9552-3215 FU Division of Diabetes, Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases; National Eye Institute; National Institute of Neurological Disorders and Stroke; General Clinical Research Centers Program; Clinical and Translational Science Awards Program; National Center for Research Resources; VeraLight; Genentech; National Institute of Diabetes and Digestive and Kidney Diseases; VeraLight, Inc. FX Abbott, Animas, Aventis, Becton Dickinson, Bayer, Can Am, Eli Lilly, LifeScan, Medtronic MiniMed, Omron, and Roche contributed free or discounted supplies and/or equipment. The DCCT/EDIC project is supported by contracts with the Division of Diabetes, Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases, National Eye Institute, National Institute of Neurological Disorders and Stroke, the General Clinical Research Centers Program and the Clinical and Translational Science Awards Program, National Center for Research Resources, VeraLight, and Genentech through a Cooperative Research and Development Agreement with the National Institute of Diabetes and Digestive and Kidney Diseases. T.J.O. and T.J.L. have received grant support from VeraLight, Inc. J.M. is an employee and stock option holder of VeraLight, Inc. J.W. is an employee and stock option holder of VeraLight, Inc. A. B. is an independent insulin pump trainer who receives payment from Medtronic, Animas, Spirit, and OmniPod pumps. No other potential conflicts of interest relevant to this article were reported. NR 39 TC 16 Z9 17 U1 0 U2 11 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD OCT PY 2013 VL 36 IS 10 BP 3146 EP 3153 DI 10.2337/dc12-2661 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 222RT UT WOS:000324749500055 PM 23813757 ER PT J AU Pop-Busui, R Lu, J Brooks, MM Albert, S Althouse, AD Escobedo, J Green, J Palumbo, P Perkins, BA Whitehouse, F Jones, TLZ AF Pop-Busui, Rodica Lu, Jiang Brooks, Maria Mori Albert, Stewart Althouse, Andrew D. Escobedo, Jorge Green, Jenifer Palumbo, Pasquale Perkins, Bruce A. Whitehouse, Fred Jones, Teresa L. Z. CA BARI 2D Study Grp TI Impact of Glycemic Control Strategies on the Progression of Diabetic Peripheral Neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort SO DIABETES CARE LA English DT Article ID FACTOR-KAPPA-B; COMPLICATIONS TRIAL; ROSIGLITAZONE TREATMENT; INSULIN-RESISTANCE; GAMMA-LIGAND; CELL-DEATH; PIOGLITAZONE; METFORMIN; INTERVENTIONS; NEPHROPATHY AB OBJECTIVEThe Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial demonstrated similar long-term clinical effectiveness of insulin-sensitizing (IS) versus insulin-providing (IP) treatments for type 2 diabetes on cardiovascular outcomes in a cohort with documented coronary artery disease. We evaluated the effects of randomized glycemic control strategy (IS vs. IP) on the prevalence and incidence of diabetic peripheral neuropathy (DPN).RESEARCH DESIGN AND METHODSDPN (defined as Michigan Neuropathy Screening Instrument [MNSI] clinical examination score >2) was assessed at baseline and yearly for 4 years. DPN prevalence and incidence were compared by intention-to-treat modeling by logistic generalized estimating equation models for prevalence and Kaplan-Meier estimates and Cox regression models for incidence rates.RESULTSResults are reported for 2,159 BARI 2D participants (70% males) with valid baseline and at least one follow-up MNSI score (mean age 62 9 years, mean HbA(1c) 7.7 +/- 1.6%, diabetes duration 10 +/- 9 years). There were no differences in the prevalence of DPN between the IS and the IP groups throughout the 4 years of follow-up. In 1,075 BARI 2D participants with no DPN at baseline, the 4-year cumulative incidence rate of DPN was significantly lower in the IS (66%) than in the IP (72%) strategy group (P = 0.02), which remained significant after adjusting for the in-trial HbA(1c) (P = 0.04). In subgroup analyses, IS strategy had a greater benefit in men (hazard ratio 0.75 [99% CI 0.58-0.99], P < 0.01).CONCLUSIONSAmong patients with type 2 diabetes followed for up to 4 years during BARI 2D, a glycemic control therapy with IS significantly reduced the incidence of DPN compared with IP therapy and may add further benefit for men. C1 [Pop-Busui, Rodica] Univ Michigan, Dept Internal Med, Div Metab Endocrinol & Diabet, Ann Arbor, MI 48109 USA. [Lu, Jiang; Brooks, Maria Mori; Althouse, Andrew D.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Albert, Stewart] St Louis Univ, Sch Med, Dept Internal Med, Div Endocrinol, St Louis, MO USA. [Escobedo, Jorge] Reg Hosp 1, Mexican Inst Social Secur, Unidad Invest Epidemiol Clin, Mexico City, DF, Mexico. [Green, Jenifer] Duke Univ, Med Ctr, Dept Med, Div Endocrinol, Durham, NC 27710 USA. [Palumbo, Pasquale] Mayo Clin, Div Prevent Med, Dept Internal Med, Scottsdale, AZ USA. [Perkins, Bruce A.] Univ Toronto, Dept Med, Div Endocrinol, Toronto, ON, Canada. [Whitehouse, Fred] Henry Ford Hlth Syst, Henry Ford Med Grp, Div Endocrinol & Diabet, Detroit, MI USA. [Jones, Teresa L. Z.] NIDDK, NIH, Bethesda, MD USA. RP Pop-Busui, R (reprint author), Univ Michigan, Dept Internal Med, Div Metab Endocrinol & Diabet, Ann Arbor, MI 48109 USA. EM rpbusui@umich.edu OI Brooks, Maria/0000-0002-2030-7873 FU National Heart, Lung, and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases [U01-HL-061744, U01-HL-061746, U01-HL-061748, U01-HL-063804]; GlaxoSmithKline; Bristol-Myers Squibb; Merck; Medtronic; Boehringer Ingelheim FX The trial was sponsored by the National Heart, Lung, and Blood Institute and the National Institute of Diabetes and Digestive and Kidney Diseases (U01-HL-061744, U01-HL-061746, U01-HL-061748, U01-HL-063804), with additional support from multiple industry sponsors, including the manufacturer of rosiglitazone GlaxoSmithKline (a detailed list is provided in Supplementary Funding Sources).; R.P.-B. received a research grant from Amylin Pharmaceuticals (now Bristol-Myers Squibb) unrelated to the manuscript. J.G. received a research grant from Amylin Pharmaceuticals (now Bristol-Myers Squibb) and Merck unrelated to this manuscript and is a member of the Merck speakers' bureau. B. A. P. received speaker honoraria from Medtronic Inc., Johnson and Johnson, Roche, GlaxoSmithKline Canada, Novo Nordisk, Eli Lilly, and sanofi-aventis; has received research grant support from Medtronic and Boehringer Ingelheim; and serves on an advisory board for Neurometrix, Inc. No other potential conflicts of interest relevant to this article were reported. NR 37 TC 21 Z9 21 U1 0 U2 11 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD OCT PY 2013 VL 36 IS 10 BP 3208 EP 3215 DI 10.2337/dc13-0012 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 222RT UT WOS:000324749500063 PM 23757426 ER PT J AU Chakkera, HA Pham, PT Pomeroy, J Weil, EJ Knowler, WC AF Chakkera, Harini A. Phuong-Thu Pham Pomeroy, Jeremy Weil, E. Jennifer Knowler, William C. TI Response to Comment on: Chakkera et al. Can New-Onset Diabetes After Kidney Transplant Be Prevented? Diabetes Care 2013;36:1406-1412 SO DIABETES CARE LA English DT Letter ID INSULIN C1 [Chakkera, Harini A.] Mayo Clin, Div Nephrol & Transplantat, Phoenix, AZ USA. [Phuong-Thu Pham] UCLA Hlth Syst, Internal Med Nephrol, Los Angeles, CA USA. [Pomeroy, Jeremy; Weil, E. Jennifer; Knowler, William C.] Natl Inst Diabet & Digest & Kidney Dis, Diabet Epidemiol & Clin Res Sect, NIH, Phoenix, AZ USA. RP Chakkera, HA (reprint author), Mayo Clin, Div Nephrol & Transplantat, Phoenix, AZ USA. EM chakkera.harini@mayo.edu NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD OCT PY 2013 VL 36 IS 10 BP E183 EP E183 DI 10.2337/dc13-1656 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 222RT UT WOS:000324749500010 PM 24065856 ER PT J AU Vehik, K Fiske, SW Logan, CA Agardh, D Cilio, CM Hagopian, W Simell, O Roivainen, M She, JX Briese, T Oikarinen, S Hyoty, H Ziegler, AG Rewers, M Lernmark, A Akolkar, B Krischer, JP Burkhardt, BR AF Vehik, Kendra Fiske, Steven W. Logan, Chad A. Agardh, Daniel Cilio, Corrado M. Hagopian, William Simell, Olli Roivainen, Merja She, Jin-Xiong Briese, Thomas Oikarinen, Sami Hyoty, Heikki Ziegler, Anette-G. Rewers, Marian Lernmark, Ake Akolkar, Beena Krischer, Jeffrey P. Burkhardt, Brant R. CA TEDDY Study Grp TI Methods, quality control and specimen management in an international multicentre investigation of type 1 diabetes: TEDDY SO DIABETES-METABOLISM RESEARCH AND REVIEWS LA English DT Article DE quality control; data integrity; stool sample preservation; RNA; biomarker stability; metabolic biomarkers; T-cell viability ID ENVIRONMENTAL DETERMINANTS; YOUNG; WORKSHOP; SYSTEM; BLOOD; RISK AB BackgroundThe vast array and quantity of longitudinal samples collected in The Environmental Determinants of Diabetes in the Young study present a series of challenges in terms of quality control procedures and data validity. To address this, pilot studies have been conducted to standardize and enhance both biospecimen collection and sample obtainment in terms of autoantibody collection, stool sample preservation, RNA, biomarker stability, metabolic biomarkers and T-cell viability. Research Design and MethodsThe Environmental Determinants of Diabetes in the Young is a multicentre, international prospective study (n=8677) designed to identify environmental triggers of type 1 diabetes (T1D) in genetically at-risk children from ages 3months until 15years. The study is conducted through six primary clinical centres located in four countries. ResultsAs of May 2012, over three million biological samples and 250 million total data points have been collected, which will be analysed to assess autoimmunity status, presence of inflammatory biomarkers, genetic factors, exposure to infectious agents, dietary biomarkers and other potentially important environmental exposures in relation to autoimmunity and progression to T1D. ConclusionsDetailed procedures were utilized to standardize both data harmonization and management when handling a large quantity of longitudinal samples obtained from multiple locations. In addition, a description of the available specimens is provided that serve as an invaluable repository for the elucidation of determinants in T1D focusing on autoantibody concordance and harmonization, transglutaminase autoantibody, inflammatory biomarkers (T-cells), genetic proficiency testing, RNA lab internal quality control testing, infectious agents (monitoring cross-contamination, virus preservation and nasal swab collection validity) and HbA(1c) testing. Copyright (c) 2013 John Wiley & Sons, Ltd. C1 [Vehik, Kendra; Fiske, Steven W.; Logan, Chad A.; Krischer, Jeffrey P.; Burkhardt, Brant R.] Univ S Florida, Morsani Coll Med, Pediat Epidemiol Ctr, Tampa, FL 33612 USA. [Agardh, Daniel; Cilio, Corrado M.; Lernmark, Ake] Lund Univ, Malmo Univ Hosp, Dept Clin Sci, Malmo, Sweden. [Hagopian, William] Pacific Northwest Diabet Res Inst, Seattle, WA USA. [Simell, Olli] Univ Turku, Dept Pediat, Turku, Finland. [Roivainen, Merja] Natl Inst Hlth & Welf, Helsinki, Finland. [She, Jin-Xiong] Med Coll Georgia, Augusta, GA 30912 USA. [Briese, Thomas] Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY USA. [Oikarinen, Sami; Hyoty, Heikki] Univ Tampere, Sch Med, Dept Virol, FIN-33101 Tampere, Finland. [Hyoty, Heikki] Tampere Univ Hosp, Dept Clin Microbiol, Ctr Lab Med, Tampere, Finland. [Ziegler, Anette-G.] Helmholtz Zentrum Munchen, Inst Diabet Res, Neuherberg, Germany. [Ziegler, Anette-G.] Forschergrp Diabet eV, Neuherberg, Germany. [Rewers, Marian] Univ Colorado Denver, Barbara Davis Ctr Childhood Diabet, Aurora, CO USA. [Akolkar, Beena] NIDDK, Div Diabet Endocrinol & Metab Dis, NIH, Bethesda, MD USA. [Burkhardt, Brant R.] Univ S Florida, Dept Cell Biol Microbiol & Mol Biol, Tampa, FL 33612 USA. RP Vehik, K (reprint author), Univ S Florida, Morsani Coll Med, Pediat Epidemiol Ctr, 3650 Spectrum Blvd,STE 100, Tampa, FL 33612 USA. EM kendra.vehik@epi.usf.edu RI Ziegler, Anette-Gabriele/M-4614-2014; oikarinen, sami/E-3611-2015 OI Ziegler, Anette-Gabriele/0000-0002-6290-5548; FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [U01 DK63829, U01 DK63861, U01 DK63821, U01 DK63865, U01 DK63863, U01 DK63836, U01 DK63790, UC4 DK63829, UC4 DK63861, UC4 DK63821, UC4 DK63865, UC4 DK63863, UC4 DK63836, UC4 DK63790, UC4DK095300, HHSN267200700014C]; National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Child Health and Human Development (NICHD); National Institute of Environmental Health Sciences (NIEHS); Juvenile Diabetes Research Foundation (JDRF); Centers for Disease Control and Prevention (CDC) FX The TEDDY Study Group (see online appendix) is funded by U01 DK63829, U01 DK63861, U01 DK63821, U01 DK63865, U01 DK63863, U01 DK63836, U01 DK63790, UC4 DK63829, UC4 DK63861, UC4 DK63821, UC4 DK63865, UC4 DK63863, UC4 DK63836, UC4 DK63790 and UC4DK095300 and contract no. HHSN267200700014C from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Child Health and Human Development (NICHD), National Institute of Environmental Health Sciences (NIEHS), Juvenile Diabetes Research Foundation (JDRF) and Centers for Disease Control and Prevention (CDC). NR 13 TC 17 Z9 17 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1520-7560 J9 DIABETES-METAB RES JI Diabetes-Metab. Res. Rev. PD OCT PY 2013 VL 29 IS 7 BP 557 EP 567 DI 10.1002/dmrr.2427 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 226KW UT WOS:000325035600006 PM 23674484 ER PT J AU Erdag, G Chowdhuri, SR Fetsch, P Erickson, D Hughes, MS Filie, AC AF Erdag, Gulsun Chowdhuri, Sinchita Roy Fetsch, Patricia Erickson, Dana Hughes, Marybeth S. Filie, Armando C. TI KBA.62 and S100 Protein Expression in Cytologic Samples of Metastatic Malignant Melanoma SO DIAGNOSTIC CYTOPATHOLOGY LA English DT Article DE KBA.62; S100 protein; immunocytochemistry/immunohistochemistry; cytology; melanoma ID FINE-NEEDLE-ASPIRATION; T-CELLS MART-1; IMMUNOCYTOCHEMICAL ANALYSIS; AMELANOTIC MELANOMAS; MONOCLONAL-ANTIBODY; S-100 PROTEIN; DIAGNOSIS; BIOPSY; TYROSINASE; EFFUSIONS AB The diagnosis of melanoma can be challenging, especially in metastatic lesions, due to the ability of melanoma cells to morphologically mimic carcinoma, sarcoma and even lymphoma cells. Moreover, melanomas can exhibit negative immunostaining for the melanoma markers HMB-45 and MART-1/Melan-A, often used in the diagnosis of this tumor. KBA.62 is a recently described antibody that reacts with benign and malignant melanocytic proliferations. In this study, we report our experience with KBA.62 and S100 protein immunostaining in the diagnosis of metastatic melanoma on fine-needle aspiration and effusion samples. We reviewed 60 cytology samples from 58 patients with metastatic melanoma. Our results showed that KBA.62 stained 75% of the cases and S100 protein 87% of the cases. KBA.62 and S100 protein stained the majority of metastatic melanomas that were negative for HMB-45 and MART-1; KBA.62 stained 73% of the cases and S100 protein 73% of the cases. The majority (85%) of the cases negative for HMB-45 and MART-1 were positive for KBA.62 and/or S100 protein. Additionally, we also observed that KBA.62 staining was positive in the majority of epithelioid and spindle cell type melanoma cells. In conclusion, the performances of KBA.62 and S100 protein were similar and both markers are useful in the diagnosis of metastatic melanoma in cytology material, especially when the tumor cells lack expression of HMB-45 and MART-1. Diagn. Cytopathol. 2013;41:847-851. (c) 2013 Wiley Periodicals, Inc. C1 [Erdag, Gulsun; Chowdhuri, Sinchita Roy; Fetsch, Patricia; Erickson, Dana; Filie, Armando C.] NCI, Cytopathol Sect, Pathol Lab, NIH, Bethesda, MD 20892 USA. [Hughes, Marybeth S.] NCI, Surg Branch, NIH, Bethesda, MD 20892 USA. RP Filie, AC (reprint author), NCI, Cytopathol Sect, Pathol Lab, Ctr Canc Res, 10 Ctr Dr Bldg 10 Room 2A19, Bethesda, MD 20892 USA. EM afilie@mail.nih.gov FU Intramural Research Program of the NIH, National Cancer Institute FX Contract grant sponsors: Intramural Research Program of the NIH, National Cancer Institute. NR 26 TC 0 Z9 0 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 8755-1039 J9 DIAGN CYTOPATHOL JI Diagn. Cytopathol. PD OCT PY 2013 VL 41 IS 10 BP 847 EP 851 DI 10.1002/dc.22948 PG 5 WC Medical Laboratory Technology; Pathology SC Medical Laboratory Technology; Pathology GA 224WS UT WOS:000324923000001 PM 23554410 ER PT J AU Horner-Johnson, W Dobbertin, K Lee, JC Andresen, EM AF Horner-Johnson, Willi Dobbertin, Konrad Lee, Jae Chul Andresen, Elena M. CA Expert Panel Disability Hlth TI Disparities in chronic conditions and health status by type of disability SO DISABILITY AND HEALTH JOURNAL LA English DT Article DE People with disabilities; Health status disparities; Chronic conditions; Adult; Population surveillance ID QUALITY-OF-LIFE; GENDER-DIFFERENCES; POPULATION; CARE; OBESITY; ADULTS; WOMEN AB Background: Prior research has established health disparities between people with and without disabilities. However, disparities within the disability population, such as those related to type of disability, have been much less studied. Objective: To examine differences in chronic conditions and health status between subgroups of people with different types of disability. Methods: We analyzed Medical Expenditure Panel Survey annual data files from 2002 to 2008. Logistic regression analyses considered disparity from three perspectives: 1) basic differences, unadjusted for other factors; 2) controlling for key demographic and health covariates; and 3) controlling for a larger set of demographic variables and socioeconomic status as well as health and access to healthcare. Results: Individuals with vision, physical, cognitive, or multiple disability types fared worse than people with hearing impairment on most health outcomes. This was most consistently true for people with multiple disabilities. Even when all covariates were accounted for, people with multiple types of disability were significantly more likely (p < 0.05) than those with hearing impairment (reference group) to report every poor health outcome with the exception of BMI >= 25 and lung disease. Conclusions: While many of the differences between disability types were reduced when controlling for other factors, some differences remained significant. This argues for a more individualized approach to understanding and preventing chronic conditions and poor health in specific disability groups. (C) 2013 Elsevier Inc. All rights reserved. C1 [Horner-Johnson, Willi; Dobbertin, Konrad; Andresen, Elena M.] Oregon Hlth & Sci Univ, Inst Dev & Disabil, Portland, OR 97239 USA. [Lee, Jae Chul] NIH, Dept Rehabil Med, Clin Res Ctr, Bethesda, MD 20892 USA. RP Horner-Johnson, W (reprint author), Oregon Hlth & Sci Univ, Inst Dev & Disabil, 707 SW Gaines St, Portland, OR 97239 USA. EM hornerjo@ohsu.edu OI Horner-Johnson, Willi/0000-0003-3568-1400 FU National Institute on Disability and Rehabilitation Research/DOE [H133A080031] FX This work was supported by grant # H133A080031 from the National Institute on Disability and Rehabilitation Research/DOE. However, the contents do not necessarily represent the policy of the Department of Education, and you should not assume endorsement by the Federal Government. NR 27 TC 12 Z9 13 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-6574 J9 DISABIL HEALTH J JI Disabil. Health J. PD OCT PY 2013 VL 6 IS 4 BP 280 EP 286 DI 10.1016/j.dhjo.2013.04.006 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA 224CJ UT WOS:000324858900003 PM 24060250 ER PT J AU Cannons, JL Zhao, F Schwartzberg, PL AF Cannons, Jennifer L. Zhao, Fang Schwartzberg, Pamela L. TI Ncking BCR-mediated PI3K activation SO EMBO REPORTS LA English DT Editorial Material ID RECRUITMENT; REGULATORS; FAMILY C1 [Cannons, Jennifer L.; Zhao, Fang; Schwartzberg, Pamela L.] NHGRI, Natl Inst Hlth, Bethesda, MD 20892 USA. [Zhao, Fang] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA. RP Cannons, JL (reprint author), NHGRI, Natl Inst Hlth, Bethesda, MD 20892 USA. EM pams@mail.nih.gov NR 10 TC 1 Z9 1 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1469-221X J9 EMBO REP JI EMBO Rep. PD OCT PY 2013 VL 14 IS 10 BP 852 EP 853 DI 10.1038/embor.2013.133 PG 2 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 229HL UT WOS:000325253100005 PM 23969954 ER PT J AU Matzat, LH Dale, RK Lei, EP AF Matzat, Leah H. Dale, Ryan K. Lei, Elissa P. TI Messenger RNA is a functional component of a chromatin insulator complex SO EMBO REPORTS LA English DT Article DE RNA; chromatin; insulator; Drosophila; nuclear organization ID NUCLEAR-ORGANIZATION; DROSOPHILA; ACCESSIBILITY; REPRESSION; BINDING; LOCUS; DNA AB Chromatin insulators are DNA protein complexes situated throughout the genome capable of demarcating independent transcriptional domains. Previous studies point to an important role for RNA in gypsy chromatin insulator function in Drosophila; however, the identity of these putative insulator-associated RNAs is not currently known. Here we utilize RNA-immunoprecipitation and high throughput sequencing (RIP-seq) to isolate RNAs stably associated with gypsy insulator complexes. Strikingly, these RNAs correspond to specific sense-strand, spliced and polyadenylated mRNAs, including two insulator protein transcripts. In order to assess the functional significance of these associated mRNAs independent of their coding function, we expressed untranslatable versions of these transcripts in developing flies and observed both alteration of insulator complex nuclear localization as well as improvement of enhancer-blocking activity. Together, these data suggest a novel, noncoding mechanism by which certain mRNAs contribute to chromatin insulator function. C1 [Matzat, Leah H.; Dale, Ryan K.; Lei, Elissa P.] NIDDK, Lab Cellular & Dev Biol, NIH, Bethesda, MD 20892 USA. RP Lei, EP (reprint author), NIDDK, Lab Cellular & Dev Biol, NIH, Bethesda, MD 20892 USA. EM leielissa@niddk.nih.gov OI Dale, Ryan/0000-0003-2664-3744 FU National Institute of Diabetes and Digestive and Kidney Diseases FX We thank W. Bender and V. Corces for fly strains, M. Levine for alpha-Dl antisera and N. Perrimon for the pCa4B plasmid. We thank members of the Lei laboratory, J. Birchler, E. Clough, C. Kaplan, J. Kassis and V. Sartorelli for critical reading of the manuscript. This work was funded by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases. NR 22 TC 11 Z9 11 U1 0 U2 11 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1469-221X J9 EMBO REP JI EMBO Rep. PD OCT PY 2013 VL 14 IS 10 BP 916 EP 922 DI 10.1038/embor.2013.118 PG 7 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 229HL UT WOS:000325253100016 PM 23917615 ER PT J AU Kleinau, G Neumann, S Gruters, A Krude, H Biebermann, H AF Kleinau, Gunnar Neumann, Susanne Grueters, Annette Krude, Heiko Biebermann, Heike TI Novel Insights on Thyroid-Stimulating Hormone Receptor Signal Transduction SO ENDOCRINE REVIEWS LA English DT Review ID PROTEIN-COUPLED-RECEPTORS; HUMAN THYROTROPIN RECEPTOR; HUMAN CHORIONIC-GONADOTROPIN; SITE-DIRECTED MUTAGENESIS; ADENYLATE-CYCLASE ACTIVATION; FREE ALPHA-SUBUNIT; HUMAN TSH RECEPTOR; TERMINAL EXTRACELLULAR DOMAIN; BETA(2) ADRENERGIC-RECEPTOR; RESONANCE ENERGY-TRANSFER AB The TSH receptor (TSHR) is a member of the glycoprotein hormone receptors, a subfamily of family A G protein-coupled receptors. The TSHR is of great importance for the growth and function of the thyroid gland. The TSHR and its endogenous ligand TSH are pivotal proteins with respect to a variety of physiological functions and malfunctions. The molecular events of TSHR regulation can be summarized as a process of signal transduction, including signal reception, conversion, and amplification. The steps during signal transduction from the extra-to the intracellular sites of the cell are not yet comprehensively understood. However, essential new insights have been achieved in recent years on the interrelated mechanisms at the extracellular region, the transmembrane domain, and intracellular components. This review contains a critical summary of available knowledge of the molecular mechanisms of signal transduction at the TSHR, for example, the key amino acids involved in hormone binding or in the structural conformational changes that lead to G protein activation or signaling regulation. Aspects of TSHR oligomerization, signaling promiscuity, signaling selectivity, phenotypes of genetic variations, and potential extrathyroidal receptor activity are also considered, because these are relevant to an understanding of the overall function of the TSHR, including physiological, pathophysiological, and pharmacological perspectives. Directions for future research are discussed. C1 [Kleinau, Gunnar; Grueters, Annette; Krude, Heiko; Biebermann, Heike] Charite, Inst Expt Pediat Endocrinol, D-13353 Berlin, Germany. [Neumann, Susanne] NIDDK, NIH, Lab Endocrinol & Receptor Biol, Bethesda, MD 20892 USA. RP Biebermann, H (reprint author), Charite, Inst Expt Pediat Endocrinol, Ostring 3,Augustenburger Pl 1, D-13353 Berlin, Germany. EM Gunnar.Kleinau@charite.de; Heike.Biebermann@charite.de FU Deutsche Forschungsgemeinschaft (DFG) [BI 893/6-2, BI893/5-1, KL 2334/21, KL 2334/21-2]; Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health [Z01DK011006] FX This work was supported by the Deutsche Forschungsgemeinschaft (DFG), projects BI 893/6-2, BI893/5-1, and KL 2334/21, -2, and by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (Z01DK011006). NR 413 TC 30 Z9 33 U1 2 U2 31 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0163-769X EI 1945-7189 J9 ENDOCR REV JI Endocr. Rev. PD OCT PY 2013 VL 34 IS 5 BP 691 EP 724 DI 10.1210/er.2012-1072 PG 34 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 229OQ UT WOS:000325277200004 PM 23645907 ER PT J AU Clark, ML Peel, JL Balakrishnan, K Breysse, PN Chillrud, SN Naeher, LP Rodes, CE Vette, AF Balbus, JM AF Clark, Maggie L. Peel, Jennifer L. Balakrishnan, Kalpana Breysse, Patrick N. Chillrud, Steven N. Naeher, Luke P. Rodes, Charles E. Vette, Alan F. Balbus, John M. TI Health and Household Air Pollution from Solid Fuel Use: The Need for Improved Exposure Assessment SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Review ID PARTICULATE MATTER CONCENTRATIONS; ACUTE RESPIRATORY-INFECTIONS; WOOD-SMOKE EXPOSURE; CARBON-MONOXIDE; BIOMASS FUELS; PARTICLE DEPOSITION; PULMONARY-DISEASE; LUNG-CANCER; COOK STOVES; INDOOR AB Background: Nearly 3 billion people worldwide rely on solid fuel combustion to meet basic -household energy needs. The resulting exposure to air pollution causes an estimated 4.5% of the global burden of disease. Large variability and a lack of resources for research and development have resulted in highly uncertain exposure estimates. Objective: We sought to identify research priorities for exposure assessment that will more accurately and precisely define exposure-response relationships of household air pollution necessary to inform future cleaner-burning cookstove dissemination programs. Data Sources: As part of an international workshop in May 2011, an expert group characterized the state of the science and developed recommendations for exposure assessment of household air pollution. Synthesis: The following priority research areas were identified to explain variability and reduce uncertainty of household air pollution exposure measurements: improved characterization of spatial and temporal variability for studies examining both short-and long-term health effects; development and validation of measurement technology and approaches to conduct complex exposure assessments in resource-limited settings with a large range of pollutant concentrations; and development and validation of biomarkers for estimating dose. Addressing these priority research areas, which will inherently require an increased allocation of resources for cookstove research, will lead to better characterization of exposure-response relationships. Conclusions: Although the type and extent of exposure assessment will necessarily depend on the goal and design of the cookstove study, without improved understanding of exposure-response relationships, the level of air pollution reduction necessary to meet the health targets of cookstove interventions will remain uncertain. C1 [Clark, Maggie L.; Peel, Jennifer L.] Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA. [Balakrishnan, Kalpana] Sri Ramachandra Univ, Dept Environm Hlth Engn, Madras, Tamil Nadu, India. [Breysse, Patrick N.] Johns Hopkins Univ, Baltimore, MD USA. [Chillrud, Steven N.] Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY USA. [Naeher, Luke P.] Univ Georgia, Dept Environm Hlth Sci, Athens, GA 30602 USA. [Rodes, Charles E.] Res Triangle Inst, Res Triangle Pk, NC 27709 USA. [Vette, Alan F.] US EPA, Res Triangle Pk, NC 27711 USA. [Balbus, John M.] NIEHS, NIH, Dept Hlth & Human Serv, Bethesda, MD USA. RP Clark, ML (reprint author), Colorado State Univ, 1681 Campus Delivery, Ft Collins, CO 80523 USA. EM Maggie.Clark@ColoState.edu RI Balakrishnan, Kalpana/B-6653-2015 OI Balakrishnan, Kalpana/0000-0002-5905-1801 FU U.S. Department of State; U.S. Department of Health and Human Services; National Institutes of Health (NIH); National Cancer Institute; National Eye Institute; National Heart, Lung, and Blood Institute; National Institute of Environmental Health Sciences (NIEHS); U.S. Environmental Protection Agency (EPA); Centers for Disease Control and Prevention; U.S. Agency for International Development, and the World Health Organization FX Support for the workshop was provided by the U.S. Department of State, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH) [Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; National Eye Institute; National Heart, Lung, and Blood Institute; National Institute of Environmental Health Sciences (NIEHS); John E. Fogarty International Center; and Office of Behavioral and Social Sciences Research], the U.S. Environmental Protection Agency (EPA), the Centers for Disease Control and Prevention, the U.S. Agency for International Development, and the World Health Organization. NR 72 TC 39 Z9 39 U1 8 U2 75 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD OCT PY 2013 VL 121 IS 10 BP 1120 EP 1128 DI 10.1289/ehp.1206429 PG 9 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 227YU UT WOS:000325152400012 PM 23872398 ER PT J AU Hoppin, JA Jaramillo, R London, SJ Bertelsen, RJ Salo, PM Sandler, DP Zeldin, DC AF Hoppin, Jane A. Jaramillo, Renee London, Stephanie J. Bertelsen, Randi J. Salo, Paeivi M. Sandler, Dale P. Zeldin, Darryl C. TI Phthalate Exposure and Allergy in the US Population: Results from NHANES 2005-2006 SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID NUTRITION EXAMINATION SURVEY; IN-HOUSE DUST; METABOLITE CONCENTRATIONS; REPRODUCTIVE AGE; NATIONAL-HEALTH; URINARY LEVELS; URBAN COHORT; ASTHMA; CHILDREN; MICE AB Background: Environmental exposures to phthalates, particularly high-molecular-weight (HMW) phthalates, are suspected to contribute to allergy. Objective: We assessed whether phthalate metabolites are associated with allergic symptoms and sensitization in a large nationally representative sample. Methods: We used data on urinary phthalate metabolites and allergic symptoms (hay fever, rhinitis, allergy, wheeze, asthma) and sensitization from participants >= 6 years of age in the National Health and Nutrition Examination Survey (NHANES) 2005-2006. Allergen sensitization was defined as a positive response to at least one of 19 specific IgE antigens (>= 0.35 kU/L). Odds ratios (ORs) per one log(10) unit change in phthalate concentration were estimated using logistic regression adjusting for age, race, body mass index, gender, creatinine, and cotinine. Separate analyses were conducted for children (6-17 years of age) and adults. Results: The HMW phthalate metabolite mono-benzyl phthalate (MBzP) was the only metabolite positively associated with current allergic symptoms in adults (wheeze, asthma, hay fever, and rhinitis). Mono-(3-carboxypropyl) phthalate and the sum of diethylhexyl phthalate metabolites (both representing HMW phthalate exposures) were positively associated with allergic sensitization in adults. Conversely, in children, HMW phthalate metabolites were inversely associated with asthma and hay fever. Of the low-molecular-weight phthalate metabolites, mono-ethyl phthalate was inversely associated with allergic sensitization in adults (OR = 0.79; 95% CI: 0.70, 0.90). Conclusion: In this cross-sectional analysis of a nationally representative sample, HMW phthalate metabolites, particularly MBzP, were positively associated with allergic symptoms and sensitization in adults, but there was no strong evidence for associations between phthalates and allergy in children 6-17 years of age. C1 [Hoppin, Jane A.; London, Stephanie J.; Bertelsen, Randi J.; Sandler, Dale P.] NIEHS, Epidemiol Branch, NIH, Dept Heath & Human Serv, Res Triangle Pk, NC 27709 USA. [Jaramillo, Renee] SRA Int, Durham, NC USA. [Bertelsen, Randi J.] Norwegian Inst Publ Hlth, Div Environm Med, Oslo, Norway. [Salo, Paeivi M.; Zeldin, Darryl C.] NIEHS, Biol Res Lab, NIH, DHHS, Res Triangle Pk, NC 27709 USA. RP Hoppin, JA (reprint author), NIEHS, Epidemiol Branch, MD A3-05,POB 12233, Res Triangle Pk, NC 27709 USA. EM hoppin1@niehs.nih.gov OI Sandler, Dale/0000-0002-6776-0018; London, Stephanie/0000-0003-4911-5290 FU National Institutes of Health, National Institute of Environmental Health Sciences [Z01-ES025041] FX This work was supported by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences (Z01-ES025041). NR 45 TC 29 Z9 29 U1 7 U2 41 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD OCT PY 2013 VL 121 IS 10 BP 1129 EP 1134 DI 10.1289/ehp.1206211 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 227YU UT WOS:000325152400013 PM 23799650 ER PT J AU Gosavi, RA Knudsen, GA Birnbaum, LS Pedersen, LC AF Gosavi, Rajendrakumar A. Knudsen, Gabriel A. Birnbaum, Linda S. Pedersen, Lars C. TI Mimicking of Estradiol Binding by Flame Retardants and Their Metabolites: A Crystallographic Analysis SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID HUMAN ESTROGEN SULFOTRANSFERASE; POLYBROMINATED DIPHENYL ETHERS; TETRABROMOBISPHENOL-A; CYTOSOLIC SULFOTRANSFERASES; POTENT INHIBITION; SULFURYL TRANSFER; CRYSTAL-STRUCTURE; THYROID-HORMONE; HOUSE-DUST; IN-VITRO AB Background: Brominated flame retardants (BFRs), used in many types of consumer goods, are being studied because of concerns about possible health effects related to endocrine disruption, immunotoxicity, reproductive toxicity, and neurotoxicity. Tetrabromobisphenol A (TBBPA), the most widely used BFR, and human metabolites of certain congeners of polybrominated diphenyl ether (e.g., 3-OH-BDE-47) have been suggested to inhibit estrogen sulfo-transferase, potentially affecting estrogen metabolism. Objectives: Our primary goal was to understand the structural mechanism for inhibition of the hormone-metabolizing enzyme estrogen sulfo-transferase by certain BFRs. We also sought to understand various factors that facilitate the binding of flame retardants in the enzyme binding pocket. Methods: We used X-ray crystallography to obtain atomic detail of the binding modes of TBBPA and 3-OH-BDE-47 to estrogen sulfo-transferase for comparison with binding of the endogenous substrate estradiol. Results: The crystal structures reveal how BFRs mimic estradiol binding as well as the various inter-actions between the compounds and protein residues that facilitate its binding. In addition, the structures provide insights into the ability of the sulfo-transferase substrate binding pocket to accommodate a range of halogenated compounds that satisfy minimal structural criteria. Conclusions: Our results show how BFRs or their metabolites can bind to and inhibit a key hormone-metabolizing enzyme, potentially causing endocrine disruption. C1 [Gosavi, Rajendrakumar A.; Pedersen, Lars C.] NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA. [Knudsen, Gabriel A.; Birnbaum, Linda S.] NCI, Lab Toxicol & Toxicokinet, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC USA. RP Pedersen, LC (reprint author), F3-09,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA. EM pederse2@niehs.nih.gov RI Knudsen, Gabriel/G-3706-2013 OI Knudsen, Gabriel/0000-0002-7208-6451 FU National Institute of Environmental Health Sciences; National Institutes of Health (NIH) [ZIAES102645]; National Cancer Institute, NIH [ZIABC011476] FX This research was supported in part by the Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health (NIH) (project ZIAES102645 to L.C.P.) and in part by the Intramural Research Program of the National Cancer Institute, NIH (project ZIABC011476 to L.S.B.). NR 51 TC 35 Z9 35 U1 1 U2 27 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD OCT PY 2013 VL 121 IS 10 BP 1194 EP 1199 DI 10.1289/ehp.1306902 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 227YU UT WOS:000325152400023 PM 23959441 ER PT J AU Golding, J Steer, CD Hibbeln, JR Emmett, PM Lowery, T Jones, R AF Golding, Jean Steer, Colin D. Hibbeln, Joseph R. Emmett, Pauline M. Lowery, Tony Jones, Robert TI Dietary Predictors of Maternal Prenatal Blood Mercury Levels in the ALSPAC Birth Cohort Study SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID UK TOTAL DIET; METHYLMERCURY EXPOSURE; CHILD-DEVELOPMENT; FISH CONSUMPTION; REACTION CELL; ICP-MS; POPULATION; CADMIUM; FOOD; AGE AB BACKGROUND: Very high levels of prenatal maternal mercury have adverse effects on the developing fetal brain. It has been suggested that all possible sources of mercury should be avoided. However, although seafood is a known source of mercury, little is known about other dietary components that contribute to the overall levels of blood mercury. OBJECTIVE: Our goal was to quantify the contribution of components of maternal diet to prenatal blood mercury level. METHODS: Whole blood samples and information on diet and sociodemographic factors were collected from pregnant women (n = 4,484) enrolled in the Avon Longitudinal Study of Parents and Children (ALSPAC). The blood samples were assayed for total mercury using inductively coupled plasma dynamic reaction cell mass spectrometry. Linear regression was used to estimate the relative contributions of 103 dietary variables and 6 sociodemographic characteristics to whole blood total mercury levels (TBM; untransformed and log-transformed) based on R-2 values. RESULTS: We estimated that maternal diet accounted for 19.8% of the total variation in ln-TBM, with 44% of diet-associated variability (8.75% of the total variation) associated with seafood consumption (white fish, oily fish, and shellfish). Other dietary components positively associated with TBM included wine and herbal teas, and components with significant negative associations included white bread, meat pies or pasties, and french fries. CONCLUSIONS: Although seafood is a source of dietary mercury, seafood appeared to explain a relatively small proportion of the variation in TBM in our UK study population. Our findings require confirmation, but suggest that limiting seafood intake during pregnancy may have a limited impact on prenatal blood mercury levels. C1 [Golding, Jean; Steer, Colin D.; Emmett, Pauline M.] Univ Bristol, Ctr Child & Adolescent Hlth, Bristol, Avon, England. [Hibbeln, Joseph R.] NIAAA, NIH, US Dept HHS, Bethesda, MD USA. [Lowery, Tony] NOAA, Natl Marine Fisheries Serv, Natl Seafood Inspect Lab, Pascagoula, MS USA. [Jones, Robert] Ctr Dis Control & Prevent, Inorgan & Radiat Analyt Toxicol Branch, Atlanta, GA USA. RP Golding, J (reprint author), Sch Social & Community Med, Ctr Child & Adolescent Hlth, Oakfield House,Oakfield Rd, Bristol BS8 2BN, Avon, England. EM jean.golding@bristol.ac.uk OI Emmett, Pauline/0000-0003-1076-4779; Golding, Jean/0000-0003-2826-3307 FU National Oceanic and Atmospheric Administration (NOAA); Intramural Research Program of the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health (NIH) FX The UK Medical Research Council (MRC), the Wellcome Trust, and the University of Bristol currently provide core support for ALSPAC. The assays of the maternal blood samples were carried out at the Centers for Disease Control and Prevention with funding from the National Oceanic and Atmospheric Administration (NOAA), and the statistical analyses were carried out in Bristol with funding from NOAA and support from the Intramural Research Program of the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health (NIH). NR 45 TC 26 Z9 28 U1 3 U2 35 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD OCT PY 2013 VL 121 IS 10 BP 1214 EP 1218 DI 10.1289/ehp.1206115 PG 5 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 227YU UT WOS:000325152400026 PM 23811414 ER PT J AU Verner, MA McDougall, R Glynn, A Andersen, ME Clewell, HJ Longnecker, MP AF Verner, Marc-Andre McDougall, Robin Glynn, Anders Andersen, Melvin E. Clewell, Harvey J., III Longnecker, Matthew P. TI Is the Relationship between Prenatal Exposure to PCB-153 and Decreased Birth Weight Attributable to Pharmacokinetics? SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID POLYCHLORINATED-BIPHENYLS; SERUM-LIPIDS; PREGNANCY; HUMANS; LIPOPROTEINS; AGE AB BACKGROUND: A recent meta-analysis based on data from > 7,000 pregnancies reported an -association between prenatal polychlorinated biphenyl (PCB)-153 exposure and reduced birth weight. Gestational weight gain, which is associated negatively with PCB levels in maternal and cord blood, and positively with birth weight, could substantially confound this association. OBJECTIVE: We sought to estimate the influence of gestational weight gain on the association between PCB-153 exposure and birth weight using a pharmacokinetic model. METHODS: We modified a recently published pharmacokinetic model and ran Monte Carlo simulations accounting for variability in physiologic parameters and their correlations. We evaluated the pharmacokinetic model by comparing simulated plasma PCB-153 levels during pregnancy to serial measurements in 10 pregnant women from another study population. We estimated the association between simulated plasma PCB-153 levels and birth weight using linear regression models. RESULTS: The plasma PCB-153 level profiles generated with the pharmacokinetic model were comparable to measured levels in 10 pregnant women. We estimated a 118-g decrease in birth weight (95% CI: -129, -106 g) for each 1-mu g/L increase in simulated cord plasma PCB-153, compared with the 150-g decrease estimated based on the previous meta-analysis. The estimated decrease in birth weight was reduced to -6 g (95% CI: -18, 6 g) when adjusted for simulated gestational weight gain. CONCLUSION: Our findings suggest that associations previously noted between PCB levels and birth weight may be attributable to confounding by maternal weight gain during pregnancy. C1 [Verner, Marc-Andre] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med, Boston, MA 02115 USA. [Verner, Marc-Andre] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden. [McDougall, Robin] Univ Ontario Inst Technol, Oshawa, ON, Canada. [Glynn, Anders] Swedish Natl Food Agcy, Uppsala, Sweden. [Glynn, Anders] Uppsala Univ, Evolutionary Biol Ctr, Dept Environm Toxicol, Uppsala, Sweden. [Andersen, Melvin E.; Clewell, Harvey J., III] Hamner Inst Hlth Sci, Res Triangle Pk, NC USA. [Longnecker, Matthew P.] NIEHS, Epidemiol Branch, NIH, US Dept HHS, Res Triangle Pk, NC 27709 USA. RP Verner, MA (reprint author), Brigham & Womens Hosp, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA. EM marcandre.verner@channing.harvard.edu OI Verner, Marc-Andre/0000-0002-1935-8913; Andersen, Melvin/0000-0002-3894-4811; Longnecker, Matthew/0000-0001-6073-5322 FU American Chemistry Council (ACC) Long-Range Research Initiative; Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health FX This study was supported by the American Chemistry Council (ACC) Long-Range Research Initiative and the Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health. M.-A. V. conducted this study as a consultant for the Hamner Institutes for Health Sciences, an independent nonprofit organization. M.P.L. received no compensation from the ACC. NR 26 TC 21 Z9 21 U1 1 U2 14 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD OCT PY 2013 VL 121 IS 10 BP 1219 EP 1224 DI 10.1289/ehp.1206457 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 227YU UT WOS:000325152400027 PM 23934733 ER PT J AU Ardeljan, D Meyerle, CB Agron, E Wang, JJ Mitchell, P Chew, EY Zhao, J Maminishkis, A Chan, CC Tuo, JS AF Ardeljan, Daniel Meyerle, Catherine B. Agron, Elvira Wang, Jie Jin Mitchell, Paul Chew, Emily Y. Zhao, Jing Maminishkis, Arvydas Chan, Chi-Chao Tuo, Jingsheng TI Influence of TIMP3/SYN3 polymorphisms on the phenotypic presentation of age-related macular degeneration SO EUROPEAN JOURNAL OF HUMAN GENETICS LA English DT Article DE age-related macular degeneration; TIMP3; phenotype; single-nucleotide polymorphism; Blue Mountains Eye Study; Age-Related Eye Diseases Study ID SORSBYS FUNDUS DYSTROPHY; BLUE MOUNTAINS EYE; TISSUE INHIBITOR; METALLOPROTEINASES-3 TIMP3; BRUCHS MEMBRANE; RISK-FACTORS; VISUAL-LOSS; MUTATION; DISEASE; AREDS AB Age-related macular degeneration (AMD) is a leading cause of irreversible central visual loss in the elderly. A recent genome-wide association studies (GWAS) reported that rs9621532 near the tissue inhibitor of metalloproteinase 3 (TIMP3)/synapsin III (SYN3) region of 22q12.3 is associated with AMD. In this study, we characterize its phenotypic influence on AMD using three independent study cohorts: case-control studies from the National Eye Institute Clinical Center (NEI, n = 397) and the Age-Related Eye Disease Study (n = 523) as well as a nested case-control study from Blue Mountains Eye Study (BMES, n = 852). Comparisons between cases and controls show no association between rs9621532 and AMD in the three sample sets. However, stratifying NEI cases uncovers a moderate protective role of rs9621532 in neovascular AMD (nAMD) and the association adhered to a dominant model (odds ratios = 0.32; 95% CI: 0.11-0.89; P = 0.02). The BMES data followed the same pattern of association with nAMD as that seen in the NEI sample but did not reach statistical significance. Polychotomous logistic regression showed a trend that rs9621532 correlates with less severe disease, for example, with the majority of carriers having intermediate AMD rather than nAMD/geographic atrophy AMD. Functionally, rs9621532 influences TIMP3 mRNA expression in cultured primary human fetal retinal pigment epithelium (hfRPE) cells. In hfRPE donors carrying the protective rs9625132 allele, we measured a reduction in TIMP3 mRNA by quantitative RT-PCR. Our data suggest that rs9621532 carriers have a lower risk of developing nAMD, potentially because of decreased transcription of TIMP3. C1 [Ardeljan, Daniel; Chan, Chi-Chao; Tuo, Jingsheng] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA. [Meyerle, Catherine B.; Agron, Elvira; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA. [Wang, Jie Jin; Mitchell, Paul] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Westmead, NSW 2145, Australia. [Wang, Jie Jin; Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Westmead, NSW 2145, Australia. [Zhao, Jing; Maminishkis, Arvydas] NEI, Sect Epithelial & Retinal Physiol & Dis, NIH, Bethesda, MD 20892 USA. RP Tuo, JS (reprint author), NEI, Immunol Lab, NIH, 10-10N103,10 Ctr Dr, Bethesda, MD 20892 USA. EM tuoj@nei.nih.gov RI Wang, Jie Jin/P-1499-2014; Mitchell, Paul/P-1498-2014; OI Wang, Jie Jin/0000-0001-9491-4898; Tuo, Jingsheng/0000-0002-1372-7810 FU Intramural Research Program of National Eye Institute, NIH; Australian National Health and Medical Research Council FX We thank Angel Garced, Katherine Shimel, and Sun-min Ro, for their assistance in contacting study participants and collecting blood samples. We also thank the study participants and their families for enrolling in this study. This research was supported by the Intramural Research Program of National Eye Institute, NIH and the Australian National Health and Medical Research Council. NR 31 TC 11 Z9 11 U1 0 U2 7 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1018-4813 J9 EUR J HUM GENET JI Eur. J. Hum. Genet. PD OCT PY 2013 VL 21 IS 10 BP 1152 EP 1157 DI 10.1038/ejhg.2013.14 PG 6 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 222JO UT WOS:000324727200026 PM 23422939 ER PT J AU Zanotti-Fregonara, P Lammertsma, AA Innis, RB AF Zanotti-Fregonara, Paolo Lammertsma, Adriaan A. Innis, Robert B. TI Suggested pathway to assess radiation safety of F-18-labeled PET tracers for first-in-human studies SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING LA English DT Letter ID DOSIMETRY; BIODISTRIBUTION; CANCER; HUMANS; PROBE C1 [Zanotti-Fregonara, Paolo; Innis, Robert B.] NIMH, Mol Imaging Branch, NIH, Bethesda, MD 20892 USA. [Lammertsma, Adriaan A.] Vrije Univ Amsterdam Med Ctr, Dept Radiol & Nucl Med, Amsterdam, Netherlands. RP Innis, RB (reprint author), NIMH, Mol Imaging Branch, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA. EM robert.innis@nih.gov FU Intramural NIH HHS [Z99 MH999999] NR 20 TC 10 Z9 10 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1619-7070 J9 EUR J NUCL MED MOL I JI Eur. J. Nucl. Med. Mol. Imaging PD OCT PY 2013 VL 40 IS 11 BP 1781 EP 1783 DI 10.1007/s00259-013-2512-x PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 227QO UT WOS:000325128800016 PM 23868334 ER PT J AU Slezak, JM Katz, JL AF Slezak, Jonathan M. Katz, Jonathan L. TI An Influence of Delayed Reinforcement on the Effectiveness of Psychostimulants to Enhance Indices of Attention Under a Five-Choice Serial Reaction Time Procedure in Male Rats SO EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY LA English DT Article DE five-choice serial reaction time procedure; d-amphetamine; methylphenidate; ADHD; delayed reinforcement ID DEFICIT/HYPERACTIVITY DISORDER ADHD; DEFICIT HYPERACTIVITY DISORDER; D-AMPHETAMINE; STIMULANT-DRUGS; TASK; PERFORMANCE; METHYLPHENIDATE; SENSITIVITY; ATOMOXETINE; FRUSTRATION AB The five-choice serial reaction time (5-CSRT) procedure has been considered a translational tool for assessments of the psychopharmacology of attention in preclinical research. Because greater sensitivity to delayed reinforcement may promote the development of attention-deficit/hyperactivity disorder (ADHD) symptoms, effects of reinforcer delay and psychostimulants on performances under a 5-CSRT procedure were determined. Male rats were trained to respond under a 5-CSRT procedure with different delay-of-reinforcement conditions (0, 2, 4, 8, 16 s), and effects of d-amphetamine, methylphenidate, and morphine (as a negative control) were assessed at 0- and 16-s delays. Under nondrug conditions, as the delay increased both response latency and the number of trials in which a response did not occur (omissions) increased, and the percent correct on trials when responses were emitted decreased. Only modest increases in the percent correct were found with psychostimulants during the 0-s delay condition; however, more substantial enhancements were found with a 16-s delay. Consistent effects of both psychostimulants at either delay on omissions and response latency were not observed. Morphine increased omissions and response latency at both delays and decreased the percent correct (16-s delay). Generally, responses during the intertrial interval were not systematically affected under any condition. The current results demonstrate that measures of attention in a 5-CSRT procedure are sensitive to changes in the delay to reinforcer delivery. More important, psychostimulants significantly enhanced a measure of attention only when reinforcers were delayed, which may be reflective of the psychopharmacological mechanisms involved with clinical treatment of ADHD symptoms. C1 [Slezak, Jonathan M.; Katz, Jonathan L.] NIDA, Psychobiol Sect, Mol Targets & Medicat Discovery Res Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA. [Slezak, Jonathan M.] Johns Hopkins Univ, Dept Neurol, Sch Med, Baltimore, MD 21218 USA. RP Katz, JL (reprint author), NIDA, Psychobiol Sect, Intramural Res Program, NIH, 251 Bayview Blvd,Suite 200, Baltimore, MD 21224 USA. EM jkatz@intra.nida.nih.gov OI Katz, Jonathan/0000-0002-1068-1159 FU National Institute on Drug Abuse FX Financial support for this project was provided by the National Institute on Drug Abuse Intramural Research Program. The authors would like to acknowledge the expert technical assistance of Bettye Campbell. All authors have contributed in a significant way to the manuscript, and all authors have read and approved the final manuscript. No authors have conflicts of interest. NR 32 TC 1 Z9 1 U1 0 U2 5 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1064-1297 J9 EXP CLIN PSYCHOPHARM JI Exp. Clin. Psychopharmacol. PD OCT PY 2013 VL 21 IS 5 SI SI BP 355 EP 362 DI 10.1037/a0033726 PG 8 WC Psychology, Biological; Psychology, Clinical; Pharmacology & Pharmacy; Psychiatry SC Psychology; Pharmacology & Pharmacy; Psychiatry GA 229DK UT WOS:000325241800003 PM 24099356 ER PT J AU Mishra, PK Ottmann, AR Basrai, MA AF Mishra, Prashant K. Ottmann, Alicia R. Basrai, Munira A. TI Structural Integrity of Centromeric Chromatin and Faithful Chromosome Segregation Requires Pat1 SO GENETICS LA English DT Article ID H3 VARIANT CSE4; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; HISTONE H3; TRANSMISSION FIDELITY; KINETOCHORE FUNCTION; TOPOISOMERASE-II; DNA; PROTEIN; GENE AB The kinetochore (centromeric DNA and associated protein complex) is essential for faithful chromosome segregation and maintenance of genome stability. Here we report that an evolutionarily conserved protein Pat1 is a structural component of Saccharomyces cerevisiae kinetochore and associates with centromeres in a NDC10-dependent manner. Consistent with a role for Pat1 in kinetochore structure and function, a deletion of PAT1 results in delay in sister chromatid separation, errors in chromosome segregation, and defects in structural integrity of centromeric chromatin. Pat1 is involved in topological regulation of minichromosomes as altered patterns of DNA supercoiling were observed in pat1 Delta cells. Studies with pat1 alleles uncovered an evolutionarily conserved region within the central domain of Pat1 that is required for its association with centromeres, sister chromatid separation, and faithful chromosome segregation. Taken together, our data have uncovered a novel role for Pat1 in maintaining the structural integrity of centromeric chromatin to facilitate faithful chromosome segregation and proper kinetochore function. C1 [Mishra, Prashant K.; Ottmann, Alicia R.; Basrai, Munira A.] NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. RP Basrai, MA (reprint author), NCI, Genet Branch, Ctr Canc Res, NIH, 41 Medlars Dr,Room B624, Bethesda, MD 20892 USA. EM basraim@mail.nih.gov FU National Cancer Institute, National Institutes of Health FX We thank Roy Parker, Duncan Clarke, Sue Biggins, Jennifer Gerton, Jeff Bachant, and Richard Baker for reagents, Kathy McKinnon of the NCI Vaccine branch FACS Core, Thomas Johnson for help with Southern hybridization, Suresh Ambudkar, Suneet Shukla, and Eduardo Chufan for assistance with phospho-imaging, and members of the Basrai lab for discussions. Support for this research was provided by the Intramural Research Program of the National Cancer Institute, National Institutes of Health. NR 62 TC 10 Z9 10 U1 0 U2 2 PU GENETICS SOC AM PI BETHESDA PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA SN 1943-2631 J9 GENETICS JI Genetics PD OCT PY 2013 VL 195 IS 2 BP 369 EP + DI 10.1534/genetics.113.155291 PG 16 WC Genetics & Heredity SC Genetics & Heredity GA 229RY UT WOS:000325286200008 PM 23893485 ER PT J AU Wesolowska, N Amariei, FL Rong, YKS AF Wesolowska, Natalia Amariei, Flavia L. Rong, Yikang S. TI Clustering and Protein Dynamics of Drosophila melanogaster Telomeres SO GENETICS LA English DT Article ID NUCLEAR-ENVELOPE; DNA-SEQUENCES; INTERPHASE NUCLEI; SIR4 PROTEINS; CHROMOSOME; YEAST; CELLS; LOCALIZATION; CENTROMERES; KLARSICHT AB Telomeres are obligatory chromosomal landmarks that demarcate the ends of linear chromosomes to distinguish them from broken ends and can also serve to organize the genome. In both budding and fission yeast, they cluster at the periphery of the nucleus, potentially to establish a compartment of silent chromatin. To gain insight into telomere organization in higher organisms, we investigated their distribution in interphase nuclei of Drosophila melanogaster. We focused on the syncytial blastoderm, an excellent developmental stage for live imaging due to the synchronous division of the nuclei at this time. We followed the EGFP-labeled telomeric protein HOAP in vivo and found that the 16 telomeres yield four to six foci per nucleus, indicative of clustering. Furthermore, we confirmed clustering in other somatic tissues. Importantly, we observed that HOAP signal intensity in the clusters increases in interphase, potentially due to loading of HOAP to newly replicated telomeres. To determine the rules governing clustering, we used in vivo imaging and fluorescence in situ hybridization to test several predictions. First, we inspected mutant embryos that develop as haploids and found that clustering is not mediated by associations between homologs. Second, we probed specifically for a telomere of novel sequence and found strong evidence against DNA sequence identity and homology as critical factors. Third, we ruled out predominance of intrachromosomal interactions by marking both ends of a chromosome. Based on these results, we propose that clustering is independent of sequence and is likely maintained by an as yet undetermined factor. C1 [Wesolowska, Natalia; Amariei, Flavia L.; Rong, Yikang S.] NCI, Lab Biochem & Mol Biol, NIH, Bethesda, MD 20892 USA. [Wesolowska, Natalia] NIH, Bethesda, MD 20892 USA. [Wesolowska, Natalia] Johns Hopkins Univ, Grad Partnership Program, Bethesda, MD 20892 USA. RP Wesolowska, N (reprint author), NIH, Lab Biochem & Mol Biol, 37 Convent Dr,Room 6056, Bethesda, MD 20892 USA. EM wesolown@mail.nih.gov; rongy@mail.nih.gov NR 49 TC 7 Z9 7 U1 2 U2 8 PU GENETICS SOC AM PI BETHESDA PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA SN 1943-2631 J9 GENETICS JI Genetics PD OCT PY 2013 VL 195 IS 2 BP 381 EP + DI 10.1534/genetics.113.155408 PG 17 WC Genetics & Heredity SC Genetics & Heredity GA 229RY UT WOS:000325286200009 PM 23893488 ER PT J AU Brown, JL Kassis, JA AF Brown, J. Lesley Kassis, Judith A. TI Architectural and Functional Diversity of Polycomb Group Response Elements in Drosophila SO GENETICS LA English DT Article ID GROUP PROTEIN COMPLEXES; DNA-BINDING PROTEIN; ENGRAILED GENE; HOMEOTIC GENE; METHYLTRANSFERASE ACTIVITY; CHROMATIN BINDING; BITHORAX COMPLEX; REGULATORY DNA; TARGET GENES; GAGA FACTOR AB Polycomb group response elements (PREs) play an essential role in gene regulation by the Polycomb group (PcG) repressor proteins in Drosophila. PREs are required for the recruitment and maintenance of repression by the PcG proteins. PREs are made up of binding sites for multiple DNA-binding proteins, but it is still unclear what combination(s) of binding sites is required for PRE activity. Here we compare the binding sites and activities of two closely linked yet separable PREs of the Drosophila engrailed (en) gene, PRE1 and PRE2. Both PRE1 and PRE2 contain binding sites for multiple PRE-DNA-binding proteins, but the number, arrangement, and spacing of the sites differs between the two PREs. These differences have functional consequences. Both PRE1 and PRE2 mediate pairing-sensitive silencing of mini-white, a functional assay for PcG repression; however, PRE1 requires two binding sites for Pleiohomeotic (Pho), whereas PRE2 requires only one Pho-binding site for this activity. Furthermore, for full pairing-sensitive silencing activity, PRE1 requires an AT-rich region not found in PRE2. These two PREs behave differently in a PRE embryonic and larval reporter construct inserted at an identical location in the genome. Our data illustrate the diversity of architecture and function of PREs. C1 [Brown, J. Lesley; Kassis, Judith A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Genom Differentiat, NIH, Bethesda, MD 20892 USA. RP Kassis, JA (reprint author), 6 Ctr Dr MSC 2785,Bldg 6B,Rm 3B-331, Bethesda, MD 20892 USA. EM jkassis@mail.nih.gov OI Kassis, Judith/0000-0001-9268-3213 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health FX We thank Miki Fujioka for the bxd-Ubx-lacZ RCME vector and for transgenic lines; Bill McGinnis for the generous gift of Grh antibodies; and Emma Hornick for construction of the bxd-Ubx-lacZ reporter constructs. We also thank Yuzhong Cheng, Payal Ray, and Sandip De for critical reading of this manuscript. This work was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health. NR 77 TC 12 Z9 12 U1 0 U2 8 PU GENETICS SOC AM PI BETHESDA PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA SN 1943-2631 J9 GENETICS JI Genetics PD OCT PY 2013 VL 195 IS 2 BP 407 EP 419 DI 10.1534/genetics.113.153247 PG 13 WC Genetics & Heredity SC Genetics & Heredity GA 229RY UT WOS:000325286200011 PM 23934890 ER PT J AU Guo, YB Park, JM Cui, BW Humes, E Gangadharan, S Hung, S FitzGerald, PC Hoe, KL Grewal, SIS Craig, NL Levin, HL AF Guo, Yabin Park, Jung Min Cui, Bowen Humes, Elizabeth Gangadharan, Sunil Hung, Stevephen FitzGerald, Peter C. Hoe, Kwang-Lae Grewal, Shiv I. S. Craig, Nancy L. Levin, Henry L. TI Integration Profiling of Gene Function With Dense Maps of Transposon Integration SO GENETICS LA English DT Article ID YEAST SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; GENOME; DNA; SCREEN; HIV-1 AB Understanding how complex networks of genes integrate to produce dividing cells is an important goal that is limited by the difficulty in defining the function of individual genes. Current resources for the systematic identification of gene function such as siRNA libraries and collections of deletion strains are costly and organism specific. We describe here integration profiling, a novel approach to identify the function of eukaryotic genes based upon dense maps of transposon integration. As a proof of concept, we used the transposon Hermes to generate a library of 360,513 insertions in the genome of Schizosaccharomyces pombe. On average, we obtained one insertion for every 29 bp of the genome. Hermes integrated more often into nucleosome free sites and 33% of the insertions occurred in ORFs. We found that ORFs with low integration densities successfully identified the genes that are essential for cell division. Importantly, the nonessential ORFs with intermediate levels of insertion correlated with the nonessential genes that have functions required for colonies to reach full size. This finding indicates that integration profiles can measure the contribution of nonessential genes to cell division. While integration profiling succeeded in identifying genes necessary for propagation, it also has the potential to identify genes important for many other functions such as DNA repair, stress response, and meiosis. C1 [Guo, Yabin; Park, Jung Min; Humes, Elizabeth; Hung, Stevephen; Levin, Henry L.] NCI, Sect Eukaryot Transposable Elements, Program Cellular Regulat & Metab,NIH, Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD 20892 USA. [Cui, Bowen; Grewal, Shiv I. S.] NCI, Lab Biochem & Mol Biol, NIH, Bethesda, MD 20892 USA. [FitzGerald, Peter C.] NCI, Genome Anal Unit, NIH, Bethesda, MD 20892 USA. [Gangadharan, Sunil; Craig, Nancy L.] Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA. [Gangadharan, Sunil; Craig, Nancy L.] Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA. [Hoe, Kwang-Lae] Chungnam Natl Univ, Dept New Drug Discovery & Dev, Taejon 305764, South Korea. RP Levin, HL (reprint author), NIH, 18 Lib Dr,Room 106, Bethesda, MD 20892 USA. EM henry_levin@nih.gov OI , Guo/0000-0001-8316-8527 FU National Institutes of Health (NIH) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; NIH [RO1GM076425] FX We thank Jacqueline Hayles for kindly sharing data on the colony size of the strains with gene deletions. This research was supported by the Intramural Research Program of the National Institutes of Health (NIH) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and by the Intramural Program of the National Cancer Institute. The work by S. G. and N.L.C. was supported by NIH grant RO1GM076425. NR 27 TC 8 Z9 8 U1 2 U2 12 PU GENETICS SOCIETY AMERICA PI BETHESDA PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA SN 0016-6731 EI 1943-2631 J9 GENETICS JI Genetics PD OCT PY 2013 VL 195 IS 2 BP 599 EP + DI 10.1534/genetics.113.152744 PG 29 WC Genetics & Heredity SC Genetics & Heredity GA 229RY UT WOS:000325286200026 PM 23893486 ER PT J AU Neyret-Kahn, H Benhamed, M Ye, T Le Gras, S Cossec, JC Lapaquette, P Bischof, O Ouspenskaia, M Dasso, M Seeler, J Davidson, I Dejean, A AF Neyret-Kahn, Helene Benhamed, Moussa Ye, Tao Le Gras, Stephanie Cossec, Jack-Christophe Lapaquette, Pierre Bischof, Oliver Ouspenskaia, Maia Dasso, Mary Seeler, Jacob Davidson, Irwin Dejean, Anne TI Sumoylation at chromatin governs coordinated repression of a transcriptional program essential for cell growth and proliferation SO GENOME RESEARCH LA English DT Article ID RNA-POLYMERASE-III; SUMO MODIFICATION; HETEROCHROMATIN FORMATION; SUBSTRATE PROTEINS; DNA-REPAIR; SENESCENCE; GENES; EXPRESSION; YEAST; CTCF AB Despite numerous studies on specific sumoylated transcriptional regulators, the global role of SUMO on chromatin in relation to transcription regulation remains largely unknown. Here, we determined the genome-wide localization of SUMO1 and SUMO2/3, as well as of UBC9 (encoded by UBE2I) and PIASY (encoded by PIAS4), two markers for active sumoylation, along with Pol II and histone marks in proliferating versus senescent human fibroblasts together with gene expression profiling. We found that, whereas SUMO alone is widely distributed over the genome with strong association at active promoters, active sumoylation occurs most prominently at promoters of histone and protein biogenesis genes, as well as Pol I rRNAs and Pol III tRNAs. Remarkably, these four classes of genes are up-regulated by inhibition of sumoylation, indicating that SUMO normally acts to restrain their expression. In line with this finding, sumoylation-deficient cells show an increase in both cell size and global protein levels. Strikingly, we found that in senescent cells, the SUMO machinery is selectively retained at histone and tRNA gene clusters, whereas it is massively released from all other unique chromatin regions. These data, which reveal the highly dynamic nature of the SUMO landscape, suggest that maintenance of a repressive environment at histone and tRNA loci is a hallmark of the senescent state. The approach taken in our study thus permitted the identification of a common biological output and uncovered hitherto unknown functions for active sumoylation at chromatin as a key mechanism that, in dynamically marking chromatin by a simple modifier, orchestrates concerted transcriptional regulation of a network of genes essential for cell growth and proliferation. C1 [Neyret-Kahn, Helene; Benhamed, Moussa; Cossec, Jack-Christophe; Lapaquette, Pierre; Bischof, Oliver; Seeler, Jacob; Dejean, Anne] Inst Pasteur, Dept Cell Biol & Infect, Lab Nucl Org & Oncogenesis, F-75015 Paris, France. [Neyret-Kahn, Helene; Benhamed, Moussa; Cossec, Jack-Christophe; Lapaquette, Pierre; Bischof, Oliver; Seeler, Jacob; Dejean, Anne] INSERM, U993, F-75015 Paris, France. [Neyret-Kahn, Helene; Benhamed, Moussa; Cossec, Jack-Christophe; Lapaquette, Pierre; Bischof, Oliver; Seeler, Jacob; Davidson, Irwin; Dejean, Anne] Equipe Labellisee Ligue Canc, F-75013 Paris, France. [Ye, Tao; Le Gras, Stephanie; Davidson, Irwin] CNRS INSERM UDS, Inst Genet & Biol Mol & Cellulaire, Dept Funct Genom & Canc, F-67404 Illkirch Graffenstaden, France. [Ouspenskaia, Maia; Dasso, Mary] NICHHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA. RP Davidson, I (reprint author), Equipe Labellisee Ligue Canc, F-75013 Paris, France. EM irwin@igbmc.fr; anne.dejean@pasteur.fr OI Seeler, Jacob/0000-0001-8209-8555; Dasso, Mary/0000-0002-5410-1371; Davidson, Irwin/0000-0001-5533-1171 FU LNCC; Odyssey-RE; INCa; Universite de Strasbourg; ANR; ERC; EEC (EuTRACC); MRT; ARC FX We thank R. Santoro and M. Werner for rRNA/tRNA reagents and advice. We acknowledge A. Andrieux for technical assistance. This work was supported by grants from LNCC, Odyssey-RE, INCa, Universite de Strasbourg, ANR, ERC, and EEC (EuTRACC). The IGBMC high-throughput sequencing facility is a member of the "France Genomique" consortium (ANR10-INBS-09-08). H.N.-K. was supported by the MRT and ARC. NR 55 TC 32 Z9 32 U1 0 U2 19 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 1088-9051 J9 GENOME RES JI Genome Res. PD OCT PY 2013 VL 23 IS 10 BP 1563 EP 1579 DI 10.1101/gr.154872.113 PG 17 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity GA 228QQ UT WOS:000325202100001 PM 23893515 ER PT J AU Mandyam, MC Soliman, EZ Alonso, A Dewland, TA Heckbert, SR Vittinghoff, E Cummings, SR Ellinor, PT Chaitman, BR Stocke, K Applegate, WB Arking, DE Butler, J Loehr, LR Magnani, JW Murphy, RA Satterfield, S Newman, AB Marcus, GM AF Mandyam, Mala C. Soliman, Elsayed Z. Alonso, Alvaro Dewland, Thomas A. Heckbert, Susan R. Vittinghoff, Eric Cummings, Steven R. Ellinor, Patrick T. Chaitman, Bernard R. Stocke, Karen Applegate, William B. Arking, Dan E. Butler, Javed Loehr, Laura R. Magnani, Jared W. Murphy, Rachel A. Satterfield, Suzanne Newman, Anne B. Marcus, Gregory M. TI The QT interval and risk of incident atrial fibrillation SO HEART RHYTHM LA English DT Article DE Atrial fibrillation; Epidemiology; Risk; QT interval; Electrocardiogram; ECG ID CARDIOVASCULAR HEALTH; REFRACTORY PERIOD; DELAYED AFTERDEPOLARIZATIONS; ATHEROSCLEROSIS RISK; ASSOCIATION; HEART; PREVALENCE; ECG; CONTRIBUTES; ARRHYTHMIAS AB BACKGROUND Abnormal atrial repolarization is important in the development of atrial fibrillation (AF), but no direct measurement is available in clinical medicine. OBJECTIVE To determine whether the QT interval, a marker of ventricular repolarization, could be used to predict incident AF. METHODS We examined a prolonged QT interval corrected by using the Framingham formula (QTFram) as a predictor of incident AF in the Atherosclerosis Risk in Communities (ARIC) study. The Cardiovascular Health Study (CHS) and Health, Aging, and Body Composition (ABC) study were used for validation. Secondary predictors included QT duration as a continuous variable, a short QT interval, and QT intervals corrected by using other formulas. RESULTS Among 14,538 ARIC study participants, a prolonged QTFram predicted a roughly 2-fold increased risk of AF (hazard ratio [HR] 2.05; 95% confidence interval [CI] 1.42-2.96; P < .001). No substantive attenuation was observed after adjustment for age, race, sex, study center, body mass index, hypertension, diabetes, coronary disease, and heart failure. The findings were validated in Cardiovascular Health Study and Health, Aging, and Body Composition study and were similar across various QT correction methods. Also in the ARIC study, each 10-ms increase in QTFram was associated with an increased unadjusted (HR 1.14; 95% CI 1.10-1.17; P < .001) and adjusted (HR 1.11; 95% CI 1.07-1.14; P < .001) risk of AF. Findings regarding a short QT interval were inconsistent across cohorts. CONCLUSION A prolonged QT interval is associated with an increased risk of incident AF. C1 [Mandyam, Mala C.; Dewland, Thomas A.; Marcus, Gregory M.] Univ Calif San Francisco, Div Cardiol, Electrophysiol Sect, San Francisco, CA 94143 USA. [Soliman, Elsayed Z.] Wake Forest Univ, Sch Med, Epidemiol Cardiol Res Ctr, Dept Epidemiol & Prevent, Winston Salem, NC 27109 USA. [Alonso, Alvaro] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Heckbert, Susan R.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Vittinghoff, Eric] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Cummings, Steven R.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA USA. [Chaitman, Bernard R.] St Louis Univ, Sch Med, ECG Core Lab, St Louis, MO USA. [Stocke, Karen] St Louis Univ, Sch Med, ECG Core Lab, St Louis, MO USA. [Applegate, William B.] Wake Forest Univ, Sch Med, Div Gerontol & Geriatr Med, Winston Salem, NC 27109 USA. [Arking, Dan E.] Johns Hopkins Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA. [Butler, Javed] Emory Univ, Dept Med, Div Cardiol, Atlanta, GA 30322 USA. [Loehr, Laura R.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Magnani, Jared W.] Boston Univ, Cardiovasc Med Sect, Dept Med, Boston, MA 02215 USA. [Murphy, Rachel A.] Natl Inst Aging, Intramural Res Program, Lab Populat Sci, Bethesda, MD USA. [Satterfield, Suzanne] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA. [Newman, Anne B.] Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. RP Marcus, GM (reprint author), Univ Calif San Francisco, Div Cardiol, Electrophysiol Sect, 505 Parnassus Ave,M-1180B,Box 0124, San Francisco, CA 94143 USA. EM marcusg@medicine.ucsf.edu RI Newman, Anne/C-6408-2013; Alonso, Alvaro/A-4917-2010 OI Newman, Anne/0000-0002-0106-1150; Alonso, Alvaro/0000-0002-2225-8323 FU University of California San Franciscos Clinical & Translational Science Institute (UCSF CTSI); National Center for Research Resources; National Center for Advancing Translational Sciences; Office of the Director, National Institutes of Health (NIH) [TL1 RR024129]; National Heart, Lung, and Blood Institute (NHLBI) [HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, HHSN268201100012C]; NHLBI [HHSN268201200036C, N01HC85239, N01 HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, HL080295, HL068986]; National Institute on Aging (NIA) [AG023629]; NIA [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050]; National Institute of Nursing Research grant [R01-NR012459]; Intramural Research Program of the NIH, NIA FX This research was supported by the following: For the University of California San Franciscos Clinical & Translational Science Institute (UCSF CTSI): the National Center for Research Resources, the National Center for Advancing Translational Sciences, and the Office of the Director, National Institutes of Health (NIH), through UCSF-CTSI grant number TL1 RR024129; for the Atherosclerosis Risk in Communities (ARIC) study: a collaborative support from National Heart, Lung, and Blood Institute (NHLBI) contracts HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C; for the Cardiovascular Health Study (CHS): a support from NHLBI contracts HHSN268201200036C, N01HC85239, N01 HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, and N01HC85086 and grants HL080295 and HL068986, with additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support was provided by AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at http://www.chs-nhlbi.org/PI.htm; for the Health, Aging, and Body Composition (Health ABC) study: a support from NIA contracts N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106 and grant R01-AG028050, as well as the National Institute of Nursing Research grant R01-NR012459. This research was supported in part by the Intramural Research Program of the NIH, NIA. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of any of the supporting agencies or sources. NR 34 TC 15 Z9 16 U1 0 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1547-5271 J9 HEART RHYTHM JI Heart Rhythm PD OCT PY 2013 VL 10 IS 10 BP 1562 EP 1568 DI 10.1016/j.hrthm.2013.07.023 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 227XZ UT WOS:000325150300030 PM 23872693 ER PT J AU Wang, H Feng, DC Park, O Yin, S Gao, B AF Wang, Hua Feng, Dechun Park, Ogyi Yin, Shi Gao, Bin TI Invariant NKT Cell Activation Induces Neutrophil Accumulation and Hepatitis: Opposite Regulation by IL-4 and IFN-gamma SO HEPATOLOGY LA English DT Article ID KILLER T-CELLS; LIVER NATURAL-KILLER; PHASE I/II TRIAL; ALPHA-GALACTOSYLCERAMIDE; INTERFERON-GAMMA; MEDIATED HEPATITIS; CONCANAVALIN-A; IN-VIVO; INJURY; MICE AB Alpha-Galactosylceramide (-Galcer), a specific agonist for invariant natural killer T (iNKT) cells, is being evaluated in clinical trials for the treatment of viral hepatitis and liver cancer. However, the results from -Galcer treatment are mixed, partially because of the variety of cytokines produced by activated iNKT cells that have an unknown synergistic effect on the progression of liver disease. It is well documented that injection of -Galcer induces mild hepatitis with a rapid elevation in the levels of interleukin (IL)-4 and a delayed elevation in the levels of interferon-gamma (IFN-), and both of these cytokines are thought to mediate many functions of iNKT cells. Surprisingly, genetic deletion of both IL-4 and IFN- aggravated, rather than abolished, -Galcer-induced iNKT hepatitis. Moreover, genetic ablation of IL-4, the IL-4 receptor, or its downstream signaling molecule signal transducer and activator of transcription (STAT)6 ameliorated -Galcer-induced neutrophil infiltration, liver injury, and hepatitis. In contrast, genetic deletion of IFN-, the IFN- receptor, or its downstream signaling molecule STAT1 enhanced liver neutrophil accumulation, thereby exacerbating liver injury and hepatitis. Moreover, depletion of neutrophils eradicated -Galcer-induced liver injury in wild-type, STAT1 knockout, and IFN- knockout mice. Conclusion: Our results propose a model in which activated iNKT cells rapidly release IL-4, which promotes neutrophil survival and hepatitis but also sequentially produce IFN-, which acts in a negative feedback loop to ameliorate iNKT hepatitis by inducing neutrophil apoptosis. Thus, modification of iNKT production of IL-4 and IFN- may have the potential to improve the efficacy of -Galcer in the treatment of liver disease. (Hepatology 2013;58:1474-1485) C1 [Wang, Hua; Feng, Dechun; Park, Ogyi; Yin, Shi; Gao, Bin] NIAAA, Lab Liver Dis, NIH, Bethesda, MD 20892 USA. RP Gao, B (reprint author), NIAAA, Lab Liver Dis, NIH, Bethesda, MD 20892 USA. EM bgao@mail.nih.gov RI Feng, Dechun/Q-5962-2016 FU NIAAA, NIH FX This work was supported by the intramural program of NIAAA, NIH (to B.G.). NR 39 TC 19 Z9 20 U1 1 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 IS 4 BP 1474 EP 1485 DI 10.1002/hep.26471 PG 12 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 227XX UT WOS:000325150100032 PM 23686838 ER PT J AU Hernandez-Hernandez, V Pravincumar, P Diaz-Font, A May-Simera, H Jenkins, D Knight, M Beales, PL AF Hernandez-Hernandez, Victor Pravincumar, Priyanka Diaz-Font, Anna May-Simera, Helen Jenkins, Dagan Knight, Martin Beales, Philip L. TI Bardet-Biedl syndrome proteins control the cilia length through regulation of actin polymerization SO HUMAN MOLECULAR GENETICS LA English DT Article ID PLANAR CELL POLARITY; MEDIATES CILIOGENESIS; FOCAL ADHESIONS; BBSOME; RHO; DYNAMICS; COMPLEX; MECHANOTRANSDUCTION; CHONDROCYTES; CYTOSKELETON AB Primary cilia are cellular appendages important for signal transduction and sensing the environment. Bardet-Biedl syndrome proteins form a complex that is important for several cytoskeleton-related processes such as ciliogenesis, cell migration and division. However, the mechanisms by which BBS proteins may regulate the cytoskeleton remain unclear. We discovered that Bbs4- and Bbs6-deficient renal medullary cells display a characteristic behaviour comprising poor migration, adhesion and division with an inability to form lamellipodial and filopodial extensions. Moreover, fewer mutant cells were ciliated [48% +/- 6 for wild-type (WT) cells versus 23% +/- 7 for Bbs4 null cells; P < 0.0001] and their cilia were shorter (2.55 mu m +/- 0.41 for WT cells versus 2.16 mu m +/- 0.23 for Bbs4 null cells; P < 0.0001). While the microtubular cytoskeleton and cortical actin were intact, actin stress fibre formation was severely disrupted, forming abnormal apical stress fibre aggregates. Furthermore, we observed over-abundant focal adhesions (FAs) in Bbs4-, Bbs6- and Bbs8-deficient cells. In view of these findings and the role of RhoA in regulation of actin filament polymerization, we showed that RhoA-GTP levels were highly upregulated in the absence of Bbs proteins. Upon treatment of Bbs4- deficient cells with chemical inhibitors of RhoA, we were able to restore the cilia length and number as well as the integrity of the actin cytoskeleton. Together these findings indicate that Bbs proteins play a central role in the regulation of the actin cytoskeleton and control the cilia length through alteration of RhoA levels. C1 [Hernandez-Hernandez, Victor; Diaz-Font, Anna; Jenkins, Dagan; Beales, Philip L.] UCL Inst Child Hlth London, Mol Med Unit, London, England. [Pravincumar, Priyanka; Knight, Martin] Queen Mary Univ London, Sch Engn & Mat Sci, London, England. [May-Simera, Helen] Natl Inst Deafness & Commun Disorders, NIH, Bethesda, MD USA. RP Beales, PL (reprint author), UCL Inst Child Hlth London, Mol Med Unit, London, England. EM p.beales@ucl.ac.uk OI Knight, Martin/0000-0003-3755-1597 FU NEWLIFE; WELLCOME TRUST ViP Award; SYSCILIA [EU-FP7 241955]; WELLCOME TRUST; EPSRC FX This work was funded by grants from NEWLIFE, a WELLCOME TRUST ViP Award to D.J., SYSCILIA (EU-FP7 241955), and WELLCOME TRUST. P.L.B. is a Wellcome Trust Senior Research Fellow. Priyanka Pravincumar is funded by an EPSRC PhD Studentship. Funding to pay the Open Access publication charges for this article was provided by Wellcome Trust. NR 48 TC 20 Z9 20 U1 1 U2 12 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 J9 HUM MOL GENET JI Hum. Mol. Genet. PD OCT 1 PY 2013 VL 22 IS 19 BP 3858 EP 3868 DI 10.1093/hmg/ddt241 PG 11 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 228CX UT WOS:000325163900004 PM 23716571 ER PT J AU Parrow, NL Fleming, RE Minnick, MF AF Parrow, Nermi L. Fleming, Robert E. Minnick, Michael F. TI Sequestration and Scavenging of Iron in Infection SO INFECTION AND IMMUNITY LA English DT Review ID OUTER-MEMBRANE PROTEIN; INTRACELLULAR HEME-TRAFFICKING; PATHOGENIC ESCHERICHIA-COLI; REGULATORY PEPTIDE HEPCIDIN; STAPHYLOCOCCUS-AUREUS ISDG; ACUTE-PHASE PROTEINS; BINDING PROTEIN; VIBRIO-CHOLERAE; HAEMOPHILUS-INFLUENZAE; DIETARY IRON AB The proliferative capability of many invasive pathogens is limited by the bioavailability of iron. Pathogens have thus developed strategies to obtain iron from their host organisms. In turn, host defense strategies have evolved to sequester iron from invasive pathogens. This review explores the mechanisms employed by bacterial pathogens to gain access to host iron sources, the role of iron in bacterial virulence, and iron-related genes required for the establishment or maintenance of infection. Host defenses to limit iron availability for bacterial growth during the acute-phase response and the consequences of iron overload conditions on susceptibility to bacterial infection are also examined. The evidence summarized herein demonstrates the importance of iron bioavailability in influencing the risk of infection and the ability of the host to clear the pathogen. C1 [Parrow, Nermi L.] NIDDK, Div Mol & Clin Nutr, NIH, Bethesda, MD USA. [Fleming, Robert E.] St Louis Univ, Sch Med, Dept Pediat, St Louis, MO 63104 USA. [Minnick, Michael F.] Univ Montana, Div Biol Sci, Missoula, MT 59812 USA. RP Minnick, MF (reprint author), Univ Montana, Div Biol Sci, Missoula, MT 59812 USA. EM mike.minnick@mso.umt.edu FU Intramural Research Program of the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases FX N.L.P. is supported by the Intramural Research Program of the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. NR 178 TC 25 Z9 25 U1 3 U2 18 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 EI 1098-5522 J9 INFECT IMMUN JI Infect. Immun. PD OCT PY 2013 VL 81 IS 10 BP 3503 EP 3514 DI 10.1128/IAI.00602-13 PG 12 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 219SF UT WOS:000324528700002 PM 23836822 ER PT J AU Alaro, JR Partridge, A Miura, K Diouf, A Lopez, AM Angov, E Long, CA Burns, JM AF Alaro, James R. Partridge, Andrea Miura, Kazutoyo Diouf, Ababacar Lopez, Ana M. Angov, Evelina Long, Carole A. Burns, James M., Jr. TI A Chimeric Plasmodium falciparum Merozoite Surface Protein Vaccine Induces High Titers of Parasite Growth Inhibitory Antibodies SO INFECTION AND IMMUNITY LA English DT Article ID CARBOXYL-TERMINAL FRAGMENT; STAGE MALARIA VACCINE; PROTECTIVE IMMUNE-RESPONSES; FACTOR-LIKE DOMAINS; B-CELL EPITOPES; T-CELL; CPG OLIGODEOXYNUCLEOTIDE; RECOMBINANT PROTEIN; CHALLENGE INFECTION; ESCHERICHIA-COLI AB The C-terminal 19-kDa domain of Plasmodium falciparum merozoite surface protein 1 (PfMSP1(19)) is an established target of protective antibodies. However, clinical trials of PfMSP1(42), a leading blood-stage vaccine candidate which contains the protective epitopes of PfMSP1(19), revealed suboptimal immunogenicity and efficacy. Based on proof-of-concept studies in the Plasmodium yoelii murine model, we produced a chimeric vaccine antigen containing recombinant PfMSP1(19) (rPfMSP1(19)) fused to the N terminus of P. falciparum merozoite surface protein 8 that lacked its low-complexity Asn/Asp-rich domain, rPfMSP8 (Delta Asn/Asp). Immunization of mice with the chimeric rPfMSP1/8 vaccine elicited strong T cell responses to conserved epitopes associated with the rPfMSP8 (Delta Asn/Asp) fusion partner. While specific for PfMSP8, this T cell response was adequate to provide help for the production of high titers of antibodies to both PfMSP1(19) and rPfMSP8 (Delta Asn/Asp) components. This occurred with formulations adjuvanted with either Quil A or with Montanide ISA 720 plus CpG oligodeoxynucleotide (ODN) and was observed in both inbred and outbred strains of mice. PfMSP1/8-induced antibodies were highly reactive with two major alleles of PfMSP1(19) (FVO and 3D7). Of particular interest, immunization with PfMSP1/8 elicited higher titers of PfMSP1(19)-specific antibodies than a combined formulation of rPfMSP1(42) and rPfMSP8 (Delta Asn/Asp). As a measure of functionality, PfMSP1/8-specific rabbit IgG was shown to potently inhibit the in vitro growth of blood-stage parasites of the FVO and 3D7 strains of P. falciparum. These data support the further testing and evaluation of this chimeric PfMSP1/8 antigen as a component of a multivalent vaccine for P. falciparum malaria. C1 [Alaro, James R.; Partridge, Andrea; Lopez, Ana M.; Long, Carole A.; Burns, James M., Jr.] Drexel Univ, Coll Med, Ctr Mol Parasitol, Dept Microbiol & Immunol, Philadelphia, PA 19104 USA. [Alaro, James R.; Miura, Kazutoyo; Diouf, Ababacar; Long, Carole A.] NIAID, Malaria Immunol Sect, Lab Malaria & Vector Res, NIH, Rockville, MD USA. [Angov, Evelina] Walter Reed Army Inst Res, US Mil Malaria Res Program, Malaria Vaccine Branch, Silver Spring, MD USA. RP Burns, JM (reprint author), Drexel Univ, Coll Med, Ctr Mol Parasitol, Dept Microbiol & Immunol, Philadelphia, PA 19104 USA. EM jburns@drexelmed.edu FU NIH-NIAID [AI035661]; PATH Malaria Vaccine Initiative FX This work was supported by NIH-NIAID grant AI035661 (J.M.B.) and the Intramural Program of NIH-NIAID (C.A.L.). The GIA Reference Center where the GIA assay was performed is supported by the PATH Malaria Vaccine Initiative. NR 73 TC 6 Z9 6 U1 0 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD OCT PY 2013 VL 81 IS 10 BP 3843 EP 3854 DI 10.1128/IAI.00522-13 PG 12 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 219SF UT WOS:000324528700035 PM 23897613 ER PT J AU Sullivan, MD Katon, WJ Lovato, LC Miller, ME Murray, AM Horowitz, KR Bryan, RN Gerstein, HC Marcovina, S Akpunonu, BE Johnson, J Yale, JF Williamson, J Launer, LJ AF Sullivan, Mark D. Katon, Wayne J. Lovato, Laura C. Miller, Michael E. Murray, Anne M. Horowitz, Karen R. Bryan, R. Nick Gerstein, Hertzel C. Marcovina, Santica Akpunonu, Basil E. Johnson, Janice Yale, Jean Francois Williamson, Jeff Launer, Lenore J. TI Association of Depression With Accelerated Cognitive Decline Among Patients With Type 2 Diabetes in the ACCORD-MIND Trial SO JAMA PSYCHIATRY LA English DT Article ID CONTROL CARDIOVASCULAR RISK; 3 DECADES LATER; MAJOR DEPRESSION; HIPPOCAMPAL VOLUME; INSULIN-RESISTANCE; DEMENTIA; SYMPTOMS; METAANALYSIS; DISEASE; IMPAIRMENT AB IMPORTANCE Depression has been identified as a risk factor for dementia among patients with type 2 diabetes mellitus but the cognitive domains and patient groups most affected have not been identified. OBJECTIVE To determine whether comorbid depression in patients with type 2 diabetes accelerates cognitive decline. DESIGN A 40-month cohort study of participants in the Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) trial. SETTING Fifty-two clinics organized into 6 clinical networks across the United States and Canada. PARTICIPANTS Two thousand nine hundred seventy-seven participants with type 2 diabetes at high risk for cardiovascular events. INTERVENTION The Digit Symbol Substitution Test, Rey Auditory Verbal Learning Test, and the modified Stroop test were used to assess cognition. The 9-item Patient Health Questionnaire was used to assess depression. MAIN OUTCOMES AND MEASURES Mixed-effects statistical models were used to analyze cognitive test outcomes incorporating depression as a time-dependent covariate. RESULTS Participants with scores indicative of depression (9-item Patient Health Questionnaire, >= 10) showed greater cognitive decline during 40-month follow-up on all tests, with the following differences in estimated least squares means: Digit Symbol Substitution Test, 0.72 (95% CI, 0.25 to 1.19; P = .003), Rey Auditory Verbal Learning Test, 0.18 (95% CI, 0.07 to 0.29; P = .001), and Stroop interference, -1.06 (95% CI, -1.93 to -0.18; P = .02). This effect of depression on risk of cognitive decline did not differ according to previous cardiovascular disease; baseline cognition or age; or intensive vs standard glucose-lowering treatment, blood pressure treatment, lipid treatment, or insulin treatment. Addition of demographic and clinical covariates to models did not significantly change the cognitive decline associated with depression. CONCLUSIONS AND RELEVANCE Depression in patients with type 2 diabetes was associated with greater cognitive decline in all domains, across all treatment arms, and in all participant subgroups assessed. Future randomized trials will be necessary to determine if depression treatment can lower the risk of cognitive decline in patients with diabetes. C1 [Sullivan, Mark D.; Katon, Wayne J.; Marcovina, Santica; Johnson, Janice] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Lovato, Laura C.; Miller, Michael E.; Williamson, Jeff] Wake Forest Univ, Dept Publ Hlth Sci, Winston Salem, NC 27109 USA. [Murray, Anne M.] Univ Minnesota, Dept Internal Med, Minneapolis, MN USA. [Horowitz, Karen R.] Case Western Univ, Dept Internal Med, Cleveland, OH USA. [Bryan, R. Nick] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. [Gerstein, Hertzel C.] McMaster Univ, Dept Internal Med, Hamilton, ON, Canada. [Akpunonu, Basil E.] Univ Toledo, Dept Med, Toledo, OH 43606 USA. [Yale, Jean Francois] McGill Univ, Dept Internal Med, Montreal, PQ, Canada. [Launer, Lenore J.] NIA, Bethesda, MD 20892 USA. RP Sullivan, MD (reprint author), Univ Washington, POB 356560, Seattle, WA 98195 USA. EM sullimar@uw.edu FU National Institute on Aging [AG-0002]; National Heart, Lung, and Blood Institute [AG-0002, N01-HC-95178, N01-HC-95179, N01-HC-95180, N01-HC-95181, N01-HC-95182, N01-HC-95183, N01-HC-95184]; National Institute on Aging Intramural Research Program FX ACCORD-MIND was funded through an intra-agency agreement between the National Institute on Aging and National Heart, Lung, and Blood Institute (grant AG-0002) and the National Institute on Aging Intramural Research Program. ACCORD was funded by National Heart, Lung, and Blood Institute grants N01-HC-95178; N01-HC-95179; N01-HC-95180; N01-HC-95181; N01-HC-95182; N01-HC-95183; and N01-HC-95184. NR 48 TC 36 Z9 39 U1 5 U2 23 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-622X J9 JAMA PSYCHIAT JI JAMA Psychiatry PD OCT PY 2013 VL 70 IS 10 BP 1041 EP 1047 DI 10.1001/jamapsychiatry.2013.1965 PG 7 WC Psychiatry SC Psychiatry GA 228KE UT WOS:000325184100008 PM 23945905 ER PT J AU Kumar, R Nguyen, EA Roth, LA Oh, SS Gignoux, CR Huntsman, S Eng, C Moreno-Estrada, A Sandoval, K Penaloza-Espinosa, RI Lopez-Lopez, M Avila, PC Farber, HJ Tcheurekdjian, H Rodriguez-Cintron, W Rodriguez-Santana, JR Serebrisky, D Thyne, SM Williams, LK Winkler, C Bustamante, CD Perez-Stable, EJ Borrell, LN Burchard, EG AF Kumar, Rajesh Nguyen, Elizabeth A. Roth, Lindsey A. Oh, Sam S. Gignoux, Christopher R. Huntsman, Scott Eng, Celeste Moreno-Estrada, Andres Sandoval, Karla Penaloza-Espinosa, Rosenda I. Lopez-Lopez, Marisol Avila, Pedro C. Farber, Harold J. Tcheurekdjian, Haig Rodriguez-Cintron, William Rodriguez-Santana, Jose R. Serebrisky, Denise Thyne, Shannon M. Williams, L. Keoki Winkler, Cheryl Bustamante, Carlos D. Perez-Stable, Eliseo J. Borrell, Luisa N. Burchard, Esteban G. TI Factors associated with degree of atopy in Latino children in a nationwide pediatric sample: The Genes-environments and Admixture in Latino Asthmatics (GALA II) study SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Latino; atopy; region of origin; genetic ancestry; immigration; kin test; aeroallergen ID DAY-CARE ATTENDANCE; DUST-MITE ALLERGEN; BLOOD IGE LEVELS; BIRTH COHORT; SOCIOECONOMIC-STATUS; CHILDHOOD ASTHMA; PUERTO-RICAN; 1ST YEAR; COCKROACH ALLERGEN; MEXICAN-AMERICANS AB Background: Atopy varies by ethnicity, even within Latino groups. This variation might be due to environmental, sociocultural, or genetic factors. Objective: We sought to examine risk factors for atopy within a nationwide study of US Latino children with and without asthma. Methods: Aeroallergen skin test responses were analyzed in 1830 US Latino subjects. Key determinants of atopy included country/region of origin, generation in the United States, acculturation, genetic ancestry, and site to which subjects migrated. Serial multivariate zero-inflated negative binomial regressions stratified by asthma status examined the association of each key determinant variable with the number of positive skin test responses. In addition, the independent effect of each key variable was determined by including all key variables in the final models. Results: In baseline analyses African ancestry was associated with 3 times (95% CI, 1.62-5.57) as many positive skin test responses in asthmatic participants and 3.26 times (95% CI, 1.02-10.39) as many positive skin test responses in control participants. Generation and recruitment site were also associated with atopy in crude models. In final models adjusted for key variables, asthmatic patients of Puerto Rican (exp[beta] [95% CI], 1.31 [1.021.69]) and mixed (exp[beta] [95% CI], 1.27 [1.03-1.56]) ethnicity had a greater probability of positive skin test responses compared with Mexican asthmatic patients. Ancestry associations were abrogated by recruitment site but not region of origin. Conclusions: Puerto Rican ethnicity and mixed origin were associated with degree of atopy within US Latino children with asthma. African ancestry was not associated with degree of atopy after adjusting for recruitment site. Local environment variation, represented by site, was associated with degree of sensitization. C1 [Kumar, Rajesh] Northwestern Univ, Childrens Mem Hosp, Div Allergy & Immunol, Chicago, IL 60614 USA. [Kumar, Rajesh] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA. [Nguyen, Elizabeth A.; Roth, Lindsey A.; Oh, Sam S.; Gignoux, Christopher R.; Huntsman, Scott; Eng, Celeste; Perez-Stable, Eliseo J.; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Moreno-Estrada, Andres; Sandoval, Karla; Bustamante, Carlos D.] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA. [Penaloza-Espinosa, Rosenda I.; Lopez-Lopez, Marisol] Univ Autonoma Metropolitana Xochimilco, Div Biol & Hlth Sci, Dept Syst Biol, Mexico City, DF, Mexico. [Avila, Pedro C.] Northwestern Univ, Div Allergy Immunol, Feinberg Sch Med, Chicago, IL 60611 USA. [Farber, Harold J.] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Sect Pulmonol, Houston, TX 77030 USA. [Tcheurekdjian, Haig] Case Western Reserve Univ, Allergy Immunol Associates, Cleveland, OH 44106 USA. [Tcheurekdjian, Haig] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA. [Tcheurekdjian, Haig] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA. [Rodriguez-Cintron, William] Vet Caribbean Hlth Care Syst, San Juan, PR USA. [Rodriguez-Santana, Jose R.] CSP, Ctr Neumol Pediatr, San Juan, PR USA. [Serebrisky, Denise] Jacobi Med Ctr, Pediat Pulm Div, Bronx, NY USA. [Thyne, Shannon M.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA. [Williams, L. Keoki] Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI USA. [Winkler, Cheryl] NCI, Ctr Canc Res, Basic Res Lab, SAIC Frederick, Frederick, MD 21701 USA. [Borrell, Luisa N.] CUNY, Dept Hlth Sci, Grad Program Publ Hlth, Lehman Coll, Bronx, NY USA. [Burchard, Esteban G.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA. RP Kumar, R (reprint author), Childrens Mem Hosp, Div Allergy & Clin Immunol, 2300 Childrens Plaza,Box 60, Chicago, IL 60614 USA. EM rkumar@childrensmemorial.org OI Nguyen, Elizabeth/0000-0002-8070-6382 FU National Institutes of Health [ES015794, AI077439, HL088133, HL078885, CA113710, AI079139, HL004464, HL104608, AI061774, HL079055, DK064695, M01-RR00188, HHSN26120080001E, MD006902]; Flight Attendant Medical Research Institute (FAMRI); RWJF Amos Medical Faculty; Sandler Foundation; American Asthma Foundation; Ernest S. Bazley Grant; National Heart, Lung, and Blood Institute K23 [K23HL093023]; National Institute on Minority Health and Health Disparities of the National Institutes of Health [P60MD006902]; National Institutes of Health, National Cancer Institute, Center for Cancer Research; National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (NIH); NHLBI/National Institute of Allergy and Infectious Diseases (NIAID); EMD China; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIAID; Merck FX Supported in part by the National Institutes of Health grants (ES015794, AI077439, HL088133, HL078885, CA113710, AI079139, HL004464, HL104608, AI061774, HL079055, DK064695, and M01-RR00188; HHSN26120080001E; and MD006902); the Flight Attendant Medical Research Institute (FAMRI); an RWJF Amos Medical Faculty Development Award (to E. G. B.); the Sandler Foundation; the American Asthma Foundation (to E. G. B); an Ernest S. Bazley Grant (to P.C.A.); National Heart, Lung, and Blood Institute K23 (K23HL093023, to R.K.). In addition, the research reported in this publication was also supported by the National Institute on Minority Health and Health Disparities of the National Institutes of Health under award no. P60MD006902. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Furthermore, the content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. This research was supported in part by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research.; Disclosure of potential conflict of interest: R. Kumar, E. A. Nguyen, S. S. Oh, S. Huntsman, C. Eng, A. Moreno-Estrada, K. Sandoval, R. I. Penaloza- Espinosa, M. Lopez-Lopez, P. C. Avila, W. Rodriguez-Cintron, J. R. Rodriguez-Santana, D. Serebrisky, S. M. Thyne, C. Winkler, C. D. Bustamante, E. J. Perez-Stable, L. N. Borrell, and E. G. Burchard received research support from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institutes of Health (NIH). C. R. Gignoux has received research support from the NHLBI and NIH and owns stock in 23 and Me. L. A. Roth, S. Huntsman, C. Eng, D. Serebrisky, and C. D. Bustamante have received research support from the NHLBI. P. C. Avila has received research support from the NHLBI/National Institute of Allergy and Infectious Diseases (NIAID). H. J. Farber has received grants from the NIH and NHLBI and has received honoraria for talks on asthma from EMD China. L. K. Williams has received research support from the NHLBI, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and NIAID and has received research support from Merck. The rest of the authors declare that they have no relevant conflicts of interest. NR 66 TC 9 Z9 10 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD OCT PY 2013 VL 132 IS 4 BP 896 EP + DI 10.1016/j.jaci.2013.02.046 PG 11 WC Allergy; Immunology SC Allergy; Immunology GA 227FR UT WOS:000325096500017 PM 23684070 ER PT J AU Vernon, R Shen, Y Baker, D Lange, OF AF Vernon, Robert Shen, Yang Baker, David Lange, Oliver F. TI Improved chemical shift based fragment selection for CS-Rosetta using Rosetta3 fragment picker SO JOURNAL OF BIOMOLECULAR NMR LA English DT Article DE Protein structure; NMR; Sparse data; Chemical shifts ID PROTEIN-STRUCTURE DETERMINATION; NMR STRUCTURE DETERMINATION; STRUCTURE PREDICTION; STRUCTURE GENERATION; SECONDARY STRUCTURE; DIPOLAR COUPLINGS; RECOGNITION; REPLACEMENT; FEATURES; PLUS AB A new fragment picker has been developed for CS-Rosetta that combines beneficial features of the original fragment picker, MFR, used with CS-Rosetta, and the fragment picker, NNMake, that was used for purely sequence based fragment selection in the context of ROSETTA de-novo structure prediction. Additionally, the new fragment picker has reduced sensitivity to outliers and other difficult to match data points rendering the protocol more robust and less likely to introduce bias towards wrong conformations in cases where data is bad, missing or inconclusive. The fragment picker protocol gives significant improvements on 6 of 23 CS-Rosetta targets. An independent benchmark on 39 protein targets, whose NMR data sets were published only after protocol optimization had been finished, also show significantly improved performance for the new fragment picker (van der Schot et al. in J Biomol NMR, 2013). C1 [Vernon, Robert; Lange, Oliver F.] Tech Univ Munich, Dept Chem, Biomol NMR, D-85747 Garching, Germany. [Vernon, Robert; Lange, Oliver F.] Tech Univ Munich, Munich Ctr Integrated Prot Sci, D-85747 Garching, Germany. [Vernon, Robert; Baker, David] Univ Washington, Dept Biochem, Seattle, WA 98195 USA. [Shen, Yang] NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA. [Baker, David] Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA. [Lange, Oliver F.] Helmholtz Zentrum Munchen, Inst Biol Struct, D-85764 Neuherberg, Germany. RP Lange, OF (reprint author), Tech Univ Munich, Dept Chem, Biomol NMR, Lichtenbergstr 4, D-85747 Garching, Germany. EM oliver.lange@tum.de RI Shen, Yang/C-3064-2008; Baker, David/K-8941-2012 OI Shen, Yang/0000-0003-1408-8034; Baker, David/0000-0001-7896-6217 NR 30 TC 14 Z9 14 U1 0 U2 16 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0925-2738 J9 J BIOMOL NMR JI J. Biomol. NMR PD OCT PY 2013 VL 57 IS 2 BP 117 EP 127 DI 10.1007/s10858-013-9772-4 PG 11 WC Biochemistry & Molecular Biology; Spectroscopy SC Biochemistry & Molecular Biology; Spectroscopy GA 228BP UT WOS:000325160400004 PM 23975356 ER PT J AU Ali, MS Starke, RM Jabbour, PM Tjoumakaris, SI Gonzalez, LF Rosenwasser, RH Owens, GK Koch, WJ Greig, NH Dumont, AS AF Ali, Muhammad S. Starke, Robert M. Jabbour, Pascal M. Tjoumakaris, Stavropoula I. Gonzalez, L. Fernando Rosenwasser, Robert H. Owens, Gary K. Koch, Walter J. Greig, Nigel H. Dumont, Aaron S. TI TNF-alpha induces phenotypic modulation in cerebral vascular smooth muscle cells: implications for cerebral aneurysm pathology SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE Cerebral aneurysm; Cerebral vascular smooth muscle cells; Smooth muscle cell phenotypic modulation; TNF-alpha ID NECROSIS-FACTOR-ALPHA; INTRACRANIAL ANEURYSMS; GENE-EXPRESSION; IN-VIVO; ATHEROSCLEROSIS; DIFFERENTIATION; INFLAMMATION; DISEASE; RATS; NEUROINFLAMMATION AB Little is known about vascular smooth muscle cell (SMC) phenotypic modulation in the cerebral circulation or pathogenesis of intracranial aneurysms. Tumor necrosis factor-alpha (TNF-alpha) has been associated with aneurysms, but potential mechanisms are unclear. Cultured rat cerebral SMCs overexpressing myocardin induced expression of key SMC contractile genes (SM-alpha-actin, SM-22 alpha, smooth muscle myosin heavy chain), while dominant-negative cells suppressed expression. Tumor necrosis factor-alpha treatment inhibited this contractile phenotype and induced pro-inflammatory/matrix-remodeling genes (monocyte chemoattractant protein-1, matrix metalloproteinase-3, matrix metalloproteinase-9, vascular cell adhesion molecule-1, interleukin-1 beta). Tumor necrosis factor-alpha increased expression of KLF4, a known regulator of SMC differentiation. Kruppel-like transcription factor 4 (KLF4) small interfering RNA abrogated TNF-alpha activation of inflammatory genes and suppression of contractile genes. These mechanisms were confirmed in vivo after exposure of rat carotid arteries to TNF-alpha and early on in a model of cerebral aneurysm formation. Treatment with the synthesized TNF-alpha inhibitor 3,6-dithiothalidomide reversed pathologic vessel wall alterations after induced hypertension and hemodynamic stress. Chromatin immunoprecipitation assays in vivo and in vitro demonstrated that TNF-alpha promotes epigenetic changes through KLF4-dependent alterations in promoter regions of myocardin, SMCs, and inflammatory genes. In conclusion, TNF-alpha induces phenotypic modulation of cerebral SMCs through myocardin and KLF4-regulated pathways. These results demonstrate a novel role for TNF-alpha in promoting a pro-inflammatory/matrix-remodeling phenotype, which has important implications for the mechanisms behind intracranial aneurysm formation. C1 [Ali, Muhammad S.; Starke, Robert M.; Jabbour, Pascal M.; Tjoumakaris, Stavropoula I.; Gonzalez, L. Fernando; Rosenwasser, Robert H.; Dumont, Aaron S.] Thomas Jefferson Univ, Joseph & Marie Field Cerebrovasc Res Lab, Div Neurovasc & Endovasc Surg, Dept Neurol Surg, Philadelphia, PA 19107 USA. [Starke, Robert M.] Univ Virginia, Dept Neurol Surg, Charlottesville, VA USA. [Owens, Gary K.] Robert M Berne Cardiovasc Res Ctr, Dept Mol Physiol & Biophys, Charlottesville, VA USA. [Koch, Walter J.] Temple Univ, Ctr Translat Med, Philadelphia, PA 19122 USA. [Koch, Walter J.] Temple Univ, Dept Pharmacol, Philadelphia, PA 19122 USA. [Greig, Nigel H.] NIA, NIH, Translat Gerontol Branch, Intramural Res Program, Baltimore, MD 21224 USA. RP Dumont, AS (reprint author), Thomas Jefferson Univ, Joseph & Marie Field Cerebrovasc Res Lab, Div Neurovasc & Endovasc Surg, Dept Neurol Surg, 909 Walnut St,2nd Floor, Philadelphia, PA 19107 USA. EM aaron.dumont@jefferson.edu FU NIH [K08NS067072, R01 HL57353, R01 HL098538, R01 HL087867, P01 HL091799, P01 HL07544]; Intramural Research Program of NIH FX This work was supported by NIH grants K08NS067072 to ASD, NIH grants R01 HL57353 (GKO), R01 HL098538 (GKO), and R01 HL087867 to GKO, and NIH P01 HL091799 and P01 HL07544 Project 2 to WJK. NHG is supported by the Intramural Research Program of NIH. NR 42 TC 34 Z9 36 U1 1 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD OCT PY 2013 VL 33 IS 10 BP 1564 EP 1573 DI 10.1038/jcbfm.2013.109 PG 10 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 228PV UT WOS:000325199600011 PM 23860374 ER PT J AU Galeano, ME Martinez, M Amarilla, AA Russomando, G Miagostovich, MP Parra, GI Leite, JP AF Galeano, Maria Eugenia Martinez, Magaly Amarilla, Alberto A. Russomando, Graciela Miagostovich, Marize Pereira Parra, Gabriel I. Leite, Jose Paulo TI Molecular epidemiology of norovirus strains in Paraguayan children during 2004-2005: Description of a possible new GII.4 cluster SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Norovirus; Acute gastroenteritis; Paraguayan children; GII.4 norovirus ID NORWALK-LIKE VIRUSES; A ROTAVIRUS STRAINS; RIO-DE-JANEIRO; UNITED-STATES; GENOGROUP-II; HOSPITALIZED CHILDREN; ACUTE GASTROENTERITIS; BRAZIL; ARGENTINA; OUTBREAKS AB Background: Noroviruses (NoV) have been shown to be an important cause of morbidity and mortality in children worldwide, only second after Group A rotaviruses (RVA). In Paraguay, acute gastroenteritis (AGE) is the third cause of mortality in children <= 5 years old. Objectives: To analyze the presence and diversity of NoV in Paraguayan children <5 years old presenting AGE. Study design: Three hundred seventy eight fecal samples, negative for pathogenic bacteria and RVA, were collected from children admitted as ambulatory and hospitalized patients in a large private hospital from Asuncion, Paraguay from 2004 to 2005. The presence and diversity of NoV was determined by two different RT-PCR strategies and nucleotide sequencing. Results: One hundred and sixty one samples were positive for NoV by partial amplification of the viral polymerase gene (RdRp). No seasonality or differences in the viral prevalence for the different age-groups were detected. Gil and GI NoVs were associated to 58% and 42% of the infections, respectively. The genotype was determined in 18% (291161) NoV-positive samples. The genotypes detected were: GII.4 (18%), GII.17 (18%), GII.6 (14%), GII.7 (14%), GII.3 (10%), GII.5 (3%), GII.8 (3%), GII.16 (3%), GI.3 (14%) and GI.8 (3%). Amplification of the ORF2 from the GII.4 strains showed the presence of a new GII.4 variant. Conclusions: The results showed a continuous circulation of NoV in children throughout the two years of study and an extensive diversity of genotypes co-circulating, highlighting the need for better surveillance of NoV in Paraguayan children. (C) 2013 Elsevier B.V. All rights reserved. C1 [Galeano, Maria Eugenia; Miagostovich, Marize Pereira; Leite, Jose Paulo] Minist Hlth, Oswaldo Cruz Fdn, Inst Oswaldo Cruz, Lab Comparat & Environm Virol, Rio De Janeiro, Brazil. [Galeano, Maria Eugenia; Martinez, Magaly; Amarilla, Alberto A.; Russomando, Graciela; Parra, Gabriel I.] Natl Univ Asuncion, Hlth Sci Res Inst, Dept Mol Biol & Genet, Asuncion, Paraguay. RP Parra, GI (reprint author), NIAID, NIH, Infect Dis Lab, Caliciviruses Sect, 9000 Rockville Pike, Bethesda, MD 20892 USA. EM gabriel.parra@hotmail.com RI Amarilla, Alberto/C-3112-2012; Leite, Joao/B-9070-2012; OI Amarilla, Alberto/0000-0002-4151-2024; Leite, Joao/0000-0003-0558-3519; Parra, Gabriel/0000-0002-1102-4740 FU National Council for Scientific and Technological Development (CNPq); Brazilian Federal Agency for Support and Evaluation of Graduate Education (CAPES), through the Exchange Student Post-graduation Program (PEC-PG); National University of Asuncion; Oswaldo Cruz Institute/Fiocruz; PROEP/CNPq; Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro (FAPERJ); CAPES; CNPq FX MEG was a scholarship recipient from the National Council for Scientific and Technological Development (CNPq), and the Brazilian Federal Agency for Support and Evaluation of Graduate Education (CAPES), through the Exchange Student Post-graduation Program (PEC-PG). This study was partially supported by the National University of Asuncion, Oswaldo Cruz Institute/Fiocruz, PROEP/CNPq, Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro (FAPERJ), CAPES and CNPq. NR 51 TC 9 Z9 9 U1 0 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 J9 J CLIN VIROL JI J. Clin. Virol. PD OCT PY 2013 VL 58 IS 2 BP 378 EP 384 DI 10.1016/j.jcv.2013.07.008 PG 7 WC Virology SC Virology GA 222RY UT WOS:000324750000011 PM 23932334 ER PT J AU Mattson, MP AF Mattson, Mark P. TI Exercise and the brain: a slap on the HAND SO JOURNAL OF NEUROVIROLOGY LA English DT Editorial Material ID NEUROTROPHIC FACTOR; HIV; NEUROTOXICITY; NEUROGENESIS; SENSITIVITY; DEPRESSION; PLASTICITY; NEURONS; DISEASE; HEALTH C1 NIA, Neurosci Lab, Intramural Res Program, Baltimore, MD 21224 USA. RP Mattson, MP (reprint author), NIA, Neurosci Lab, Intramural Res Program, Baltimore, MD 21224 USA. EM mattsonm@grc.nia.nih.gov FU Intramural NIH HHS [Z01 AG000312-08, Z01 AG000317-08, ZIA AG000317-12] NR 22 TC 0 Z9 0 U1 0 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 IS 5 BP 407 EP 409 DI 10.1007/s13365-013-0208-4 PG 3 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 228YM UT WOS:000325228100001 PM 24072548 ER PT J AU Lee, MH Amin, ND Venkatesan, A Wang, TG Tyagi, R Pant, HC Nath, A AF Lee, Myoung-Hwa Amin, Niranjana D. Venkatesan, Arun Wang, Tongguang Tyagi, Richa Pant, Harish C. Nath, Avindra TI Impaired neurogenesis and neurite outgrowth in an HIV-gp120 transgenic model is reversed by exercise via BDNF production and Cdk5 regulation SO JOURNAL OF NEUROVIROLOGY LA English DT Article DE HIV-gp120; Exercise; Adult neurogenesis; Dendritic arborization; BDNF; Cdk5 ID CYCLIN-DEPENDENT KINASE-5; COAT PROTEIN GP120; OBJECT RECOGNITION MEMORY; GENERATED GRANULE CELLS; ADULT BRAIN; HIPPOCAMPAL NEUROGENESIS; PHYSICAL-EXERCISE; NERVOUS-SYSTEM; DENTATE GYRUS; MOUSE MODEL AB Human immunodeficiency virus (HIV) infection-associated neurocognitive disorders is accompanied with brain atrophy. In these patients, impairment of adult neurogenesis and neurite outgrowth in the hippocampus may contribute to cognitive dysfunction. Although running exercises can enhance neurogenesis and normalize neurite outgrowth, the underlying molecular mechanisms are not well understood. The HIV envelope protein, gp120, has been shown to impair neurogenesis. Using a gp120 transgenic mouse model, we demonstrate that exercise stimulated neural progenitor cell (NPC) proliferation in the hippocampal dentate gyrus and increased the survival rate and generation of newborn cells. However, sustained exercise activity was necessary as the effects were reversed by detraining. Exercise also normalized dendritic outgrowth of neurons. Furthermore, it increased the expression of hippocampal brain-derived neurotrophic factor (BDNF) and normalized hyperactivation of cyclin-dependent kinase 5 (Cdk5). Hyperactivated Cdk5 or gp120 treatment led to aberrant neurite outgrowth and BDNF treatment normalized the neurite outgrowth in NPC cultures. These results suggest that sustained exercise has trophic activity on the neuronal lineage which is mediated by Cdk5 modulation of the BDNF pathway. C1 [Lee, Myoung-Hwa; Wang, Tongguang; Tyagi, Richa; Nath, Avindra] NIH, Sect Infect Nervous Syst, Bethesda, MD 20892 USA. [Amin, Niranjana D.; Pant, Harish C.] NINDS, Neuronal Cytoskeletal Prot Regulatory Sect, NIH, Bethesda, MD 20892 USA. [Venkatesan, Arun] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA. RP Nath, A (reprint author), NIH, Sect Infect Nervous Syst, MD Bldg 10,Room 7C-103,10 Ctr Dr, Bethesda, MD 20892 USA. EM natha@mail.nih.gov FU NIH [R01-DA024593, R01-NS039253]; NINDS intramural funds FX We thank Dr. Valerie Toodle for technical assistance. This work was supported by grants from the NIH (R01-DA024593; R01-NS039253) and NINDS intramural funds. NR 61 TC 18 Z9 18 U1 1 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 IS 5 BP 418 EP 431 DI 10.1007/s13365-013-0194-6 PG 14 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 228YM UT WOS:000325228100003 PM 23982957 ER PT J AU Kranick, SM Zerbe, CS AF Kranick, Sarah M. Zerbe, Christa S. TI Case report from the NIH Clinical Center: CNS nocardiosis SO JOURNAL OF NEUROVIROLOGY LA English DT Article ID BRAIN-ABSCESS; TRANSVALENSIS; INFECTIONS C1 [Kranick, Sarah M.] NINDS, Sect Infect Nervous Syst, NINDS Consult Serv, Bethesda, MD 20892 USA. [Zerbe, Christa S.] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA. RP Kranick, SM (reprint author), NINDS, Sect Infect Nervous Syst, NINDS Consult Serv, Bldg 10 Rm 6-5700,10 Ctr Dr, Bethesda, MD 20892 USA. EM sarah.kranick@nih.gov FU NIH Intramural Program FX This research was supported by the NIH Intramural Program NR 9 TC 2 Z9 2 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 IS 5 BP 505 EP 507 DI 10.1007/s13365-013-0193-7 PG 3 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 228YM UT WOS:000325228100012 PM 23996690 ER PT J AU Erba, PA Minichilli, F Giona, F Linari, S Dambrosia, J Pierini, A Filocamo, M Di Rocco, M Buffoni, F Brady, RO Mariani, G AF Erba, Paola A. Minichilli, Fabrizio Giona, Fiorina Linari, Silvia Dambrosia, James Pierini, Anna Filocamo, Mirella Di Rocco, Maja Buffoni, Ferdinando Brady, Roscoe O. Mariani, Giuliano TI Tc-99m-Sestamibi Scintigraphy to Monitor the Long-Term Efficacy of Enzyme Replacement Therapy on Bone Marrow Infiltration in Patients with Gaucher Disease SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article DE Tc-99m-sestamibi; Gaucher disease; bone marrow disease; scintigraphic score; enzyme replacement therapy ID TYPE-1; INVOLVEMENT; GLUCOCEREBROSIDASE; IMIGLUCERASE; DEFICIENCY; CHILDREN; OUTCOMES; SCORE; MRI AB Assessing the skeletal response to enzyme replacement therapy (ERT) in Gaucher disease (GD) is problematic. We investigated the reliability of Tc-99m-sestamibi scintigraphy in monitoring changes in bone marrow involvement induced by ERT. Methods: In 52 GD patients, the efficacy of ERT on bone marrow disease was monitored using at least 2 sequential Tc-99m-sestamibi scans; 17 patients were receiving ERT at enrollment, and 35 were ERT-naive. We elaborated a dose-response model by statistical analysis based on linear mixed models. Results: Patients whose marrow disease improved had received a significantly higher ERT dose per month than patients who did not improve. Significantly more patients reached near-disappearance of marrow disease if their disease burden at enrollment had been lower and the duration of clinical signs shorter. The response of the marrow scintigraphic score was more pronounced in ERT-naive patients. No relevant effect of ERT on marrow disease was observed until platelet count and splenomegaly had improved. Conclusion: Although based on localized evaluation, changes in the Tc-99m-sestamibi score closely correlated with the main determinants of ERT, with a definite dose-response relationship. The threshold at which ERT induced any improvement in bone marrow disease was 35-36 U/kg/mo; in ERT-naive patients, the scintigraphic score declined by 1 unit after ERT at 28 U/kg/mo. C1 [Erba, Paola A.; Mariani, Giuliano] Univ Pisa, Reg Ctr Nucl Med, I-56126 Pisa, Italy. [Minichilli, Fabrizio; Pierini, Anna] CNR, Inst Clin Physiol, I-56100 Pisa, Italy. [Giona, Fiorina] Univ Roma La Sapienza, Dept Cell Biotechnol & Hematol, I-00185 Rome, Italy. [Linari, Silvia] Careggi Univ Hosp, Agcy Hemophilia, Florence, Italy. [Linari, Silvia] Careggi Univ Hosp, Reg Reference Ctr Inherited Bleeding Disorders, Florence, Italy. [Dambrosia, James] NINDS, Biostat Branch, NIH, Bethesda, MD 20892 USA. [Filocamo, Mirella; Di Rocco, Maja] G Gaslini Childrens Hosp, Genoa, Italy. [Buffoni, Ferdinando] Town Hosp, Nucl Med Serv, Massa, Italy. [Brady, Roscoe O.] NINDS, Dev & Metab Neurol Branch, NIH, Bethesda, MD 20892 USA. RP Mariani, G (reprint author), Univ Pisa, Reg Ctr Nucl Med, Via Roma 67, I-56126 Pisa, Italy. EM giuliano.mariani@med.unipi.it FU Italian Association of Gaucher Disease FX We thank all patients who participated in this investigation and the Italian Association of Gaucher Disease for its support. Thanks are also due to the following colleagues who either referred patients for the study or performed some of the 99mTc-sestamibi scans: Rosanna Gatti (Genoa, Italy), Angela Amendola (formerly in Rome, now in Potenza, Italy), Assuero Giorgetti, Marzio Perri, Isabella Raugei (Pisa, Italy), Isabella Raugei, Giuseppe Villa (Genoa, Italy), Massimo Morfini (Florence, Italy), and Maria D. Cappellini (Milan, Italy). NR 40 TC 1 Z9 1 U1 0 U2 2 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 J9 J NUCL MED JI J. Nucl. Med. PD OCT 1 PY 2013 VL 54 IS 10 BP 1717 EP 1724 DI 10.2967/jnumed.113.121871 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 230LP UT WOS:000325341300010 PM 23990684 ER PT J AU Gumuscu, B Thompson, EI Grovas, AC Zach, TL Warkentin, PI Coccia, PF AF Gumuscu, Burak Thompson, Elizabeth I. Grovas, Alfred C. Zach, Terrence L. Warkentin, Phyllis I. Coccia, Peter F. TI Successful Unrelated Cord Blood Transplantation For Homozygous alpha-Thalassemia SO JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY LA English DT Article DE homozygous -thalassemia; stem cell transplantation for hemoglobinopathies; cord blood transplantation; hydrops fetalis ID BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; INTRAUTERINE TRANSFUSIONS; BETA-THALASSEMIA; HYDROPS-FETALIS; IRON OVERLOAD; BARTS HYDROPS; DISEASE; CHILDREN AB A now 10-year-old Laotian female was delivered at 30-week gestation by cesarean section because of severe hydrops. Fetal blood sampling revealed homozygous -thalassemia. After immediate resuscitation, the infant was supported with frequent red cell transfusions. At 44 months of age, she received a 5 of 6 human leukocyte antigen-matched unrelated cord blood transplantation. She was treated with phlebotomy and chelation therapy with Deferasirox for correction of hemosiderosis and has been transfusion-independent since 41 days after transplant. She is currently 6 years after transplantation with stable, 100% donor engraftment, resolved iron overload, and normal growth and development. C1 [Gumuscu, Burak] NCI, NIH, Expt Transplantat & Immunol Branch, Bethesda, MD 20892 USA. [Gumuscu, Burak] Childrens Natl Med Ctr, Dept Pediat Hematol Oncol, Washington, DC 20010 USA. [Thompson, Elizabeth I.; Grovas, Alfred C.; Warkentin, Phyllis I.; Coccia, Peter F.] Univ Nebraska, Med Ctr, Dept Pediat, Div Hematol Oncol, Omaha, NE USA. [Warkentin, Phyllis I.] Univ Nebraska, Med Ctr, Dept Pathol Microbiol, Omaha, NE USA. [Zach, Terrence L.] Creighton Univ, Sch Med, Dept Pediat, Omaha, NE 68178 USA. RP Coccia, PF (reprint author), Univ Nebraska, Med Ctr, Dept Pediat, 982168 Nebraska Med Ctr, Omaha, NE 68198 USA. EM pcoccia@unmc.edu NR 20 TC 3 Z9 3 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1077-4114 J9 J PEDIAT HEMATOL ONC JI J. Pediatr. Hematol. Oncol. PD OCT PY 2013 VL 35 IS 7 BP 570 EP 572 DI 10.1097/MPH.0b013e31827e7f6a PG 3 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 228VS UT WOS:000325220400031 PM 23337553 ER PT J AU Rajan, A Kotlyar, D Giaccone, G AF Rajan, Arun Kotlyar, David Giaccone, Giuseppe TI Acute Autoimmune Hepatitis, Myositis, and Myasthenic Crisis in a Patient with Thymoma SO JOURNAL OF THORACIC ONCOLOGY LA English DT Article ID GRAVIS C1 [Rajan, Arun; Kotlyar, David; Giaccone, Giuseppe] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA. RP Giaccone, G (reprint author), NCI, Med Oncol Branch, 12N-226,10 Ctr Dr, Bethesda, MD 20892 USA. EM giacconeg@mail.nih.gov RI Giaccone, Giuseppe/E-8297-2017 OI Giaccone, Giuseppe/0000-0002-5023-7562 FU Intramural NIH HHS [Z01 BC010854-01] NR 4 TC 2 Z9 2 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD OCT PY 2013 VL 8 IS 10 BP E87 EP E88 DI 10.1097/JTO.0b013e318298832b PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA 222SL UT WOS:000324751300001 PM 24457247 ER PT J AU Izumi, T Burdick, R Shigemi, M Plisov, S Hu, WS Pathak, VK AF Izumi, Taisuke Burdick, Ryan Shigemi, Mayu Plisov, Sergey Hu, Wei-Shau Pathak, Vinay K. TI Mov10 and APOBEC3G Localization to Processing Bodies Is Not Required for Virion Incorporation and Antiviral Activity SO JOURNAL OF VIROLOGY LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-1 GENOMIC RNA; P-BODIES; 7SL RNA; REVERSE TRANSCRIPTION; ANTIRETROVIRAL FACTOR; CYTIDINE DEAMINASES; STRESS GRANULES; MESSENGER-RNAS; REPLICATION AB Mov10 and APOBEC3G (A3G) localize to cytoplasmic granules called processing bodies (P bodies), incorporate into human immunodeficiency virus type 1 (HIV-1) virions, and inhibit viral replication. The functional relevance of Mov10/A3G P-body localization to virion incorporation and antiviral activity has not been fully explored. We found that a helicase V mutant of Mov10 exhibits significantly reduced localization to P bodies but still efficiently inhibits viral infectivity via virion incorporation. Disruption of the P bodies by DDX6 knockdown also confirmed Mov10 antiviral activity without P-body localization. In addition, overexpression of SRP19, which binds to 7SL RNA, depleted A3G from P bodies but did not affect its virion incorporation. Sucrose gradient sedimentation assays revealed that the majority of Mov10, A3G, HIV-1 RNA, and Gag formed high-molecular-mass (HMM) complexes that are converted to low-molecular-mass (LMM) complexes after RNase A treatment. In contrast, the P-body markers DCP2, LSM1, eIF4e, DDX6, and AGO1 were in LMM complexes, whereas AGO2, an effector protein of the RNA-induced silencing complex that localizes to P bodies, was present in both LMM and HMM complexes. Depletion of AGO2 indicated that RNA-induced silencing function is required for Mov10's ability to reduce Gag expression upon overexpression, but not its virion incorporation or effect on virus infectivity. We conclude that the majority of Mov10 and A3G are in HMM complexes, whereas most of the P-body markers are in LMM complexes, and that virion incorporation and the antiviral activities of Mov10 and A3G do not require their localization to P bodies. C1 [Izumi, Taisuke; Burdick, Ryan; Shigemi, Mayu; Pathak, Vinay K.] NCI, Ctr Canc Res, HIV Drug Resistance Program, Viral Mutat Sect, Frederick, MD 21701 USA. [Plisov, Sergey; Hu, Wei-Shau] NCI, Ctr Canc Res, HIV Drug Resistance Program, Viral Recombinat Sect, Frederick, MD 21701 USA. RP Pathak, VK (reprint author), NCI, Ctr Canc Res, HIV Drug Resistance Program, Viral Mutat Sect, Frederick, MD 21701 USA. EM vinay.pathak@nih.gov RI Izumi, Taisuke/J-5607-2014 OI Izumi, Taisuke/0000-0002-9694-1459 FU Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research; JSPS Research Fellowship for Japanese Biomedical and Behavioral Researchers at NIH FX This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. T. I. was supported by a JSPS Research Fellowship for Japanese Biomedical and Behavioral Researchers at NIH. NR 68 TC 14 Z9 14 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD OCT PY 2013 VL 87 IS 20 BP 11047 EP 11062 DI 10.1128/JVI.02070-13 PG 16 WC Virology SC Virology GA 229OF UT WOS:000325275800011 PM 23926332 ER PT J AU Sloan, EA Kearney, MF Gray, LR Anastos, K Daar, ES Margolick, J Maldarelli, F Hammarskjold, ML Rekosh, D AF Sloan, Emily A. Kearney, Mary F. Gray, Laurie R. Anastos, Kathryn Daar, Eric S. Margolick, Joseph Maldarelli, Frank Hammarskjold, Marie-Louise Rekosh, David TI Limited Nucleotide Changes in the Rev Response Element (RRE) during HIV-1 Infection Alter Overall Rev-RRE Activity and Rev Multimerization SO JOURNAL OF VIROLOGY LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; CTL ESCAPE VIRUS; HIV-1-INFECTED INDIVIDUALS; PERIPHERAL-BLOOD; RAPID SELECTION; NUCLEAR-EXPORT; T-CELLS; IN-VIVO; RNA; TRANSMISSION AB HIV-1 Rev and the Rev response element (RRE) enable a critical step in the viral replication cycle by facilitating the nuclear export of intron-containing mRNAs, yet their activities have rarely been analyzed in natural infections. This study characterized their genetic and functional variation in a small cohort of HIV-infected individuals. Multiple Rev and RRE sequences were obtained using single-genome sequencing (SGS) of plasma samples collected within 6 months after seroconversion and at a later time. This allowed the identification of cognate sequences that were linked in vivo in the same viral genome and acted together as a functional unit. Phylogenetic analyses of these sequences indicated that 4/5 infections were founded by a single transmission event. Rev and RRE variants from each time point were subjected to functional analysis as both cognate pairs and as individual components. While a range of Rev-RRE activities were seen, the activity of cognate pairs from a single time point clustered to a discrete level, which was termed the set point. In 3/5 patients, this set point changed significantly over the time period studied. In all patients, RRE activity was more sensitive to sequence variation than Rev activity and acted as the primary driver of the cognate set point. Selected patient RREs were also shown to have differences in Rev multimerization using gel shift binding assays. Thus, rather than acting as a simple on-off switch or maintaining a constant level of activity throughout infection, the Rev-RRE system can fluctuate, presumably to control replication. C1 [Sloan, Emily A.; Gray, Laurie R.; Hammarskjold, Marie-Louise; Rekosh, David] Univ Virginia, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22903 USA. [Sloan, Emily A.; Gray, Laurie R.; Hammarskjold, Marie-Louise; Rekosh, David] Univ Virginia, Myles H Thaler Ctr AIDS & Human Retrovirus Res, Charlottesville, VA USA. [Kearney, Mary F.; Maldarelli, Frank] NCI, HIV Drug Resistance Program, Frederick, MD 21701 USA. [Anastos, Kathryn] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Anastos, Kathryn] Montefiore Med Ctr, Dept Med, Bronx, NY 10467 USA. [Daar, Eric S.] Univ Calif Los Angeles, Med Ctr, Angeles Biomed Res Inst Harbor, Torrance, CA 90509 USA. [Margolick, Joseph] Johns Hopkins Bloomberg Sch Publ, Baltimore, MD USA. RP Rekosh, D (reprint author), Univ Virginia, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22903 USA. EM dr4u@virginia.edu FU National Institutes of Health [AI087505, AI068501, UO1-AI-35004]; University of Virginia FX This work was supported by grants AI087505 and AI068501 as well as ARRA supplements or other supplements to WIHS grant UO1-AI-35004 from the National Institutes of Health. Salary support for M.-L.H. and D. R. was provided by the Charles H. Ross, Jr., and Myles H. Thaler Endowments at the University of Virginia. NR 54 TC 9 Z9 10 U1 0 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD OCT PY 2013 VL 87 IS 20 BP 11173 EP 11186 DI 10.1128/JVI.01392-13 PG 14 WC Virology SC Virology GA 229OF UT WOS:000325275800022 PM 23926352 ER PT J AU Govindasamy, L DiMattia, MA Gurda, BL Halder, S McKenna, R Chiorini, JA Muzyczka, N Zolotukhin, S Agbandje-McKenna, M AF Govindasamy, Lakshmanan DiMattia, Michael A. Gurda, Brittney L. Halder, Sujata McKenna, Robert Chiorini, John A. Muzyczka, Nicholas Zolotukhin, Sergei Agbandje-McKenna, Mavis TI Structural Insights into Adeno-Associated Virus Serotype 5 SO JOURNAL OF VIROLOGY LA English DT Article ID ADENO-ASSOCIATED VIRUS; HEPARAN-SULFATE PROTEOGLYCAN; PHOTOREALISTIC MOLECULAR GRAPHICS; LEBER CONGENITAL AMAUROSIS; MEDIATED GENE-THERAPY; ELECTRON-DENSITY MAPS; AAV2 CAPSID GENE; EFFICIENT TRANSDUCTION; SIALIC-ACID; TYPE-2 CAPSIDS AB The adeno-associated viruses (AAVs) display differential cell binding, transduction, and antigenic characteristics specified by their capsid viral protein (VP) composition. Toward structure-function annotation, the crystal structure of AAV5, one of the most sequence diverse AAV serotypes, was determined to 3.45-angstrom resolution. The AAV5 VP and capsid conserve topological features previously described for other AAVs but uniquely differ in the surface-exposed HI loop between beta H and beta I of the core beta-barrel motif and have pronounced conformational differences in two of the AAV surface variable regions (VRs), VR-IV and VR-VII. The HI loop is structurally conserved in other AAVs despite amino acid differences but is smaller in AAV5 due to an amino acid deletion. This HI loop is adjacent to VR-VII, which is largest in AAV5. The VR-IV, which forms the larger outermost finger-like loop contributing to the protrusions surrounding the icosahedral 3-fold axes of the AAVs, is shorter in AAV5, creating a smoother capsid surface topology. The HI loop plays a role in AAV capsid assembly and genome packaging, and VR-IV and VR-VII are associated with transduction and antigenic differences, respectively, between the AAVs. A comparison of interior capsid surface charge and volume of AAV5 to AAV2 and AAV4 showed a higher propensity of acidic residues but similar volumes, consistent with comparable DNA packaging capacities. This structure provided a three-dimensional (3D) template for functional annotation of the AAV5 capsid with respect to regions that confer assembly efficiency, dictate cellular transduction phenotypes, and control antigenicity. C1 [Govindasamy, Lakshmanan; DiMattia, Michael A.; Gurda, Brittney L.; Halder, Sujata; McKenna, Robert; Agbandje-McKenna, Mavis] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Ctr Struct Biol,McKnight Brain Inst, Gainesville, FL 32610 USA. [Chiorini, John A.] NIDCR, NIH, MPTB, Bethesda, MD USA. [Muzyczka, Nicholas] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL USA. [Muzyczka, Nicholas] Univ Florida, Coll Med, Powell Gene Therapy Ctr, Gainesville, FL USA. [Zolotukhin, Sergei] Univ Florida, Coll Med, Dept Pediat, Div Cell & Mol Therapy, Gainesville, FL USA. RP Agbandje-McKenna, M (reprint author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, Ctr Struct Biol,McKnight Brain Inst, Gainesville, FL 32610 USA. EM mckenna@ufl.edu OI Gurda, Brittney /0000-0002-0174-9385 FU U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-AC02-98CH10886]; U.S. Department of Energy, Basic Energy Sciences, Office of Science [W-31-109-Eng-38]; National Science Foundation; National Institutes of Health/National Institute of General Medical Sciences under NSF [DMR-0936384]; National Institute of General Medical Sciences, National Institutes of Health [GM-103485]; Intramural Research Program of the NIH; NIDCR; NIH [R01 GM082946, P01 HL51811] FX The NSLS is supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences, under contract number DE-AC02-98CH10886. Use of the Advanced Photon Source was supported by the U.S. Department of Energy, Basic Energy Sciences, Office of Science, under contract number W-31-109-Eng-38. CHESS is supported by the National Science Foundation and the National Institutes of Health/National Institute of General Medical Sciences under NSF award DMR-0936384 and the MacCHESS facility through award GM-103485 from the National Institute of General Medical Sciences, National Institutes of Health. This research was supported by the Intramural Research Program of the NIH and NIDCR to J.A.C. and NIH R01 GM082946 (M.A.-M., R. M., N.M., and S.Z.) and P01 HL51811 (M.A.-M., R. M., and N.M.). NR 122 TC 18 Z9 18 U1 0 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD OCT PY 2013 VL 87 IS 20 BP 11187 EP 11199 DI 10.1128/JVI.00867-13 PG 13 WC Virology SC Virology GA 229OF UT WOS:000325275800023 PM 23926356 ER PT J AU Frey, S Pircher, H Follo, M Collins, P Krempl, C Ehl, S AF Frey, Stefanie Pircher, Hanspeter Follo, Marie Collins, Peter Krempl, Christine Ehl, Stephan TI In Situ Evolution of Virus-Specific Cytotoxic T Cell Responses in the Lung SO JOURNAL OF VIROLOGY LA English DT Article ID RESPIRATORY SYNCYTIAL VIRUS; PNEUMONIA VIRUS; INFLUENZA-VIRUS; MICE; INFECTION; DISEASE; PATHOGENESIS; EXPRESSION; IMMUNITY; MEMORY AB Cytotoxic T cells (CTL) play a critical role in the clearance of respiratory viral infections, but they also contribute to disease manifestations. In this study, we infected mice with a genetically modified pneumonia virus of mice (PVM) that allowed visualization of virus-specific CTL and infected cells in situ. The first virus-specific T cells entered the lung via blood vessels in the scattered foci of PVM-infected cells, which densely clustered around the bronchi at day 7 after infection. At this time, overall pulmonary virus load was maximal, but the mice showed no overt signs of disease. On days 8 to 9, T cells gained access to the infected bronchial epithelium and to the lung interstitium, which was associated with a reduction in the number of virus-infected cells within the initial clusters but could not prevent further virus spread throughout the lung tissue. Interestingly, recruitment of virus-specific CTL throughout the parenchyma was still ongoing on day 10, when the virus infection was already largely controlled. This also represented the peak of clinical disease. Thus, disease was associated with an exuberant T cell infiltration late in the course of the infection, which may be required to completely eliminate virus at residual foci of infection. PVM-induced immunopathology may thus result from the need to generate widespread T cell infiltrates to complete the elimination of virus-infected cells in a large organ like the lung. This experimental model provides the first insights into the spatiotemporal evolution of pulmonary antiviral T cell immunity in vivo. C1 [Frey, Stefanie; Ehl, Stephan] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany. [Pircher, Hanspeter] Univ Freiburg, Inst Med Microbiol & Hyg, D-79106 Freiburg, Germany. [Follo, Marie] Univ Med Ctr Freiburg, Dept Internal Med 1, Freiburg, Germany. [Collins, Peter] NIAID, Bethesda, MD 20892 USA. [Krempl, Christine] Julius Maximilian Univ, Inst Virol & Immunobiol, Wurzburg, Germany. [Ehl, Stephan] Univ Med Ctr Freiburg, Ctr Pediat & Adolescent Med, Freiburg, Germany. RP Ehl, S (reprint author), Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany. EM stephan.ehl@uniklinik-freiburg.de RI Krempl, Christine/O-2081-2015 FU Bundesministerium fur Bildung und Forschung [BMBF 01 EO 0803]; Deutsche Forschungsgemeinschaft [DFG EH145/4-2, KR2964/1-2]; Intramural Research Program of NIAID, NIH FX This work was supported by the Bundesministerium fur Bildung und Forschung (BMBF 01 EO 0803) and the Deutsche Forschungsgemeinschaft (DFG EH145/4-2 and KR2964/1-2). P. C. was supported by the Intramural Research Program of NIAID, NIH. NR 33 TC 1 Z9 1 U1 1 U2 12 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD OCT PY 2013 VL 87 IS 20 BP 11267 EP 11275 DI 10.1128/JVI.00255-13 PG 9 WC Virology SC Virology GA 229OF UT WOS:000325275800030 PM 23946463 ER PT J AU Bakkum-Gamez, JN Wentzensen, N Maurer, M Podratz, K Sherman, M Shridhar, V AF Bakkum-Gamez, Jamie N. Wentzensen, Nicolas Maurer, Matt Podratz, Karl Sherman, Mark Shridhar, Viji TI Detecting Endometrial Cancer Using the Common Tampon SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Wentzensen, Nicolas; Sherman, Mark] NCI, Hormonal & Reprod Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD OCT 1 PY 2013 VL 22 IS 10 BP 882 EP 882 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 227TD UT WOS:000325136500017 ER PT J AU Lai, C Grant, C Dunleavy, K AF Lai, Catherine Grant, Cliona Dunleavy, Kieron TI Interpreting MYC and BCL2 in diffuse large B-cell lymphoma SO LEUKEMIA & LYMPHOMA LA English DT Editorial Material ID RITUXIMAB PLUS CYCLOPHOSPHAMIDE; POOR-PROGNOSIS; C-MYC; VINCRISTINE; DOXORUBICIN; PREDNISONE; EXPRESSION C1 [Lai, Catherine; Grant, Cliona; Dunleavy, Kieron] NCI, Ctr Canc Res, Bethesda, MD 20892 USA. RP Dunleavy, K (reprint author), NCI, Metab Branch, Bldg 10,Room 4N-115,9000 Rockville Pike, Bethesda, MD 20892 USA. EM dunleavk@mail.nih.gov NR 10 TC 3 Z9 3 U1 0 U2 3 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PD OCT PY 2013 VL 54 IS 10 BP 2091 EP 2092 DI 10.3109/10428194.2013.806803 PG 2 WC Oncology; Hematology SC Oncology; Hematology GA 220MX UT WOS:000324589800002 PM 24041377 ER PT J AU Cherry, BM Korde, N Kwok, M Manasanch, EE Bhutani, M Mulquin, M Zuchlinski, D Yancey, MA Maric, I Calvo, KR Braylan, R Stetler-Stevenson, M Yuan, C Tembhare, P Zingone, A Costello, R Roschewski, MJ Landgren, O AF Cherry, Benjamin M. Korde, Neha Kwok, Mary Manasanch, Elisabet E. Bhutani, Manisha Mulquin, Marcia Zuchlinski, Diamond Yancey, Mary Ann Maric, Irina Calvo, Katherine R. Braylan, Raul Stetler-Stevenson, Maryalice Yuan, Constance Tembhare, Prashant Zingone, Adriana Costello, Rene Roschewski, Mark J. Landgren, Ola TI Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study SO LEUKEMIA & LYMPHOMA LA English DT Article DE Multiple myeloma; smoldering myeloma; disease classification ID UNDETERMINED SIGNIFICANCE MGUS; EARLY TREATMENT STRATEGIES; LIGHT-CHAIN RATIO; MONOCLONAL GAMMOPATHY; PRECURSOR DISEASE; FUTURE AB The risk of progression to multiple myeloma (MM) from the precursor condition smoldering MM (SMM) varies considerably among individual patients. Reliable markers for progression to MM are vital to advance the understanding of myeloma precursor disease and for the development of intervention trials designed to delay/prevent MM. The Mayo Clinic and Spanish PETHEMA have proposed models to stratify patient risk based on clinical parameters. The aim of our study was to define the degree of concordance between these two models by comparing the distribution of patients with SMM classified as low, medium and high risk for progression. A total of 77 patients with SMM were enrolled in our prospective natural history study. Per study protocol, each patient was assigned risk scores based on both the Mayo and the Spanish models. The Mayo Clinic model identified 38, 35 and four patients as low, medium and high risk, respectively. The Spanish PETHEMA model classified 17, 22 and 38 patients as low, medium and high risk, respectively. There was significant discordance in overall patient risk classification (28.6% concordance) and in classifying patients as low versus high (p < 0.0001), low versus non-low (p = 0.0007) and high versus non-high (p < 0.0001) risk. There is a need for prospectively validated models to characterize individual patient risk of transformation to MM. C1 [Cherry, Benjamin M.; Korde, Neha; Kwok, Mary; Manasanch, Elisabet E.; Bhutani, Manisha; Mulquin, Marcia; Zuchlinski, Diamond; Yancey, Mary Ann; Zingone, Adriana; Costello, Rene; Roschewski, Mark J.; Landgren, Ola] NCI, Multiple Myeloma Sect, NIH, Bethesda, MD 20892 USA. [Kwok, Mary] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA. [Maric, Irina; Calvo, Katherine R.; Braylan, Raul] NIH, Hematol Serv, Dept Lab Med, Bethesda, MD 20892 USA. [Stetler-Stevenson, Maryalice; Yuan, Constance; Tembhare, Prashant] NCI, Pathol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. RP Landgren, O (reprint author), NCI, Multiple Myeloma Sect, Metab Branch, NIH, 9000 Rockville Pike,Bldg 10 Room 13N240, Bethesda, MD 20892 USA. EM landgreo@mail.nih.gov OI Roschewski, Mark/0000-0003-0278-2635; Calvo, Katherine/0000-0002-0771-4191 FU Intramural Research Program of the NCI of the National Institutes of Health (NIH) FX This work was supported by the Intramural Research Program of the NCI of the National Institutes of Health (NIH). NR 11 TC 30 Z9 30 U1 0 U2 5 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PD OCT PY 2013 VL 54 IS 10 BP 2215 EP 2218 DI 10.3109/10428194.2013.764419 PG 4 WC Oncology; Hematology SC Oncology; Hematology GA 220MX UT WOS:000324589800023 PM 23311294 ER PT J AU Jang, H Subramanian, S Devasahayam, N Saito, K Matsumoto, S Krishna, MC McMillan, AB AF Jang, Hyungseok Subramanian, Sankaran Devasahayam, Nallathamby Saito, Keita Matsumoto, Shingo Krishna, Murali C. McMillan, Alan B. TI Single Acquisition Quantitative Single-Point Electron Paramagnetic Resonance Imaging SO MAGNETIC RESONANCE IN MEDICINE LA English DT Article DE EPR imaging; quantitative imaging; single point imaging; gridding; tissue oxygenation; hypoxia ID DATA EXTRAPOLATION METHOD; TIME-DOMAIN EPR; TRUNCATION ARTIFACTS; CYCLING HYPOXIA; TUMOR HYPOXIA; RESOLUTION; OXYGENATION; REMOVAL; RECONSTRUCTION; TRANSFORM AB PurposeElectron paramagnetic resonance imaging has emerged as a promising noninvasive technology to dynamically image tissue oxygenation. Owing to its extremely short spin-spin relaxation times, electron paramagnetic resonance imaging benefits from a single-point imaging scheme where the entire free induction decay signal is captured using pure phase encoding. However, direct T-2(*)/pO(2) quantification is inhibited owing to constant magnitude gradients which result in time-decreasing field of view. Therefore, conventional acquisition techniques require repeated imaging experiments with differing gradient amplitudes (typically 3), which results in long acquisition time. MethodsIn this study, gridding was evaluated as a method to reconstruct images with equal field of view to enable direct T-2(*)/pO(2) quantification within a single imaging experiment. Additionally, an enhanced reconstruction technique that shares high spatial k-space regions throughout different phase-encoding time delays was investigated (k-space extrapolation). ResultsThe combined application of gridding and k-space extrapolation enables pixelwise quantification of T-2(*) from a single acquisition with improved image quality across a wide range of phase-encoding time delays. The calculated T-2(*)/pO(2) does not vary across this time range. ConclusionsBy utilizing gridding and k-space extrapolation, accurate T-2(*)/pO(2) quantification can be achieved within a single data set to allow enhanced temporal resolution (by a factor of 3). Magn Reson Med, 70:1173-1181, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Jang, Hyungseok; McMillan, Alan B.] Univ Wisconsin, Dept Radiol, Wisconsin Inst Med Res, Madison, WI 53706 USA. [Subramanian, Sankaran; Devasahayam, Nallathamby; Saito, Keita; Matsumoto, Shingo; Krishna, Murali C.] NCI, Radiat Biol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. RP McMillan, AB (reprint author), Univ Wisconsin, Dept Radiol, Wisconsin Inst Med Res, Rm 1305,1111 Highland Ave, Madison, WI 53706 USA. EM abmcmillan@wisc.edu FU National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health [1R21EB013770] FX Grant sponsor: The National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health under Award Number 1R21EB013770. NR 33 TC 3 Z9 3 U1 0 U2 19 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0740-3194 J9 MAGN RESON MED JI Magn. Reson. Med. PD OCT PY 2013 VL 70 IS 4 BP 1173 EP 1181 DI 10.1002/mrm.24886 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 227TB UT WOS:000325136300030 PM 23913515 ER PT J AU Valera, A Colomo, L Martinez, A de Jong, D Balague, O Matheu, G Martinez, M Taddesse-Heath, L Jaffe, ES Bacchi, CE Campo, E AF Valera, Alexandra Colomo, Lluis Martinez, Antonio de Jong, Daphne Balague, Olga Matheu, Gabriel Martinez, Monica Taddesse-Heath, Lekidelu Jaffe, Elaine S. Bacchi, Carlos E. Campo, Elias TI ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements SO MODERN PATHOLOGY LA English DT Article DE ALK-positive large B-cell lymphoma; ALK; MYC; plasmablastic lymphoma; STAT3 ID T(2/5)(P23,Q35) CHROMOSOME-TRANSLOCATION; OF-THE-LITERATURE; C-MYC; CLINICOPATHOLOGICAL ENTITY; PLASMABLASTIC LYMPHOMA; COMPLEX KARYOTYPE; KINASE; FUSION; TRANSCRIPTION; PROGNOSIS AB ALK-positive large B-cell lymphoma is an aggressive lymphoid neoplasm characterized by a monomorphic proliferation of immunoblast-like cells expressing a plasmablastic phenotype and carrying ALK rearrangements. MYC rearrangements are frequent in plasmablastic lymphomas, advanced plasma cell myelomas and a subgroup of diffuse large B-cell lymphomas, but their presence in ALK-positive large B-cell lymphomas is unknown. MYC expression is downregulated by BLIMP1, a master modulator of plasma cell differentiation. BLIMP1 and MYC are upregulated by STAT3, a signal transducer activated by ALK. To determine the role of BLIMP1, MYC and STAT3 in the pathogenesis of ALK-positive large B-cell lymphomas, we investigated MYC rearrangement and the expression of MYC, phosphorylated STAT3, BLIMP1, PAX5 and XBP1 in 12 ALK-positive large B-cell lymphomas. All cases expressed ALK with a granular cytoplasmic pattern. Nine cases had a split signal consistent with an ALK rearrangement. Three additional cases showed a deletion of the 50 or 30 end of the ALK probe consistent with cryptic translocation. PAX5 was virtually negative in all cases tested, whereas BLIMP1 was expressed in all tumors and XBP1 in 11 of 12. Phosphorylated STAT3 was observed in all cases with a strong and diffuse nuclear pattern. MYC rearrangements were not identified in any tumor, but MYC gains and amplification were detected in six cases and one case, respectively. MYC protein was expressed in all tumors independently of MYC gene alterations. These results indicate that ALK-positive large B-cell lymphomas express a complete plasmablastic differentiation program but, contrary to plasmablastic lymphomas, do not have MYC rearrangements. STAT3 is constantly activated and may be an alternative mechanism to promote MYC expression in these tumors. The relevance of the ALK/STAT3 pathway in the pathogenesis of ALK-positive large B-cell lymphomas may offer an attractive target for new therapies. C1 [Valera, Alexandra; Colomo, Lluis; Martinez, Antonio; Campo, Elias] Univ Barcelona, Hematopathol Sect, Pathol Lab, Hosp Clin Barcelona,Inst Invest Biomed August Pi, E-08036 Barcelona, Spain. [de Jong, Daphne; Balague, Olga] Antoni Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Pathol, Amsterdam, Netherlands. [Matheu, Gabriel] Hosp Manacor, Dept Pathol, Mallorca, Spain. [Martinez, Monica] Lab Hematopatol, Mendoza, Argentina. [Taddesse-Heath, Lekidelu] Howard Univ Hosp, Dept Pathol, Washington, DC USA. [Jaffe, Elaine S.] NCI, Dept Pathol, NIH, Bethesda, MD USA. [Bacchi, Carlos E.] Consultoria Patol, Botucatu, SP, Brazil. RP Campo, E (reprint author), Univ Barcelona, Hematopathol Sect, Pathol Lab, Hosp Clin Barcelona,Inst Invest Biomed August Pi, Villarroel 170, E-08036 Barcelona, Spain. EM ecampo@clinic.ub.es RI Jaffe, Elaine/G-8984-2014; Colomo, Luis/A-2259-2016; OI Jaffe, Elaine/0000-0003-4632-0301; Colomo, Luis/0000-0001-5236-5085; Campo, elias/0000-0001-9850-9793 FU 'Comision Interministerial de Ciencia y Tecnologia Espanola' (CICYT) [SAF 12/38432]; Red Tematica de Investigacion Cooperativa del Cancer (RTICC) [RD12/0036/0086]; Conveni Programa de Feno/Genotipatge per al diagnostic i tractament individualitzat del pacient oncologic, La Caixa FX We thank Elena Gonzalvo, Laura Gelabert and Monica Marin for their excellent technical assistance. This study was funded by 'Comision Interministerial de Ciencia y Tecnologia Espanola' (CICYT) SAF 12/38432, Red Tematica de Investigacion Cooperativa del Cancer (RTICC) (RD12/0036/0086) and 'Conveni Programa de Feno/Genotipatge per al diagnostic i tractament individualitzat del pacient oncologic, La Caixa'. Figure 3 was produced using Servier Medical Art (http://www.servier.com/). NR 57 TC 9 Z9 10 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD OCT PY 2013 VL 26 IS 10 BP 1329 EP 1337 DI 10.1038/modpathol.2013.73 PG 9 WC Pathology SC Pathology GA 228TR UT WOS:000325214000006 PM 23599149 ER PT J AU Li, SL Park, H Trempus, CS Gordon, D Liu, YP Cotsarelis, G Morris, RJ AF Li, Shulan Park, Heuijoon Trempus, Carol S. Gordon, Derek Liu, Yaping Cotsarelis, George Morris, Rebecca J. TI A Keratin 15 Containing Stem Cell Population From the Hair Follicle Contributes to Squamous Papilloma Development in the Mouse SO MOLECULAR CARCINOGENESIS LA English DT Article DE skin carcinogenesis; stem cells; hair follicles; papillomas ID SKIN-CANCER; EPIDERMAL TUMORS; CARCINOGENESIS; EXPRESSION; BULGE; RAS; CARCINOMAS; INITIATION; PROMOTION; TARGETS AB The multistage model of nonmelanoma skin carcinogenesis has contributed significantly to our understanding of epithelial cancer in general. We used the Krt1-15CrePR1;R26R transgenic mouse to determine the contribution of keratin 15+ cells from the hair follicle to skin tumor development by following the labeled progeny of the keratin 15 expressing cells into papillomas. We present three novel observations. First, we found that keratin 15 expressing cells contribute to most of the papillomas by 20 weeks of promotion. Second, in contrast to the transient behavior of labeled keratin 15-derived progeny in skin wound healing, keratin 15 progeny persist in papillomas, and some malignancies for many months following transient induction of the reporter gene. Third, papillomas have surprising heterogeneity not only in their cellular composition, but also in their expression of the codon 61 signature Ha-ras mutation with approximately 30% of keratin 15-derived regions expressing the mutation. Together, these results demonstrate that keratin 15 expressing cells of the hair follicle contribute to cutaneous papillomas with long term persistence and a subset of which express the Ha-ras signature mutation characteristic of initiated cells. (c) 2012 Wiley Periodicals, Inc. C1 [Li, Shulan; Park, Heuijoon; Morris, Rebecca J.] Columbia Univ, Dept Dermatol, Med Ctr, New York, NY 10027 USA. [Trempus, Carol S.] NIEHS, Lab Resp Biol, Res Triangle Pk, NC 27709 USA. [Gordon, Derek] Rutgers State Univ, Dept Genet, Piscataway, NJ USA. [Liu, Yaping; Cotsarelis, George] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Morris, Rebecca J.] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA. RP Morris, RJ (reprint author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA. FU NIH [CA097957] FX This work was supported by NIH grant CA097957 to R.J.M. and G. C. This work was conducted (in part) in the Intramural Research Program of the NIH and National Institute of Environmental Health Sciences (NIEHS). We thank Leon C. King from the National Health and Environmental Effects Research Laboratory, United States Environmental Protection Agency, Research Triangle Park, NC for performing the adduct analysis. We thank Xiao-Jing Wang of the Department of Dermatology, OHSU for providing the CrePr1 construct. We also thank Ann Bode and Ashok Singh of The Hormel Institute for critically reading the manuscript and for their helpful suggestions, and Ashok Singh for assistance with submission of the manuscript. NR 31 TC 8 Z9 8 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0899-1987 J9 MOL CARCINOGEN JI Mol. Carcinog. PD OCT PY 2013 VL 52 IS 10 BP 751 EP 759 DI 10.1002/mc.21896 PG 9 WC Biochemistry & Molecular Biology; Oncology SC Biochemistry & Molecular Biology; Oncology GA 227JL UT WOS:000325108800001 PM 22431489 ER PT J AU Jefferson, WN Chevalier, DM Phelps, JY Cantor, AM Padilla-Banks, E Newbold, RR Archer, TK Kinyamu, HK Williams, CJ AF Jefferson, Wendy N. Chevalier, Dominique M. Phelps, Jazma Y. Cantor, Amy M. Padilla-Banks, Elizabeth Newbold, Retha R. Archer, Trevor K. Kinyamu, H. Karimi Williams, Carmen J. TI Persistently Altered Epigenetic Marks in the Mouse Uterus After Neonatal Estrogen Exposure SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID ENDOCRINE-DISRUPTING CHEMICALS; POLYCOMB GROUP PROTEINS; EMBRYONIC STEM-CELLS; DIETHYLSTILBESTROL EXPOSURE; REPRODUCTIVE-TRACT; DEVELOPMENTAL EXPOSURE; LACTOFERRIN GENE; HISTONE H3; EXPRESSION; RECEPTOR AB Neonatal exposure to diethylstilbestrol (DES) causes permanent alterations in female reproductive tract gene expression, infertility, and uterine cancer in mice. To determine whether epigenetic mechanisms could explain these phenotypes, we first tested whether DES altered uterine expression of chromatin-modifying proteins. DES treatment significantly reduced expression of methylcytosine dioxygenase TET oncogene family, member 1 (TET1) on postnatal day 5; this decrease was correlated with a subtle decrease in DNA 5-hydroxymethylcytosine in adults. There were also significant reductions in histone methyltransferase enhancer of zeste homolog 2 (EZH2), histone lysine acetyltransferase 2A (KAT2A), and histone deacetylases HDAC1, HDAC2, and HDAC3. Uterine chromatin immunoprecipitation was used to analyze the locus-specific association of modified histones with 2 genes, lactoferrin (Ltf) and sine oculis homeobox 1 (Six1), which are permanently upregulated in adults after neonatal DES treatment. Three histone modifications associated with active transcription, histone H3 lysine 9 acetylation (H3K9ac), H3 lysine 4 trimethylation (H3K4me3), and H4 lysine 5 acetylation (H4K5ac) were enriched at specific Ltf promoter regions after DES treatment, but this enrichment was not maintained in adults. H3K9ac, H4K5ac, and H3K4me3 were enriched at Six1 exon 1 immediately after neonatal DES treatment. As adults, DES-treated mice had greater differences in H4K5ac and H3K4me3 occupancy at Six1 exon 1 and new differences in these histone marks at an upstream region. These findings indicate that neonatal DES exposure temporarily alters expression of multiple chromatin-modifying proteins and persistently alters epigenetic marks in the adult uterus at the Six1 locus, suggesting a mechanism for developmental exposures leading to altered reproductive function and increased cancer risk. C1 [Jefferson, Wendy N.; Chevalier, Dominique M.; Phelps, Jazma Y.; Cantor, Amy M.; Padilla-Banks, Elizabeth; Williams, Carmen J.] NIEHS, Lab Reprod & Dev Toxicol, NIH, Res Triangle Pk, NC 27709 USA. [Archer, Trevor K.; Kinyamu, H. Karimi] NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA. [Newbold, Retha R.] NIEHS, Natl Toxicol Program, NIH, Res Triangle Pk, NC 27709 USA. RP Williams, CJ (reprint author), NIEHS, NIH, US Dept Hlth & Human Serv, POB 12233,MD E4-05, Res Triangle Pk, NC 27709 USA. EM williamsc5@niehs.nih.gov RI Williams, Carmen/E-2170-2013 OI Williams, Carmen/0000-0001-6440-7086 FU Intramural Research Program of the National Institutes of Health, National Institutes of Environmental Health Sciences [ES102405, ES071006] FX This work was supported by the Intramural Research Program of the National Institutes of Health, National Institutes of Environmental Health Sciences, ES102405 (to C.J.W.) and ES071006 (to T.K.A.). NR 51 TC 14 Z9 14 U1 0 U2 8 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD OCT PY 2013 VL 27 IS 10 BP 1666 EP 1677 DI 10.1210/me.2013-1211 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 226YA UT WOS:000325071600009 PM 24002655 ER PT J AU ZeRuth, GT Takeda, Y Jetten, AM AF ZeRuth, Gary T. Takeda, Yukimasa Jetten, Anton M. TI The Kruppel-Like Protein Gli-Similar 3 (Glis3) Functions as a Key Regulator of Insulin Transcription SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID NEONATAL DIABETES-MELLITUS; LOOP-HELIX PROTEIN; BETA-CELL FUNCTION; GENE-TRANSCRIPTION; ZINC-FINGER; ACETYLTRANSFERASE ACTIVITY; PHYSIOLOGICAL FUNCTIONS; P300; ACTIVATION; ASSOCIATION AB Transcriptional regulation of insulin in pancreatic beta-cells is mediated primarily through enhancer elements located within the 5' upstream regulatory region of the preproinsulin gene. Recently, the Kruppel-like transcription factor, Gli-similar 3 (Glis3), was shown to bind the insulin (INS) promoter and positively influence insulin transcription. In this report, we examined in detail the synergistic activation of insulin transcription by Glis3 with coregulators, CREB-binding protein (CBP)/p300, pancreatic and duodenal homeobox 1 (Pdx1), neuronal differentiation 1 (NeuroD1), and v-maf musculoaponeurotic fibrosarcoma oncogene homolog A (MafA). Our data show that Glis3 expression, the binding of Glis3 to GlisBS, and its recruitment of CBP are required for optimal activation of the insulin promoter in pancreatic beta-cells not only by Glis3, but also by Pdx1, MafA, and NeuroD1. Mutations in the GlisBS or small interfering RNA-directed knockdown of GLIS3 diminished insulin promoter activation by Pdx1, NeuroD1, and MafA, and neither Pdx1 nor MafA was able to stably associate with the insulin promoter when the GlisBS were mutated. In addition, a GlisBS mutation in the INS promoter implicated in the development of neonatal diabetes similarly abated activation by Pdx1, NeuroD1, and MafA that could be reversed by increased expression of exogenous Glis3. We therefore propose that recruitment of CBP/p300 by Glis3 provides a scaffold for the formation of a larger transcriptional regulatory complex that stabilizes the binding of Pdx1, NeuroD1, and MafA complexes to their respective binding sites within the insulin promoter. Taken together, these results indicate that Glis3 plays a pivotal role in the transcriptional regulation of insulin and may serve as an important therapeutic target for the treatment of diabetes. C1 [ZeRuth, Gary T.; Takeda, Yukimasa; Jetten, Anton M.] NIEHS, Cell Biol Sect, Div Intramural Res, NIH, Res Triangle Pk, NC 27709 USA. RP Jetten, AM (reprint author), NIEHS, Div Intramural Res, NIH, POB 12233, Res Triangle Pk, NC 27709 USA. EM jetten@niehs.nih.gov OI Jetten, Anton/0000-0003-0954-4445 FU Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health [Z01-ES-100485] FX This work was supported by the Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health (Z01-ES-100485). NR 45 TC 13 Z9 13 U1 0 U2 4 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD OCT PY 2013 VL 27 IS 10 BP 1692 EP 1705 DI 10.1210/me.2013-1117 PG 14 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 226YA UT WOS:000325071600011 PM 23927931 ER PT J AU Ikonomidou, VN Richert, ND Vortmeyer, A Tovar-Moll, F Bielekova, B Cook, NE Duyn, JH Bagnato, F AF Ikonomidou, Vasiliki N. Richert, Nancy D. Vortmeyer, Alexander Tovar-Moll, Fernanda Bielekova, Bibiana Cook, Natalie E. Duyn, Jeff H. Bagnato, Francesca TI Evolution of tumefactive lesions in multiple sclerosis: A 12-year study with serial imaging in a single patient SO MULTIPLE SCLEROSIS JOURNAL LA English DT Article DE Multiple sclerosis; tumefactive lesion; magnetic resonance imaging; recovery; magnetization transfer imaging; tissue-specific imaging AB We describe the acute presentation and the long-term evolution of recurrent tumefactive lesions (TLs) in a patient with relapsing-remitting multiple sclerosis. Five TLs occurred on three different occasions over a period of 12 years and these were followed by 73 serial magnetic resonance images (MRI). TL evolution was described by means of magnetization transfer imaging (MTI) and cerebrospinal fluid tissue specific imaging (TSI) over the follow-up period. During the study period, the patient had three clinical relapses with only minimal disability progression. MTI demonstrated that only the peripheral portion of each TL reverted to pre-lesional MT ratios within six months' post-enhancement. Recurring TLs may present a similar pattern of evolution that may be associated with a long-term favourable clinical outcome. C1 [Ikonomidou, Vasiliki N.] George Mason Univ, Volgenau Sch Engn, Dept Bioengn, Fairfax, VA 22030 USA. [Ikonomidou, Vasiliki N.; Richert, Nancy D.; Tovar-Moll, Fernanda; Bielekova, Bibiana; Cook, Natalie E.; Bagnato, Francesca] NINDS, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA. [Vortmeyer, Alexander] NINDS, Neurosurg Branch, NIH, Bethesda, MD 20892 USA. [Duyn, Jeff H.] NINDS, Adv MRI Sect, LFMI, NIH, Bethesda, MD 20892 USA. [Bagnato, Francesca] Univ Maryland, Dept Neurol, Baltimore, MD 21201 USA. RP Bagnato, F (reprint author), Univ Maryland, Dept Neurol, 110 Paca St, Baltimore, MD 21201 USA. EM fbagnato@umm.edu FU Intramural Research Program of the NINDS-NIH FX This research was supported by the Intramural Research Program of the NINDS-NIH. NR 9 TC 1 Z9 2 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 J9 MULT SCLER J JI Mult. Scler. J. PD OCT PY 2013 VL 19 IS 11 BP 1539 EP 1543 DI 10.1177/1352458513498124 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 222QE UT WOS:000324745400016 PM 24062416 ER PT J AU Hyde, RK Liu, PP AF Hyde, R. Katherine Liu, P. Paul TI Germline PAX5 mutations and B cell leukemia SO NATURE GENETICS LA English DT Editorial Material ID ACUTE MYELOID-LEUKEMIA; GATA2 C1 [Hyde, R. Katherine; Liu, P. Paul] US Natl Inst Hlth, Natl Human Genome Res Inst, Genet & Mol Biol Branch, Bethesda, MD USA. RP Hyde, RK (reprint author), US Natl Inst Hlth, Natl Human Genome Res Inst, Genet & Mol Biol Branch, Bethesda, MD USA. EM pliu@nhgri.nih.gov OI Hyde, R. Katherine/0000-0003-2808-1749 NR 11 TC 1 Z9 1 U1 0 U2 10 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD OCT PY 2013 VL 45 IS 10 SI SI BP 1104 EP 1105 DI 10.1038/ng.2778 PG 2 WC Genetics & Heredity SC Genetics & Heredity GA 225UQ UT WOS:000324989600002 PM 24071841 ER PT J AU Weinstein, JN Collisson, EA Mills, GB Shaw, KRM Ozenberger, BA Ellrott, K Shmulevich, I Sander, C Stuart, JM AF Weinstein, John N. Collisson, Eric A. Mills, Gordon B. Shaw, Kenna R. Mills Ozenberger, Brad A. Ellrott, Kyle Shmulevich, Ilya Sander, Chris Stuart, Joshua M. CA Canc Genome Atlas Res Network TI The Cancer Genome Atlas Pan-Cancer analysis project SO NATURE GENETICS LA English DT Editorial Material ID SQUAMOUS-CELL CARCINOMA; HUMAN BREAST-TUMORS; LUNG-CANCER; MOLECULAR PORTRAITS; DRUG-SENSITIVITY; PROSTATE-CANCER; MUTATIONS; GENE; IDENTIFICATION; HALLMARKS AB The Cancer Genome Atlas (TCGA) Research Network has profiled and analyzed large numbers of human tumors to discover molecular aberrations at the DNA, RNA, protein and epigenetic levels. The resulting rich data provide a major opportunity to develop an integrated picture of commonalities, differences and emergent themes across tumor lineages. The Pan-Cancer initiative compares the first 12 tumor types profiled by TCGA. Analysis of the molecular aberrations and their functional roles across tumor types will teach us how to extend therapies effective in one cancer type to others with a similar genomic profile. C1 [Weinstein, John N.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA. [Weinstein, John N.; Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA. [Collisson, Eric A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Shaw, Kenna R. Mills] NCI, Ctr Canc Genom, The Canc Genome Atlas Program Off, Bethesda, MD 20892 USA. [Shaw, Kenna R. Mills] Univ Texas MD Anderson Canc Ctr, Inst Personalized Canc Therapy, Houston, TX 77030 USA. [Ozenberger, Brad A.] US Natl Inst Hlth, Natl Human Genome Res Inst, Bethesda, MD USA. [Ellrott, Kyle; Stuart, Joshua M.] Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA. [Ellrott, Kyle; Stuart, Joshua M.] Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA. [Shmulevich, Ilya] Inst Syst Biol, Seattle, WA USA. [Sander, Chris] Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, New York, NY 10021 USA. RP Stuart, JM (reprint author), Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA. EM jstuart@ucsc.edu RI Reva, Boris/B-6436-2014; Tang, Macy/B-9798-2014; Vaske, Charles/D-6018-2013; Senbabaoglu, Yasin/I-4922-2013; Li, Jun/O-9911-2014; Yuan, Yuan/H-4007-2013; Jacobsen, Anders/K-1081-2013; tamborero, david/M-5283-2015; Gao, Jianjiong/B-5673-2016; Hirst, Martin/B-7684-2016; Lee, Semin/S-2629-2016; Marra, Marco/B-5987-2008; OI Sinha, Rileen/0000-0001-5497-5055; Herbrich, Shelley/0000-0002-3825-6752; Ellrott, Kyle/0000-0002-6573-5900; Yang, Da/0000-0002-8336-9457; Xia, Zheng/0000-0003-3364-8324; Perou, Charles/0000-0001-9827-2247; Gehlenborg, Nils/0000-0003-0327-8297; Miller, Martin L/0000-0003-3161-8690; Reva, Boris/0000-0002-8805-389X; Schultz, Nikolaus/0000-0002-0131-4904; Kandoth, Cyriac/0000-0002-1345-3573; Benz, Stephen/0000-0002-4067-0602; Seth, Sahil/0000-0003-4579-3959; Lopez-Bigas, Nuria/0000-0003-4925-8988; Pot, David/0000-0002-1480-9826; Gonzalez-Perez, Abel/0000-0002-8582-4660; Vaske, Charles/0000-0001-8151-6612; Senbabaoglu, Yasin/0000-0003-0958-958X; Li, Jun/0000-0002-1171-7141; Yuan, Yuan/0000-0003-4706-7897; Jacobsen, Anders/0000-0001-6847-4980; tamborero, david/0000-0002-7218-2806; Gao, Jianjiong/0000-0002-5739-1781; Lee, Semin/0000-0002-9015-6046; Ojesina, Akinyemi/0000-0003-0755-3639; Nelander, Sven/0000-0003-1758-1262 NR 43 TC 484 Z9 497 U1 23 U2 81 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 EI 1546-1718 J9 NAT GENET JI Nature Genet. PD OCT PY 2013 VL 45 IS 10 SI SI BP 1113 EP 1120 DI 10.1038/ng.2764 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA 225UQ UT WOS:000324989600005 ER PT J AU Westra, HJ Peters, MJ Esko, T Yaghootkar, H Schurmann, C Kettunen, J Christiansen, MW Fairfax, BP Schramm, K Powell, JE Zhernakova, A Zhernakova, DV Veldink, JH Van den Berg, LH Karjalainen, J Withoff, S Uitterlinden, AG Hofman, A Rivadeneira, F 't Hoen, PAC Reinmaa, E Fischer, K Nelis, M Milani, L Melzer, D Ferrucci, L Singleton, AB Hernandez, DG Nalls, MA Homuth, G Nauck, M Radke, D Volker, U Perola, M Salomaa, V Brody, J Suchy-Dicey, A Gharib, SA Enquobahrie, DA Lumley, T Montgomery, GW Makino, S Prokisch, H Herder, C Roden, M Grallert, H Meitinger, T Strauch, K Li, Y Jansen, RC Visscher, PM Knight, JC Psaty, BM Ripatti, S Teumer, A Frayling, TM Metspalu, A van Meurs, JBJ Franke, L AF Westra, Harm-Jan Peters, Marjolein J. Esko, Tonu Yaghootkar, Hanieh Schurmann, Claudia Kettunen, Johannes Christiansen, Mark W. Fairfax, Benjamin P. Schramm, Katharina Powell, Joseph E. Zhernakova, Alexandra Zhernakova, Daria V. Veldink, Jan H. Van den Berg, Leonard H. Karjalainen, Juha Withoff, Sebo Uitterlinden, Andre G. Hofman, Albert Rivadeneira, Fernando 't Hoen, Peter A. C. Reinmaa, Eva Fischer, Krista Nelis, Mari Milani, Lili Melzer, David Ferrucci, Luigi Singleton, Andrew B. Hernandez, Dena G. Nalls, Michael A. Homuth, Georg Nauck, Matthias Radke, Doerte Voelker, Uwe Perola, Markus Salomaa, Veikko Brody, Jennifer Suchy-Dicey, Astrid Gharib, Sina A. Enquobahrie, Daniel A. Lumley, Thomas Montgomery, Grant W. Makino, Seiko Prokisch, Holger Herder, Christian Roden, Michael Grallert, Harald Meitinger, Thomas Strauch, Konstantin Li, Yang Jansen, Ritsert C. Visscher, Peter M. Knight, Julian C. Psaty, Bruce M. Ripatti, Samuli Teumer, Alexander Frayling, Timothy M. Metspalu, Andres van Meurs, Joyce B. J. Franke, Lude TI Systematic identification of trans eQTLs as putative drivers of known disease associations SO NATURE GENETICS LA English DT Article ID GENOME-WIDE ASSOCIATION; GENE-EXPRESSION; LUPUS-ERYTHEMATOSUS; MYOCARDIAL-INFARCTION; SUSCEPTIBILITY LOCI; RISK; POPULATION; BLOOD; INTERFERON; VARIANTS AB Identifying the downstream effects of disease-associated SNPs is challenging. To help overcome this problem, we performed expression quantitative trait locus (eQTL) meta-analysis in non-transformed peripheral blood samples from 5,311 individuals with replication in 2,775 individuals. We identified and replicated trans eQTLs for 233 SNPs (reflecting 103 independent loci) that were previously associated with complex traits at genome-wide significance. Some of these SNPs affect multiple genes in trans that are known to be altered in individuals with disease: rs4917014, previously associated with systemic lupus erythematosus (SLE)(1), altered gene expression of C1QB and five type I interferon response genes, both hallmarks of SLE2-4. DeepSAGE RNA sequencing showed that rs4917014 strongly alters the 3' UTR levels of IKZF1 in cis, and chromatin immunoprecipitation and sequencing analysis of the trans-regulated genes implicated IKZF1 as the causal gene. Variants associated with cholesterol metabolism and type 1 diabetes showed similar phenomena, indicating that large-scale eQTL mapping provides insight into the downstream effects of many trait-associated variants. C1 [Westra, Harm-Jan; Zhernakova, Alexandra; Zhernakova, Daria V.; Karjalainen, Juha; Withoff, Sebo; Franke, Lude] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands. [Peters, Marjolein J.; Uitterlinden, Andre G.; Rivadeneira, Fernando; van Meurs, Joyce B. J.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands. [Peters, Marjolein J.; Uitterlinden, Andre G.; Hofman, Albert; Rivadeneira, Fernando; van Meurs, Joyce B. J.] Netherlands Genom Initiat Sponsored Netherlands C, Leiden, Netherlands. [Peters, Marjolein J.; Uitterlinden, Andre G.; Hofman, Albert; Rivadeneira, Fernando; van Meurs, Joyce B. J.] Netherlands Genom Initiat Sponsored Netherlands C, Rotterdam, Netherlands. [Esko, Tonu; Reinmaa, Eva; Fischer, Krista; Nelis, Mari; Milani, Lili; Perola, Markus; Metspalu, Andres] Univ Tartu, Estonian Genome Ctr, EE-50090 Tartu, Estonia. [Yaghootkar, Hanieh; Frayling, Timothy M.] Univ Exeter, Sch Med, Exeter, Devon, England. [Schurmann, Claudia; Homuth, Georg; Voelker, Uwe; Teumer, Alexander] Univ Med Greifswald, Interfac Inst Genet & Funct Genom, Dept Funct Genom, Greifswald, Germany. [Kettunen, Johannes; Ripatti, Samuli] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland. [Kettunen, Johannes; Perola, Markus; Salomaa, Veikko; Ripatti, Samuli] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Helsinki, Finland. [Christiansen, Mark W.; Brody, Jennifer; Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Fairfax, Benjamin P.; Makino, Seiko; Knight, Julian C.] Wellcome Trust Ctr Human Genet, Oxford, England. [Fairfax, Benjamin P.] Churchill Hosp, Canc & Haematol Ctr, Dept Oncol, Oxford OX3 7LJ, England. [Schramm, Katharina; Prokisch, Holger; Meitinger, Thomas] Helmholz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Human Genet, Neuherberg, Germany. [Schramm, Katharina; Prokisch, Holger; Meitinger, Thomas] Tech Univ Munich, Inst Human Genet, D-80290 Munich, Germany. [Powell, Joseph E.; Visscher, Peter M.] Univ Queensland, Princess Alexandra Hosp, Diamantina Inst, Brisbane, Qld, Australia. [Powell, Joseph E.; Visscher, Peter M.] Univ Queensland, Queensland Brain Inst, Brisbane, Qld, Australia. [Veldink, Jan H.; Van den Berg, Leonard H.] Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Neurol, Utrecht, Netherlands. [Uitterlinden, Andre G.; Hofman, Albert; Rivadeneira, Fernando] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands. ['t Hoen, Peter A. C.] Leiden Univ Med Ctr, Ctr Human & Clin Genet, Leiden, Netherlands. [Melzer, David] Univ Exeter, Sch Med, Inst Biomed & Clin Sci, Exeter, Devon, England. [Ferrucci, Luigi] NIA, Clin Res Branch, Adv Studies Translat Res Aging ASTRA Unit, Harbor Hosp, Baltimore, MD 21224 USA. [Singleton, Andrew B.; Hernandez, Dena G.; Nalls, Michael A.] NIA, Neurogenet Lab, US NIH, Bethesda, MD 20892 USA. [Hernandez, Dena G.] UCL, Inst Neurol, Reta Lila Labs, Dept Mol Neurosci, London, England. [Nauck, Matthias] Univ Med Greifswald, Inst Clin Chem & Lab Med, Greifswald, Germany. [Radke, Doerte] Univ Med Greifswald, Inst Community Med, Greifswald, Germany. [Suchy-Dicey, Astrid; Enquobahrie, Daniel A.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Gharib, Sina A.] Univ Washington, Ctr Lung Biol, Dept Med, Div Pulm & Crit Care Med,Computat Med Core, Seattle, WA 98195 USA. [Lumley, Thomas] Univ Auckland, Dept Stat, Auckland 1, New Zealand. [Montgomery, Grant W.] Queensland Inst Med Res, Herston, Qld 4006, Australia. [Herder, Christian; Roden, Michael] Univ Dusseldorf, Leibniz Ctr Diabet Res, German Diabet Ctr, Inst Clin Diabetol, D-40225 Dusseldorf, Germany. [Roden, Michael] Univ Dusseldorf, Univ Hosp Dusseldorf, Dept Endocrinol & Diabetol, D-40225 Dusseldorf, Germany. [Roden, Michael] Univ Dusseldorf, Univ Hosp Dusseldorf, Dept Metab Dis, D-40225 Dusseldorf, Germany. [Grallert, Harald] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Res Unit Mol Epidemiol, Neuherberg, Germany. [Meitinger, Thomas] German Ctr Cardiovasc Res DZHK, Gottingen, Germany. [Meitinger, Thomas] Munich Heart Alliance, Munich, Germany. [Strauch, Konstantin] Univ Munich, Inst Med Informat Biometry & Epidemiol, Neuherberg, Germany. [Strauch, Konstantin] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Genet Epidemiol, Neuherberg, Germany. [Li, Yang; Jansen, Ritsert C.] Univ Groningen, Groningen Bioinformat Ctr, Groningen, Netherlands. [Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA. [Ripatti, Samuli] Wellcome Trust Res Labs, Sanger Inst, Cambridge, England. RP Franke, L (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands. EM lude@ludesign.nl RI Knight, Julian/C-7242-2009; Grallert, Harald/B-3424-2013; Milani, Lili/C-8759-2011; Ripatti, Samuli/H-9446-2014; Montgomery, Grant/B-7148-2008; Meitinger, Thomas/O-1318-2015; Rivadeneira, Fernando/O-5385-2015; Schurmann, Claudia/L-1204-2016; Zhernakova, Daria/M-5619-2016; Franke, Lude/P-7036-2016; Prokisch, Holger/N-8964-2013; Singleton, Andrew/C-3010-2009; Powell, Joseph/G-3027-2014; Karjalainen, Juha/P-8624-2016 OI Visscher, Peter/0000-0002-2143-8760; Esko, Tonu/0000-0003-1982-6569; Zhernakova, Alexandra/0000-0002-4574-0841; Peters, Marjolein/0000-0003-3167-9063; Melzer, David/0000-0002-0170-3838; Knight, Julian/0000-0002-0377-5536; Milani, Lili/0000-0002-5323-3102; Ripatti, Samuli/0000-0002-0504-1202; Montgomery, Grant/0000-0002-4140-8139; Rivadeneira, Fernando/0000-0001-9435-9441; Schurmann, Claudia/0000-0003-4158-9192; Zhernakova, Daria/0000-0001-6531-3890; Franke, Lude/0000-0002-5159-8802; Powell, Joseph/0000-0001-9031-6356; FU Intramural NIH HHS [Z99 AG999999]; Medical Research Council [G0500070]; NHLBI NIH HHS [R01 HL073410, R01 HL085251]; Wellcome Trust [090532] NR 59 TC 393 Z9 397 U1 7 U2 60 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 EI 1546-1718 J9 NAT GENET JI Nature Genet. PD OCT PY 2013 VL 45 IS 10 SI SI BP 1238 EP U195 DI 10.1038/ng.2756 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA 225UQ UT WOS:000324989600022 PM 24013639 ER PT J AU Torisu, T Torisu, K Lee, IH Liu, J Malide, D Combs, CA Wu, XFS Rovira, II Fergusson, MM Weigert, R Connelly, PS Daniels, MP Komatsu, M Cao, L Finkel, T AF Torisu, Takehiro Torisu, Kumiko Lee, In Hye Liu, Jie Malide, Daniela Combs, Christian A. Wu, Xufeng S. Rovira, Ilsa I. Fergusson, Maria M. Weigert, Roberto Connelly, Patricia S. Daniels, Mathew P. Komatsu, Masaaki Cao, Liu Finkel, Toren TI Autophagy regulates endothelial cell processing, maturation and secretion of von Willebrand factor SO NATURE MEDICINE LA English DT Article ID WEIBEL-PALADE BODIES; UNCONVENTIONAL SECRETION; VONWILLEBRAND-FACTOR; GENE ATG16L1; MICE; DISEASE; PROTEIN; MOUSE; ANGIOGENESIS; BIOGENESIS AB Endothelial secretion of von Willebrand factor (VWF) from intracellular organelles known as Weibel-Palade bodies (WPBs) is required for platelet adhesion to the injured vessel wall. Here we demonstrate that WPBs are often found near or within autophagosomes and that endothelial autophagosomes contain abundant VWF protein. Pharmacological inhibitors of autophagy or knockdown of the essential autophagy genes Atg5 or Atg7 inhibits the in vitro secretion of VWF. Furthermore, although mice with endothelial-specific deletion of Atg7 have normal vessel architecture and capillary density, they exhibit impaired epinephrine-stimulated VWF release, reduced levels of high-molecular weight VWF multimers and a corresponding prolongation of bleeding times. Endothelial-specific deletion of Atg5 or pharmacological inhibition of autophagic flux results in a similar in vivo alteration of hemostasis. Thus, autophagy regulates endothelial VWF secretion, and transient pharmacological inhibition of autophagic flux may be a useful strategy to prevent thrombotic events. C1 [Torisu, Takehiro; Torisu, Kumiko; Lee, In Hye; Liu, Jie; Rovira, Ilsa I.; Fergusson, Maria M.; Finkel, Toren] NHLBI, Ctr Mol Med, NIH, Bethesda, MD 20892 USA. [Malide, Daniela; Combs, Christian A.] NHLBI, Light Microscopy Core, NIH, Bethesda, MD 20892 USA. [Wu, Xufeng S.] NHLBI, Cell Biol & Physiol Ctr, NIH, Bethesda, MD 20892 USA. [Weigert, Roberto] Natl Inst Dent & Craniofacial Res, Intracellular Membrane Trafficking Unit, NIH, Bethesda, MD USA. [Connelly, Patricia S.; Daniels, Mathew P.] NHLBI, Electron Microscopy Core Facil, NIH, Bethesda, MD 20892 USA. [Komatsu, Masaaki] Tokyo Metropolitan Inst Med Sci, Lab Frontier Sci, Tokyo 113, Japan. [Cao, Liu] China Med Univ, Key Lab Med Cell Biol, Shenyang, Peoples R China. RP Finkel, T (reprint author), NHLBI, Ctr Mol Med, NIH, Bldg 10, Bethesda, MD 20892 USA. EM finkelt@nih.gov FU NIH Intramural Funds; Japan Society for the Promotion of Science Research Fellowship in Biomedical and Behavioral Research at the NIH FX We are grateful to S. Gutkind (NIH) for help with primary endothelial cell isolation, T. Carter for the gift of the VWF monomeric GFP plasmid (VWF-mGFP), J. Lippincott-Schwartz (NIH) for the LC3-mCherry plasmid and Y. Fitz (NIH) for help with coagulation measurements. We thank B. Zinselmeyer (NIH) for assistance with the spot cluster analysis and C. A. Brantner (NIH) for help performing cryo-immunogold electron microscopy. This work was supported by NIH Intramural Funds. T.T. is a recipient of a Japan Society for the Promotion of Science Research Fellowship in Biomedical and Behavioral Research at the NIH. NR 57 TC 53 Z9 55 U1 2 U2 22 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD OCT PY 2013 VL 19 IS 10 BP 1281 EP + DI 10.1038/nm.3288 PG 10 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 232YW UT WOS:000325531700027 PM 24056772 ER PT J AU Falzarano, D de Wit, E Rasmussen, AL Feldmann, F Okumura, A Scott, DP Brining, D Bushmaker, T Martellaro, C Baseler, L Benecke, AG Katze, MG Munster, VJ Feldmann, H AF Falzarano, Darryl de Wit, Emmie Rasmussen, Angela L. Feldmann, Friederike Okumura, Atsushi Scott, Dana P. Brining, Doug Bushmaker, Trenton Martellaro, Cynthia Baseler, Laura Benecke, Arndt G. Katze, Michael G. Munster, Vincent J. Feldmann, Heinz TI Treatment with interferon-alpha 2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques SO NATURE MEDICINE LA English DT Article ID ACUTE RESPIRATORY SYNDROME; SONIC HEDGEHOG; CONVALESCENT PLASMA; HUMAN CORONAVIRUS; SARS PATIENTS; HEPATITIS-C; TGF-BETA; LUNG; PNEUMONIA; GROWTH AB The emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) is of global concern: the virus has caused severe respiratory illness, with 111 confirmed cases and 52 deaths1 at the time of this article's publication. Therapeutic interventions have not been evaluated in vivo; thus, patient management relies exclusively on supportive care, which, given the high case-fatality rate, is not highly effective. The rhesus macaque is the only known model organism for MERS-CoV infection, developing an acute localized to widespread pneumonia with transient clinical disease(2,3) that recapitulates mild to moderate human MERSCoV cases(4,5). The combination of interferon-alpha 2b and ribavirin was effective in reducing MERS-CoV replication in vitro(6); therefore, we initiated this treatment 8 h after inoculation of rhesus macaques. In contrast to untreated, infected macaques, treated animals did not develop breathing abnormalities and showed no or very mild radiographic evidence of pneumonia. Moreover, treated animals showed lower levels of systemic (serum) and local (lung) proinflammatory markers, in addition to fewer viral genome copies, distinct gene expression and less severe histopathological changes in the lungs. Taken together, these data suggest that treatment of MERS-CoV infected rhesus macaques with IFN-alpha 2b and ribavirin reduces virus replication, moderates the host response and improves clinical outcome. As these two drugs are already used in combination in the clinic for other infections, IFN-alpha 2b and ribavirin should be considered for the management of MERS-CoV cases. C1 [Falzarano, Darryl; de Wit, Emmie; Martellaro, Cynthia; Baseler, Laura; Feldmann, Heinz] NIAID, Dis Modeling & Transmiss Unit, Virol Lab, Div Intramural Res,NIH,Rocky Mt Labs, Hamilton, MT USA. [Rasmussen, Angela L.; Okumura, Atsushi; Benecke, Arndt G.; Katze, Michael G.] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA. [Feldmann, Friederike; Scott, Dana P.; Brining, Doug] NIAID, Rocky Mt Vet Branch, Div Intramural Res, NIH,Rocky Mt Labs, Hamilton, MT USA. [Bushmaker, Trenton; Munster, Vincent J.] NIAID, Virus Ecol Unit, Virol Lab, Div Intramural Res,NIH,Rocky Mt Labs, Hamilton, MT USA. [Baseler, Laura] Purdue Univ, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA. [Benecke, Arndt G.] Univ Paris 06, CNRS, UMR7224, Paris, France. [Katze, Michael G.] Univ Washington, Washington Natl Primate Res Ctr, Seattle, WA 98195 USA. [Feldmann, Heinz] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada. RP Feldmann, H (reprint author), NIAID, Dis Modeling & Transmiss Unit, Virol Lab, Div Intramural Res,NIH,Rocky Mt Labs, Hamilton, MT USA. EM feldmannh@niaid.nih.gov RI Okumura, Atsushi/E-8012-2015 OI Okumura, Atsushi/0000-0002-7779-3059 FU Intramural Research Program, NIAID, NIH; NIAID Regional Centers of Excellence [U54 AI081680]; Systems Virology (NIH/ NIAID) [HHSN272200800060C]; Washington National Primate Research Center [P51OD010425] FX D.F., E.d.W., V.J.M. and H.F. conceived of and designed the study. D.F., E.d.W., A.L.R., F.F., A.O., D.P.S., T.B., C.M. and D.B. performed the experiments. D.F., E.d.W., A.L.R., A.O., D.P.S., L.B., A.G.B., V.J.M., M.G.K. and H.F. analyzed the data. D.F., A.L.R., M.G.K. and H.F. wrote the manuscript. This work was supported in part by the Intramural Research Program, NIAID, NIH, in addition to the NIAID Regional Centers of Excellence (U54 AI081680), Systems Virology (NIH/ NIAID contract number HHSN272200800060C) and Washington National Primate Research Center (P51OD010425) to M.G.K. NR 37 TC 100 Z9 112 U1 0 U2 19 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD OCT PY 2013 VL 19 IS 10 BP 1313 EP + DI 10.1038/nm.3362 PG 6 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 232YW UT WOS:000325531700031 PM 24013700 ER PT J AU Pandey, GS Yanover, C Miller-Jenkins, LM Garfield, S Cole, SA Curran, JE Moses, EK Rydz, N Simhadri, V Kimchi-Sarfaty, C Lillicrap, D Viel, KR Przytycka, TM Pierce, GF Howard, TE Sauna, ZE AF Pandey, Gouri Shankar Yanover, Chen Miller-Jenkins, Lisa M. Garfield, Susan Cole, Shelley A. Curran, Joanne E. Moses, Eric K. Rydz, Natalia Simhadri, Vijaya Kimchi-Sarfaty, Chava Lillicrap, David Viel, Kevin R. Przytycka, Teresa M. Pierce, Glenn F. Howard, Tom E. Sauna, Zuben E. CA PATH Personalized Alternative TI Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A SO NATURE MEDICINE LA English DT Article ID COAGULATION-FACTOR VIII; MONOCLONAL-ANTIBODIES; HUMAN-LIVER; INHIBITOR; ANTIGEN; HISTORY; GENE AB Neutralizing antibodies (inhibitors) to replacement factor VIII (FVIII, either plasma derived or recombinant) impair the effective management of hemophilia A1. Individuals with hemophilia A due to major deletions of the FVIII gene (F8) lack antigenically cross-reactive material in their plasma ("CRM-negative"), and the prevalence of inhibitors in these individuals may be as high as 90%. Conversely, individuals with hemophilia A caused by F8 missense mutations are CRM-positive, and their overall prevalence of inhibitors is < 10% (ref. 2). Individuals with the F8 intron 22 inversion (found in similar to 50% of individuals with severe hemophilia A) have been grouped with the former on the basis of their genetic defect and CRM-negative status. However, only similar to 20% of these individuals develop inhibitors3. Here we demonstrate that the levels of F8 mRNA and intracellular FVIII protein in B lymphoblastoid cells and liver biopsies from individuals with the intron 22 inversion are comparable to those in healthy controls. These results support the hypothesis that most individuals with the intron 22 inversion are tolerized to FVIII and thus do not develop inhibitors. Furthermore, we developed a new pharmacogenetic algorithm that permits the stratification of inhibitor risk for individuals and subpopulations by predicting the immunogenicity of replacement FVIII using, as input, the number of putative T cell epitopes in the infused protein and the competence of major histocompatibility complex class II molecules to present such epitopes. This algorithm showed statistically significant accuracy in predicting the presence of inhibitors in 25 unrelated individuals with the intron 22 inversion. C1 [Pandey, Gouri Shankar; Simhadri, Vijaya; Kimchi-Sarfaty, Chava; Sauna, Zuben E.] US FDA, Ctr Biol Evaluat & Res, Div Hematol, Lab Hemostasis, Bethesda, MD 20892 USA. [Yanover, Chen] Fred Hutchinson Canc Res Ctr, Program Computat Biol, Seattle, WA 98104 USA. [Miller-Jenkins, Lisa M.] NCI, Lab Cell Biol, Expt Carcinogenesis Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA. [Garfield, Susan] NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Cole, Shelley A.; Curran, Joanne E.; Moses, Eric K.] Texas Biomed Res Inst, Dept Genet, San Antonio, TX USA. [Rydz, Natalia; Lillicrap, David] Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada. [Viel, Kevin R.] Histonis, Atlanta, GA USA. [Przytycka, Teresa M.] Natl Ctr Biotechnol Informat, Natl Lib Med, NIH, Bethesda, MD USA. [Pierce, Glenn F.] Biogen Idec Hemophilia, Waltham, MA USA. [Howard, Tom E.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Howard, Tom E.] Univ So Calif, Keck Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90033 USA. [Howard, Tom E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA. RP Sauna, ZE (reprint author), US FDA, Ctr Biol Evaluat & Res, Div Hematol, Lab Hemostasis, Bethesda, MD 20892 USA. EM tom.howard@va.gov; zuben.sauna@fda.hhs.gov RI Yanover, Chen/A-3754-2012 OI Yanover, Chen/0000-0003-3663-4286 FU US National Institute of Allergy and Infectious Diseases Committee on Human Research [10-01178]; modernization of science program of the Center for Biologics Evaluation and Research, US Food and Drug Administration; National Heart, Lung and Blood Institute, National Institutes of Health [1RC2-HL101851, HL-71130, HL-72533)]; Bayer Healthcare Corporation; Bayer Hemophilia Awards Program; Baxter Healthcare Corporation; Clinical Translational Science Institute at the University of Southern California; Intramural Program of the US National Library of Medicine, NIH FX We would like to thank P. Matzinger, B. Golding, J. Lozier, D. Levin, M. Carcao, V. Blanchette, G. Rivard and V. La Terza for helpful comments and J. Sauna for help with the graphics. We thank S. V. Ambudkar (US National Cancer Institute) for the use of facilities, M. J. Lenardo and K. Shafer-Weaver (US National Institute of Allergy and Infectious Diseases) for the gift of the purified C2 domain of FVIII and P. Stock (University of California, San Francisco) for liver tissue samples. These samples were obtained under the University of California University-Wide AIDS Research Program (TP-99-SF-001) Committee on Human Research (H802423454) and the Solid Organ Transplantation in HIV: Multi-Site Study (AI052748) funded by the US National Institute of Allergy and Infectious Diseases Committee on Human Research (10-01178). Research conducted in the laboratory of Z. E. S. is funded by the modernization of science program of the Center for Biologics Evaluation and Research, US Food and Drug Administration. Research conducted in the laboratory of T. E. H. is funded by grants from the National Heart, Lung and Blood Institute, National Institutes of Health (1RC2-HL101851, HL-71130 and HL-72533), the Bayer Healthcare Corporation, Bayer Hemophilia Awards Program, Baxter Healthcare Corporation and the Clinical Translational Science Institute at the University of Southern California. The work of T. M. P. is fully supported by the Intramural Program of the US National Library of Medicine, NIH. NR 22 TC 27 Z9 27 U1 2 U2 19 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD OCT PY 2013 VL 19 IS 10 BP 1318 EP + DI 10.1038/nm.3270 PG 10 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 232YW UT WOS:000325531700032 PM 24037092 ER PT J AU Fridlyand, J Simon, RM Walrath, JC Roach, N Buller, R Schenkein, DP Flaherty, KT Allen, JD Sigal, EV Scher, HI AF Fridlyand, Jane Simon, Richard M. Walrath, Jessica C. Roach, Nancy Buller, Richard Schenkein, David P. Flaherty, Keith T. Allen, Jeff D. Sigal, Ellen V. Scher, Howard I. TI Considerations for the successful co-development of targeted cancer therapies and companion diagnostics SO NATURE REVIEWS DRUG DISCOVERY LA English DT Article ID CLINICAL-TRIAL DESIGNS; ADAPTIVE SIGNATURE DESIGN; GROWTH-FACTOR RECEPTOR; PREDICTIVE BIOMARKERS; MONOCLONAL-ANTIBODY; IMATINIB MESYLATE; WORKING GROUP; TUMOR-CELLS; ONCOLOGY; EXPRESSION AB As diagnostic tests become increasingly important for optimizing the use of drugs to treat cancers, the co-development of a targeted therapy and its companion diagnostic test is becoming more prevalent and necessary. In July 2011, the US Food and Drug Administration released a draft guidance that gave the agency's formal definition of companion diagnostics and introduced a drug-diagnostic co-development process for gaining regulatory approval. Here, we identify areas of drug-diagnostic co-development that were either not covered by the guidance or that would benefit from increased granularity, including how to determine when clinical studies should be limited to biomarker-positive patients, defining the diagnostically selected patient population in which to use a companion diagnostic, and defining and clinically validating a biomarker signature for assays that use more than one biomarker. We propose potential approaches that sponsors could use to deal with these challenges and provide strategies to help guide the future co-development of drugs and diagnostics. C1 [Fridlyand, Jane] Genentech Inc, San Francisco, CA 94080 USA. [Simon, Richard M.] US Natl Canc Inst, Bethesda, MD 20892 USA. [Walrath, Jessica C.; Allen, Jeff D.; Sigal, Ellen V.] Friends Canc Res, South Washington, DC 20036 USA. [Roach, Nancy] Fight Colorectal Canc, Alexandria, VA 22314 USA. [Buller, Richard] Pfizer, San Diego, CA 92121 USA. [Schenkein, David P.] Agios Pharmaceut, Cambridge, MA 02139 USA. [Flaherty, Keith T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Scher, Howard I.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA. RP Walrath, JC (reprint author), Friends Canc Res, 1800 M St NW,Suite 1050, South Washington, DC 20036 USA. EM jwalrath@focr.org NR 47 TC 24 Z9 25 U1 3 U2 22 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1474-1776 J9 NAT REV DRUG DISCOV JI Nat. Rev. Drug Discov. PD OCT PY 2013 VL 12 IS 10 BP 743 EP 755 DI 10.1038/nrd4101 PG 13 WC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy SC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy GA 227XT UT WOS:000325149700013 PM 24008432 ER PT J AU Bersani, FS Girardi, N Sanna, L Mazzarini, L Santucci, C Kotzalidis, GD Sani, G De Rossi, P Raccah, RN Caltagirone, SS Battipaglia, M Capezzuto, S Bersani, G Girardi, P AF Bersani, Francesco Saverio Girardi, Nicoletta Sanna, Livia Mazzarini, Lorenzo Santucci, Chiara Kotzalidis, Giorgio D. Sani, Gabriele De Rossi, Pietro Raccah, Ruggero N. Caltagirone, Saverio Simone Battipaglia, Mariella Capezzuto, Silvia Bersani, Giuseppe Girardi, Paolo TI Deep Transcranial Magnetic Stimulation for treatment-resistant bipolar depression: A case report of acute and maintenance efficacy SO NEUROCASE LA English DT Article DE Deep Transcranial Magnetic Stimulation; Treatment-resistant bipolar disorder; Bipolar depression; Prefrontal cortex; Maintenance treatment of bipolar disorder ID BRAIN-REGIONS; RATING-SCALE; H-COIL; ADD-ON; DISORDER; FEASIBILITY; ECT; DEFINITION; IMPAIRMENT; SYMPTOMS AB Deep Transcranial Magnetic Stimulation (dTMS) is currently being evaluated as a possible treatment for several neuropsychiatric disorders and has been demonstrated as a safe and effective procedure. This case presents a patient with bipolar depression that has been treated with 20 daily consecutive dTMS sessions and with one dTMS session every 2 weeks for the following 3 months. Depressive symptoms improved rapidly and response was maintained during the next 6 months; cognitive performances also improved. This report suggests that add-on dTMS may help overcoming drug-resistance in bipolar depression and protect from subsequent bipolar episodes of any polarity. C1 [Bersani, Francesco Saverio; Girardi, Nicoletta] Univ Roma La Sapienza, Dept Neurol & Psychiat, I-00185 Rome, Italy. [Sanna, Livia; Mazzarini, Lorenzo; Santucci, Chiara; Kotzalidis, Giorgio D.; Sani, Gabriele; De Rossi, Pietro; Caltagirone, Saverio Simone; Battipaglia, Mariella; Girardi, Paolo] Univ Roma La Sapienza, NESMOS Dept Neurosci Mental Hlth & Sensory Organs, Sch Med & Psychol, St Andrea Hosp, I-00185 Rome, Italy. [Mazzarini, Lorenzo; Capezzuto, Silvia; Girardi, Paolo] Suore Hosp Sacred Heart Jesus, Dept Neuropsychiat, Viterbo, Italy. [Raccah, Ruggero N.] ATID Ltd Adv Technol Innovat Distribut, Rome, Italy. [Bersani, Giuseppe] Sapienza Univ Rome, Dept Med Surg Sci & Biotechnol, Latina, Italy. [De Rossi, Pietro] NIMH, Bethesda, MD 20892 USA. RP Bersani, FS (reprint author), Univ Roma La Sapienza, Dept Neurol & Psychiat, Viale Univ 30, I-00185 Rome, Italy. EM bersani.fs@tiscali.it OI Bersani, Francesco Saverio/0000-0002-7555-8020 NR 48 TC 19 Z9 19 U1 1 U2 9 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1355-4794 EI 1465-3656 J9 NEUROCASE JI Neurocase PD OCT 1 PY 2013 VL 19 IS 5 BP 451 EP 457 DI 10.1080/13554794.2012.690429 PG 7 WC Clinical Neurology; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 225QO UT WOS:000324977600006 PM 22827578 ER PT J AU Yeatts, SD Palesch, YY Moy, CS Selim, M AF Yeatts, Sharon D. Palesch, Yuko Y. Moy, Claudia S. Selim, Magdy TI High Dose Deferoxamine in Intracerebral Hemorrhage (Hi-Def) Trial: Rationale, Design, and Methods SO NEUROCRITICAL CARE LA English DT Article DE Intracerebral hemorrhage; Deferoxamine; Clinical trial; Futility design ID ACTIVATED FACTOR-VII; PERIHEMATOMAL EDEMA; IRON CHELATOR; STROKE TRIALS; BRAIN-INJURY; RAT MODEL; HEMATOMA; SAFETY; TOLERABILITY; EXPRESSION AB Hemoglobin degradation products, in particular iron, have been implicated in secondary neuronal injury following intracerebral hemorrhage (ICH). The iron chelator Deferoxamine Mesylate (DFO) exerts diverse neuroprotective effects, reduces perihematoma edema (PHE) and neuronal damage, and improves functional recovery after experimental ICH. We hypothesize that treatment with DFO could minimize neuronal injury and improve outcome in ICH patients. As a prelude to test this hypothesis, we conducted a Phase I, open-label study to determine the tolerability, safety, and maximum tolerated dose (MTD) of DFO in patients with ICH. Intravenous infusions of DFO in doses up to 62 mg/kg/day (up to a maximum of 6000 mg/day) were well-tolerated and did not seem to increase serious adverse events (SAEs) or mortality. We have initiated a multi-center, double-blind, randomized, placebo-controlled, Phase II clinical trial (High Dose Deferoxamine [HI-DEF] in Intracerebral Hemorrhage) to determine if it is futile to move DFO forward to Phase III efficacy evaluation. We will randomize 324 subjects with spontaneous ICH to either DFO at 62 mg/kg/day (up to a maximum daily dose of 6000 mg/day) or saline placebo, given by intravenous infusion for 5 consecutive days. Treatment will be initiated within 24 hours after ICH symptom onset. All subjects will be followed for 3 months and will receive standard of care therapy while participating in the study. At 3 months, the proportion of DFO-treated subjects with a good clinical outcome, assessed by modified Rankin Scale, will be compared to the placebo proportion in a futility analysis. The Hi-Def trial is expected to advance our understanding of the pathopgysiology of secondary neuronal injury in ICH and will provide a crucial "Go/No Go" signal as to whether a Phase III trial to investigate the efficacy of DFO is warranted. C1 [Yeatts, Sharon D.; Palesch, Yuko Y.] Med Univ S Carolina, Coll Med, Dept Publ Hlth Sci, Data Coordinat Unit, Charleston, SC 29425 USA. [Moy, Claudia S.] NINDS, NIH, Bethesda, MD 20892 USA. [Selim, Magdy] Beth Israel Deaconess Med Ctr, Dept Neurol, Stroke Div, Boston, MA 02215 USA. RP Selim, M (reprint author), Beth Israel Deaconess Med Ctr, Dept Neurol, Stroke Div, 330 Brookline Ave,Palmer 127, Boston, MA 02215 USA. EM mselim@bidmc.harvard.edu FU National Institute of Health [U01 NS074425] FX The study was supported by the National Institute of Health (Grant # U01 NS074425). NR 33 TC 24 Z9 24 U1 0 U2 8 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1541-6933 J9 NEUROCRIT CARE JI Neurocrit. Care PD OCT PY 2013 VL 19 IS 2 BP 257 EP 266 DI 10.1007/s12028-013-9861-y PG 10 WC Critical Care Medicine; Clinical Neurology SC General & Internal Medicine; Neurosciences & Neurology GA 221GB UT WOS:000324644800017 PM 23943316 ER PT J AU Cotch, MF Freeman, EE AF Cotch, Mary Frances Freeman, Ellen E. TI Health Care Services: Addressing the Global Challenge of Universal Eye Health SO OPHTHALMIC EPIDEMIOLOGY LA English DT Editorial Material C1 [Cotch, Mary Frances] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA. [Freeman, Ellen E.] Univ Montreal, Dept Ophtalmol, Montreal, PQ, Canada. RP Cotch, MF (reprint author), NEI, Div Epidemiol & Clin Applicat, NIH, 10 Ctr Dr Clin Res Ctr,Room 3-2531,MSC 1204, Bethesda, MD 20892 USA. EM mfc@nei.nih.gov OI Cotch, Mary Frances/0000-0002-2046-4350; Freeman, Ellen/0000-0002-1403-8427 FU Intramural NIH HHS [Z99 EY999999] NR 11 TC 0 Z9 0 U1 1 U2 3 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0928-6586 J9 OPHTHAL EPIDEMIOL JI Ophthalmic Epidemiol. PD OCT PY 2013 VL 20 IS 5 BP 255 EP 257 DI 10.3109/09286586.2013.823217 PG 3 WC Ophthalmology SC Ophthalmology GA 226BC UT WOS:000325008200001 PM 24007494 ER PT J AU Ramasamy, D Joseph, S Valaguru, V Mitta, VP Ravilla, TD Cotch, MF AF Ramasamy, Dhivya Joseph, Sanil Valaguru, Vijayakumar Mitta, Vinod P. Ravilla, Thulasiraj D. Cotch, Mary Frances TI Cluster Randomized Trial to Compare Spectacle Delivery Systems at Outreach Eye Camps in South India SO OPHTHALMIC EPIDEMIOLOGY LA English DT Article DE Eye camp; India; outreach; refractive error; spectacle dispensing; spectacles ID CATARACT-SURGERY; BLINDNESS; BARRIERS AB Purpose: To study the optimal method for delivery of spectacles at eye camps to maximize procurement and use. Methods: A cluster randomized controlled trial, undertaken in the catchment districts of Aravind Eye Hospital - Theni, in the state of Tamil Nadu, India. Community eye camps (n = 21) were allocated to offer one of three types of service for purchase of spectacles to correct refractive error: (1) Issuance of a prescription only; (2) booking orders for spectacles with subsequent delivery; (3) on-the-spot fitting and dispensing of spectacles. Follow-up questionnaires were administered 6 weeks after interventions to assess patient outcomes. The primary outcome measured was spectacle procurement at follow-up 6 weeks post-screening. Secondary outcomes included use of and satisfaction with spectacles. Reasons for purchase/non-purchase were also assessed. Results: Compared to those who were issued only a prescription and adjusting for distance from base hospital, spectacle procurement was significantly higher for those allowed to book spectacles for subsequent delivery (odds ratio, OR, 8.79, 95% confidence interval, CI, 4.61-16.78) and for those receiving spectacles on the spot (OR 13.97, 95% CI 8.12-24.05). Among those with spectacles at 6 weeks, spectacle use was nearly universal and satisfaction with spectacles varied between 92 and 94% among the three different dispensing modalities. Conclusion: Making spectacles available on the spot is important to ensure procurement in a context where availability and access to dispensing opticians is poor. C1 [Ramasamy, Dhivya; Joseph, Sanil; Valaguru, Vijayakumar; Ravilla, Thulasiraj D.] Aravind Eye Care Syst, LAICO, Madurai 625020, Tamil Nadu, India. [Mitta, Vinod P.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Cotch, Mary Frances] NEI, NIH, Bethesda, MD 20892 USA. RP Ramasamy, D (reprint author), Aravind Eye Care Syst, LAICO, 72 Kuruvikaran Salai, Madurai 625020, Tamil Nadu, India. EM dhivya@aravind.org OI Cotch, Mary Frances/0000-0002-2046-4350 FU Aravind Eye Care System FX This study was internally funded by Aravind Eye Care System NR 15 TC 1 Z9 1 U1 0 U2 3 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0928-6586 J9 OPHTHAL EPIDEMIOL JI Ophthalmic Epidemiol. PD OCT PY 2013 VL 20 IS 5 BP 308 EP 314 DI 10.3109/09286586.2013.822897 PG 7 WC Ophthalmology SC Ophthalmology GA 226BC UT WOS:000325008200010 PM 24070102 ER PT J AU Arana, Y Verastegui, M Tuero, I Grandjean, L Garcia, HH Gilman, RH AF Arana, Yanina Verastegui, Manuela Tuero, Iskra Grandjean, Louis Garcia, Hector H. Gilman, Robert H. TI Characterization of the carbohydrate components of Taenia solium oncosphere proteins and their role in the antigenicity SO PARASITOLOGY RESEARCH LA English DT Article ID ENTAMOEBA-HISTOLYTICA; PORCINE CYSTICERCOSIS; GLYCOPROTEIN ANTIGENS; TRICHINELLA-SPIRALIS; CELL-SURFACE; PIGS; VACCINATION; PARASITES; EPITOPES; LECTIN AB This study examines the carbohydrate composition of Taenia solium whole oncosphere antigens (WOAs), in order to improve the understanding of the antigenicity of the T. solium. Better knowledge of oncosphere antigens is crucial to accurately diagnose previous exposure to T. solium eggs and thus predict the development of neurocysticercosis. A set of seven lectins conjugates with wide carbohydrate specificity were used on parasite fixations and somatic extracts. Lectin fluorescence revealed that d-mannose, d-glucose, d-galactose and N-acetyl-d-galactosamine residues were the most abundant constituents of carbohydrate chains on the surface of T. solium oncosphere. Lectin blotting showed that posttranslational modification with N-glycosylation was abundant while little evidence of O-linked carbohydrates was observed. Chemical oxidation and enzymatic deglycosylation in situ were performed to investigate the immunoreactivity of the carbohydrate moieties. Linearizing or removing the carbohydrate moieties from the protein backbones did not diminish the immunoreactivity of these antigens, suggesting that a substantial part of the host immune response against T. solium oncosphere is directed against the peptide epitopes on the parasite antigens. Finally, using carbohydrate probes, we demonstrated for the first time that the presence of several lectins on the surface of the oncosphere was specific to carbohydrates found in intestinal mucus, suggesting a possible role in initial attachment of the parasite to host cells. C1 [Arana, Yanina; Verastegui, Manuela; Grandjean, Louis; Garcia, Hector H.; Gilman, Robert H.] Univ Peruana Cayetano Heredia, Fac Sci & Philosophy, Dept Cellular & Mol Sci, Lima, Peru. [Tuero, Iskra] NCI, Vaccine Branch, NIH, Bethesda, MD 20892 USA. [Grandjean, Louis] Univ London Imperial Coll Sci Technol & Med, Wellcome Ctr Clin Trop Med, London W2 1PG, England. [Garcia, Hector H.] Inst Ciencias Neurol, Cysticercosis Unit, Lima, Peru. [Gilman, Robert H.] Johns Hopkins Univ, Dept Int Hlth, Bloomberg Sch Hyg & Publ Hlth, Baltimore, MD 21205 USA. [Gilman, Robert H.] AB PRISMA, Lima 32, Peru. RP Verastegui, M (reprint author), Univ Peruana Cayetano Heredia, Fac Sci & Philosophy, Dept Cellular & Mol Sci, POB 5045, Lima, Peru. EM mveraste@jhsph.edu FU Gates project [23981]; International Foundation for Science (IFS) [B/4103-1]; RG-ER anonymous fund for Tropical Research FX Funding for this project came from the Gates project 23981, International Foundation for Science (IFS) grant B/4103-1 and the RG-ER anonymous fund for Tropical Research. We thank Dr. Eric Cossio, Dr. Carlos Carmona, Cecilia Casaravilla, and Dr. Holger Mayta and the administrative help of Ms. Marjory Meza and the technical assistance of MSc. Milagros Zavaleta. NR 40 TC 2 Z9 2 U1 0 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0932-0113 EI 1432-1955 J9 PARASITOL RES JI Parasitol. Res. PD OCT PY 2013 VL 112 IS 10 BP 3569 EP 3578 DI 10.1007/s00436-013-3542-9 PG 10 WC Parasitology SC Parasitology GA 216ZR UT WOS:000324326500024 PM 23982308 ER PT J AU Blanch-Hartigan, D AF Blanch-Hartigan, Danielle TI Patient satisfaction with physician errors in detecting and identifying patient emotion cues SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Emotion recognition; Emotion cue; Physician-patient relationship; Patient-centered care ID MEDICAL CONSULTATIONS; CARE; METAANALYSIS; RESPONSES; ACCURACY; STUDENTS; SYSTEM; SKILLS AB Objective: Previous research has examined physicians' ability to respond to or identify the type of emotion cues. Yet in physician-patient interactions, identification and response are preceded by the ability to detect whether an emotion cue has occurred. This research assesses consequences of emotion detection errors for patient satisfaction. Methods: Participants responding to an online survey read one of six randomly assigned descriptions of a physician-patient interaction varying on: whether the patient presented an emotion cue; whether the physician detected an emotion cue; and whether the physician correctly identified the cue. Participants then rated satisfaction with the physician. Results: Satisfaction was highest when the physician correctly detected the patient's emotion cue and lowest when the physician failed to detect the patient's emotion. Failing to detect the emotion cue had lower satisfaction than other emotion processing errors, including falsely detecting an emotion cue that was not there or incorrectly identifying the type of emotion. Conclusions: Emotion cue detection has implications for patient satisfaction distinct from emotion identification. Practice implications: Results suggest it may be better for physicians to incorrectly identify than miss an emotion. Training for healthcare providers should consider incorporating emotion detection. Published by Elsevier Ireland Ltd. C1 [Blanch-Hartigan, Danielle] NCI, Off Canc Survivorship, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. RP Blanch-Hartigan, D (reprint author), NCI, Off Canc Survivorship, 6116 Execut Blvd,Suite 404,MSC 8336, Bethesda, MD 20892 USA. EM danielleblanch@gmail.com NR 31 TC 5 Z9 6 U1 1 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD OCT PY 2013 VL 93 IS 1 BP 56 EP 62 DI 10.1016/j.pec.2013.04.010 PG 7 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 226TE UT WOS:000325058100008 PM 23669151 ER PT J AU Nesheim, SR Hardnett, F Wheeling, JT Siberry, GK Paul, ME Emmanuel, P Bohannon, B Dominguez, K AF Nesheim, Steven R. Hardnett, Felicia Wheeling, John T. Siberry, George K. Paul, Mary E. Emmanuel, Patricia Bohannon, Beverly Dominguez, Kenneth CA LEGACY Consortium TI Incidence of Opportunistic Illness Before and After Initiation of Highly Active Antiretroviral Therapy in Children SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE HIV infection; pediatric; immune reconstitution inflammatory syndrome; opportunistic infection; highly active antiretroviral therapy ID IMMUNE RECONSTITUTION SYNDROME; HIV-INFECTED CHILDREN; BACILLE-CALMETTE-GUERIN; INFLAMMATORY-SYNDROME; BCG; LYMPHADENITIS; MANIFESTATION; TUBERCULOSIS; DISEASE; ZOSTER AB Background: Little is known about immune reconstitution inflammatory syndrome in children in the United States. Methods: LEGACY is a longitudinal cohort study of HIV-infected participants 0-24 years at enrollment during 2005 to 2007 from 22 US clinics. For this analysis, we included participants with complete medical record abstraction from birth or time of HIV diagnosis through 2006. Opportunistic illness (OI) included AIDS-defining conditions and selected HIV-related diagnoses. We calculated the incidence (#/100 patient-years) of OI diagnosed in the months pre- and postinitiation of the first highly active antiretroviral therapy (HAART) regimen which was followed by 1 log reduction in HIV viral load. We defined OI as immune reconstitution inflammatory syndrome if an OI incidence increased after HAART initiation. Responders were defined as experiencing 1 log decline in viral load within 6 months after HAART initiation. Results: Among 575 patients with complete chart abstraction, 524 received HAART. Of these 524 patients, 343 were responders, 181 were nonresponders and 86 experienced OI. Responders accounted for 98 of 124 (79%) of OI. Pre-HAART and post-HAART OI incidences were 43.7 and 24.4 (P = 0.003), respectively, among responders and 15.9 and 9.1 (P = 0.2), respectively, among nonresponders. Overall, OI incidences among responders and nonresponders were 33.8 and 12.3, respectively (P = 0.002). Responders were more likely than nonresponders to experience herpes simplex and herpes zoster before HAART initiation (all, P < 0.002). Conclusions: The lack of immune reconstitution inflammatory syndrome in participants initiating HAART may be due to low overall OI rates. The unexpectedly higher OI prevalence comprised mainly of herpes simplex and zoster, before HAART initiation among responders, may have motivated them to better adhere to HAART. C1 [Nesheim, Steven R.] Emory Univ, Sch Med, Atlanta, GA USA. [Nesheim, Steven R.; Bohannon, Beverly; Dominguez, Kenneth] Ctr Dis Control & Prevent, Epidemiol Branch, Atlanta, GA 30333 USA. [Hardnett, Felicia] Ctr Dis Control & Prevent, Quantitat Sci & Informat Branch, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Wheeling, John T.] Northrop Grumman Inc, Atlanta, GA USA. [Siberry, George K.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Adolescent Maternal AIDS Branch, NIH, Rockville, MD USA. [Paul, Mary E.] Baylor Coll Med, Houston, TX 77030 USA. [Emmanuel, Patricia] Univ S Florida, Sch Med, Tampa, FL 33620 USA. RP Nesheim, SR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM sxn9@cdc.gov FU Centers for Disease Control and Prevention, Atlanta, GA [200-2004-09976] FX The LEGACY project was funded by the Centers for Disease Control and Prevention, Atlanta, GA, contract number 200-2004-09976. NR 30 TC 2 Z9 2 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD OCT PY 2013 VL 32 IS 10 BP 1089 EP 1095 DI 10.1097/INF.0b013e31829ee893 PG 7 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 224ML UT WOS:000324890500016 PM 24067552 ER PT J AU Rice, ML Zeldow, B Siberry, GK Purswani, M Malee, K Hoffman, HJ Frederick, T Buchanan, A Sirois, PA Allison, SM Williams, PL AF Rice, Mabel L. Zeldow, Bret Siberry, George K. Purswani, Murli Malee, Kathleen Hoffman, Howard J. Frederick, Toni Buchanan, Ashley Sirois, Patricia A. Allison, Susannah M. Williams, Paige L. CA PHACS TI Evaluation of Risk for Late Language Emergence After In Utero Antiretroviral Drug Exposure in HIV-exposed Uninfected Infants SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE pregnancy; HIV-exposed infants; antiretroviral; cohort study; language delay ID BILIRUBIN INDUCES APOPTOSIS; INFECTED WOMEN; NEONATAL HYPERBILIRUBINEMIA; CHILDREN; PREGNANCY; OUTCOMES; BORN; DELIVERY; PROTEASE; NEURONS AB Background: Combination antiretroviral (cARV) regimens are recommended for pregnant women with HIV to prevent perinatal HIV transmission. Safety is a concern for infants who were HIV-exposed but uninfected, particularly for neurodevelopmental problems, such as language delays. Methods: We studied late language emergence (LLE) in HIV-exposed but uninfected children enrolled in a US-based prospective cohort study. LLE was defined as a caregiver-reported score 10th percentile in any of 4 domains of the MacArthur-Bates Communicative Development Inventory for 1-year olds and as 1 standard deviation below age-specific norms for the Ages and Stages Questionnaire for 2-year olds. Logistic regression models were used to evaluate associations of in utero cARV exposure with LLE, adjusting for infant, maternal and environmental characteristics. Results: 1129 language assessments were conducted among 792 1- and 2-year-old children (50% male, 62% black and 37% Hispanic). Overall, 86% had in utero exposure to cARV and 83% to protease inhibitors. LLE was identified in 26% of 1-year olds and 23% of 2-year olds, with higher rates among boys. In adjusted models, LLE was not associated with maternal cARV or ARV drug classes in either age group. Among cARV-exposed 1-year olds, increased odds of LLE was observed for those exposed to atazanavir (adjusted odds ratio = 1.83, 95% confidence interval: 1.10-3.04), particularly after the first trimester (adjusted odds ratio = 3.56, P = 0.001), compared with atazanavir-unexposed infants. No associations of individual ARV drugs with LLE were observed among 2-year olds. Conclusions: In utero cARV exposure showed little association with LLE, except for a higher risk of language delay observed in 1-year-old infants with atazanavir exposure. C1 [Rice, Mabel L.] Univ Kansas, Hearing Dept, Lawrence, KS 66045 USA. [Zeldow, Bret; Buchanan, Ashley; Williams, Paige L.] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA. [Siberry, George K.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Maternal & Pediat Infect Dis Branch, NIH, Bethesda, MD USA. [Purswani, Murli] Albert Einstein Coll Med, Bronx Lebanon Hosp Ctr, Bronx, NY 10467 USA. [Malee, Kathleen] Northwestern Univ, Feinberg Sch Med Psychiat & Behav Sci, Chicago, IL 60611 USA. [Hoffman, Howard J.] Natl Inst Deafness & Other Commun Disorders, Epidemiol & Stat Program, Div Sci Programs, NIH, Bethesda, MD USA. [Frederick, Toni] USC, Keck Sch Med, Dept Res Pediat, Maternal Child & Adolescent Program Infect Dis &, Los Angeles, CA USA. [Sirois, Patricia A.] Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA. [Allison, Susannah M.] NIMH, NIH, Bethesda, MD 20892 USA. RP Rice, ML (reprint author), Univ Kansas, Dole Human Dev Ctr 3031, 1000 Sunnyside Ave, Lawrence, KS 66045 USA. EM mabel@ku.edu OI Rice, Mabel/0000-0002-8150-5523 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse; National Institute of Allergy and Infectious Diseases; Office of AIDS Research; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; National Institute on Deafness and Other Communication Disorders; National Heart Lung and Blood Institute; National Institute of Dental and Craniofacial Research; National Institute on Alcohol Abuse and Alcoholism through Harvard University School of Public Health [HD052102, 3 U01 HD052102-05S1, 3 U01 HD052102-06S3]; Tulane University School of Medicine [HD052104, 3U01HD052104-06S1] FX The Pediatric HIV/AIDS Cohort Study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development with cofunding from the National Institute on Drug Abuse, the National Institute of Allergy and Infectious Diseases, the Office of AIDS Research, the National Institute of Mental Health, the National Institute of Neurological Disorders and Stroke, the National Institute on Deafness and Other Communication Disorders, the National Heart Lung and Blood Institute, the National Institute of Dental and Craniofacial Research and the National Institute on Alcohol Abuse and Alcoholism, through cooperative agreements with the Harvard University School of Public Health (HD052102, 3 U01 HD052102-05S1, 3 U01 HD052102-06S3) and the Tulane University School of Medicine (HD052104, 3U01HD052104-06S1). The authors have no other funding or conflicts of interest to disclose. NR 27 TC 14 Z9 14 U1 2 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD OCT PY 2013 VL 32 IS 10 BP E406 EP E413 DI 10.1097/INF.0b013e31829b80ee PG 8 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 224ML UT WOS:000324890500005 PM 24067563 ER PT J AU Jacobson, O Chen, XY AF Jacobson, Orit Chen, Xiaoyuan TI Interrogating Tumor Metabolism and Tumor Microenvironments Using Molecular Positron Emission Tomography Imaging. Theranostic Approaches to Improve Therapeutics SO PHARMACOLOGICAL REVIEWS LA English DT Review ID GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; INTEGRIN ALPHA(V)BETA(3) EXPRESSION; UROKINASE PLASMINOGEN-ACTIVATOR; METASTATIC BREAST-CANCER; PROLIFERATION IN-VIVO; MET-BINDING PEPTIDE; PROSTATE-CANCER; NEUROENDOCRINE TUMORS; TYROSINE KINASE AB Positron emission tomography (PET) is a noninvasive molecular imaging technology that is becoming increasingly important for the measurement of physiologic, biochemical, and pharmacological functions at cellular and molecular levels in patients with cancer. Formation, development, and aggressiveness of tumor involve a number of molecular pathways, including intrinsic tumor cell mutations and extrinsic interaction between tumor cells and the microenvironment. Currently, evaluation of these processes is mainly through biopsy, which is invasive and limited to the site of biopsy. Ongoing research on specific target molecules of the tumor and its microenvironment for PET imaging is showing great potential. To date, the use of PET for diagnosing local recurrence and metastatic sites of various cancers and evaluation of treatment response is mainly based on [F-18]fluorodeoxyglucose ([F-18]FDG), which measures glucose metabolism. However, [F-18]FDG is not a target-specific PET tracer and does not give enough insight into tumor biology and/or its vulnerability to potential treatments. Hence, there is an increasing need for the development of selective biologic radiotracers that will yield specific biochemical information and allow for noninvasive molecular imaging. The possibility of cancer-associated targets for imaging will provide the opportunity to use PET for diagnosis and therapy response monitoring (theranostics) and thus personalized medicine. This article will focus on the review of non-[F-18]FDG PET tracers for specific tumor biology processes and their preclinical and clinical applications. C1 [Jacobson, Orit; Chen, Xiaoyuan] Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD USA. RP Chen, XY (reprint author), Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD USA. EM shawn.chen@nih.gov FU Intramural Research Program of the National Institutes of Health [National Institute of Biomedical Imaging and Bioengineering] FX This work is supported by the Intramural Research Program of the National Institutes of Health [National Institute of Biomedical Imaging and Bioengineering]. NR 362 TC 8 Z9 8 U1 2 U2 23 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0031-6997 J9 PHARMACOL REV JI Pharmacol. Rev. PD OCT PY 2013 VL 65 IS 4 BP 1214 EP 1256 DI 10.1124/pr.113.007625 PG 43 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 227BU UT WOS:000325083600005 PM 24064460 ER PT J AU Zhang, LW Simpson, DA Innes, CL Chou, J Bushel, PR Paules, RS Kaufmann, WK Zhou, T AF Zhang, Liwen Simpson, Dennis A. Innes, Cynthia L. Chou, Jeff Bushel, Pierre R. Paules, Richard S. Kaufmann, William K. Zhou, Tong TI Gene expression signatures but not cell cycle checkpoint functions distinguish AT carriers from normal individuals SO PHYSIOLOGICAL GENOMICS LA English DT Article DE ataxia telangiectasia-mutated; ionizing radiation; gene expression signature ID ATAXIA-TELANGIECTASIA HETEROZYGOTES; BREAST-CANCER SUSCEPTIBILITY; DNA-DAMAGE; ATM MUTATIONS; IONIZING-RADIATION; CHROMOSOMAL RADIOSENSITIVITY; INCREASED SENSITIVITY; GAMMA-IRRADIATION; SEQUENCE VARIANTS; HUMAN FIBROBLASTS AB Ataxia telangiectasia (AT) is a rare autosomal recessive disease caused by mutations in the ataxia telangiectasia-mutated gene (ATM). AT carriers with one mutant ATM allele are usually not severely affected although they carry an increased risk of developing cancer. There has not been an easy and reliable diagnostic method to identify AT carriers. Cell cycle checkpoint functions upon ionizing radiation (IR)-induced DNA damage and gene expression signatures were analyzed in the current study to test for differential responses in human lymphoblastoid cell lines with different ATM genotypes. While both dose- and time-dependent G1 and G2 checkpoint functions were highly attenuated in ATM-/- cell lines, these functions were preserved in ATM+/- cell lines equivalent to ATM+/+ cell lines. However, gene expression signatures at both baseline (consisting of 203 probes) and post-IR treatment (consisting of 126 probes) were able to distinguish ATM+/- cell lines from ATM+/+ and ATM-/- cell lines. Gene ontology (GO) and pathway analysis of the genes in the baseline signature indicate that ATM function-related categories, DNA metabolism, cell cycle, cell death control, and the p53 signaling pathway, were overrepresented. The same analyses of the genes in the IR-responsive signature revealed that biological categories including response to DNA damage stimulus, p53 signaling, and cell cycle pathways were overrepresented, which again confirmed involvement of ATM functions. The results indicate that AT carriers who have unaffected G1 and G2 checkpoint functions can be distinguished from normal individuals and AT patients by expression signatures of genes related to ATM functions. C1 [Zhang, Liwen] Fudan Univ, Peoples Hosp Shanghai 5, Dept Obstet & Gynecol, Shanghai 200433, Peoples R China. [Simpson, Dennis A.; Kaufmann, William K.; Zhou, Tong] Univ N Carolina, Ctr Environm Hlth & Susceptibil, Dept Pathol & Lab Med, Chapel Hill, NC USA. [Simpson, Dennis A.; Kaufmann, William K.; Zhou, Tong] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Innes, Cynthia L.; Paules, Richard S.] NIEHS, Environm Stress & Canc Grp, Lab Toxicol & Pharmacol, Res Triangle Pk, NC 27709 USA. [Chou, Jeff] Wake Forest Univ, Bowman Gray Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Bushel, Pierre R.] NIEHS, Biostat Branch, Res Triangle Pk, NC 27709 USA. [Zhou, Tong] Gentris Corp, Morrisville, NC 27560 USA. RP Zhou, T (reprint author), Gentris Corp, 133 Southctr Ct, Morrisville, NC 27560 USA. EM Tong.Zhou@gentris.com FU Public Health Service [ES-10126, ES-11391]; Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences Grant [Z01 ES102345-04] FX This work was supported in part by Public Health Service Grants ES-10126 and ES-11391 and in part by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences Grant Z01 ES102345-04. NR 59 TC 0 Z9 0 U1 0 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1094-8341 J9 PHYSIOL GENOMICS JI Physiol. Genomics PD OCT PY 2013 VL 45 IS 19 BP 907 EP 916 DI 10.1152/physiolgenomics.00064.2013 PG 10 WC Cell Biology; Genetics & Heredity; Physiology SC Cell Biology; Genetics & Heredity; Physiology GA 227PM UT WOS:000325125800004 PM 23943852 ER PT J AU Khattar, SK Samal, S LaBranche, CC Montefiori, DC Collins, PL Samal, SK AF Khattar, Sunil K. Samal, Sweety LaBranche, Celia C. Montefiori, David C. Collins, Peter L. Samal, Siba K. TI Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector SO PLOS ONE LA English DT Article ID TYPE-1 ENVELOPE GLYCOPROTEIN; NEUTRALIZING ANTIBODY-RESPONSE; VACCINE DEVELOPMENT; MONOMERIC GP120; FOREIGN GENE; IMMUNODEFICIENCY; IMMUNIZATION; PROTEIN; ELICITS; TRIMERS AB The development of a vaccine against human immunodeficiency virus-1 (HIV-1) capable of inducing broad humoral and cellular responses at both the systemic and mucosal levels will be critical for combating the global AIDS epidemic. We previously demonstrated the ability of Newcastle disease virus (NDV) as a vaccine vector to express oligomeric Env protein gp160 and induce potent humoral and mucosal immune responses. In the present study, we used NDV vaccine strain LaSota as a vector to compare the biochemical and immunogenic properties of vector-expressed gp160, gp120, and two versions of gp140 (a derivative of gp160 made by deleting the transmembrane and cytoplasmic domains), namely: gp140L, which contained the complete membrane-proximal external region (MPER), and gp140S, which lacks the distal half of MPER. We show that, similar to gp160, NDV-expressed gp140S and gp120, but not gp140L, formed higher-order oligomers that retained recognition by conformationally sensitive monoclonal antibodies. Immunization of guinea pigs by the intranasal route with rLaSota/gp140S resulted in significantly greater systemic and mucosal antibody responses compared to the other recombinants. Immunization with rLaSota/140S, rLaSota/140L rLaSota/120 resulted in mixed Th1/Th2 immune responses as compared to Th1-biased immune responses induced by rLaSota/160. Importantly, rLaSota/gp140S induced neutralizing antibody responses to homologous HIV-1 strain BaL.26 and laboratory adapted HIV-1 strain MN.3 that were stronger than those elicited by the other NDV recombinants. Additionally, rLaSota/gp140S induced greater CD4+ and CD8+ T-cell responses in mice. These studies illustrate that rLaSota/gp140S is a promising vaccine candidate to elicit potent mucosal, humoral and cellular immune responses to the HIV-1 Env protein. C1 [Khattar, Sunil K.; Samal, Sweety; Samal, Siba K.] Univ Maryland, Virginia Maryland Reg Coll Vet Med, College Pk, MD 20742 USA. [LaBranche, Celia C.; Montefiori, David C.] Duke Univ, Div Surg Sci, Durham, NC USA. [Collins, Peter L.] NIAID, Infect Dis Lab, Bethesda, MD 20892 USA. RP Samal, SK (reprint author), Univ Maryland, Virginia Maryland Reg Coll Vet Med, College Pk, MD 20742 USA. EM ssamal@umd.edu FU NIH [AI-093198]; NIAID Primate Central Immunology Laboratory [HHSN27201100016C]; NIAID, NIH Intramural Research Program FX This research was supported by NIH R21 grant AI-093198 awarded to S.K.S and by the NIAID Primate Central Immunology Laboratory Contract HHSN27201100016C awarded to D.C.M. P.L.C. was supported by the NIAID, NIH Intramural Research Program. The views expressed herein neither necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 57 TC 7 Z9 7 U1 0 U2 12 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 1 PY 2013 VL 8 IS 10 AR e78521 DI 10.1371/journal.pone.0078521 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 231OR UT WOS:000325427100089 PM 24098600 ER PT J AU Likhtarov, I Thomas, G Kovgan, L Masiuk, S Chepurny, M Ivanova, O Gerasymenko, V Tronko, M Bogdanova, T Bouville, A AF Likhtarov, I. Thomas, G. Kovgan, L. Masiuk, S. Chepurny, M. Ivanova, O. Gerasymenko, V. Tronko, M. Bogdanova, T. Bouville, A. TI Reconstruction of individual thyroid doses to the Ukrainian subjects enrolled in the Chernobyl Tissue Bank SO RADIATION PROTECTION DOSIMETRY LA English DT Article ID SHORT-LIVED RADIOIODINES; EXPOSED IN-UTERO; RADIOACTIVE CONTAMINATION; REGION UKRAINE; ACCIDENT; CANCER; I-131; CHILDREN; DISEASES; COHORT AB The Chernobyl Tissue Bank (CTB) is an organisation that collects and stores samples of tumoral thyroid tissue obtained from Ukrainian and Russian subjects who were treated surgically for a thyroid cancer and had been exposed to I-131 from the Chernobyl accident. By 2012, the CTB had collected specimens of thyroid tissue from 2267 residents of Ukraine for the purpose of radiation research. Arithmetic mean thyroid doses and uncertainties have been estimated for all but 24 subjects for whom residence at the time of exposure was not found. The subjects have been classified into six groups or sub-groups according to the type of dosimetry-related information that is available for each of them. Excluding the 325 subjects with negligible radiation exposure, the arithmetic mean of the thyroid dose over all subjects is estimated as 0.4 Gy, with individual values ranging from 1 mGy to 13 Gy. The uncertainties in the individual thyroid dose estimates, characterised by the geometric standard deviations of their probability distributions, range from 1.3 to 8.7, with an arithmetic mean of 3.2. C1 [Likhtarov, I.; Kovgan, L.; Masiuk, S.; Chepurny, M.; Ivanova, O.; Gerasymenko, V.] Natl Acad Med Sci Ukraine, Natl Res Ctr Radiat Med, State Inst, UA-04050 Kiev, Ukraine. [Likhtarov, I.; Kovgan, L.; Masiuk, S.; Chepurny, M.; Ivanova, O.; Gerasymenko, V.] Ukrainian Radiat Protect Inst, UA-04050 Kiev, Ukraine. [Thomas, G.] Univ London Imperial Coll Sci Technol & Med, London, England. [Tronko, M.; Bogdanova, T.] Natl Acad Med Sci Ukraine, VP Komisarenko Inst Endocrinol & Metab, State Inst, UA-04114 Kiev, Ukraine. [Bouville, A.] US Natl Canc Inst, Bethesda, MD 20892 USA. RP Masiuk, S (reprint author), Natl Acad Med Sci Ukraine, Natl Res Ctr Radiat Med, State Inst, 53 Melnykova St, UA-04050 Kiev, Ukraine. EM masja1979@gmail.com FU European Union FX This research was funded by the European Union through the contract between Imperial College London and Ukrainian Radiation Protection Institute. NR 54 TC 3 Z9 4 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0144-8420 EI 1742-3406 J9 RADIAT PROT DOSIM JI Radiat. Prot. Dosim. PD OCT PY 2013 VL 156 IS 4 BP 407 EP 423 DI 10.1093/rpd/nct096 PG 17 WC Environmental Sciences; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging GA 228KO UT WOS:000325185200003 PM 23595409 ER PT J AU Hao, M Cheng, TJ Wang, YL Bryant, HS AF Hao Ming Cheng Tiejun Wang Yanli Bryant, H. Stephen TI Web search and data mining of natural products and their bioactivities in PubChem SO SCIENCE CHINA-CHEMISTRY LA English DT Article DE natural products; drug discovery; PubChem; public database; data mining ID SMALL MOLECULES; MEDICINAL CHEMISTRY; DRUG DISCOVERY; INFORMATION; STRATEGIES; INHIBITORS; DATABASES AB Natural products, as major resources for drug discovery historically, are gaining more attentions recently due to the advancement in genomic sequencing and other technologies, which makes them attractive and amenable to drug candidate screening. Collecting and mining the bioactivity information of natural products are extremely important for accelerating drug development process by reducing cost. Lately, a number of publicly accessible databases have been established to facilitate the access to the chemical biology data for small molecules including natural products. Thus, it is imperative for scientists in related fields to exploit these resources in order to expedite their researches on natural products as drug leads/candidates for disease treatment. PubChem, as a public database, contains large amounts of natural products associated with bioactivity data. In this review, we introduce the information system provided at PubChem, and systematically describe the applications for a set of PubChem web services for rapid data retrieval, analysis, and downloading of natural products. We hope this work can serve as a starting point for the researchers to perform data mining on natural products using PubChem. C1 [Hao Ming; Cheng Tiejun; Wang Yanli; Bryant, H. Stephen] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA. RP Wang, YL (reprint author), NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA. EM ywang@ncbi.nlm.nih.gov; bryant@ncbi.nlm.nih.gov RI Cheng, Tiejun/A-5344-2010 OI Cheng, Tiejun/0000-0002-4486-3356 FU Intramural Research Program of the National Institutes of Health, National Library of Medicine FX This research was supported by the Intramural Research Program of the National Institutes of Health, National Library of Medicine. NR 26 TC 2 Z9 2 U1 3 U2 30 PU SCIENCE PRESS PI BEIJING PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA SN 1674-7291 J9 SCI CHINA CHEM JI Sci. China-Chem. PD OCT PY 2013 VL 56 IS 10 BP 1424 EP 1435 DI 10.1007/s11426-013-4910-0 PG 12 WC Chemistry, Multidisciplinary SC Chemistry GA 230VT UT WOS:000325372100011 ER PT J AU Meschia, JF Arnett, DK Ay, H Brown, RD Benavente, OR Cole, JW de Bakker, PIW Dichgans, M Doheny, KF Fornage, M Grewal, RP Gwinn, K Jern, C Conde, JJ Johnson, JA Jood, K Laurie, CC Lee, JM Lindgren, A Markus, HS McArdle, PF McClure, LA Mitchell, BD Schmidt, R Rexrode, KM Rich, SS Rosand, J Rothwell, PM Rundek, T Sacco, RL Sharma, P Shuldiner, AR Slowik, A Wassertheil-Smoller, S Sudlow, C Thijs, VNS Woo, D Worrall, BB Wu, O Kittner, SJ AF Meschia, James F. Arnett, Donna K. Ay, Hakan Brown, Robert D. Benavente, Oscar R. Cole, John W. de Bakker, Paul I. W. Dichgans, Martin Doheny, Kimberly F. Fornage, Myriam Grewal, Raji P. Gwinn, Katrina Jern, Christina Conde, Jordi Jimenez Johnson, Julie A. Jood, Katarina Laurie, Cathy C. Lee, Jin-Moo Lindgren, Arne Markus, Hugh S. McArdle, Patrick F. McClure, Leslie A. Mitchell, Braxton D. Schmidt, Reinhold Rexrode, Kathryn M. Rich, Stephen S. Rosand, Jonathan Rothwell, Peter M. Rundek, Tatjana Sacco, Ralph L. Sharma, Pankaj Shuldiner, Alan R. Slowik, Agnieszka Wassertheil-Smoller, Sylvia Sudlow, Cathie Thijs, Vincent N. S. Woo, Daniel Worrall, Bradford B. Wu, Ona Kittner, Steven J. CA NINDS SiGN Study TI Stroke Genetics Network (SiGN) Study Design and Rationale for a Genome-Wide Association Study of Ischemic Stroke Subtypes SO STROKE LA English DT Article DE cerebral infarct; genetics; genomics ID CAUSATIVE CLASSIFICATION; ATHEROSCLEROTIC STROKE; RISK; VARIANTS; SYSTEM; HEALTH AB Background and Purpose Meta-analyses of extant genome-wide data illustrate the need to focus on subtypes of ischemic stroke for gene discovery. The National Institute of Neurological Disorders and Stroke SiGN (Stroke Genetics Network) contributes substantially to meta-analyses that focus on specific subtypes of stroke. Methods The National Institute of Neurological Disorders and Stroke SiGN includes ischemic stroke cases from 24 genetic research centers: 13 from the United States and 11 from Europe. Investigators harmonize ischemic stroke phenotyping using the Web-based causative classification of stroke system, with data entered by trained and certified adjudicators at participating genetic research centers. Through the Center for Inherited Diseases Research, the Network plans to genotype 10 296 carefully phenotyped stroke cases using genome-wide single nucleotide polymorphism arrays and adds to these another 4253 previously genotyped cases, for a total of 14 549 cases. To maximize power for subtype analyses, the study allocates genotyping resources almost exclusively to cases. Publicly available studies provide most of the control genotypes. Center for Inherited Diseases Research-generated genotypes and corresponding phenotypes will be shared with the scientific community through the US National Center for Biotechnology Information database of Genotypes and Phenotypes, and brain MRI studies will be centrally archived. Conclusions The Stroke Genetics Network, with its emphasis on careful and standardized phenotyping of ischemic stroke and stroke subtypes, provides an unprecedented opportunity to uncover genetic determinants of ischemic stroke. C1 [Meschia, James F.] Mayo Clin Jacksonville, Jacksonville, FL USA. [Arnett, Donna K.; McClure, Leslie A.] Univ Alabama Birmingham, Birmingham, AL USA. [Brown, Robert D.] Mayo Clin Rochester, Rochester, MN USA. [Ay, Hakan; Rosand, Jonathan; Wu, Ona] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Benavente, Oscar R.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Cole, John W.; McArdle, Patrick F.; Mitchell, Braxton D.; Shuldiner, Alan R.; Kittner, Steven J.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Cole, John W.; McArdle, Patrick F.; Mitchell, Braxton D.; Shuldiner, Alan R.; Kittner, Steven J.] Vet Adm Med Ctr, Baltimore, MD 21218 USA. [de Bakker, Paul I. W.] Univ Med Ctr Utrecht, Utrecht, Netherlands. [de Bakker, Paul I. W.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA. [de Bakker, Paul I. W.] MIT, Broad Inst Harvard, Cambridge, MA USA. [Dichgans, Martin] Univ Munich, Klinikum Univ Munchen, Munich, Germany. [Doheny, Kimberly F.] Johns Hopkins Univ, Baltimore, MD USA. [Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Grewal, Raji P.] St Francis Med Ctr, Lynwood, CA USA. [Gwinn, Katrina] NINDS Neurogenet Cluster, Bethesda, MD USA. [Conde, Jordi Jimenez] Univ Mar, IMIM Hosp, Barcelona, Spain. [Johnson, Julie A.] Univ Florida, Coll Pharm, Gainesville, FL USA. [Jern, Christina; Jood, Katarina] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Gothenburg, Sweden. [Laurie, Cathy C.] Univ Washington, Seattle, WA 98195 USA. [Lee, Jin-Moo] Washington Univ, Sch Med, St Louis, MO USA. [Lindgren, Arne] Lund Univ, Lund, Sweden. [Markus, Hugh S.] St Georges Univ London, London, England. [Schmidt, Reinhold] Med Univ Graz, Graz, Austria. [Rexrode, Kathryn M.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Rich, Stephen S.; Worrall, Bradford B.] Univ Virginia, Charlottesville, VA USA. [Rothwell, Peter M.] Radcliffe Infirm, Oxford OX2 6HE, England. [Rundek, Tatjana; Sacco, Ralph L.] Univ Miami, Coral Gables, FL 33124 USA. [Sharma, Pankaj] Imperial Coll London, London, England. [Slowik, Agnieszka] Jagiellonian Univ, Krakow, Poland. [Wassertheil-Smoller, Sylvia] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Sudlow, Cathie] Univ Edinburgh, Edinburgh, Midlothian, Scotland. [Thijs, Vincent N. S.] Univ Ziekenhuizen Leuven, Louvain, Belgium. [Woo, Daniel] Univ Cincinnati, Cincinnati, OH USA. RP Kittner, SJ (reprint author), Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA. EM skittner@umaryland.edu RI de Bakker, Paul/B-8730-2009; Lee, Jin-Moo/K-2024-2015; McClure, Leslie/P-2929-2015; JIMENEZ-CONDE, JORDI/C-1941-2012; OI de Bakker, Paul/0000-0001-7735-7858; Lee, Jin-Moo/0000-0002-3979-0906; Thijs, Vincent/0000-0002-6614-8417; Rexrode, Kathryn/0000-0003-3387-8429; Bevan, Steve/0000-0003-0490-6830; Mitchell, Braxton/0000-0003-4920-4744; Anderson, Christopher/0000-0002-0053-2002; Gwinn, Katrina/0000-0002-8277-651X FU National Institute of Neurological Disorders and Stroke (NINDS) [U01 NS069208]; Ministerio de Sanidad y Consumo de Espana; Instituto de Salud Carlos III (ISC III) [PI051737]; GWA study of LeukoAraiosis (GWALA) Bases geneticas de la leucoaraiosis; Fondos de Investigacion Sanitaria ISC III [PI10/02064]; Fondos FEDER/EDRF Red de Investigacion Cardiovascular [RD12/0042/0020]; Fundacio la Marato TV3 [76/C/2011]; British Council (UKIERI); Henry Smith Charity; Department of Health (UK); Department of Health; National Institutes of Health [HHSN268200782096C, NS 030678]; Wellcome Trust Clinical Research Facility, Western General Hospital, Edinburgh; Binks Trust; Council Brain Imaging Research Centre; Division of Clinical Neurosciences, University of Edinburgh, a core area of the Wellcome Trust Clinical Research Facility; Scottish Imaging Network - A Platform for Scientific Excellence (SINAPSE) collaboration; Scottish Funding Council; Chief Scientist Office; Wellcome Trust as part of the Wellcome Trust Case Control Consortium [085475/B/08/Z, 085475/Z/08/Z, WT084724MA]; National Institutes of Health Genes Affecting Stroke Risks and Outcomes Study (GASROS) [K23 NS042720]; American Heart Association/Bugher Foundation Centers for Stroke Prevention Research [0775010N]; NINDS [K23NS042695, R01NS059727, R01 NS42733, R01 NS39987, R37 NS029993, R01 NS27517]; Deane Institute for Integrative Research in Atrial Fibrillation and Stroke; Keane Stroke Genetics Fund; National Center for Research Resources [U54RR020278]; National Institutes of Health Genes, Environment and Health Initiative (GEI)as part of the Gene Environment Association Studies (GENEVA) consortium under GEI [U01 HG004436]; Mid-Atlantic Nutrition and Obesity Research Center [P30 DK072488]; Office of Research and Development, Medical Research Service; Baltimore Geriatrics Research, Education, and Clinical Center of the Department of Veterans Affairs; National Institutes of Health (NIH) Office of Research on Women's Health [R01 NS45012, U01 NS069208-01]; Austrian Science Fund (FWF) [P20545-P05, P13180, I904-B13]; National Institute on Aging [Z01 AG000954-06, Z01 AG000015-50]; Polish Ministry of Science and Higher Education for Leading National Research Centers (KNOW); Medical College, Jagiellonian University in Krakow, Poland [K/ZDS/002848]; Department of Neurology of the University Hospitals Leuven; Fundamental Clinical Research grant from FWO Flanders [1.8.009.08.N.00, 1800913N]; Swedish Research Council, Region Skane [K2010-61X-20378-04-3]; Freemasons Lodge of Instruction EOS in Lund; King Gustaf V's and Queen Victoria's Foundation; Lund University; Swedish Stroke Association; New Jersey Neuroscience Institute/JFK Medical Center, Edison, NJ; Neurogenetics Foundation, Cranbury, NJ; Department of Neurology at University of Miami Miller School of Medicine; Evelyn McKnight Brain Institute; National Institutes of Health from the National Heart Lung and Blood Institute [HL088521, HL34594]; National Cancer Institute [CA87969, CA49449]; Stroke Association; Medical Research Council; Wellcome Trust; Dunhill Medical Trust; National Institutes of Health Research (NIHR); NIHR Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust; University of Oxford; NIHR; NINDS, National Institutes of Health, and Department of Health and Human Service [U01 NS041588]; Swedish Research Council [K2011-65X-14605-09-6]; Swedish Heart and Lung Foundation [20100256]; Swedish state/Sahlgrenska University Hospital [ALFGBG-148861]; Swedish Society of Medicine; Rune and Ulla Amlov Foundation; US National Institute of Health and Neurological Disorders and Stroke [U01NS38529-04A1]; Wellcome Trust, as part of the Wellcome Trust Case Control Consortium [085475/B/08/Z, 085475/Z/08/Z, WT084724MA]; National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services [N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118, 32119, 32122, 42107-26, 42129-32, 44221]; National Institutes of Neurological Disorders and Stroke [R01NS042618]; Washington University SPOTRIAS Center [P50 NS055977]; Barnes-Jewish Hospital Foundation; [R01 NS073346] FX SiGN: The study was funded by a cooperative agreement grant from the National Institute of Neurological Disorders and Stroke (NINDS) U01 NS069208.; BASICMAR: The BASICMAR Genetic Study was supported by the Ministerio de Sanidad y Consumo de Espana, Instituto de Salud Carlos III (ISC III) with the grants: "Registro BASICMAR" Funding for Research in Health (PI051737); GWA study of LeukoAraiosis (GWALA) Bases geneticas de la leucoaraiosis. Estudio de Genome Wide Association en poblacion espanola. Consorcio Espanol de Genetica del Ictus (Genestroke). "GWALA project" from Fondos de Investigacion Sanitaria ISC III (PI10/02064); and Fondos FEDER/EDRF Red de Investigacion Cardiovascular (RD12/0042/0020). Additional support provided by the Fundacio la Marato TV3 with the grant "Genetic contribution to functional Outcome and Disability after Stroke (GOD's) project" (76/C/2011). Assistance with data cleaning was provided by the Research in Cardiovascular and Inflammatory Diseases Program of Institute of Medical Investigations Mar, Hospital del Mar, and the Barcelona Biomedical Research Park.; BRAINS: BRAINS was supported by the British Council (UKIERI), Henry Smith Charity, and Department of Health (UK). Dr Sharma was supported by a Department of Health Senior Fellowship. CIDR: Genotyping services were provided by the Johns Hopkins University Center for Inherited Disease Research (CIDR), which is fully funded through a federal contract from the National Institutes of Health to the Johns Hopkins University (contract number HHSN268200782096C).; EDINBURGH: The Edinburgh Stroke Study was supported by the Wellcome Trust (clinician scientist award to Dr Sudlow) and the Binks Trust. Sample processing occurred in the Genetics Core Laboratory of the Wellcome Trust Clinical Research Facility, Western General Hospital, Edinburgh. Much of the neuroimaging occurred in the Scottish Funding Council Brain Imaging Research Centre (www.sbirc.ed.ac.uk), Division of Clinical Neurosciences, University of Edinburgh, a core area of the Wellcome Trust Clinical Research Facility and part of the Scottish Imaging Network - A Platform for Scientific Excellence (SINAPSE) collaboration (www.sinapse.ac.uk), funded by the Scottish Funding Council and the Chief Scientist Office. Genotyping was performed at the Wellcome Trust Sanger Institute in the UK and funded by the Wellcome Trust as part of the Wellcome Trust Case Control Consortium 2 project (085475/B/08/Z and 085475/Z/08/Z and WT084724MA).; GASROS: The Massachusetts General Hospital Stroke Genetics Group was supported by the National Institutes of Health Genes Affecting Stroke Risks and Outcomes Study (GASROS) grant K23 NS042720, the American Heart Association/Bugher Foundation Centers for Stroke Prevention Research 0775010N, and NINDS K23NS042695, R01NS059727, the Deane Institute for Integrative Research in Atrial Fibrillation and Stroke, and by the Keane Stroke Genetics Fund. Genotyping services were provided by the Broad Institute Center for Genotyping and Analysis, supported by grant U54RR020278 from the National Center for Research Resources.; GCNKSS: The Greater Cincinnati/Northern Kentucky Stroke Study was supported by the National Institutes of Health (NS 030678).; GEOS: The GEOS Study was supported by the National Institutes of Health Genes, Environment and Health Initiative (GEI) grant U01 HG004436, as part of the Gene Environment Association Studies (GENEVA) consortium under GEI, with additional support provided by the Mid-Atlantic Nutrition and Obesity Research Center (P30 DK072488) and the Office of Research and Development, Medical Research Service, and the Baltimore Geriatrics Research, Education, and Clinical Center of the Department of Veterans Affairs. Genotyping services were provided by the Johns Hopkins University CIDR, which is fully funded through a federal contract from the National Institutes of Health to the Johns Hopkins University (contract number HHSN268200782096C). Assistance with data cleaning was provided by the GENEVA Coordinating Center (U01 HG 004446; PI Bruce S Weir). Study recruitment and assembly of data sets were supported by a Cooperative Agreement with the Division of Adult and Community Health, Centers for Disease Control and by grants from the NINDS and the National Institutes of Health (NIH) Office of Research on Women's Health (R01 NS45012, U01 NS069208-01).; GRAZ: The Austrian Stroke Prevention Study was supported by the Austrian Science Fund (FWF) grant numbers P20545-P05 and P13180 and I904-B13 (Era-Net). The Medical University of Graz supports the databases of the Graz Stroke Study and the Austrian Stroke Prevention Study.; ISGS and SWISS: The Ischemic Stroke Genetics Study (ISGS) was supported by the NINDS (R01 NS42733; PI Dr Meschia). The Sibling with Ischemic Stroke Study (SWISS) was supported by the NINDS (R01 NS39987; PI Dr Meschia). Both SWISS and ISGS received additional support, in part, from the Intramural Research Program of the National Institute on Aging (Z01 AG000954-06; PI Andrew Singleton). SWISS and ISGS used samples and clinical data from the NIH-NINDS Human Genetics Resource Center DNA and Cell Line Repository (http://ccr.coriell.org/ninds), human subjects protocol numbers 2003-081 and 2004-147. SWISS and ISGS used stroke-free participants from the Baltimore Longitudinal Study of Aging (BLSA) as controls with the permission of Dr Luigi Ferrucci. The inclusion of BLSA samples was supported, in part, by the Intramural Research Program of the National Institute on Aging (Z01 AG000015-50), human subjects protocol number 2003-078. This study used the high-performance computational capabilities of the Biowulf Linux cluster at the NIH (http://biowulf.nih.gov).; KRAKOW: Phenotypic data and genetic specimens collection were funded by the grant from the Polish Ministry of Science and Higher Education for Leading National Research Centers (KNOW) and by the grant from the Medical College, Jagiellonian University in Krakow, Poland: K/ZDS/002848.; LEUVEN: The Leuven Stroke genetics study was supported by personal research funds from the Department of Neurology of the University Hospitals Leuven. Vincent Thijs is supported by a Fundamental Clinical Research grant from FWO Flanders (numbers 1.8.009.08.N.00 and 1800913N).; LUND: The Lund Stroke Register was supported by the Swedish Research Council (K2010-61X-20378-04-3), Region Skane, the Freemasons Lodge of Instruction EOS in Lund, King Gustaf V's and Queen Victoria's Foundation, Lund University, and the Swedish Stroke Association. Biobank services were provided by Region Skane Competence Centre (RSKC Malmo), Skane University Hospital, Malmo, Sweden, and Biobank, LabmedicinSkane, University and Regional Laboratories Region Skane, Sweden.; MCISS: The Middlesex County Ischemic Stroke Study (MCISS) was supported by intramural funding from the New Jersey Neuroscience Institute/JFK Medical Center, Edison, NJ, and The Neurogenetics Foundation, Cranbury, NJ. We acknowledge Dr Souvik Sen for his advice and encouragement in the initiation and design of this study.; MIAMISR and NOMAS(S): The Northern Manhattan Study (NOMAS) was supported by grants from the NINDS (R37 NS029993, R01 NS27517). The Cerebrovascular Biorepository at University of Miami/Jackson Memorial Hospital (The Miami Stroke Registry, Institutional Review Board No. 20070386) was supported by the Department of Neurology at University of Miami Miller School of Medicine and Evelyn McKnight Brain Institute. Biorepository and DNA extraction services were provided by the Hussmann Institute for Human Genomics at the Miller School of Medicine.; MUNICH: The MUNICH study was supported by the Vascular Dementia Research Foundation and the Jackstaedt Stiftung.; NHS: The Nurses' Health Study work on stroke is supported by grants from the National Institutes of Health, including HL088521 and HL34594 from the National Heart Lung and Blood Institute, as well as grants from the National Cancer Institute funding the questionnaire follow-up and blood collection: CA87969 and CA49449.; OXVASC: The Oxford Vascular Study was supported by the Stroke Association, Medical Research Council, Wellcome Trust, Dunhill Medical Trust, National Institutes of Health Research (NIHR), and NIHR Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust and University of Oxford. Rothwell is in receipt of Senior Investigator Awards from the Wellcome Trust and the NIHR.; REGARDS: The Reasons for Geographic and Racial Differences in Stroke Study was supported by a cooperative agreement U01 NS041588 from the NINDS, National Institutes of Health, and Department of Health and Human Service. A full list of participating REGARDS investigators and institutions can be found at http://www.regardsstudy.org.; SAHLSIS: SAHLSIS was supported by the Swedish Research Council (K2011-65X-14605-09-6), the Swedish Heart and Lung Foundation (20100256), the Swedish state/Sahlgrenska University Hospital (ALFGBG-148861), the Swedish Stroke Association, the Swedish Society of Medicine, and the Rune and Ulla Amlov Foundation.; SPS3: The Secondary Prevention of Small Subcortical Strokes trial was funded by the US National Institute of Health and Neurological Disorders and Stroke grant No. U01NS38529-04A1 (principal investigator, O.R.B.; co-principal investigator, R. G. H.). The SPS3 Genetic Substudy (SPS3-GENES) was funded by R01 NS073346 (co-principal investigators, J.A.J, O.R.B, A. R. S.).; ST. GEORGE'S: The principal funding for this study was provided by the Wellcome Trust, as part of the Wellcome Trust Case Control Consortium 2 project (085475/B/08/Z and 085475/Z/08/Z and WT084724MA). Collection of some of the St George's stroke cohort was supported by project grant support from the Stroke Association.; WHI: The Women's Health Initiatives (WHI) program was funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services through contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118 to 32119, 32122, 42107-26, 42129-32, and 44221. The Hormones and Biomarkers Predicting Stroke (HaBPS) was supported by a grant from the National Institutes of Neurological Disorders and Stroke (R01NS042618).; WUSTL: The collection, extraction of DNA from blood, and storage of specimens were supported by the Washington University SPOTRIAS Center grant (P50 NS055977, NINDS, NIH). Basic demographic and clinical characterization of stroke phenotype was prospectively collected in the Cognitive Rehabilitation and Recovery Group (CRRG) registry. The Recovery Genomics after Ischemic Stroke (ReGenesIS) study was supported by a grant from the Barnes-Jewish Hospital Foundation. NR 15 TC 19 Z9 19 U1 0 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD OCT PY 2013 VL 44 IS 10 BP 2694 EP 2702 DI 10.1161/STROKEAHA.113.001857 PG 9 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 223TC UT WOS:000324831900020 PM 24021684 ER PT J AU Yadav, S Cotlarciuc, I Munroe, PB Khan, MS Nalls, MA Bevan, S Cheng, YC Chen, WM Malik, R McCarthy, NS Holliday, EG Speed, D Hasan, N Pucek, M Rinne, PE Sever, P Stanton, A Shields, DC Maguire, JM McEvoy, M Scott, RJ Ferrucci, L Macleod, MJ Attia, J Markus, HS Sale, MM Worrall, BB Mitchell, BD Dichgans, M Sudlow, C Meschia, JF Rothwell, PM Caulfield, M Sharma, P AF Yadav, Sunaina Cotlarciuc, Ioana Munroe, Patricia B. Khan, Muhammad S. Nalls, Michael A. Bevan, Steve Cheng, Yu-Ching Chen, Wei-Min Malik, Rainer McCarthy, Nina S. Holliday, Elizabeth G. Speed, Douglas Hasan, Nazeeha Pucek, Mateusz Rinne, Paul E. Sever, Peter Stanton, Alice Shields, Denis C. Maguire, Jane M. McEvoy, Mark Scott, Rodney J. Ferrucci, Luigi Macleod, Mary J. Attia, John Markus, Hugh S. Sale, Michele M. Worrall, Bradford B. Mitchell, Braxton D. Dichgans, Martin Sudlow, Cathy Meschia, James F. Rothwell, Peter M. Caulfield, Mark Sharma, Pankaj CA Int Stroke Genetics Consortium TI Genome-Wide Analysis of Blood Pressure Variability and Ischemic Stroke SO STROKE LA English DT Article DE blood pressure variability; genes; GWAS; polymorphism; stroke ID EPISODIC HYPERTENSION; POPULATION-STRUCTURE; COMMON VARIANTS; RISK-FACTORS; ASSOCIATION; METAANALYSIS; TRIAL; PREVENTION; INFARCTION; RATIONALE AB Background and Purpose Visit-to-visit variability in blood pressure (vBP) is associated with ischemic stroke. We sought to determine whether such variability has genetic causes and whether genetic variants associated with BP variability are also associated with ischemic stroke. Methods A Genome Wide Association Study (GWAS) for loci influencing BP variability was undertaken in 3802 individuals from the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT) study, in which long-term visit-to-visit and within-visit BP measures were available. Because BP variability is strongly associated with ischemic stroke, we genotyped the sentinel single nucleotide polymorphism in an independent ischemic stroke population comprising 8624 cases and 12 722 controls and in 3900 additional (Scandinavian) participants from the ASCOT study to replicate our findings. Results The ASCOT discovery GWAS identified a cluster of 17 correlated single nucleotide polymorphisms within the NLGN1 gene (3q26.31) associated with BP variability. The strongest association was with rs976683 (P=1.4x10(-8)). Conditional analysis of rs976683 provided no evidence of additional independent associations at the locus. Analysis of rs976683 in patients with ischemic stroke found no association for overall stroke (odds ratio, 1.02; 95% CI, 0.97-1.07; P=0.52) or its subtypes: cardioembolic (odds ratio, 1.07; 95% CI, 0.97-1.16; P=0.17), large vessel disease (odds ratio, 0.98; 95% CI, 0.89-1.07; P=0.60), and small vessel disease (odds ratio, 1.07; 95% CI, 0.97-1.17; P=0.19). No evidence for association was found between rs976683 and BP variability in the additional (Scandinavian) ASCOT participants (P=0.18). Conclusions We identified a cluster of single nucleotide polymorphisms at the NLGN1 locus showing significant association with BP variability. Follow-up analyses did not support an association with risk of ischemic stroke and its subtypes. C1 [Yadav, Sunaina; Cotlarciuc, Ioana; Khan, Muhammad S.; Hasan, Nazeeha; Pucek, Mateusz; Rinne, Paul E.; Sever, Peter] Imperial Coll London, Imperial Coll Cerebrovascular Res Unit, London, England. [Sever, Peter] Imperial Coll Cerebrovasc Res Unit, London, England. Imperial Coll London, London, England. [Holliday, Elizabeth G.; McEvoy, Mark; Attia, John] Univ Newcastle, Ctr Clin Epidemiol & Biostat, Sch Med & Publ Hlth, Newcastle, NSW 2300, Australia. [Maguire, Jane M.] Univ Newcastle, Sch Nursing & Midwifery, Newcastle, NSW 2300, Australia. [Scott, Rodney J.] Univ Newcastle, Sch Biomed Sci & Pharm, Newcastle, NSW 2300, Australia. [Holliday, Elizabeth G.; Maguire, Jane M.; McEvoy, Mark; Scott, Rodney J.; Attia, John] Hunter Med Res Inst, Newcastle, NSW, Australia. [Malik, Rainer; Dichgans, Martin] Univ Munich, Inst Stroke & Dementia Res ISD, Med Ctr, Klinikum Univ Munchen, Munich, Germany. [Malik, Rainer; Dichgans, Martin] Munich Cluster Syst Neurol SyNergy, Munich, Germany. [Bevan, Steve; Markus, Hugh S.] St Georges Univ London, Stroke & Dementia Res Ctr, London, England. [Meschia, James F.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA. [Cheng, Yu-Ching] Baltimore Vet Affairs Med Ctr, Baltimore, MD USA. [Nalls, Michael A.] US Natl Inst Hlth, Natl Inst Aging, Neurogenet Lab, Bethesda, MD USA. [Worrall, Bradford B.] Univ Virginia, Dept Neurol & Publ Hlth Sci, Charlottesville, VA USA. [Sale, Michele M.] Univ Virginia, Div Cardiovasc Med, Dept Internal Med, Charlottesville, VA USA. [Chen, Wei-Min; Sale, Michele M.] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA USA. [Chen, Wei-Min] Univ Virginia, Dept Publ Hlth Sci, Charlottesville, VA USA. [Sudlow, Cathy] Univ Edinburgh, Inst Genet & Mol Med, Div Clin Neurosci, Edinburgh, Midlothian, Scotland. [Rothwell, Peter M.] John Radcliffe Hosp, Dept Clin Neurol, Oxford OX3 9DU, England. [Speed, Douglas] UCL, UCL Genet Inst, London, England. [Macleod, Mary J.] Univ Aberdeen, Div Appl Med, Aberdeen, Scotland. [McCarthy, Nina S.] Univ Western Australia, Ctr Genet Origins Hlth & Dis, Crawley, WA, Australia. [McCarthy, Nina S.; Stanton, Alice] Royal Coll Surgeons Ireland, Dublin 2, Ireland. [Shields, Denis C.] Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland. [Munroe, Patricia B.; Caulfield, Mark] Barts & London Med Sch, William Harvey Res Inst, Ctr Clin Pharmacol, London, England. [Maguire, Jane M.] Gosford Hosp, Dept Neurosci, Gosford, NSW, Australia. [Scott, Rodney J.] Hunter Area Pathol Serv, Div Genet, Newcastle, NSW, Australia. [Cheng, Yu-Ching; Mitchell, Braxton D.] Univ Maryland, Dept Med, Baltimore, MD 21201 USA. [Ferrucci, Luigi] NIH, Natl Inst Aging, Clin Res Branch, Longitudinal Studies Sect, Baltimore, MD USA. RP Sharma, P (reprint author), Imperial Coll London, London SW7 2AZ, England. EM pankaj.sharma@imperial.ac.uk RI Stanton, Alice/F-4697-2012; Attia, John/F-5376-2013; OI Macleod, Mary Joan/0000-0003-2115-8184; Attia, John/0000-0001-9800-1308; Speed, Doug/0000-0002-0096-9765; Stanton, Alice/0000-0002-4961-165X; Bevan, Steve/0000-0003-0490-6830; Mitchell, Braxton/0000-0003-4920-4744 FU Pfizer (NY, Servier Research Group, Paris, France); Leo Laboratories (Copenhagen, Denmark); Hunter Medical Research Institute; National health, Medical Research Council, University of Newcastle; Vincent Fairfax Family Foundation; Department of Health (United Kingdom); Henry Smith Charity; British Council; United Kingdom-India Education and Research Institute (UKIERI); Qatar National Research Foundation; National Institutes of Health (NIH) Genes, Environment, and Health Initiative (GEI) [U01 HG004436]; NIH [HHSN268200782096C]; GENEVA Coordinating Center [U01 HG 004446]; Office of Research and Development, Medical Research Service, Baltimore Geriatrics Research, Education, and Clinical Centre of the Department of Veterans Affairs; National Institute of Neurological Disorders and Stroke (NINDS), NIH Office of Research on Women's Health [R01 NS45012, U01 NS069208-01]; Department of Veterans Affairs BLR&D Career Development Award (CDA-2); National Institute on Aging [Z01 AG-000954-06, Z01 AG-000015-50]; NIH-NINDS [R01 NS-42733, R01 NS-39987]; NINDS/NIH [R01 NS34447]; National Human Genome Research Institute [U01 HG005160]; Wellcome Trust [085475/B/08/Z, 085475/Z/08/Z, WT084724MA] FX Anglo-Scandinavian Cardiac Outcome Trial was supported by Pfizer (NY, Servier Research Group, Paris, France) and Leo Laboratories (Copenhagen, Denmark). Australian Stroke Genetics Collaborative was funded through grants from the Hunter Medical Research Institute and the National health, Medical Research Council, University of Newcastle, and the Vincent Fairfax Family Foundation. Bio-Repository of DNA in Stroke received support from Department of Health (United Kingdom), Henry Smith Charity, British Council, United Kingdom-India Education and Research Institute (UKIERI), and the Qatar National Research Foundation (www.BrainsGenetics.com). Genetics of Early Onset Stroke was supported by the following grants: National Institutes of Health (NIH) Genes, Environment, and Health Initiative (GEI) Grant U01 HG004436; NIH grant HHSN268200782096C; GENEVA Coordinating Center grant U01 HG 004446; Office of Research and Development, Medical Research Service, Baltimore Geriatrics Research, Education, and Clinical Centre of the Department of Veterans Affairs; National Institute of Neurological Disorders and Stroke (NINDS), NIH Office of Research on Women's Health (R01 NS45012, U01 NS069208-01); and Department of Veterans Affairs BLR&D Career Development Award (CDA-2). Ischemic Stroke Genetics Study and Siblings with Ischemic Stroke Study was supported in part by the Intramural Research Program of the National Institute on Aging (NIH project Z01 AG-000954-06 and NIH project Z01 AG-000015-50), NIH-NINDS grant R01 NS-42733 (ISGS, Dr Meschia), and NIH-NINDS grant R01 NS-39987 (SWISS, Dr Meschia). Vitamin Intervention for Stroke Prevention was funded by the NINDS/NIH (R01 NS34447) and National Human Genome Research Institute (grant U01 HG005160). Welcome Trust Case Control Consortium-Germany (WTCCC) and WTCCC-UK were funded by the Wellcome Trust as part of the WTCCC2 project (085475/B/08/Z, 085475/Z/08/Z, and WT084724MA). The other authors report no conflicts. NR 41 TC 7 Z9 9 U1 0 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA,